Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 1877 offsetEnd: 2026 A: polyadenylation signal accompanied by a poly(T) sequence and a target site duplication. The insertion site matched the consensus recognition sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 3672 offsetEnd: 3813 A: site consensus sequence that is critical for splicing enhancer activity. Mutations within this pseudo-5' splice site sequence have a dramatic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 2835 offsetEnd: 2983 A: a non-standard polyadenylation consensus sequence while the 3kb transcript contains a standard consensus sequence but within the open reading frame.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12556531 offsetBegin: 2077 offsetEnd: 2223 A: extra polyadenylation site at 19 nt. The 3'-untranslated region sequence is AU-rich and has putative consensus sequences for RNA-binding proteins.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 2026 offsetEnd: 2165 A: sequence and a target site duplication. The insertion site matched the consensus recognition sequence for the L1 endonuclease, indicating a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 2674 offsetEnd: 2835 A: UTR. Furthermore, the 4.2kb transcript contains a non-standard polyadenylation consensus sequence while the 3kb transcript contains a standard consensus sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 2141 offsetEnd: 2291 A: an AU-rich domain corresponding to the consensus UA(A/U)UU polyadenylation signal or variants, the cleavage and polyadenylation site that is generally
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 2291 offsetEnd: 2435 A: consensus UA(A/U)UU polyadenylation signal or variants, the cleavage and polyadenylation site that is generally denoted by U residue and flanked
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12446815 offsetBegin: 4398 offsetEnd: 4546 A: contained both the consensus stem-loop sequence and the polyadenylation signals but lacked the consensus histone downstream element that is involved
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 2165 offsetEnd: 2327 A: The insertion site matched the consensus recognition sequence for the L1 endonuclease, indicating a retrotransposon-mediated event, although the inserted sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1551 offsetEnd: 1690 A: and 3'-flanking regions revealed a consensus TATA-box sequence located 28 bp upstream of the transcription initiation site as determined by
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 3398 offsetEnd: 3534 A: specifically to SEalpha2. SEalpha2 also includes an element resembling a 5' splice site consensus sequence that is critical for splicing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 3534 offsetEnd: 3672 A: an element resembling a 5' splice site consensus sequence that is critical for splicing enhancer activity. Mutations within this pseudo-5'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 2582 offsetEnd: 2701 A: exon 4, via factors binding to an intronic enhancer element that contains both 3' and 5' splice site consensus sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 2833 offsetEnd: 2960 A: both 3' and 5' splice site consensus sequence elements. In cell types that preferentially exclude exon 4, addition of wild-type
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 3382 offsetEnd: 3536 A: untranslated region contains consensus polyadenylation signal (AATAAA). We also isolated an intronless gene with 93% nucleotide sequence similarity to the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 1101 offsetEnd: 1251 A: poly(A) tail attachment sites. However, polyadenylation consensus sequence AAUAAA was not seen at the 3'-untranslated sequence. PSG076 contained a 299
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12556531 offsetBegin: 1949 offsetEnd: 2077 A: with 225 microM emetine exhibited an extra polyadenylation site at 19 nt. The 3'-untranslated region sequence is AU-rich and has
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4200 offsetEnd: 4330 A: The late polyadenylation signal was found to contain a single high-affinity site for CstF, as well as one consensus hexanucleotide
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9837805 offsetBegin: 3940 offsetEnd: 4102 A: the consensus protease cleavage site. Genomic and cDNA sequence analysis has identified promoters, cap sites, intron-exon boundaries, polyadenylation signals, and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1277 offsetEnd: 1420 A: bp, all have conserved junction sequences (GT..AG). Sequence analysis of the 5'- and 3'-flanking regions revealed a consensus TATA-box sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1968 offsetEnd: 2107 A: determined by primer extension analysis, and a putative polyadenylation signal observed 29 bp upstream of the polyadenylation site based on
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 2107 offsetEnd: 2247 A: a putative polyadenylation signal observed 29 bp upstream of the polyadenylation site based on cDNA sequence. Genomic Southern blot analysis
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 2604 offsetEnd: 2728 A: a prominent binding site, 130 base pairs upstream of the EBER1 gene, contains two E-boxes providing a consensus sequence for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 2745 offsetEnd: 2876 A: tract for directing polyadenylation and a gene end sequence that differs from the consensus sequence. We have tested the hypothesis
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21558555 offsetBegin: 1814 offsetEnd: 1960 A: prominent kinase with a consensus site for phosphorylation that overlapped with caspase recognition motifs. We then evaluated potential targets of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 3676 offsetEnd: 3827 A: for ubiquitin thioester formation and the active site consensus sequence that defines the ubiquitin-conjugating enzyme class. These observations are of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 3827 offsetEnd: 3979 A: active site consensus sequence that defines the ubiquitin-conjugating enzyme class. These observations are of particular relevance for analysis of UbcM4
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 2931 offsetEnd: 3104 A: These experiments identified cleavage and polyadenylation specificity factor 1 (CPSF1) among protein-binding candidates. A consensus polyadenylation signal AAUAAA is present
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10832023 offsetBegin: 939 offsetEnd: 1089 A: 1alpha-hydroxylase and human vitamin D(3) 25-hydroxylase genes. A polyadenylation signal AUUAAA that differs from the consensus sequence at the second
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10832023 offsetBegin: 1089 offsetEnd: 1222 A: genes. A polyadenylation signal AUUAAA that differs from the consensus sequence at the second residue was identified 16 bp downstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 2701 offsetEnd: 2833 A: an intronic enhancer element that contains both 3' and 5' splice site consensus sequence elements. In cell types that preferentially
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23308270 offsetBegin: 1386 offsetEnd: 1523 A: as a direct and prominent target of Gfi1b. Examination of the meis1 promoter sequence revealed multiple Gfi1/1b consensus binding motifs.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 1718 offsetEnd: 1877 A: certain characteristics of retrotransposons: an antisense polyadenylation signal accompanied by a poly(T) sequence and a target site duplication. The insertion
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 3370 offsetEnd: 3504 A: identify a consensus sequence but did reveal weak putative 3'-end formation signals in all of the transcripts. Similarly, no consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 815 offsetEnd: 965 A: with different length were produced from the single gene based on different poly(A) tail attachment sites. However, polyadenylation consensus sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 965 offsetEnd: 1101 A: the single gene based on different poly(A) tail attachment sites. However, polyadenylation consensus sequence AAUAAA was not seen at the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10448076 offsetBegin: 2703 offsetEnd: 2863 A: polyadenylation site was identified in the 3' flanking region. SP-HSP70 protein sequence resembles the cytosolic/nuclear HSP70 cluster. RT-PCR studies confirmed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3463 offsetEnd: 3595 A: in vivo and exon polyadenylation in vitro. An additional PTB binding site was identified close to the AAUAAA hexanucleotide sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 967 offsetEnd: 1089 A: the highest for the consensus sequence and the lowest for splice sites differing most from the consensus sequence and used
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12446815 offsetBegin: 4262 offsetEnd: 4398 A: The 3'UTRs of the histone genes contained both the consensus stem-loop sequence and the polyadenylation signals but lacked the consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 634 offsetEnd: 749 A: site consensus is TATAT, with a 4bp target site duplication TATA. The LTRs are short (142bp) and contain a TATA-box
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 1470 offsetEnd: 1641 A: polyprotein coding sequence contains scattered stop codons and deletions/insertions at non-homologous positions. The consensus sequence among the three full-length copies,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21558555 offsetBegin: 1547 offsetEnd: 1676 A: caspases and kinases. We identified the protein kinase CK2 as the most prominent kinase with a consensus site for phosphorylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21558555 offsetBegin: 1676 offsetEnd: 1814 A: protein kinase CK2 as the most prominent kinase with a consensus site for phosphorylation that overlapped with caspase recognition motifs.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/8442668 offsetBegin: 2357 offsetEnd: 2499 A: acetylator phenotype and NAT2 genotype. A prominent alteration in one of the variants was obliteration of the consensus polyadenylation signal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 2611 offsetEnd: 2737 A: A sequence overlapping this sense start site contains a good match to an initiator consensus for the transcription start sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 833 offsetEnd: 969 A: untranslated regions of the actA gene contain a consensus TATA box, a CCAAT motif, pyrimidine stretches and the polyadenylation sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 969 offsetEnd: 1107 A: contain a consensus TATA box, a CCAAT motif, pyrimidine stretches and the polyadenylation sequence AATAA. The predicted protein (375 amino
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9266998 offsetBegin: 3098 offsetEnd: 3237 A: prominent polyadenylation consensus motifs in the region of UL54. All transcripts were identified early in the infectious cycle, except for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10329424 offsetBegin: 1258 offsetEnd: 1390 A: start site at -263. Furthermore, the 2.75 and 3 kb transcripts utilize conserved polyadenylation consensus sites at +2469 and +2751,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 3824 offsetEnd: 3965 A: processing and polyadenylation of the reporter mRNA. In addition, a pre-mRNA cleavage site for polyadenylation was defined. Interaction of T.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 2535 offsetEnd: 2674 A: presence of a 463bp long 5' UTR. Furthermore, the 4.2kb transcript contains a non-standard polyadenylation consensus sequence while the 3kb
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2341 offsetEnd: 2475 A: arise from alternative polyadenylation site usage. The promoter does not contain an obvious TATA box, and the sequence surrounding the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2589 offsetEnd: 2710 A: obvious TATA box, and the sequence surrounding the start site does not conform to the consensus for an initiator promoter
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1420 offsetEnd: 1551 A: (GT..AG). Sequence analysis of the 5'- and 3'-flanking regions revealed a consensus TATA-box sequence located 28 bp upstream of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 517 offsetEnd: 634 A: (319bp) have been isolated. The target site consensus is TATAT, with a 4bp target site duplication TATA. The LTRs are
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 2623 offsetEnd: 2745 A: gene end having the shortest U tract for directing polyadenylation and a gene end sequence that differs from the consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 3520 offsetEnd: 3676 A: retaining the key cysteine residue essential for ubiquitin thioester formation and the active site consensus sequence that defines the ubiquitin-conjugating
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/8442668 offsetBegin: 2499 offsetEnd: 2656 A: prominent alteration in one of the variants was obliteration of the consensus polyadenylation signal (AATAAA-->AAAAAA). Several mutations were discernible in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 1566 offsetEnd: 1718 A: The sequence of the insertion had certain characteristics of retrotransposons: an antisense polyadenylation signal accompanied by a poly(T) sequence and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 2082 offsetEnd: 2215 A: region had a potential polyadenylation signal with the sequence ATTAAA which is a common natural variant of the conventional sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9266998 offsetBegin: 2958 offsetEnd: 3098 A: distance downstream of either of two prominent polyadenylation consensus motifs in the region of UL54. All transcripts were identified early
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 1690 offsetEnd: 1835 A: and Olf-1. A single canonical polyadenylation signal (AATAAA) was found at position +3252/+3257 and the polyadenylation site was 3274 nucleotides
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3200 offsetEnd: 3329 A: consensus sequence for the binding of U2AF eliminated enhancement of exon inclusion in vivo and exon polyadenylation in vitro. An
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 3024 offsetEnd: 3158 A: actin mRNA. Base changes in the UAAA sequence produced alterations to the polyadenylation site of the reporter mRNAs, while nucleotide
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 3158 offsetEnd: 3297 A: UAAA sequence produced alterations to the polyadenylation site of the reporter mRNAs, while nucleotide substitutions at either side of UAAA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11722011 offsetBegin: 2258 offsetEnd: 2385 A: capping site at position 82384 of the genome as well as the identification of a consensus polyadenylation signal at 84490-84495
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12588979 offsetBegin: 1966 offsetEnd: 2069 A: a TTP sequence (amino acids 60 to 62) or mutation of a consensus cyclin binding site (amino acids 99 to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9266998 offsetBegin: 2827 offsetEnd: 2958 A: found to terminate at the expected distance downstream of either of two prominent polyadenylation consensus motifs in the region of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15727844 offsetBegin: 928 offsetEnd: 1060 A: gene contain a consensus TATA box, a CCAAT motif, a large pyrimidine stretch, and the polyadenylation sequence AATAAA. The predicted
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 2883 offsetEnd: 3024 A: was polyadenylated similarly to the endogenous actin mRNA. Base changes in the UAAA sequence produced alterations to the polyadenylation site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10448076 offsetBegin: 2566 offsetEnd: 2703 A: the SP-HSP70 5' flanking region. A polyadenylation site was identified in the 3' flanking region. SP-HSP70 protein sequence resembles the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 854 offsetEnd: 988 A: RNA polymerase II which reads through the region containing early polyadenylation signals and proceeds to a poly(A) site downstream of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 988 offsetEnd: 1111 A: the region containing early polyadenylation signals and proceeds to a poly(A) site downstream of L1. In this study, we have
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 1111 offsetEnd: 1263 A: and proceeds to a poly(A) site downstream of L1. In this study, we have investigated the mechanisms regulating differentiation-dependent polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4575 offsetEnd: 4729 A: consensus hexanucleotide sequence. By using a reporter assay, it was determined that the HPV-31 early polyadenylation sequences allowed significant levels
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1690 offsetEnd: 1826 A: TATA-box sequence located 28 bp upstream of the transcription initiation site as determined by primer extension analysis, and a putative
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1826 offsetEnd: 1968 A: of the transcription initiation site as determined by primer extension analysis, and a putative polyadenylation signal observed 29 bp upstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 2247 offsetEnd: 2372 A: bp upstream of the polyadenylation site based on cDNA sequence. Genomic Southern blot analysis suggests that a single Ae gene
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 2622 offsetEnd: 2767 A: ribonuclease protection assay (RPA). A proximal and two distal mRNA cleavage sites were identified by RPA downstream of consensus polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 2767 offsetEnd: 2909 A: and two distal mRNA cleavage sites were identified by RPA downstream of consensus polyadenylation signals that create variant transcripts with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 2909 offsetEnd: 3041 A: were identified by RPA downstream of consensus polyadenylation signals that create variant transcripts with a 3' UTR ranging from 30
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 3041 offsetEnd: 3174 A: consensus polyadenylation signals that create variant transcripts with a 3' UTR ranging from 30 bases to approximately 4 Kb. Northern
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 3270 offsetEnd: 3398 A: SF2/ASF and hnRNP H, that bind specifically to SEalpha2. SEalpha2 also includes an element resembling a 5' splice site consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1320 offsetEnd: 1443 A: all of which encode an identical protein. Here we report a conserved consensus p53-binding DNA sequence in the first intron
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1443 offsetEnd: 1567 A: protein. Here we report a conserved consensus p53-binding DNA sequence in the first intron of bovine and human mimecan genes
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 1201 offsetEnd: 1315 A: differing most from the consensus sequence and used PWMS as a proxy for splicing strength. HAC1, which is known to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 3453 offsetEnd: 3599 A: pUL46 is heavily phosphorylated in at least 23 sites. One phosphorylation site matched the consensus 14-3-3 phospho-binding motif, consistent with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 3006 offsetEnd: 3159 A: G418-resistant clones demonstrated that mutation of consensus LTR polyadenylation signals generated Rth viral RNA in the infected GES-1 cells. Phenotypic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 1775 offsetEnd: 1904 A: initiation site is located 498 nucleotides upstream of the initiator codon and showed that two polyadenylation sites may be used,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 2964 offsetEnd: 3084 A: minor poly(A) site of the wild-type gene, and is preceded by a sequence AATGAATATA. Three other sites are located within
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3104 offsetEnd: 3248 A: specificity factor 1 (CPSF1) among protein-binding candidates. A consensus polyadenylation signal AAUAAA is present in intron 6 of IL7R directly
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3248 offsetEnd: 3377 A: candidates. A consensus polyadenylation signal AAUAAA is present in intron 6 of IL7R directly downstream from the 5' splice site.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12588979 offsetBegin: 2172 offsetEnd: 2300 A: consensus cyclin binding site (amino acids 99 to 104) stabilizes SLBP in G2 and mitosis. These two threonines are phosphorylated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 2962 offsetEnd: 3070 A: novel DMS-79 GR mRNA sequence is derived from intron G, between exons 7 and 8. No splice site mutations were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 3827 offsetEnd: 3972 A: two regions at the 3' untranslated end of exon 3 that include putative polyadenylation and transcriptional termination signals. Sequence analyses
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 144 offsetEnd: 304 A: RNA polymerase II (RNApII) largest subunit consists of multiple heptapeptide repeats with the consensus sequence YSPTSPS. Different CTD phosphorylation patterns
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 2737 offsetEnd: 2883 A: site contains a good match to an initiator consensus for the transcription start sites of Drosophila LTR retrotransposons. Interestingly, analysis
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 4233 offsetEnd: 4350 A: alignment of the amino acid sequence with other species showed a possible cut site between Tyr87 and Thr88 that would
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 1501 offsetEnd: 1637 A: tracts, which precede AG splice acceptor sites. However, as opposed to higher eukaryotes there is no consensus polyadenylation signal in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 1637 offsetEnd: 1776 A: sites. However, as opposed to higher eukaryotes there is no consensus polyadenylation signal in trypanosomatid mRNAs. RESULTS: We refined a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 1776 offsetEnd: 1918 A: eukaryotes there is no consensus polyadenylation signal in trypanosomatid mRNAs. RESULTS: We refined a previously reported method to target 5'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 2619 offsetEnd: 2784 A: investigated a novel approach for predicting polyadenylation (poly(A)) sites in-silico, by comparing query sequences to polyadenylated expressed sequence tags (ESTs)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 2784 offsetEnd: 2958 A: polyadenylation (poly(A)) sites in-silico, by comparing query sequences to polyadenylated expressed sequence tags (ESTs) using position-specific scanning matrices (PSSMs). An
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 261 offsetEnd: 379 A: RNA element that represses splicing and promotes polyadenylation of viral RNA. The NRS acts as a pseudo 5' splice site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 379 offsetEnd: 507 A: promotes polyadenylation of viral RNA. The NRS acts as a pseudo 5' splice site (ss), and serine-arginine (SR) proteins, U1snRNP,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 1259 offsetEnd: 1406 A: polyadenylation sequence AATAA. The predicted protein (375 amino acids) revealed high identity to gamma-actins from fungi (> 90%). Gene phylogenies
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15676283 offsetBegin: 2606 offsetEnd: 2747 A: potential NRSE/RE-1 site is located nearby. Two active polyadenylation sites identified by 3'-RACE are conserved in human, mouse, and chicken
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10929203 offsetBegin: 3142 offsetEnd: 3278 A: cDNA sequence has two CAYUG elements flanking a single polyadenylation site. The temporal and spatial expression patterns of desmin mRNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 3243 offsetEnd: 3370 A: of the induced transcripts failed to identify a consensus sequence but did reveal weak putative 3'-end formation signals in all
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 5008 offsetEnd: 5176 A: was preferentially expressed in IB4-binding neurons. Computational analyses of the 3'-UTR sequence predict that UTR-extension introduces consensus sites for RNA-binding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 3696 offsetEnd: 3845 A: than NIH3T3. According to sequence analysis of the approximately 0.8kb 5'-flanking region, GC rich segments including consensus sequences for binding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 3644 offsetEnd: 3788 A: in chromosome 19 were found. HMM consensus sequences had a conserved modular LTR structure. Target site duplications (TG-CA), TATA (occasionally
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 3928 offsetEnd: 4068 A: LTR structure. Target site duplications (TG-CA), TATA (occasionally absent), an AATAAA box and a T-rich region were prominent features. Most
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11376942 offsetBegin: 1044 offsetEnd: 1165 A: spans eight exons within a total length of 2.3 kb located on mouse chromosome 3. Consensus sites for polyadenylation were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11376942 offsetBegin: 1289 offsetEnd: 1423 A: mouse chromosome 3. Consensus sites for polyadenylation were identified 1.3 kb downstream of the gene, defining a long 3' untranslated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 3215 offsetEnd: 3382 A: putative transcription factor-binding elements. The 3' untranslated region contains consensus polyadenylation signal (AATAAA). We also isolated an intronless gene with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 1251 offsetEnd: 1378 A: consensus sequence AAUAAA was not seen at the 3'-untranslated sequence. PSG076 contained a 299 bp 5' untranslated region and an
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 4671 offsetEnd: 4801 A: Exon 3. A limited number of weak consensus polyadenylation signals in the 3' region suggest at least three different transcription
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 4801 offsetEnd: 4944 A: weak consensus polyadenylation signals in the 3' region suggest at least three different transcription terminators that apparently give rise to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 1847 offsetEnd: 1992 A: least one AATAAA polyadenylation signal. In their 5' region, the transcription initiation sites with a conserved sequence of 5'-PyATTCPu-3' known
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 2122 offsetEnd: 2234 A: sites with a conserved sequence of 5'-PyATTCPu-3' known as the CAP site were present in all genes except to H2B,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 4424 offsetEnd: 4555 A: H4 and H3 genes, matching perfectly with the consensus sequence defined for histone genes. There were several slightly more complex
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15121831 offsetBegin: 2036 offsetEnd: 2172 A: zinc cluster transcription factors, and is part of an Snf1p consensus phosphorylation site. Single mutations at this site are sufficient
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15121831 offsetBegin: 2172 offsetEnd: 2304 A: part of an Snf1p consensus phosphorylation site. Single mutations at this site are sufficient to completely change the carbon source
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 1985 offsetEnd: 2157 A: +3252/+3257 and the polyadenylation site was 3274 nucleotides downstream from ATG. Transfection experiments with chimeric luciferase constructs containing various truncated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 3169 offsetEnd: 3322 A: region from its AcMNPV counterpart (GCGCAGT), with consequent elimination of the consensus early transcription start site motif (underlined). Peak levels
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 2989 offsetEnd: 3120 A: new ratiometric tandem reporter assay. Constructs bearing just 200 base pairs on either side of the consensus poly(A) addition site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12556531 offsetBegin: 2223 offsetEnd: 2369 A: The 3'-untranslated region sequence is AU-rich and has putative consensus sequences for RNA-binding proteins. We detected a RNA-protein complex in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 3965 offsetEnd: 4098 A: mRNA. In addition, a pre-mRNA cleavage site for polyadenylation was defined. Interaction of T. vaginalis proteins with the UAAA motif
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11931652 offsetBegin: 1011 offsetEnd: 1177 A: MMP-26 promoter has distinctive structural and functional features among MMP genes. An unusual polyadenylation site proximal to the transcription-factor-binding sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 3112 offsetEnd: 3269 A: consensus sequence but within the open reading frame. Following in vitro transfection of a DFCP1-containing expression construct, confocal microscopy studies
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 858 offsetEnd: 991 A: chromosomes. An initial analysis of SIRE sequences from 21 genomic fragments allowed us to derive a consensus nucleotide sequence and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 991 offsetEnd: 1124 A: sequences from 21 genomic fragments allowed us to derive a consensus nucleotide sequence and structure for the element, consisting of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 3471 offsetEnd: 3614 A: Nramp2 gene produces several mRNAs, including prominent 3.3- and 2.3-kb species generated by the use of alternative polyadenylation signals. In
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 1980 offsetEnd: 2108 A: sites in Schizosaccharomyces pombe. At one of the most prominent DSB sites, mbs1 (meiotic break site 1), the chromatin structure
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 2108 offsetEnd: 2242 A: of the most prominent DSB sites, mbs1 (meiotic break site 1), the chromatin structure has a constitutively accessible configuration at
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 3351 offsetEnd: 3475 A: differences from and similarities to mbs1. For example, the tdh1+ locus, which harbors a CRE consensus sequence near the DSB
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 3595 offsetEnd: 3728 A: harbors a CRE consensus sequence near the DSB site, shows a meiotically induced open chromatin configuration, similar to ade6-M26. In
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 6392 offsetEnd: 6539 A: binding site for CstF into the early polyadenylation region significantly reduced the level of read-through, suggesting that these factors modulate
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 3029 offsetEnd: 3157 A: 796/797 relative to the translation start site. Type 1b is encoded by a single exon. A putative polyadenylation signal consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 3157 offsetEnd: 3283 A: site. Type 1b is encoded by a single exon. A putative polyadenylation signal consensus motif was identified at position +4118;
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 3283 offsetEnd: 3414 A: a single exon. A putative polyadenylation signal consensus motif was identified at position +4118; 2.7 kb of the 5'-flanking region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2216 offsetEnd: 2341 A: forms of MAGP-2 in the mouse arise from alternative polyadenylation site usage. The promoter does not contain an obvious TATA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 3910 offsetEnd: 4038 A: in a 40% reduction of PTH-stimulated luciferase activity. When three tandem repeats of the AP-2 consensus sequence were fused to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 4169 offsetEnd: 4304 A: of the AP-2 consensus sequence were fused to a luciferase reporter, PTH stimulated a 25% increase in reporter activity. Electrophoretic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 435 offsetEnd: 595 A: and TRalpha2, with antagonistic functions. Alternative processing of these mRNAs involves the mutually exclusive use of a TRalpha1-specific polyadenylation site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 898 offsetEnd: 1043 A: polyadenylation site or TRalpha2-specific 5' splice site. A previous investigation of TRalpha minigene expression defined a critical role for the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 3813 offsetEnd: 3953 A: for splicing enhancer activity. Mutations within this pseudo-5' splice site sequence have a dramatic effect on splicing and protein binding.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 3953 offsetEnd: 4081 A: this pseudo-5' splice site sequence have a dramatic effect on splicing and protein binding. Thus SEa2 and its associated factors
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1567 offsetEnd: 1689 A: consensus p53-binding DNA sequence in the first intron of bovine and human mimecan genes and show that wild-type p53 binds
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 670 offsetEnd: 792 A: cell nuclear extract yielded a sequence motif that evolved from UAA after one round of splicing toward a UACUAAC consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 2689 offsetEnd: 2846 A: polyadenylation motif, was found to be required only for polyadenylation. In an independent experiment, sequences surrounding an optimal branchpoint sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 272 offsetEnd: 404 A: scalaris. Three full-length copies (4226, 4160 and 4129bp) and a truncated one (319bp) have been isolated. The target site consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 1641 offsetEnd: 1803 A: codons and deletions/insertions at non-homologous positions. The consensus sequence among the three full-length copies, however, has an uninterrupted open reading
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 2857 offsetEnd: 2989 A: contains two E-boxes providing a consensus sequence for binding of the transcription factor and oncoprotein c-Myc to the EBV genome.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 3599 offsetEnd: 3749 A: least 23 sites. One phosphorylation site matched the consensus 14-3-3 phospho-binding motif, consistent with our identification of 14-3-3 proteins and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 2854 offsetEnd: 3006 A: RNA from infected pools and individual G418-resistant clones demonstrated that mutation of consensus LTR polyadenylation signals generated Rth viral RNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18630746 offsetBegin: 1997 offsetEnd: 2141 A: consensus sequences are the most prominent characteristics of plant introns. Detailed surveys of site-directed mutant introns tested in vivo and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18630746 offsetBegin: 2570 offsetEnd: 2715 A: mutant introns analyzed in planta emphasize the effects of changing individual nucleotides in these splice site consensus sequences and highlight
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18630746 offsetBegin: 2715 offsetEnd: 2860 A: the effects of changing individual nucleotides in these splice site consensus sequences and highlight a number of noncanonical dinucleotides that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 2260 offsetEnd: 2387 A: is the most downstream. Sequence analysis of the promoter region showed no TATA box but identified consensus binding motifs for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 1881 offsetEnd: 2033 A: alternative polyadenylation cleavage sites downstream of a single polyadenylation signal in vivo. By screening more than 300 000 sequences corresponding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 3919 offsetEnd: 4045 A: silico data show that the selection of the specific cleavage site for poly(A) addition using a given polyadenylation signal is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12588979 offsetBegin: 2069 offsetEnd: 2172 A: to 62) or mutation of a consensus cyclin binding site (amino acids 99 to 104) stabilizes SLBP in G2 and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 3972 offsetEnd: 4119 A: end of exon 3 that include putative polyadenylation and transcriptional termination signals. Sequence analyses of the 5' proximal promoter revealed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9614270 offsetBegin: 2763 offsetEnd: 2888 A: from RNA or genomic sequences. A cleavage stimulating factor (CstF) binding element 3 of the polyadenylation site in the mRNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9614270 offsetBegin: 2888 offsetEnd: 3016 A: cleavage stimulating factor (CstF) binding element 3 of the polyadenylation site in the mRNA precursor serves as a test example.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 304 offsetEnd: 454 A: consists of multiple heptapeptide repeats with the consensus sequence YSPTSPS. Different CTD phosphorylation patterns act as recognition sites for the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 454 offsetEnd: 601 A: the consensus sequence YSPTSPS. Different CTD phosphorylation patterns act as recognition sites for the binding of various messenger RNA processing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3996 offsetEnd: 4121 A: interleukin-converting enzyme (ICE) cut site is found in sbIL-1 beta, but the alignment of the amino acid sequence with other
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 4121 offsetEnd: 4233 A: found in sbIL-1 beta, but the alignment of the amino acid sequence with other species showed a possible cut site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 4807 offsetEnd: 4950 A: lack consensus TATA and CCAAT boxes, but was found to contain several putative cis-acting regulatory elements. These included consensus binding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 503 offsetEnd: 658 A: involved in facilitating communication between polyadenylation and splicing are largely unknown. Even less is known about the regulation of polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 2960 offsetEnd: 3096 A: consensus sequence elements. In cell types that preferentially exclude exon 4, addition of wild-type SRp20 enhances exon 4 inclusion via
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 4103 offsetEnd: 4251 A: precision and to increase polyadenylation site prediction from 22% to 47% within 100 nucleotides. CONCLUSION: We propose a simplified trans-splicing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 1862 offsetEnd: 1975 A: -305 and -589. The proximal 1.5 kb region does not possess consensus TATA or CAAT boxes but has several consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 1975 offsetEnd: 2105 A: kb region does not possess consensus TATA or CAAT boxes but has several consensus sequences for regulatory elements including USF,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 1107 offsetEnd: 1259 A: CCAAT motif, pyrimidine stretches and the polyadenylation sequence AATAA. The predicted protein (375 amino acids) revealed high identity to gamma-actins
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15676283 offsetBegin: 2343 offsetEnd: 2477 A: 4.8-kb promoter contains eight consensus Sp1-binding sites and two Inr sites. A potential NRSE/RE-1 site is located nearby. Two active
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15676283 offsetBegin: 2747 offsetEnd: 2884 A: Two active polyadenylation sites identified by 3'-RACE are conserved in human, mouse, and chicken SCN8A. Sequence comparison of human and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9740674 offsetBegin: 1788 offsetEnd: 1906 A: unique start site located 70 bp upstream of the ATG initiation codon that conforms to the consensus Inr motif. Several
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 2672 offsetEnd: 2780 A: of proteins (family 20). The expected active site consensus motif G X D E and catalytic Asp and Glu residues
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23308270 offsetBegin: 1665 offsetEnd: 1808 A: promoter sequence revealed multiple Gfi1/1b consensus binding motifs. Distinct regions of the promoter were occupied by Gfi1b and its cofactors
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 3504 offsetEnd: 3638 A: reveal weak putative 3'-end formation signals in all of the transcripts. Similarly, no consensus sequence was found when the sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 5176 offsetEnd: 5338 A: Computational analyses of the 3'-UTR sequence predict that UTR-extension introduces consensus sites for RNA-binding proteins (RBPs) including the embryonic lethal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 3788 offsetEnd: 3928 A: consensus sequences had a conserved modular LTR structure. Target site duplications (TG-CA), TATA (occasionally absent), an AATAAA box and a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 1407 offsetEnd: 1568 A: any previously characterized polyadenylation site. CTH2 mRNA accumulation was not inhibited by mutations in 3'-cleavage and polyadenylation factors, Rna14, Rna15
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1740 offsetEnd: 1851 A: nuclear localized during viral infection. We mapped the 5' end of the 5-kb RNA to a consensus splice donor site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 2974 offsetEnd: 3111 A: sequence databases. Cloning and analysis of the putative PART-1 promoter region identified a potential binding site for the homeobox gene
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 3111 offsetEnd: 3247 A: the putative PART-1 promoter region identified a potential binding site for the homeobox gene PBX-la, but no consensus androgen response
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23077630 offsetBegin: 4355 offsetEnd: 4473 A: has to be verified for the 3'-end formation of some mt transcripts, and its consensus sequence has been here carefully
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23077630 offsetBegin: 4473 offsetEnd: 4603 A: 3'-end formation of some mt transcripts, and its consensus sequence has been here carefully characterized in ticks. Indeed, in the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9266998 offsetBegin: 2678 offsetEnd: 2827 A: initiation sites were identified. Transcription was found to terminate at the expected distance downstream of either of two prominent polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20553951 offsetBegin: 2972 offsetEnd: 3133 A: into at least two distinct stem-loop conformations. These alternate structures expose/sequester a consensus binding site for hnRNP-I/PTB-1, a trans-acting factor
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20553951 offsetBegin: 3133 offsetEnd: 3329 A: conformations. These alternate structures expose/sequester a consensus binding site for hnRNP-I/PTB-1, a trans-acting factor with post-transcriptional regulatory properties. hnRNP-I/PTB-1 exhibits
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20553951 offsetBegin: 3329 offsetEnd: 3509 A: consensus binding site for hnRNP-I/PTB-1, a trans-acting factor with post-transcriptional regulatory properties. hnRNP-I/PTB-1 exhibits different affinities for the alternate 3'UTR
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10329424 offsetBegin: 1104 offsetEnd: 1258 A: consistent with the previously identified transcriptional start site at -263. Furthermore, the 2.75 and 3 kb transcripts utilize conserved polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10329424 offsetBegin: 1390 offsetEnd: 1523 A: 2.75 and 3 kb transcripts utilize conserved polyadenylation consensus sites at +2469 and +2751, respectively. Thus, this is the first
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 3057 offsetEnd: 3215 A: CCAAT box as well as various putative transcription factor-binding elements. The 3' untranslated region contains consensus polyadenylation signal (AATAAA). We
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 3536 offsetEnd: 3673 A: (AATAAA). We also isolated an intronless gene with 93% nucleotide sequence similarity to the rabbit PIN cDNA. Sequence analysis indicates
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 1992 offsetEnd: 2122 A: their 5' region, the transcription initiation sites with a conserved sequence of 5'-PyATTCPu-3' known as the CAP site were present
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 4282 offsetEnd: 4424 A: sequences (5'-TGATATATG-3') was identified from the H4 and H3 genes, matching perfectly with the consensus sequence defined for histone genes.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 4555 offsetEnd: 4691 A: with the consensus sequence defined for histone genes. There were several slightly more complex repetitive DNA in the intergene regions.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12533698 offsetBegin: 2168 offsetEnd: 2296 A: upstream non-consensus exonic donor. Target 1 RNAs carry the UL37x1 polyadenylation (PA) signal and site as well as a downstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 1835 offsetEnd: 1985 A: signal (AATAAA) was found at position +3252/+3257 and the polyadenylation site was 3274 nucleotides downstream from ATG. Transfection experiments with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10448076 offsetBegin: 2315 offsetEnd: 2438 A: boxes as well as 11 putative heat shock elements were identified in the SP-HSP70 5' flanking region. A polyadenylation site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 1665 offsetEnd: 1769 A: tract and CAG directly abutting on a 5' splice site sequence to form a pseudoexon. Here we show that the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3595 offsetEnd: 3719 A: vitro. An additional PTB binding site was identified close to the AAUAAA hexanucleotide sequence of the exon 4 poly(A) site.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 3015 offsetEnd: 3169 A: sequence that differed in the corresponding region from its AcMNPV counterpart (GCGCAGT), with consequent elimination of the consensus early transcription
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 3322 offsetEnd: 3467 A: with consequent elimination of the consensus early transcription start site motif (underlined). Peak levels of lef-8 transcripts were attained by
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 2781 offsetEnd: 2919 A: sequence in the distal portion that was necessary for transcriptional activation by RA. Within this sequence DNase I footprinting revealed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 4877 offsetEnd: 5015 A: of the Pira6 transcription start sites that reside within the initiator consensus sequence motif. These results provide important clues to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 5015 offsetEnd: 5159 A: that reside within the initiator consensus sequence motif. These results provide important clues to the coordinate regulation observed for PIR-A
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 3120 offsetEnd: 3241 A: bearing just 200 base pairs on either side of the consensus poly(A) addition site terminated 98% and 86% of transcription
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15727844 offsetBegin: 1197 offsetEnd: 1344 A: stretch, and the polyadenylation sequence AATAAA. The predicted protein (375 amino acids) revealed high identity to gamma-actins from fungi (>90%),
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12556531 offsetBegin: 1793 offsetEnd: 1949 A: mRNA 3'-untranslated region. Interestingly, trophozoites grown with 225 microM emetine exhibited an extra polyadenylation site at 19 nt. The 3'-untranslated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 626 offsetEnd: 742 A: upstream of the cleavage site containing a motif with consensus AAUAAA, followed by a U or UG rich region downstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 550 offsetEnd: 700 A: complex recognizes a polyadenylation signal, generally the hexanucleotide AAUAAA in metazoans, to direct processing of the pre-mRNA. Based on sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 4098 offsetEnd: 4236 A: site for polyadenylation was defined. Interaction of T. vaginalis proteins with the UAAA motif was shown by electrophoretic mobility shift
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 1439 offsetEnd: 1543 A: gene of 6384 nt, and a trailer region of 70 nt. There was TGAAAAAAA (TGA7) consensus sequence in the end
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 1992 offsetEnd: 2111 A: had a GAGAAAAAAA sequence in the end of the non-coding G-L region. There were AACAYYYCT consensus start signal close to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11931652 offsetBegin: 1177 offsetEnd: 1338 A: functional features among MMP genes. An unusual polyadenylation site proximal to the transcription-factor-binding sites protects transcription of the MMP-26 gene
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 253 offsetEnd: 385 A: contains: (1) an N-terminal Cys-His cluster with some homology to many zinc finger domains; (2) a consensus sequence consistent with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 385 offsetEnd: 506 A: with some homology to many zinc finger domains; (2) a consensus sequence consistent with an ATP/GTP binding site; and (3)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 506 offsetEnd: 633 A: finger domains; (2) a consensus sequence consistent with an ATP/GTP binding site; and (3) a C-terminal domain unique because it
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 1124 offsetEnd: 1244 A: us to derive a consensus nucleotide sequence and structure for the element, consisting of three regions (I, II, and III)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 3614 offsetEnd: 3768 A: prominent 3.3- and 2.3-kb species generated by the use of alternative polyadenylation signals. In contrast to the previously described macrophage-specific
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 3475 offsetEnd: 3595 A: For example, the tdh1+ locus, which harbors a CRE consensus sequence near the DSB site, shows a meiotically induced open
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 1590 offsetEnd: 1757 A: differentiation-dependent polyadenylation and read-through in HPV-31. HPV-31 early transcripts were found to utilize a heterogeneous series of polyadenylation sites in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 1757 offsetEnd: 1908 A: HPV-31 early transcripts were found to utilize a heterogeneous series of polyadenylation sites in undifferentiated cells. The sites for polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 2821 offsetEnd: 2964 A: the heterogeneous distribution of 3' ends was detected. The early polyadenylation region was found to contain a single consensus hexanucleotide
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 2964 offsetEnd: 3100 A: was detected. The early polyadenylation region was found to contain a single consensus hexanucleotide sequence, AAUAAA, as well as three
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4071 offsetEnd: 4200 A: downstream of the late AAUAAA element. The late polyadenylation signal was found to contain a single high-affinity site for CstF,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4330 offsetEnd: 4455 A: to contain a single high-affinity site for CstF, as well as one consensus hexanucleotide sequence. By using a reporter assay,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/6312290 offsetBegin: 1427 offsetEnd: 1544 A: contain a prominent 5' end at the normal position (nucleotide 325) in addition to several other prominent 5' ends not
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9837805 offsetBegin: 3806 offsetEnd: 3940 A: long, and the protein VII lacks the consensus protease cleavage site. Genomic and cDNA sequence analysis has identified promoters, cap
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 4038 offsetEnd: 4169 A: luciferase activity. When three tandem repeats of the AP-2 consensus sequence were fused to a luciferase reporter, PTH stimulated a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 2365 offsetEnd: 2493 A: to be high affinity, by comparison to a functionally derived consensus BvgA-binding sequence. The other binding site is a fairly
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 2493 offsetEnd: 2621 A: to a functionally derived consensus BvgA-binding sequence. The other binding site is a fairly poor match to this consensus, with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 595 offsetEnd: 739 A: processing of these mRNAs involves the mutually exclusive use of a TRalpha1-specific polyadenylation site or TRalpha2-specific 5' splice site. A
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 739 offsetEnd: 898 A: mutually exclusive use of a TRalpha1-specific polyadenylation site or TRalpha2-specific 5' splice site. A previous investigation of TRalpha minigene expression
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 2821 offsetEnd: 2943 A: bind strongly to spliceosomes than those that bind weakly. The 3' splice site features a prominent poly-U tract before the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 3064 offsetEnd: 3182 A: site features a prominent poly-U tract before the 3'AG. Our results suggest the potential of using PWMS as a screening
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 1297 offsetEnd: 1470 A: different degrees and presumably inactive. The polyprotein coding sequence contains scattered stop codons and deletions/insertions at non-homologous positions. The consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 3075 offsetEnd: 3214 A: coding region, the target site specificity for AT-rich sequences, and the protein sequence similarity to blastopia, mdg3 and micropia place
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 2728 offsetEnd: 2857 A: pairs upstream of the EBER1 gene, contains two E-boxes providing a consensus sequence for binding of the transcription factor and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 881 offsetEnd: 1058 A: related gene research. METHODS: The polyadenylation signal-deficient retrovirus vector mutated by PCR site-directed mutagenesis was used to make polyadenylation signal-deficient
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 3159 offsetEnd: 3299 A: consensus LTR polyadenylation signals generated Rth viral RNA in the infected GES-1 cells. Phenotypic analysis results showed that the GES-1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 2029 offsetEnd: 2185 A: a binding site for a trans-acting repressor. The sequences that direct repression overlap and include cytoplasmic polyadenylation elements (CPEs), sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18630746 offsetBegin: 1851 offsetEnd: 1997 A: and 3' splice sites and branchpoint consensus sequences are the most prominent characteristics of plant introns. Detailed surveys of site-directed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 2876 offsetEnd: 3017 A: gene end sequence that differs from the consensus sequence. We have tested the hypothesis that elevated M-F readthrough transcription results
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 2849 offsetEnd: 2964 A: these sites is identical to the minor poly(A) site of the wild-type gene, and is preceded by a sequence AATGAATATA.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11722011 offsetBegin: 2511 offsetEnd: 2649 A: identification of a consensus polyadenylation signal at 84490-84495 allowed us to establish that the 2.2 kb transcript corresponds to that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 1736 offsetEnd: 1881 A: transcripts and reflect the use of alternative polyadenylation cleavage sites downstream of a single polyadenylation signal in vivo. By screening
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 3792 offsetEnd: 3919 A: site selection. Both experimental and in silico data show that the selection of the specific cleavage site for poly(A) addition
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10699189 offsetBegin: 394 offsetEnd: 547 A: locations. Occasionally, the 3' end processing machinery may bypass the L1 polyadenylation signal and instead utilize a second downstream polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10699189 offsetBegin: 547 offsetEnd: 689 A: machinery may bypass the L1 polyadenylation signal and instead utilize a second downstream polyadenylation site. To determine the frequency of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 1276 offsetEnd: 1388 A: cell GR the sequence normally derived from exons 8 and 9 is replaced by sequence unmatched in the DNA databases.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/8442668 offsetBegin: 2656 offsetEnd: 2812 A: variants was obliteration of the consensus polyadenylation signal (AATAAA-->AAAAAA). Several mutations were discernible in all regions of the second variant
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 2370 offsetEnd: 2501 A: TART 5'-untranslated region (5'-UTR), rather than at the start of the 5'-UTR. A sequence overlapping this sense start site contains
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 3822 offsetEnd: 3963 A: These methods were able to simplify splice junction prediction without loss of precision and to increase polyadenylation site prediction from
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 3963 offsetEnd: 4103 A: splice junction prediction without loss of precision and to increase polyadenylation site prediction from 22% to 47% within 100 nucleotides.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 3573 offsetEnd: 3706 A: NRS. The NRS harbors a branch point-like/pyrimidine tract sequence (BP/Py) just upstream of the U1/U11 site that is characteristic of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 5286 offsetEnd: 5403 A: involves at least two elements in addition to the U11 consensus sequence and may have implications for U11 binding to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15676283 offsetBegin: 2477 offsetEnd: 2606 A: sites and two Inr sites. A potential NRSE/RE-1 site is located nearby. Two active polyadenylation sites identified by 3'-RACE are
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 1201 offsetEnd: 1328 A: peptide. The protein as a whole shares considerable sequence similarity with 'classic' NAG. The primary sequence of Pb NAG1 was
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 1328 offsetEnd: 1469 A: shares considerable sequence similarity with 'classic' NAG. The primary sequence of Pb NAG1 was used to infer phylogenetic relationships. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 2559 offsetEnd: 2672 A: regions of the glycosyl hydrolase group of proteins (family 20). The expected active site consensus motif G X D E
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 3353 offsetEnd: 3472 A: 20. The nucleotide sequence of Pb nag1 and its flanking regions have been deposited, along with the amino acid sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23308270 offsetBegin: 1260 offsetEnd: 1386 A: meis1, which encodes a homeobox protein, as a direct and prominent target of Gfi1b. Examination of the meis1 promoter sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 1413 offsetEnd: 1566 A: mRNA, creating a premature stop codon. The sequence of the insertion had certain characteristics of retrotransposons: an antisense polyadenylation signal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 2327 offsetEnd: 2490 A: recognition sequence for the L1 endonuclease, indicating a retrotransposon-mediated event, although the inserted sequence did not match any known retrotransposons.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10072078 offsetBegin: 1439 offsetEnd: 1567 A: the proximal polyA site seems to contribute to its neglect in naive T cells. These alternative polyadenylation events ensure the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 1964 offsetEnd: 2082 A: 109 to 190bp. The 3' flanking region had a potential polyadenylation signal with the sequence ATTAAA which is a common
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 3247 offsetEnd: 3387 A: a potential binding site for the homeobox gene PBX-la, but no consensus androgen response element or sterol-regulatory element binding sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11376942 offsetBegin: 1165 offsetEnd: 1289 A: length of 2.3 kb located on mouse chromosome 3. Consensus sites for polyadenylation were identified 1.3 kb downstream of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 3142 offsetEnd: 3266 A: site sequences in accordance with the "GU-AG" consensus rule. The deduced SmF3H protein is 343 amino acid residues in length
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23077630 offsetBegin: 4603 offsetEnd: 4722 A: and its consensus sequence has been here carefully characterized in ticks. Indeed, in the whole mtDNA of all ticks, the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10329424 offsetBegin: 1523 offsetEnd: 1666 A: conserved polyadenylation consensus sites at +2469 and +2751, respectively. Thus, this is the first report of the identification of full-length
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 3673 offsetEnd: 3801 A: gene with 93% nucleotide sequence similarity to the rabbit PIN cDNA. Sequence analysis indicates that the open reading frame was
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 4566 offsetEnd: 4671 A: C close to the end of Exon 3. A limited number of weak consensus polyadenylation signals in the 3' region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12533698 offsetBegin: 2296 offsetEnd: 2409 A: RNAs carry the UL37x1 polyadenylation (PA) signal and site as well as a downstream SV40 early PA signal. Both the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3074 offsetEnd: 3200 A: the enhancer pyrimidine tract to a consensus sequence for the binding of U2AF eliminated enhancement of exon inclusion in vivo
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3329 offsetEnd: 3463 A: U2AF eliminated enhancement of exon inclusion in vivo and exon polyadenylation in vitro. An additional PTB binding site was identified
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 1870 offsetEnd: 1980 A: 3' end of the transcript was mapped to a site 17 nt downstream of a canonical polyadenylation signal located 7
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 4722 offsetEnd: 4877 A: ubiquitous transcription factors were identified upstream of the Pira6 transcription start sites that reside within the initiator consensus sequence motif.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 3241 offsetEnd: 3373 A: either side of the consensus poly(A) addition site terminated 98% and 86% of transcription for ACTB and HBB sequences, respectively.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15727844 offsetBegin: 1060 offsetEnd: 1197 A: a CCAAT motif, a large pyrimidine stretch, and the polyadenylation sequence AATAAA. The predicted protein (375 amino acids) revealed high
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 1543 offsetEnd: 1660 A: trailer region of 70 nt. There was TGAAAAAAA (TGA7) consensus sequence in the end of each gene in Flury-LEP-C genome,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 1660 offsetEnd: 1772 A: was TGAAAAAAA (TGA7) consensus sequence in the end of each gene in Flury-LEP-C genome, except G gene which had a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11931652 offsetBegin: 1913 offsetEnd: 2049 A: stringent transcriptional regulation of the gene. The MMP-26 gene has a consensus TATA-box and one transcriptional start site located 60
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11931652 offsetBegin: 2049 offsetEnd: 2170 A: The MMP-26 gene has a consensus TATA-box and one transcriptional start site located 60 and 35 nucleotides upstream of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024279 offsetBegin: 2983 offsetEnd: 3112 A: the 3kb transcript contains a standard consensus sequence but within the open reading frame. Following in vitro transfection of a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2090 offsetEnd: 2216 A: clones suggests that the two mRNA forms of MAGP-2 in the mouse arise from alternative polyadenylation site usage. The promoter
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 725 offsetEnd: 843 A: 3' splice sites (ss) by position weight matrix scores (PWMSs), which is the highest for the consensus sequence and the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 1089 offsetEnd: 1201 A: and the lowest for splice sites differing most from the consensus sequence and used PWMS as a proxy for splicing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 2943 offsetEnd: 3064 A: that bind weakly. The 3' splice site features a prominent poly-U tract before the 3'AG. Our results suggest the potential
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 1304 offsetEnd: 1422 A: contained a conserved AAUAAAG motif that proved to be functional both as a polyadenylation signal and a branch site in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 1422 offsetEnd: 1545 A: proved to be functional both as a polyadenylation signal and a branch site in a competitive manner. Characterization of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 404 offsetEnd: 517 A: and 4129bp) and a truncated one (319bp) have been isolated. The target site consensus is TATAT, with a 4bp target
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 749 offsetEnd: 875 A: 4bp target site duplication TATA. The LTRs are short (142bp) and contain a TATA-box and a polyadenylation signal. The isolated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 1803 offsetEnd: 1951 A: The consensus sequence among the three full-length copies, however, has an uninterrupted open reading frame and, presumably, represents the original
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 2938 offsetEnd: 3075 A: order of domains in the polyprotein coding region, the target site specificity for AT-rich sequences, and the protein sequence similarity
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18630746 offsetBegin: 1723 offsetEnd: 1851 A: and high variation in their 5' and 3' splice sites and branchpoint consensus sequences are the most prominent characteristics of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12588979 offsetBegin: 1860 offsetEnd: 1966 A: phase. Mutation of any residues in a TTP sequence (amino acids 60 to 62) or mutation of a consensus cyclin
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 4119 offsetEnd: 4284 A: putative polyadenylation and transcriptional termination signals. Sequence analyses of the 5' proximal promoter revealed the presence of several putative homeodomain
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9614270 offsetBegin: 3016 offsetEnd: 3139 A: 3 of the polyadenylation site in the mRNA precursor serves as a test example. Alternatively, the regulatory RNA element may
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 2501 offsetEnd: 2611 A: at the start of the 5'-UTR. A sequence overlapping this sense start site contains a good match to an initiator
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 1983 offsetEnd: 2141 A: polyadenylation. Results evidenced the presence of an AU-rich domain corresponding to the consensus UA(A/U)UU polyadenylation signal or variants, the cleavage
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 1732 offsetEnd: 1886 A: polyadenylation factor to an alternative polyadenylation site. The gene under study codes for the peptides calcitonin and calcitonin gene-related peptide.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 3706 offsetEnd: 3843 A: point-like/pyrimidine tract sequence (BP/Py) just upstream of the U1/U11 site that is characteristic of 3' splice sites. Deletion of this
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 5174 offsetEnd: 5286 A: U11 binding to the isolated NRS involves at least two elements in addition to the U11 consensus sequence and may
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 702 offsetEnd: 833 A: with fungal consensus splice-site junctions. The untranslated regions of the actA gene contain a consensus TATA box, a CCAAT motif,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 2780 offsetEnd: 2880 A: active site consensus motif G X D E and catalytic Asp and Glu residues at positions 373 and 374 were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10929203 offsetBegin: 3021 offsetEnd: 3142 A: the 3' UTR of the zebrafish cDNA sequence has two CAYUG elements flanking a single polyadenylation site. The temporal and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15681073 offsetBegin: 2978 offsetEnd: 3102 A: at a late consensus motif internal to pif coding sequences, ending at the same polyadenylation signal as the pif transcript.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 2643 offsetEnd: 2771 A: inserted sequence did not match any known retrotransposons. The origin of the inserted sequence was mapped to a gene-poor region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 3765 offsetEnd: 3896 A: no consensus sequence was found when the sequences surrounding the 3'-ends of the longest transcripts were compared, but again weak
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1945 offsetEnd: 2048 A: 5-kb RNA to a consensus splice donor site and localized the 3' end in the vicinity of a splice acceptor
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16778175 offsetBegin: 1885 offsetEnd: 2011 A: binding site for p53 to activate the MKP2 gene. This GC-rich palindrome is completely different from the consensus p53 binding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 3235 offsetEnd: 3362 A: long first exon encoding most of the protein. The splice site boundaries closely match consensus sequences and the exons appear
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 3495 offsetEnd: 3646 A: element, in the promoter of H2B, there was another sequence, 5'-GGATCGAAACGTTC-3', which was similar to the consensus sequence of 5'-GGAATAAACGTATTC-3'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 3646 offsetEnd: 3816 A: there was another sequence, 5'-GGATCGAAACGTTC-3', which was similar to the consensus sequence of 5'-GGAATAAACGTATTC-3' corresponding to the H2B-specific promoter element.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 1557 offsetEnd: 1665 A: The enhancer consists of a pyrimidine tract and CAG directly abutting on a 5' splice site sequence to form a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 1769 offsetEnd: 1869 A: a 5' splice site sequence to form a pseudoexon. Here we show that the binding of PTB to the enhancer
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 1259 offsetEnd: 1378 A: Transcription of lef-9 initiated at two independent sites: from a GCACT sequence located at -38 nt and a CTCTT sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 5176 offsetEnd: 5294 A: transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15727844 offsetBegin: 678 offsetEnd: 810 A: introns with fungal consensus splice-site junctions. The untranslated regions of the actA gene contain a consensus TATA box, a CCAAT
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 507 offsetEnd: 626 A: characterized as an A rich region upstream of the cleavage site containing a motif with consensus AAUAAA, followed by a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11931652 offsetBegin: 1338 offsetEnd: 1502 A: unusual polyadenylation site proximal to the transcription-factor-binding sites protects transcription of the MMP-26 gene from the upstream promoters and represents
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 3797 offsetEnd: 3931 A: with a direct CAR effect on Mcl-1 transcription. Indeed, site-directed mutagenesis of a putative CAR consensus binding sequence on the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 1908 offsetEnd: 2049 A: utilize a heterogeneous series of polyadenylation sites in undifferentiated cells. The sites for polyadenylation extended over a range of 100
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2710 offsetEnd: 2847 A: surrounding the start site does not conform to the consensus for an initiator promoter element. Additionally, the mouse promoter contains
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 843 offsetEnd: 967 A: weight matrix scores (PWMSs), which is the highest for the consensus sequence and the lowest for splice sites differing most
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 1545 offsetEnd: 1674 A: a polyadenylation signal and a branch site in a competitive manner. Characterization of the branchpoint in these clones to either
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 2021 offsetEnd: 2144 A: showed that two polyadenylation sites may be used, while the most frequent is the most downstream. Sequence analysis of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12446815 offsetBegin: 4546 offsetEnd: 4681 A: and the polyadenylation signals but lacked the consensus histone downstream element that is involved in the processing of histone mRNAs
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11722011 offsetBegin: 2385 offsetEnd: 2511 A: the genome as well as the identification of a consensus polyadenylation signal at 84490-84495 allowed us to establish that the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 2435 offsetEnd: 2551 A: the cleavage and polyadenylation site that is generally denoted by U residue and flanked by two U-rich tracts, and a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 1473 offsetEnd: 1604 A: 3'-terminal exon via an effect on the efficiency of binding of a polyadenylation factor to an alternative polyadenylation site. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 3116 offsetEnd: 3243 A: of the sequences surrounding the 3'-ends of the induced transcripts failed to identify a consensus sequence but did reveal weak
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1851 offsetEnd: 1945 A: mapped the 5' end of the 5-kb RNA to a consensus splice donor site and localized the 3' end in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 2875 offsetEnd: 3009 A: and three introns within the coding region, with all the splice donor/acceptor site sequences in accordance with the "GU-AG" consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 3009 offsetEnd: 3142 A: region, with all the splice donor/acceptor site sequences in accordance with the "GU-AG" consensus rule. The deduced SmF3H protein is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10448076 offsetBegin: 2438 offsetEnd: 2566 A: heat shock elements were identified in the SP-HSP70 5' flanking region. A polyadenylation site was identified in the 3' flanking
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 1378 offsetEnd: 1489 A: independent sites: from a GCACT sequence located at -38 nt and a CTCTT sequence located at -50 nt, with respect
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 3297 offsetEnd: 3434 A: polyadenylation site of the reporter mRNAs, while nucleotide substitutions at either side of UAAA did not. Furthermore, relocation of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 3697 offsetEnd: 3824 A: of the UAAA motif redirected the processing and polyadenylation of the reporter mRNA. In addition, a pre-mRNA cleavage site for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 3931 offsetEnd: 4087 A: Mcl-1 transcription. Indeed, site-directed mutagenesis of a putative CAR consensus binding sequence on the Mcl-1 promoter decreased Mcl-1 promoter activity.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 4087 offsetEnd: 4233 A: a putative CAR consensus binding sequence on the Mcl-1 promoter decreased Mcl-1 promoter activity. Mcl-1 transgenic animals demonstrated little to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 2129 offsetEnd: 2254 A: 3' end of several mRNAs, always transcribed from the sense strand, contributing the polyadenylation site in 63% of the cases.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 2386 offsetEnd: 2518 A: the polyadenylation site in 63% of the cases. This study led to the characterization of VIPER (vestigial interposed retroelement), a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2475 offsetEnd: 2589 A: The promoter does not contain an obvious TATA box, and the sequence surrounding the start site does not conform to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 2735 offsetEnd: 2849 A: poly(A) sites. The most prominent of these sites is identical to the minor poly(A) site of the wild-type gene, and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 1604 offsetEnd: 1732 A: the efficiency of binding of a polyadenylation factor to an alternative polyadenylation site. The gene under study codes for the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 1469 offsetEnd: 1586 A: NAG. The primary sequence of Pb NAG1 was used to infer phylogenetic relationships. The amino acid sequence of Pb NAG1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23308270 offsetBegin: 1523 offsetEnd: 1665 A: of Gfi1b. Examination of the meis1 promoter sequence revealed multiple Gfi1/1b consensus binding motifs. Distinct regions of the promoter were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 2490 offsetEnd: 2643 A: indicating a retrotransposon-mediated event, although the inserted sequence did not match any known retrotransposons. The origin of the inserted sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 2215 offsetEnd: 2337 A: with the sequence ATTAAA which is a common natural variant of the conventional sequence AATAAA. The gene was AT-rich, with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 3816 offsetEnd: 3983 A: was similar to the consensus sequence of 5'-GGAATAAACGTATTC-3' corresponding to the H2B-specific promoter element. The presence of enhancer sequences (5'-TGATATATG-3')
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 2935 offsetEnd: 3074 A: to the enhancer-located pyrimidine tract. Altering the enhancer pyrimidine tract to a consensus sequence for the binding of U2AF eliminated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12446815 offsetBegin: 4129 offsetEnd: 4262 A: different from many standard model organisms. The 3'UTRs of the histone genes contained both the consensus stem-loop sequence and the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 2436 offsetEnd: 2559 A: was observed with the active site regions of the glycosyl hydrolase group of proteins (family 20). The expected active site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 3362 offsetEnd: 3491 A: the protein. The splice site boundaries closely match consensus sequences and the exons appear to be identically placed among the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 1980 offsetEnd: 2091 A: mapped to a site 17 nt downstream of a canonical polyadenylation signal located 7 nt downstream of the first of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 2254 offsetEnd: 2386 A: transcribed from the sense strand, contributing the polyadenylation site in 63% of the cases. This study led to the characterization
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 6258 offsetEnd: 6392 A: The insertion of the late high-affinity binding site for CstF into the early polyadenylation region significantly reduced the level of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 1907 offsetEnd: 2027 A: the polyadenylation machinery, and the RNA downstream of the cleavage site is degraded. Here we show that Rtt103 and the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10832023 offsetBegin: 1222 offsetEnd: 1332 A: differs from the consensus sequence at the second residue was identified 16 bp downstream of the 3' end of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 3638 offsetEnd: 3765 A: in all of the transcripts. Similarly, no consensus sequence was found when the sequences surrounding the 3'-ends of the longest
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 2795 offsetEnd: 2935 A: antagonistic to the binding of U2AF to the enhancer-located pyrimidine tract. Altering the enhancer pyrimidine tract to a consensus sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 6120 offsetEnd: 6258 A: increased read-through of the early sequence. The insertion of the late high-affinity binding site for CstF into the early polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 1787 offsetEnd: 1907 A: site, the RNA is cleaved by the polyadenylation machinery, and the RNA downstream of the cleavage site is degraded. Here
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12727900 offsetBegin: 3482 offsetEnd: 3615 A: the junction between the target site duplications and the 5'-flanking sequences exhibited the same TT/AAAA consensus found for the L1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 1845 offsetEnd: 1980 A: natural meiotic DNA double-strand break (DSB) sites in Schizosaccharomyces pombe. At one of the most prominent DSB sites, mbs1 (meiotic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 718 offsetEnd: 854 A: late HPV genes are transcribed by RNA polymerase II which reads through the region containing early polyadenylation signals and proceeds
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 1425 offsetEnd: 1590 A: we have investigated the mechanisms regulating differentiation-dependent polyadenylation and read-through in HPV-31. HPV-31 early transcripts were found to utilize a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 5489 offsetEnd: 5616 A: approximately 50%, indicating that use of the early site decreased. Differentiation was also found to induce a 40% reduction in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 7009 offsetEnd: 7156 A: demonstrate that HPV-31 late gene expression is regulated in a large part by posttranscriptional mechanisms, including the polyadenylation of early
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/6312290 offsetBegin: 1312 offsetEnd: 1427 A: of this RNA are heterogeneous but contain a prominent 5' end at the normal position (nucleotide 325) in addition to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 1875 offsetEnd: 2004 A: originate from specific RNA processing of a single gene that spans approximately 4.1 kb. The transcription start site was defined
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 2004 offsetEnd: 2130 A: a single gene that spans approximately 4.1 kb. The transcription start site was defined by 5'-inverse PCR analysis at position
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 2545 offsetEnd: 2677 A: to differential transcriptional initiation and processing. Type 1a is encoded by two exons; 2152 bp of intronic sequence are removed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 2791 offsetEnd: 2915 A: exons; 2152 bp of intronic sequence are removed by splicing at position 796/797 relative to the translation start site. Type
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 3414 offsetEnd: 3553 A: signal consensus motif was identified at position +4118; 2.7 kb of the 5'-flanking region were sequenced, and putative transcription factor
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 2198 offsetEnd: 2342 A: annotated open reading frames (ORFs), excluding pseudogenes. In the majority of cases, a 15-nucleotide consensus core motif was present upstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 4818 offsetEnd: 4971 A: signal. However, a large number of PASs were not preceded by this motif, suggesting alternative polyadenylation mechanisms. Pyrimidine-rich coding strand
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 3124 offsetEnd: 3243 A: promoter contains 22 copies of a CT dinucleotide repeat sequence located approximately 155 bp 5' to exon 1. MAGP-2 gene
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 3243 offsetEnd: 3358 A: CT dinucleotide repeat sequence located approximately 155 bp 5' to exon 1. MAGP-2 gene and compared it with that of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1025 offsetEnd: 1155 A: 16,914 bp. Twenty-one introns, differing in length from 76 bp to 4020 bp, all have conserved junction sequences (GT..AG). Sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9869401 offsetBegin: 1155 offsetEnd: 1277 A: length from 76 bp to 4020 bp, all have conserved junction sequences (GT..AG). Sequence analysis of the 5'- and 3'-flanking
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15474003 offsetBegin: 1904 offsetEnd: 2056 A: regulation of Ba2+ currents through recombinant Ca2+ channels. We found two N-glycosylation consensus sites (NX(S/T)) in the extracellular alpha2 domain
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 4437 offsetEnd: 4577 A: signal elements in a polyadenylation reporter assay. We demonstrate the heterogeneity of human sFlt1 that arises from alternate splicing and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 1173 offsetEnd: 1319 A: minigene expression defined a critical role for the TRalpha2 5' splice site in directing alternative processing. Mutational analysis reported here
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 1319 offsetEnd: 1457 A: for the TRalpha2 5' splice site in directing alternative processing. Mutational analysis reported here shows that purine residues within a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1162 offsetEnd: 1320 A: initiation, alternative polyadenylation, and differential splicing, all of which encode an identical protein. Here we report a conserved consensus p53-binding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 0 offsetEnd: 132 A: It is widely accepted that at least 10% of all mutations causing human inherited disease disrupt splice-site consensus sequences. In
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 2138 offsetEnd: 2281 A: and gain of ESSs among inherited disease-causing variants relative to neutral polymorphisms, indicating that exon skipping may play a prominent
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 2281 offsetEnd: 2430 A: disease-causing variants relative to neutral polymorphisms, indicating that exon skipping may play a prominent role in aberrant gene regulation. Both
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 2430 offsetEnd: 2575 A: indicating that exon skipping may play a prominent role in aberrant gene regulation. Both computational and biochemical approaches underscore the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 2575 offsetEnd: 2724 A: a prominent role in aberrant gene regulation. Both computational and biochemical approaches underscore the relevance of exonic splicing enhancer loss
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 543 offsetEnd: 670 A: of functional branchpoint sequences in HeLa cell nuclear extract yielded a sequence motif that evolved from UAA after one round
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 3305 offsetEnd: 3453 A: as post-translational modifications. We demonstrated that pUL46 is heavily phosphorylated in at least 23 sites. One phosphorylation site matched the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 3000 offsetEnd: 3155 A: six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 3155 offsetEnd: 3306 A: heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains. Oviductin expression was analyzed by real
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 3306 offsetEnd: 3469 A: recognition and/or interaction amino acid consensus (CRAC) domains. Oviductin expression was analyzed by real time quantitative polymerase chain reaction (RT-qPCR)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 710 offsetEnd: 881 A: functions of retroviruses in gastric cancer related gene research. METHODS: The polyadenylation signal-deficient retrovirus vector mutated by PCR site-directed mutagenesis
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 2024 offsetEnd: 2165 A: and soft agar assay were run to test the transformed cells. RESULTS: polyadenylation signal-deficient retroviruses could be packaged by PA317
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 4164 offsetEnd: 4316 A: soft agar with a higher efficiency than control or uninfected cells. CONCLUSION: Host readthrough transcripts generated by polyadenylation signal mutant
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 4316 offsetEnd: 4480 A: than control or uninfected cells. CONCLUSION: Host readthrough transcripts generated by polyadenylation signal mutant viruses may contribute to transformation GES-1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 3229 offsetEnd: 3383 A: We demonstrate that relief of repression and cytoplasmic polyadenylation are intimately linked. Repressing elements do not override the stimulatory effect
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 145 offsetEnd: 291 A: is thought to involve a sequential stop-start mechanism whereby monocistronic mRNAs are produced by polyadenylation and termination of 3' upstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 1501 offsetEnd: 1644 A: interrupted between transmembrane domains 6 and 7. We established that the transcription initiation site is located 498 nucleotides upstream of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 1228 offsetEnd: 1339 A: TAA stop codon. A single poly(A) site was mapped 24-25 bp downstream of the first AATAAA. Further, we show that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 1339 offsetEnd: 1456 A: site was mapped 24-25 bp downstream of the first AATAAA. Further, we show that a mutant octopine synthase gene, which
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 1815 offsetEnd: 1955 A: its 3'-untranslated region by deletion, is still active. This mutant gene terminates 19 bp upstream from the major wild-type polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 3084 offsetEnd: 3204 A: gene, and is preceded by a sequence AATGAATATA. Three other sites are located within the adjacent plant DNA, giving rise
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11722011 offsetBegin: 1911 offsetEnd: 2036 A: 0.7 kb that accumulated simultaneously from 6 to 24 hours post-infection (p.i.). S1 nuclease mapping of the UL12 capping site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21527498 offsetBegin: 2909 offsetEnd: 3062 A: luciferase activity, suggesting a prominent role for HMGB1 in activation of estrogen/ER-responsive genes. Therefore, these data advocate that the minimal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 2033 offsetEnd: 2164 A: a single polyadenylation signal in vivo. By screening more than 300 000 sequences corresponding to human, mouse and rat transcripts
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 2826 offsetEnd: 2977 A: and 22% rat) show cleavage site heterogeneity. When analyzing SAGE-generated expression data, this phenomenon should be considered, since, according to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 3397 offsetEnd: 3530 A: human transcripts show two or more different SAGE tags corresponding to a single gene because of alternative cleavage site selection.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 3530 offsetEnd: 3665 A: different SAGE tags corresponding to a single gene because of alternative cleavage site selection. Both experimental and in silico data
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10699189 offsetBegin: 2527 offsetEnd: 2659 A: L1s and found two long transduced sequences. Thus, L1 retrotransposition in vivo commonly transduces sequence flanking the 3' end of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 2304 offsetEnd: 2449 A: approximately 0.7, 1.5, 2.1, and 2.6 kb, observed on Northern blots, are differentiated by their utilization of alternative UbcM4 polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 2764 offsetEnd: 2921 A: UbcM4 polyadenylation sites. A single alternative splice variant cDNA, termed UbcM4Deltaex2, was also identified. The polypeptide encoded by UbcM4Deltaex2 is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3377 offsetEnd: 3485 A: is present in intron 6 of IL7R directly downstream from the 5' splice site. Mutations to this site and CPSF1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3485 offsetEnd: 3606 A: IL7R directly downstream from the 5' splice site. Mutations to this site and CPSF1 knockdown both resulted in an increase
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3828 offsetEnd: 3942 A: an increase in exon 6 inclusion. We found no evidence that this site is used to produce cleaved and polyadenylated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 4486 offsetEnd: 4618 A: with spliceosome binding to the exon 6 5' splice site. Our results suggest that competing mRNA splicing and polyadenylation regulate
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 4906 offsetEnd: 5045 A: polyadenylation regulate exon 6 inclusion and consequently determine the ratios of soluble to membrane-bound IL7R. This may be relevant for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12588979 offsetBegin: 1755 offsetEnd: 1860 A: rapidly degraded as cells exit S phase. Mutation of any residues in a TTP sequence (amino acids 60 to 62)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 3070 offsetEnd: 3189 A: derived from intron G, between exons 7 and 8. No splice site mutations were found in PCR-amplified DMS-79 DNA fragments
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 3623 offsetEnd: 3772 A: junctions. Further sequencing indicated that the aberrant GR transcript appears to be generated by use of a consensus cleavage/polyadenylation signal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 3772 offsetEnd: 3903 A: aberrant GR transcript appears to be generated by use of a consensus cleavage/polyadenylation signal found 3650 base pairs into the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 3903 offsetEnd: 4031 A: generated by use of a consensus cleavage/polyadenylation signal found 3650 base pairs into the normal intron G. We conclude that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 5080 offsetEnd: 5216 A: bp promoter region. Notably absent from these 5' sequences, however, are consensus binding sites for either Egr-1 or Lim-2 transcription
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11865048 offsetBegin: 0 offsetEnd: 129 A: RNA polymerase II (RNAP II) has previously been shown to be required for the pre-mRNA polyadenylation cleavage reaction in vitro.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/8442668 offsetBegin: 2812 offsetEnd: 2966 A: polyadenylation signal (AATAAA-->AAAAAA). Several mutations were discernible in all regions of the second variant allele, including silent (codon 153) and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031412 offsetBegin: 2674 offsetEnd: 2829 A: the consensus transport motif. Post-transcriptional processing is also conserved. Phylogenetic analysis grouped NrampC with other fish Nramps and closer to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 4027 offsetEnd: 4164 A: are commonly used as reference housekeeping genes. The P2 contains an unmethylated CpG island, multiple Sp-1 consensus binding sites and,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 4164 offsetEnd: 4287 A: genes. The P2 contains an unmethylated CpG island, multiple Sp-1 consensus binding sites and, unlike P1, does not contain a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 4287 offsetEnd: 4404 A: CpG island, multiple Sp-1 consensus binding sites and, unlike P1, does not contain a TATA box, features all common to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 2485 offsetEnd: 2617 A: of protein coding genes. In rat1-1 or rai1Delta cells, RNA 3' to polyadenylation sites is greatly stabilized and termination defects
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 2617 offsetEnd: 2744 A: or rai1Delta cells, RNA 3' to polyadenylation sites is greatly stabilized and termination defects are seen at many genes. These
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 2744 offsetEnd: 2875 A: polyadenylation sites is greatly stabilized and termination defects are seen at many genes. These findings support a model in which
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 2875 offsetEnd: 3007 A: termination defects are seen at many genes. These findings support a model in which poly(A) site cleavage and subsequent degradation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 3007 offsetEnd: 3135 A: genes. These findings support a model in which poly(A) site cleavage and subsequent degradation of the 3'-downstream RNA by Rat1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201123 offsetBegin: 2932 offsetEnd: 3067 A: (2) identify three biochemically distinct classes of acetylation sites, and (3) provide evidence that SIRT3 is a prominent regulator in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201123 offsetBegin: 3067 offsetEnd: 3205 A: of acetylation sites, and (3) provide evidence that SIRT3 is a prominent regulator in CR adaptation by coordinately deacetylating proteins
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 1880 offsetEnd: 2013 A: TART transcripts. In contrast to other Drosophila non-LTR elements, a major initiation site for sense transcripts was mapped near the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 1709 offsetEnd: 1874 A: encodes four different transcripts, as determined from cDNA library screening, reverse transcriptase-PCR (RT-PCR) and/or EST (expressed sequence tag) database search
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 1874 offsetEnd: 2037 A: from cDNA library screening, reverse transcriptase-PCR (RT-PCR) and/or EST (expressed sequence tag) database search analysis. NIPP-1alpha mRNA represents the major
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 2037 offsetEnd: 2185 A: (RT-PCR) and/or EST (expressed sequence tag) database search analysis. NIPP-1alpha mRNA represents the major transcript in human tissues and various
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 4529 offsetEnd: 4694 A: endoribonuclease activity and lacks an RVXF consensus motif for interaction with protein phosphatase-1. While the NIPP-1alpha/beta/delta-transcripts were found to be
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16308319 offsetBegin: 1661 offsetEnd: 1803 A: remarkably well and requires G-rich elements just downstream of the consensus U11 binding site. We present evidence that heterogeneous nuclear
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 1358 offsetEnd: 1488 A: with six cytokine RNA instability motifs (ATTTA), and a polyadenylation signal (AATAAA) at 13 nucleotides upstream of the poly (A)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 0 offsetEnd: 140 A: Betacellulin (BTC) belongs to the epidermal growth factor (EGF) family of peptide ligands that are characterized by a six-cysteine consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 437 offsetEnd: 586 A: six-cysteine consensus motif (EGF-motif) that forms three intra-molecular disulfide bonds, crucial for binding the ErbB receptor family. A variety of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 2222 offsetEnd: 2375 A: bacterial artificial chromosome (BAC) library. Three positive clones containing the entire gene were isolated. DNA sequence analysis identified six exons
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 2375 offsetEnd: 2507 A: positive clones containing the entire gene were isolated. DNA sequence analysis identified six exons (1-6) and five introns (A-E); a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 2507 offsetEnd: 2638 A: were isolated. DNA sequence analysis identified six exons (1-6) and five introns (A-E); a structure conserved among the EGF family.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 4010 offsetEnd: 4148 A: Multiple transcription start sites and one poly(A) site, located 18 bp downstream of a polyadenylation signal sequence, were identified by
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 4148 offsetEnd: 4292 A: poly(A) site, located 18 bp downstream of a polyadenylation signal sequence, were identified by 5'- and 3'-RACE, respectively. Approximately 2.6
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 4950 offsetEnd: 5099 A: but was found to contain several putative cis-acting regulatory elements. These included consensus binding sites for transcription factors HNF3 beta,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 5099 offsetEnd: 5254 A: putative cis-acting regulatory elements. These included consensus binding sites for transcription factors HNF3 beta, USF, Nkx2-5, AP-4, and Sp1. Functional
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 5254 offsetEnd: 5397 A: consensus binding sites for transcription factors HNF3 beta, USF, Nkx2-5, AP-4, and Sp1. Functional promoter analysis of the 5'-flanking region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12727900 offsetBegin: 2621 offsetEnd: 2754 A: of alternative splicing or multiple polyadenylation signals. RPC distribution among the HMGs was not even, with 33-65 each for HMGB1,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 1747 offsetEnd: 1858 A: 1c, E1-E10) encoding two groups of mRNAs differing in length and sequence at their 5' UTRs, referred to as type
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 614 offsetEnd: 766 A: alternatively spliced exons encoding different N-termini. Two candidate promoters with consensus sites for transcription factors Sp1, AP-1, and AP-2 are
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 1375 offsetEnd: 1513 A: shutoff exonuclease. Rapid amplification of cDNA ends analysis revealed that they share a common polyadenylation signal but have two start
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 2667 offsetEnd: 2809 A: transcripts. Reporter assays with Hep3B cells showed activation of both transcripts by hypoxia. The ORF34-37 promoter region has six consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 2809 offsetEnd: 2971 A: showed activation of both transcripts by hypoxia. The ORF34-37 promoter region has six consensus HREs. Sequential deletion, site-directed mutagenesis experiments,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 2971 offsetEnd: 3126 A: hypoxia. The ORF34-37 promoter region has six consensus HREs. Sequential deletion, site-directed mutagenesis experiments, and Northern blot analysis of RNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 3126 offsetEnd: 3281 A: six consensus HREs. Sequential deletion, site-directed mutagenesis experiments, and Northern blot analysis of RNA produced by constructs indicated that the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 2196 offsetEnd: 2322 A: mono-snRNP in vitro and that a G-rich element located downstream of the U11 site is required for efficient binding. Mutational
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 2453 offsetEnd: 2572 A: U11 site is required for efficient binding. Mutational analyses indicated that two of four G tracts in this region were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17581856 offsetBegin: 593 offsetEnd: 744 A: however, that Shaker-like N- and P/C-type mechanisms are likely not involved. Kv4 channels also display prominent inactivation from preactivated closed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11105754 offsetBegin: 1413 offsetEnd: 1541 A: Z-F et al., Genes & Dev, 1996, 10:3028-3040]. The primary sequence identity between human and Caenorhabditis elegans RBDs is 55%
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 567 offsetEnd: 704 A: is marked by the presence of two polyadenylation signals but used with different frequencies. RNase protection and 5' rapid amplification
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 704 offsetEnd: 852 A: two polyadenylation signals but used with different frequencies. RNase protection and 5' rapid amplification of cDNA ends (RACE) identified multiple
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 1720 offsetEnd: 1862 A: independent transcriptional activity localized between nucleotide -305 and -589. The proximal 1.5 kb region does not possess consensus TATA or
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 2105 offsetEnd: 2229 A: TATA or CAAT boxes but has several consensus sequences for regulatory elements including USF, GATA, AP1, AP4, MyoD, GKLF and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 2229 offsetEnd: 2362 A: several consensus sequences for regulatory elements including USF, GATA, AP1, AP4, MyoD, GKLF and Ikaros that could explain the broad
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 430 offsetEnd: 569 A: showing an open reading frame of 1691 bp, interrupted by five introns with fungal consensus splice-site junctions. The untranslated regions
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 1700 offsetEnd: 1835 A: relationships. The amino acid sequence of Pb NAG1 has 45, 31 and 30% identity, respectively, with homologous sequences from Trichoderma
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 2152 offsetEnd: 2300 A: from Trichoderma harzianum, Aspergillus nidulans and Candida albicans. In particular, striking homology was observed with the active site regions of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10929203 offsetBegin: 3278 offsetEnd: 3426 A: flanking a single polyadenylation site. The temporal and spatial expression patterns of desmin mRNA during early zebrafish development were studied.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16006100 offsetBegin: 5172 offsetEnd: 5310 A: DNA-J domain. These studies suggest that alternative splicing is not a prominent mechanism for generating G protein subunit diversity from
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16006100 offsetBegin: 5310 offsetEnd: 5442 A: alternative splicing is not a prominent mechanism for generating G protein subunit diversity from within the human or mouse genomes.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 267 offsetEnd: 388 A: genes are known to produce truncated transcripts that end within the coding sequence of longer transcripts: CBP1 , AEP2 /
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 4184 offsetEnd: 4336 A: 10 kb beyond the annotated gene terminus to a highly conserved alternate polyadenylation site. Quantitative PCR (qPCR) analyses of fluorescent-activated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 4336 offsetEnd: 4497 A: terminus to a highly conserved alternate polyadenylation site. Quantitative PCR (qPCR) analyses of fluorescent-activated cell sorted (FACS) DRG neurons confirmed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 4497 offsetEnd: 4670 A: polyadenylation site. Quantitative PCR (qPCR) analyses of fluorescent-activated cell sorted (FACS) DRG neurons confirmed that this 3'-UTR-extended variant was preferentially
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 5338 offsetEnd: 5500 A: predict that UTR-extension introduces consensus sites for RNA-binding proteins (RBPs) including the embryonic lethal abnormal vision (ELAV)/Hu family proteins. We
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 2021 offsetEnd: 2153 A: codon as determined by rapid amplification of cDNA ends (5'-RACE) analysis. Two potential polyadenylation sites are 3233 and 3293 bp
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 3563 offsetEnd: 3696 A: activity was much higher in AtT-20 than NIH3T3. According to sequence analysis of the approximately 0.8kb 5'-flanking region, GC rich
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 3400 offsetEnd: 3519 A: a low cutoff, for screening, 71% of all LTRs found by RepeatMasker in chromosome 19 were found. HMM consensus sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 3519 offsetEnd: 3644 A: of all LTRs found by RepeatMasker in chromosome 19 were found. HMM consensus sequences had a conserved modular LTR structure.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 4068 offsetEnd: 4195 A: TATA (occasionally absent), an AATAAA box and a T-rich region were prominent features. Most of the conservation was located in,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 4758 offsetEnd: 4894 A: LTRs contained long ORFs inserted after the second A rich module. HMM consensus alignment allowed comparison of functional features like
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 4894 offsetEnd: 5040 A: the second A rich module. HMM consensus alignment allowed comparison of functional features like transcriptional start sites (sense and antisense)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 1260 offsetEnd: 1407 A: mapped to a [GU(3-5)](5) repeat, unlike any previously characterized polyadenylation site. CTH2 mRNA accumulation was not inhibited by mutations in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1010 offsetEnd: 1117 A: HCMV. The 5-kb RNA is highly AT rich in sequence and lacks open reading frames likely to be translated into
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1117 offsetEnd: 1232 A: AT rich in sequence and lacks open reading frames likely to be translated into protein. We confirmed the absence of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 2406 offsetEnd: 2548 A: using at least three different polyadenylation signals. The PART-1 cDNA and putative protein are not significantly homologous to any sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20553951 offsetBegin: 0 offsetEnd: 171 A: The distal 3'UTR of prothrombin mRNA exhibits significant sequence heterogeneity reflecting an inexact 3'-cleavage/polyadenylation reaction. This same region encompasses a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20553951 offsetBegin: 171 offsetEnd: 361 A: exhibits significant sequence heterogeneity reflecting an inexact 3'-cleavage/polyadenylation reaction. This same region encompasses a single-nucleotide polymorphism that enhances the normal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20553951 offsetBegin: 2825 offsetEnd: 2972 A: or more positions, and can fold into at least two distinct stem-loop conformations. These alternate structures expose/sequester a consensus binding
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 1126 offsetEnd: 1248 A: long sharing 100% of its deduced amino acid sequence with rat PIN. Using a radiolabelled riboprobe derived from the rabbit
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22958278 offsetBegin: 2380 offsetEnd: 2533 A: no binding site information between the interacting protein molecules. FINDINGS: A plausible protein-protein hetero-complex was fished out from 10 docked
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 2024 offsetEnd: 2153 A: sequence did not show a significant similarity to any genes deposited in the public database. Southern blot indicated that PSG076
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 6322 offsetEnd: 6482 A: absence of Repeat 4 immunoreactivity. CONCLUSIONS: The strong conservation in intron-exon positions, gene structure, and protein sequence among mammals supports
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 6482 offsetEnd: 6630 A: The strong conservation in intron-exon positions, gene structure, and protein sequence among mammals supports an important biological role for these
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 1571 offsetEnd: 1709 A: cell cycle, including two different termination signals, the hairpin structure and at least one AATAAA polyadenylation signal. In their 5'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12533698 offsetBegin: 2033 offsetEnd: 2168 A: resulted in aberrant splicing to an upstream non-consensus exonic donor. Target 1 RNAs carry the UL37x1 polyadenylation (PA) signal and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17942399 offsetBegin: 3973 offsetEnd: 4094 A: eIF4G, it binds 4E-T, in a manner independent of the consensus eIF4E-binding site, YSKEELL. Wild type and Y-A mutant 4E-T
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17942399 offsetBegin: 4094 offsetEnd: 4227 A: manner independent of the consensus eIF4E-binding site, YSKEELL. Wild type and Y-A mutant 4E-T (which binds eIF4E1b but not eIF4E1a),
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15121831 offsetBegin: 1894 offsetEnd: 2036 A: region, a regulatory domain conserved among zinc cluster transcription factors, and is part of an Snf1p consensus phosphorylation site. Single
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 838 offsetEnd: 954 A: 1-kb fragment upstream from the start codon was rich in GC, lacked consensus TATA or CAAT box, but contained several
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 954 offsetEnd: 1091 A: codon was rich in GC, lacked consensus TATA or CAAT box, but contained several Sp1-binding sites. Other potential cis-regulatory elements
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 1091 offsetEnd: 1240 A: consensus TATA or CAAT box, but contained several Sp1-binding sites. Other potential cis-regulatory elements found in the 5'-flanking region included
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 1395 offsetEnd: 1548 A: cis-regulatory elements found in the 5'-flanking region included AP2, USF, Stat-6, NFkappaB and Olf-1. A single canonical polyadenylation signal (AATAAA)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 3734 offsetEnd: 3860 A: Sp1 binding to GC-rich sequences. The search for sequence variants within a fragment covering 1.7 kb of 5'-flanking region and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 5142 offsetEnd: 5293 A: which was showed to affect alpha2B-adrenergic receptor function. Based on transfection data and computer-assisted sequence analysis, the -98 G/C single
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 5293 offsetEnd: 5443 A: receptor function. Based on transfection data and computer-assisted sequence analysis, the -98 G/C single nucleotide polymorphism was located within a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 5732 offsetEnd: 5868 A: within a portion of the 5'-UTR (-127/+3) affecting luciferase activity and it created additional putative binding site for Sp1. However,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 5868 offsetEnd: 6019 A: (-127/+3) affecting luciferase activity and it created additional putative binding site for Sp1. However, G/C substitution had no significant incidence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 6019 offsetEnd: 6157 A: created additional putative binding site for Sp1. However, G/C substitution had no significant incidence on promoter activity in BHK-21 or
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 3467 offsetEnd: 3617 A: early transcription start site motif (underlined). Peak levels of lef-8 transcripts were attained by 24 h p.i. Immunocopurification analyses suggested
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 2919 offsetEnd: 3050 A: was necessary for transcriptional activation by RA. Within this sequence DNase I footprinting revealed that RA induced binding of a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 3050 offsetEnd: 3171 A: RA. Within this sequence DNase I footprinting revealed that RA induced binding of a nuclear protein complex to an element
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 4930 offsetEnd: 5051 A: in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 6682 offsetEnd: 6831 A: from RA-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and CREB2 were identified by competition EMSA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 1760 offsetEnd: 1897 A: polyadenylation signals and six mRNA instability sequences. A soluble form of PIR-A6 may be generated by alternative splicing. The exonic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 2803 offsetEnd: 2938 A: intronic sequences. Extensive sequence homology was found between Pira6 and Pirb from approximately 2 kb upstream of the ATG initiation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 3594 offsetEnd: 3725 A: chromosome 7 based on the present data and an analysis of currently available mouse genomic sequence databases. One region contains
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 3725 offsetEnd: 3849 A: data and an analysis of currently available mouse genomic sequence databases. One region contains a single Pir gene which is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 3849 offsetEnd: 3974 A: available mouse genomic sequence databases. One region contains a single Pir gene which is almost identical to Pira6, and the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15965016 offsetBegin: 153 offsetEnd: 316 A: a database containing authenticated polyadenylation [poly(A)] sites, we analyzed the composition of mRNA poly(A) signals in Arabidopsis (Arabidopsis thaliana), and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15965016 offsetBegin: 2306 offsetEnd: 2448 A: were not previously revealed by conventional mutagenesis and are contemplated as a cluster of signals for cleavage site recognition. Moreover,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15727844 offsetBegin: 405 offsetEnd: 545 A: trispora, showing an open reading frame of 1561 bp interrupted by four introns with fungal consensus splice-site junctions. The untranslated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12556531 offsetBegin: 1336 offsetEnd: 1480 A: with 225 microM emetine. Polyadenylation sites were detected at 118-, 156-, and 189-nucleotide (nt) positions of the EhPgp5 mRNA 3'-untranslated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12556531 offsetBegin: 1628 offsetEnd: 1793 A: 189-nucleotide (nt) positions of the EhPgp5 mRNA 3'-untranslated region. Interestingly, trophozoites grown with 225 microM emetine exhibited an extra polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 1110 offsetEnd: 1255 A: RESULTS: We studied these signals using exhaustive databases of cleavage sites obtained from aligning raw expressed sequence tags (EST) sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 2049 offsetEnd: 2182 A: fly. In addition, de novo motif searches generated a refined description of the U-rich downstream sequence (DSE) element, which shows
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 1387 offsetEnd: 1537 A: UAA translation stop codon) could be the polyadenylation signal in Trichomonas vaginalis, a parasitic protozoon that causes human trichomoniasis. This
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 2239 offsetEnd: 2371 A: There were AACAYYYCT consensus start signal close to the TGA7. Flury-LEP-C has 310 nucleotides more than HEP-Flury in G-L intergenic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11931652 offsetBegin: 858 offsetEnd: 1011 A: Altogether, our findings indicate that the MMP-26 promoter has distinctive structural and functional features among MMP genes. An unusual polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 4533 offsetEnd: 4680 A: little to no acute liver injury after administration of Jo2, signifying Mcl-1 cytoprotection. In conclusion, these observations support a prominent
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 4680 offsetEnd: 4844 A: after administration of Jo2, signifying Mcl-1 cytoprotection. In conclusion, these observations support a prominent role for CAR cytoprotection against Fas-mediated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 676 offsetEnd: 812 A: cDNA clones corresponding to a second mouse Nramp gene, which we designate Nramp2. Nucleotide and predicted amino acid sequence analyses
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 812 offsetEnd: 948 A: mouse Nramp gene, which we designate Nramp2. Nucleotide and predicted amino acid sequence analyses of full-length cDNA clones for Nramp2
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 948 offsetEnd: 1086 A: Nramp2. Nucleotide and predicted amino acid sequence analyses of full-length cDNA clones for Nramp2 indicate that this novel Nramp protein
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 1086 offsetEnd: 1220 A: sequence analyses of full-length cDNA clones for Nramp2 indicate that this novel Nramp protein is closely homologous to the previously
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 3196 offsetEnd: 3336 A: mRNA transcripts in normal mouse tissues by Northern blotting revealed that the Nramp2 gene produces several mRNAs, including prominent 3.3-
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 158 offsetEnd: 301 A: of fission yeast is defined by a cyclic AMP-responsive element (CRE)-like heptanucleotide sequence, 5'-ATGACGT-3', which acts as a binding site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 301 offsetEnd: 466 A: a cyclic AMP-responsive element (CRE)-like heptanucleotide sequence, 5'-ATGACGT-3', which acts as a binding site for the Atf1/Pcr1 heterodimeric transcription factor
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 466 offsetEnd: 609 A: sequence, 5'-ATGACGT-3', which acts as a binding site for the Atf1/Pcr1 heterodimeric transcription factor required for hot spot activation. We
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 760 offsetEnd: 903 A: transcription factor required for hot spot activation. We previously demonstrated that the local chromatin around the M26 sequence motif alters
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 1263 offsetEnd: 1425 A: downstream of L1. In this study, we have investigated the mechanisms regulating differentiation-dependent polyadenylation and read-through in HPV-31. HPV-31 early
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 2175 offsetEnd: 2299 A: for polyadenylation extended over a range of 100 nucleotides from within the E5 ORF to upstream of L2. Upon differentiation,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 3100 offsetEnd: 3225 A: was found to contain a single consensus hexanucleotide sequence, AAUAAA, as well as three weak binding sites for the cleavage
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 3225 offsetEnd: 3361 A: consensus hexanucleotide sequence, AAUAAA, as well as three weak binding sites for the cleavage stimulatory factor, CstF. In contrast to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4455 offsetEnd: 4575 A: for CstF, as well as one consensus hexanucleotide sequence. By using a reporter assay, it was determined that the HPV-31
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4729 offsetEnd: 4874 A: reporter assay, it was determined that the HPV-31 early polyadenylation sequences allowed significant levels of read-through into the late region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 4874 offsetEnd: 5034 A: the HPV-31 early polyadenylation sequences allowed significant levels of read-through into the late region in undifferentiated cells. Upon differentiation, this
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 5339 offsetEnd: 5489 A: differentiation, this read-through was increased by approximately 50%, indicating that use of the early site decreased. Differentiation was also found
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 5616 offsetEnd: 5736 A: the early site decreased. Differentiation was also found to induce a 40% reduction in the levels of CstF subunits, which
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 6539 offsetEnd: 6707 A: early polyadenylation region significantly reduced the level of read-through, suggesting that these factors modulate read-through activity. Our studies demonstrate that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/6312290 offsetBegin: 1661 offsetEnd: 1763 A: addition to several other prominent 5' ends not seen in wild-type RNA. The 3' end of this RNA does not
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 2130 offsetEnd: 2262 A: 4.1 kb. The transcription start site was defined by 5'-inverse PCR analysis at position -227. RT-PCR analysis points to differential
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11356716 offsetBegin: 2677 offsetEnd: 2791 A: Type 1a is encoded by two exons; 2152 bp of intronic sequence are removed by splicing at position 796/797 relative
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9837805 offsetBegin: 1804 offsetEnd: 1943 A: bovine adenovirus type 3 and ovine adenovirus, which lack virion-associated RNA genes, the nucleotide sequence analysis of the viral genome
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9837805 offsetBegin: 1943 offsetEnd: 2083 A: adenovirus, which lack virion-associated RNA genes, the nucleotide sequence analysis of the viral genome indicates that it encodes one short
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 1904 offsetEnd: 2056 A: and polyadenylation sites (PASs). Individual and clustered TSSs were found preceding 104 annotated open reading frames (ORFs), excluding pseudogenes. In
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 4971 offsetEnd: 5134 A: PASs were not preceded by this motif, suggesting alternative polyadenylation mechanisms. Pyrimidine-rich coding strand sequences were found immediately upstream of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 5134 offsetEnd: 5300 A: motif, suggesting alternative polyadenylation mechanisms. Pyrimidine-rich coding strand sequences were found immediately upstream of both types of PASs, signifying an
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2979 offsetEnd: 3124 A: initiator promoter element. Additionally, the mouse promoter contains 22 copies of a CT dinucleotide repeat sequence located approximately 155 bp
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 2628 offsetEnd: 2754 A: of the transcription start site that was responsive to PTH. Within the -59 base pairs there are CCAAT/enhancer binding protein
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 4592 offsetEnd: 4730 A: activity. Electrophoretic mobility shift assays using UMR106-01 cell nuclear extracts showed that PTH caused a prominent shifted band in a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 4730 offsetEnd: 4855 A: UMR106-01 cell nuclear extracts showed that PTH caused a prominent shifted band in a probe spanning the region containing all
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15474003 offsetBegin: 424 offsetEnd: 559 A: One of the most prominent roles of CaValpha2delta is to increase whole-cell Ca2+ current amplitude. Using N-glycosidase F and truncated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15474003 offsetBegin: 1756 offsetEnd: 1904 A: within the CaValpha2delta subunit on the regulation of Ba2+ currents through recombinant Ca2+ channels. We found two N-glycosylation consensus sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15474003 offsetBegin: 2056 offsetEnd: 2196 A: Ca2+ channels. We found two N-glycosylation consensus sites (NX(S/T)) in the extracellular alpha2 domain of the protein that are functional.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 4295 offsetEnd: 4437 A: then confirmed by mutagenesis of putative signal elements in a polyadenylation reporter assay. We demonstrate the heterogeneity of human sFlt1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 4577 offsetEnd: 4723 A: assay. We demonstrate the heterogeneity of human sFlt1 that arises from alternate splicing and from alternative polyadenylation directed by strong
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 4723 offsetEnd: 4871 A: human sFlt1 that arises from alternate splicing and from alternative polyadenylation directed by strong intronic poly(A) signal sequences leading to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12904181 offsetBegin: 1058 offsetEnd: 1200 A: its structure and transcriptional regulation. We have accurately mapped the transcription initiation site 6.5 kb upstream of the coding region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 1739 offsetEnd: 1880 A: -10 elements and transcriptional start sites. We also demonstrated, for Pfim3, that the conserved sequence corresponds to BvgA binding sites.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 2621 offsetEnd: 2725 A: sequence. The other binding site is a fairly poor match to this consensus, with 10 of 14 bp belonging to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 3563 offsetEnd: 3687 A: lack of a recognizable -35 element (CCCCCC versus TTGACA), and the occupation of this site by BvgA∼P suggest that activation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 3814 offsetEnd: 3942 A: of this site by BvgA∼P suggest that activation of the fim promoters involves unusual interactions among BvgA, RNA polymerase and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11421362 offsetBegin: 1043 offsetEnd: 1173 A: site. A previous investigation of TRalpha minigene expression defined a critical role for the TRalpha2 5' splice site in directing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1689 offsetEnd: 1813 A: first intron of bovine and human mimecan genes and show that wild-type p53 binds to this sequence in vitro. Co-transfections
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1813 offsetEnd: 1934 A: mimecan genes and show that wild-type p53 binds to this sequence in vitro. Co-transfections of Saos-2, HeLa, NIH 3T3, and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11342211 offsetBegin: 1934 offsetEnd: 2064 A: p53 binds to this sequence in vitro. Co-transfections of Saos-2, HeLa, NIH 3T3, and primary bovine corneal keratocytes with bovine
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 132 offsetEnd: 278 A: least 10% of all mutations causing human inherited disease disrupt splice-site consensus sequences. In contrast to splice-site mutations, the role
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21750108 offsetBegin: 278 offsetEnd: 430 A: human inherited disease disrupt splice-site consensus sequences. In contrast to splice-site mutations, the role of auxiliary cis-acting elements such as
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 395 offsetEnd: 543 A: of pre-mRNAs containing randomized regions. Selection of functional branchpoint sequences in HeLa cell nuclear extract yielded a sequence motif that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 1038 offsetEnd: 1171 A: UACUAAC consensus after seven rounds. A significant part of the selected sequences contained a conserved AAUAAAG motif that proved to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 1171 offsetEnd: 1304 A: significant part of the selected sequences contained a conserved AAUAAAG motif that proved to be functional both as a polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 2545 offsetEnd: 2689 A: guanosine, adjacent to the common AAUAAA polyadenylation motif, was found to be required only for polyadenylation. In an independent experiment,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 2846 offsetEnd: 3004 A: required only for polyadenylation. In an independent experiment, sequences surrounding an optimal branchpoint sequence were selected from two randomized 20-nt
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 3004 offsetEnd: 3160 A: independent experiment, sequences surrounding an optimal branchpoint sequence were selected from two randomized 20-nt regions. The clones selected after six
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 3160 offsetEnd: 3299 A: branchpoint sequence were selected from two randomized 20-nt regions. The clones selected after six rounds of splicing revealed an extended
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 3557 offsetEnd: 3677 A: an extended polypyrimidine tract with a high frequency of UCCU motifs and a highly conserved YAG sequence in the extreme
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 1951 offsetEnd: 2101 A: full-length copies, however, has an uninterrupted open reading frame and, presumably, represents the original sequence of the active element. Southern
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 2101 offsetEnd: 2246 A: open reading frame and, presumably, represents the original sequence of the active element. Southern hybridization experiments showed TROMB to be
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 2246 offsetEnd: 2373 A: the original sequence of the active element. Southern hybridization experiments showed TROMB to be present at a low copy number
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 2251 offsetEnd: 2372 A: B-cell lines. RESULTS: Several novel in vivo protein binding sites were found in the EBER locus. Among those, a prominent
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 2372 offsetEnd: 2491 A: vivo protein binding sites were found in the EBER locus. Among those, a prominent binding site, 130 base pairs upstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 2491 offsetEnd: 2604 A: in the EBER locus. Among those, a prominent binding site, 130 base pairs upstream of the EBER1 gene, contains two
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 120 offsetEnd: 245 A: infect, viruses must also regulate their life cycles. Herpes simples virus type 1 (HSV-1), a prominent human pathogen, uses a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 245 offsetEnd: 379 A: life cycles. Herpes simples virus type 1 (HSV-1), a prominent human pathogen, uses a promoter-rich genome in conjunction with multiple
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 379 offsetEnd: 527 A: 1 (HSV-1), a prominent human pathogen, uses a promoter-rich genome in conjunction with multiple viral trans-activating factors. Following entry into
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 811 offsetEnd: 928 A: amino acid sequences. Our objective in this study was to sequence the full open reading frame of the feline oviductin
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 0 offsetEnd: 154 A: OBJECTIVE: To verify if mutated polyadenylation signal retroviruses can produce viral-host readthrough transcripts (Rth) and have the ability to transform
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 557 offsetEnd: 710 A: cells, and to discuss the new functions of retroviruses in gastric cancer related gene research. METHODS: The polyadenylation signal-deficient retrovirus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 1889 offsetEnd: 2024 A: by Northern blot. The cell growth and soft agar assay were run to test the transformed cells. RESULTS: polyadenylation signal-deficient
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 2711 offsetEnd: 2854 A: cells. Northern blot analysis of viral RNA from infected pools and individual G418-resistant clones demonstrated that mutation of consensus LTR
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 4480 offsetEnd: 4638 A: Host readthrough transcripts generated by polyadenylation signal mutant viruses may contribute to transformation GES-1 cell phenotypes. The mutant vectors and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 0 offsetEnd: 149 A: Translational control is prominent during meiotic maturation and early development. In this report, we investigate a mode of translational repression
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 2362 offsetEnd: 2517 A: overlap and include cytoplasmic polyadenylation elements (CPEs), sequences known to promote cytoplasmic polyadenylation. However, the presence of a CPE per
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 3066 offsetEnd: 3229 A: contain CPEs are not translationally repressed. We demonstrate that relief of repression and cytoplasmic polyadenylation are intimately linked. Repressing elements
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 3383 offsetEnd: 3524 A: and cytoplasmic polyadenylation are intimately linked. Repressing elements do not override the stimulatory effect of a long poly(A) tail, and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 3524 offsetEnd: 3647 A: Repressing elements do not override the stimulatory effect of a long poly(A) tail, and polyadenylation of cyclin B1 mRNA is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 3647 offsetEnd: 3778 A: stimulatory effect of a long poly(A) tail, and polyadenylation of cyclin B1 mRNA is required for its translational recruitment. Our
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 291 offsetEnd: 439 A: stop-start mechanism whereby monocistronic mRNAs are produced by polyadenylation and termination of 3' upstream gene followed by reinitiation at the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 439 offsetEnd: 570 A: produced by polyadenylation and termination of 3' upstream gene followed by reinitiation at the downstream start site. For a number
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 3017 offsetEnd: 3164 A: the consensus sequence. We have tested the hypothesis that elevated M-F readthrough transcription results from an inefficient termination signal at
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 4277 offsetEnd: 4399 A: the SH-HN gene junction. Chimeric SV5 minigenomes were constructed to contain exchanges of a 10 base gene end sequence and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9705920 offsetBegin: 4399 offsetEnd: 4508 A: minigenomes were constructed to contain exchanges of a 10 base gene end sequence and the U tract from the M-F
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18237440 offsetBegin: 4601 offsetEnd: 4751 A: tightly with the KIFC1 targeting domain using affinity chromatography. In addition to the leucine-rich repeats, TLRR contains a consensus-binding site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18237440 offsetBegin: 4751 offsetEnd: 4920 A: using affinity chromatography. In addition to the leucine-rich repeats, TLRR contains a consensus-binding site for protein phosphatase-1 (PP1). Immunocytochemistry using
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18237440 offsetBegin: 5086 offsetEnd: 5241 A: consensus-binding site for protein phosphatase-1 (PP1). Immunocytochemistry using a TLRR specific antibody demonstrates that this protein is found near the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 1359 offsetEnd: 1501 A: spanning 10kb, with the coding region interrupted between transmembrane domains 6 and 7. We established that the transcription initiation site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 2387 offsetEnd: 2501 A: of the promoter region showed no TATA box but identified consensus binding motifs for Sp1, CREB, and half sites of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 2501 offsetEnd: 2626 A: TATA box but identified consensus binding motifs for Sp1, CREB, and half sites of the estrogen receptor binding site. However
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 1006 offsetEnd: 1124 A: two AATAAA hexanucleotides, respectively 119 bp and 170 bp downstream of the TAA stop codon. A single poly(A) site was
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 3204 offsetEnd: 3340 A: sequence AATGAATATA. Three other sites are located within the adjacent plant DNA, giving rise to hybrid T-DNA/plant DNA transcripts. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18487515 offsetBegin: 675 offsetEnd: 811 A: approach to prepare 3' end fragments from polyadenylated RNA, and mapped the position of the poly(A) addition site using oligonucleotide
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18487515 offsetBegin: 3817 offsetEnd: 3968 A: 36 dimethylation is more prominent. Lysine 36 methylation decreases at or near the site of polyadenylation, sometimes disappearing before disappearance
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21527498 offsetBegin: 3062 offsetEnd: 3190 A: for HMGB1 in activation of estrogen/ER-responsive genes. Therefore, these data advocate that the minimal target site for ER is a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21527498 offsetBegin: 3190 offsetEnd: 3306 A: genes. Therefore, these data advocate that the minimal target site for ER is a cHERE (consensus HERE) that occurs in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21527498 offsetBegin: 3306 offsetEnd: 3418 A: the minimal target site for ER is a cHERE (consensus HERE) that occurs in many different contexts and that HMGB1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 1607 offsetEnd: 1736 A: tags can be attributed to TG transcripts and reflect the use of alternative polyadenylation cleavage sites downstream of a single
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 2678 offsetEnd: 2826 A: mRNA transcripts (44% human, 22% mouse and 22% rat) show cleavage site heterogeneity. When analyzing SAGE-generated expression data, this phenomenon
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10699189 offsetBegin: 689 offsetEnd: 833 A: signal and instead utilize a second downstream polyadenylation site. To determine the frequency of L1-mediated transduction in the human genome,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10699189 offsetBegin: 833 offsetEnd: 986 A: downstream polyadenylation site. To determine the frequency of L1-mediated transduction in the human genome, we selected 66 previously uncharacterized L1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 2449 offsetEnd: 2600 A: kb, observed on Northern blots, are differentiated by their utilization of alternative UbcM4 polyadenylation sites. A single alternative splice variant
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 2600 offsetEnd: 2764 A: differentiated by their utilization of alternative UbcM4 polyadenylation sites. A single alternative splice variant cDNA, termed UbcM4Deltaex2, was also identified.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10501966 offsetBegin: 3372 offsetEnd: 3520 A: ubiquitin-thioester in contrast to UbcM4, despite retaining the key cysteine residue essential for ubiquitin thioester formation and the active site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 2617 offsetEnd: 2775 A: identify trans-acting protein factors that bind exon 6 and regulate its splicing. These experiments identified cleavage and polyadenylation specificity factor
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 2775 offsetEnd: 2931 A: exon 6 and regulate its splicing. These experiments identified cleavage and polyadenylation specificity factor 1 (CPSF1) among protein-binding candidates. A
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3606 offsetEnd: 3720 A: splice site. Mutations to this site and CPSF1 knockdown both resulted in an increase in exon 6 inclusion. We found
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3720 offsetEnd: 3828 A: and CPSF1 knockdown both resulted in an increase in exon 6 inclusion. We found no evidence that this site is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 3942 offsetEnd: 4069 A: We found no evidence that this site is used to produce cleaved and polyadenylated mRNAs, suggesting that CPSF1 interaction with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 4069 offsetEnd: 4216 A: site is used to produce cleaved and polyadenylated mRNAs, suggesting that CPSF1 interaction with intronic IL7R pre-mRNA interferes with spliceosome
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 4757 offsetEnd: 4906 A: suggest that competing mRNA splicing and polyadenylation regulate exon 6 inclusion and consequently determine the ratios of soluble to membrane-bound
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 1172 offsetEnd: 1276 A: abnormal GR mRNA. In this DMS-79 cell GR the sequence normally derived from exons 8 and 9 is replaced by
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 2854 offsetEnd: 2962 A: normal GR gene revealed that the novel DMS-79 GR mRNA sequence is derived from intron G, between exons 7 and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 3189 offsetEnd: 3324 A: 7 and 8. No splice site mutations were found in PCR-amplified DMS-79 DNA fragments surrounding the downstream splice junctions. Further
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 1315 offsetEnd: 1474 A: the transcriptional initiation site retained gonadotroph-specific expression and the sexually dimorphic pattern of male greater than female FSHbeta mRNA levels
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 3035 offsetEnd: 3199 A: promoter elements. In silico phylogenetic comparisons of mammalian FSHbeta genes revealed five islands of highly conserved sequence homology corresponding precisely
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 3199 offsetEnd: 3345 A: of mammalian FSHbeta genes revealed five islands of highly conserved sequence homology corresponding precisely to the proximal 5' promoter region,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 4945 offsetEnd: 5080 A: sites within the highly conserved -350 bp promoter region. Notably absent from these 5' sequences, however, are consensus binding sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 5216 offsetEnd: 5345 A: these 5' sequences, however, are consensus binding sites for either Egr-1 or Lim-2 transcription factors known to be critical for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11865048 offsetBegin: 129 offsetEnd: 260 A: previously been shown to be required for the pre-mRNA polyadenylation cleavage reaction in vitro. This activity was found to reside
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/8442668 offsetBegin: 2094 offsetEnd: 2232 A: chain reaction with liver and leukocyte DNA from 13 subjects of established acetylator phenotype and NAT2 genotype. A prominent alteration
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/8442668 offsetBegin: 2232 offsetEnd: 2357 A: DNA from 13 subjects of established acetylator phenotype and NAT2 genotype. A prominent alteration in one of the variants was
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031412 offsetBegin: 893 offsetEnd: 1023 A: NrampCa-2912 nucleotides (nt), NrampCb-3245 nt, and NrampCc-3721 nt. At the 5' end, the transcripts have a common 2263 nt sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031412 offsetBegin: 1959 offsetEnd: 2082 A: amino acid sequence of the channel catfish Nramp (NrampC) has high homology to Nramp from other vertebrates and a predicted
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031412 offsetBegin: 2508 offsetEnd: 2674 A: contains the 12 transmembrane domains, and the consensus transport motif. Post-transcriptional processing is also conserved. Phylogenetic analysis grouped NrampC with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9614270 offsetBegin: 902 offsetEnd: 1069 A: experiments with computational approaches. Depending on available knowledge, three different strategies are employed. RESULTS: Searching with a consensus template, new
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9614270 offsetBegin: 1069 offsetEnd: 1218 A: available knowledge, three different strategies are employed. RESULTS: Searching with a consensus template, new RNAs with regulatory RNA elements can
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9614270 offsetBegin: 1218 offsetEnd: 1352 A: employed. RESULTS: Searching with a consensus template, new RNAs with regulatory RNA elements can be identified in genomic screens. By
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 778 offsetEnd: 896 A: two extra exons (exon -2 or exons -2, -1, respectively), but the first ATG codon and predicted amino-acid sequence are
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 1016 offsetEnd: 1145 A: first ATG codon and predicted amino-acid sequence are the same as in the transcript from P1. Luciferase assays confirmed promoter
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 2103 offsetEnd: 2227 A: units. Serial 5' deletions of P2 led to changes in reporter activity, the most prominent decreases were observed in deletion
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 5365 offsetEnd: 5486 A: well as exons -2 and -1, did not contain any sequence variations, with the exception of the known polymorphism rs10908459
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 2027 offsetEnd: 2140 A: downstream of the cleavage site is degraded. Here we show that Rtt103 and the Rat1/Rai1 5' --> 3' exonuclease are
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15565157 offsetBegin: 2362 offsetEnd: 2485 A: exonuclease are localized at 3' ends of protein coding genes. In rat1-1 or rai1Delta cells, RNA 3' to polyadenylation sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201123 offsetBegin: 3205 offsetEnd: 3348 A: evidence that SIRT3 is a prominent regulator in CR adaptation by coordinately deacetylating proteins involved in diverse pathways of metabolism
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 892 offsetEnd: 1030 A: We have used rapid amplification of cDNA ends (RACE) to identify multiple transcription initiation and polyadenylation sites for sense and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 1755 offsetEnd: 1880 A: the production of an array of TART transcripts. In contrast to other Drosophila non-LTR elements, a major initiation site for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 2013 offsetEnd: 2142 A: Drosophila non-LTR elements, a major initiation site for sense transcripts was mapped near the 3' end of the TART 5'-untranslated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 2955 offsetEnd: 3097 A: residue. The other transcripts, termed NIPP-1beta, gamma and delta, are generated by alternative 5'-splice site usage, by exon skipping and/or
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 4235 offsetEnd: 4378 A: 'activator of RNA decay-1' (Ard-1) which, unlike NIPP-1alpha, displays in vitro and endoribonuclease activity and lacks an RVXF consensus motif
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 4378 offsetEnd: 4529 A: unlike NIPP-1alpha, displays in vitro and endoribonuclease activity and lacks an RVXF consensus motif for interaction with protein phosphatase-1. While
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 4694 offsetEnd: 4853 A: consensus motif for interaction with protein phosphatase-1. While the NIPP-1alpha/beta/delta-transcripts were found to be present in various human tissues, the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16308319 offsetBegin: 507 offsetEnd: 629 A: as genomic RNA for progeny virions and also promotes polyadenylation of the unspliced RNA. Integral to NRS function is the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16308319 offsetBegin: 1803 offsetEnd: 1941 A: just downstream of the consensus U11 binding site. We present evidence that heterogeneous nuclear ribonucleoprotein (hnRNP) H binds to the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 1235 offsetEnd: 1358 A: acid protein, a 342-bp 3' UTR with six cytokine RNA instability motifs (ATTTA), and a polyadenylation signal (AATAAA) at 13
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3246 offsetEnd: 3382 A: and expression level was maximal after 4h. The predicted 253 amino acid sequence shares 23.5-88.5% identity and 43.9-93.3% similarity to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3382 offsetEnd: 3512 A: 4h. The predicted 253 amino acid sequence shares 23.5-88.5% identity and 43.9-93.3% similarity to known IL-1 beta. Thus, IL-1 beta
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3512 offsetEnd: 3638 A: sequence shares 23.5-88.5% identity and 43.9-93.3% similarity to known IL-1 beta. Thus, IL-1 beta is very conserved in fish of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 4350 offsetEnd: 4467 A: with other species showed a possible cut site between Tyr87 and Thr88 that would give rise to a 166-amino-acid mature
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 4467 offsetEnd: 4588 A: cut site between Tyr87 and Thr88 that would give rise to a 166-amino-acid mature peptide. The putative mature peptide was
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 140 offsetEnd: 287 A: growth factor (EGF) family of peptide ligands that are characterized by a six-cysteine consensus motif (EGF-motif) that forms three intra-molecular
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 287 offsetEnd: 437 A: ligands that are characterized by a six-cysteine consensus motif (EGF-motif) that forms three intra-molecular disulfide bonds, crucial for binding the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 3222 offsetEnd: 3342 A: length, respectively. The EGF-motif is encoded by exons 3 and 4 with an intron (intron C) disrupting the coding sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 3454 offsetEnd: 3593 A: an intron (intron C) disrupting the coding sequence between the second and third disulfide loops. All exon-intron boundaries are consistent
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 3593 offsetEnd: 3742 A: coding sequence between the second and third disulfide loops. All exon-intron boundaries are consistent with the "gt-ag" rule. Multiple transcription
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 4292 offsetEnd: 4436 A: of a polyadenylation signal sequence, were identified by 5'- and 3'-RACE, respectively. Approximately 2.6 kb of 5'-flanking region was sequenced
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12727900 offsetBegin: 3781 offsetEnd: 3943 A: the same TT/AAAA consensus found for the L1 endonuclease, supporting an L1-mediated retrotransposition mechanism. Finally, because our algorithm included aligning
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15665278 offsetBegin: 1035 offsetEnd: 1158 A: were found in the essential promoter area, one of which is located in a Sp1 recognition site (-216). Transient transfection
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15665278 offsetBegin: 1158 offsetEnd: 1277 A: area, one of which is located in a Sp1 recognition site (-216). Transient transfection in human cancer and primary cell
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15665278 offsetBegin: 1277 offsetEnd: 1421 A: in a Sp1 recognition site (-216). Transient transfection in human cancer and primary cell lines showed significantly different promoter activity
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 1634 offsetEnd: 1747 A: composed of 13 exons (E1a, 1b, 1c, E1-E10) encoding two groups of mRNAs differing in length and sequence at their
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 3249 offsetEnd: 3360 A: 2 messages usually contain exons E1a, 1c, part of E1 and E2-E10. The translation start site is localized in the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 1839 offsetEnd: 1983 A: that could be involved in pre-mRNA polyadenylation. Results evidenced the presence of an AU-rich domain corresponding to the consensus UA(A/U)UU
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 3202 offsetEnd: 3348 A: mRNA folding of genes with known polyadenylation site. The molecular organization of pre-mRNA 3'-UTR cis-regulatory elements appears to be roughly
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 3348 offsetEnd: 3511 A: polyadenylation site. The molecular organization of pre-mRNA 3'-UTR cis-regulatory elements appears to be roughly conserved through evolutionary scale, whereas the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 458 offsetEnd: 614 A: and have seven exons, including two alternatively spliced exons encoding different N-termini. Two candidate promoters with consensus sites for transcription
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 1746 offsetEnd: 1885 A: spaced polyadenylation signals, and both are used. A proposed third splice variant encoding a 31-residue N-terminal extension was not found
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 2746 offsetEnd: 2885 A: recombination with unrelated DNA from chromosome 2. FXYD2 is on chromosome 11q23 close to a site of tumorigenic chromosomal translocations,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 339 offsetEnd: 503 A: vertebrate polyadenylation, the factors and mechanisms involved in facilitating communication between polyadenylation and splicing are largely unknown. Even less is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 658 offsetEnd: 786 A: and splicing are largely unknown. Even less is known about the regulation of polyadenylation in genes in which 3'-terminal exons
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 786 offsetEnd: 925 A: less is known about the regulation of polyadenylation in genes in which 3'-terminal exons are alternatively recognized. Here we demonstrate
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 925 offsetEnd: 1064 A: of polyadenylation in genes in which 3'-terminal exons are alternatively recognized. Here we demonstrate that an SR protein, SRp20, affects
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 4460 offsetEnd: 4590 A: the exon 4 poly(A) site. This is the first demonstration that an SR protein can influence alternative polyadenylation and suggests
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 4590 offsetEnd: 4723 A: is the first demonstration that an SR protein can influence alternative polyadenylation and suggests that this family of proteins may
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9710581 offsetBegin: 4723 offsetEnd: 4851 A: SR protein can influence alternative polyadenylation and suggests that this family of proteins may play a role in recognition of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 1513 offsetEnd: 1646 A: ends analysis revealed that they share a common polyadenylation signal but have two start sites. Two transcripts were identified, one
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16809309 offsetBegin: 1646 offsetEnd: 1774 A: a common polyadenylation signal but have two start sites. Two transcripts were identified, one 3.4 kb encoding ORF35-37, and the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 2325 offsetEnd: 2470 A: the pyrimidine content of query sequences into a scoring function. We also investigated a novel approach for predicting polyadenylation (poly(A))
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 2470 offsetEnd: 2619 A: into a scoring function. We also investigated a novel approach for predicting polyadenylation (poly(A)) sites in-silico, by comparing query sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 2958 offsetEnd: 3119 A: query sequences to polyadenylated expressed sequence tags (ESTs) using position-specific scanning matrices (PSSMs). An additional analysis of the distribution of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 4819 offsetEnd: 4968 A: comparative sequence analysis. We discuss the impact of certain regions surrounding the poly(A) sites on prediction rates and contemplate correlating
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 0 offsetEnd: 136 A: The Rous sarcoma virus (RSV) negative regulator of splicing (NRS) is an RNA element that represses splicing and promotes polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 507 offsetEnd: 641 A: NRS acts as a pseudo 5' splice site (ss), and serine-arginine (SR) proteins, U1snRNP, and U6 small nuclear ribonucleoproteins (snRNPs)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 641 offsetEnd: 787 A: splice site (ss), and serine-arginine (SR) proteins, U1snRNP, and U6 small nuclear ribonucleoproteins (snRNPs) are implicated in its function. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 2322 offsetEnd: 2453 A: G-rich element located downstream of the U11 site is required for efficient binding. Mutational analyses indicated that two of four
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17581856 offsetBegin: 744 offsetEnd: 905 A: mechanisms are likely not involved. Kv4 channels also display prominent inactivation from preactivated closed states [closed-state inactivation (CSI)], a process
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17581856 offsetBegin: 905 offsetEnd: 1055 A: channels also display prominent inactivation from preactivated closed states [closed-state inactivation (CSI)], a process that appears to be absent in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11105754 offsetBegin: 1290 offsetEnd: 1413 A: was identified in human HBP [Wang Z-F et al., Genes & Dev, 1996, 10:3028-3040]. The primary sequence identity between human
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11105754 offsetBegin: 1541 offsetEnd: 1680 A: 1996, 10:3028-3040]. The primary sequence identity between human and Caenorhabditis elegans RBDs is 55% compared to 38% for the full-length
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 431 offsetEnd: 567 A: were characterized. The 3' flanking region is marked by the presence of two polyadenylation signals but used with different frequencies.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 0 offsetEnd: 153 A: The nucleotide sequence of a 3240-bp genomic fragment including the gamma-actin-encoding gene from Acremonium chrysogenum has been determined, showing an
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11152070 offsetBegin: 569 offsetEnd: 702 A: 1691 bp, interrupted by five introns with fungal consensus splice-site junctions. The untranslated regions of the actA gene contain a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15676283 offsetBegin: 2214 offsetEnd: 2343 A: to brain and spinal cord. The 4.8-kb promoter contains eight consensus Sp1-binding sites and two Inr sites. A potential NRSE/RE-1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 611 offsetEnd: 783 A: cis-acting sequences that direct cleavage and polyadenylation of the pre-mRNA. Termination of nonpolyadenylated [non-poly(A)] Pol II transcripts in Saccharomyces cerevisiae
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 1539 offsetEnd: 1674 A: termination elements downstream of the SNR13 and SNR47 snoRNA genes. This approach detected two common RNA sequence motifs, GUA[AG] and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 1674 offsetEnd: 1801 A: and SNR47 snoRNA genes. This approach detected two common RNA sequence motifs, GUA[AG] and UCUU. The first motif corresponds to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 1801 offsetEnd: 1928 A: detected two common RNA sequence motifs, GUA[AG] and UCUU. The first motif corresponds to the known Nrd1-binding site, which we
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 2906 offsetEnd: 3035 A: a significant role in defining non-poly(A) terminators. As is the case with poly(A) terminators, there is no strong consensus for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9740674 offsetBegin: 1567 offsetEnd: 1675 A: TNFR2 lacks a canonical TATA box, the gene is transcribed from a unique start site located 70 bp upstream of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9740674 offsetBegin: 1675 offsetEnd: 1788 A: the gene is transcribed from a unique start site located 70 bp upstream of the ATG initiation codon that conforms
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9740674 offsetBegin: 1906 offsetEnd: 2047 A: upstream of the ATG initiation codon that conforms to the consensus Inr motif. Several cis-elements for transcription factors were identified
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9740674 offsetBegin: 2047 offsetEnd: 2188 A: that conforms to the consensus Inr motif. Several cis-elements for transcription factors were identified in the 5' flanking region, including
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 1586 offsetEnd: 1700 A: NAG1 was used to infer phylogenetic relationships. The amino acid sequence of Pb NAG1 has 45, 31 and 30% identity,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 3227 offsetEnd: 3353 A: NAG1 belongs to glycosyl hydrolase family 20. The nucleotide sequence of Pb nag1 and its flanking regions have been deposited,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 3472 offsetEnd: 3592 A: nag1 and its flanking regions have been deposited, along with the amino acid sequence of the deduced protein, in GenBank
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10929203 offsetBegin: 1285 offsetEnd: 1410 A: amino acid sequence of the zebrafish desmin shares a high degree of similarity to other vertebrate desmins, but also contains
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10929203 offsetBegin: 1410 offsetEnd: 1534 A: desmin shares a high degree of similarity to other vertebrate desmins, but also contains a sequence at the carboxyl terminal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10929203 offsetBegin: 1534 offsetEnd: 1654 A: similarity to other vertebrate desmins, but also contains a sequence at the carboxyl terminal of the tail domain that is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16006100 offsetBegin: 5038 offsetEnd: 5172 A: a chaperone-like protein related to its DNA-J domain. These studies suggest that alternative splicing is not a prominent mechanism for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15681073 offsetBegin: 891 offsetEnd: 1027 A: infectivity factor) gene. The sequence of a 2.4 kb fragment that includes pif was determined. Multiple transcripts encompassing pif were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15681073 offsetBegin: 2861 offsetEnd: 2978 A: small ORF. This transcript would start at a late consensus motif internal to pif coding sequences, ending at the same
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 141 offsetEnd: 267 A: with different 3'-ends. Of these, four genes are known to produce truncated transcripts that end within the coding sequence of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 388 offsetEnd: 497 A: transcripts that end within the coding sequence of longer transcripts: CBP1 , AEP2 / ATP13 , RNA14 and SIR1 .
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 497 offsetEnd: 594 A: sequence of longer transcripts: CBP1 , AEP2 / ATP13 , RNA14 and SIR1 . It has been shown that the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9753737 offsetBegin: 4181 offsetEnd: 4324 A: again weak putative 3'-end formation signals were identified. These data are suggestive of carbon source regulation of alternative poly(A) site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 4046 offsetEnd: 4184 A: the novel transcript contains an additional 10 kb beyond the annotated gene terminus to a highly conserved alternate polyadenylation site.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23817991 offsetBegin: 4845 offsetEnd: 5008 A: neurons confirmed that this 3'-UTR-extended variant was preferentially expressed in IB4-binding neurons. Computational analyses of the 3'-UTR sequence predict that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 1514 offsetEnd: 1638 A: to the center of chromosome 16, using a radiation hybrid-mapping panel. The major transcription start site is 80 bp upstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 1638 offsetEnd: 1761 A: using a radiation hybrid-mapping panel. The major transcription start site is 80 bp upstream of the ATG initiation codon as
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 1761 offsetEnd: 1882 A: major transcription start site is 80 bp upstream of the ATG initiation codon as determined by rapid amplification of cDNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 1882 offsetEnd: 2021 A: bp upstream of the ATG initiation codon as determined by rapid amplification of cDNA ends (5'-RACE) analysis. Two potential polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 2153 offsetEnd: 2293 A: of cDNA ends (5'-RACE) analysis. Two potential polyadenylation sites are 3233 and 3293 bp downstream of the termination codon, respectively.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 2293 offsetEnd: 2451 A: potential polyadenylation sites are 3233 and 3293 bp downstream of the termination codon, respectively. Transient transfection of reporter plasmids containing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 3423 offsetEnd: 3563 A: starting site. Furthermore, the transfected luciferase activity was much higher in AtT-20 than NIH3T3. According to sequence analysis of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 3987 offsetEnd: 4115 A: GC rich segments including consensus sequences for binding of the transcription factor Sp1, but no TATA/CAAT boxes, exist in the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 4195 offsetEnd: 4306 A: and a T-rich region were prominent features. Most of the conservation was located in, or adjacent to, R and U5,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 5040 offsetEnd: 5195 A: consensus alignment allowed comparison of functional features like transcriptional start sites (sense and antisense) between XRVs and ERVs. CONCLUSION: The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 1711 offsetEnd: 1858 A: mutations in 3'-cleavage and polyadenylation factors, Rna14, Rna15 and Pap1, which block accumulation of other mRNAs. The 3'-extended CTH2 pre-mRNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 909 offsetEnd: 1010 A: is a stable intron encoded by HCMV. The 5-kb RNA is highly AT rich in sequence and lacks open reading
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10072078 offsetBegin: 1567 offsetEnd: 1707 A: contribute to its neglect in naive T cells. These alternative polyadenylation events ensure the rapid accumulation of high concentrations of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10072078 offsetBegin: 1707 offsetEnd: 1858 A: T cells. These alternative polyadenylation events ensure the rapid accumulation of high concentrations of NF-ATc necessary to exceed critical threshold
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 1846 offsetEnd: 1964 A: four introns ranging in size from 109 to 190bp. The 3' flanking region had a potential polyadenylation signal with the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 2457 offsetEnd: 2583 A: conventional sequence AATAAA. The gene was AT-rich, with a GC content of 37.2%. Southern blot analysis of W. bancrofti genomic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 2814 offsetEnd: 2928 A: bancrofti genomic DNA indicated that the gene is possibly found as a single copy. The actin amino acid sequence of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10704593 offsetBegin: 2928 offsetEnd: 3035 A: gene is possibly found as a single copy. The actin amino acid sequence of W. bancrofti showed a high degree
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 2128 offsetEnd: 2268 A: relative to other normal human tissues and is expressed as different transcripts using at least three different polyadenylation signals. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 2548 offsetEnd: 2690 A: signals. The PART-1 cDNA and putative protein are not significantly homologous to any sequences in the nonredundant public sequence databases.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 2690 offsetEnd: 2831 A: protein are not significantly homologous to any sequences in the nonredundant public sequence databases. Cloning and analysis of the putative
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 2831 offsetEnd: 2974 A: any sequences in the nonredundant public sequence databases. Cloning and analysis of the putative PART-1 promoter region identified a potential
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10706094 offsetBegin: 3387 offsetEnd: 3531 A: homeobox gene PBX-la, but no consensus androgen response element or sterol-regulatory element binding sites were identified. We used a radiation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11376942 offsetBegin: 1423 offsetEnd: 1563 A: polyadenylation were identified 1.3 kb downstream of the gene, defining a long 3' untranslated region. The minimal functional VDUP1 promoter
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11376942 offsetBegin: 2319 offsetEnd: 2450 A: the TATA with homology to the USF binding site was identified as a potential regulator of VDUP1gene expression. Expression analysis
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11376942 offsetBegin: 2450 offsetEnd: 2591 A: USF binding site was identified as a potential regulator of VDUP1gene expression. Expression analysis determined that VDUP1 mRNA was markedly
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 1835 offsetEnd: 1969 A: (UTR) and a 163 bp long 3'UTR containing three putative polyadenylation signals (AATAAA) and an ATTTA element. The secondary structure
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 1969 offsetEnd: 2110 A: 3'UTR containing three putative polyadenylation signals (AATAAA) and an ATTTA element. The secondary structure of the mRNA predicted by MFOLD
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 2743 offsetEnd: 2875 A: structure of Smf3h includes four exons and three introns within the coding region, with all the splice donor/acceptor site sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16147863 offsetBegin: 3266 offsetEnd: 3381 A: "GU-AG" consensus rule. The deduced SmF3H protein is 343 amino acid residues in length and has 40% and 39% identity
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16778175 offsetBegin: 1527 offsetEnd: 1658 A: mediating apoptosis. Moreover, we identify a 10-bp perfect palindrome motif (CTGGCGCCAG) in the MKP2 promoter as a new binding site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16778175 offsetBegin: 2142 offsetEnd: 2270 A: is completely different from the consensus p53 binding sequence. Induction of MKP2 is highly responsive to oxidative stress in a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9651483 offsetBegin: 2104 offsetEnd: 2234 A: by two introns spanning approx. 2.3kb of genomic DNA. 5' RACE analysis mapped the transcriptional initiation site 98bp upstream of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12631330 offsetBegin: 1915 offsetEnd: 2043 A: site) was a consensus motif for the initiation region in vitro, as reported in vivo. Mutation analysis defined functionally that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12631330 offsetBegin: 2573 offsetEnd: 2711 A: the CTCA motif is a determinant of transcription initiation sites but not transcript levels. Polyadenylation sites were determined from in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12631330 offsetBegin: 2711 offsetEnd: 2863 A: of transcription initiation sites but not transcript levels. Polyadenylation sites were determined from in vivo transcripts, located 12-21 nt downstream
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12631330 offsetBegin: 2863 offsetEnd: 3013 A: transcript levels. Polyadenylation sites were determined from in vivo transcripts, located 12-21 nt downstream from likely poly(A) signals. Four major
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17656373 offsetBegin: 115 offsetEnd: 228 A: disease modifier gene that is required for efficient in vivo splicing of a mutant splice donor site in the sodium
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17656373 offsetBegin: 228 offsetEnd: 343 A: for efficient in vivo splicing of a mutant splice donor site in the sodium channel Scn8a. It was previously unclear
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17656373 offsetBegin: 343 offsetEnd: 464 A: a mutant splice donor site in the sodium channel Scn8a. It was previously unclear whether the modifier effect on splicing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22958278 offsetBegin: 2107 offsetEnd: 2231 A: This approach becomes even more useful in the event of little or no binding site information between the interacting protein
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22958278 offsetBegin: 2231 offsetEnd: 2380 A: in the event of little or no binding site information between the interacting protein molecules. FINDINGS: A plausible protein-protein hetero-complex
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 313 offsetEnd: 448 A: hybridization and 5'/3' RACE techniques. PSG076 was shown to exhibit multi-site polyadenylation by sequencing the 3' ends of the cDNAs.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 448 offsetEnd: 575 A: was shown to exhibit multi-site polyadenylation by sequencing the 3' ends of the cDNAs. At least six transcripts with different
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 1690 offsetEnd: 1794 A: 663 bp encoding a 221 amino acid peptide with pI of 4.31. A blast search revealed that this sequence did
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 1794 offsetEnd: 1907 A: acid peptide with pI of 4.31. A blast search revealed that this sequence did not show a significant similarity to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15248021 offsetBegin: 1907 offsetEnd: 2024 A: A blast search revealed that this sequence did not show a significant similarity to any genes deposited in the public
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 766 offsetEnd: 893 A: RNA in normal and knockout mice. METHODS: The DNA sequence was determined by sub-cloning restriction fragments of the IRBP gene
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 893 offsetEnd: 1023 A: METHODS: The DNA sequence was determined by sub-cloning restriction fragments of the IRBP gene from 129/Sv P1 clones. Primers were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 3118 offsetEnd: 3235 A: bovine and human genes, with a long first exon encoding most of the protein. The splice site boundaries closely match
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 3622 offsetEnd: 3751 A: exons appear to be identically placed among the three species (bovine, human, and mouse). A region containing a repeated sequence
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 3751 offsetEnd: 3877 A: among the three species (bovine, human, and mouse). A region containing a repeated sequence of low complexity is located about
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 3990 offsetEnd: 4108 A: repeated sequence of low complexity is located about 1.75 to 1.4 kb upstream of the transcription start site. A second
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12434304 offsetBegin: 4465 offsetEnd: 4566 A: complexity repeat is found in Intron C close to the end of Exon 3. A limited number of weak consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 1709 offsetEnd: 1847 A: signals, the hairpin structure and at least one AATAAA polyadenylation signal. In their 5' region, the transcription initiation sites with
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17381045 offsetBegin: 2234 offsetEnd: 2346 A: 5'-PyATTCPu-3' known as the CAP site were present in all genes except to H2B, generally 37-45 bp upstream of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12533698 offsetBegin: 3619 offsetEnd: 3762 A: RNAs carrying the corresponding UL37 exonic and intronic sequences. Moreover, alternative splicing using two novel UL37 exon 3 consensus splice
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12533698 offsetBegin: 3762 offsetEnd: 3891 A: and intronic sequences. Moreover, alternative splicing using two novel UL37 exon 3 consensus splice donors (di and dii) was found
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12533698 offsetBegin: 4794 offsetEnd: 4937 A: precise UL37x1 donor selection is modulated by 3'-distal UL37 intronic sequences; and (iii) UL37 exon 3 contains multiple alternative consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17942399 offsetBegin: 3841 offsetEnd: 3973 A: in pull-down assays, rather than binding eIF4G, it binds 4E-T, in a manner independent of the consensus eIF4E-binding site, YSKEELL.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15121831 offsetBegin: 2304 offsetEnd: 2444 A: site. Single mutations at this site are sufficient to completely change the carbon source regulation of the KlCat8p transactivation activity
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15121831 offsetBegin: 4658 offsetEnd: 4813 A: Unlike that of S. cerevisiae ScCAT8, KlCAT8 transcription is not carbon source regulated, illustrating the prominent role of posttranscriptional regulation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 1548 offsetEnd: 1690 A: region included AP2, USF, Stat-6, NFkappaB and Olf-1. A single canonical polyadenylation signal (AATAAA) was found at position +3252/+3257 and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 3860 offsetEnd: 3980 A: search for sequence variants within a fragment covering 1.7 kb of 5'-flanking region and the coding region allowed us to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15037199 offsetBegin: 5443 offsetEnd: 5589 A: and computer-assisted sequence analysis, the -98 G/C single nucleotide polymorphism was located within a portion of the 5'-UTR (-127/+3) affecting
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10448076 offsetBegin: 2863 offsetEnd: 3021 A: 3' flanking region. SP-HSP70 protein sequence resembles the cytosolic/nuclear HSP70 cluster. RT-PCR studies confirmed SP-HSP70 mRNA expression in corals grown
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3719 offsetEnd: 3844 A: was identified close to the AAUAAA hexanucleotide sequence of the exon 4 poly(A) site. These observations suggest a dual role
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9858533 offsetBegin: 3844 offsetEnd: 3973 A: hexanucleotide sequence of the exon 4 poly(A) site. These observations suggest a dual role for PTB in facilitating recognition of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12124466 offsetBegin: 2616 offsetEnd: 2742 A: was seen from 36 h post-infection (p.i.). The transcription of lef-8 initiated early in infection from a GTGCAAT sequence that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 2657 offsetEnd: 2781 A: was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA. Within
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 5051 offsetEnd: 5176 A: on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 5667 offsetEnd: 5787 A: as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/14993281 offsetBegin: 6534 offsetEnd: 6682 A: binding array analysis of nuclear lysate from RA-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 1365 offsetEnd: 1508 A: single Ig-like extracellular domain, and exon 9 encodes the transmembrane region, cytoplasmic tail and 3' UTR with four polyadenylation signals
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 1508 offsetEnd: 1643 A: 9 encodes the transmembrane region, cytoplasmic tail and 3' UTR with four polyadenylation signals and six mRNA instability sequences. A
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 1643 offsetEnd: 1760 A: tail and 3' UTR with four polyadenylation signals and six mRNA instability sequences. A soluble form of PIR-A6 may be
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 2531 offsetEnd: 2666 A: Pirb gene, thus defining Pira and Pirb as genes with relatively short intronic sequences. Extensive sequence homology was found between
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694571 offsetBegin: 2666 offsetEnd: 2803 A: Pirb as genes with relatively short intronic sequences. Extensive sequence homology was found between Pira6 and Pirb from approximately 2
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024296 offsetBegin: 553 offsetEnd: 706 A: analysis, which determined the transcription start point (tsp) and polyadenylation site, respectively, showed that the gene produces single mRNA species.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024296 offsetBegin: 706 offsetEnd: 853 A: point (tsp) and polyadenylation site, respectively, showed that the gene produces single mRNA species. The potential promoter region lacks distinct
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024296 offsetBegin: 853 offsetEnd: 989 A: showed that the gene produces single mRNA species. The potential promoter region lacks distinct TATAAA or CCAAT box consensus sequences.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024296 offsetBegin: 989 offsetEnd: 1124 A: mRNA species. The potential promoter region lacks distinct TATAAA or CCAAT box consensus sequences. RNA blot analysis revealed that the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024296 offsetBegin: 1124 offsetEnd: 1252 A: lacks distinct TATAAA or CCAAT box consensus sequences. RNA blot analysis revealed that the gene encodes a 1.4kb transcript that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11024296 offsetBegin: 1252 offsetEnd: 1390 A: consensus sequences. RNA blot analysis revealed that the gene encodes a 1.4kb transcript that could be detected throughout development and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 3373 offsetEnd: 3514 A: addition site terminated 98% and 86% of transcription for ACTB and HBB sequences, respectively. The nearly 10-fold difference in read-through
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 4109 offsetEnd: 4248 A: additional downstream poly(A) sequence was included for each gene. Both poly(A) regions proved very effective at termination when 1100 base
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 4891 offsetEnd: 5031 A: simply due to the increased template length, we inserted several kilobases of heterologous coding sequence downstream of each poly(A) region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19587781 offsetBegin: 5031 offsetEnd: 5185 A: length, we inserted several kilobases of heterologous coding sequence downstream of each poly(A) region test fragment. Unexpectedly, the additional length
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15965016 offsetBegin: 0 offsetEnd: 153 A: Using a novel program, SignalSleuth, and a database containing authenticated polyadenylation [poly(A)] sites, we analyzed the composition of mRNA poly(A)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15965016 offsetBegin: 2448 offsetEnd: 2585 A: mutagenesis and are contemplated as a cluster of signals for cleavage site recognition. Moreover, a single-nucleotide profile scan on the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15965016 offsetBegin: 2585 offsetEnd: 2731 A: cluster of signals for cleavage site recognition. Moreover, a single-nucleotide profile scan on the 3'-UTR regions unveiled a distinct arrangement
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15727844 offsetBegin: 0 offsetEnd: 144 A: We determined the nucleotide sequence of a 4599-bp DNA genomic fragment including the gamma-actin encoding gene from Blakeslea trispora, showing
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 742 offsetEnd: 851 A: a motif with consensus AAUAAA, followed by a U or UG rich region downstream of the cleavage site. RESULTS: We
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 1255 offsetEnd: 1397 A: exhaustive databases of cleavage sites obtained from aligning raw expressed sequence tags (EST) sequences to genomic sequences in Homo sapiens
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 1397 offsetEnd: 1536 A: from aligning raw expressed sequence tags (EST) sequences to genomic sequences in Homo sapiens and Drosophila melanogaster. These data show
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 1536 offsetEnd: 1675 A: (EST) sequences to genomic sequences in Homo sapiens and Drosophila melanogaster. These data show that the polyadenylation signal is highly
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 1805 offsetEnd: 1930 A: data show that the polyadenylation signal is highly conserved in human and fly. In addition, de novo motif searches generated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 2182 offsetEnd: 2324 A: searches generated a refined description of the U-rich downstream sequence (DSE) element, which shows more divergence between the two species.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 2324 offsetEnd: 2463 A: the U-rich downstream sequence (DSE) element, which shows more divergence between the two species. These refined motifs are applied, within
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 3104 offsetEnd: 3215 A: DSE is a specific motif in both human and Drosophila. These findings shed light on the sequence correlates of a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 3215 offsetEnd: 3348 A: both human and Drosophila. These findings shed light on the sequence correlates of a highly conserved biological process, and improve
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16836751 offsetBegin: 3348 offsetEnd: 3471 A: shed light on the sequence correlates of a highly conserved biological process, and improve in silico prediction of 3' mRNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 968 offsetEnd: 1104 A: on sequence analysis of several cDNAs, we have previously suggested that the UAAA tetranucleotide (which may include the UAA translation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 1242 offsetEnd: 1387 A: UAAA tetranucleotide (which may include the UAA translation stop codon) could be the polyadenylation signal in Trichomonas vaginalis, a parasitic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 1537 offsetEnd: 1685 A: the polyadenylation signal in Trichomonas vaginalis, a parasitic protozoon that causes human trichomoniasis. This proposal is analyzed here with the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22467744 offsetBegin: 2336 offsetEnd: 2476 A: sequences). When cells were transfected with a plasmid bearing the original 3' untranslated region (UTR) sequence containing the UAAA motif,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 1875 offsetEnd: 1992 A: Flury-LEP-C genome, except G gene which had a GAGAAAAAAA sequence in the end of the non-coding G-L region. There were
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423522 offsetBegin: 2111 offsetEnd: 2239 A: end of the non-coding G-L region. There were AACAYYYCT consensus start signal close to the TGA7. Flury-LEP-C has 310 nucleotides
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 4844 offsetEnd: 5006 A: cytoprotection. In conclusion, these observations support a prominent role for CAR cytoprotection against Fas-mediated hepatocyte injury via a mechanism involving
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16799968 offsetBegin: 5006 offsetEnd: 5160 A: a prominent role for CAR cytoprotection against Fas-mediated hepatocyte injury via a mechanism involving upregulation of Mcl-1 and, likely, downregulation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 1514 offsetEnd: 1660 A: and III) each harboring distinctive features. Analysis of 158 transcribed SIREs demonstrates that the consensus is highly conserved. The sequences
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 3855 offsetEnd: 3992 A: C-terminal amino acids derive from codons specified by SIRE's region II. The amino acid sequence of VIPER's reverse transcriptase-RNase H
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 3992 offsetEnd: 4126 A: specified by SIRE's region II. The amino acid sequence of VIPER's reverse transcriptase-RNase H shares significant homology to that of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10688909 offsetBegin: 4126 offsetEnd: 4273 A: amino acid sequence of VIPER's reverse transcriptase-RNase H shares significant homology to that of long terminal repeat retrotransposons. The fact
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 2935 offsetEnd: 3066 A: sites, and a consensus transport motif. Analysis of the distribution of Nramp2 mRNA transcripts in normal mouse tissues by Northern
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/7789986 offsetBegin: 3768 offsetEnd: 3914 A: by the use of alternative polyadenylation signals. In contrast to the previously described macrophage-specific Nramp gene, Nramp2 mRNAs were found
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23954224 offsetBegin: 2334 offsetEnd: 2480 A: splice site mutations, predicted with the bioinformatics tool Human Splice Finder, were investigated and evaluated in relation to ex-vivo results.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 609 offsetEnd: 760 A: binding site for the Atf1/Pcr1 heterodimeric transcription factor required for hot spot activation. We previously demonstrated that the local chromatin
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 903 offsetEnd: 1048 A: activation. We previously demonstrated that the local chromatin around the M26 sequence motif alters to exhibit higher sensitivity to micrococcal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17827346 offsetBegin: 1048 offsetEnd: 1187 A: local chromatin around the M26 sequence motif alters to exhibit higher sensitivity to micrococcal nuclease before the initiation of meiotic
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 2049 offsetEnd: 2175 A: sites in undifferentiated cells. The sites for polyadenylation extended over a range of 100 nucleotides from within the E5 ORF
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10438805 offsetBegin: 2689 offsetEnd: 2821 A: genes increased, but no change in the heterogeneous distribution of 3' ends was detected. The early polyadenylation region was found
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/6312290 offsetBegin: 1199 offsetEnd: 1312 A: untransported nuclear RNA. The 5' ends of this RNA are heterogeneous but contain a prominent 5' end at the normal
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/6312290 offsetBegin: 1544 offsetEnd: 1661 A: the normal position (nucleotide 325) in addition to several other prominent 5' ends not seen in wild-type RNA. The 3'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9837805 offsetBegin: 0 offsetEnd: 134 A: The complete nucleotide sequence of porcine adenovirus type 3 was determined and a transcriptional map for the genome was constructed.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 1755 offsetEnd: 1904 A: the putative transcription start sites (TSSs) and polyadenylation sites (PASs). Individual and clustered TSSs were found preceding 104 annotated open
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 2342 offsetEnd: 2471 A: pseudogenes. In the majority of cases, a 15-nucleotide consensus core motif was present upstream of the ORF. This motif, however,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21490097 offsetBegin: 2471 offsetEnd: 2596 A: a 15-nucleotide consensus core motif was present upstream of the ORF. This motif, however, was also present at numerous other
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10723723 offsetBegin: 2847 offsetEnd: 2979 A: conform to the consensus for an initiator promoter element. Additionally, the mouse promoter contains 22 copies of a CT dinucleotide
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15956342 offsetBegin: 2388 offsetEnd: 2515 A: indicating that an element existed within the first -59 base pairs upstream of the transcription start site that was responsive
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15474003 offsetBegin: 2196 offsetEnd: 2338 A: consensus sites (NX(S/T)) in the extracellular alpha2 domain of the protein that are functional. Substitution of asparagines for glutamines at
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 4162 offsetEnd: 4295 A: of the distal signal sequences were then confirmed by mutagenesis of putative signal elements in a polyadenylation reporter assay. We
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17615362 offsetBegin: 4871 offsetEnd: 5016 A: splicing and from alternative polyadenylation directed by strong intronic poly(A) signal sequences leading to C-terminal variants and to an sFlt1
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12904181 offsetBegin: 914 offsetEnd: 1058 A: murine Nat2 gene, we have analysed its structure and transcriptional regulation. We have accurately mapped the transcription initiation site 6.5
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12904181 offsetBegin: 1320 offsetEnd: 1442 A: site 6.5 kb upstream of the coding region of the gene, adjacent to a recently described non-coding exon. Transcription was
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12904181 offsetBegin: 3058 offsetEnd: 3173 A: of the 13 kb sequence flanking the coding and non-coding exons of Nat2 revealed a single promoter, located close to
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 2233 offsetEnd: 2365 A: the two binding sites is predicted to be high affinity, by comparison to a functionally derived consensus BvgA-binding sequence. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20662776 offsetBegin: 3687 offsetEnd: 3814 A: (CCCCCC versus TTGACA), and the occupation of this site by BvgA∼P suggest that activation of the fim promoters involves unusual
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22162666 offsetBegin: 2698 offsetEnd: 2821 A: ICGs and higher for transcripts that bind strongly to spliceosomes than those that bind weakly. The 3' splice site features
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 792 offsetEnd: 913 A: motif that evolved from UAA after one round of splicing toward a UACUAAC consensus after seven rounds. A significant part
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 2399 offsetEnd: 2545 A: but quite promiscuously. Surprisingly, the conserved guanosine, adjacent to the common AAUAAA polyadenylation motif, was found to be required only
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10786844 offsetBegin: 3677 offsetEnd: 3790 A: high frequency of UCCU motifs and a highly conserved YAG sequence in the extreme 3' end of the randomized insert.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 1150 offsetEnd: 1297 A: The isolated copies are degenerate to different degrees and presumably inactive. The polyprotein coding sequence contains scattered stop codons and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10974564 offsetBegin: 3214 offsetEnd: 3342 A: for AT-rich sequences, and the protein sequence similarity to blastopia, mdg3 and micropia place TROMB in the gypsy-Ty3 group of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12552250 offsetBegin: 3117 offsetEnd: 3231 A: factor and oncoprotein c-Myc to the EBV genome. CONCLUSIONS: Based on the discovery of a binding site for c-Myc in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938468 offsetBegin: 3749 offsetEnd: 3893 A: matched the consensus 14-3-3 phospho-binding motif, consistent with our identification of 14-3-3 proteins and host and viral kinases as specific
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 928 offsetEnd: 1043 A: this study was to sequence the full open reading frame of the feline oviductin and to examine its expression during
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 4882 offsetEnd: 5024 A: oviductin mRNA abundance was not significantly different in the oviductal segments ampulla and isthmus. A prominent immunolabeling was seen in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/22015153 offsetBegin: 5155 offsetEnd: 5290 A: and isthmus. A prominent immunolabeling was seen in the early and late follicular stage which disappeared after ovulation, indicating a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 1058 offsetEnd: 1226 A: signal-deficient retrovirus vector mutated by PCR site-directed mutagenesis was used to make polyadenylation signal-deficient retroviruses by PA317 packaging cells. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 1226 offsetEnd: 1377 A: site-directed mutagenesis was used to make polyadenylation signal-deficient retroviruses by PA317 packaging cells. The GES-1 cells were infected by the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17044995 offsetBegin: 2314 offsetEnd: 2463 A: polyadenylation signal-deficient retroviruses could be packaged by PA317 packaging cells. The viruses had the ability to infect GES-1 cells. Northern
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 1769 offsetEnd: 1898 A: of reporter mRNA injected, suggesting that the cyclin B1 3'UTR sequences provide a binding site for a trans-acting repressor. The
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 2185 offsetEnd: 2362 A: repressor. The sequences that direct repression overlap and include cytoplasmic polyadenylation elements (CPEs), sequences known to promote cytoplasmic polyadenylation. However,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10720434 offsetBegin: 3778 offsetEnd: 3922 A: tail, and polyadenylation of cyclin B1 mRNA is required for its translational recruitment. Our results suggest that translational recruitment of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18237440 offsetBegin: 4920 offsetEnd: 5086 A: the leucine-rich repeats, TLRR contains a consensus-binding site for protein phosphatase-1 (PP1). Immunocytochemistry using a TLRR specific antibody demonstrates that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10607899 offsetBegin: 1644 offsetEnd: 1775 A: 7. We established that the transcription initiation site is located 498 nucleotides upstream of the initiator codon and showed that
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21558555 offsetBegin: 1410 offsetEnd: 1547 A: that contained overlapping recognition motifs for caspases and kinases. We identified the protein kinase CK2 as the most prominent kinase
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11894958 offsetBegin: 2491 offsetEnd: 2616 A: site. The mutant octopine synthase gene contains a minimum of four different poly(A) sites. The most prominent of these sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11722011 offsetBegin: 2036 offsetEnd: 2149 A: 6 to 24 hours post-infection (p.i.). S1 nuclease mapping of the UL12 capping site at position 82384 of the genome
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18487515 offsetBegin: 940 offsetEnd: 1068 A: position of the poly(A) addition site using oligonucleotide arrays tiling 1% of the human genome. This approach revealed more 3'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18487515 offsetBegin: 3697 offsetEnd: 3817 A: stretches of DNA in which lysine 36 dimethylation is more prominent. Lysine 36 methylation decreases at or near the site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18487515 offsetBegin: 3968 offsetEnd: 4115 A: 36 methylation decreases at or near the site of polyadenylation, sometimes disappearing before disappearance of phosphorylated RNA PolII or release
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 1484 offsetEnd: 1607 A: that the three putative TG SAGE tags can be attributed to TG transcripts and reflect the use of alternative polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 2549 offsetEnd: 2678 A: show that a considerable percentage of mRNA transcripts (44% human, 22% mouse and 22% rat) show cleavage site heterogeneity. When
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11292841 offsetBegin: 3665 offsetEnd: 3792 A: single gene because of alternative cleavage site selection. Both experimental and in silico data show that the selection of the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10699189 offsetBegin: 264 offsetEnd: 394 A: their 3' ends to new genomic locations. Occasionally, the 3' end processing machinery may bypass the L1 polyadenylation signal and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23151878 offsetBegin: 4618 offsetEnd: 4757 A: 6 5' splice site. Our results suggest that competing mRNA splicing and polyadenylation regulate exon 6 inclusion and consequently determine
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 1047 offsetEnd: 1172 A: an ectopic ACTH-producing tumor, express an abnormal GR mRNA. In this DMS-79 cell GR the sequence normally derived from exons
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9783913 offsetBegin: 1388 offsetEnd: 1495 A: from exons 8 and 9 is replaced by sequence unmatched in the DNA databases. The protein encoded by this mRNA
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 1016 offsetEnd: 1166 A: 5' truncations of the hFSHbeta promoter region to -350 bp relative to the transcriptional initiation site retained gonadotroph-specific expression and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 1166 offsetEnd: 1315 A: region to -350 bp relative to the transcriptional initiation site retained gonadotroph-specific expression and the sexually dimorphic pattern of male
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 3345 offsetEnd: 3483 A: islands of highly conserved sequence homology corresponding precisely to the proximal 5' promoter region, exon 2, the 5' translated region
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16414183 offsetBegin: 3708 offsetEnd: 3827 A: translated region of exon 3, and two regions at the 3' untranslated end of exon 3 that include putative polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11865048 offsetBegin: 260 offsetEnd: 392 A: for the pre-mRNA polyadenylation cleavage reaction in vitro. This activity was found to reside solely in the C-terminal domain (CTD)
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031412 offsetBegin: 1831 offsetEnd: 1959 A: predominant form expressed. The deduced 550 amino acid sequence of the channel catfish Nramp (NrampC) has high homology to Nramp
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 1145 offsetEnd: 1265 A: sequence are the same as in the transcript from P1. Luciferase assays confirmed promoter activity of both sites in HepG2
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 2227 offsetEnd: 2358 A: led to changes in reporter activity, the most prominent decreases were observed in deletion constructs carrying bases -353 to -658,
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 2358 offsetEnd: 2482 A: the most prominent decreases were observed in deletion constructs carrying bases -353 to -658, and -353 to -920 (numbered as
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/21256059 offsetBegin: 5265 offsetEnd: 5365 A: N370S. Both P1 and P2, as well as exons -2 and -1, did not contain any sequence variations, with the
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 1030 offsetEnd: 1178 A: cDNA ends (RACE) to identify multiple transcription initiation and polyadenylation sites for sense and antisense transcripts of three subfamilies of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 1178 offsetEnd: 1336 A: transcription initiation and polyadenylation sites for sense and antisense transcripts of three subfamilies of TART elements in Drosophila melanogaster. These
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/17020919 offsetBegin: 2883 offsetEnd: 3033 A: an initiator consensus for the transcription start sites of Drosophila LTR retrotransposons. Interestingly, analysis of 5' RACE products for antisense
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10103062 offsetBegin: 3245 offsetEnd: 3400 A: alternative 5'-splice site usage, by exon skipping and/or by alternative polyadenylation. The NIPP-1beta/delta and NIPP-1gamma mRNAs are expected to encode
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16308319 offsetBegin: 629 offsetEnd: 762 A: and also promotes polyadenylation of the unspliced RNA. Integral to NRS function is the binding of U1 small nuclear ribonucleoprotein
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16308319 offsetBegin: 1526 offsetEnd: 1661 A: of U12-dependent introns, binds the NRS remarkably well and requires G-rich elements just downstream of the consensus U11 binding site.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3126 offsetEnd: 3246 A: induced in the kidney and spleen and expression level was maximal after 4h. The predicted 253 amino acid sequence shares
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3763 offsetEnd: 3878 A: IL-1 beta is very conserved in fish of the same family. No interleukin-converting enzyme (ICE) cut site is found in
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18201905 offsetBegin: 3878 offsetEnd: 3996 A: fish of the same family. No interleukin-converting enzyme (ICE) cut site is found in sbIL-1 beta, but the alignment of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 3342 offsetEnd: 3454 A: by exons 3 and 4 with an intron (intron C) disrupting the coding sequence between the second and third disulfide
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12031500 offsetBegin: 4436 offsetEnd: 4569 A: identified by 5'- and 3'-RACE, respectively. Approximately 2.6 kb of 5'-flanking region was sequenced and was shown to lack consensus
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/12727900 offsetBegin: 2489 offsetEnd: 2621 A: of these, we found the presence of alternative splicing or multiple polyadenylation signals. RPC distribution among the HMGs was not
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15665278 offsetBegin: 0 offsetEnd: 126 A: The epidermal growth factor receptor (EGFR) plays a prominent role in cell growth and development. Its regulation in humans is
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 3360 offsetEnd: 3458 A: 1c, part of E1 and E2-E10. The translation start site is localized in the 3' end of E1, common for
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 3458 offsetEnd: 3552 A: The translation start site is localized in the 3' end of E1, common for both type 1 and type 2
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 4550 offsetEnd: 4679 A: NF-kappaB and ets consensus sequences. The cloned P1 drives efficient expression of the luciferase reporter gene. A high level of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 5267 offsetEnd: 5371 A: of P1, contains a TATA box, GC boxes, a CCAAT box and GATA and ets consensus sequences. 3' RACE provided
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 5371 offsetEnd: 5482 A: GC boxes, a CCAAT box and GATA and ets consensus sequences. 3' RACE provided evidence for variability in the 3'
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/16337094 offsetBegin: 5482 offsetEnd: 5594 A: GATA and ets consensus sequences. 3' RACE provided evidence for variability in the 3' UTR due to the presence of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/10832023 offsetBegin: 795 offsetEnd: 939 A: identical to that of the human 1alpha-hydroxylase and human vitamin D(3) 25-hydroxylase genes. A polyadenylation signal AUUAAA that differs from
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 2918 offsetEnd: 3058 A: predicted array was validated through the analysis of genomic sequences and predicted mRNA folding of genes with known polyadenylation site.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 3511 offsetEnd: 3674 A: pre-mRNA 3'-UTR cis-regulatory elements appears to be roughly conserved through evolutionary scale, whereas the polyadenylation signal seems to be species-specific
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18514032 offsetBegin: 3674 offsetEnd: 3823 A: be roughly conserved through evolutionary scale, whereas the polyadenylation signal seems to be species-specific in protozoan parasites and the novel
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 766 offsetEnd: 914 A: Two candidate promoters with consensus sites for transcription factors Sp1, AP-1, and AP-2 are present, consistent with independent transcription of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 1496 offsetEnd: 1619 A: the identified gene elements. In the FXYD2 gene, there are two closely spaced polyadenylation signals, and both are used. A
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 1619 offsetEnd: 1746 A: FXYD2 gene, there are two closely spaced polyadenylation signals, and both are used. A proposed third splice variant encoding a
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11112438 offsetBegin: 2885 offsetEnd: 3002 A: 2. FXYD2 is on chromosome 11q23 close to a site of tumorigenic chromosomal translocations, and has a number of repeat
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 4537 offsetEnd: 4679 A: simplified trans-splicing prediction tool and a novel poly(A) prediction tool based on comparative sequence analysis. We discuss the impact of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18366710 offsetBegin: 4679 offsetEnd: 4819 A: novel poly(A) prediction tool based on comparative sequence analysis. We discuss the impact of certain regions surrounding the poly(A) sites
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 136 offsetEnd: 261 A: regulator of splicing (NRS) is an RNA element that represses splicing and promotes polyadenylation of viral RNA. The NRS acts
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15252020 offsetBegin: 2094 offsetEnd: 2196 A: can bind the NRS as a mono-snRNP in vitro and that a G-rich element located downstream of the U11 site
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15093132 offsetBegin: 291 offsetEnd: 431 A: its structural organization and flanking regions were characterized. The 3' flanking region is marked by the presence of two polyadenylation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 783 offsetEnd: 952 A: polyadenylation of the pre-mRNA. Termination of nonpolyadenylated [non-poly(A)] Pol II transcripts in Saccharomyces cerevisiae requires the RNA-binding proteins Nrd1 and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15226427 offsetBegin: 3169 offsetEnd: 3307 A: poly(A) terminators, there is no strong consensus for non-poly(A) terminators, and the arrangement of Nrd1p and Nab3p binding sites varies
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/9740674 offsetBegin: 3906 offsetEnd: 4051 A: found. However, hybridization studies and amplification of cDNA ends suggest the use of a noncanonical polyadenylation signal in the untranslated
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 0 offsetEnd: 170 A: A cDNA encoding the N-acetyl-beta-D-glucosaminidase (NAG) protein of Paracoccidioides brasiliensis, Pb NAG1, was cloned and characterized. The 2663-nucleotide sequence of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 2300 offsetEnd: 2436 A: Candida albicans. In particular, striking homology was observed with the active site regions of the glycosyl hydrolase group of proteins
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15283239 offsetBegin: 3107 offsetEnd: 3227 A: 374 were found, reinforcing that Pb NAG1 belongs to glycosyl hydrolase family 20. The nucleotide sequence of Pb nag1 and
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/23308270 offsetBegin: 1135 offsetEnd: 1260 A: of these approaches revealed the oncogene meis1, which encodes a homeobox protein, as a direct and prominent target of Gfi1b.
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15681073 offsetBegin: 667 offsetEnd: 779 A: associated with a 15 kb deletion, which includes the pif (per os infectivity factor) gene. The sequence of a 2.4
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15681073 offsetBegin: 3102 offsetEnd: 3238 A: to pif coding sequences, ending at the same polyadenylation signal as the pif transcript. These transcription features resemble those of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/20827276 offsetBegin: 2903 offsetEnd: 3032 A: inserted sequence was mapped to a gene-poor region of chromosome 11. The inserted fragment was expressed in multiple human tissue
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/11913776 offsetBegin: 3845 offsetEnd: 3987 A: of the approximately 0.8kb 5'-flanking region, GC rich segments including consensus sequences for binding of the transcription factor Sp1, but
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/19365549 offsetBegin: 4638 offsetEnd: 4758 A: loops. Several of the long HML LTRs contained long ORFs inserted after the second A rich module. HMM consensus alignment
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 1120 offsetEnd: 1260 A: ends of the CTH2 mRNA were mapped to a [GU(3-5)](5) repeat, unlike any previously characterized polyadenylation site. CTH2 mRNA accumulation
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 1568 offsetEnd: 1711 A: mRNA accumulation was not inhibited by mutations in 3'-cleavage and polyadenylation factors, Rna14, Rna15 and Pap1, which block accumulation of
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 1998 offsetEnd: 2144 A: accumulation of other mRNAs. The 3'-extended CTH2 pre-mRNA strongly accumulated in strains with mutations in the TRAMP4 polyadenylation complex or
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 2144 offsetEnd: 2295 A: CTH2 pre-mRNA strongly accumulated in strains with mutations in the TRAMP4 polyadenylation complex or the Nrd1/Nab3/Sen1 complex, and contains multiple
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400782 offsetBegin: 2295 offsetEnd: 2434 A: with mutations in the TRAMP4 polyadenylation complex or the Nrd1/Nab3/Sen1 complex, and contains multiple Nrd1 and Nab3 binding sites. CTH2
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1232 offsetEnd: 1362 A: open reading frames likely to be translated into protein. We confirmed the absence of polyadenylation of the transcript and showed
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1362 offsetEnd: 1498 A: translated into protein. We confirmed the absence of polyadenylation of the transcript and showed that it is primarily nuclear localized
Q:What is the most prominent sequence consensus for the polyadenylation site? Document:http://www.ncbi.nlm.nih.gov/pubmed/15542670 offsetBegin: 1498 offsetEnd: 1630 A: absence of polyadenylation of the transcript and showed that it is primarily nuclear localized during viral infection. We mapped the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1398 offsetEnd: 1537 A: associated with ophthalmopathy. The thyrotropin receptor (TSHR) is expressed at low levels in several connective tissue depots and by their
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 0 offsetEnd: 154 A: There is increasing evidence that the membrane-bound thyrotropin receptor (TSHR) may be mediating clinically important direct effects of thyrotropin (TSH)
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1120 offsetEnd: 1258 A: in Graves' disease might play an integral role in the tissue remodeling associated with ophthalmopathy. The thyrotropin receptor (TSHR) is
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1258 offsetEnd: 1398 A: integral role in the tissue remodeling associated with ophthalmopathy. The thyrotropin receptor (TSHR) is expressed at low levels in several
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 154 offsetEnd: 305 A: membrane-bound thyrotropin receptor (TSHR) may be mediating clinically important direct effects of thyrotropin (TSH) and of TSHR antibodies (TSHRab) in
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 728 offsetEnd: 849 A: is unknown but current evidence favors an immune reaction against a thyroid and orbital tissue shared antigen such as the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 849 offsetEnd: 966 A: an immune reaction against a thyroid and orbital tissue shared antigen such as the novel protein G2s, which is highly
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 449 offsetEnd: 610 A: Several authors have presented data suggesting that extrathyroidal tissues, e.g. extraocular muscle (EOM), may contain a functional thyrotropin receptor (TSH-R).
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 610 offsetEnd: 762 A: that extrathyroidal tissues, e.g. extraocular muscle (EOM), may contain a functional thyrotropin receptor (TSH-R). We have applied Northern blotting and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 762 offsetEnd: 896 A: (EOM), may contain a functional thyrotropin receptor (TSH-R). We have applied Northern blotting and PCR amplification in an attempt to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2596 offsetEnd: 2752 A: in virtually all extra-thyroidal tissues expressing TSHRa, whereas TSHRc shows a more restricted tissue distribution. Whether these receptor transcripts are
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 0 offsetEnd: 155 A: Thyroid associated ophthalmopathy (TAO) is an autoimmune disease involving the extra ocular muscles and surrounding orbital connective and adipose tissues.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 143 offsetEnd: 297 A: thyroid associated ophthalmopathy (TAO) and a possible link with the thyroid continues. Several authors have presented data suggesting that extrathyroidal
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2659 offsetEnd: 2818 A: radioligand receptor assay. The heterodimer also stimulated cAMP production and thymidine incorporation by cultured thyroid cells and increased serum thyroxine
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 3597 offsetEnd: 3746 A: lymphatic vessels and in corpora haemorragica and albicantia. Bovine thyroid tissue showed immunostaining to both the antibodies employed. These data
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 3746 offsetEnd: 3882 A: and albicantia. Bovine thyroid tissue showed immunostaining to both the antibodies employed. These data suggest that the luteal cells of
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 0 offsetEnd: 139 A: We previously described the cloning of the full-length chicken thyrotropin receptor (TSHRa) and two splice variants, lacking exon 3 (TSHRb)
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2752 offsetEnd: 2899 A: TSHRa, whereas TSHRc shows a more restricted tissue distribution. Whether these receptor transcripts are translated to functional proteins needs to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2899 offsetEnd: 3041 A: restricted tissue distribution. Whether these receptor transcripts are translated to functional proteins needs to be verified, but if so, they
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 588 offsetEnd: 728 A: link between ophthalmopathy and thyroid autoimmunity is unknown but current evidence favors an immune reaction against a thyroid and orbital
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 0 offsetEnd: 143 A: The search for autoantigenic targets in thyroid associated ophthalmopathy (TAO) and a possible link with the thyroid continues. Several authors
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 139 offsetEnd: 261 A: the full-length chicken thyrotropin receptor (TSHRa) and two splice variants, lacking exon 3 (TSHRb) or both exons 2 and 3
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 0 offsetEnd: 128 A: Thyroid associated ophthalmopathy, or thyroid eye disease (TED), is a complex inflammatory disorder of the eye that, as its name
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 0 offsetEnd: 128 A: Thyroid associated ophthalmopathy, or thyroid eye disease (TED), is a complex inflammatory disorder of the eye that, as its name
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1910 offsetEnd: 2024 A: signs of immunity, a pathology similar to toxic nodule, the need for a total destruction of thyroid tissue to cure
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 2136 offsetEnd: 2248 A: a total destruction of thyroid tissue to cure the patients. The total analogy with toxic nodule leads us to name
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 0 offsetEnd: 132 A: The receptor of the Thyroid Stimulating Hormone (TSHr) and thyroglobin (TGB), are two proteic factors necessary for the synthesis of
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 3452 offsetEnd: 3597 A: detected in stromal cells, blood and lymphatic vessels and in corpora haemorragica and albicantia. Bovine thyroid tissue showed immunostaining to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 2024 offsetEnd: 2136 A: to toxic nodule, the need for a total destruction of thyroid tissue to cure the patients. The total analogy with
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 1192 offsetEnd: 1313 A: is highly expressed in both eye muscles and thyroid, or the TSH receptor (TSHR). Earlier, we showed that serum antibodies
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 1313 offsetEnd: 1437 A: muscles and thyroid, or the TSH receptor (TSHR). Earlier, we showed that serum antibodies against G2s were closely linked to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 1437 offsetEnd: 1586 A: receptor (TSHR). Earlier, we showed that serum antibodies against G2s were closely linked to ophthalmopathy. Although lymphocytic infiltration of the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 3996 offsetEnd: 4142 A: seven patients with Hashimoto's thyroiditis, suggesting that immune reactivity against G2s could be a marker of this progressive thyroid disorder.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 4142 offsetEnd: 4277 A: that immune reactivity against G2s could be a marker of this progressive thyroid disorder. There was no significant correlation between
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 4277 offsetEnd: 4400 A: be a marker of this progressive thyroid disorder. There was no significant correlation between T cell reactivity to G2s and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 4400 offsetEnd: 4534 A: thyroid disorder. There was no significant correlation between T cell reactivity to G2s and serum antibodies against the same protein,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 437 offsetEnd: 590 A: variable degrees of reactivity with eye muscle, orbital connective tissue, thyroid, and extra-thyroid tissue preparations when tested in an enzyme-linked
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 590 offsetEnd: 745 A: muscle, orbital connective tissue, thyroid, and extra-thyroid tissue preparations when tested in an enzyme-linked immunosorbent assay (ELISA). Eight of the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 3788 offsetEnd: 3941 A: thyroid disorders, and 20 normal subjects for reactivity with an affinity-purified nonprotein orbital antigen. The levels of serum autoantibodies against
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1537 offsetEnd: 1668 A: (TSHR) is expressed at low levels in several connective tissue depots and by their derivative fibroblasts, including those from the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1668 offsetEnd: 1811 A: in several connective tissue depots and by their derivative fibroblasts, including those from the orbit. Little direct evidence currently links
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 2119 offsetEnd: 2281 A: currently links extra-thyroidal TSHR expression with Graves' disease. Very recent observations now implicate the insulin-like growth factor-1 receptor (IGF-1R) as
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 2281 offsetEnd: 2444 A: Graves' disease. Very recent observations now implicate the insulin-like growth factor-1 receptor (IGF-1R) as a fibroblast activating antigen. When immunoglobulins
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 297 offsetEnd: 449 A: possible link with the thyroid continues. Several authors have presented data suggesting that extrathyroidal tissues, e.g. extraocular muscle (EOM), may
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2251 offsetEnd: 2372 A: in the thyroid. PCR amplification was performed on thyroid and EOM cDNAs using pairs of primers designed to amplify exons
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2513 offsetEnd: 2659 A: affinity to TSH receptors in a radioligand receptor assay. The heterodimer also stimulated cAMP production and thymidine incorporation by cultured
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2464 offsetEnd: 2596 A: and -f mRNA was also present in virtually all extra-thyroidal tissues expressing TSHRa, whereas TSHRc shows a more restricted tissue
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 384 offsetEnd: 524 A: its name implies, is usually associated with thyroid disease. Clinical observation supports the existence of three main TED subtypes, namely
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 1740 offsetEnd: 1903 A: a specific orbital or thyroid-and-orbital shared antigen(s). One well-studied candidate in this immune reaction is the thyroid-stimulating hormone receptor (TSHR),
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 2197 offsetEnd: 2348 A: receptor (TSHR), which is also expressed in the orbital fibroblast and preadipocyte. Most patients with ophthalmopathy have associated Graves' disease,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3004 offsetEnd: 3151 A: upper eyelid retraction (UER), and 10% have no apparent associated thyroid disease - so-called "euthyroid Graves' disease". Ophthalmopathy can also
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3151 offsetEnd: 3297 A: have no apparent associated thyroid disease - so-called "euthyroid Graves' disease". Ophthalmopathy can also occur in some patients with transient
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3448 offsetEnd: 3577 A: can also occur in some patients with transient thyroiditis, thyroid cancer, and Graves' disease many years after treatment of the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3577 offsetEnd: 3725 A: with transient thyroiditis, thyroid cancer, and Graves' disease many years after treatment of the hyperthyroidism - situations where TSHR antibodies
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 384 offsetEnd: 524 A: its name implies, is usually associated with thyroid disease. Clinical observation supports the existence of three main TED subtypes, namely
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 1740 offsetEnd: 1903 A: a specific orbital or thyroid-and-orbital shared antigen(s). One well-studied candidate in this immune reaction is the thyroid-stimulating hormone receptor (TSHR),
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 2197 offsetEnd: 2348 A: receptor (TSHR), which is also expressed in the orbital fibroblast and preadipocyte. Most patients with ophthalmopathy have associated Graves' disease,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3004 offsetEnd: 3151 A: upper eyelid retraction (UER), and 10% have no apparent associated thyroid disease - so-called "euthyroid Graves' disease". Ophthalmopathy can also
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3151 offsetEnd: 3297 A: have no apparent associated thyroid disease - so-called "euthyroid Graves' disease". Ophthalmopathy can also occur in some patients with transient
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3448 offsetEnd: 3577 A: can also occur in some patients with transient thyroiditis, thyroid cancer, and Graves' disease many years after treatment of the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3577 offsetEnd: 3725 A: with transient thyroiditis, thyroid cancer, and Graves' disease many years after treatment of the hyperthyroidism - situations where TSHR antibodies
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 1029 offsetEnd: 1153 A: and rodent fat. It is well known that thyroid disease may aggravate or induce heart disease, but the pathophysiological role
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 1153 offsetEnd: 1275 A: known that thyroid disease may aggravate or induce heart disease, but the pathophysiological role of TSH and TSHRab is not
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 448 offsetEnd: 588 A: adipose tissues. The mechanism for the link between ophthalmopathy and thyroid autoimmunity is unknown but current evidence favors an immune
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 966 offsetEnd: 1080 A: and orbital tissue shared antigen such as the novel protein G2s, which is highly expressed in both eye muscles and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 1080 offsetEnd: 1192 A: as the novel protein G2s, which is highly expressed in both eye muscles and thyroid, or the TSH receptor (TSHR).
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 289 offsetEnd: 437 A: Most of these monoclonal antibodies had variable degrees of reactivity with eye muscle, orbital connective tissue, thyroid, and extra-thyroid tissue
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 1134 offsetEnd: 1266 A: basis of their reactivity with human eye muscle or orbital connective tissue antigens, were used to affinity purify orbital membrane
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 3633 offsetEnd: 3788 A: disease, 8 patients with other nonautoimmune thyroid disorders, and 20 normal subjects for reactivity with an affinity-purified nonprotein orbital antigen.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 896 offsetEnd: 1021 A: receptor (TSH-R). We have applied Northern blotting and PCR amplification in an attempt to demonstrate the mRNA for the TSH-R
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2137 offsetEnd: 2251 A: and 4.4 kb were observed only in the thyroid. PCR amplification was performed on thyroid and EOM cDNAs using pairs
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2372 offsetEnd: 2498 A: performed on thyroid and EOM cDNAs using pairs of primers designed to amplify exons 1-->9, the extracellular domain (ECD), and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 0 offsetEnd: 161 A: Human thyrotropin (TSH), luteotropin (LH), follitropin (FSH), and chorionic gonadotropin are members of the heterodimeric glycoprotein hormone family. The common
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2383 offsetEnd: 2513 A: and FSH receptors, and showed high affinity to TSH receptors in a radioligand receptor assay. The heterodimer also stimulated cAMP
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2967 offsetEnd: 3109 A: by cultured thyroid cells and increased serum thyroxine levels in TSH-suppressed rats in vivo. This new heterodimeric glycoprotein hormone was
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 2192 offsetEnd: 2327 A: and a primary rabbit polyclonal antibody against human TGB were employed. Furthermore, the accuracy of bovine thyroid to the antibodies
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 2327 offsetEnd: 2452 A: against human TGB were employed. Furthermore, the accuracy of bovine thyroid to the antibodies used in this study was tested.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2094 offsetEnd: 2218 A: the full-length receptor, the five TSHR splice variants are most abundantly expressed in thyroid gland. TSHRb, -d, -e and -f
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2218 offsetEnd: 2337 A: splice variants are most abundantly expressed in thyroid gland. TSHRb, -d, -e and -f mRNA was also present in virtually
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 2337 offsetEnd: 2464 A: in thyroid gland. TSHRb, -d, -e and -f mRNA was also present in virtually all extra-thyroidal tissues expressing TSHRa, whereas
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 128 offsetEnd: 250 A: disease (TED), is a complex inflammatory disorder of the eye that, as its name implies, is usually associated with thyroid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 250 offsetEnd: 384 A: disorder of the eye that, as its name implies, is usually associated with thyroid disease. Clinical observation supports the existence
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 524 offsetEnd: 672 A: with thyroid disease. Clinical observation supports the existence of three main TED subtypes, namely ocular myopathy, congestive myopathy, and mixed
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 2875 offsetEnd: 3004 A: often mild and expressed mainly as upper eyelid retraction (UER), and 10% have no apparent associated thyroid disease - so-called
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3297 offsetEnd: 3448 A: - so-called "euthyroid Graves' disease". Ophthalmopathy can also occur in some patients with transient thyroiditis, thyroid cancer, and Graves' disease
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 4600 offsetEnd: 4739 A: TED we have investigated the nature and significance of antibodies targeting other eye muscle and orbital connective tissue (OCT) antigens,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 4739 offsetEnd: 4884 A: and significance of antibodies targeting other eye muscle and orbital connective tissue (OCT) antigens, in particular the calcium binding protein
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 6034 offsetEnd: 6180 A: ii) the associated extra ocular and upper eyelid muscle inflammation reflects either autoimmunity against primary skeletal muscle antigens such as
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4287 offsetEnd: 4408 A: is encoded by a single exon, however, in the salmon genes and homologous invertebrate genes, this portion of the receptor
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 128 offsetEnd: 250 A: disease (TED), is a complex inflammatory disorder of the eye that, as its name implies, is usually associated with thyroid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 250 offsetEnd: 384 A: disorder of the eye that, as its name implies, is usually associated with thyroid disease. Clinical observation supports the existence
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 524 offsetEnd: 672 A: with thyroid disease. Clinical observation supports the existence of three main TED subtypes, namely ocular myopathy, congestive myopathy, and mixed
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 2875 offsetEnd: 3004 A: often mild and expressed mainly as upper eyelid retraction (UER), and 10% have no apparent associated thyroid disease - so-called
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3297 offsetEnd: 3448 A: - so-called "euthyroid Graves' disease". Ophthalmopathy can also occur in some patients with transient thyroiditis, thyroid cancer, and Graves' disease
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 4600 offsetEnd: 4739 A: TED we have investigated the nature and significance of antibodies targeting other eye muscle and orbital connective tissue (OCT) antigens,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 4739 offsetEnd: 4884 A: and significance of antibodies targeting other eye muscle and orbital connective tissue (OCT) antigens, in particular the calcium binding protein
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 6034 offsetEnd: 6180 A: ii) the associated extra ocular and upper eyelid muscle inflammation reflects either autoimmunity against primary skeletal muscle antigens such as
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 892 offsetEnd: 1029 A: retroorbital muscle and fibroblasts, peripheral lymphocytes and rodent fat. It is well known that thyroid disease may aggravate or induce
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 745 offsetEnd: 884 A: extra-thyroid tissue preparations when tested in an enzyme-linked immunosorbent assay (ELISA). Eight of the MCABs, selected on the basis of
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 1013 offsetEnd: 1134 A: of the MCABs, selected on the basis of their reactivity with human eye muscle or orbital connective tissue antigens, were
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 1266 offsetEnd: 1406 A: eye muscle or orbital connective tissue antigens, were used to affinity purify orbital membrane antigens. All purified fractions were tested
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 3482 offsetEnd: 3633 A: patients with Hashimoto's thyroiditis without eye disease, 8 patients with other nonautoimmune thyroid disorders, and 20 normal subjects for reactivity
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 982 offsetEnd: 1120 A: the evidence suggesting that fibroblast activation in Graves' disease might play an integral role in the tissue remodeling associated with
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 2444 offsetEnd: 2598 A: implicate the insulin-like growth factor-1 receptor (IGF-1R) as a fibroblast activating antigen. When immunoglobulins from patients with the disease, with
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 3173 offsetEnd: 3320 A: fibroblasts, the receptor becomes activated and upregulates the expression of two T lymphocyte chemoattractants, IL-16 and RANTES. Thus, IGF-1R may
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2818 offsetEnd: 2967 A: stimulated cAMP production and thymidine incorporation by cultured thyroid cells and increased serum thyroxine levels in TSH-suppressed rats in vivo.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 4010 offsetEnd: 4128 A: These data suggest that the luteal cells of mature corpora lutea may be involved in the synthesis of thyroid hormones,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 4128 offsetEnd: 4253 A: cells of mature corpora lutea may be involved in the synthesis of thyroid hormones, which may modulate P(4) synthesis, acting
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 1958 offsetEnd: 2094 A: found in other vertebrate genomes. Like the full-length receptor, the five TSHR splice variants are most abundantly expressed in thyroid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 2048 offsetEnd: 2197 A: immune reaction is the thyroid-stimulating hormone receptor (TSHR), which is also expressed in the orbital fibroblast and preadipocyte. Most patients
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 5896 offsetEnd: 6034 A: TSHR in the OCT compartment, and ii) the associated extra ocular and upper eyelid muscle inflammation reflects either autoimmunity against
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4408 offsetEnd: 4533 A: however, in the salmon genes and homologous invertebrate genes, this portion of the receptor is encoded by multiple exons. In
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4533 offsetEnd: 4674 A: homologous invertebrate genes, this portion of the receptor is encoded by multiple exons. In general, the tissue-specific expression of these
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4674 offsetEnd: 4802 A: the receptor is encoded by multiple exons. In general, the tissue-specific expression of these receptors is similar to that seen
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 2048 offsetEnd: 2197 A: immune reaction is the thyroid-stimulating hormone receptor (TSHR), which is also expressed in the orbital fibroblast and preadipocyte. Most patients
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 5896 offsetEnd: 6034 A: TSHR in the OCT compartment, and ii) the associated extra ocular and upper eyelid muscle inflammation reflects either autoimmunity against
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 305 offsetEnd: 454 A: mediating clinically important direct effects of thyrotropin (TSH) and of TSHR antibodies (TSHRab) in extra-thyroidal tissues. TSHR mRNA has formerly
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 454 offsetEnd: 600 A: thyrotropin (TSH) and of TSHR antibodies (TSHRab) in extra-thyroidal tissues. TSHR mRNA has formerly been detected in thyroid, retroorbital muscle
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 2888 offsetEnd: 3031 A: disease, with or without clinical ophthalmopathy, bind IGF-1R on the surface of fibroblasts, the receptor becomes activated and upregulates the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2265 offsetEnd: 2383 A: human TSH receptors, but not LH and FSH receptors, and showed high affinity to TSH receptors in a radioligand receptor
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 2452 offsetEnd: 2571 A: the accuracy of bovine thyroid to the antibodies used in this study was tested. A positivity reaction for the anti-TSHr
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 1903 offsetEnd: 2048 A: antigen(s). One well-studied candidate in this immune reaction is the thyroid-stimulating hormone receptor (TSHR), which is also expressed in the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 4884 offsetEnd: 5031 A: eye muscle and orbital connective tissue (OCT) antigens, in particular the calcium binding protein calsequestrin (CASQ1) and the orbital fibroblast
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 1903 offsetEnd: 2048 A: antigen(s). One well-studied candidate in this immune reaction is the thyroid-stimulating hormone receptor (TSHR), which is also expressed in the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 4884 offsetEnd: 5031 A: eye muscle and orbital connective tissue (OCT) antigens, in particular the calcium binding protein calsequestrin (CASQ1) and the orbital fibroblast
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 155 offsetEnd: 299 A: autoimmune disease involving the extra ocular muscles and surrounding orbital connective and adipose tissues. The mechanism for the link between
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 299 offsetEnd: 448 A: muscles and surrounding orbital connective and adipose tissues. The mechanism for the link between ophthalmopathy and thyroid autoimmunity is unknown
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 3330 offsetEnd: 3482 A: hyperthyroidism and no eye disease, 14 patients with Hashimoto's thyroiditis without eye disease, 8 patients with other nonautoimmune thyroid disorders,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 0 offsetEnd: 133 A: Graves' disease when fully expressed affects the thyroid gland and connective tissues of the orbit and pretibium. While the glandular
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 3031 offsetEnd: 3173 A: bind IGF-1R on the surface of fibroblasts, the receptor becomes activated and upregulates the expression of two T lymphocyte chemoattractants,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 4084 offsetEnd: 4219 A: of a new ligand based on genomic approaches could facilitate the understanding of the physiological roles of extra-thyroid TSH receptor
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 4219 offsetEnd: 4376 A: genomic approaches could facilitate the understanding of the physiological roles of extra-thyroid TSH receptor systems and the structural-functional basis of
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 5781 offsetEnd: 5896 A: and T lymphocyte targeting of the TSHR in the OCT compartment, and ii) the associated extra ocular and upper eyelid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 5781 offsetEnd: 5896 A: and T lymphocyte targeting of the TSHR in the OCT compartment, and ii) the associated extra ocular and upper eyelid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 133 offsetEnd: 280 A: the thyroid gland and connective tissues of the orbit and pretibium. While the glandular disease is relatively well-characterized, the pathogenesis
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 2079 offsetEnd: 2203 A: unclear whether the reaction is in the eye muscle fiber or the surrounding connective tissue. We tested for peripheral blood
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 2203 offsetEnd: 2337 A: the eye muscle fiber or the surrounding connective tissue. We tested for peripheral blood mononuclear cell sensitization to G2s fusion
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 2337 offsetEnd: 2481 A: surrounding connective tissue. We tested for peripheral blood mononuclear cell sensitization to G2s fusion protein in patients with TAO, Graves'
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 2481 offsetEnd: 2639 A: peripheral blood mononuclear cell sensitization to G2s fusion protein in patients with TAO, Graves' hyperthyroidism or Hashimoto's thyroiditis without evident
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 2639 offsetEnd: 2795 A: G2s fusion protein in patients with TAO, Graves' hyperthyroidism or Hashimoto's thyroiditis without evident ophthalmopathy and normal subjects. Results were
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 2795 offsetEnd: 2949 A: TAO, Graves' hyperthyroidism or Hashimoto's thyroiditis without evident ophthalmopathy and normal subjects. Results were expressed as counts per min (cpm)
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 3734 offsetEnd: 3866 A: between the four groups. Tests were also positive in four out of seven patients with Hashimoto's thyroiditis, suggesting that immune
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12515285 offsetBegin: 3866 offsetEnd: 3996 A: also positive in four out of seven patients with Hashimoto's thyroiditis, suggesting that immune reactivity against G2s could be a
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 2931 offsetEnd: 3065 A: phosphatase. We tested the serum of 24 patients with Graves' ophthalmopathy, 10 patients with a history of Graves' hyperthyroidism and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 3065 offsetEnd: 3196 A: 24 patients with Graves' ophthalmopathy, 10 patients with a history of Graves' hyperthyroidism and no eye disease, 14 patients with
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 3196 offsetEnd: 3330 A: patients with a history of Graves' hyperthyroidism and no eye disease, 14 patients with Hashimoto's thyroiditis without eye disease, 8
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 4387 offsetEnd: 4532 A: with Graves' ophthalmopathy were significantly higher than those in normal subjects or patients with Graves' hyperthyroidism with no eye disease.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 4532 offsetEnd: 4658 A: than those in normal subjects or patients with Graves' hyperthyroidism with no eye disease. Although unlikely to be of primary
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/3360902 offsetBegin: 4658 offsetEnd: 4798 A: patients with Graves' hyperthyroidism with no eye disease. Although unlikely to be of primary pathogenetic significance, it is possible that
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1811 offsetEnd: 1968 A: by their derivative fibroblasts, including those from the orbit. Little direct evidence currently links extra-thyroidal TSHR expression with Graves' disease.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/14669949 offsetBegin: 1968 offsetEnd: 2119 A: from the orbit. Little direct evidence currently links extra-thyroidal TSHR expression with Graves' disease. Very recent observations now implicate the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 1550 offsetEnd: 1678 A: a significant proportion of fibroblasts. In Northern blots of poly(A) mRNA of normal human thyroid, EOM and skeletal muscle (SM)
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 1678 offsetEnd: 1795 A: Northern blots of poly(A) mRNA of normal human thyroid, EOM and skeletal muscle (SM) probed with a p32 labeled hTSH-R
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 1795 offsetEnd: 1911 A: normal human thyroid, EOM and skeletal muscle (SM) probed with a p32 labeled hTSH-R cDNA, transcripts of 4.6 and 4.4
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2017 offsetEnd: 2137 A: labeled hTSH-R cDNA, transcripts of 4.6 and 4.4 kb were observed only in the thyroid. PCR amplification was performed on
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2498 offsetEnd: 2630 A: using pairs of primers designed to amplify exons 1-->9, the extracellular domain (ECD), and exon 10, the intracellular domain (ICD).
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2630 offsetEnd: 2753 A: amplify exons 1-->9, the extracellular domain (ECD), and exon 10, the intracellular domain (ICD). Both the ECD and ICD were
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2753 offsetEnd: 2870 A: (ECD), and exon 10, the intracellular domain (ICD). Both the ECD and ICD were amplified from a thyroidal cDNA library
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2870 offsetEnd: 2973 A: domain (ICD). Both the ECD and ICD were amplified from a thyroidal cDNA library but only the ICD in the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 2973 offsetEnd: 3083 A: ICD were amplified from a thyroidal cDNA library but only the ICD in the EOM cDNA library, this probably being
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/8320423 offsetBegin: 3442 offsetEnd: 3561 A: contamination with genomic DNA. These results do not support the hypothesis that the TSH receptor, as such, would be an
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 1975 offsetEnd: 2129 A: A2/B5 heterodimeric glycoproteins, purified using cation exchange and size fractionation chromatography, activated human TSH receptors, but not LH and FSH
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 2129 offsetEnd: 2265 A: exchange and size fractionation chromatography, activated human TSH receptors, but not LH and FSH receptors, and showed high affinity to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 3247 offsetEnd: 3401 A: in vivo. This new heterodimeric glycoprotein hormone was named as thyrostimulin based on its thyroid-stimulating activity. The expression of thyrostimulin
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 3401 offsetEnd: 3545 A: hormone was named as thyrostimulin based on its thyroid-stimulating activity. The expression of thyrostimulin in the anterior pituitary known to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 3545 offsetEnd: 3692 A: on its thyroid-stimulating activity. The expression of thyrostimulin in the anterior pituitary known to express TSH receptors suggested a paracrine
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 3692 offsetEnd: 3825 A: of thyrostimulin in the anterior pituitary known to express TSH receptors suggested a paracrine mechanism. The present discovery of a
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/12045258 offsetBegin: 3825 offsetEnd: 3954 A: known to express TSH receptors suggested a paracrine mechanism. The present discovery of a new ligand based on genomic approaches
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 410 offsetEnd: 558 A: synthesis of hormones, in the thyrocite. In mammals, many immuno-histochemical reports indicate the presence of the TSHr in extra-thyroidal tissues,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 558 offsetEnd: 704 A: In mammals, many immuno-histochemical reports indicate the presence of the TSHr in extra-thyroidal tissues, but not in the ovary. Triiodothyronine
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 704 offsetEnd: 833 A: the presence of the TSHr in extra-thyroidal tissues, but not in the ovary. Triiodothyronine (T(3)) and thyroxine (T(4)) have been
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/19553036 offsetBegin: 833 offsetEnd: 975 A: extra-thyroidal tissues, but not in the ovary. Triiodothyronine (T(3)) and thyroxine (T(4)) have been widely shown to affect ovarian functions
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/18400223 offsetBegin: 1828 offsetEnd: 1958 A: no equivalents of these exons were found in other vertebrate genomes. Like the full-length receptor, the five TSHR splice variants
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 1413 offsetEnd: 1579 A: reflect an autoimmune reaction involving sensitised T lymphocytes and autoantibodies directed against a specific orbital or thyroid-and-orbital shared antigen(s). One
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 1579 offsetEnd: 1740 A: T lymphocytes and autoantibodies directed against a specific orbital or thyroid-and-orbital shared antigen(s). One well-studied candidate in this immune reaction
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 2348 offsetEnd: 2500 A: in the orbital fibroblast and preadipocyte. Most patients with ophthalmopathy have associated Graves' disease, 10% have Hashimoto's thyroiditis in which
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 2500 offsetEnd: 2639 A: Most patients with ophthalmopathy have associated Graves' disease, 10% have Hashimoto's thyroiditis in which the eye changes are often mild
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 2639 offsetEnd: 2765 A: Graves' disease, 10% have Hashimoto's thyroiditis in which the eye changes are often mild and expressed mainly as upper eyelid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3725 offsetEnd: 3857 A: Graves' disease many years after treatment of the hyperthyroidism - situations where TSHR antibodies are not expected to be present,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/20464711 offsetBegin: 3857 offsetEnd: 3992 A: of the hyperthyroidism - situations where TSHR antibodies are not expected to be present, suggesting that the relationship between TSHR
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 0 offsetEnd: 170 A: Similar to the higher vertebrates, the pituitary in bony fishes express three glycoprotein hormones: thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH)
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 170 offsetEnd: 343 A: pituitary in bony fishes express three glycoprotein hormones: thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). In addition
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 343 offsetEnd: 515 A: glycoprotein hormones: thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). In addition to the appropriate secretion of these
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 657 offsetEnd: 795 A: In addition to the appropriate secretion of these hormones, the timely and quantitative expression of their specific receptors (TSHR, FSHR
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 795 offsetEnd: 923 A: of these hormones, the timely and quantitative expression of their specific receptors (TSHR, FSHR and LHR) in the target tissues
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 923 offsetEnd: 1055 A: quantitative expression of their specific receptors (TSHR, FSHR and LHR) in the target tissues is an essential requirement for their
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 1055 offsetEnd: 1183 A: (TSHR, FSHR and LHR) in the target tissues is an essential requirement for their physiological action. In fishes that constitute
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 1183 offsetEnd: 1320 A: target tissues is an essential requirement for their physiological action. In fishes that constitute a very diverse group of vertebrates,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 1566 offsetEnd: 1694 A: of vertebrates, there are only a few published reports of primary structure of these receptors although other examples have been
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 1694 offsetEnd: 1838 A: few published reports of primary structure of these receptors although other examples have been communicated briefly. This review will summarize
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 1838 offsetEnd: 1967 A: of these receptors although other examples have been communicated briefly. This review will summarize these reports as well as to
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2092 offsetEnd: 2213 A: will summarize these reports as well as to describe the insights gained from what is known about the mammalian receptors.
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2213 offsetEnd: 2337 A: as to describe the insights gained from what is known about the mammalian receptors. The structural organization of the fish
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2337 offsetEnd: 2466 A: from what is known about the mammalian receptors. The structural organization of the fish receptors (as deduced from the encoding
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2466 offsetEnd: 2601 A: mammalian receptors. The structural organization of the fish receptors (as deduced from the encoding cDNAs) is highly homologous to the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2601 offsetEnd: 2726 A: the fish receptors (as deduced from the encoding cDNAs) is highly homologous to the higher vertebrate receptors in that there
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2726 offsetEnd: 2852 A: the encoding cDNAs) is highly homologous to the higher vertebrate receptors in that there is a 7-pass transmembrane region and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2852 offsetEnd: 2991 A: to the higher vertebrate receptors in that there is a 7-pass transmembrane region and an N-terminal extracellular domain, which contributes
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 2991 offsetEnd: 3131 A: that there is a 7-pass transmembrane region and an N-terminal extracellular domain, which contributes to ligand specificity. In mammals, the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 3131 offsetEnd: 3262 A: region and an N-terminal extracellular domain, which contributes to ligand specificity. In mammals, the FSHR and the TSHR genes are
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 3479 offsetEnd: 3582 A: genes are composed of 10 exons whereas the LHR gene is composed of 11 exons. The position of the 'extra
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 3582 offsetEnd: 3690 A: whereas the LHR gene is composed of 11 exons. The position of the 'extra intron' is conserved in the catfish
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 3690 offsetEnd: 3795 A: of 11 exons. The position of the 'extra intron' is conserved in the catfish LHR gene. In the mammals, the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 3795 offsetEnd: 3907 A: the 'extra intron' is conserved in the catfish LHR gene. In the mammals, the transmembrane domain of each of the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 3907 offsetEnd: 4032 A: the catfish LHR gene. In the mammals, the transmembrane domain of each of the three glycoprotein hormone receptors is encoded
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4032 offsetEnd: 4158 A: mammals, the transmembrane domain of each of the three glycoprotein hormone receptors is encoded by a single exon, however, in
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4158 offsetEnd: 4287 A: of the three glycoprotein hormone receptors is encoded by a single exon, however, in the salmon genes and homologous invertebrate
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4802 offsetEnd: 4938 A: exons. In general, the tissue-specific expression of these receptors is similar to that seen in mammals, however, the gonadal expression
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/11399468 offsetBegin: 4938 offsetEnd: 5052 A: of these receptors is similar to that seen in mammals, however, the gonadal expression of TSHR in the striped bass
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 1413 offsetEnd: 1579 A: reflect an autoimmune reaction involving sensitised T lymphocytes and autoantibodies directed against a specific orbital or thyroid-and-orbital shared antigen(s). One
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 1579 offsetEnd: 1740 A: T lymphocytes and autoantibodies directed against a specific orbital or thyroid-and-orbital shared antigen(s). One well-studied candidate in this immune reaction
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 2348 offsetEnd: 2500 A: in the orbital fibroblast and preadipocyte. Most patients with ophthalmopathy have associated Graves' disease, 10% have Hashimoto's thyroiditis in which
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 2500 offsetEnd: 2639 A: Most patients with ophthalmopathy have associated Graves' disease, 10% have Hashimoto's thyroiditis in which the eye changes are often mild
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 2639 offsetEnd: 2765 A: Graves' disease, 10% have Hashimoto's thyroiditis in which the eye changes are often mild and expressed mainly as upper eyelid
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3725 offsetEnd: 3857 A: Graves' disease many years after treatment of the hyperthyroidism - situations where TSHR antibodies are not expected to be present,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/22125104 offsetBegin: 3857 offsetEnd: 3992 A: of the hyperthyroidism - situations where TSHR antibodies are not expected to be present, suggesting that the relationship between TSHR
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 991 offsetEnd: 1125 A: on the 4 other kindreds secondarily described in the literature, the phenotypic expression is: a high incidence of hyperthyroidism, an
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1125 offsetEnd: 1256 A: described in the literature, the phenotypic expression is: a high incidence of hyperthyroidism, an early onset of disease, a higher
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1256 offsetEnd: 1383 A: expression is: a high incidence of hyperthyroidism, an early onset of disease, a higher men/women ratio (17/32) than in Graves,
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1383 offsetEnd: 1518 A: hyperthyroidism, an early onset of disease, a higher men/women ratio (17/32) than in Graves, disease, the absence of ophthalmopathy and
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1518 offsetEnd: 1650 A: a higher men/women ratio (17/32) than in Graves, disease, the absence of ophthalmopathy and of circulating and intrathyroid signs of
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1650 offsetEnd: 1783 A: in Graves, disease, the absence of ophthalmopathy and of circulating and intrathyroid signs of immunity, a pathology similar to toxic
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 1783 offsetEnd: 1910 A: ophthalmopathy and of circulating and intrathyroid signs of immunity, a pathology similar to toxic nodule, the need for a total
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 2655 offsetEnd: 2816 A: hyperplasia'. Among 92 successive diffuse nonfamilial thyrotoxicosis cases (initially considered as Graves) we isolated 5 cases without extra- and intrathyroidal
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 2816 offsetEnd: 2965 A: thyrotoxicosis cases (initially considered as Graves) we isolated 5 cases without extra- and intrathyroidal autoimmunity, raising the question of the
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/9167947 offsetBegin: 2965 offsetEnd: 3101 A: we isolated 5 cases without extra- and intrathyroidal autoimmunity, raising the question of the existence of an apparent "sporadic' form
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 600 offsetEnd: 756 A: (TSHRab) in extra-thyroidal tissues. TSHR mRNA has formerly been detected in thyroid, retroorbital muscle and fibroblasts, peripheral lymphocytes and rodent
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 756 offsetEnd: 892 A: has formerly been detected in thyroid, retroorbital muscle and fibroblasts, peripheral lymphocytes and rodent fat. It is well known that
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 1872 offsetEnd: 2005 A: Reverse transcriptase polymerase chain reactions revealed TSHR in human heart and Northern blot on extracted RNA showed a RNA species
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 2005 offsetEnd: 2110 A: TSHR in human heart and Northern blot on extracted RNA showed a RNA species of 4.4 kb. TSH stimulation of
Q:Which extra thyroid tissues have thyrotropin (TSH) receptors? Document:http://www.ncbi.nlm.nih.gov/pubmed/7794253 offsetBegin: 2110 offsetEnd: 2230 A: blot on extracted RNA showed a RNA species of 4.4 kb. TSH stimulation of cultured mouse AT-1 cardiomyocytes elevated the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3906 offsetEnd: 4018 A: at the same time. Examples are type I and type II cancer family syndrome and multiple endocrine neoplasia type 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4018 offsetEnd: 4134 A: type I and type II cancer family syndrome and multiple endocrine neoplasia type 1 2a, and 2b. The secondly diagnosed
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 0 offsetEnd: 146 A: Multiple endocrine neoplasia type 1 is an autosomal dominant cancer predisposition syndrome caused by mutations in the tumor-suppressor gene MEN1.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2959 offsetEnd: 3124 A: organ hyperplasia, which determines hyperfunction, or endocrine organs neoplasia. For patients with multiple endocrine neoplasia type 1 syndrome, endocrine neoplasia
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 0 offsetEnd: 144 A: BACKGROUND: Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal, dominantly inherited cancer syndrome, with tumours in various endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 0 offsetEnd: 141 A: Multiple endocrine neoplasia (MEN) type 1 syndrome or Wermer syndrome is a classical malignant neoplasia syndrome, inherited in the autosomal
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 3124 offsetEnd: 3276 A: endocrine organs neoplasia. For patients with multiple endocrine neoplasia type 1 syndrome, endocrine neoplasia develops earlier than in sporadic cases;
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 127 offsetEnd: 263 A: a tumor suppressor gene MEN1, mutations of which are responsible for multiple endocrine neoplasia type 1, an autosomal dominant familial
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 135 offsetEnd: 263 A: mutations as the molecular cause of familial multiple endocrine neoplasia type 1 syndrome (MEN1) has had a significant impact on
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 263 offsetEnd: 395 A: familial multiple endocrine neoplasia type 1 syndrome (MEN1) has had a significant impact on clinical patient care. In the following
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 0 offsetEnd: 146 A: Hyperparathyroidism (HPT) in the syndrome of multiple endocrine neoplasia type 1 (MEN-1) exhibits a different picture regarding its propensity for
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 0 offsetEnd: 147 A: Multiple endocrine neoplasia type 1 (MEN-1) is a well characterized hereditary syndrome with the occurrence of primary hyperparathyroidism (HPT) in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3640 offsetEnd: 3777 A: to high grade malignant for poorly differentiated carcinomas. The Multiple Endocrine Neoplasia type 1 syndrome (MEN1) gene is involved in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 644 offsetEnd: 785 A: mutations in RET cause multiple endocrine neoplasia type 2 (MEN 2), an inherited cancer syndrome characterized by medullary thyroid carcinoma
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4134 offsetEnd: 4261 A: family syndrome and multiple endocrine neoplasia type 1 2a, and 2b. The secondly diagnosed tumours are not caused by metastatic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 125 offsetEnd: 249 A: sporadic endocrine tumour may be different from those that present as part of the multiple endocrine neoplasia type 1 (MEN1)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 6289 offsetEnd: 6450 A: review is to introduce medical-practitioners to the newest theories of type 1 multiple endocrine neoplasia syndrome pathogenesis, clinical peculiarities, methods
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 0 offsetEnd: 152 A: Multiple endocrine neoplasia syndrome IIB is an inherited autosomal dominant disorder with variable penetrance. Multiple organ systems are involved with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 0 offsetEnd: 135 A: The recent identification of MEN1 gene mutations as the molecular cause of familial multiple endocrine neoplasia type 1 syndrome (MEN1)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 382 offsetEnd: 536 A: of the multiple endocrine neoplasia type 1 (MEN1) syndrome. As primary hyperparathyroidism (pHPT) and pancreaticoduodenal endocrine tumours (PETs) are the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3777 offsetEnd: 3910 A: differentiated carcinomas. The Multiple Endocrine Neoplasia type 1 syndrome (MEN1) gene is involved in the genesis of a proportion of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 3276 offsetEnd: 3431 A: multiple endocrine neoplasia type 1 syndrome, endocrine neoplasia develops earlier than in sporadic cases; multifocality is typical for them. Multifocality
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 0 offsetEnd: 128 A: The phenotype of the multiple endocrine neoplasia type 1 (MEN1) syndrome cannot be explained solely by the expression pattern of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2799 offsetEnd: 2959 A: all the patients diagnosed with endocrine organ hyperplasia, which determines hyperfunction, or endocrine organs neoplasia. For patients with multiple endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 401 offsetEnd: 539 A: associated as part of a tumour syndrome including Von Hippel Lindau (VHL), Multiple Endocrine Neoplasia (MEN) 2 and Neurofibromatosis Type
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 539 offsetEnd: 684 A: syndrome including Von Hippel Lindau (VHL), Multiple Endocrine Neoplasia (MEN) 2 and Neurofibromatosis Type 1. VHL is associated with multi-organ
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 263 offsetEnd: 398 A: of which are responsible for multiple endocrine neoplasia type 1, an autosomal dominant familial cancer syndrome. We isolated rat menin
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 0 offsetEnd: 152 A: As pheochromocytoma sometimes is accompanied by medullary thyroid carcinoma (in the sense of multiple endocrine adonomatosis type II = Sipple-Syndrome),
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 146 offsetEnd: 294 A: multiple endocrine neoplasia type 1 (MEN-1) exhibits a different picture regarding its propensity for recurrence compared with sporadic primary HPT.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 135 offsetEnd: 275 A: and clinical genetics of solid tumors associated with the various multiple endocrine neoplasias (MEN) syndromes. MEN type 1 (MEN1) describes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 4301 offsetEnd: 4453 A: which is also important in determining the inheritors of mutations, potential patients. After genetically diagnosing multiple endocrine neoplasia type 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 4453 offsetEnd: 4596 A: the inheritors of mutations, potential patients. After genetically diagnosing multiple endocrine neoplasia type 1 syndrome, it is not enough to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 785 offsetEnd: 945 A: neoplasia type 2 (MEN 2), an inherited cancer syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PC), and hyperparathyroidism (HPT).
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 254 offsetEnd: 388 A: isolated cases, sometimes due to a predisposing syndrome. In multiple endocrine neoplasia type 1, they often associate with a mutation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 388 offsetEnd: 526 A: predisposing syndrome. In multiple endocrine neoplasia type 1, they often associate with a mutation of the menin gene, a tumor-suppressing
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3791 offsetEnd: 3906 A: syndromes different organs may be affected at the same time. Examples are type I and type II cancer family syndrome
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 2978 offsetEnd: 3114 A: and Ki67 below 1%. Considering the patient's clinical history, an inherited cause was postulated and multiple endocrine neoplasia type 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3114 offsetEnd: 3254 A: patient's clinical history, an inherited cause was postulated and multiple endocrine neoplasia type 1 was first investigated, but the result
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4039 offsetEnd: 4189 A: distant tumor recurrences are usually reported in radically operated on von Hippel-Lindau pancreatic neuroendocrine tumor patients after a median time
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 249 offsetEnd: 382 A: from those that present as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome. As primary hyperparathyroidism (pHPT) and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 898 offsetEnd: 1048 A: Production of growth hormone-releasing hormone (GHRH) by an ectopic tumor was suspected and, after additional investigations, a large pancreatic tumor
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 532 offsetEnd: 666 A: endocrine neoplasia type 1) tumor suppressor gene, represents a common feature of several fatty liver mouse models. The liver specific
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 275 offsetEnd: 424 A: associated with the various multiple endocrine neoplasias (MEN) syndromes. MEN type 1 (MEN1) describes the association of pituitary, parathyroid, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2643 offsetEnd: 2799 A: syndrome developing should be estimated for all the patients diagnosed with endocrine organ hyperplasia, which determines hyperfunction, or endocrine organs
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 4596 offsetEnd: 4727 A: After genetically diagnosing multiple endocrine neoplasia type 1 syndrome, it is not enough to analyze and look after patients with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 530 offsetEnd: 644 A: in every cell of the body) mutations in RET cause multiple endocrine neoplasia type 2 (MEN 2), an inherited cancer
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 0 offsetEnd: 127 A: Menin is a protein product of a tumor suppressor gene MEN1, mutations of which are responsible for multiple endocrine neoplasia
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 0 offsetEnd: 146 A: A 51-year-old Caucasian man with multiple endocrine neoplasia (MEN) type I syndrome presented with clinical features of acromegaly. Exploration of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1048 offsetEnd: 1177 A: by an ectopic tumor was suspected and, after additional investigations, a large pancreatic tumor was detected and removed. As the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 403 offsetEnd: 532 A: the product of the MEN1 (multiple endocrine neoplasia type 1) tumor suppressor gene, represents a common feature of several fatty
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 0 offsetEnd: 143 A: Adrenal lesions belong to the spectrum of multiple endocrine neoplasia type 1 (MEN-1) syndrome. However, the prevalence of adrenal involvement,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 0 offsetEnd: 146 A: Multiple gland parathyroid disease is one of the hallmarks of multiple endocrine neoplasia (MEN) type 1. Often mislabeled parathyroid hyperplasia,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3254 offsetEnd: 3387 A: was postulated and multiple endocrine neoplasia type 1 was first investigated, but the result was negative. Then, a missense mutation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3473 offsetEnd: 3640 A: to low-grade malignant for well-differentiated tumours/carcinomas to high grade malignant for poorly differentiated carcinomas. The Multiple Endocrine Neoplasia type 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 6157 offsetEnd: 6289 A: The main purpose of this literature review is to introduce medical-practitioners to the newest theories of type 1 multiple endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 143 offsetEnd: 296 A: of multiple endocrine neoplasia type 1 (MEN-1) syndrome. However, the prevalence of adrenal involvement, the characteristics, and the clinical management
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1544 offsetEnd: 1687 A: the important immunological features of type 1 diabetes. The prevalences of anti-islet autoantibodies in patients with Japanese type 1 diabetes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 266 offsetEnd: 403 A: the impaired hepatic expression of menin, the product of the MEN1 (multiple endocrine neoplasia type 1) tumor suppressor gene, represents
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 399 offsetEnd: 545 A: The endocrine phenotype is assessed by the expression of general and specific endocrine markers. General endocrine markers associate to organelles
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 2546 offsetEnd: 2678 A: function would be an appealing role for a tumor suppressor. However, menin does not specifically associate with telomeres in somatic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 2678 offsetEnd: 2805 A: for a tumor suppressor. However, menin does not specifically associate with telomeres in somatic cells, as indicated by lack of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 276 offsetEnd: 401 A: It may occur sporadically or be associated as part of a tumour syndrome including Von Hippel Lindau (VHL), Multiple Endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 124 offsetEnd: 254 A: familial context, or they can be isolated cases, sometimes due to a predisposing syndrome. In multiple endocrine neoplasia type 1,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 0 offsetEnd: 157 A: An asymptomatic 12-year-old girl with multiple endocrine neoplasia, type 2, had high urinary levels of vanillylmandelic acid that suggested pheochromocytoma;
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1252 offsetEnd: 1403 A: circulating autoantibodies to multiple islet autoantigens including GAD, insulin, and IA-2 are the important immunological features of type 1 diabetes.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4981 offsetEnd: 5131 A: neuroendocrine tumor associated with von Hippel-Lindau syndrome may behave more aggressively than that has previously been described, thus requiring a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 152 offsetEnd: 294 A: medullary thyroid carcinoma (in the sense of multiple endocrine adonomatosis type II = Sipple-Syndrome), serum calcitonin (CT) was measured by
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 294 offsetEnd: 448 A: of multiple endocrine adonomatosis type II = Sipple-Syndrome), serum calcitonin (CT) was measured by radioimmunoassay in 4 patients with pheochromocytoma.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 536 offsetEnd: 691 A: 1 (MEN1) syndrome. As primary hyperparathyroidism (pHPT) and pancreaticoduodenal endocrine tumours (PETs) are the most common organ manifestations of MEN1,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 946 offsetEnd: 1114 A: lesions. MEN type 2 (MEN2) conditions represent at least four different syndromes that associate pheochromocytoma with medullary thyroid carcinoma, hyperparathyroidism,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 940 offsetEnd: 1093 A: benign (pheochromocytomas) and malignant (medullary thyroid carcinomas, MTCs) tumors from patients with multiple endocrine neoplasia (MEN) type 2A or 2B,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 1233 offsetEnd: 1368 A: multiple endocrine neoplasia (MEN) type 2A or 2B, related syndromes that result from distinctive mutations in the RET receptor tyrosine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 430 offsetEnd: 586 A: multiple endocrine neoplasia type 2a (MEN2a). Several databases were searched throughout the year 2000, including MEDLINE, CINAHL, CancerLit, PsychINFO, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 945 offsetEnd: 1123 A: inherited cancer syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PC), and hyperparathyroidism (HPT). This knowledge has allowed molecular diagnosis
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 684 offsetEnd: 829 A: Multiple Endocrine Neoplasia (MEN) 2 and Neurofibromatosis Type 1. VHL is associated with multi-organ involvement of benign and malignant tumours
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 398 offsetEnd: 524 A: endocrine neoplasia type 1, an autosomal dominant familial cancer syndrome. We isolated rat menin cDNA clones from a fetal rat
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1687 offsetEnd: 1827 A: 1 diabetes. The prevalences of anti-islet autoantibodies in patients with Japanese type 1 diabetes are 60-70% for GAD autoantibodies, 45-50%
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4696 offsetEnd: 4837 A: recurrence after a very long period of time, suggesting that a pancreatic neuroendocrine tumor associated with von Hippel-Lindau syndrome may
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4837 offsetEnd: 4981 A: of time, suggesting that a pancreatic neuroendocrine tumor associated with von Hippel-Lindau syndrome may behave more aggressively than that has
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 128 offsetEnd: 251 A: neoplasia type 1 (MEN1) syndrome cannot be explained solely by the expression pattern of the predisposing gene MEN1 and its
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 1744 offsetEnd: 1893 A: hepatomesenteric trunk variant of aberrant arterial anatomy) for multifocal PNTs in the setting of multiple neuroendocrine neoplasia type 1 syndrome.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 146 offsetEnd: 298 A: endocrine neoplasia (MEN) type I syndrome presented with clinical features of acromegaly. Exploration of the pituitary gland only revealed somatotrophic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1177 offsetEnd: 1326 A: and, after additional investigations, a large pancreatic tumor was detected and removed. As the pancreatic tail contained multiple (occult) adenomas,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3910 offsetEnd: 4029 A: type 1 syndrome (MEN1) gene is involved in the genesis of a proportion of both well- and poorly differentiated sporadic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 1093 offsetEnd: 1233 A: carcinomas, MTCs) tumors from patients with multiple endocrine neoplasia (MEN) type 2A or 2B, related syndromes that result from distinctive
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 140 offsetEnd: 289 A: about the diagnosis, treatment, and follow-care of people with the inherited disorder multiple endocrine neoplasia type 2a (MEN2a). Several databases
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 289 offsetEnd: 430 A: of people with the inherited disorder multiple endocrine neoplasia type 2a (MEN2a). Several databases were searched throughout the year 2000,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 402 offsetEnd: 530 A: derived from neural crest. Germline (present in every cell of the body) mutations in RET cause multiple endocrine neoplasia type
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2049 offsetEnd: 2182 A: of such gene testing. There appears to be a correlation between specific RET mutation type and organ-specific tumor development. Such
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2182 offsetEnd: 2318 A: to be a correlation between specific RET mutation type and organ-specific tumor development. Such knowledge might be useful in tailoring
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2318 offsetEnd: 2459 A: RET mutation type and organ-specific tumor development. Such knowledge might be useful in tailoring targeted surveillance in the near future.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 551 offsetEnd: 671 A: 1 diabetes in children is very low compared to European countries. However, there are more patients with type 1 diabetes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 3049 offsetEnd: 3170 A: as type 1A diabetes. Although the majority of patients with type 1 diabetes are young, lean, and ketosis-prone, there are
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 3414 offsetEnd: 3528 A: there are a number of patients with type 1 diabetes initially diagnosed as having type 2 diabetes at disease onset
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1380 offsetEnd: 1524 A: now known as the biggest endocrine organ of the human body. This tissue secretes a number of substances--adipocytokines--with multiple functions
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 1893 offsetEnd: 2032 A: anatomy) for multifocal PNTs in the setting of multiple neuroendocrine neoplasia type 1 syndrome. The procedure resulted in pain abolition,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 2032 offsetEnd: 2178 A: setting of multiple neuroendocrine neoplasia type 1 syndrome. The procedure resulted in pain abolition, a significant improvement in the patient's
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 545 offsetEnd: 689 A: the expression of general and specific endocrine markers. General endocrine markers associate to organelles like large dense core vesicles (e.g.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 689 offsetEnd: 843 A: endocrine markers. General endocrine markers associate to organelles like large dense core vesicles (e.g. chromogranin A) and small synaptic-like vesicles
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 726 offsetEnd: 858 A: patients having more than one organ affected by an endocrine disorder and patients having separate distinct endocrine diseases for G
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2315 offsetEnd: 2462 A: in proliferating cells only. Consequently cancer mutations also depend on cell proliferation. If an inherited cancer mutation predisposes to cancer
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 2927 offsetEnd: 3049 A: of these autoantibodies and are classified as type 1A diabetes. Although the majority of patients with type 1 diabetes are
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 3528 offsetEnd: 3649 A: with type 1 diabetes initially diagnosed as having type 2 diabetes at disease onset called LADA. These patients with LADA
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1158 offsetEnd: 1268 A: regarded only as an energy storage organ until the last decade, is now known as the biggest endocrine organ of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1326 offsetEnd: 1478 A: pancreatic tumor was detected and removed. As the pancreatic tail contained multiple (occult) adenomas, lifelong follow-up was considered necessary. The
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2509 offsetEnd: 2643 A: the patient. The risk of this syndrome developing should be estimated for all the patients diagnosed with endocrine organ hyperplasia,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2598 offsetEnd: 2720 A: If an inherited cancer mutation predisposes to cancer formation in certain organs, then the cancer risk in these organs is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 146 offsetEnd: 290 A: of the hallmarks of multiple endocrine neoplasia (MEN) type 1. Often mislabeled parathyroid hyperplasia, the process is actually the development
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1268 offsetEnd: 1380 A: organ until the last decade, is now known as the biggest endocrine organ of the human body. This tissue secretes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 3170 offsetEnd: 3288 A: majority of patients with type 1 diabetes are young, lean, and ketosis-prone, there are a number of patients with type
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 0 offsetEnd: 131 A: Endocrine tumours of gut and pancreas tract are rare entities originating from cells of the diffuse endocrine system. The endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 264 offsetEnd: 399 A: cells of the diffuse endocrine system. The endocrine phenotype is assessed by the expression of general and specific endocrine markers.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 2412 offsetEnd: 2546 A: virtually all malignancies, regulation of telomere function would be an appealing role for a tumor suppressor. However, menin does not
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 303 offsetEnd: 475 A: variable penetrance. Multiple organ systems are involved with a characteristic triad of medullary thyroid carcinoma, pheochromocytoma, and alimentary tract ganglioneuromas.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1078 offsetEnd: 1239 A: multiple endocrine neoplasias has recently been identified in MENI-negative subjects on the gene CDKN1B encoding for p27(kip1)protein. Carney Complex syndrome--a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 479 offsetEnd: 597 A: occur in a number of endocrine diseases. We have examined tissues from patients having more than one organ affected by
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7557 offsetEnd: 7699 A: early occurrence, the multifocal and bilateral localisation, its occurrence as cancer family syndrome or by second primary malignancies. It is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7699 offsetEnd: 7834 A: localisation, its occurrence as cancer family syndrome or by second primary malignancies. It is thus recommended to screen patients and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7834 offsetEnd: 7965 A: syndrome or by second primary malignancies. It is thus recommended to screen patients and families with hereditary cancer for first
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2373 offsetEnd: 2490 A: 67 (26.8%) MEN-1 patients and were diagnosed 5 years later than MEN-1. The median tumor diameter at diagnosis was 3.0
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2490 offsetEnd: 2606 A: diagnosed 5 years later than MEN-1. The median tumor diameter at diagnosis was 3.0 cm (range 1.2-15.0 cm), with most
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 0 offsetEnd: 150 A: Type 1 diabetes is an organ-specific autoimmune disease characterized by T cell-mediated destruction of pancreatic beta cells. In Japanese population,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 423 offsetEnd: 551 A: Japanese population, the incidence of type 1 diabetes in children is very low compared to European countries. However, there are
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3613 offsetEnd: 3739 A: missense mutation in exon 3 of the VHL gene (ACT>ATT; Thr157Ile) was found. CONCLUSION: Although no local and/or distant tumor
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3739 offsetEnd: 3880 A: the VHL gene (ACT>ATT; Thr157Ile) was found. CONCLUSION: Although no local and/or distant tumor recurrences are usually reported in radically
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3880 offsetEnd: 4039 A: found. CONCLUSION: Although no local and/or distant tumor recurrences are usually reported in radically operated on von Hippel-Lindau pancreatic neuroendocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 2168 offsetEnd: 2308 A: amounting 1 and 4 ng/mg wet tissue. These findings suggest that hypercalcitonism in patients with pheochromocytoma cannot always be ascribed
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3140 offsetEnd: 3250 A: young age at onset (< 35 years) and/or multiple MEN 1-related lesions in a single organ or two distinct organs
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3250 offsetEnd: 3383 A: years) and/or multiple MEN 1-related lesions in a single organ or two distinct organs affected. Application of these criteria yielded
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 2032 offsetEnd: 2159 A: as a tumor suppressor, tumorigenesis could depend on the inability of such tissues to adequately compensate for MEN1 gene loss,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1018 offsetEnd: 1152 A: or three lesions classically associated with the syndrome whilst only one of them is required for individuals belonging to established
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 0 offsetEnd: 135 A: We present an update on molecular and clinical genetics of solid tumors associated with the various multiple endocrine neoplasias (MEN)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 424 offsetEnd: 562 A: neoplasias (MEN) syndromes. MEN type 1 (MEN1) describes the association of pituitary, parathyroid, and pancreatic islet cell tumors with a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 821 offsetEnd: 946 A: with a variety of many other lesions. MEN type 2 (MEN2) conditions represent at least four different syndromes that associate
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 1114 offsetEnd: 1282 A: represent at least four different syndromes that associate pheochromocytoma with medullary thyroid carcinoma, hyperparathyroidism, and a number of other manifestations.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 771 offsetEnd: 940 A: we performed microarray expression analysis on benign (pheochromocytomas) and malignant (medullary thyroid carcinomas, MTCs) tumors from patients with multiple endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 1994 offsetEnd: 2127 A: of epithelial to mesenchymal transition, many associated with the tumor growth factor beta pathway, were up-regulated in MEN 2B MTCs.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 493 offsetEnd: 699 A: (autoimmune regulator). APECED affects mainly endocrine organs resulting in hypoparathyroidism, adrenocortical failure, diabetes mellitus, hypogonadism, and hypothyroidism. Nonendocrine organ manifestations
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2706 offsetEnd: 2818 A: near future. Somatic (in the tumor only) RET mutations have been found in a proportion of sporadic MTCs and PCs.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 152 offsetEnd: 303 A: an inherited autosomal dominant disorder with variable penetrance. Multiple organ systems are involved with a characteristic triad of medullary thyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 785 offsetEnd: 931 A: a tumor-suppressing gene. A new germinal mutation predisposing to the development of multiple endocrine neoplasias has recently been identified in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 931 offsetEnd: 1078 A: mutation predisposing to the development of multiple endocrine neoplasias has recently been identified in MENI-negative subjects on the gene CDKN1B
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 157 offsetEnd: 308 A: endocrine neoplasia, type 2, had high urinary levels of vanillylmandelic acid that suggested pheochromocytoma; she also had bilateral medullary thyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3460 offsetEnd: 3625 A: medullary hyperplasia was wild-type. Patient 3 had an aggressive corticotroph adenoma and developed Nelson's syndrome after bilateral adrenalectomy. The corticotroph
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2462 offsetEnd: 2598 A: mutations also depend on cell proliferation. If an inherited cancer mutation predisposes to cancer formation in certain organs, then the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3675 offsetEnd: 3791 A: the female breast. In cancer family syndromes different organs may be affected at the same time. Examples are type I
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4261 offsetEnd: 4374 A: type 1 2a, and 2b. The secondly diagnosed tumours are not caused by metastatic spread. Tumours in two organs will
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 822 offsetEnd: 957 A: total of 66 patients with confirmed MEN1 germline mutations and 1 additional patient with typical manifestations in three organ systems
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 957 offsetEnd: 1094 A: MEN1 germline mutations and 1 additional patient with typical manifestations in three organ systems were monitored in a regular screening
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2606 offsetEnd: 2716 A: The median tumor diameter at diagnosis was 3.0 cm (range 1.2-15.0 cm), with most tumors being 3 cm or smaller.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 290 offsetEnd: 438 A: neoplasia (MEN) type 1. Often mislabeled parathyroid hyperplasia, the process is actually the development of multiple adenomas. Some clinicians have
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 150 offsetEnd: 296 A: autoimmune disease characterized by T cell-mediated destruction of pancreatic beta cells. In Japanese population, the incidence of type 1 diabetes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 671 offsetEnd: 808 A: low compared to European countries. However, there are more patients with type 1 diabetes in adults, including latent autoimmune diabetes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 4753 offsetEnd: 4887 A: be helpful to predict future insulin dependency in LADA patients. In conclusion, Japanese patients with type 1 diabetes are clinically
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 4887 offsetEnd: 5037 A: dependency in LADA patients. In conclusion, Japanese patients with type 1 diabetes are clinically heterogeneous and the determination of immunological
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1524 offsetEnd: 1681 A: organ of the human body. This tissue secretes a number of substances--adipocytokines--with multiple functions in metabolic profile and immunological process.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 146 offsetEnd: 284 A: a dominantly inherited familial cancer syndrome, develop a variety of tumors in different organ systems which make the clinical management
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4189 offsetEnd: 4324 A: in radically operated on von Hippel-Lindau pancreatic neuroendocrine tumor patients after a median time of five years of follow-up, the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 1674 offsetEnd: 1848 A: CT response. In hydrochloric acid extracts from the two corresponding pheochromocytoma tissues, immunoreactive-Calcitonin (IR-CT) was detected, the concentrations amounting 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 1848 offsetEnd: 2009 A: from the two corresponding pheochromocytoma tissues, immunoreactive-Calcitonin (IR-CT) was detected, the concentrations amounting 1 and 4 ng/mg wet tissue. These
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 4331 offsetEnd: 4486 A: differ from that in sporadic endocrine neoplasia, calling for individual management. Genetic counselling and dedicated endocrine surgery should be integral
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 144 offsetEnd: 279 A: (MEN 1) is an autosomal, dominantly inherited cancer syndrome, with tumours in various endocrine glands. In 1997 the responsible tumour
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 147 offsetEnd: 310 A: is a well characterized hereditary syndrome with the occurrence of primary hyperparathyroidism (HPT) in combination with pancreatic-duodenal endocrine and anterior
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 1282 offsetEnd: 1476 A: that associate pheochromocytoma with medullary thyroid carcinoma, hyperparathyroidism, and a number of other manifestations. Other pheochromocytoma-associated syndromes include von Hippel-Lindau
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 2359 offsetEnd: 2518 A: known as carcinoids) express all general markers of endocrine differentiation and various hormones. Poorly differentiated endocrine carcinomas lack large dense
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 2682 offsetEnd: 2848 A: hormones. Poorly differentiated endocrine carcinomas lack large dense core vesicles markers (chromogranin A), while widely express synaptophysin and cytosol endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 2848 offsetEnd: 3001 A: large dense core vesicles markers (chromogranin A), while widely express synaptophysin and cytosol endocrine markers. The clinical behaviour of endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3001 offsetEnd: 3145 A: A), while widely express synaptophysin and cytosol endocrine markers. The clinical behaviour of endocrine tumours spans from benign to low-grade
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 1860 offsetEnd: 1994 A: that genes involved in the process of epithelial to mesenchymal transition, many associated with the tumor growth factor beta pathway,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3795 offsetEnd: 3956 A: abnormalities in MEN 2B patients. These findings provide molecular evidence that associate the previously unexplained skeletal abnormalities and early malignancy
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3956 offsetEnd: 4105 A: findings provide molecular evidence that associate the previously unexplained skeletal abnormalities and early malignancy in MEN 2B compared with MEN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8819 offsetEnd: 8964 A: to represent a target of IgG autoantibodies highly associated with diabetes development in first-degree relatives of type 1 diabetic individuals.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8964 offsetEnd: 9123 A: autoantibodies highly associated with diabetes development in first-degree relatives of type 1 diabetic individuals. In addition, the GM2-1 ganglioside appears
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 141 offsetEnd: 294 A: syndrome or Wermer syndrome is a classical malignant neoplasia syndrome, inherited in the autosomal dominant pattern, when hyperplastic and/or neoplastic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 4727 offsetEnd: 4838 A: type 1 syndrome, it is not enough to analyze and look after patients with malignant neoplasia, or to make early
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 0 offsetEnd: 140 A: This paper summarizes what is known about the diagnosis, treatment, and follow-care of people with the inherited disorder multiple endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 146 offsetEnd: 289 A: an autosomal dominant cancer predisposition syndrome caused by mutations in the tumor-suppressor gene MEN1. The gene encodes a nuclear protein,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 913 offsetEnd: 1079 A:  had bilateral pheochromocytoma (metastatic in the former two). Bilateral adrenalectomy was performed. Diffuse, non-nodular adrenal medullary hyperplasia was present.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 597 offsetEnd: 726 A: diseases. We have examined tissues from patients having more than one organ affected by an endocrine disorder and patients having
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 520 offsetEnd: 626 A: the organism, and only leads to cancer if in a somatic cell a complete set of specific cancer mutations is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 626 offsetEnd: 751 A: cancer if in a somatic cell a complete set of specific cancer mutations is accumulated. Since one defective anti-oncogene has
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7422 offsetEnd: 7557 A: by family history, but also by early occurrence, the multifocal and bilateral localisation, its occurrence as cancer family syndrome or
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 296 offsetEnd: 423 A: destruction of pancreatic beta cells. In Japanese population, the incidence of type 1 diabetes in children is very low compared
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 808 offsetEnd: 949 A: there are more patients with type 1 diabetes in adults, including latent autoimmune diabetes in adults (LADA). The circulating autoantibodies
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1403 offsetEnd: 1544 A: including GAD, insulin, and IA-2 are the important immunological features of type 1 diabetes. The prevalences of anti-islet autoantibodies in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1827 offsetEnd: 1970 A: autoantibodies in patients with Japanese type 1 diabetes are 60-70% for GAD autoantibodies, 45-50% for insulin autoantibodies (IAA), and 60-65%
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 3288 offsetEnd: 3414 A: diabetes are young, lean, and ketosis-prone, there are a number of patients with type 1 diabetes initially diagnosed as having
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 5037 offsetEnd: 5179 A: Japanese patients with type 1 diabetes are clinically heterogeneous and the determination of immunological features are helpful to clarify the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 0 offsetEnd: 146 A: CONTEXT: Patients with von Hippel-Lindau syndrome, a dominantly inherited familial cancer syndrome, develop a variety of tumors in different organ
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3387 offsetEnd: 3493 A: type 1 was first investigated, but the result was negative. Then, a missense mutation in exon 3 of the VHL
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 3189 offsetEnd: 3322 A: Type II diabetes and the metabolic syndrome. WAT is involved in extensive cross-talk with other organs and multiple metabolic systems
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 279 offsetEnd: 420 A: inherited cancer syndrome, with tumours in various endocrine glands. In 1997 the responsible tumour suppressor gene was identified. MEN1 gene
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 691 offsetEnd: 836 A: (pHPT) and pancreaticoduodenal endocrine tumours (PETs) are the most common organ manifestations of MEN1, the prevalence of germline mutations in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 1777 offsetEnd: 1916 A: of individual tissues to MEN1-associated tumorigenesis. In tissues in which menin acts as a tumor suppressor, tumorigenesis could depend on
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 1916 offsetEnd: 2032 A: In tissues in which menin acts as a tumor suppressor, tumorigenesis could depend on the inability of such tissues to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 754 offsetEnd: 898 A: growth hormone (GH) levels remained elevated. Production of growth hormone-releasing hormone (GHRH) by an ectopic tumor was suspected and, after
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 902 offsetEnd: 1018 A: the recognition of at least two or three lesions classically associated with the syndrome whilst only one of them is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 1999 offsetEnd: 2152 A: recently defined paraganglioma syndromes type 1, 3, and 4; Carney-Stratakis syndrome; and the Carney triad. Carney-Stratakis syndrome is characterized by
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 2518 offsetEnd: 2682 A: markers of endocrine differentiation and various hormones. Poorly differentiated endocrine carcinomas lack large dense core vesicles markers (chromogranin A), while
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3145 offsetEnd: 3307 A: cytosol endocrine markers. The clinical behaviour of endocrine tumours spans from benign to low-grade malignant for well-differentiated tumours/carcinomas to high
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2127 offsetEnd: 2242 A: associated with the tumor growth factor beta pathway, were up-regulated in MEN 2B MTCs. This MEN 2B MTC profile may
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1619 offsetEnd: 1732 A: this MEN 1 gene mutation, when the penetration of mutation is almost 100 percent. An early stage of this syndrome
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 2225 offsetEnd: 2375 A: literature describes morbidity and mortality outcomes of disease treatment, and the monitoring of multiple organ systems. Research is scant concerning
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2459 offsetEnd: 2589 A: development. Such knowledge might be useful in tailoring targeted surveillance in the near future. Somatic (in the tumor only) RET
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 1246 offsetEnd: 1430 A: performed. Diffuse, non-nodular adrenal medullary hyperplasia was present. This hyperplasia was characterized by increased medullary mitotic activity, decreased corticomedullary ratio,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 858 offsetEnd: 994 A: affected by an endocrine disorder and patients having separate distinct endocrine diseases for G protein gene mutations. G protein genes
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4819 offsetEnd: 4933 A: per organ and the growth kinetics differ. In this case the second tumour is called a second primary malignancy and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 949 offsetEnd: 1102 A: 1 diabetes in adults, including latent autoimmune diabetes in adults (LADA). The circulating autoantibodies to multiple islet autoantigens including GAD,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4324 offsetEnd: 4455 A: pancreatic neuroendocrine tumor patients after a median time of five years of follow-up, the present patient had a recurrence after
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 4565 offsetEnd: 4696 A: follow-up, the present patient had a recurrence after a very long period of time, suggesting that a pancreatic neuroendocrine tumor
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2169 offsetEnd: 2309 A: mutations were revealed in 16/16 MEN 1 patients/families (100%). Based on our clinical experience with MEN 1 patients/families we formulated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2309 offsetEnd: 2455 A: 1 patients/families (100%). Based on our clinical experience with MEN 1 patients/families we formulated clinical criteria to identify disease gene
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 9123 offsetEnd: 9249 A: in first-degree relatives of type 1 diabetic individuals. In addition, the GM2-1 ganglioside appears to be one of the antigens
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 2375 offsetEnd: 2520 A: of disease treatment, and the monitoring of multiple organ systems. Research is scant concerning the psychological consequences and social impact
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 2520 offsetEnd: 2663 A: of multiple organ systems. Research is scant concerning the psychological consequences and social impact of the MEN2a diagnosis, treatment, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 526 offsetEnd: 652 A: type 1, they often associate with a mutation of the menin gene, a tumor-suppressing gene. A new germinal mutation predisposing
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 1079 offsetEnd: 1246 A: the former two). Bilateral adrenalectomy was performed. Diffuse, non-nodular adrenal medullary hyperplasia was present. This hyperplasia was characterized by increased
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 2055 offsetEnd: 2186 A: adrenal). The results in this case suggest that diffuse hyperplasia of the adrenal medulla may be the precursor of pheochromocytoma
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2720 offsetEnd: 2840 A: to cancer formation in certain organs, then the cancer risk in these organs is enhanced by 10(4)-10(5) times. Tumours in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 6905 offsetEnd: 7044 A: enhanced tumour incidence in hereditary cancer is helpful for the clinical recognition of hereditary cancer. That is, hereditary cancer can
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 767 offsetEnd: 902 A: of MEN-1, the possible probands, necessitates the recognition of at least two or three lesions classically associated with the syndrome
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 131 offsetEnd: 264 A: tract are rare entities originating from cells of the diffuse endocrine system. The endocrine phenotype is assessed by the expression
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2589 offsetEnd: 2706 A: in tailoring targeted surveillance in the near future. Somatic (in the tumor only) RET mutations have been found in a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 5179 offsetEnd: 5321 A: are clinically heterogeneous and the determination of immunological features are helpful to clarify the characteristics of the Japanese type 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 652 offsetEnd: 785 A: a mutation of the menin gene, a tumor-suppressing gene. A new germinal mutation predisposing to the development of multiple endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 0 offsetEnd: 149 A: Pheochromocytoma is a rare catecholamine-secreting tumour typically arising within the adrenal medulla. It may occur sporadically or be associated as
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 149 offsetEnd: 276 A: typically arising within the adrenal medulla. It may occur sporadically or be associated as part of a tumour syndrome including
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 2195 offsetEnd: 2348 A: years old Chinese gentleman who presented to our institution for further management of bilateral pheochromocytoma and retinal angioblastoma with problems
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1868 offsetEnd: 2007 A: gene located on 17q22-24 that encodes the regulatory subunit 1 of protein kinase A, PRKARIA. Isolated familial pituitary adenomas represent
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2401 offsetEnd: 2511 A: identified was at codon 201 of Gs alpha (gsp), which encoded a change from arginine to cysteine. Patient 1 had
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 161 offsetEnd: 304 A: cancer genes are defective (mutated) anti-oncogenes (tumour suppressor genes). This inherited mutation is present in all cells of the organism,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 304 offsetEnd: 423 A: (tumour suppressor genes). This inherited mutation is present in all cells of the organism, and only leads to cancer if
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 751 offsetEnd: 894 A: a complete set of specific cancer mutations is accumulated. Since one defective anti-oncogene has been inherited, only three additional somatic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 1047 offsetEnd: 1200 A: anti-oncogene has been inherited, only three additional somatic cancer mutations are required, according to our previously published view (Anticancer Res
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 1200 offsetEnd: 1340 A: additional somatic cancer mutations are required, according to our previously published view (Anticancer Res 10:1990). The number of de novo
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4497 offsetEnd: 4608 A: by metastatic spread. Tumours in two organs will arise at difference times if the number of end cells per organ
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 8236 offsetEnd: 8386 A: for first and second primary tumours. Treatment of patients with hereditary tumours requires extra care to avoid additional cancer mutations.(ABSTRACT
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1230 offsetEnd: 1365 A: organ systems were monitored in a regular screening program that included evaluation of the adrenals (median follow-up 96 months; range
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 3649 offsetEnd: 3778 A: as having type 2 diabetes at disease onset called LADA. These patients with LADA often progress toward an insulin-deficient state
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 0 offsetEnd: 151 A: Obesity is a well-known risk factor for the development of insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1025 offsetEnd: 1158 A: abnormalities termed metabolic syndrome. Adipose tissue, regarded only as an energy storage organ until the last decade, is now known
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1681 offsetEnd: 1850 A: tissue secretes a number of substances--adipocytokines--with multiple functions in metabolic profile and immunological process. Therefore, excessive fat mass may trigger
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 1492 offsetEnd: 1674 A: and pentagastrin stimulation produced no exaggerated CT response. In hydrochloric acid extracts from the two corresponding pheochromocytoma tissues, immunoreactive-Calcitonin (IR-CT)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 2009 offsetEnd: 2168 A: immunoreactive-Calcitonin (IR-CT) was detected, the concentrations amounting 1 and 4 ng/mg wet tissue. These findings suggest that hypercalcitonism in patients
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 2308 offsetEnd: 2462 A: tissue. These findings suggest that hypercalcitonism in patients with pheochromocytoma cannot always be ascribed to the thyroid, i.e. increased calcitonin
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 2462 offsetEnd: 2600 A: in patients with pheochromocytoma cannot always be ascribed to the thyroid, i.e. increased calcitonin levels do not necessarily indicate a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 395 offsetEnd: 534 A: syndrome (MEN1) has had a significant impact on clinical patient care. In the following consensus statement we will present recommendations
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 1282 offsetEnd: 1475 A: mutational analysis should be performed in individuals with newly diagnosed MEN1-typical endocrine neoplasia (e.g., primary hyperparathyroidism, gastroenteropancreatic tumor, pituitary adenoma)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 1475 offsetEnd: 1667 A: individuals with newly diagnosed MEN1-typical endocrine neoplasia (e.g., primary hyperparathyroidism, gastroenteropancreatic tumor, pituitary adenoma) if additional diagnostic criteria are met
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2264 offsetEnd: 2399 A: neoplasia; two or more organ systems affected). Genetic family screening is advisable in first degree relatives of MEN1 patients during
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 4486 offsetEnd: 4635 A: neoplasia, calling for individual management. Genetic counselling and dedicated endocrine surgery should be integral parts of current medical care in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 429 offsetEnd: 560 A: propensity for recurrence compared with sporadic primary HPT. In order to shed further light on the MEN-1 syndrome an investigation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 4384 offsetEnd: 4540 A: evident that WAT is highly integrated into overall physiological regulation, involving extensive crosstalk with other organs and multiple metabolic systems.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 4540 offsetEnd: 4704 A: into overall physiological regulation, involving extensive crosstalk with other organs and multiple metabolic systems. Whether major changes in adipokine production
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 3056 offsetEnd: 3189 A: of diseases linked to obesity, particularly Type II diabetes and the metabolic syndrome. WAT is involved in extensive cross-talk with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 691 offsetEnd: 825 A: MEN1 gene germ-line mutations are detected in the vast majority of MEN 1 patients, however, with regard to case-finding, unfortunately
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 825 offsetEnd: 945 A: in the vast majority of MEN 1 patients, however, with regard to case-finding, unfortunately only at a very low frequency
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1745 offsetEnd: 1847 A: had no family history of MEN1, only one organ manifestation and were aged 40 years or less at the time
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1847 offsetEnd: 1959 A: only one organ manifestation and were aged 40 years or less at the time of diagnosis. Fifteen patients with pHPT
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 4006 offsetEnd: 4135 A: Sporadic pHPT due to multiglandular disease in patients younger than 40 years may represent the first organ manifestation of MEN1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2380 offsetEnd: 2519 A: to suffer from peptic ulcer disease caused by hyperparathyroidism and, during screening for other organ involvement associated with the MEN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2519 offsetEnd: 2657 A: caused by hyperparathyroidism and, during screening for other organ involvement associated with the MEN I syndrome, two tumors were found,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 2802 offsetEnd: 2943 A: prior to clinically overt disease. The primary biochemical screening programme for MEN-1 includes serum prolactin and insulin growth factor 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 4471 offsetEnd: 4617 A: current primary screening procedure has yielded about 10% false positives when compared with RFLP data. Pancreatic endocrine tumour diagnosis must
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 4617 offsetEnd: 4766 A: about 10% false positives when compared with RFLP data. Pancreatic endocrine tumour diagnosis must be biochemically established since radiology fails
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 4766 offsetEnd: 4902 A: with RFLP data. Pancreatic endocrine tumour diagnosis must be biochemically established since radiology fails to show lesions in half of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 696 offsetEnd: 821 A: parathyroid, and pancreatic islet cell tumors with a variety of many other lesions. MEN type 2 (MEN2) conditions represent at
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 1675 offsetEnd: 1824 A: hormones produced by tumour cells. Two major categories of endocrine tumours are identified as (i) well-differentiated and (ii) poorly differentiated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 5766 offsetEnd: 5905 A: performed directly on TLC plates or by ELISA, have been described in several autoimmune disorders such as Guillain-Barré syndrome, multiple
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 5905 offsetEnd: 6069 A: by ELISA, have been described in several autoimmune disorders such as Guillain-Barré syndrome, multiple sclerosis, lupus erythematosus, Hashimoto's thyroiditis and,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 6069 offsetEnd: 6244 A: several autoimmune disorders such as Guillain-Barré syndrome, multiple sclerosis, lupus erythematosus, Hashimoto's thyroiditis and, last but not least, insulin-dependent (type
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 911 offsetEnd: 1073 A: parathyroid gland, pancreas islets, hypophysis, and rarer in other neuroendocrine organs. The syndrome develops when germinative MEN 1--neoplasia suppression gene
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1073 offsetEnd: 1227 A: rarer in other neuroendocrine organs. The syndrome develops when germinative MEN 1--neoplasia suppression gene inactivation mutations occurs. More than 95
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 4344 offsetEnd: 4477 A: to guide the development of risk management strategies for patients with this inherited cancer syndrome. Since MEN2a has been labeled
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 180 offsetEnd: 325 A: a rare autosomal recessive disorder caused by mutations in the gene AIRE (autoimmune regulator). APECED affects mainly endocrine organs resulting
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 699 offsetEnd: 904 A: organs resulting in hypoparathyroidism, adrenocortical failure, diabetes mellitus, hypogonadism, and hypothyroidism. Nonendocrine organ manifestations are autoimmune hepatitis, vitiligo, pernicious anemia,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 1103 offsetEnd: 1295 A: organ manifestations are autoimmune hepatitis, vitiligo, pernicious anemia, exocrine pancreatic insufficiency, and alopecia. APECED's first manifestation generally is mucocutaneous candidiasis
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 2399 offsetEnd: 2535 A: chronic interstitial nephritis (CIN), which progressed to end-stage renal failure. She was transplanted 1 yr later. Common causes of CIN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 2658 offsetEnd: 2816 A: transplanted 1 yr later. Common causes of CIN were excluded. APECED was suspected first because she developed progressively hypoparathyroidism, adrenocortical
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 2805 offsetEnd: 2942 A: does not specifically associate with telomeres in somatic cells, as indicated by lack of co-localization with the known telomeric protein
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 829 offsetEnd: 974 A: Neurofibromatosis Type 1. VHL is associated with multi-organ involvement of benign and malignant tumours characterized by the presence of retinal
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 1917 offsetEnd: 2055 A: and increased total catecholamine content (left adrenal). The results in this case suggest that diffuse hyperplasia of the adrenal medulla
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 359 offsetEnd: 479 A: Such mutations have been shown to occur in a number of endocrine diseases. We have examined tissues from patients having
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2511 offsetEnd: 2630 A: Gs alpha (gsp), which encoded a change from arginine to cysteine. Patient 1 had the mutation in a corticotroph adenoma,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3308 offsetEnd: 3460 A: pheochromocytoma, but an adrenal gland with medullary hyperplasia was wild-type. Patient 3 had an aggressive corticotroph adenoma and developed Nelson's
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3788 offsetEnd: 3949 A: developed Nelson's syndrome after bilateral adrenalectomy. The corticotroph adenoma was wild-type, but both hyperplastic adrenal glands had the mutation. Patient
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5423 offsetEnd: 5534 A: in all cases. We conclude that G protein gene mutations occur in a wider range of endocrine conditions than has
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5534 offsetEnd: 5655 A: G protein gene mutations occur in a wider range of endocrine conditions than has been recognized hereto. In addition, the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 0 offsetEnd: 161 A: In hereditary cancers the responsible inherited cancer genes are defective (mutated) anti-oncogenes (tumour suppressor genes). This inherited mutation is present
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 894 offsetEnd: 1047 A: mutations is accumulated. Since one defective anti-oncogene has been inherited, only three additional somatic cancer mutations are required, according to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4608 offsetEnd: 4717 A: organs will arise at difference times if the number of end cells per organ and the growth kinetics differ. In
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 5163 offsetEnd: 5298 A: malignancy and is not caused by metastatic spread. A good example are the second primary malignancies in hereditary retinoblastoma. The
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7044 offsetEnd: 7169 A: is helpful for the clinical recognition of hereditary cancer. That is, hereditary cancer can be recognized not only by family
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7293 offsetEnd: 7422 A: cancer can be recognized not only by family history, but also by early occurrence, the multifocal and bilateral localisation, its
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7965 offsetEnd: 8093 A: It is thus recommended to screen patients and families with hereditary cancer for first and second primary tumours. Treatment of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 701 offsetEnd: 822 A: not yet been clearly defined. A total of 66 patients with confirmed MEN1 germline mutations and 1 additional patient with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1094 offsetEnd: 1230 A: patient with typical manifestations in three organ systems were monitored in a regular screening program that included evaluation of the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 596 offsetEnd: 748 A: the development of multiple adenomas. Some clinicians have reported results of selective parathyroidectomy in this group, removing only grossly enlarged
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 4731 offsetEnd: 4862 A: MEN-1 patients all develop multiple gland disease, and this reality must be used in planning operative management for patients with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1102 offsetEnd: 1252 A: autoimmune diabetes in adults (LADA). The circulating autoantibodies to multiple islet autoantigens including GAD, insulin, and IA-2 are the important
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 298 offsetEnd: 446 A: type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. Rather than the total amount of fat, central distribution of adipose tissue
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 877 offsetEnd: 1025 A: the pathophysiology of this constellation of abnormalities termed metabolic syndrome. Adipose tissue, regarded only as an energy storage organ until
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 284 offsetEnd: 413 A: develop a variety of tumors in different organ systems which make the clinical management of these patients complex. CASE REPORT:
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 1122 offsetEnd: 1282 A: suspected or established MEN1 syndrome. MEN1 mutational analysis should be performed in individuals with newly diagnosed MEN1-typical endocrine neoplasia (e.g.,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 1987 offsetEnd: 2121 A: are met (e.g., age <40 years; positive family history; multifocal or recurrent neoplasia; two or more organ systems affected). Genetic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 4183 offsetEnd: 4331 A: MEN1 mutation carriers and patients may differ from that in sporadic endocrine neoplasia, calling for individual management. Genetic counselling and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 560 offsetEnd: 675 A: primary HPT. In order to shed further light on the MEN-1 syndrome an investigation in vitro was made of parathyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 0 offsetEnd: 120 A: White adipose tissue (WAT) is now recognized as a major endocrine and secretory organ, releasing a wide range of protein
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 3551 offsetEnd: 3714 A: obesity, increased circulating levels of inflammatory markers reflecting spillover from an 'inflamed' tissue, leading to the obesity-associated pathologies of type
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 3714 offsetEnd: 3862 A: markers reflecting spillover from an 'inflamed' tissue, leading to the obesity-associated pathologies of type 2 diabetes and the metabolic syndrome.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 4704 offsetEnd: 4851 A: crosstalk with other organs and multiple metabolic systems. Whether major changes in adipokine production in obesity, particularly of those factors
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 1246 offsetEnd: 1401 A: vascular endothelial growth factor, plasminogen activator inhibitor 1 and haptoglobin, are linked to inflammation and the inflammatory response. Obesity is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 1401 offsetEnd: 1534 A: inhibitor 1 and haptoglobin, are linked to inflammation and the inflammatory response. Obesity is characterized by a state of chronic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 558 offsetEnd: 691 A: responsible tumour suppressor gene was identified. MEN1 gene germ-line mutations are detected in the vast majority of MEN 1 patients,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 945 offsetEnd: 1078 A: 1 patients, however, with regard to case-finding, unfortunately only at a very low frequency in patients with apparently sporadic MEN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2038 offsetEnd: 2169 A: In this study MEN1 gene germ-line mutations were revealed in 16/16 MEN 1 patients/families (100%). Based on our clinical experience
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3023 offsetEnd: 3140 A: criteria for MEN 1-suspected patients are: young age at onset (< 35 years) and/or multiple MEN 1-related lesions in a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3383 offsetEnd: 3509 A: in a single organ or two distinct organs affected. Application of these criteria yielded MEN1 gene germ-line mutations in nine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3648 offsetEnd: 3779 A: criteria yielded MEN1 gene germ-line mutations in nine of 15 MEN 1-suspected patients (60%), thus identifying novel MEN 1 families.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3779 offsetEnd: 3897 A: in nine of 15 MEN 1-suspected patients (60%), thus identifying novel MEN 1 families. Follow up was also guaranteed for
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3897 offsetEnd: 4038 A: patients (60%), thus identifying novel MEN 1 families. Follow up was also guaranteed for patients not fulfilling these criteria. CONCLUSIONS:
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4038 offsetEnd: 4178 A: 1 families. Follow up was also guaranteed for patients not fulfilling these criteria. CONCLUSIONS: The clinical criteria for MEN 1-suspected
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4755 offsetEnd: 4897 A: among patients with apparently sporadic MEN 1-related tumours. These criteria may be used for (presymptomatic) identification of MEN 1 disease
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4897 offsetEnd: 5043 A: 1-related tumours. These criteria may be used for (presymptomatic) identification of MEN 1 disease gene-carriers, thus enabling early detection of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 5043 offsetEnd: 5192 A: used for (presymptomatic) identification of MEN 1 disease gene-carriers, thus enabling early detection of tumour development and timely treatment, as
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 0 offsetEnd: 125 A: BACKGROUND: The appropriate treatment for a sporadic endocrine tumour may be different from those that present as part of the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1635 offsetEnd: 1745 A: operated on between 1987 and 2001 had no family history of MEN1, only one organ manifestation and were aged 40
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 0 offsetEnd: 145 A: Pancreatic neuroendocrine tumors (PNTs) are relatively uncommon although these neoplasms have been noted to grow in occurrence in recent decades.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 145 offsetEnd: 277 A: uncommon although these neoplasms have been noted to grow in occurrence in recent decades. Surgical removal of locally advanced PNTs
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 298 offsetEnd: 450 A: presented with clinical features of acromegaly. Exploration of the pituitary gland only revealed somatotrophic hyperplasia and his plasma growth hormone
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 450 offsetEnd: 599 A: Exploration of the pituitary gland only revealed somatotrophic hyperplasia and his plasma growth hormone (GH) levels remained elevated. Production of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1478 offsetEnd: 1627 A: As the pancreatic tail contained multiple (occult) adenomas, lifelong follow-up was considered necessary. The patient has been recurrence-free for 10
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1897 offsetEnd: 2015 A: for 10 years. All 19 living relatives of this patient were analysed for endocrine disorders related to MEN I syndrome.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2015 offsetEnd: 2135 A: relatives of this patient were analysed for endocrine disorders related to MEN I syndrome. A brother was found to suffer
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2135 offsetEnd: 2251 A: for endocrine disorders related to MEN I syndrome. A brother was found to suffer from peptic ulcer disease caused by
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2657 offsetEnd: 2772 A: for other organ involvement associated with the MEN I syndrome, two tumors were found, one (4 cm) in the pancreatic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1152 offsetEnd: 1279 A: the syndrome whilst only one of them is required for individuals belonging to established MEN-1 kindreds. A distinct feature of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 2943 offsetEnd: 3087 A: primary biochemical screening programme for MEN-1 includes serum prolactin and insulin growth factor 1 (IGF-1) for pituitary lesions, intact PTH
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 6824 offsetEnd: 6957 A: involvement or duodenal carcinoids. Early diagnosis of pancreatic endocrine tumours in MEN-1 is enhanced by the use of a standardized
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 1542 offsetEnd: 1675 A: The specific markers correspond to the hormones produced by tumour cells. Two major categories of endocrine tumours are identified as
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 2175 offsetEnd: 2359 A: poorly differentiated neoplasms. Well-differentiated tumours/carcinomas (also known as carcinoids) express all general markers of endocrine differentiation and various hormones. Poorly
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2457 offsetEnd: 2586 A: profile may explain the early onset of malignancy in MEN 2B compared with MEN 2A patients. Furthermore, chondromodulin-1, a known
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3649 offsetEnd: 3795 A: associated with the presence of skeletal abnormalities in MEN 2B patients. These findings provide molecular evidence that associate the previously
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 1761 offsetEnd: 1906 A: gangliosides are expressed in cytosol membranes like those of secretory granules of some endocrine cells (adrenal medulla, pancreatic islets). As
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 2035 offsetEnd: 2164 A: some endocrine cells (adrenal medulla, pancreatic islets). As far as the role of gangliosides in diseases is concerned, there are
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 6244 offsetEnd: 6407 A: syndrome, multiple sclerosis, lupus erythematosus, Hashimoto's thyroiditis and, last but not least, insulin-dependent (type 1) diabetes mellitus. This last disease
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 6854 offsetEnd: 7038 A: autoimmune destruction of insulin-producing pancreatic islet cells in genetically predisposed individuals. Autoantibodies and T lymphocytes directed towards multiple islet autoantigens
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 7038 offsetEnd: 7200 A: cells in genetically predisposed individuals. Autoantibodies and T lymphocytes directed towards multiple islet autoantigens have been detected in the circulation,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 7200 offsetEnd: 7335 A: and T lymphocytes directed towards multiple islet autoantigens have been detected in the circulation, well before the clinical onset of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1227 offsetEnd: 1373 A: syndrome develops when germinative MEN 1--neoplasia suppression gene inactivation mutations occurs. More than 95 percent of patients have this MEN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1373 offsetEnd: 1505 A: suppression gene inactivation mutations occurs. More than 95 percent of patients have this MEN 1 gene mutation, when the penetration
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1505 offsetEnd: 1619 A: than 95 percent of patients have this MEN 1 gene mutation, when the penetration of mutation is almost 100 percent.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1851 offsetEnd: 1974 A: 100 percent. An early stage of this syndrome is hyperfunction in organs, with the syndromes of hormone excess, later benign
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1974 offsetEnd: 2112 A: this syndrome is hyperfunction in organs, with the syndromes of hormone excess, later benign and/or malign neoplasia develops, this mostly
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 745 offsetEnd: 899 A: year 2000, including MEDLINE, CINAHL, CancerLit, PsychINFO, and Dissertation Abstracts International. MEN2a is a complex disease involving cancer care and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 1048 offsetEnd: 1187 A: is a complex disease involving cancer care and control by surgery, health maintenance, and life-long observation of gene mutation carriers.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 4216 offsetEnd: 4344 A: this disorder and it is necessary to guide the development of risk management strategies for patients with this inherited cancer
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 4477 offsetEnd: 4623 A: management strategies for patients with this inherited cancer syndrome. Since MEN2a has been labeled a prototype for medical genetics, information
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 4623 offsetEnd: 4760 A: inherited cancer syndrome. Since MEN2a has been labeled a prototype for medical genetics, information on MEN2a patient experiences may be
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 325 offsetEnd: 493 A: by mutations in the gene AIRE (autoimmune regulator). APECED affects mainly endocrine organs resulting in hypoparathyroidism, adrenocortical failure, diabetes mellitus,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 904 offsetEnd: 1103 A: diabetes mellitus, hypogonadism, and hypothyroidism. Nonendocrine organ manifestations are autoimmune hepatitis, vitiligo, pernicious anemia, exocrine pancreatic insufficiency, and alopecia. APECED's
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 2535 offsetEnd: 2658 A: to end-stage renal failure. She was transplanted 1 yr later. Common causes of CIN were excluded. APECED was suspected first
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 4026 offsetEnd: 4181 A: 1) in common with the wild-type protein. Immunosuppression after the first renal transplant included prednisone, azathioprine, and cyclosporine A. Multiple
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 1123 offsetEnd: 1295 A: thyroid carcinoma (MTC), pheochromocytoma (PC), and hyperparathyroidism (HPT). This knowledge has allowed molecular diagnosis and presymptomatic DNA-based testing to become
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 2348 offsetEnd: 2496 A: to our institution for further management of bilateral pheochromocytoma and retinal angioblastoma with problems of duodenal ulcer and anaemia. There
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1751 offsetEnd: 1868 A: to the inactivation mutation of a gene located on 17q22-24 that encodes the regulatory subunit 1 of protein kinase A,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 2007 offsetEnd: 2138 A: the regulatory subunit 1 of protein kinase A, PRKARIA. Isolated familial pituitary adenomas represent 1.9 to 3.2% of the population
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 767 offsetEnd: 913 A: mother and maternal aunt and uncle  had bilateral pheochromocytoma (metastatic in the former two). Bilateral adrenalectomy was performed. Diffuse,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3028 offsetEnd: 3175 A: nodular hyperplastic adrenal gland. patient 2 had the mutation in an extraadrenal pheochromocytoma, but an adrenal gland with medullary hyperplasia
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3625 offsetEnd: 3788 A: had an aggressive corticotroph adenoma and developed Nelson's syndrome after bilateral adrenalectomy. The corticotroph adenoma was wild-type, but both hyperplastic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5655 offsetEnd: 5781 A: a wider range of endocrine conditions than has been recognized hereto. In addition, the presence of gsp mutations in different
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 423 offsetEnd: 520 A: is present in all cells of the organism, and only leads to cancer if in a somatic cell a complete
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2021 offsetEnd: 2167 A: is about 10(4)-10(5). This can be observed e.g. in retinoblastoma. Mutations occur in proliferating cells only. Consequently cancer mutations also
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2167 offsetEnd: 2315 A: observed e.g. in retinoblastoma. Mutations occur in proliferating cells only. Consequently cancer mutations also depend on cell proliferation. If an
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3435 offsetEnd: 3555 A: This is of course observed in paired organs, like the retina and the female breast. In cancer family syndromes different
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4933 offsetEnd: 5049 A: differ. In this case the second tumour is called a second primary malignancy and is not caused by metastatic spread.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 7169 offsetEnd: 7293 A: of hereditary cancer. That is, hereditary cancer can be recognized not only by family history, but also by early occurrence,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2184 offsetEnd: 2305 A: conserved among these three species. Rat MEN1 transcripts were detected not only in the endocrine tissues but also in the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 438 offsetEnd: 596 A: parathyroid hyperplasia, the process is actually the development of multiple adenomas. Some clinicians have reported results of selective parathyroidectomy in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 3961 offsetEnd: 4114 A: total parathyroid weight may correlate with development of hypercalcemia and indications for operation, the involvement of multiple parathyroid glands in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 4252 offsetEnd: 4377 A: operation, the involvement of multiple parathyroid glands in MEN-1 is a function of time, as independent events in each gland
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 4490 offsetEnd: 4613 A: of time, as independent events in each gland must occur. Given time, MEN-1 patients all develop multiple gland disease, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 4613 offsetEnd: 4731 A: each gland must occur. Given time, MEN-1 patients all develop multiple gland disease, and this reality must be used in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 151 offsetEnd: 298 A: for the development of insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. Rather than the total amount of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 1850 offsetEnd: 2004 A: multiple functions in metabolic profile and immunological process. Therefore, excessive fat mass may trigger metabolic and hemostatic disturbances as well
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2121 offsetEnd: 2264 A: positive family history; multifocal or recurrent neoplasia; two or more organ systems affected). Genetic family screening is advisable in first
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 4035 offsetEnd: 4183 A: Diagnostic procedures and treatment in symptomatic MEN1 mutation carriers and patients may differ from that in sporadic endocrine neoplasia, calling
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 675 offsetEnd: 807 A: further light on the MEN-1 syndrome an investigation in vitro was made of parathyroid hormone (PTH) release of dispersed parathyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 120 offsetEnd: 246 A: recognized as a major endocrine and secretory organ, releasing a wide range of protein factors and signals termed adipokines -
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 3996 offsetEnd: 4111 A: of type 2 diabetes and the metabolic syndrome. From the wide range of adipokines now identified, it is evident that
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 0 offsetEnd: 119 A: White adipose tissue (WAT) is a major endocrine and secretory organ, which releases a wide range of protein signals and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 2929 offsetEnd: 3056 A: to be important in the development of diseases linked to obesity, particularly Type II diabetes and the metabolic syndrome. WAT
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1906 offsetEnd: 2038 A: criteria were needed. DESIGN AND RESULTS: In this study MEN1 gene germ-line mutations were revealed in 16/16 MEN 1 patients/families
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2455 offsetEnd: 2609 A: clinical experience with MEN 1 patients/families we formulated clinical criteria to identify disease gene carriers among patients with apparently sporadic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 2178 offsetEnd: 2306 A: 1 syndrome. The procedure resulted in pain abolition, a significant improvement in the patient's life quality and allowed her to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 599 offsetEnd: 754 A: revealed somatotrophic hyperplasia and his plasma growth hormone (GH) levels remained elevated. Production of growth hormone-releasing hormone (GHRH) by an
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1768 offsetEnd: 1897 A: necessary. The patient has been recurrence-free for 10 years. All 19 living relatives of this patient were analysed for endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1279 offsetEnd: 1416 A: them is required for individuals belonging to established MEN-1 kindreds. A distinct feature of MEN-1 comprises the multiplicity of organ
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 3087 offsetEnd: 3223 A: includes serum prolactin and insulin growth factor 1 (IGF-1) for pituitary lesions, intact PTH and albumin corrected total serum calcium
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 6677 offsetEnd: 6824 A: the presence of advanced pancreatic tumour involvement or duodenal carcinoids. Early diagnosis of pancreatic endocrine tumours in MEN-1 is enhanced
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 1666 offsetEnd: 1847 A: other manifestations. Other pheochromocytoma-associated syndromes include von Hippel-Lindau disease; neurofibromatosis 1; the recently defined paraganglioma syndromes type 1, 3, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 1847 offsetEnd: 1999 A: von Hippel-Lindau disease; neurofibromatosis 1; the recently defined paraganglioma syndromes type 1, 3, and 4; Carney-Stratakis syndrome; and the Carney
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 3389 offsetEnd: 3519 A: is yet another form of MEN that is characterized by skin tumors and pigmented lesions, myxomas, schwannomas, and various endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 1824 offsetEnd: 1999 A: major categories of endocrine tumours are identified as (i) well-differentiated and (ii) poorly differentiated neoplasms. Well-differentiated tumours/carcinomas (also known as
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2242 offsetEnd: 2355 A: beta pathway, were up-regulated in MEN 2B MTCs. This MEN 2B MTC profile may explain the early onset of malignancy
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2586 offsetEnd: 2719 A: of malignancy in MEN 2B compared with MEN 2A patients. Furthermore, chondromodulin-1, a known regulator of cartilage and bone growth,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 5238 offsetEnd: 5359 A: and neoplasia, or to apply means of prevention and start well-timed treatment, but also to diagnose this syndrome for the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 5359 offsetEnd: 5491 A: of prevention and start well-timed treatment, but also to diagnose this syndrome for the patient's relatives, and to determine their
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 5491 offsetEnd: 5612 A: but also to diagnose this syndrome for the patient's relatives, and to determine their risk of getting cancer. This opens
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 1693 offsetEnd: 1849 A: diverticula, and mucosal abnormality may be seen radiographically. Gastrointestinal symptoms are common, may be the presenting manifestation of the syndrome
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 1849 offsetEnd: 1990 A: seen radiographically. Gastrointestinal symptoms are common, may be the presenting manifestation of the syndrome early in life, and allow the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 2115 offsetEnd: 2238 A: the syndrome early in life, and allow the radiologist to suggest the proper diagnosis. Five patients are described. All had
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 618 offsetEnd: 767 A: medullary thyroid carcinoma and hyperparathyroidism. Her mother and maternal aunt and uncle  had bilateral pheochromocytoma (metastatic in the former
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 247 offsetEnd: 359 A: of G proteins have been described. Such mutations have been shown to occur in a number of endocrine diseases. We
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 994 offsetEnd: 1122 A: patients having separate distinct endocrine diseases for G protein gene mutations. G protein genes encoding for Gs alpha and Gi2
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2630 offsetEnd: 2760 A: change from arginine to cysteine. Patient 1 had the mutation in a corticotroph adenoma, a chemodectoma, and a nodular hyperplastic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5909 offsetEnd: 6038 A: addition, the presence of gsp mutations in different endocrine disorders in the same patient is suggestive of a common underlying
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2840 offsetEnd: 2964 A: then the cancer risk in these organs is enhanced by 10(4)-10(5) times. Tumours in these organs will appear simultaneously if
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3555 offsetEnd: 3675 A: paired organs, like the retina and the female breast. In cancer family syndromes different organs may be affected at the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4717 offsetEnd: 4819 A: if the number of end cells per organ and the growth kinetics differ. In this case the second tumour is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 5049 offsetEnd: 5163 A: tumour is called a second primary malignancy and is not caused by metastatic spread. A good example are the second
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 524 offsetEnd: 648 A: dominant familial cancer syndrome. We isolated rat menin cDNA clones from a fetal rat brain cDNA library. We also determined
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 4114 offsetEnd: 4252 A: development of hypercalcemia and indications for operation, the involvement of multiple parathyroid glands in MEN-1 is a function of time,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 2806 offsetEnd: 2927 A: of patients express at least one of these autoantibodies and are classified as type 1A diabetes. Although the majority of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 413 offsetEnd: 542 A: different organ systems which make the clinical management of these patients complex. CASE REPORT: The long clinical history of a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 119 offsetEnd: 245 A: major endocrine and secretory organ, which releases a wide range of protein signals and factors termed adipokines. A number of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 420 offsetEnd: 558 A: various endocrine glands. In 1997 the responsible tumour suppressor gene was identified. MEN1 gene germ-line mutations are detected in the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 310 offsetEnd: 472 A: with the occurrence of primary hyperparathyroidism (HPT) in combination with pancreatic-duodenal endocrine and anterior pituitary tumours. The diagnosis of MEN-1,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 472 offsetEnd: 635 A: (HPT) in combination with pancreatic-duodenal endocrine and anterior pituitary tumours. The diagnosis of MEN-1, the possible probands, necessitates the recognition
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 6957 offsetEnd: 7081 A: of pancreatic endocrine tumours in MEN-1 is enhanced by the use of a standardized meal stimulation test with measurements of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 3307 offsetEnd: 3473 A: of endocrine tumours spans from benign to low-grade malignant for well-differentiated tumours/carcinomas to high grade malignant for poorly differentiated carcinomas.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 1732 offsetEnd: 1851 A: the penetration of mutation is almost 100 percent. An early stage of this syndrome is hyperfunction in organs, with the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 3431 offsetEnd: 3587 A: endocrine neoplasia develops earlier than in sporadic cases; multifocality is typical for them. Multifocality of neoplasia, typical combinations of injuries
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 899 offsetEnd: 1048 A: PsychINFO, and Dissertation Abstracts International. MEN2a is a complex disease involving cancer care and control by surgery, health maintenance, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 2261 offsetEnd: 2399 A: She had renal dysfunction due to chronic interstitial nephritis (CIN), which progressed to end-stage renal failure. She was transplanted 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 2496 offsetEnd: 2635 A: of bilateral pheochromocytoma and retinal angioblastoma with problems of duodenal ulcer and anaemia. There was no family history of similar
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 1430 offsetEnd: 1598 A: was present. This hyperplasia was characterized by increased medullary mitotic activity, decreased corticomedullary ratio, increased total adrenal weight, and increased
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3175 offsetEnd: 3308 A: had the mutation in an extraadrenal pheochromocytoma, but an adrenal gland with medullary hyperplasia was wild-type. Patient 3 had an
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5781 offsetEnd: 5909 A: than has been recognized hereto. In addition, the presence of gsp mutations in different endocrine disorders in the same patient
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 6629 offsetEnd: 6764 A: abnormality is dominant at the level of the chromosome. The 10(4)-10(5) times enhanced tumour incidence in hereditary cancer is helpful
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 8093 offsetEnd: 8236 A: patients and families with hereditary cancer for first and second primary tumours. Treatment of patients with hereditary tumours requires extra
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 1970 offsetEnd: 2109 A: 1 diabetes are 60-70% for GAD autoantibodies, 45-50% for insulin autoantibodies (IAA), and 60-65% for IA-2 autoantibodies at disease onset,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14679108 offsetBegin: 2671 offsetEnd: 2806 A: combinatorial analysis of these autoantibodies, 90% of patients express at least one of these autoantibodies and are classified as type
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 3862 offsetEnd: 3996 A: tissue, leading to the obesity-associated pathologies of type 2 diabetes and the metabolic syndrome. From the wide range of adipokines
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 907 offsetEnd: 1083 A: 1beta), IL-6, monocyte chemotactic protein-1, macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth factor, plasminogen activator inhibitor 1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 1083 offsetEnd: 1246 A: migration inhibitory factor, nerve growth factor, vascular endothelial growth factor, plasminogen activator inhibitor 1 and haptoglobin, are linked to inflammation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 3223 offsetEnd: 3364 A: factor 1 (IGF-1) for pituitary lesions, intact PTH and albumin corrected total serum calcium for the parathyroids and for duodenal/pancreatic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 132 offsetEnd: 266 A: metabolic syndrome. Here, we show that the impaired hepatic expression of menin, the product of the MEN1 (multiple endocrine neoplasia
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 2303 offsetEnd: 2460 A: the Carney triad. Carney-Stratakis syndrome is characterized by the association of paragangliomas and familial gastrointestinal stromal tumors. In the Carney
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 1622 offsetEnd: 1761 A: and in signal transduction. In addition, gangliosides are expressed in cytosol membranes like those of secretory granules of some endocrine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 1906 offsetEnd: 2035 A: like those of secretory granules of some endocrine cells (adrenal medulla, pancreatic islets). As far as the role of gangliosides
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 765 offsetEnd: 911 A: metachronously in the cells of the parathyroid gland, pancreas islets, hypophysis, and rarer in other neuroendocrine organs. The syndrome develops
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2250 offsetEnd: 2387 A: later benign and/or malign neoplasia develops, this mostly determines the prognosis for the patient. The risk of this syndrome developing
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 2079 offsetEnd: 2225 A: MEN2a. A substantial body of scientific literature describes morbidity and mortality outcomes of disease treatment, and the monitoring of multiple
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2760 offsetEnd: 2881 A: 1 had the mutation in a corticotroph adenoma, a chemodectoma, and a nodular hyperplastic adrenal gland. patient 2 had the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 6764 offsetEnd: 6905 A: of the chromosome. The 10(4)-10(5) times enhanced tumour incidence in hereditary cancer is helpful for the clinical recognition of hereditary
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2305 offsetEnd: 2433 A: MEN1 transcripts were detected not only in the endocrine tissues but also in the tissues of the nervous, digestive, reproductive
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 836 offsetEnd: 957 A: are the most common organ manifestations of MEN1, the prevalence of germline mutations in the MEN1 gene was determined in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1416 offsetEnd: 1561 A: to established MEN-1 kindreds. A distinct feature of MEN-1 comprises the multiplicity of organ involvement, the multicentricity of tumours within
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 2152 offsetEnd: 2303 A: 3, and 4; Carney-Stratakis syndrome; and the Carney triad. Carney-Stratakis syndrome is characterized by the association of paragangliomas and familial
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 1990 offsetEnd: 2115 A: may be the presenting manifestation of the syndrome early in life, and allow the radiologist to suggest the proper diagnosis.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 942 offsetEnd: 1089 A: of parathyroid hormone (PTH) release of dispersed parathyroid cell from 11 patients with parathyroid hyperplasia associated with MEN-1, 10 patients
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2355 offsetEnd: 2457 A: 2B MTCs. This MEN 2B MTC profile may explain the early onset of malignancy in MEN 2B compared with MEN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 1237 offsetEnd: 1391 A: with parathyroid hyperplasia associated with MEN-1, 10 patients with single parathyroid adenomas, and 10 preparations of normal bovine parathyroid glands.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1561 offsetEnd: 1695 A: feature of MEN-1 comprises the multiplicity of organ involvement, the multicentricity of tumours within the affected organs as well as
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2433 offsetEnd: 2562 A: in the endocrine tissues but also in the tissues of the nervous, digestive, reproductive and immune systems. The MEN1 transcripts
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 1089 offsetEnd: 1237 A: dispersed parathyroid cell from 11 patients with parathyroid hyperplasia associated with MEN-1, 10 patients with single parathyroid adenomas, and 10
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2387 offsetEnd: 2509 A: this mostly determines the prognosis for the patient. The risk of this syndrome developing should be estimated for all the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1695 offsetEnd: 1821 A: of organ involvement, the multicentricity of tumours within the affected organs as well as the complex pattern of the clinical
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 289 offsetEnd: 424 A: caused by mutations in the tumor-suppressor gene MEN1. The gene encodes a nuclear protein, menin, with no recognized functional motifs.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 424 offsetEnd: 550 A: gene MEN1. The gene encodes a nuclear protein, menin, with no recognized functional motifs. Menin has been shown negatively to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 1118 offsetEnd: 1241 A: this interaction in normal cell physiology and how the absence of menin leads to tumorigenesis are unknown. Menin is highly
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 1241 offsetEnd: 1370 A: and how the absence of menin leads to tumorigenesis are unknown. Menin is highly expressed in testes. We used immunocytochemistry
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 1370 offsetEnd: 1501 A: leads to tumorigenesis are unknown. Menin is highly expressed in testes. We used immunocytochemistry to explore its role in meiosis
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 3076 offsetEnd: 3224 A: lack of co-localization with the known telomeric protein TRF2. Cells overexpressing menin had normal telomerase activity, and tumors with homozygous
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 3224 offsetEnd: 3373 A: telomeric protein TRF2. Cells overexpressing menin had normal telomerase activity, and tumors with homozygous MEN1 mutations showed no aberrations in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 3373 offsetEnd: 3515 A: had normal telomerase activity, and tumors with homozygous MEN1 mutations showed no aberrations in telomere length, indicating that menin does
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12203793 offsetBegin: 3515 offsetEnd: 3661 A: with homozygous MEN1 mutations showed no aberrations in telomere length, indicating that menin does not directly regulate telomerase activity. The
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 0 offsetEnd: 122 A: NKX2-1 (NK2 homeobox 1) is a critical regulator of transcription for the surfactant protein (SP)-B and -C genes (SFTPB and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 268 offsetEnd: 407 A: surfactant protein (SP)-B and -C genes (SFTPB and SFTPC, respectively). We identified and functionally characterized two new de novo NKX2-1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 407 offsetEnd: 565 A: (SFTPB and SFTPC, respectively). We identified and functionally characterized two new de novo NKX2-1 mutations c.493C>T (p.R165W) and c.786_787del2 (p.L263fs)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 565 offsetEnd: 715 A: and functionally characterized two new de novo NKX2-1 mutations c.493C>T (p.R165W) and c.786_787del2 (p.L263fs) in infants with closely similar severe
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 715 offsetEnd: 871 A: novo NKX2-1 mutations c.493C>T (p.R165W) and c.786_787del2 (p.L263fs) in infants with closely similar severe interstitial lung disease (ILD), hypotonia, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1040 offsetEnd: 1205 A: similar severe interstitial lung disease (ILD), hypotonia, and congenital hypothyroidism. Functional analyses using A549 and HeLa cells revealed that NKX2-1-p.L263fs
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1205 offsetEnd: 1363 A: hypotonia, and congenital hypothyroidism. Functional analyses using A549 and HeLa cells revealed that NKX2-1-p.L263fs induced neither SFTPB nor SFTPC promoter
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1363 offsetEnd: 1498 A: using A549 and HeLa cells revealed that NKX2-1-p.L263fs induced neither SFTPB nor SFTPC promoter activation and had a dominant negative
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1498 offsetEnd: 1634 A: that NKX2-1-p.L263fs induced neither SFTPB nor SFTPC promoter activation and had a dominant negative effect on wild-type (WT) NKX2-1. In
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1634 offsetEnd: 1783 A: SFTPC promoter activation and had a dominant negative effect on wild-type (WT) NKX2-1. In contrast,NKX2-1-p.R165W activated SFTPC, to a significantly
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1783 offsetEnd: 1936 A: dominant negative effect on wild-type (WT) NKX2-1. In contrast,NKX2-1-p.R165W activated SFTPC, to a significantly greater extent than did WTNKX2-1, while
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 1936 offsetEnd: 2094 A: NKX2-1. In contrast,NKX2-1-p.R165W activated SFTPC, to a significantly greater extent than did WTNKX2-1, while SFTPB activation was only significantly reduced
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 2094 offsetEnd: 2231 A: a significantly greater extent than did WTNKX2-1, while SFTPB activation was only significantly reduced in HeLa cells. In accordance with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 2231 offsetEnd: 2356 A: WTNKX2-1, while SFTPB activation was only significantly reduced in HeLa cells. In accordance with our in vitro data, we found
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 2859 offsetEnd: 3017 A: bronchoalveolar lavage fluid (patient with p.L263fs) and features of altered surfactant protein metabolism on lung histology (patient with NKX2-1-p.R165W). In
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 3017 offsetEnd: 3162 A: and features of altered surfactant protein metabolism on lung histology (patient with NKX2-1-p.R165W). In conclusion, ILD in patients with NKX2-1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 3162 offsetEnd: 3313 A: metabolism on lung histology (patient with NKX2-1-p.R165W). In conclusion, ILD in patients with NKX2-1 mutations was associated with altered surfactant
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 3313 offsetEnd: 3459 A: NKX2-1-p.R165W). In conclusion, ILD in patients with NKX2-1 mutations was associated with altered surfactant protein metabolism, and both gain and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 3459 offsetEnd: 3589 A: with NKX2-1 mutations was associated with altered surfactant protein metabolism, and both gain and loss of function of the mutated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 3589 offsetEnd: 3722 A: altered surfactant protein metabolism, and both gain and loss of function of the mutated NKX2-1 genes on surfactant protein promoters
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20020530 offsetBegin: 3722 offsetEnd: 3855 A: gain and loss of function of the mutated NKX2-1 genes on surfactant protein promoters were associated with ILD in "Brain-Lung-Thyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 475 offsetEnd: 645 A: involved with a characteristic triad of medullary thyroid carcinoma, pheochromocytoma, and alimentary tract ganglioneuromas. Most patients have characteristic facies with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/6129792 offsetBegin: 645 offsetEnd: 817 A: medullary thyroid carcinoma, pheochromocytoma, and alimentary tract ganglioneuromas. Most patients have characteristic facies with patulous lips and thickened tarsal plates
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 974 offsetEnd: 1125 A: with multi-organ involvement of benign and malignant tumours characterized by the presence of retinal angiomas, hemangioblastomas of the cerebellum and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1125 offsetEnd: 1287 A: malignant tumours characterized by the presence of retinal angiomas, hemangioblastomas of the cerebellum and spinal cord, renal cell carcinomas, pheochromocytomas
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1287 offsetEnd: 1433 A: of retinal angiomas, hemangioblastomas of the cerebellum and spinal cord, renal cell carcinomas, pheochromocytomas and other cystic lesions in the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1433 offsetEnd: 1574 A: cerebellum and spinal cord, renal cell carcinomas, pheochromocytomas and other cystic lesions in the kidneys, pancreas, and epididymis. It is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1574 offsetEnd: 1718 A: carcinomas, pheochromocytomas and other cystic lesions in the kidneys, pancreas, and epididymis. It is a rare disorder with prevalence estimated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1718 offsetEnd: 1837 A: in the kidneys, pancreas, and epididymis. It is a rare disorder with prevalence estimated at 2-3 per 100,000. This case
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1837 offsetEnd: 1946 A: It is a rare disorder with prevalence estimated at 2-3 per 100,000. This case report describes a 37 years old
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16898326 offsetBegin: 1946 offsetEnd: 2067 A: prevalence estimated at 2-3 per 100,000. This case report describes a 37 years old Chinese gentleman who presented to our
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 0 offsetEnd: 124 A: Pituitary adenomas can occur in a familial context, or they can be isolated cases, sometimes due to a predisposing syndrome.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1239 offsetEnd: 1386 A: identified in MENI-negative subjects on the gene CDKN1B encoding for p27(kip1)protein. Carney Complex syndrome--a rare disease--is in more than 60%
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1386 offsetEnd: 1516 A: gene CDKN1B encoding for p27(kip1)protein. Carney Complex syndrome--a rare disease--is in more than 60% of the cases linked to the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1516 offsetEnd: 1636 A: Complex syndrome--a rare disease--is in more than 60% of the cases linked to the inactivation mutation of a gene located
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 1636 offsetEnd: 1751 A: than 60% of the cases linked to the inactivation mutation of a gene located on 17q22-24 that encodes the regulatory
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 2138 offsetEnd: 2277 A: kinase A, PRKARIA. Isolated familial pituitary adenomas represent 1.9 to 3.2% of the population of subjects presenting a pituitary adenoma.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 2277 offsetEnd: 2421 A: adenomas represent 1.9 to 3.2% of the population of subjects presenting a pituitary adenoma. Low penetrance non-sense mutations, Q14X, IVS3-IG>A
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 2421 offsetEnd: 2573 A: the population of subjects presenting a pituitary adenoma. Low penetrance non-sense mutations, Q14X, IVS3-IG>A and R304X, in 11q12-11q13 region encoding
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 2573 offsetEnd: 2737 A: pituitary adenoma. Low penetrance non-sense mutations, Q14X, IVS3-IG>A and R304X, in 11q12-11q13 region encoding AIP protein, (Aryl hydrocarbon receptor Interacting
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/17961654 offsetBegin: 2737 offsetEnd: 2888 A: Q14X, IVS3-IG>A and R304X, in 11q12-11q13 region encoding AIP protein, (Aryl hydrocarbon receptor Interacting Protein), have been described by Vierimaa
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 308 offsetEnd: 471 A: urinary levels of vanillylmandelic acid that suggested pheochromocytoma; she also had bilateral medullary thyroid carcinoma and hyperparathyroidism. Her mother and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/1110583 offsetBegin: 471 offsetEnd: 618 A: suggested pheochromocytoma; she also had bilateral medullary thyroid carcinoma and hyperparathyroidism. Her mother and maternal aunt and uncle  had
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 153 offsetEnd: 290 A: and their relatives have not been re-assessed since their separation into early- or late-onset MG (EOMG, LOMG), or thymoma-associated MG.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 290 offsetEnd: 425 A: re-assessed since their separation into early- or late-onset MG (EOMG, LOMG), or thymoma-associated MG. Here, we analysed 226 EOMG-, 97
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 425 offsetEnd: 560 A: or late-onset MG (EOMG, LOMG), or thymoma-associated MG. Here, we analysed 226 EOMG-, 97 LOMG-, and 150 thymoma-patients for autoimmune
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 560 offsetEnd: 706 A: thymoma-associated MG. Here, we analysed 226 EOMG-, 97 LOMG-, and 150 thymoma-patients for autoimmune disorders in themselves and their relatives.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 706 offsetEnd: 834 A: EOMG-, 97 LOMG-, and 150 thymoma-patients for autoimmune disorders in themselves and their relatives. From 283 of them sera were
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 834 offsetEnd: 971 A: for autoimmune disorders in themselves and their relatives. From 283 of them sera were tested for different organ- and non-organ-specific
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 971 offsetEnd: 1123 A: their relatives. From 283 of them sera were tested for different organ- and non-organ-specific autoantibodies (autoAbs) by immunofluorescence test (IFT)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1123 offsetEnd: 1280 A: sera were tested for different organ- and non-organ-specific autoantibodies (autoAbs) by immunofluorescence test (IFT) and ELISA; genotyping was performed in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1280 offsetEnd: 1449 A: and non-organ-specific autoantibodies (autoAbs) by immunofluorescence test (IFT) and ELISA; genotyping was performed in 213 patients. Relatives with autoimmune disorders
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1449 offsetEnd: 1584 A: test (IFT) and ELISA; genotyping was performed in 213 patients. Relatives with autoimmune disorders were reported by more patients with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1584 offsetEnd: 1710 A: performed in 213 patients. Relatives with autoimmune disorders were reported by more patients with EOMG (40% of 210) than LOMG
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1710 offsetEnd: 1816 A: autoimmune disorders were reported by more patients with EOMG (40% of 210) than LOMG (20% of 89; p < 0.01)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1816 offsetEnd: 1907 A: patients with EOMG (40% of 210) than LOMG (20% of 89; p < 0.01) than thymomas (8% of 150; p
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 1907 offsetEnd: 2007 A: than LOMG (20% of 89; p < 0.01) than thymomas (8% of 150; p < 0.001). In 150 genotyped EOMG-females,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 2007 offsetEnd: 2112 A: < 0.01) than thymomas (8% of 150; p < 0.001). In 150 genotyped EOMG-females, the known risk allele of the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 2112 offsetEnd: 2240 A: 150; p < 0.001). In 150 genotyped EOMG-females, the known risk allele of the immuno-regulatory PTPN2 2 (R620W) appeared commoner
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 2240 offsetEnd: 2385 A: genotyped EOMG-females, the known risk allele of the immuno-regulatory PTPN2 2 (R620W) appeared commoner in those with second autoimmune diseases
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 3119 offsetEnd: 3251 A: all MG-patients, autoAbs to striated muscle only in patients with thymoma-MG (62%) or LOMG (61%). Titers against adrenal cortex were
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 3251 offsetEnd: 3398 A: only in patients with thymoma-MG (62%) or LOMG (61%). Titers against adrenal cortex were lower in LOMG-patients. Disease-associated autoAbs against
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 3398 offsetEnd: 3546 A: or LOMG (61%). Titers against adrenal cortex were lower in LOMG-patients. Disease-associated autoAbs against systemic targets or 'natural autoAbs' -
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 3546 offsetEnd: 3686 A: cortex were lower in LOMG-patients. Disease-associated autoAbs against systemic targets or 'natural autoAbs' - except of autoAbs to nuclei -
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 3802 offsetEnd: 3913 A: autoAbs' - except of autoAbs to nuclei - were uncommon in all groups (< 13%). Thus-with rare exceptions in EOMG
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 3913 offsetEnd: 4030 A: nuclei - were uncommon in all groups (< 13%). Thus-with rare exceptions in EOMG and LOMG-we found minimal support for
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23792059 offsetBegin: 4030 offsetEnd: 4158 A: groups (< 13%). Thus-with rare exceptions in EOMG and LOMG-we found minimal support for the notion that autoimmune patients have
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 1242 offsetEnd: 1356 A: protein genes encoding for Gs alpha and Gi2 alpha were examined for activating mutations at codons 201 and 227 (Gs
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 1356 offsetEnd: 1464 A: and Gi2 alpha were examined for activating mutations at codons 201 and 227 (Gs alpha) and codons 179 and 205
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 1464 offsetEnd: 1602 A: activating mutations at codons 201 and 227 (Gs alpha) and codons 179 and 205 (Gi2 alpha) using site-directed oligonucleotide hybridization
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 1602 offsetEnd: 1737 A: 227 (Gs alpha) and codons 179 and 205 (Gi2 alpha) using site-directed oligonucleotide hybridization and direct sequencing of tissue DNA
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2173 offsetEnd: 2290 A: reaction. Tissues from six patients were examined. The only mutation that was identified was at codon 201 of Gs alpha
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2290 offsetEnd: 2401 A: examined. The only mutation that was identified was at codon 201 of Gs alpha (gsp), which encoded a change from
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 2881 offsetEnd: 3028 A: corticotroph adenoma, a chemodectoma, and a nodular hyperplastic adrenal gland. patient 2 had the mutation in an extraadrenal pheochromocytoma, but
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 3949 offsetEnd: 4075 A: The corticotroph adenoma was wild-type, but both hyperplastic adrenal glands had the mutation. Patient 4 had the mutation in a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 4441 offsetEnd: 4571 A: two hyperplastic parathyroid glands. Patient 5 had the mutation in both a primary and a metastatic pheochromocytoma. Patient 6 had
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 4571 offsetEnd: 4692 A: had the mutation in both a primary and a metastatic pheochromocytoma. Patient 6 had the mutation in a parathyroid adenoma
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 4692 offsetEnd: 4828 A: primary and a metastatic pheochromocytoma. Patient 6 had the mutation in a parathyroid adenoma and also in histologically normal thyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5094 offsetEnd: 5215 A: normal thyroid and parathyroid tissue. Leukocyte DNA was examined from five patients and was found to be wild-type in all
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5215 offsetEnd: 5321 A: DNA was examined from five patients and was found to be wild-type in all cases. We conclude that G protein
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/7745022 offsetBegin: 5321 offsetEnd: 5423 A: and was found to be wild-type in all cases. We conclude that G protein gene mutations occur in a wider
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 1340 offsetEnd: 1461 A: according to our previously published view (Anticancer Res 10:1990). The number of de novo arising tumour cells in such a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 1461 offsetEnd: 1570 A: (Anticancer Res 10:1990). The number of de novo arising tumour cells in such a person is thus multiplied by a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 1774 offsetEnd: 1884 A: by a factor equal to the reverse of the mutant frequency, that is about 10(4)-10(5). This can be observed e.g.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 1884 offsetEnd: 2021 A: reverse of the mutant frequency, that is about 10(4)-10(5). This can be observed e.g. in retinoblastoma. Mutations occur in proliferating
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 2964 offsetEnd: 3086 A: organs is enhanced by 10(4)-10(5) times. Tumours in these organs will appear simultaneously if the number of cells and the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3086 offsetEnd: 3204 A: Tumours in these organs will appear simultaneously if the number of cells and the growth kinetics are similar. This is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3204 offsetEnd: 3323 A: simultaneously if the number of cells and the growth kinetics are similar. This is of course observed in paired organs,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 3323 offsetEnd: 3435 A: and the growth kinetics are similar. This is of course observed in paired organs, like the retina and the female
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 4374 offsetEnd: 4497 A: secondly diagnosed tumours are not caused by metastatic spread. Tumours in two organs will arise at difference times if the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 5607 offsetEnd: 5753 A: retinoblastoma. The inherited defective anti-oncogene is a recessive gene. This defective inherited gene causes a 10(4)-10(5) fold increase of the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 5753 offsetEnd: 5883 A: a recessive gene. This defective inherited gene causes a 10(4)-10(5) fold increase of the normal tumour incidence. This means that
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 5883 offsetEnd: 6004 A: gene causes a 10(4)-10(5) fold increase of the normal tumour incidence. This means that nearly always one or more tumours
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2190527 offsetBegin: 6494 offsetEnd: 6629 A: the erroneous conclusion that the genetic abnormality is dominant at the level of the chromosome. The 10(4)-10(5) times enhanced tumour
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 1506 offsetEnd: 1643 A: rat and mouse menin are highly homologous to human menin. All of the previously reported disease-associated missense mutations and single
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 1643 offsetEnd: 1787 A: homologous to human menin. All of the previously reported disease-associated missense mutations and single amino acid deletions were observed at
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 1787 offsetEnd: 1935 A: the previously reported disease-associated missense mutations and single amino acid deletions were observed at the residues that are conserved among
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 1935 offsetEnd: 2063 A: and single amino acid deletions were observed at the residues that are conserved among these three species. Rat MEN1 transcripts
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2063 offsetEnd: 2184 A: observed at the residues that are conserved among these three species. Rat MEN1 transcripts were detected not only in the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2562 offsetEnd: 2701 A: in the tissues of the nervous, digestive, reproductive and immune systems. The MEN1 transcripts were abundantly expressed in the developing
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2701 offsetEnd: 2835 A: digestive, reproductive and immune systems. The MEN1 transcripts were abundantly expressed in the developing rat brain on day 14-18 of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2835 offsetEnd: 2982 A: MEN1 transcripts were abundantly expressed in the developing rat brain on day 14-18 of gestation. Immunoblotting and immunocytochemical analysis of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 2982 offsetEnd: 3118 A: the developing rat brain on day 14-18 of gestation. Immunoblotting and immunocytochemical analysis of the COS-7 cells transfected with a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10612420 offsetBegin: 3118 offsetEnd: 3268 A: 14-18 of gestation. Immunoblotting and immunocytochemical analysis of the COS-7 cells transfected with a rat menin-expression vector revealed that the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 296 offsetEnd: 442 A: (MEN-1) syndrome. However, the prevalence of adrenal involvement, the characteristics, and the clinical management of adrenal lesions have not yet
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 576 offsetEnd: 701 A: clinical management of adrenal lesions have not yet been clearly defined. A total of 66 patients with confirmed MEN1 germline
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1365 offsetEnd: 1492 A: regular screening program that included evaluation of the adrenals (median follow-up 96 months; range 12 to 300 months). Age at
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1492 offsetEnd: 1598 A: of the adrenals (median follow-up 96 months; range 12 to 300 months). Age at the diagnosis of MEN-1 and of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1598 offsetEnd: 1716 A: months; range 12 to 300 months). Age at the diagnosis of MEN-1 and of adrenal tumors and the clinical characteristics,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1716 offsetEnd: 1847 A: Age at the diagnosis of MEN-1 and of adrenal tumors and the clinical characteristics, genotype, treatment, and follow-up of adrenal
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1847 offsetEnd: 1992 A: and of adrenal tumors and the clinical characteristics, genotype, treatment, and follow-up of adrenal disease were analyzed. Adrenal lesions were
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 1992 offsetEnd: 2138 A: clinical characteristics, genotype, treatment, and follow-up of adrenal disease were analyzed. Adrenal lesions were identified in 18 of 67 (26.8%)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2138 offsetEnd: 2259 A: of adrenal disease were analyzed. Adrenal lesions were identified in 18 of 67 (26.8%) MEN-1 patients and were diagnosed 5
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2259 offsetEnd: 2373 A: lesions were identified in 18 of 67 (26.8%) MEN-1 patients and were diagnosed 5 years later than MEN-1. The median
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2716 offsetEnd: 2828 A: was 3.0 cm (range 1.2-15.0 cm), with most tumors being 3 cm or smaller. Eight patients had bilateral tumors. Ten
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2828 offsetEnd: 2956 A: with most tumors being 3 cm or smaller. Eight patients had bilateral tumors. Ten patients had nonfunctional benign tumors, three
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 2956 offsetEnd: 3097 A: or smaller. Eight patients had bilateral tumors. Ten patients had nonfunctional benign tumors, three had benign adrenal Cushing syndrome, and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 3097 offsetEnd: 3238 A: tumors. Ten patients had nonfunctional benign tumors, three had benign adrenal Cushing syndrome, and one patient had a pheochromocytoma. Four
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 3238 offsetEnd: 3392 A: tumors, three had benign adrenal Cushing syndrome, and one patient had a pheochromocytoma. Four patients developed adrenocortical carcinomas (ACCs), three
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 3392 offsetEnd: 3552 A: syndrome, and one patient had a pheochromocytoma. Four patients developed adrenocortical carcinomas (ACCs), three of which were functional. Nine adrenalectomies
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 3552 offsetEnd: 3726 A: pheochromocytoma. Four patients developed adrenocortical carcinomas (ACCs), three of which were functional. Nine adrenalectomies and one subtotal adrenalectomy were performed
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 3869 offsetEnd: 4001 A: Nine adrenalectomies and one subtotal adrenalectomy were performed in six patients. Three patients with ACC died owing to the tumor.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4001 offsetEnd: 4116 A: were performed in six patients. Three patients with ACC died owing to the tumor. Patients with mutations in exons 2
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4116 offsetEnd: 4239 A: patients with ACC died owing to the tumor. Patients with mutations in exons 2 and 10 developed adrenal tumors significantly
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4239 offsetEnd: 4366 A: the tumor. Patients with mutations in exons 2 and 10 developed adrenal tumors significantly more often than patients with other
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4366 offsetEnd: 4495 A: exons 2 and 10 developed adrenal tumors significantly more often than patients with other mutations (p <0.01). Adrenal tumors are
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4495 offsetEnd: 4621 A: tumors significantly more often than patients with other mutations (p <0.01). Adrenal tumors are a common feature of MEN-1 but
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4621 offsetEnd: 4730 A: with other mutations (p <0.01). Adrenal tumors are a common feature of MEN-1 but occur later in the course of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4730 offsetEnd: 4834 A: tumors are a common feature of MEN-1 but occur later in the course of the disease. The lesions are often
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/12016472 offsetBegin: 4834 offsetEnd: 4949 A: MEN-1 but occur later in the course of the disease. The lesions are often small and nonfunctional and can therefore
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2070 offsetEnd: 2226 A: parathyroidectomy results from a single institution series. Patients who had initial parathyroid exploration for hyperparathyroidism in the setting of MEN-1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2226 offsetEnd: 2371 A: series. Patients who had initial parathyroid exploration for hyperparathyroidism in the setting of MEN-1 were reviewed. This study includes those
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2371 offsetEnd: 2503 A: exploration for hyperparathyroidism in the setting of MEN-1 were reviewed. This study includes those patients who had the weights of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2503 offsetEnd: 2623 A: of MEN-1 were reviewed. This study includes those patients who had the weights of the resected glands documented; 23 men
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2623 offsetEnd: 2739 A: includes those patients who had the weights of the resected glands documented; 23 men and 21 women met the criteria.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2739 offsetEnd: 2855 A: weights of the resected glands documented; 23 men and 21 women met the criteria. The total weight of the parathyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 2855 offsetEnd: 2957 A: 23 men and 21 women met the criteria. The total weight of the parathyroid glands did not vary with the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15490065 offsetBegin: 4377 offsetEnd: 4490 A: glands in MEN-1 is a function of time, as independent events in each gland must occur. Given time, MEN-1 patients
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 726 offsetEnd: 877 A: adipose tissue is very important in the pathophysiology of this constellation of abnormalities termed metabolic syndrome. Adipose tissue, regarded only
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 3335 offsetEnd: 3487 A: by the adipose tissue. Particularly, we review the role of adiponectin, leptin, resistin, angiotensinogen, TNF-alpha, and PAI-1, describing their impact
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 3487 offsetEnd: 3646 A: review the role of adiponectin, leptin, resistin, angiotensinogen, TNF-alpha, and PAI-1, describing their impact on insulin resistance and cardiovascular risk,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/18220614 offsetBegin: 3646 offsetEnd: 3798 A: resistin, angiotensinogen, TNF-alpha, and PAI-1, describing their impact on insulin resistance and cardiovascular risk, based on more recent findings in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 779 offsetEnd: 891 A: of a 45-year-old woman started at 22 years of age when she had surgery for a right adrenal pheochromocytoma. Two
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 891 offsetEnd: 1022 A: 22 years of age when she had surgery for a right adrenal pheochromocytoma. Two years later, a pancreaticoduodenectomy was performed
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1022 offsetEnd: 1162 A: had surgery for a right adrenal pheochromocytoma. Two years later, a pancreaticoduodenectomy was performed to remove a pancreatic mass which
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1162 offsetEnd: 1300 A: pheochromocytoma. Two years later, a pancreaticoduodenectomy was performed to remove a pancreatic mass which turned out to be a pancreatic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1300 offsetEnd: 1419 A: was performed to remove a pancreatic mass which turned out to be a pancreatic neuroendocrine tumor. After a long period
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1419 offsetEnd: 1538 A: mass which turned out to be a pancreatic neuroendocrine tumor. After a long period of relative wellness, 21 years after
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1538 offsetEnd: 1667 A: a pancreatic neuroendocrine tumor. After a long period of relative wellness, 21 years after the surgical resection of her primary
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1667 offsetEnd: 1807 A: long period of relative wellness, 21 years after the surgical resection of her primary pancreatic neuroendocrine tumor, abdominal lymph node
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1807 offsetEnd: 1967 A: years after the surgical resection of her primary pancreatic neuroendocrine tumor, abdominal lymph node metastases of pancreatic neuroendocrine origin occurred.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 1967 offsetEnd: 2127 A: her primary pancreatic neuroendocrine tumor, abdominal lymph node metastases of pancreatic neuroendocrine origin occurred. In fact, three abdominal nodules were
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 2127 offsetEnd: 2273 A: lymph node metastases of pancreatic neuroendocrine origin occurred. In fact, three abdominal nodules were removed by laparoscopic surgery, and the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 2273 offsetEnd: 2442 A: origin occurred. In fact, three abdominal nodules were removed by laparoscopic surgery, and the histological examination showed well-differentiated neuroendocrine tumors
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 2442 offsetEnd: 2627 A: nodules were removed by laparoscopic surgery, and the histological examination showed well-differentiated neuroendocrine tumors with similar immunohistochemical characteristics and Ki67
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 2627 offsetEnd: 2811 A: and the histological examination showed well-differentiated neuroendocrine tumors with similar immunohistochemical characteristics and Ki67 below 1%. Considering the patient's clinical
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 2811 offsetEnd: 2978 A: neuroendocrine tumors with similar immunohistochemical characteristics and Ki67 below 1%. Considering the patient's clinical history, an inherited cause was postulated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19734639 offsetBegin: 3493 offsetEnd: 3613 A: the result was negative. Then, a missense mutation in exon 3 of the VHL gene (ACT>ATT; Thr157Ile) was found. CONCLUSION:
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 448 offsetEnd: 609 A: = Sipple-Syndrome), serum calcitonin (CT) was measured by radioimmunoassay in 4 patients with pheochromocytoma. Before extirpation of the adreno-medullary tumor,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 609 offsetEnd: 761 A: measured by radioimmunoassay in 4 patients with pheochromocytoma. Before extirpation of the adreno-medullary tumor, serum CT was distinctly increased to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 761 offsetEnd: 890 A: with pheochromocytoma. Before extirpation of the adreno-medullary tumor, serum CT was distinctly increased to 3 and 30 ng/ml in 2
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 890 offsetEnd: 1013 A: adreno-medullary tumor, serum CT was distinctly increased to 3 and 30 ng/ml in 2 of 4 patients, respectively. After removal
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 1013 offsetEnd: 1115 A: increased to 3 and 30 ng/ml in 2 of 4 patients, respectively. After removal of the tumor, serum CT was
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 1115 offsetEnd: 1229 A: in 2 of 4 patients, respectively. After removal of the tumor, serum CT was normal in the patients and pentagastrin
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/672141 offsetBegin: 1229 offsetEnd: 1358 A: After removal of the tumor, serum CT was normal in the patients and pentagastrin stimulation produced no exaggerated CT response.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 821 offsetEnd: 977 A: present recommendations for clinical screening and follow-up in patients and relatives with suspected or established MEN1 syndrome. MEN1 mutational analysis
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 977 offsetEnd: 1122 A: follow-up in patients and relatives with suspected or established MEN1 syndrome. MEN1 mutational analysis should be performed in individuals with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 1667 offsetEnd: 1841 A: neoplasia (e.g., primary hyperparathyroidism, gastroenteropancreatic tumor, pituitary adenoma) if additional diagnostic criteria are met (e.g., age <40 years; positive family
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2399 offsetEnd: 2541 A: affected). Genetic family screening is advisable in first degree relatives of MEN1 patients during early adolescence to reliably assess future
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2541 offsetEnd: 2680 A: in first degree relatives of MEN1 patients during early adolescence to reliably assess future MEN1 disease risk. In symptomatic individuals
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2680 offsetEnd: 2827 A: patients during early adolescence to reliably assess future MEN1 disease risk. In symptomatic individuals carrying MEN1 germ line mutations, annual
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2827 offsetEnd: 2977 A: assess future MEN1 disease risk. In symptomatic individuals carrying MEN1 germ line mutations, annual clinical and biochemical (calcium, PTH, gastrin,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 2977 offsetEnd: 3131 A: symptomatic individuals carrying MEN1 germ line mutations, annual clinical and biochemical (calcium, PTH, gastrin, prolactin) follow-up as well as routine
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 3420 offsetEnd: 3571 A: as routine pancreatic and pituitary imaging may be complemented as individually needed. In contrast, relatives without family-specific MEN1 mutation do
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 3571 offsetEnd: 3731 A: may be complemented as individually needed. In contrast, relatives without family-specific MEN1 mutation do not require routine follow-up. Diagnostic procedures
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 3731 offsetEnd: 3890 A: In contrast, relatives without family-specific MEN1 mutation do not require routine follow-up. Diagnostic procedures and treatment in symptomatic MEN1 mutation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10989951 offsetBegin: 3890 offsetEnd: 4035 A: mutation do not require routine follow-up. Diagnostic procedures and treatment in symptomatic MEN1 mutation carriers and patients may differ from
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 807 offsetEnd: 942 A: an investigation in vitro was made of parathyroid hormone (PTH) release of dispersed parathyroid cell from 11 patients with parathyroid
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 1391 offsetEnd: 1524 A: 10 patients with single parathyroid adenomas, and 10 preparations of normal bovine parathyroid glands. The two patient groups had the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 1524 offsetEnd: 1650 A: and 10 preparations of normal bovine parathyroid glands. The two patient groups had the same average serum calcium value prior
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 2222 offsetEnd: 2366 A: incubations at extracellular calcium concentrations of 0.5-3.0 mmol/l. Compared with the normal bovine parathyroid cells, the cells of the MEN-1
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 2366 offsetEnd: 2498 A: 0.5-3.0 mmol/l. Compared with the normal bovine parathyroid cells, the cells of the MEN-1 patients had a reduced calcium sensitivity
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 2498 offsetEnd: 2621 A: bovine parathyroid cells, the cells of the MEN-1 patients had a reduced calcium sensitivity of the PTH release and secreted
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 2621 offsetEnd: 2740 A: the MEN-1 patients had a reduced calcium sensitivity of the PTH release and secreted smaller amounts of hormone at both
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 3406 offsetEnd: 3558 A: the cells of the hyperplastic and adenomatous parathyroid glands. Although individual parathyroid glands were investigated in only three MEN-1 patients,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 3558 offsetEnd: 3723 A: adenomatous parathyroid glands. Although individual parathyroid glands were investigated in only three MEN-1 patients, the results suggested the secretory regulation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 3723 offsetEnd: 3852 A: glands were investigated in only three MEN-1 patients, the results suggested the secretory regulation to be less defective in the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 3852 offsetEnd: 3975 A: MEN-1 patients, the results suggested the secretory regulation to be less defective in the small glands of each patient. It
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 4210 offsetEnd: 4332 A: patient. It is concluded that in patient groups matched for serum calcium, the parathyroid tissue of MEN-1 patients has an
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/2880443 offsetBegin: 4332 offsetEnd: 4460 A: patient groups matched for serum calcium, the parathyroid tissue of MEN-1 patients has an abnormality of the PTH release similar
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 246 offsetEnd: 367 A: secretory organ, releasing a wide range of protein factors and signals termed adipokines - in addition to fatty acids and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 1079 offsetEnd: 1239 A: hypothalamus in the control of appetite and energy balance. A number of adipokines, including adiponectin, tumour necrosis factor-alpha, interleukin (IL)-1beta,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 1239 offsetEnd: 1414 A: and energy balance. A number of adipokines, including adiponectin, tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, IL-8, IL-10, monocyte chemoattractant protein-1,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 1414 offsetEnd: 1610 A: adipokines, including adiponectin, tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, IL-8, IL-10, monocyte chemoattractant protein-1, macrophage migration inhibitory factor, nerve growth
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 1610 offsetEnd: 1797 A: interleukin (IL)-1beta, IL-6, IL-8, IL-10, monocyte chemoattractant protein-1, macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth factor, plasminogen
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 1797 offsetEnd: 1982 A: chemoattractant protein-1, macrophage migration inhibitory factor, nerve growth factor, vascular endothelial growth factor, plasminogen activator inhibitor-1 and haptoglobin, are linked
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 1982 offsetEnd: 2147 A: nerve growth factor, vascular endothelial growth factor, plasminogen activator inhibitor-1 and haptoglobin, are linked to inflammation and the inflammatory response.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 2147 offsetEnd: 2299 A: factor, plasminogen activator inhibitor-1 and haptoglobin, are linked to inflammation and the inflammatory response. Obesity is characterized by a state
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16026420 offsetBegin: 4111 offsetEnd: 4237 A: metabolic syndrome. From the wide range of adipokines now identified, it is evident that WAT is highly integrated into overall
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 387 offsetEnd: 546 A: signals and factors termed adipokines. A number of adipokines, including leptin, adiponectin, tumour necrosis factor alpha, IL-1beta (interleukin 1beta), IL-6,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 546 offsetEnd: 728 A: number of adipokines, including leptin, adiponectin, tumour necrosis factor alpha, IL-1beta (interleukin 1beta), IL-6, monocyte chemotactic protein-1, macrophage migration inhibitory
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16246049 offsetBegin: 728 offsetEnd: 907 A: tumour necrosis factor alpha, IL-1beta (interleukin 1beta), IL-6, monocyte chemotactic protein-1, macrophage migration inhibitory factor, nerve growth factor, vascular endothelial
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1078 offsetEnd: 1215 A: case-finding, unfortunately only at a very low frequency in patients with apparently sporadic MEN 1-related tumours. In order to increase
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1215 offsetEnd: 1344 A: low frequency in patients with apparently sporadic MEN 1-related tumours. In order to increase the detection rate of disease gene
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1344 offsetEnd: 1480 A: sporadic MEN 1-related tumours. In order to increase the detection rate of disease gene carriers among patients with apparently sporadic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1480 offsetEnd: 1621 A: to increase the detection rate of disease gene carriers among patients with apparently sporadic MEN 1-related tumours, clinical criteria were
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1621 offsetEnd: 1764 A: disease gene carriers among patients with apparently sporadic MEN 1-related tumours, clinical criteria were needed. DESIGN AND RESULTS: In this
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 1764 offsetEnd: 1906 A: apparently sporadic MEN 1-related tumours, clinical criteria were needed. DESIGN AND RESULTS: In this study MEN1 gene germ-line mutations were
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2609 offsetEnd: 2754 A: we formulated clinical criteria to identify disease gene carriers among patients with apparently sporadic MEN 1-related tumours. The criteria for
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2754 offsetEnd: 2895 A: disease gene carriers among patients with apparently sporadic MEN 1-related tumours. The criteria for MEN 1-suspected patients are: young age
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 2895 offsetEnd: 3023 A: apparently sporadic MEN 1-related tumours. The criteria for MEN 1-suspected patients are: young age at onset (< 35 years) and/or
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 3509 offsetEnd: 3648 A: distinct organs affected. Application of these criteria yielded MEN1 gene germ-line mutations in nine of 15 MEN 1-suspected patients (60%),
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4178 offsetEnd: 4327 A: guaranteed for patients not fulfilling these criteria. CONCLUSIONS: The clinical criteria for MEN 1-suspected patients increase the detection rate of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4327 offsetEnd: 4476 A: criteria. CONCLUSIONS: The clinical criteria for MEN 1-suspected patients increase the detection rate of germ-line MEN1 gene mutations among patients
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4476 offsetEnd: 4624 A: MEN 1-suspected patients increase the detection rate of germ-line MEN1 gene mutations among patients with apparently sporadic MEN 1-related tumours.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10849016 offsetBegin: 4624 offsetEnd: 4755 A: rate of germ-line MEN1 gene mutations among patients with apparently sporadic MEN 1-related tumours. These criteria may be used for
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 957 offsetEnd: 1082 A: of MEN1, the prevalence of germline mutations in the MEN1 gene was determined in young patients with apparently sporadic pHPT
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1082 offsetEnd: 1205 A: mutations in the MEN1 gene was determined in young patients with apparently sporadic pHPT or PETs. METHODS: Eighteen of 705
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1205 offsetEnd: 1326 A: determined in young patients with apparently sporadic pHPT or PETs. METHODS: Eighteen of 705 patients with pHPT and 11 of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1326 offsetEnd: 1436 A: sporadic pHPT or PETs. METHODS: Eighteen of 705 patients with pHPT and 11 of 93 patients with PETs operated on
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1436 offsetEnd: 1534 A: of 705 patients with pHPT and 11 of 93 patients with PETs operated on between 1987 and 2001 had no
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 1534 offsetEnd: 1635 A: 11 of 93 patients with PETs operated on between 1987 and 2001 had no family history of MEN1, only one
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2063 offsetEnd: 2181 A: the time of diagnosis. Fifteen patients with pHPT and eight with PETs agreed to MEN1 gene mutation analysis, which was
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2181 offsetEnd: 2318 A: with pHPT and eight with PETs agreed to MEN1 gene mutation analysis, which was performed by single-strand conformational variant analysis
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2318 offsetEnd: 2465 A: agreed to MEN1 gene mutation analysis, which was performed by single-strand conformational variant analysis and direct DNA sequencing. RESULTS: Two
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2465 offsetEnd: 2602 A: which was performed by single-strand conformational variant analysis and direct DNA sequencing. RESULTS: Two of 15 patients (13.3 (95 per
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2602 offsetEnd: 2726 A: variant analysis and direct DNA sequencing. RESULTS: Two of 15 patients (13.3 (95 per cent confidence interval (c.i.) 1.6 to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2726 offsetEnd: 2847 A: RESULTS: Two of 15 patients (13.3 (95 per cent confidence interval (c.i.) 1.6 to 40.4) per cent) with apparently sporadic
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2847 offsetEnd: 2969 A: (95 per cent confidence interval (c.i.) 1.6 to 40.4) per cent) with apparently sporadic pHPT had a MEN1 germline mutation.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 2969 offsetEnd: 3089 A: 1.6 to 40.4) per cent) with apparently sporadic pHPT had a MEN1 germline mutation. Both mutations were found in patients
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3089 offsetEnd: 3222 A: apparently sporadic pHPT had a MEN1 germline mutation. Both mutations were found in patients with pHPT due to multiglandular disease,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3222 offsetEnd: 3357 A: germline mutation. Both mutations were found in patients with pHPT due to multiglandular disease, whereas the remaining 13 patients had
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3357 offsetEnd: 3479 A: in patients with pHPT due to multiglandular disease, whereas the remaining 13 patients had a solitary adenoma. None of the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3479 offsetEnd: 3607 A: multiglandular disease, whereas the remaining 13 patients had a solitary adenoma. None of the eight patients with PETs carried a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3607 offsetEnd: 3736 A: patients had a solitary adenoma. None of the eight patients with PETs carried a MEN1 germline mutation. CONCLUSION: Sporadic pHPT
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3736 offsetEnd: 3869 A: of the eight patients with PETs carried a MEN1 germline mutation. CONCLUSION: Sporadic pHPT due to multiglandular disease in patients
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/14648742 offsetBegin: 3869 offsetEnd: 4006 A: carried a MEN1 germline mutation. CONCLUSION: Sporadic pHPT due to multiglandular disease in patients younger than 40 years may represent
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 251 offsetEnd: 380 A: be explained solely by the expression pattern of the predisposing gene MEN1 and its encoded protein, menin. This review addresses
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 380 offsetEnd: 548 A: pattern of the predisposing gene MEN1 and its encoded protein, menin. This review addresses putative factors determining MEN1-associated tissue-selective tumorigenesis.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 548 offsetEnd: 745 A: and its encoded protein, menin. This review addresses putative factors determining MEN1-associated tissue-selective tumorigenesis. Menin's interaction with mixed-lineage leukemia protein-containing
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 745 offsetEnd: 959 A: review addresses putative factors determining MEN1-associated tissue-selective tumorigenesis. Menin's interaction with mixed-lineage leukemia protein-containing histone methyl transferase (MLL-HMT) complex mediates
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 959 offsetEnd: 1177 A: tissue-selective tumorigenesis. Menin's interaction with mixed-lineage leukemia protein-containing histone methyl transferase (MLL-HMT) complex mediates tissue-selective tumor-suppressing and tumor-promoting effects of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 1177 offsetEnd: 1352 A: leukemia protein-containing histone methyl transferase (MLL-HMT) complex mediates tissue-selective tumor-suppressing and tumor-promoting effects of menin, and as such could be
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 1352 offsetEnd: 1508 A: complex mediates tissue-selective tumor-suppressing and tumor-promoting effects of menin, and as such could be decisive for the predisposition of individual
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 1508 offsetEnd: 1645 A: effects of menin, and as such could be decisive for the predisposition of individual tissues to MEN1-associated tumorigenesis. In tissues
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 1645 offsetEnd: 1777 A: could be decisive for the predisposition of individual tissues to MEN1-associated tumorigenesis. In tissues in which menin acts as a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 2159 offsetEnd: 2289 A: depend on the inability of such tissues to adequately compensate for MEN1 gene loss, whereas the variable clinical presentation of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 2289 offsetEnd: 2424 A: tissues to adequately compensate for MEN1 gene loss, whereas the variable clinical presentation of MEN1 in individual patients could be
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 2424 offsetEnd: 2563 A: gene loss, whereas the variable clinical presentation of MEN1 in individual patients could be a reflection of additional epigenetic factors
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 2563 offsetEnd: 2704 A: presentation of MEN1 in individual patients could be a reflection of additional epigenetic factors and/or modifier genes. Further research on
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/19654304 offsetBegin: 2992 offsetEnd: 3130 A: research on this topic may facilitate development of novel therapeutic strategies that could prevent or delay the onset of MEN1-associated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 277 offsetEnd: 409 A: noted to grow in occurrence in recent decades. Surgical removal of locally advanced PNTs involving major vessels and adjacent organs
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 409 offsetEnd: 539 A: recent decades. Surgical removal of locally advanced PNTs involving major vessels and adjacent organs is warranted by reason of an
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 539 offsetEnd: 674 A: advanced PNTs involving major vessels and adjacent organs is warranted by reason of an appreciably more favorable prognosis as compared
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 674 offsetEnd: 803 A: adjacent organs is warranted by reason of an appreciably more favorable prognosis as compared to exocrine pancreas cancer. We are
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 803 offsetEnd: 936 A: of an appreciably more favorable prognosis as compared to exocrine pancreas cancer. We are reporting a case of successful multi-organ
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 936 offsetEnd: 1066 A: as compared to exocrine pancreas cancer. We are reporting a case of successful multi-organ resection combined with a wide excision
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 1066 offsetEnd: 1199 A: We are reporting a case of successful multi-organ resection combined with a wide excision of the superior mesenteric, common, proper,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 1199 offsetEnd: 1341 A: successful multi-organ resection combined with a wide excision of the superior mesenteric, common, proper, left and right hepatic arteries (in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/23443490 offsetBegin: 2442 offsetEnd: 2565 A: the patient's life quality and allowed her to return to work. Follow-up computed tomography at 15 mo post-surgery showed no
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 1627 offsetEnd: 1768 A: (occult) adenomas, lifelong follow-up was considered necessary. The patient has been recurrence-free for 10 years. All 19 living relatives of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2251 offsetEnd: 2380 A: I syndrome. A brother was found to suffer from peptic ulcer disease caused by hyperparathyroidism and, during screening for other
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/8551667 offsetBegin: 2772 offsetEnd: 2870 A: the MEN I syndrome, two tumors were found, one (4 cm) in the pancreatic tail region and one in the
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 635 offsetEnd: 767 A: and anterior pituitary tumours. The diagnosis of MEN-1, the possible probands, necessitates the recognition of at least two or three
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 1821 offsetEnd: 1935 A: tumours within the affected organs as well as the complex pattern of the clinical signs of these tumours and their
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 2209 offsetEnd: 2359 A: and their sometimes temporarily variable profile of hormone excess. Thorough screening studies have demonstrated that the MEN-1 trait is biochemically
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 2359 offsetEnd: 2502 A: of hormone excess. Thorough screening studies have demonstrated that the MEN-1 trait is biochemically detectable virtually two decades prior to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 2502 offsetEnd: 2649 A: have demonstrated that the MEN-1 trait is biochemically detectable virtually two decades prior to clinically overt disease. The primary biochemical
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 2649 offsetEnd: 2802 A: is biochemically detectable virtually two decades prior to clinically overt disease. The primary biochemical screening programme for MEN-1 includes serum
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 4192 offsetEnd: 4337 A: meal stimulatory test analysing serum polypeptides (PP) and gastrin is recommended. Our current primary screening procedure has yielded about 10%
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 4337 offsetEnd: 4471 A: (PP) and gastrin is recommended. Our current primary screening procedure has yielded about 10% false positives when compared with RFLP
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 5040 offsetEnd: 5177 A: radiology fails to show lesions in half of the patients. Pancreatic involvement in young MEN-1 patients is most consistently demonstrated
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 5177 offsetEnd: 5322 A: half of the patients. Pancreatic involvement in young MEN-1 patients is most consistently demonstrated by analysing serum insulin, proinsulin, PP
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 5322 offsetEnd: 5462 A: in young MEN-1 patients is most consistently demonstrated by analysing serum insulin, proinsulin, PP as well as plasma glucagon chromogranin
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 7817 offsetEnd: 7924 A: whose mean age was 25 years. False-positive stimulation due to the meal test has been found in about 10% of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 7924 offsetEnd: 8054 A: False-positive stimulation due to the meal test has been found in about 10% of previous investigated individuals. The diagnosis of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 8054 offsetEnd: 8178 A: test has been found in about 10% of previous investigated individuals. The diagnosis of MEN-1 pancreatic tumours is based on
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 8178 offsetEnd: 8312 A: 10% of previous investigated individuals. The diagnosis of MEN-1 pancreatic tumours is based on biochemical screening alone and it has
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9681845 offsetBegin: 8312 offsetEnd: 8444 A: diagnosis of MEN-1 pancreatic tumours is based on biochemical screening alone and it has been substantiated that an unequivocal rise
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 0 offsetEnd: 132 A: Fatty liver is strongly associated with metabolic syndrome. Here, we show that the impaired hepatic expression of menin, the product
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 666 offsetEnd: 791 A: gene, represents a common feature of several fatty liver mouse models. The liver specific ablation of MEN1 gene expression in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 791 offsetEnd: 924 A: several fatty liver mouse models. The liver specific ablation of MEN1 gene expression in healthy mice induced hepatic steatosis under
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/22001208 offsetBegin: 924 offsetEnd: 1076 A: liver specific ablation of MEN1 gene expression in healthy mice induced hepatic steatosis under high-fat dietary conditions. Moreover, overexpression of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 562 offsetEnd: 696 A: (MEN1) describes the association of pituitary, parathyroid, and pancreatic islet cell tumors with a variety of many other lesions. MEN
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 1476 offsetEnd: 1666 A: carcinoma, hyperparathyroidism, and a number of other manifestations. Other pheochromocytoma-associated syndromes include von Hippel-Lindau disease; neurofibromatosis 1; the recently defined
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 2460 offsetEnd: 2624 A: characterized by the association of paragangliomas and familial gastrointestinal stromal tumors. In the Carney triad, patients can manifest gastrointestinal stromal
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 2624 offsetEnd: 2792 A: and familial gastrointestinal stromal tumors. In the Carney triad, patients can manifest gastrointestinal stromal tumors, lung chondroma, paraganglioma, adrenal adenoma
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 2792 offsetEnd: 2965 A: the Carney triad, patients can manifest gastrointestinal stromal tumors, lung chondroma, paraganglioma, adrenal adenoma and pheochromocytoma, esophageal leiomyoma, and other
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 2965 offsetEnd: 3136 A: gastrointestinal stromal tumors, lung chondroma, paraganglioma, adrenal adenoma and pheochromocytoma, esophageal leiomyoma, and other conditions. The Carney complex is yet
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 3136 offsetEnd: 3271 A: adrenal adenoma and pheochromocytoma, esophageal leiomyoma, and other conditions. The Carney complex is yet another form of MEN that is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/20951316 offsetBegin: 3271 offsetEnd: 3389 A: and other conditions. The Carney complex is yet another form of MEN that is characterized by skin tumors and pigmented
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 843 offsetEnd: 983 A: to organelles like large dense core vesicles (e.g. chromogranin A) and small synaptic-like vesicles (e.g. synaptophysin), or to the cytosol,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15077908 offsetBegin: 1999 offsetEnd: 2175 A: identified as (i) well-differentiated and (ii) poorly differentiated neoplasms. Well-differentiated tumours/carcinomas (also known as carcinoids) express all general markers of
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 0 offsetEnd: 157 A: Identifying the molecular basis for genotype-phenotype correlations in human diseases has direct implications for understanding the disease process and hence
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 450 offsetEnd: 603 A: and hence for the identification of potential therapeutic targets. To this end, we performed microarray expression analysis on benign (pheochromocytomas)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 603 offsetEnd: 771 A: potential therapeutic targets. To this end, we performed microarray expression analysis on benign (pheochromocytomas) and malignant (medullary thyroid carcinomas, MTCs)
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 1368 offsetEnd: 1494 A: or 2B, related syndromes that result from distinctive mutations in the RET receptor tyrosine kinase. Comparisons of MEN 2B and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 1736 offsetEnd: 1860 A: 2B and MEN 2A MTCs revealed that genes involved in the process of epithelial to mesenchymal transition, many associated with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2719 offsetEnd: 2861 A: with MEN 2A patients. Furthermore, chondromodulin-1, a known regulator of cartilage and bone growth, was expressed at high levels specifically
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2861 offsetEnd: 2988 A: a known regulator of cartilage and bone growth, was expressed at high levels specifically in MEN 2B MTCs. Chondromodulin-1 mRNA
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 2988 offsetEnd: 3120 A: bone growth, was expressed at high levels specifically in MEN 2B MTCs. Chondromodulin-1 mRNA and protein expression was localized to
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3120 offsetEnd: 3248 A: levels specifically in MEN 2B MTCs. Chondromodulin-1 mRNA and protein expression was localized to the malignant C cells, and its
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3248 offsetEnd: 3385 A: Chondromodulin-1 mRNA and protein expression was localized to the malignant C cells, and its high expression was directly associated with
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3385 offsetEnd: 3515 A: localized to the malignant C cells, and its high expression was directly associated with the presence of skeletal abnormalities in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15173001 offsetBegin: 3515 offsetEnd: 3649 A: and its high expression was directly associated with the presence of skeletal abnormalities in MEN 2B patients. These findings provide
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 705 offsetEnd: 859 A: shown that gangliosides are almost ubiquitous molecules expressed in all vertebrate tissues. Within cells, gangliosides are usually associated with plasma
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 859 offsetEnd: 1000 A: molecules expressed in all vertebrate tissues. Within cells, gangliosides are usually associated with plasma membranes, where they can act as
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 1000 offsetEnd: 1131 A: Within cells, gangliosides are usually associated with plasma membranes, where they can act as receptors for a variety of molecules
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 2817 offsetEnd: 3008 A: process. These diseases include two major forms of ganglioside storage, namely GM2-gangliosidosis (Tay-Sachs and its beta-hexosaminidase deficiency) and GM1-gangliosidosis (beta-galactosidase
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 3008 offsetEnd: 3208 A: forms of ganglioside storage, namely GM2-gangliosidosis (Tay-Sachs and its beta-hexosaminidase deficiency) and GM1-gangliosidosis (beta-galactosidase deficiency), where the most prominent pathological
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 3208 offsetEnd: 3409 A: (Tay-Sachs and its beta-hexosaminidase deficiency) and GM1-gangliosidosis (beta-galactosidase deficiency), where the most prominent pathological characteristic is the lysosomal ganglioside accumulation
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 3409 offsetEnd: 3602 A: GM1-gangliosidosis (beta-galactosidase deficiency), where the most prominent pathological characteristic is the lysosomal ganglioside accumulation in neurons. Other inflammatory or degenerative
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 3907 offsetEnd: 4031 A: or degenerative diseases both within and outside the nervous system have been shown to be associated with an altered pattern
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 4031 offsetEnd: 4154 A: outside the nervous system have been shown to be associated with an altered pattern of ganglioside expression in the target
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 4154 offsetEnd: 4285 A: shown to be associated with an altered pattern of ganglioside expression in the target organ. Since monoclonal antibodies have been
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 4285 offsetEnd: 4422 A: altered pattern of ganglioside expression in the target organ. Since monoclonal antibodies have been discovered and used in immunology, a
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 4422 offsetEnd: 4556 A: the target organ. Since monoclonal antibodies have been discovered and used in immunology, a large variety of ganglioside antigens has
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 6407 offsetEnd: 6547 A: thyroiditis and, last but not least, insulin-dependent (type 1) diabetes mellitus. This last disease is caused by the autoimmune destruction
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 6547 offsetEnd: 6697 A: insulin-dependent (type 1) diabetes mellitus. This last disease is caused by the autoimmune destruction of insulin-producing pancreatic islet cells in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8009 offsetEnd: 8143 A: target autoantigens, some are of protein nature but others are acidic glycolipids such as sulphatides158 and the gangliosides GT3, GD3
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8143 offsetEnd: 8278 A: nature but others are acidic glycolipids such as sulphatides158 and the gangliosides GT3, GD3 and especially GM2-1. This last component
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8278 offsetEnd: 8419 A: such as sulphatides158 and the gangliosides GT3, GD3 and especially GM2-1. This last component is specifically expressed in pancreatic islets
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8419 offsetEnd: 8548 A: GT3, GD3 and especially GM2-1. This last component is specifically expressed in pancreatic islets and has been shown to represent
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 8679 offsetEnd: 8819 A: pancreatic islets and has been shown to represent a target of IgG autoantibodies highly associated with diabetes development in first-degree
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/9307889 offsetBegin: 9249 offsetEnd: 9386 A: diabetic individuals. In addition, the GM2-1 ganglioside appears to be one of the antigens recognized by cytoplasmic ICA, a heterogeneous
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 294 offsetEnd: 465 A: classical malignant neoplasia syndrome, inherited in the autosomal dominant pattern, when hyperplastic and/or neoplastic injury develops synchronously or metachronously in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 2112 offsetEnd: 2250 A: with the syndromes of hormone excess, later benign and/or malign neoplasia develops, this mostly determines the prognosis for the patient.
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 3732 offsetEnd: 3871 A: them. Multifocality of neoplasia, typical combinations of injuries and anamnesis of the family helps to diagnose the syndrome. Diagnosis is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 3871 offsetEnd: 4002 A: of injuries and anamnesis of the family helps to diagnose the syndrome. Diagnosis is confirmed through genetical analysis, which is
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 4002 offsetEnd: 4145 A: family helps to diagnose the syndrome. Diagnosis is confirmed through genetical analysis, which is also important in determining the inheritors
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 5612 offsetEnd: 5741 A: for the patient's relatives, and to determine their risk of getting cancer. This opens new possibilities in early diagnostics and
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/15170420 offsetBegin: 5741 offsetEnd: 5878 A: determine their risk of getting cancer. This opens new possibilities in early diagnostics and prevention of malignant neoplasia. The main
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/11835593 offsetBegin: 4760 offsetEnd: 4890 A: been labeled a prototype for medical genetics, information on MEN2a patient experiences may be relevant to the care of individuals
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 3184 offsetEnd: 3375 A: hypoparathyroidism, adrenocortical failure, glucose intolerance, and hypothyroidism. RESULTS: Genetic analysis revealed a large homozygous deletion (g.424_2157del1734), spanning exons 2-4, in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 3375 offsetEnd: 3535 A: hypothyroidism. RESULTS: Genetic analysis revealed a large homozygous deletion (g.424_2157del1734), spanning exons 2-4, in the AIRE gene. The predicted protein,
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 3535 offsetEnd: 3670 A: large homozygous deletion (g.424_2157del1734), spanning exons 2-4, in the AIRE gene. The predicted protein, if it is produced, has only
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 3670 offsetEnd: 3770 A: 2-4, in the AIRE gene. The predicted protein, if it is produced, has only 44 amino acids (exon 1) in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 3770 offsetEnd: 3896 A: predicted protein, if it is produced, has only 44 amino acids (exon 1) in common with the wild-type protein. Immunosuppression
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/16263818 offsetBegin: 3896 offsetEnd: 4026 A: has only 44 amino acids (exon 1) in common with the wild-type protein. Immunosuppression after the first renal transplant included
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 0 offsetEnd: 142 A: The RET proto-oncogene, located on chromosome subband 10q11.2, encodes a receptor tyrosine kinase expressed in tissues and tumors derived from
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 142 offsetEnd: 279 A: subband 10q11.2, encodes a receptor tyrosine kinase expressed in tissues and tumors derived from neural crest. Germline (present in every
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 279 offsetEnd: 402 A: kinase expressed in tissues and tumors derived from neural crest. Germline (present in every cell of the body) mutations in
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 2931 offsetEnd: 3043 A: in a proportion of sporadic MTCs and PCs. Whether the presence of somatic RET mutation is associated with a poor
Q:Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome? Document:http://www.ncbi.nlm.nih.gov/pubmed/10458257 offsetBegin: 3043 offsetEnd: 3167 A: and PCs. Whether the presence of somatic RET mutation is associated with a poor prognosis is currently being investigated as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1105 offsetEnd: 1260 A: presentation, and treatment options for juvenile myasthenia gravis. RECENT FINDINGS: Randomized clinical studies of myasthenia gravis have been carried out
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22337799 offsetBegin: 619 offsetEnd: 792 A: acetylcholinesterase inhibitors (AChEIs). AChEIs are used for the treatment of Alzheimer's Disease and Myasthenia Gravis. In the open-tubular capillary electrochromatography
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22634638 offsetBegin: 4589 offsetEnd: 4722 A: can be considered for symptomatic treatment of myasthenia gravis and other congenital myasthenic syndromes as an inhibitor of AChE in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 0 offsetEnd: 151 A: Inhibitors of acetylcholinesterase are compounds widely used in the treatment of various diseases, such as Alzheimer's disease, glaucoma and Myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 3198 offsetEnd: 3343 A: suspected to have CMS, especially if treatment response is incomplete, or no CMS gene mutation is identified. Treatment with acetylcholinesterase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 3343 offsetEnd: 3493 A: treatment response is incomplete, or no CMS gene mutation is identified. Treatment with acetylcholinesterase inhibitors may benefit some CNM patients.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4002 offsetEnd: 4179 A: myasthenia gravis patients diagnosed by an internationally accepted definition.Types of interventions: treatment with any form of acetylcholinesterase inhibitor.Types of outcome
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 8445 offsetEnd: 8606 A: trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis. Response to acetylcholinesterase inhibitors in observational studies
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 8606 offsetEnd: 8765 A: use of acetylcholinesterase inhibitors in myasthenia gravis. Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22337799 offsetBegin: 458 offsetEnd: 619 A: the separation of the pharmaceutical substances acetylcholinesterase inhibitors (AChEIs). AChEIs are used for the treatment of Alzheimer's Disease and Myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 2510 offsetEnd: 2671 A: keywords were used: myasthenia gravis AND neuromuscular blocking agents, myasthenia gravis AND sevoflurane, myasthenia gravis AND epidural, myasthenia gravis AND
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 2350 offsetEnd: 2510 A: references of the articles. The following keywords were used: myasthenia gravis AND neuromuscular blocking agents, myasthenia gravis AND sevoflurane, myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 2671 offsetEnd: 2844 A: neuromuscular blocking agents, myasthenia gravis AND sevoflurane, myasthenia gravis AND epidural, myasthenia gravis AND neuromuscular blockade reversal and myasthenia gravis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 2844 offsetEnd: 3011 A: sevoflurane, myasthenia gravis AND epidural, myasthenia gravis AND neuromuscular blockade reversal and myasthenia gravis AND pyridostigmine. The articles included were
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 0 offsetEnd: 119 A: We report a 33-year-old woman with myasthenia gravis (MG) who developed optic neuritis after the treatment of MG for 22
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1963 offsetEnd: 2114 A: prospective randomized controlled data to evaluate treatment outcomes and efficacy. A recent retrospective series suggests that, as in adult myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 1360 offsetEnd: 1475 A: inhibitor drugs are used in treatment of CMS. A seven-month old male patient was brought to our department with the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 2680 offsetEnd: 2843 A: quasi-randomised controlled trials regarding usage of acetylcholinesterase inhibitors in myasthenia gravis. Two authors scanned the articles for any study eligible
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 7160 offsetEnd: 7314 A: trials. MAIN RESULTS: We did not find any large randomised or quasi-randomised trials of acetylcholinesterase inhibitors in generalised myasthenia gravis.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 0 offsetEnd: 160 A: OPINION STATEMENT: Treatment of patients with acquired (autoimmune) myasthenia gravis should rely on evidence-based therapeutic choices, taking into account the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 609 offsetEnd: 758 A: concordance occurs in approximately one third of such identical twin pairs; and treatment for myasthenia gravis, when described,is usually concordant
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 901 offsetEnd: 1047 A: treatment for myasthenia gravis, when described,is usually concordant in identical twin pairs (2). OBJECTIVE: To report an 11-year clinical course
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 1828 offsetEnd: 1968 A: that the muscle weakness seen in these animals can be significantly alleviated by treatment with an acetylcholinesterase inhibitor. Based on
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 2964 offsetEnd: 3133 A: of the individuals. All five patients showed improved muscle strength and motor function, and/or reduced fatigability following acetylcholinesterase inhibitor treatment.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 3133 offsetEnd: 3308 A: showed improved muscle strength and motor function, and/or reduced fatigability following acetylcholinesterase inhibitor treatment. Together, our results suggest that deficits
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 3308 offsetEnd: 3480 A: function, and/or reduced fatigability following acetylcholinesterase inhibitor treatment. Together, our results suggest that deficits at the neuromuscular junction may play
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22634638 offsetBegin: 4283 offsetEnd: 4439 A: respiratory diaphragm muscles and external intercostal muscles. These observations show that C-547 can be considered for symptomatic treatment of myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22634638 offsetBegin: 4439 offsetEnd: 4589 A: muscles. These observations show that C-547 can be considered for symptomatic treatment of myasthenia gravis and other congenital myasthenic syndromes
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 1608 offsetEnd: 1765 A: XLMTM case) showed improved strength with acetylcholinesterase inhibitor treatment. We also studied neuromuscular junction structure and function in the MTM1
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 1765 offsetEnd: 1930 A: acetylcholinesterase inhibitor treatment. We also studied neuromuscular junction structure and function in the MTM1 knockdown zebrafish model of XLMTM, demonstrating
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 3665 offsetEnd: 3822 A: neurophysiology may still have MG. Treatment should be directed at ameliorating weakness with acetylcholinesterase blockers and modulating the immune system.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 427 offsetEnd: 558 A: is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 194 offsetEnd: 387 A: and pyridinium-isoquinolinium compounds were prepared as molecules potentially applicable in myasthenia gravis treatment. Their inhibitory ability towards human recombinant acetylcholinesterase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 165 offsetEnd: 318 A: promising therapeutic agents for the treatment of several neurological disorders such as Alzheimer's disease (AD), senile dementia, ataxia and myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 0 offsetEnd: 162 A: OBJECTIVE: To evaluate the incidence, clinical features, diagnostic, and treatment trends of pediatric myasthenia in Canada. METHODS: Through established Canadian
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 3660 offsetEnd: 3809 A: beneficial and sustained response to acetylcholinesterase inhibitor treatment. Most of the patients who had a muscle biopsy showed tubular aggregates
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 5109 offsetEnd: 5246 A: compared to placebo, no treatment or some other treatment; and (c) results reported separately for patients with ocular myasthenia (grade
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 119 offsetEnd: 230 A: myasthenia gravis (MG) who developed optic neuritis after the treatment of MG for 22 years. At 10 years of age,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 3485 offsetEnd: 3626 A: disappeared completely after the treatment with steroid pulse and plasma exchange. This case had 23 years of immunosuppressive treatment free
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 764 offsetEnd: 941 A: important differences regarding presentation and therapeutic options. We review the pathophysiology, clinical presentation, and treatment options for juvenile myasthenia gravis.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 941 offsetEnd: 1105 A: options. We review the pathophysiology, clinical presentation, and treatment options for juvenile myasthenia gravis. RECENT FINDINGS: Randomized clinical studies of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1260 offsetEnd: 1410 A: myasthenia gravis. RECENT FINDINGS: Randomized clinical studies of myasthenia gravis have been carried out primarily in adult populations. As juvenile
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1676 offsetEnd: 1817 A: As juvenile myasthenia gravis is rare, it has been difficult to collect prospective randomized controlled data to evaluate treatment outcomes
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 2114 offsetEnd: 2257 A: treatment outcomes and efficacy. A recent retrospective series suggests that, as in adult myasthenia gravis, thymectomy is a viable therapeutic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 764 offsetEnd: 950 A: have antibodies against muscle-specific kinase. Information on the clinical course, treatment alternatives, and prognosis of pediatric muscle-specific kinase antibody-positive myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 1216 offsetEnd: 1360 A: serum acetylcholine receptor antibodies. Acetylcholine esterase inhibitor drugs are used in treatment of CMS. A seven-month old male patient was
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 352 offsetEnd: 532 A: junction abolishes the naturally occurring 'safety factor' of synaptic transmission. Acetylcholinesterase inhibitors provide temporary symptomatic treatment of muscle weakness, but
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 532 offsetEnd: 704 A: factor' of synaptic transmission. Acetylcholinesterase inhibitors provide temporary symptomatic treatment of muscle weakness, but there is controversy about their long-term
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 1009 offsetEnd: 1158 A: their long-term efficacy, dosage and side effects. OBJECTIVES: To evaluate the efficacy of acetylcholinesterase inhibitors in all forms of myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 1306 offsetEnd: 1466 A: of acetylcholinesterase inhibitors in all forms of myasthenia gravis. SEARCH STRATEGY: We searched The Cochrane Neuromuscular Disease Group Specialized Register
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 3829 offsetEnd: 4002 A: quasi-randomised trials. TYPES OF PARTICIPANTS: all myasthenia gravis patients diagnosed by an internationally accepted definition.Types of interventions: treatment with any
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 7314 offsetEnd: 7484 A: find any large randomised or quasi-randomised trials of acetylcholinesterase inhibitors in generalised myasthenia gravis. One cross-over randomised trial using intranasal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 8292 offsetEnd: 8445 A: of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis. Response
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 1968 offsetEnd: 2115 A: these animals can be significantly alleviated by treatment with an acetylcholinesterase inhibitor. Based on these results, we reviewed the clinical
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 2115 offsetEnd: 2250 A: by treatment with an acetylcholinesterase inhibitor. Based on these results, we reviewed the clinical history of five patients with two
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 882 offsetEnd: 1023 A: as insecticide carbofuran, nerve agents, sarin, soman, tabun and VX. Beside toxins, drugs for treatment of Alzheimer's disease and myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 1023 offsetEnd: 1170 A: soman, tabun and VX. Beside toxins, drugs for treatment of Alzheimer's disease and myasthenia gravis, such as galantamine, donepezil, rivastigmine,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 1170 offsetEnd: 1337 A: drugs for treatment of Alzheimer's disease and myasthenia gravis, such as galantamine, donepezil, rivastigmine, tacrine, huperzine, pyridostigmine and neostigmine, are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23559196 offsetBegin: 1879 offsetEnd: 2054 A: had elevated acetylcholine receptor (AChR) antibodies, and 1 had thymoma. Treatment varied, but 4 patients required acetylcholinesterase inhibitors, multiple immunosuppressive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23559196 offsetBegin: 2054 offsetEnd: 2216 A: and 1 had thymoma. Treatment varied, but 4 patients required acetylcholinesterase inhibitors, multiple immunosuppressive drugs, and intravenous immune globulin or
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22634638 offsetBegin: 4722 offsetEnd: 4852 A: of myasthenia gravis and other congenital myasthenic syndromes as an inhibitor of AChE in leg muscles at concentrations much lower
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 760 offsetEnd: 914 A: 10 weeks previously. An acetylcholine receptor antibody titre was consistent with acquired myasthenia gravis. Withdrawal of methimazole and treatment with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 1255 offsetEnd: 1430 A: also showed electrophysiological features of a neuromuscular transmission defect. Three (including the XLMTM case) showed improved strength with acetylcholinesterase inhibitor
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 1430 offsetEnd: 1608 A: neuromuscular transmission defect. Three (including the XLMTM case) showed improved strength with acetylcholinesterase inhibitor treatment. We also studied neuromuscular junction
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 0 offsetEnd: 157 A: Myasthenia gravis (MG) is an antibody-mediated, neuromuscular transmission disorder, which ranges in clinical manifestations of ocular myasthenia that may be
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 3511 offsetEnd: 3665 A: who have negative antibodies and normal neurophysiology may still have MG. Treatment should be directed at ameliorating weakness with acetylcholinesterase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 558 offsetEnd: 689 A: in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 387 offsetEnd: 580 A: molecules potentially applicable in myasthenia gravis treatment. Their inhibitory ability towards human recombinant acetylcholinesterase and human plasmatic butyrylcholinesterase was determined
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 0 offsetEnd: 165 A: Acetylcholinesterase (AChE) inhibitors are considered as promising therapeutic agents for the treatment of several neurological disorders such as Alzheimer's disease
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 608 offsetEnd: 751 A: and myasthenia gravis. There are only few synthetic medicines with adverse effects, available for treatment of cognitive dysfunction and memory
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 271 offsetEnd: 399 A: the outcome of myasthenia gravis (MG) in children. MATERIAL AND METHOD: Children aged 16 years or less with diagnosed myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4016 offsetEnd: 4162 A: myasthenia gravis, adverse effects of medications commonly used in internal medicine, some of them inducing myasthenic syndromes. The treatment is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 162 offsetEnd: 337 A: features, diagnostic, and treatment trends of pediatric myasthenia in Canada. METHODS: Through established Canadian Pediatric Surveillance Program methodology, physicians were
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 3358 offsetEnd: 3519 A: of life with characteristic limb-girdle weakness and fatigue. A common feature was beneficial and sustained response to acetylcholinesterase inhibitor treatment.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 3519 offsetEnd: 3660 A: and fatigue. A common feature was beneficial and sustained response to acetylcholinesterase inhibitor treatment. Most of the patients who had
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 3244 offsetEnd: 3421 A: pyridostigmine, an acetylcholinesterase inhibitor, to ameliorate aspects of the behavioral phenotype related to NMJ dysfunction. Pyridostigmine treatment resulted in significant
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1155 offsetEnd: 1331 A: therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments. This review focuses on treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 4823 offsetEnd: 4969 A: three criteria: (a) randomized (or quasi-randomized) controlled study design; (b) active treatment compared to placebo, no treatment or some other
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 4969 offsetEnd: 5109 A: controlled study design; (b) active treatment compared to placebo, no treatment or some other treatment; and (c) results reported separately
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 5246 offsetEnd: 5378 A: some other treatment; and (c) results reported separately for patients with ocular myasthenia (grade 1) as defined by the Myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 5378 offsetEnd: 5518 A: reported separately for patients with ocular myasthenia (grade 1) as defined by the Myasthenia Gravis Foundation of America. DATA COLLECTION
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 298 offsetEnd: 446 A: disorder. The pathophysiology of juvenile myasthenia gravis is similar to that of adult myasthenia gravis, though there remain important differences
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1410 offsetEnd: 1538 A: studies of myasthenia gravis have been carried out primarily in adult populations. As juvenile myasthenia gravis is rare, it has
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 2399 offsetEnd: 2548 A: adult myasthenia gravis, thymectomy is a viable therapeutic option for selected cases of generalized juvenile myasthenia gravis. This is corroborated
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 950 offsetEnd: 1109 A: on the clinical course, treatment alternatives, and prognosis of pediatric muscle-specific kinase antibody-positive myasthenia gravis is limited because of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 1047 offsetEnd: 1216 A: findings, electromyography, genetic tests, determination of serum acetylcholine receptor antibodies. Acetylcholine esterase inhibitor drugs are used in treatment of CMS.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 2164 offsetEnd: 2300 A: he was diagnosed with congenital myasthenia and treatment was started. CMS should be suspected in patients with no pathological findings
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 0 offsetEnd: 120 A: This is the first report of a runner with myasthenia gravis who completed an ultra endurance event. Myasthenia gravis, a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 120 offsetEnd: 258 A: a runner with myasthenia gravis who completed an ultra endurance event. Myasthenia gravis, a neuromuscular disease that usually results in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 1158 offsetEnd: 1306 A: effects. OBJECTIVES: To evaluate the efficacy of acetylcholinesterase inhibitors in all forms of myasthenia gravis. SEARCH STRATEGY: We searched The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 2510 offsetEnd: 2680 A: 2009) for randomised controlled trials and quasi-randomised controlled trials regarding usage of acetylcholinesterase inhibitors in myasthenia gravis. Two authors scanned
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 2843 offsetEnd: 2989 A: acetylcholinesterase inhibitors in myasthenia gravis. Two authors scanned the articles for any study eligible for inclusion. We also contacted the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 7484 offsetEnd: 7637 A: trials of acetylcholinesterase inhibitors in generalised myasthenia gravis. One cross-over randomised trial using intranasal neostigmine in a total of 10
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24164490 offsetBegin: 1619 offsetEnd: 1775 A: a lymphocytic thymoma. Two weeks postremoval, the cat developed myasthenia gravis, which was controlled with prednisolone and pyridostigmine. The myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 758 offsetEnd: 901 A: of such identical twin pairs; and treatment for myasthenia gravis, when described,is usually concordant in identical twin pairs (2). OBJECTIVE:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 2969 offsetEnd: 3163 A: Alzheimer's disease (e.g. huperzine, metrifonate, tacrine, donepezil) and Myasthenia gravis (e.g. pyridostigmine) treatment and other compounds (propidium, ethidium, decamethonium). CONCLUSIONS:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 3163 offsetEnd: 3338 A: donepezil) and Myasthenia gravis (e.g. pyridostigmine) treatment and other compounds (propidium, ethidium, decamethonium). CONCLUSIONS: The crucial role of the cholinesterases
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 3415 offsetEnd: 3554 A: to be increasing. The risk of complications in corticosteroid treatment appears to depend on drug dosage, treatment duration, and patients'
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 3554 offsetEnd: 3709 A: complications in corticosteroid treatment appears to depend on drug dosage, treatment duration, and patients' characteristics, and the serious side effects
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 3505 offsetEnd: 3704 A: to spontaneously reactivate dimethoxy phosphorylated acetylcholinesterase and efficiently detoxify organophosphates may prevent severe inhibition of muscle acetylcholinesterase following acute severe
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 3666 offsetEnd: 3829 A: but 9 days of pyridostigmine treatment precipitated generalised muscle weakness. In contrast, one week of treatment with 3,4-diaminopyridine enhanced neuromuscular
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 0 offsetEnd: 143 A: Autoimmune myasthenia gravis (MG), affecting both ocular and generalized muscles, results in various symptoms. Ocular myasthenia (OM) is a form
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23909021 offsetBegin: 989 offsetEnd: 1114 A: transient myasthenia gravis are among the aetiologies. We report on a case of congenital myasthenia caused by mutation in the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 453 offsetEnd: 630 A: performed in nontumoral myasthenia gravis according to the Myasthenia Gravis Foundation of America recommendations. BACKGROUND DATA: Thoracoscopic unilateral extended thymectomy
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 5518 offsetEnd: 5655 A: myasthenia (grade 1) as defined by the Myasthenia Gravis Foundation of America. DATA COLLECTION AND ANALYSIS: We collected data regarding
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 154 offsetEnd: 298 A: is a relatively rare autoimmune neuromuscular disorder. The pathophysiology of juvenile myasthenia gravis is similar to that of adult myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3569 offsetEnd: 3710 A: all, adult research on myasthenia gravis is applicable to children and adolescents with juvenile myasthenia gravis. Adult research can inform
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 0 offsetEnd: 138 A: Autoimmune myasthenia gravis is rarely seen during infancy. Similar to adults, 85% to 90% of generalized pediatric myasthenia gravis cases
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22337799 offsetBegin: 792 offsetEnd: 941 A: for the treatment of Alzheimer's Disease and Myasthenia Gravis. In the open-tubular capillary electrochromatography (OT-CEC) mode, the PEM coating is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 2019 offsetEnd: 2164 A: difficulty. With clinical and laboratory findings, he was diagnosed with congenital myasthenia and treatment was started. CMS should be suspected
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1635 offsetEnd: 1785 A: of anti-muscle-specific kinase (MuSK) myasthenia gravis. Mice received 14 daily injections of IgG from patients with anti-MuSK myasthenia gravis. This
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 914 offsetEnd: 1066 A: antibody titre was consistent with acquired myasthenia gravis. Withdrawal of methimazole and treatment with pyridostigmine was followed by resolution of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23337001 offsetBegin: 160 offsetEnd: 318 A: autoimmune disorder. Its management is not standardized. Juvenile myasthenia gravis is pathophysiologically similar to myasthenia gravis in adults. However, a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23337001 offsetBegin: 318 offsetEnd: 482 A: standardized. Juvenile myasthenia gravis is pathophysiologically similar to myasthenia gravis in adults. However, a number of significant particularities related to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 151 offsetEnd: 281 A: used in the treatment of various diseases, such as Alzheimer's disease, glaucoma and Myasthenia gravis (MG). Compounds used in the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1470 offsetEnd: 1613 A: long-term disease-modifying treatments. This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine. Despite
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 283 offsetEnd: 453 A: of thoracoscopic unilateral extended thymectomy (TUET) performed in nontumoral myasthenia gravis according to the Myasthenia Gravis Foundation of America recommendations.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 1873 offsetEnd: 2019 A: falling of the eyelids and swallowing difficulty. With clinical and laboratory findings, he was diagnosed with congenital myasthenia and treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4179 offsetEnd: 4374 A: internationally accepted definition.Types of interventions: treatment with any form of acetylcholinesterase inhibitor.Types of outcome measuresPrimary outcome measureImprovement in the presenting
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 2791 offsetEnd: 2969 A: secondary metabolites (e.g. aflatoxins), drugs for Alzheimer's disease (e.g. huperzine, metrifonate, tacrine, donepezil) and Myasthenia gravis (e.g. pyridostigmine) treatment and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 1066 offsetEnd: 1210 A: myasthenia gravis. Withdrawal of methimazole and treatment with pyridostigmine was followed by resolution of clinical signs and reduction of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 3973 offsetEnd: 4143 A: with acetylcholinesterase blockers and modulating the immune system. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Most patients with generalised
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4162 offsetEnd: 4295 A: commonly used in internal medicine, some of them inducing myasthenic syndromes. The treatment is well codified: the treatment is well
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 0 offsetEnd: 154 A: PURPOSE OF REVIEW: Juvenile myasthenia gravis is a relatively rare autoimmune neuromuscular disorder. The pathophysiology of juvenile myasthenia gravis is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4426 offsetEnd: 4583 A: treatment is well codified: the treatment is well codified: (1) respect of adverse drugs contra-indications, systematically use of cholinesterase inhibitors,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1613 offsetEnd: 1721 A: on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine. Despite a lack of data from well
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24164490 offsetBegin: 1775 offsetEnd: 1924 A: the cat developed myasthenia gravis, which was controlled with prednisolone and pyridostigmine. The myasthenia gravis resolved, but the cat developed
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4295 offsetEnd: 4426 A: of them inducing myasthenic syndromes. The treatment is well codified: the treatment is well codified: (1) respect of adverse drugs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23337001 offsetBegin: 0 offsetEnd: 160 A: Juvenile myasthenia gravis is an uncommon autoimmune disorder. Its management is not standardized. Juvenile myasthenia gravis is pathophysiologically similar to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 3344 offsetEnd: 3485 A: Furthermore blephalopstosis caused by MG has disappeared completely after the treatment with steroid pulse and plasma exchange. This case had
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 3626 offsetEnd: 3762 A: steroid pulse and plasma exchange. This case had 23 years of immunosuppressive treatment free durations with stable condition. The cause
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22713949 offsetBegin: 268 offsetEnd: 410 A: release matrix formulation of pyridostigmine bromide, an effective drug in myasthenia gravis and poisoning with nerve gas, using hydrophilic -
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22713949 offsetBegin: 410 offsetEnd: 554 A: an effective drug in myasthenia gravis and poisoning with nerve gas, using hydrophilic - hydrophobic polymers via D-optimal experimental design.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 446 offsetEnd: 592 A: gravis is similar to that of adult myasthenia gravis, though there remain important differences regarding presentation and therapeutic options. We
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1538 offsetEnd: 1676 A: carried out primarily in adult populations. As juvenile myasthenia gravis is rare, it has been difficult to collect prospective randomized
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 2257 offsetEnd: 2399 A: retrospective series suggests that, as in adult myasthenia gravis, thymectomy is a viable therapeutic option for selected cases of generalized
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3181 offsetEnd: 3308 A: affected by juvenile myasthenia gravis over a number of years. SUMMARY: Recent studies illustrate that some, but not all, adult
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3308 offsetEnd: 3435 A: a number of years. SUMMARY: Recent studies illustrate that some, but not all, adult research on myasthenia gravis is applicable
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3435 offsetEnd: 3569 A: studies illustrate that some, but not all, adult research on myasthenia gravis is applicable to children and adolescents with juvenile
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3710 offsetEnd: 3847 A: is applicable to children and adolescents with juvenile myasthenia gravis. Adult research can inform pediatric studies, but should not be
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3847 offsetEnd: 3981 A: with juvenile myasthenia gravis. Adult research can inform pediatric studies, but should not be regarded as a substitute for dedicated
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 975 offsetEnd: 1110 A: balance, and whether such changes can be corrected. We studied the influence of AChR loss, caused by experimental autoimmune myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 1110 offsetEnd: 1241 A: be corrected. We studied the influence of AChR loss, caused by experimental autoimmune myasthenia gravis (EAMG), on muscle AChE, as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21732154 offsetBegin: 1303 offsetEnd: 1436 A: now remained in good condition for over 1 year. Although dysphagia is a typical symptom of myasthenia gravis, swallowing disturbances
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21732154 offsetBegin: 1436 offsetEnd: 1570 A: over 1 year. Although dysphagia is a typical symptom of myasthenia gravis, swallowing disturbances should not be attributed hastily to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21732154 offsetBegin: 1570 offsetEnd: 1703 A: a typical symptom of myasthenia gravis, swallowing disturbances should not be attributed hastily to this disease, since they may also
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 1531 offsetEnd: 1676 A: Here, we present a 14-month-old girl with muscle-specific kinase antibody-positive myasthenia gravis as one of the youngest patients described so
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23404334 offsetBegin: 5566 offsetEnd: 5718 A: or impaired neuromuscular transmission as part of a more severe multisystem disorder. Our findings suggest that treatment with cholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23404334 offsetBegin: 5718 offsetEnd: 5859 A: of a more severe multisystem disorder. Our findings suggest that treatment with cholinesterase inhibitors may improve muscle function in many
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 0 offsetEnd: 182 A: Antibodies against acetylcholine receptors (AChRs) cause pathogenicity in myasthenia gravis (MG) patients through complement pathway-mediated destruction of postsynaptic membranes at
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 182 offsetEnd: 367 A: pathogenicity in myasthenia gravis (MG) patients through complement pathway-mediated destruction of postsynaptic membranes at neuromuscular junctions (NMJs). However, antibodies against
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 2716 offsetEnd: 2900 A: complement activation is not necessary for the onset of MuSK-MG. Furthermore, MuSK-injected mice exhibited acetylcholinesterase (AChE) inhibitor-evoked cholinergic hypersensitivity, as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 2900 offsetEnd: 3078 A: the onset of MuSK-MG. Furthermore, MuSK-injected mice exhibited acetylcholinesterase (AChE) inhibitor-evoked cholinergic hypersensitivity, as is observed in MuSK-MG patients, and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 4142 offsetEnd: 4271 A: activity by autoantibodies causes MG. This mouse model of EAMG could be used to develop appropriate medications for the treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24145588 offsetBegin: 2049 offsetEnd: 2200 A: our article, we elaborate on key aspects of the epidemiology, pathogenesis, diagnostic evaluation, and therapeutic options for patients with myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 0 offsetEnd: 142 A: About 10% of patients with generalized myasthenia gravis do not have detectable antibodies to acetylcholine receptor or muscle specific kinase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 142 offsetEnd: 295 A: myasthenia gravis do not have detectable antibodies to acetylcholine receptor or muscle specific kinase (double seronegative myasthenia). The presence of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21864038 offsetBegin: 0 offsetEnd: 148 A: Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies to acetylcholine receptors (AChRs) or muscle specific tyrosine kinase (MuSK).
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 258 offsetEnd: 405 A: completed an ultra endurance event. Myasthenia gravis, a neuromuscular disease that usually results in skeletal muscle weakness, which worsens with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 704 offsetEnd: 857 A: provide temporary symptomatic treatment of muscle weakness, but there is controversy about their long-term efficacy, dosage and side effects. OBJECTIVES:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 857 offsetEnd: 1009 A: weakness, but there is controversy about their long-term efficacy, dosage and side effects. OBJECTIVES: To evaluate the efficacy of acetylcholinesterase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5356 offsetEnd: 5487 A: in impairment measured by a recognised and preferably validated scale, such as the quantitative myasthenia gravis score within 1 to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 7637 offsetEnd: 7767 A: myasthenia gravis. One cross-over randomised trial using intranasal neostigmine in a total of 10 subjects was only available as an
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 8918 offsetEnd: 9050 A: observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23794683 offsetBegin: 0 offsetEnd: 167 A: OBJECTIVE: To identify patients with GFPT1-related limb-girdle myasthenia and analyze phenotypic consequences of the mutations. METHODS: We performed genetic analysis,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 160 offsetEnd: 323 A: acquired (autoimmune) myasthenia gravis should rely on evidence-based therapeutic choices, taking into account the individual's needs according to disease severity
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 1845 offsetEnd: 2039 A: symptoms by improving neuromuscular junction transmission (cholinesterase inhibitors) and/or modifying the underlying immunopathogenetic cause of acquired myasthenia gravis via immunosuppression
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 2039 offsetEnd: 2230 A: (cholinesterase inhibitors) and/or modifying the underlying immunopathogenetic cause of acquired myasthenia gravis via immunosuppression or immunomodulation. Myasthenic patients with operable
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 2230 offsetEnd: 2400 A: immunopathogenetic cause of acquired myasthenia gravis via immunosuppression or immunomodulation. Myasthenic patients with operable thymoma should be referred for surgery
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23013366 offsetBegin: 771 offsetEnd: 949 A: cholinesterase activity. These compounds can be used for pharmacological management of various disorders (e.g., Alzheimer's disease, myasthenia Gravis). Moreover, organophosphate
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23013366 offsetBegin: 949 offsetEnd: 1119 A: used for pharmacological management of various disorders (e.g., Alzheimer's disease, myasthenia Gravis). Moreover, organophosphate poisoning is frequently diagnosed via a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23013366 offsetBegin: 1119 offsetEnd: 1292 A: disorders (e.g., Alzheimer's disease, myasthenia Gravis). Moreover, organophosphate poisoning is frequently diagnosed via a cholinesterase activity assay. This broad variety
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 150 offsetEnd: 288 A: myasthenia gravis (MG) cases seem different between Oriental and Caucasian populations, but there have rarely been any clinical studies on
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 1478 offsetEnd: 1648 A: identical twins concordant for generalized acetylcholine receptor antibody–positive nonthymomatous myasthenia gravis in whom only 1 was treated with extended transsternal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 1690 offsetEnd: 1828 A: severe motor phenotype. We further demonstrate that the muscle weakness seen in these animals can be significantly alleviated by treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 625 offsetEnd: 792 A: acetylcholinesterase (AChE), AChE plays the key role in ending cholinergic neurotransmission. Cholinesterase inhibitors are substances, either natural or man-made that
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23117946 offsetBegin: 2021 offsetEnd: 2180 A: A subset of patients with generalized disease have antibodies to muscle-specific receptor tyrosine kinase (MuSK). Acetylcholinesterase inhibitors are often the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23117946 offsetBegin: 2180 offsetEnd: 2335 A: disease have antibodies to muscle-specific receptor tyrosine kinase (MuSK). Acetylcholinesterase inhibitors are often the first modality of therapy for MG.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23117946 offsetBegin: 2335 offsetEnd: 2477 A: tyrosine kinase (MuSK). Acetylcholinesterase inhibitors are often the first modality of therapy for MG. As an immune-mediated disorder, MG can
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 4130 offsetEnd: 4270 A: late- and elderly- onset MG. Although nonspecific, current immunosuppressive treatment is highly effective in most MG patients, the need for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 4270 offsetEnd: 4422 A: nonspecific, current immunosuppressive treatment is highly effective in most MG patients, the need for prolonged administration and unwanted effects are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 2616 offsetEnd: 2747 A: type II atrophy) seen on biopsy; seronegative autoimmune myasthenia gravis, when CMS is of late onset; and metabolic myopathy, with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 161 offsetEnd: 336 A: common medical emergency with high fatality in agricultural communities of Asia. Organophosphate compounds inhibit acetylcholinesterase and prolonged neuromuscular weakness is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 3326 offsetEnd: 3505 A: no treatment. The ability of rats to spontaneously reactivate dimethoxy phosphorylated acetylcholinesterase and efficiently detoxify organophosphates may prevent severe inhibition
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 159 offsetEnd: 317 A: is impaired by the antibody-mediated loss of postsynaptic acetylcholine receptors (AChRs). Muscle weakness can be improved upon treatment with pyridostigmine,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1785 offsetEnd: 1927 A: Mice received 14 daily injections of IgG from patients with anti-MuSK myasthenia gravis. This caused reductions in postsynaptic AChR densities
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 3517 offsetEnd: 3666 A: autoantibodies did not display overt weakness, but 9 days of pyridostigmine treatment precipitated generalised muscle weakness. In contrast, one week
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 4806 offsetEnd: 4962 A: in endplate ACh receptor density. These results thus suggest that ongoing pyridostigmine treatment potentiates anti-MuSK-induced AChR loss by prolonging the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23559196 offsetBegin: 266 offsetEnd: 400 A: unclear if West Nile virus (WNV) initiates autoimmunity. METHODS: We describe 6 cases of myasthenia gravis (MG) that developed several
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23559196 offsetBegin: 400 offsetEnd: 542 A: initiates autoimmunity. METHODS: We describe 6 cases of myasthenia gravis (MG) that developed several months after WNV infection. All patients
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23559196 offsetBegin: 2216 offsetEnd: 2394 A: but 4 patients required acetylcholinesterase inhibitors, multiple immunosuppressive drugs, and intravenous immune globulin or plasmapheresis for recurrent MG crises. CONCLUSIONS:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 322 offsetEnd: 509 A: nurse practitioner (NP) student in the emergency department (ED). Characteristics, epidemiology, pathophysiology, diagnostic considerations, and appropriate testing options for myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 509 offsetEnd: 697 A: emergency department (ED). Characteristics, epidemiology, pathophysiology, diagnostic considerations, and appropriate testing options for myasthenia gravis (MG) are included. DATA SOURCES:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 697 offsetEnd: 859 A: diagnostic considerations, and appropriate testing options for myasthenia gravis (MG) are included. DATA SOURCES: Findings from the history, physical examination,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 859 offsetEnd: 1002 A: for myasthenia gravis (MG) are included. DATA SOURCES: Findings from the history, physical examination, and diagnostic testing of a 41-year-old
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 2322 offsetEnd: 2457 A: Multiple patient encounters with the healthcare system often occur prior to diagnosis. Many viable treatment options now exist that can
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 2457 offsetEnd: 2580 A: system often occur prior to diagnosis. Many viable treatment options now exist that can enhance quality of life and improve
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 2580 offsetEnd: 2708 A: Many viable treatment options now exist that can enhance quality of life and improve function. IMPLICATIONS FOR PRACTICE: The NP
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22634638 offsetBegin: 4852 offsetEnd: 4982 A: myasthenic syndromes as an inhibitor of AChE in leg muscles at concentrations much lower than those inhibiting muscle and ganglion
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 2743 offsetEnd: 2912 A: MG, treated with pyridostigmine and corticosteroids and/or intravenous immunoglobulins. In all 3 patients, β(2)-adrenergic agonist treatment allowed only partial control
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 3066 offsetEnd: 3227 A: patients, β(2)-adrenergic agonist treatment allowed only partial control of dyspnea. In one case, respiratory symptoms were alleviated when pyridostigmine dosage
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 3620 offsetEnd: 3745 A: A treatment strategy, discriminated by ptosis or diplopia, is necessary to improve the ocular symptoms and QOL in OM patients
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23460475 offsetBegin: 2765 offsetEnd: 2913 A: weeks of a single-dose treatment with crotamine. CONCLUSIONS: These results indicate that crotamine is more efficient than neostigmine for enhancing
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 268 offsetEnd: 402 A: autoimmune myasthenia gravis (all Chinese Han from Guangdong Province) referred to our department. Their mean onset age was 13.4 years
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 1230 offsetEnd: 1399 A: patients (range 1.62-19.8 nmol/L). Thymectomy was performed in six patients, who received corticosteroids /immune inhibitor plus pyridostigmine treatments after surgery.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 1399 offsetEnd: 1552 A: performed in six patients, who received corticosteroids /immune inhibitor plus pyridostigmine treatments after surgery. The other patients were placed on
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 3437 offsetEnd: 3589 A: (12/15). When compared to familial autoimmune myasthenia gravis in other countries, we observed peculiar characteristics of Chinese populations, such as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 3589 offsetEnd: 3740 A: myasthenia gravis in other countries, we observed peculiar characteristics of Chinese populations, such as the within-family consistency was only found
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 604 offsetEnd: 760 A: for hyper-thyroidism, which had been diagnosed 10 weeks previously. An acetylcholine receptor antibody titre was consistent with acquired myasthenia gravis.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 2002 offsetEnd: 2147 A: with pyridostigmine, and no recurrence of clinical signs was observed. Myasthenia gravis is an uncommon but clinically significant adverse effect
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 2147 offsetEnd: 2286 A: clinical signs was observed. Myasthenia gravis is an uncommon but clinically significant adverse effect of methimazole therapy in cats, and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 2670 offsetEnd: 2819 A: immunomodulatory properties of this drug. An adverse drug reaction should be considered in cats receiving methimazole that develop myasthenia gravis,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 3074 offsetEnd: 3198 A: biopsy should be considered in infants suspected to have CMS, especially if treatment response is incomplete, or no CMS gene
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23670841 offsetBegin: 0 offsetEnd: 161 A: Ocular myasthenia gravis, although clinically often characterized by typical classical features, can cause considerable diagnostic problems. This article aims to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 434 offsetEnd: 579 A: the underlying mechanism is still unknown. CASE REPORT: In 2007, a 50-year-old woman with generalized, limb predominated, myasthenia gravis (MG),
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 579 offsetEnd: 715 A: CASE REPORT: In 2007, a 50-year-old woman with generalized, limb predominated, myasthenia gravis (MG), whose MG status has been "minimal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 715 offsetEnd: 870 A: woman with generalized, limb predominated, myasthenia gravis (MG), whose MG status has been "minimal manifestation" for several years, developed moderately
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 157 offsetEnd: 311 A: neuromuscular transmission disorder, which ranges in clinical manifestations of ocular myasthenia that may be visually disabling to myasthenic crisis with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 311 offsetEnd: 478 A: clinical manifestations of ocular myasthenia that may be visually disabling to myasthenic crisis with patients suffering life-threatening respiratory insufficiency. MG
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 1835 offsetEnd: 1959 A: MG has been reduced over the last century, but adverse effects of treatment compromise patient care and rigorous evidence to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 286 offsetEnd: 427 A: Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 1331 offsetEnd: 1476 A: developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23909021 offsetBegin: 543 offsetEnd: 702 A: which might lead to diagnostic difficulties. Disorders of the neuromuscular junction, such as congenital myasthenic syndromes and neonatal transient myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 0 offsetEnd: 194 A: Two series of non-symmetrical bisquaternary pyridinium-quinolinium and pyridinium-isoquinolinium compounds were prepared as molecules potentially applicable in myasthenia gravis treatment. Their
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 1717 offsetEnd: 1952 A: 1-(10-(pyridinium-1-yl)decyl)quinolinium dibromide and 1-(12-(pyridinium-1-yl)dodecyl)quinolinium dibromide, showed very promising affinity for acetylcholinesterase with their IC50 values reaching nM inhibition of acetylcholinesterase.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 1952 offsetEnd: 2111 A: very promising affinity for acetylcholinesterase with their IC50 values reaching nM inhibition of acetylcholinesterase. These most active compounds also showed
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 2111 offsetEnd: 2279 A: their IC50 values reaching nM inhibition of acetylcholinesterase. These most active compounds also showed satisfactory selectivity towards acetylcholinesterase and they
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 2279 offsetEnd: 2435 A: of acetylcholinesterase. These most active compounds also showed satisfactory selectivity towards acetylcholinesterase and they seem to be very promising as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22689834 offsetBegin: 142 offsetEnd: 271 A: presenting symptoms of patients with myasthenia gravis (MG), most common being ptosis. However, ptosis may be caused by a variety
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 3644 offsetEnd: 3780 A: to the target tissue. MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune MG. As AChR deficiency is typically
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23279780 offsetBegin: 0 offsetEnd: 148 A: BACKGROUND AND PURPOSE: Several small retrospective studies have observed that patients with a purely ocular manifestation of myasthenia gravis (MG)
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23279780 offsetBegin: 148 offsetEnd: 285 A: studies have observed that patients with a purely ocular manifestation of myasthenia gravis (MG) are significantly less likely to convert
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22183934 offsetBegin: 0 offsetEnd: 169 A: BACKGROUND: Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22183934 offsetBegin: 169 offsetEnd: 328 A: and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported in only few patients, mostly non-Caucasians.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 0 offsetEnd: 157 A: This paper describes the preparation and in vitro evaluation of 18 newly prepared bis-quinolinium inhibitors on human recombinant acetylcholinesterase (AChE)
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 1007 offsetEnd: 1152 A: dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride. One novel compound was found to be a promising inhibitor of hAChE (in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 318 offsetEnd: 461 A: of several neurological disorders such as Alzheimer's disease (AD), senile dementia, ataxia and myasthenia gravis. There are only few synthetic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 461 offsetEnd: 608 A: Alzheimer's disease (AD), senile dementia, ataxia and myasthenia gravis. There are only few synthetic medicines with adverse effects, available for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1395 offsetEnd: 1530 A: activity and so may be relevant to the treatment of neurodegenerative disorders such as AD. Hence, developing potential AChE inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 320 offsetEnd: 485 A: a cholinergic crisis after neostigmine administration. CASE SUMMARY: An 18-month-old neutered male Maltese-crossbred dog was diagnosed with acquired focal myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 485 offsetEnd: 632 A: CASE SUMMARY: An 18-month-old neutered male Maltese-crossbred dog was diagnosed with acquired focal myasthenia gravis based on history and clinical
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 3377 offsetEnd: 3538 A: subsequently achieved a clinical and serologic remission from myasthenia gravis without further treatment. NEW OR UNIQUE INFORMATION PROVIDED: Cholinergic crisis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 1504 offsetEnd: 1651 A: DNA sequence analysis disclosed 2 novel missense mutations (p.E256Q and p.M499T) in GFPT1. Treatment with oral cholinesterase inhibitors produced a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 399 offsetEnd: 523 A: in children. MATERIAL AND METHOD: Children aged 16 years or less with diagnosed myasthenia gravis (MG) seen at Queen Sirikit
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 523 offsetEnd: 644 A: aged 16 years or less with diagnosed myasthenia gravis (MG) seen at Queen Sirikit National Institute of Child Health over
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 0 offsetEnd: 152 A: Myasthenia gravis is an autoimmune disease due to specific antibodies inducing a neuromuscular transmission defect causing muscle fatigability. If onset
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 286 offsetEnd: 425 A: neuromuscular transmission defect causing muscle fatigability. If onset of the disease may be at any age, myasthenia gravis concerns mostly
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 3532 offsetEnd: 3698 A: internist have been highlighted in this article: diagnostic traps, associated autoimmune diseases, including inflammatory myopathies that may mimic myasthenia gravis,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 3698 offsetEnd: 3869 A: article: diagnostic traps, associated autoimmune diseases, including inflammatory myopathies that may mimic myasthenia gravis, adverse effects of medications commonly used
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 1814 offsetEnd: 1950 A: treatment with cholinesterase inhibitors, and the presence of tubular aggregates on muscle biopsy. We showed that DPAGT1 is required for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 857 offsetEnd: 1007 A: of pediatric myasthenia using a standardized clinical questionnaire containing deidentified data. Inclusion criteria were any child <18 years old with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 1534 offsetEnd: 1683 A: (2) skeletal muscle weakness or fatigue, and (3) any of the following supportive tests: clinical response to acetylcholinesterase inhibitor, positive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 1683 offsetEnd: 1847 A: and (3) any of the following supportive tests: clinical response to acetylcholinesterase inhibitor, positive antibodies, abnormal slow repetitive nerve stimulation,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 1847 offsetEnd: 2030 A: supportive tests: clinical response to acetylcholinesterase inhibitor, positive antibodies, abnormal slow repetitive nerve stimulation, or single-fiber electromyography. RESULTS: In 2
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 2602 offsetEnd: 2736 A: 34 generalized and 18 ocular reports of juvenile myasthenia gravis plus 5 congenital myasthenic syndrome cases. There were 14 incident
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 4365 offsetEnd: 4510 A: 17 ocular cases. CONCLUSIONS: This study represents the largest descriptive series of pediatric myasthenia in North America and provides valuable
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 4510 offsetEnd: 4665 A: represents the largest descriptive series of pediatric myasthenia in North America and provides valuable information about clinical characteristics. A high
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 4665 offsetEnd: 4811 A: pediatric myasthenia in North America and provides valuable information about clinical characteristics. A high index of suspicion is important for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 311 offsetEnd: 474 A: syndrome (LEMS), the mainstay of symptomatic treatment in LEMS is 3,4-diaminopyridine (3,4-DAP). Data from four randomized, placebo-controlled trials have revealed
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 474 offsetEnd: 644 A: treatment in LEMS is 3,4-diaminopyridine (3,4-DAP). Data from four randomized, placebo-controlled trials have revealed that muscle strength scores increased significantly
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 1545 offsetEnd: 1703 A: modest. Meta-analysis of the mean change in compound muscle action potential amplitude following 3,4-DAP treatment revealed a significant improvement compared
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 1703 offsetEnd: 1860 A: in compound muscle action potential amplitude following 3,4-DAP treatment revealed a significant improvement compared to placebo. However, most patients with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 1860 offsetEnd: 2031 A: following 3,4-DAP treatment revealed a significant improvement compared to placebo. However, most patients with noncancer LEMS require long-term immunosuppression, usually
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23341732 offsetBegin: 0 offsetEnd: 166 A: Autoimmune myasthenia gravis (MG) is a neuromuscular disorder caused by autoantibodies directed against the acetylcholine receptor (AChR). Current symptomatic therapy
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23341732 offsetBegin: 166 offsetEnd: 340 A: neuromuscular disorder caused by autoantibodies directed against the acetylcholine receptor (AChR). Current symptomatic therapy is based on acetylcholinesterase (AChE) drugs.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 281 offsetEnd: 410 A: diseases, such as Alzheimer's disease, glaucoma and Myasthenia gravis (MG). Compounds used in the therapy of MG posses a positive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 0 offsetEnd: 152 A: Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 795 offsetEnd: 969 A: are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 1382 offsetEnd: 1527 A: long-term results were lacking. METHODS: Two hundred forty patients with nontumoral myasthenia gravis who underwent surgery between 1999 and 2009
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 5298 offsetEnd: 5432 A: morbidity, and comparable long-term results to open surgery, TUET can be regarded as the best treatment option for patients undergoing
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 804 offsetEnd: 942 A: with three interdaily ip injections of streptozotocin (STZ). Mice were severely hyperglycemic within 7 days after the STZ treatment began.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 2898 offsetEnd: 3057 A: acetylcholine esterase (AChE). Greater sensitivity of mEPC decay time to the selective butyrylcholinesterase (BChE) inhibitor PEC suggests that muscle attempts
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 3200 offsetEnd: 3350 A: butyrylcholinesterase (BChE) inhibitor PEC suggests that muscle attempts to compensate for reduced AChE levels by increasing expression of BChE. These
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22973658 offsetBegin: 0 offsetEnd: 157 A: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of neuromuscular transmission (NMJ) that shares many clinical features with myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22973658 offsetBegin: 157 offsetEnd: 296 A: rare autoimmune disorder of neuromuscular transmission (NMJ) that shares many clinical features with myasthenia gravis (MG). We report a 73
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22973658 offsetBegin: 296 offsetEnd: 417 A: (NMJ) that shares many clinical features with myasthenia gravis (MG). We report a 73 year-old lady who presented 10 years
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 8503 offsetEnd: 8657 A: form of treatment for ocular myasthenia. Data from several reasonably good quality observational studies suggest that corticosteroids and azathioprine may
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 462 offsetEnd: 614 A: been documented previously. OBJECTIVE: To describe the clinical characteristics and outcome of children with myasthenia gravis at two tertiary hospitals
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 3897 offsetEnd: 4032 A: treatment free durations with stable condition. The cause of development of optic neuritis would be her predisposed tendency other than
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22713949 offsetBegin: 127 offsetEnd: 268 A: to design and optimize a prolonged release matrix formulation of pyridostigmine bromide, an effective drug in myasthenia gravis and poisoning
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 592 offsetEnd: 764 A: adult myasthenia gravis, though there remain important differences regarding presentation and therapeutic options. We review the pathophysiology, clinical presentation, and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 1817 offsetEnd: 1963 A: it has been difficult to collect prospective randomized controlled data to evaluate treatment outcomes and efficacy. A recent retrospective series
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 0 offsetEnd: 173 A: Cholinesterase enzyme family consisting of acetylcholinesterase (AChE) and butrylcholinesterase (BChE) is important in pathogenesis of Alzheimer's disease (AD), explained by
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 1092 offsetEnd: 1248 A: Consequently, cholinesterase inhibition has become one of the most-prescribed treatment strategies for AD. In fact, cholinesterase inhibitors have been also
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 1390 offsetEnd: 1539 A: AD. In fact, cholinesterase inhibitors have been also reported for their effectiveness in some other diseases including glaucoma, myasthenia gravies,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 1539 offsetEnd: 1678 A: been also reported for their effectiveness in some other diseases including glaucoma, myasthenia gravies, as well as Down syndrome, lately.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 134 offsetEnd: 269 A: costs of managing rare diseases, and comprehensive healthcare costs have not been reported for myasthenia gravis (MG). We evaluated the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 416 offsetEnd: 557 A: reported for myasthenia gravis (MG). We evaluated the direct costs and healthcare resource utilization in insured MG patients. METHODS: Costs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 2608 offsetEnd: 2766 A: cholinesterase inhibitors, and corticosteroids accounted for 9.3%, 5.7%, and 0.2% of pharmacy costs, respectively. CONCLUSIONS: Costs related to the treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 2766 offsetEnd: 2891 A: 9.3%, 5.7%, and 0.2% of pharmacy costs, respectively. CONCLUSIONS: Costs related to the treatment of MG are higher than those
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 2891 offsetEnd: 3028 A: costs, respectively. CONCLUSIONS: Costs related to the treatment of MG are higher than those of many other chronic neurological diseases.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 0 offsetEnd: 169 A: Controlled regulation of synaptic nicotinic acetylcholine receptors (AChRs) and acetylcholinesterase (AChE), together with maintenance of a dynamic balance between them,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 169 offsetEnd: 317 A: receptors (AChRs) and acetylcholinesterase (AChE), together with maintenance of a dynamic balance between them, is a requirement for proper function
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21732154 offsetBegin: 0 offsetEnd: 153 A: An 85-year-old man with myasthenia gravis was successfully treated with methotrexate (10 mg/week), pyridostigmine and prednisolone (0-30 mg/day) for over
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 138 offsetEnd: 290 A: during infancy. Similar to adults, 85% to 90% of generalized pediatric myasthenia gravis cases have acetylcholine receptor antibodies. Approximately 30%
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 602 offsetEnd: 764 A: Approximately 30% of the remaining cases have antibodies against muscle-specific kinase. Information on the clinical course, treatment alternatives, and prognosis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 1252 offsetEnd: 1394 A: antibody-positive myasthenia gravis is limited because of the small number of cases. Here, we present a 14-month-old girl with muscle-specific
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 1394 offsetEnd: 1531 A: of the small number of cases. Here, we present a 14-month-old girl with muscle-specific kinase antibody-positive myasthenia gravis as one
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 2300 offsetEnd: 2432 A: and treatment was started. CMS should be suspected in patients with no pathological findings on the physical examination, and normal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 128 offsetEnd: 268 A: Robert Lisak has made important contributions to our understanding of the pathophysiology and therapy of myasthenia gravis. This review will
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 1400 offsetEnd: 1537 A: that we acknowledge as myasthenia gravis coincides with the introduction of monoclonal antibodies and other new therapies that can target
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 8765 offsetEnd: 8918 A: gravis. Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 1624 offsetEnd: 1805 A: Lipid peroxidation (LPO), superoxide dismutase (SOD), catalase, glutathione peroxidase, DNA damage, total antioxidant capacity (TAC), total thiol molecules, and acetylcholinesterase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 1805 offsetEnd: 1969 A: catalase, glutathione peroxidase, DNA damage, total antioxidant capacity (TAC), total thiol molecules, and acetylcholinesterase (AChE) activity were measured in the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 1969 offsetEnd: 2125 A: antioxidant capacity (TAC), total thiol molecules, and acetylcholinesterase (AChE) activity were measured in the blood of subjects. Clinical examination and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 2831 offsetEnd: 2991 A: for tumor recurrence. A concerted international effort is addressing treatment recommendations for thymectomy in myasthenic patients with no radiologic evidence
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 2991 offsetEnd: 3135 A: effort is addressing treatment recommendations for thymectomy in myasthenic patients with no radiologic evidence of thymoma who are positive for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 3284 offsetEnd: 3437 A: radiologic evidence of thymoma who are positive for circulating acetylcholine receptor antibodies. There is a lack of evidence-based treatment guidelines
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 3437 offsetEnd: 3591 A: positive for circulating acetylcholine receptor antibodies. There is a lack of evidence-based treatment guidelines for both acute and long-term management
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24164490 offsetBegin: 1482 offsetEnd: 1619 A: with a thoracic mass diagnosed as a lymphocytic thymoma. Two weeks postremoval, the cat developed myasthenia gravis, which was controlled
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 148 offsetEnd: 301 A: effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 301 offsetEnd: 437 A: of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 437 offsetEnd: 583 A: previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 0 offsetEnd: 150 A: Clinical classification and age distribution in myasthenia gravis (MG) cases seem different between Oriental and Caucasian populations, but there have
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 888 offsetEnd: 1031 A: survey of myasthenia gravis in a hospital in China, establishing contemporary cohort data and clinical features. 1,108 unselected patients with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 173 offsetEnd: 323 A: gravis despite the absence of randomized clinical trials (1). Myasthenia gravis is uncommonly reported in monozygous twins; disease concordance occurs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 323 offsetEnd: 467 A: clinical trials (1). Myasthenia gravis is uncommonly reported in monozygous twins; disease concordance occurs in approximately one third of such
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 467 offsetEnd: 609 A: uncommonly reported in monozygous twins; disease concordance occurs in approximately one third of such identical twin pairs; and treatment for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 1320 offsetEnd: 1478 A: clinical course of a pair of identical twins concordant for generalized acetylcholine receptor antibody–positive nonthymomatous myasthenia gravis in whom only
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 1648 offsetEnd: 1797 A: receptor antibody–positive nonthymomatous myasthenia gravis in whom only 1 was treated with extended transsternal thymectomy. CASE REPORT: Twin A was
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 3480 offsetEnd: 3621 A: inhibitor treatment. Together, our results suggest that deficits at the neuromuscular junction may play an important role in the pathogenesis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 458 offsetEnd: 625 A: Of the two types, butyrylcholinesterase and acetylcholinesterase (AChE), AChE plays the key role in ending cholinergic neurotransmission. Cholinesterase inhibitors are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 3338 offsetEnd: 3494 A: treatment and other compounds (propidium, ethidium, decamethonium). CONCLUSIONS: The crucial role of the cholinesterases in neural transmission makes them a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23242891 offsetBegin: 0 offsetEnd: 123 A: QUESTION: One of my patients who has been diagnosed with myasthenia gravis (MG) is planning pregnancy. Her MG is controlled
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 0 offsetEnd: 169 A: Patients with myasthenia gravis (MG) are divided into 3 groups: anti-acetylcholine receptor antibody-positive MG (AChR MG), anti-muscle specific kinase antibody-positive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 4910 offsetEnd: 5065 A: chloride injection may support the clinical diagnosis of MuSK-MG. Further, only small doses of acetylcholinesterase inhibitors are administered to patients
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 6599 offsetEnd: 6747 A: or adult MG in morbidity, sex distribution, progress, laboratory examination and treatment. The prevalence of myasthenia gravis crisis and mortality
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 6747 offsetEnd: 6893 A: distribution, progress, laboratory examination and treatment. The prevalence of myasthenia gravis crisis and mortality rate in MG children is low,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 6893 offsetEnd: 7015 A: The prevalence of myasthenia gravis crisis and mortality rate in MG children is low, and few are accompanied with thymoma.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21532824 offsetBegin: 491 offsetEnd: 669 A: exercise. Thoracic radiographs revealed megaesophagus and aspiration pneumonia. Serum antibodies against acetylcholine receptors confirmed the diagnosis of myasthenia gravis. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21532824 offsetBegin: 669 offsetEnd: 831 A: aspiration pneumonia. Serum antibodies against acetylcholine receptors confirmed the diagnosis of myasthenia gravis. The unusual clinical history and case outcome
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23117946 offsetBegin: 0 offsetEnd: 131 A: Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction (NMJ), with an estimated prevalence between 25 and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21970202 offsetBegin: 0 offsetEnd: 142 A: Ninety-six patients with ocular myasthenia gravis (OMG) seen at Siriraj Hospital during 1994 to 2004 were retrospectively reviewed. There were
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21784757 offsetBegin: 3357 offsetEnd: 3491 A: CONCLUSIONS: This study suggests that tacrolimus has a potential advantage as a steroid-sparing agent in the treatment of MG patients.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21784757 offsetBegin: 3491 offsetEnd: 3630 A: has a potential advantage as a steroid-sparing agent in the treatment of MG patients. CLINICAL TRIAL REGISTRATION NUMBER: NCT00309088. Name
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 0 offsetEnd: 147 A: INTRODUCTION: Both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are present in the body in large amounts. AChE is an important part
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 1337 offsetEnd: 1500 A: and myasthenia gravis, such as galantamine, donepezil, rivastigmine, tacrine, huperzine, pyridostigmine and neostigmine, are known. AREAS COVERED: The review gives
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 756 offsetEnd: 905 A: muscles. Immunosuppression is the mainstay of treatment for MG, and patients with MG are currently treated with immunomodulating or immunosuppressive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 905 offsetEnd: 1051 A: treatment for MG, and patients with MG are currently treated with immunomodulating or immunosuppressive agents. This review summarizes the current
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 3284 offsetEnd: 3415 A: late- and elderly-onset MG is reported to be increasing. The risk of complications in corticosteroid treatment appears to depend on
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 3985 offsetEnd: 4130 A: side effects should be increased in late- and elderly- onset MG. Although nonspecific, current immunosuppressive treatment is highly effective in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 2481 offsetEnd: 2616 A: distribution of fibers (type I predominance, type II atrophy) seen on biopsy; seronegative autoimmune myasthenia gravis, when CMS is of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 2747 offsetEnd: 2882 A: seronegative autoimmune myasthenia gravis, when CMS is of late onset; and metabolic myopathy, with the presence of lipidosis in muscle.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 501 offsetEnd: 662 A: autoimmune process, or improve residual neuromuscular transmission OBJECTIVES: The objective was to examine the efficacy of treatment in Lambert-Eaton myasthenic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 812 offsetEnd: 974 A: examine the efficacy of treatment in Lambert-Eaton myasthenic syndrome. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group Specialized Register
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 800 offsetEnd: 955 A: morbidity and mortality of poisoning. Organophosphate pesticide induced muscle weakness may not only arise from inhibition of acetylcholinesterase but also
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 955 offsetEnd: 1134 A: pesticide induced muscle weakness may not only arise from inhibition of acetylcholinesterase but also from non-cholinergic pathomechanisms, particularly mitochondrial dysfunction,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 2716 offsetEnd: 2879 A: following monocrotophos administration was associated with inhibition of muscle acetylcholinesterase (30-60%) but not with reduced ATP production. The rats rapidly
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 3159 offsetEnd: 3326 A: rats rapidly recovered muscle strength with no treatment. The ability of rats to spontaneously reactivate dimethoxy phosphorylated acetylcholinesterase and efficiently
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 0 offsetEnd: 159 A: In myasthenia gravis, the neuromuscular junction is impaired by the antibody-mediated loss of postsynaptic acetylcholine receptors (AChRs). Muscle weakness can
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 317 offsetEnd: 490 A: of postsynaptic acetylcholine receptors (AChRs). Muscle weakness can be improved upon treatment with pyridostigmine, a cholinesterase inhibitor, or with 3,4-diaminopyridine,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 490 offsetEnd: 642 A: weakness can be improved upon treatment with pyridostigmine, a cholinesterase inhibitor, or with 3,4-diaminopyridine, which increases the release of ACh
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1487 offsetEnd: 1635 A: compounds in the antibody-induced mouse model of anti-muscle-specific kinase (MuSK) myasthenia gravis. Mice received 14 daily injections of IgG from
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1927 offsetEnd: 2079 A: IgG from patients with anti-MuSK myasthenia gravis. This caused reductions in postsynaptic AChR densities and in endplate potential amplitudes. Systemic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 3368 offsetEnd: 3517 A: Mice receiving smaller amounts of MuSK autoantibodies did not display overt weakness, but 9 days of pyridostigmine treatment precipitated generalised
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 3829 offsetEnd: 3996 A: precipitated generalised muscle weakness. In contrast, one week of treatment with 3,4-diaminopyridine enhanced neuromuscular transmission in the diaphragm muscle. Both
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 4634 offsetEnd: 4806 A: only pyridostigmine potentiated the anti-MuSK-induced decline in endplate ACh receptor density. These results thus suggest that ongoing pyridostigmine treatment potentiates
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 4962 offsetEnd: 5110 A: results thus suggest that ongoing pyridostigmine treatment potentiates anti-MuSK-induced AChR loss by prolonging the activity of ACh in the synaptic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23559196 offsetBegin: 542 offsetEnd: 692 A: cases of myasthenia gravis (MG) that developed several months after WNV infection. All patients had serologically confirmed WNV neuroinvasive disease.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 240 offsetEnd: 362 A: patients with treated myasthenia gravis (MG) who present with dyspnea not related to MG. METHODS: We analyzed the files of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 2912 offsetEnd: 3066 A: and/or intravenous immunoglobulins. In all 3 patients, β(2)-adrenergic agonist treatment allowed only partial control of dyspnea. In one case, respiratory
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 3806 offsetEnd: 3943 A: should be investigated for asthma using PFT before being diagnosed with refractory MG. If asthma is diagnosed, a bronchodilator treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 3943 offsetEnd: 4077 A: PFT before being diagnosed with refractory MG. If asthma is diagnosed, a bronchodilator treatment should be instituted and a reduction
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 3330 offsetEnd: 3477 A: QOL impairment. Ocular-QMG score was a factor associated with the unfavorable condition. A treatment strategy, discriminated by ptosis or diplopia,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 3477 offsetEnd: 3620 A: factor associated with the unfavorable condition. A treatment strategy, discriminated by ptosis or diplopia, is necessary to improve the ocular
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21296574 offsetBegin: 118 offsetEnd: 240 A: with myasthenia gravis (MG) at the time of diagnosis to look for evidence of thymoma or thymic hyperplasia. However, there
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23460475 offsetBegin: 2628 offsetEnd: 2765 A: number of fatigue episodes after 2 weeks of a single-dose treatment with crotamine. CONCLUSIONS: These results indicate that crotamine is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 0 offsetEnd: 131 A: We observed, during a 25-year period, 15 patients from 6 families with autoimmune myasthenia gravis (all Chinese Han from Guangdong
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 131 offsetEnd: 268 A: 15 patients from 6 families with autoimmune myasthenia gravis (all Chinese Han from Guangdong Province) referred to our department. Their
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 1552 offsetEnd: 1730 A: corticosteroids /immune inhibitor plus pyridostigmine treatments after surgery. The other patients were placed on therapy with azathioprine, cyclophosphamide, corticosteroids and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 1730 offsetEnd: 1904 A: after surgery. The other patients were placed on therapy with azathioprine, cyclophosphamide, corticosteroids and acetylcholinesterase inhibitors. All patients responded well
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 1904 offsetEnd: 2092 A: placed on therapy with azathioprine, cyclophosphamide, corticosteroids and acetylcholinesterase inhibitors. All patients responded well to immunosuppressants, and psychiatric symptoms were
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 2092 offsetEnd: 2258 A: corticosteroids and acetylcholinesterase inhibitors. All patients responded well to immunosuppressants, and psychiatric symptoms were observed only in one patient who
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 3300 offsetEnd: 3437 A: and HLA-DRB1 0901 in 12 patients (12/15). When compared to familial autoimmune myasthenia gravis in other countries, we observed peculiar
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 1210 offsetEnd: 1361 A: treatment with pyridostigmine was followed by resolution of clinical signs and reduction of the acetylcholine -receptor antibody titre. Medical control
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22957965 offsetBegin: 1853 offsetEnd: 2002 A: achieved with carbimazole, administered in conjunction with pyridostigmine, and no recurrence of clinical signs was observed. Myasthenia gravis is an
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23376659 offsetBegin: 661 offsetEnd: 792 A: review six patients who presented with only DHS, responded to intravenous edrophonium and turned out to have myasthenia gravis (MG)
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23376659 offsetBegin: 792 offsetEnd: 931 A: only DHS, responded to intravenous edrophonium and turned out to have myasthenia gravis (MG) including similar patients who were previously
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23376659 offsetBegin: 931 offsetEnd: 1068 A: and turned out to have myasthenia gravis (MG) including similar patients who were previously documented. Six patients presented with neck
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 3163 offsetEnd: 3303 A: myasthenia gravis AND pyridostigmine. The articles included were from reviews and clinical trials written in English. MG patients can easily
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 0 offsetEnd: 163 A: Congenital myasthenia gravis is caused by genetic mutations affecting neuromuscular transmission, characterized by muscle weakness usually starting in childhood. A
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 1605 offsetEnd: 1735 A: dosage of cholinesterase inhibitor was temporarily increased. The symptoms resolved and she was back to her previous status in one
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 4679 offsetEnd: 4821 A: Challenge with other brands of statin or with reduced dosage is not beneficial in these patients. Non-pharmacological treatment and non-statin
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 0 offsetEnd: 131 A: Myasthenia gravis (MG) is caused by failure of chemical transmission at the neuromuscular junction. It is an autoimmune disorder in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 3822 offsetEnd: 3973 A: should be directed at ameliorating weakness with acetylcholinesterase blockers and modulating the immune system. Pyridostigmine is the most widely used
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 4143 offsetEnd: 4312 A: immune system. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Most patients with generalised MG require immunomodulatory therapy and prednisolone
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 4312 offsetEnd: 4475 A: widely used acetylcholinesterase inhibitor. Most patients with generalised MG require immunomodulatory therapy and prednisolone is generally used as the first-line
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 689 offsetEnd: 850 A: inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 1011 offsetEnd: 1170 A: was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 1170 offsetEnd: 1331 A: tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 1476 offsetEnd: 1624 A: treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23909021 offsetBegin: 702 offsetEnd: 853 A: Disorders of the neuromuscular junction, such as congenital myasthenic syndromes and neonatal transient myasthenia gravis are among the aetiologies. We
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23909021 offsetBegin: 853 offsetEnd: 989 A: as congenital myasthenic syndromes and neonatal transient myasthenia gravis are among the aetiologies. We report on a case of congenital
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 1486 offsetEnd: 1717 A: and experimental compound BW284C51. Two compounds, 1-(10-(pyridinium-1-yl)decyl)quinolinium dibromide and 1-(12-(pyridinium-1-yl)dodecyl)quinolinium dibromide, showed very promising affinity for acetylcholinesterase with their IC50
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 2435 offsetEnd: 2587 A: also showed satisfactory selectivity towards acetylcholinesterase and they seem to be very promising as leading structures for further modifications and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22689834 offsetBegin: 0 offsetEnd: 142 A: Ophthalmologic signs are the most often presenting symptoms of patients with myasthenia gravis (MG), most common being ptosis. However, ptosis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 3780 offsetEnd: 3913 A: myasthenia gravis (MG) accounts for 5-15% of autoimmune MG. As AChR deficiency is typically mild and as cholinesterase inhibitors are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278573 offsetBegin: 554 offsetEnd: 679 A: auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278573 offsetBegin: 1048 offsetEnd: 1178 A: and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 157 offsetEnd: 329 A: in vitro evaluation of 18 newly prepared bis-quinolinium inhibitors on human recombinant acetylcholinesterase (AChE) and human plasmatic butyrylcholinesterase (BChE). Their
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 509 offsetEnd: 688 A: acetylcholinesterase (AChE) and human plasmatic butyrylcholinesterase (BChE). Their inhibitory (IC(50)) and was compared to the chosen standards ambenonium dichloride, edrophonium
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 1152 offsetEnd: 1266 A: hydrochloride. One novel compound was found to be a promising inhibitor of hAChE (in nM range) and was better than
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 1266 offsetEnd: 1378 A: to be a promising inhibitor of hAChE (in nM range) and was better than edrophonium chloride or BW284c51, but was
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 1779 offsetEnd: 1912 A: This compound also showed selectivity towards hAChE and it was confirmed as a non-competitive inhibitor of hAChE by kinetic analysis.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 2045 offsetEnd: 2185 A: a non-competitive inhibitor of hAChE by kinetic analysis. A molecular modelling study further confirmed its binding to the peripheral active
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 751 offsetEnd: 895 A: few synthetic medicines with adverse effects, available for treatment of cognitive dysfunction and memory loss associated with these diseases. A
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 895 offsetEnd: 1029 A: available for treatment of cognitive dysfunction and memory loss associated with these diseases. A variety of plants has been reported
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1267 offsetEnd: 1395 A: been reported to possess AChE inhibitory activity and so may be relevant to the treatment of neurodegenerative disorders such as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 632 offsetEnd: 782 A: Maltese-crossbred dog was diagnosed with acquired focal myasthenia gravis based on history and clinical signs of dysphagia and regurgitation, multiple
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 3219 offsetEnd: 3377 A: ventilation, the dog recovered uneventfully and subsequently achieved a clinical and serologic remission from myasthenia gravis without further treatment. NEW
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 0 offsetEnd: 152 A: INTRODUCTION: Limb-girdle myasthenia with tubular aggregates (LGM with TAs) is a subtype of congenital myasthenic syndrome caused by recessive mutations
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 1651 offsetEnd: 1812 A: missense mutations (p.E256Q and p.M499T) in GFPT1. Treatment with oral cholinesterase inhibitors produced a dramatic improvement in muscle strength. CONCLUSIONS:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 1812 offsetEnd: 1956 A: GFPT1. Treatment with oral cholinesterase inhibitors produced a dramatic improvement in muscle strength. CONCLUSIONS: GFPT1 is the key enzyme in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 644 offsetEnd: 770 A: diagnosed myasthenia gravis (MG) seen at Queen Sirikit National Institute of Child Health over a 15-year period with a minimum
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 892 offsetEnd: 1029 A: Health over a 15-year period with a minimum follow-up of 6 months were reviewed. Demographic, clinical characteristics, treatment and the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 1029 offsetEnd: 1176 A: a minimum follow-up of 6 months were reviewed. Demographic, clinical characteristics, treatment and the outcome were analyzed. RESULTS: One hundred
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 4728 offsetEnd: 4837 A: the age of onset is earlier than GMG. Early treatment by prednisolone may have the favorable effect on OMG in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 4837 offsetEnd: 4956 A: than GMG. Early treatment by prednisolone may have the favorable effect on OMG in the progression to GMG and subsequent
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 425 offsetEnd: 540 A: If onset of the disease may be at any age, myasthenia gravis concerns mostly young adults, in majority females. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 540 offsetEnd: 678 A: be at any age, myasthenia gravis concerns mostly young adults, in majority females. The disease characteristic features are the following:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 3869 offsetEnd: 4016 A: including inflammatory myopathies that may mimic myasthenia gravis, adverse effects of medications commonly used in internal medicine, some of them
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 1385 offsetEnd: 1524 A: the first step of N-linked protein glycosylation. DPAGT1 patients are characterized by weakness of limb muscles, response to treatment with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 1524 offsetEnd: 1675 A: glycosylation. DPAGT1 patients are characterized by weakness of limb muscles, response to treatment with cholinesterase inhibitors, and the presence of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 1675 offsetEnd: 1814 A: weakness of limb muscles, response to treatment with cholinesterase inhibitors, and the presence of tubular aggregates on muscle biopsy. We
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 510 offsetEnd: 689 A: established Canadian Pediatric Surveillance Program methodology, physicians were anonymously surveyed for cases of pediatric myasthenia using a standardized clinical questionnaire
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 689 offsetEnd: 857 A: physicians were anonymously surveyed for cases of pediatric myasthenia using a standardized clinical questionnaire containing deidentified data. Inclusion criteria were
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 2465 offsetEnd: 2602 A: confirmed cases were reported. There were 34 generalized and 18 ocular reports of juvenile myasthenia gravis plus 5 congenital myasthenic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 2736 offsetEnd: 2856 A: of juvenile myasthenia gravis plus 5 congenital myasthenic syndrome cases. There were 14 incident cases in 2010 and 6 in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 4225 offsetEnd: 4365 A: generalized cases and 15 (88%) of 17 ocular cases. CONCLUSIONS: This study represents the largest descriptive series of pediatric myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 2980 offsetEnd: 3128 A: are isolated case reports of medium term benefit from rituximab. Overall, a combination of symptomatic treatment with 3,4-DAP and immunosuppression,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 3128 offsetEnd: 3278 A: term benefit from rituximab. Overall, a combination of symptomatic treatment with 3,4-DAP and immunosuppression, with or without antitumor therapy, is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 3278 offsetEnd: 3429 A: combination of symptomatic treatment with 3,4-DAP and immunosuppression, with or without antitumor therapy, is often successful for most LEMS patients,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23337001 offsetBegin: 482 offsetEnd: 615 A: similar to myasthenia gravis in adults. However, a number of significant particularities related to race, age at onset, severity, and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23341732 offsetBegin: 506 offsetEnd: 668 A: symptomatic therapy is based on acetylcholinesterase (AChE) drugs. The available long-term current therapy includes steroids and other immunomodulatory agents. MG
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 3809 offsetEnd: 3946 A: inhibitor treatment. Most of the patients who had a muscle biopsy showed tubular aggregates in myofibers. Analysis of endplate morphology
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 2915 offsetEnd: 3087 A: receptor gene expression and subcellular localization. We additionally determined the ability of pyridostigmine, an acetylcholinesterase inhibitor, to ameliorate aspects of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 3421 offsetEnd: 3581 A: aspects of the behavioral phenotype related to NMJ dysfunction. Pyridostigmine treatment resulted in significant improvement in fatigable weakness and treadmill
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 2926 offsetEnd: 3048 A: lactate and low levels of NAC and VLDL/LDL were observed in the deltamethrin treatment group. Treating rats with a mixture
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 3181 offsetEnd: 3338 A: deltamethrin treatment group. Treating rats with a mixture of dichlorvos and deltamethrin caused an increase in serum lactate, trimethylamine-N-oxide (TMAO),
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 4500 offsetEnd: 4623 A: serum TMAO, alanine, choline and acetone in this treatment group were higher than in rats treated with either dichlorvos or
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 4623 offsetEnd: 4755 A: in this treatment group were higher than in rats treated with either dichlorvos or deltamethrin. These results suggest that exposing
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 316 offsetEnd: 474 A: junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 633 offsetEnd: 795 A: guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2697 offsetEnd: 2829 A: over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2829 offsetEnd: 2967 A: considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 4786 offsetEnd: 4913 A: well tolerated and effective in relieving the symptoms of MG, further efforts are required to improve treatment options for the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 1857 offsetEnd: 2005 A: share a number of common clinical features, including involvement of proximal limb muscles, response to treatment with cholinesterase inhibitors and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 1236 offsetEnd: 1382 A: have shown promising midterm results but long-term results were lacking. METHODS: Two hundred forty patients with nontumoral myasthenia gravis who
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 1527 offsetEnd: 1660 A: hundred forty patients with nontumoral myasthenia gravis who underwent surgery between 1999 and 2009 were eligible for the study. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 942 offsetEnd: 1074 A: streptozotocin (STZ). Mice were severely hyperglycemic within 7 days after the STZ treatment began. Whereas performance of mice on a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 1074 offsetEnd: 1192 A: within 7 days after the STZ treatment began. Whereas performance of mice on a rotating rod remained normal, the twitch
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 3057 offsetEnd: 3200 A: mEPC decay time to the selective butyrylcholinesterase (BChE) inhibitor PEC suggests that muscle attempts to compensate for reduced AChE levels
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22973658 offsetBegin: 417 offsetEnd: 539 A: with myasthenia gravis (MG). We report a 73 year-old lady who presented 10 years previously with stiffness of both calves,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 145 offsetEnd: 285 A: myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1162 offsetEnd: 1293 A: assess the effects of treatments for ocular myasthenia and to answer three specific questions. Are there any treatments that impact
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 4653 offsetEnd: 4823 A: information. SELECTION CRITERIA: Inclusion required meeting three criteria: (a) randomized (or quasi-randomized) controlled study design; (b) active treatment compared to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 5796 offsetEnd: 5943 A: DATA COLLECTION AND ANALYSIS: We collected data regarding the risk of progression to generalized myasthenia gravis, improvement in ocular symptoms,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 6378 offsetEnd: 6518 A: treatment-related side effects. MAIN RESULTS: In the original review, we identified two RCTs relevant to the treatment of ocular myasthenia,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 8361 offsetEnd: 8503 A: conclusions about the efficacy of any form of treatment for ocular myasthenia. Data from several reasonably good quality observational studies
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 2685 offsetEnd: 2838 A: the coexistence of 20 Hz-decremental responses in proximal muscles and severe denervation in distal muscles. Red blood cell acetylcholinesterase activity
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 2838 offsetEnd: 2986 A: in proximal muscles and severe denervation in distal muscles. Red blood cell acetylcholinesterase activity progressively normalized on day 60, while
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 2986 offsetEnd: 3148 A: in distal muscles. Red blood cell acetylcholinesterase activity progressively normalized on day 60, while plasma butyrylcholinesterase activity remained low until
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 2761 offsetEnd: 2912 A: and prednisone. Eight patients had thymectomy. Four patients (12%) entered remission. There were two deaths. CONCLUSIONS: Myasthenia gravis in Jamaican
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 2912 offsetEnd: 3047 A: Four patients (12%) entered remission. There were two deaths. CONCLUSIONS: Myasthenia gravis in Jamaican children is similar to that in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 230 offsetEnd: 336 A: neuritis after the treatment of MG for 22 years. At 10 years of age, she was diagnosed with generalized MG
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 2548 offsetEnd: 2690 A: viable therapeutic option for selected cases of generalized juvenile myasthenia gravis. This is corroborated by the clinical experience of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 2690 offsetEnd: 2821 A: of generalized juvenile myasthenia gravis. This is corroborated by the clinical experience of the authors in a referral center with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 3051 offsetEnd: 3181 A: center with a cohort of patients affected by juvenile myasthenia gravis over a number of years. SUMMARY: Recent studies illustrate
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 1248 offsetEnd: 1390 A: of the most-prescribed treatment strategies for AD. In fact, cholinesterase inhibitors have been also reported for their effectiveness in some
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 1678 offsetEnd: 1798 A: in some other diseases including glaucoma, myasthenia gravies, as well as Down syndrome, lately. They play a role in the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 1798 offsetEnd: 1917 A: myasthenia gravies, as well as Down syndrome, lately. They play a role in the action of mechanism of insecticidal drugs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 269 offsetEnd: 416 A: comprehensive healthcare costs have not been reported for myasthenia gravis (MG). We evaluated the direct costs and healthcare resource utilization
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 1241 offsetEnd: 1366 A: of AChR loss, caused by experimental autoimmune myasthenia gravis (EAMG), on muscle AChE, as well as the reciprocal effect of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 1366 offsetEnd: 1492 A: autoimmune myasthenia gravis (EAMG), on muscle AChE, as well as the reciprocal effect of an antisense targeted towards AChE on
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 3078 offsetEnd: 3235 A: mice exhibited acetylcholinesterase (AChE) inhibitor-evoked cholinergic hypersensitivity, as is observed in MuSK-MG patients, and a decrease in both AChE and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21614992 offsetBegin: 868 offsetEnd: 1047 A: the diagnosis of this disease: clinical findings, electromyography, genetic tests, determination of serum acetylcholine receptor antibodies. Acetylcholine esterase inhibitor drugs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 390 offsetEnd: 506 A: and therapy of myasthenia gravis. This review will touch upon some of his work as it discusses current therapies and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 1119 offsetEnd: 1259 A: disease. The recognition of different immune mechanisms that can cause the phenotype that we acknowledge as myasthenia gravis coincides with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 1259 offsetEnd: 1400 A: mechanisms that can cause the phenotype that we acknowledge as myasthenia gravis coincides with the introduction of monoclonal antibodies and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 2454 offsetEnd: 2565 A: stress. The medical team was in the novel situation to look after a runner with myasthenia gravis and needed to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 2565 offsetEnd: 2681 A: the novel situation to look after a runner with myasthenia gravis and needed to be aware of the patient's condition,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 2681 offsetEnd: 2800 A: a runner with myasthenia gravis and needed to be aware of the patient's condition, symptoms, and risk factors to safely
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21854656 offsetBegin: 272 offsetEnd: 410 A: 'ocular myasthenia gravis' must be considered. The diagnosis can be difficult because of the subtle symptoms and less sensitive diagnostic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 0 offsetEnd: 170 A: BACKGROUND: In myasthenia gravis, antibody-mediated blockade of acetylcholine receptors at the neuromuscular junction abolishes the naturally occurring 'safety factor' of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 170 offsetEnd: 352 A: of acetylcholine receptors at the neuromuscular junction abolishes the naturally occurring 'safety factor' of synaptic transmission. Acetylcholinesterase inhibitors provide temporary
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 1466 offsetEnd: 1617 A: of myasthenia gravis. SEARCH STRATEGY: We searched The Cochrane Neuromuscular Disease Group Specialized Register (5 October 2009), The Cochrane Central
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 2341 offsetEnd: 2510 A: 2009), EMBASE (January 1980 to September 2009) for randomised controlled trials and quasi-randomised controlled trials regarding usage of acetylcholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4374 offsetEnd: 4528 A: with any form of acetylcholinesterase inhibitor.Types of outcome measuresPrimary outcome measureImprovement in the presenting symptoms within 1 to 14 days
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5487 offsetEnd: 5604 A: and preferably validated scale, such as the quantitative myasthenia gravis score within 1 to 14 days and more than 14
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21150643 offsetBegin: 2661 offsetEnd: 2811 A: have a clinical history and examination findings typical of homozygous CHRNE mutations, the clinical presentation of congenital myasthenia subtypes is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21150643 offsetBegin: 2811 offsetEnd: 2968 A: findings typical of homozygous CHRNE mutations, the clinical presentation of congenital myasthenia subtypes is variable, and accurate genotyping is essential
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24164490 offsetBegin: 1924 offsetEnd: 2077 A: was controlled with prednisolone and pyridostigmine. The myasthenia gravis resolved, but the cat developed severe cutaneous erosions and ulcers primarily
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23013366 offsetBegin: 0 offsetEnd: 155 A: INTRODUCTION: Determination of acetylcholinesterase and butyrylcholinesterase activity has become an important tool in drug design and discovery as well as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 758 offsetEnd: 888 A: study was to perform a comprehensive survey of myasthenia gravis in a hospital in China, establishing contemporary cohort data and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 4310 offsetEnd: 4450 A: disease duration, or application of complex diagnostic tests. The relative increase in the prevalence of ocular myasthenia can be attributed
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 0 offsetEnd: 173 A: BACKGROUND: Thymectomy is standard therapy fornonthymomatousmyasthenia gravis despite the absence of randomized clinical trials (1). Myasthenia gravis is uncommonly reported
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 145 offsetEnd: 313 A: serine hydrolases that split the neurotransmitter acetylcholine (ACh) and terminate its action. Of the two types, butyrylcholinesterase and acetylcholinesterase (AChE),
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 313 offsetEnd: 458 A: acetylcholine (ACh) and terminate its action. Of the two types, butyrylcholinesterase and acetylcholinesterase (AChE), AChE plays the key role in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 5065 offsetEnd: 5207 A: diagnosis of MuSK-MG. Further, only small doses of acetylcholinesterase inhibitors are administered to patients with MuSK-MG in order to avoid
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 5207 offsetEnd: 5357 A: doses of acetylcholinesterase inhibitors are administered to patients with MuSK-MG in order to avoid cholinergic hyperactivity. In general, both types
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 0 offsetEnd: 160 A: OBJECTIVE: To investigate and analyze the clinical manifestations, classification, therapeutic approaches and follow-up of myasthenia gravis (MG) in children in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 160 offsetEnd: 314 A: clinical manifestations, classification, therapeutic approaches and follow-up of myasthenia gravis (MG) in children in order to improve its management and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 314 offsetEnd: 448 A: follow-up of myasthenia gravis (MG) in children in order to improve its management and prognosis. METHODS: Clinical information of 135
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21784757 offsetBegin: 131 offsetEnd: 276 A: tacrolimus to reduce the corticosteroid dose in patients with myasthenia gravis (MG) and the drug's safety in a double-blind, placebo-controlled,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21784757 offsetBegin: 276 offsetEnd: 422 A: in patients with myasthenia gravis (MG) and the drug's safety in a double-blind, placebo-controlled, parallel group study. METHODS: Patients being
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 0 offsetEnd: 157 A: Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission that is primarily caused autoantibodies specific to the neuromuscular junction
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 2122 offsetEnd: 2288 A: MG. Immunosuppressive treatment is indicated for patients with disabling weakness, not sufficiently managed with cholinesterase inhibitors. Prednisolone (PSL) is used
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21532382 offsetBegin: 949 offsetEnd: 1065 A: the neck extensor muscles. Our case is the second report of isolated head drop as a presenting symptom of myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 336 offsetEnd: 498 A: in agricultural communities of Asia. Organophosphate compounds inhibit acetylcholinesterase and prolonged neuromuscular weakness is a major cause of morbidity and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 498 offsetEnd: 665 A: compounds inhibit acetylcholinesterase and prolonged neuromuscular weakness is a major cause of morbidity and mortality of poisoning. Organophosphate pesticide induced
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 1134 offsetEnd: 1314 A: only arise from inhibition of acetylcholinesterase but also from non-cholinergic pathomechanisms, particularly mitochondrial dysfunction, affecting the production of sufficient ATP
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 2541 offsetEnd: 2716 A: acetylcholinesterase. Severe muscle weakness in rats following monocrotophos administration was associated with inhibition of muscle acetylcholinesterase (30-60%) but not with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 2879 offsetEnd: 3028 A: inhibition of muscle acetylcholinesterase (30-60%) but not with reduced ATP production. The rats rapidly recovered muscle strength with no treatment.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 3704 offsetEnd: 3879 A: and efficiently detoxify organophosphates may prevent severe inhibition of muscle acetylcholinesterase following acute severe monocrotophos poisoning. This may protect rodents
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1332 offsetEnd: 1487 A: formally examined the effects of these compounds in the antibody-induced mouse model of anti-muscle-specific kinase (MuSK) myasthenia gravis. Mice received
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 3996 offsetEnd: 4163 A: one week of treatment with 3,4-diaminopyridine enhanced neuromuscular transmission in the diaphragm muscle. Both pyridostigmine and 3,4-diaminopyridine increase ACh in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23172384 offsetBegin: 0 offsetEnd: 153 A: OBJECTIVES: To find the characteristic phenotypes of 3 different types of myasthenia gravis (MG). METHODS: The clinical and electrophysiological features
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 0 offsetEnd: 118 A: AIMS: The aim of this study was to evaluate the proportion of patients with treated myasthenia gravis (MG) who present
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23051847 offsetBegin: 118 offsetEnd: 240 A: was to evaluate the proportion of patients with treated myasthenia gravis (MG) who present with dyspnea not related to MG.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 143 offsetEnd: 272 A: ocular and generalized muscles, results in various symptoms. Ocular myasthenia (OM) is a form of MG that is clinically restricted
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 272 offsetEnd: 402 A: various symptoms. Ocular myasthenia (OM) is a form of MG that is clinically restricted to extrinsic ocular muscles. Clinical signs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 3181 offsetEnd: 3330 A: mg/day (the unfavorable condition) showed severe QOL impairment. Ocular-QMG score was a factor associated with the unfavorable condition. A treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23460475 offsetBegin: 2497 offsetEnd: 2628 A: characterized by a decrease in the number of fatigue episodes after 2 weeks of a single-dose treatment with crotamine. CONCLUSIONS:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057263 offsetBegin: 3169 offsetEnd: 3300 A: HLA-B 4601 in 11 patients (11/15), and HLA-DRB1 0901 in 12 patients (12/15). When compared to familial autoimmune myasthenia gravis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23703814 offsetBegin: 4130 offsetEnd: 4268 A: development of IMS and OPIDN. Persistent inhibition of acetylcholinesterase (AChE) is responsible for muscle weakness, but this is not the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23703814 offsetBegin: 4268 offsetEnd: 4403 A: inhibition of acetylcholinesterase (AChE) is responsible for muscle weakness, but this is not the only factor involved in the incidence
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 2938 offsetEnd: 3074 A: and contribute to muscle weakness. Muscle biopsy should be considered in infants suspected to have CMS, especially if treatment response
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 822 offsetEnd: 956 A: The symptoms progressed giving the clinical impression of congenital myasthenia gravis. A series of tests were done including Ice Pack
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 956 offsetEnd: 1096 A: impression of congenital myasthenia gravis. A series of tests were done including Ice Pack Test, acetylcholine receptor antibody test, trial
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 1672 offsetEnd: 1816 A: This case illustrates the challenges in diagnosing congenital myasthenia gravis and highlights the potential benefits of neostigmine test in its
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 1313 offsetEnd: 1461 A: a few weeks after starting simvastatin 20 mg/day. Simvastatin was discontinued and dosage of cholinesterase inhibitor was temporarily increased. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 1704 offsetEnd: 1835 A: moderate the autoimmune attack. Mortality of MG has been reduced over the last century, but adverse effects of treatment compromise
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23909021 offsetBegin: 1114 offsetEnd: 1234 A: aetiologies. We report on a case of congenital myasthenia caused by mutation in the long cytoplasmic loop of the epsilon
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 580 offsetEnd: 752 A: treatment. Their inhibitory ability towards human recombinant acetylcholinesterase and human plasmatic butyrylcholinesterase was determined and the results were compared to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 752 offsetEnd: 913 A: recombinant acetylcholinesterase and human plasmatic butyrylcholinesterase was determined and the results were compared to the known effective inhibitors such as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22689834 offsetBegin: 1535 offsetEnd: 1664 A: to them with progressive weakness and double vision in which they were successful in narrowing the differentials to myasthenia by
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 3358 offsetEnd: 3498 A: signal of ColQ can be exploited to specifically deliver the transgene product to the target tissue. MuSK antibody-positive myasthenia gravis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 3498 offsetEnd: 3644 A: to specifically deliver the transgene product to the target tissue. MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23279780 offsetBegin: 285 offsetEnd: 419 A: a purely ocular manifestation of myasthenia gravis (MG) are significantly less likely to convert to a generalized disease when treated
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278573 offsetBegin: 679 offsetEnd: 810 A: EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278573 offsetBegin: 810 offsetEnd: 932 A: trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278573 offsetBegin: 1178 offsetEnd: 1301 A: period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 329 offsetEnd: 509 A: prepared bis-quinolinium inhibitors on human recombinant acetylcholinesterase (AChE) and human plasmatic butyrylcholinesterase (BChE). Their inhibitory (IC(50)) and was compared to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1530 offsetEnd: 1664 A: to the treatment of neurodegenerative disorders such as AD. Hence, developing potential AChE inhibitors from botanicals is the need of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1914 offsetEnd: 2043 A: need of the day. This review will cover some of the promising acetylcholinesterase inhibitors isolated from plants with proven in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 2043 offsetEnd: 2177 A: will cover some of the promising acetylcholinesterase inhibitors isolated from plants with proven in vitro and in vivo activities with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 3538 offsetEnd: 3697 A: remission from myasthenia gravis without further treatment. NEW OR UNIQUE INFORMATION PROVIDED: Cholinergic crisis and differentiation from a myasthenic crisis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22770539 offsetBegin: 443 offsetEnd: 568 A: Ab), as well as the thymus pathology to the clinical outcome in patients with generalized myasthenia gravis (MG). METHODS: We
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 0 offsetEnd: 138 A: OBJECTIVE: To study the clinical features, treatment, outcome and factors that affected the outcome of myasthenia gravis (MG) in children.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 138 offsetEnd: 271 A: treatment, outcome and factors that affected the outcome of myasthenia gravis (MG) in children. MATERIAL AND METHOD: Children aged 16
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 1176 offsetEnd: 1330 A: were reviewed. Demographic, clinical characteristics, treatment and the outcome were analyzed. RESULTS: One hundred and nineteen MG patients, 100 patients
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 4618 offsetEnd: 4728 A: the majority of MG patients and the age of onset is earlier than GMG. Early treatment by prednisolone may have
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 0 offsetEnd: 153 A: Besides antitumor therapy for patients with the paraneoplastic form of Lambert-Eaton myasthenic syndrome (LEMS), the mainstay of symptomatic treatment in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278581 offsetBegin: 153 offsetEnd: 311 A: the paraneoplastic form of Lambert-Eaton myasthenic syndrome (LEMS), the mainstay of symptomatic treatment in LEMS is 3,4-diaminopyridine (3,4-DAP). Data from
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 410 offsetEnd: 524 A: and Myasthenia gravis (MG). Compounds used in the therapy of MG posses a positive charge in the molecule to ensure
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 3048 offsetEnd: 3181 A: and VLDL/LDL were observed in the deltamethrin treatment group. Treating rats with a mixture of dichlorvos and deltamethrin caused an
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 474 offsetEnd: 633 A: and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1331 offsetEnd: 1470 A: for symptomatic treatment, and short- and long-term disease-modifying treatments. This review focuses on treatment of MG, mainly on the use
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1721 offsetEnd: 1843 A: the use of the AChE inhibitor pyridostigmine. Despite a lack of data from well controlled clinical trials to support their
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24088269 offsetBegin: 0 offsetEnd: 126 A: BACKGROUND: Few studies have focused on fatigue in myasthenia gravis (MG), and fatigue in relation to the autonomic system has
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 2005 offsetEnd: 2168 A: features, including involvement of proximal limb muscles, response to treatment with cholinesterase inhibitors and 3,4-diaminopyridine, and the presence of tubular
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 2168 offsetEnd: 2325 A: muscles, response to treatment with cholinesterase inhibitors and 3,4-diaminopyridine, and the presence of tubular aggregates in muscle biopsies. Analyses of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 3493 offsetEnd: 3649 A: of N-linked protein glycosylation for proper functioning of the neuromuscular junction. Using the DPAGT1-specific inhibitor tunicamycin, we show that DPAGT1
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 3649 offsetEnd: 3803 A: functioning of the neuromuscular junction. Using the DPAGT1-specific inhibitor tunicamycin, we show that DPAGT1 is required for efficient glycosylation of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 3803 offsetEnd: 3965 A: the DPAGT1-specific inhibitor tunicamycin, we show that DPAGT1 is required for efficient glycosylation of acetylcholine-receptor subunits and for efficient export
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 135 offsetEnd: 283 A: was to analyze the 10-year results of thoracoscopic unilateral extended thymectomy (TUET) performed in nontumoral myasthenia gravis according to the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 1192 offsetEnd: 1324 A: treatment began. Whereas performance of mice on a rotating rod remained normal, the twitch tension response of the isolated extensor
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 907 offsetEnd: 1035 A: published in 2006 and previously updated in 2008 and 2010. OBJECTIVES: To assess the effects of treatments for ocular myasthenia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1035 offsetEnd: 1162 A: in 2008 and 2010. OBJECTIVES: To assess the effects of treatments for ocular myasthenia and to answer three specific questions.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1293 offsetEnd: 1430 A: ocular myasthenia and to answer three specific questions. Are there any treatments that impact the progression from ocular to generalized
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 5943 offsetEnd: 6091 A: data regarding the risk of progression to generalized myasthenia gravis, improvement in ocular symptoms, and the frequency of treatment-related side
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 6091 offsetEnd: 6239 A: to generalized myasthenia gravis, improvement in ocular symptoms, and the frequency of treatment-related side effects. MAIN RESULTS: In the original
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 6518 offsetEnd: 6644 A: the original review, we identified two RCTs relevant to the treatment of ocular myasthenia, only one of which reported results
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 8231 offsetEnd: 8361 A: literature does not permit any meaningful conclusions about the efficacy of any form of treatment for ocular myasthenia. Data from
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 3148 offsetEnd: 3316 A: acetylcholinesterase activity progressively normalized on day 60, while plasma butyrylcholinesterase activity remained low until day 100. Chlorpyrifos was detectable in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 0 offsetEnd: 154 A: BACKGROUND: Myasthenia gravis is uncommon in children. The clinical characteristics in children of the English-speaking Caribbean have not been documented
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 614 offsetEnd: 754 A: the clinical characteristics and outcome of children with myasthenia gravis at two tertiary hospitals in Jamaica. METHODS: The case-notes of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 883 offsetEnd: 1017 A: tertiary hospitals in Jamaica. METHODS: The case-notes of all children with a diagnosis of myasthenia gravis managed at the University
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 3047 offsetEnd: 3174 A: were two deaths. CONCLUSIONS: Myasthenia gravis in Jamaican children is similar to that in other populations. It is more common
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 3204 offsetEnd: 3344 A: the course of the optic neuritis. Furthermore blephalopstosis caused by MG has disappeared completely after the treatment with steroid pulse
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 3762 offsetEnd: 3897 A: case had 23 years of immunosuppressive treatment free durations with stable condition. The cause of development of optic neuritis would
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 953 offsetEnd: 1092 A: in the brains of AD patients. Consequently, cholinesterase inhibition has become one of the most-prescribed treatment strategies for AD. In
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 3028 offsetEnd: 3149 A: the treatment of MG are higher than those of many other chronic neurological diseases. A large percentage of costs result
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 290 offsetEnd: 442 A: to 90% of generalized pediatric myasthenia gravis cases have acetylcholine receptor antibodies. Approximately 30% of the remaining cases have antibodies
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 1109 offsetEnd: 1252 A: and prognosis of pediatric muscle-specific kinase antibody-positive myasthenia gravis is limited because of the small number of cases. Here, we
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24145588 offsetBegin: 0 offsetEnd: 157 A: Myasthenia gravis is an antibody-mediated disorder of neuromuscular transmission that is characterized by weakness and fatigue of voluntary muscles. Weakness
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 3545 offsetEnd: 3693 A: of newly diagnosed myasthenia with anti-LRP4 antibodies. The clinical and therapeutic implications of the anti-LRP4 antibody positivity remain to be
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 268 offsetEnd: 390 A: to our understanding of the pathophysiology and therapy of myasthenia gravis. This review will touch upon some of his work
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21854656 offsetBegin: 0 offsetEnd: 135 A: When a patient complains of a fluctuating ptosis or diplopia the diagnosis 'ocular myasthenia gravis' must be considered. The diagnosis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 3674 offsetEnd: 3829 A: Types of studies: all randomised or quasi-randomised trials. TYPES OF PARTICIPANTS: all myasthenia gravis patients diagnosed by an internationally accepted
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5604 offsetEnd: 5719 A: the quantitative myasthenia gravis score within 1 to 14 days and more than 14 days after the start of treatment.(3)
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5719 offsetEnd: 5845 A: 1 to 14 days and more than 14 days after the start of treatment.(3) Myasthenia Gravis Association of America post-intervention
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5980 offsetEnd: 6136 A: of treatment.(3) Myasthenia Gravis Association of America post-intervention status more than 14 days after start of treatment.(4) Adverse events: muscarinic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23794683 offsetBegin: 167 offsetEnd: 342 A: limb-girdle myasthenia and analyze phenotypic consequences of the mutations. METHODS: We performed genetic analysis, histochemical, immunoblot, and ultrastructural studies and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 2683 offsetEnd: 2831 A: for surgery and closely followed up for tumor recurrence. A concerted international effort is addressing treatment recommendations for thymectomy in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 4162 offsetEnd: 4294 A: monitoring of the patient and institution of an efficient and safe treatment such as plasma exchange. Patient education is essential
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23242891 offsetBegin: 123 offsetEnd: 252 A: has been diagnosed with myasthenia gravis (MG) is planning pregnancy. Her MG is controlled with medications. Can her condition or
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21784757 offsetBegin: 3630 offsetEnd: 3773 A: steroid-sparing agent in the treatment of MG patients. CLINICAL TRIAL REGISTRATION NUMBER: NCT00309088. Name of the trial registry: FK506 Phase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 626 offsetEnd: 756 A: fatigability and weakness of the striated muscles. Immunosuppression is the mainstay of treatment for MG, and patients with MG are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 1798 offsetEnd: 1957 A: of corticosteroids and different classes of immunomodulating or immunosuppressive drugs used for MG. Immunosuppressive treatment is indicated for patients with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 1957 offsetEnd: 2122 A: immunomodulating or immunosuppressive drugs used for MG. Immunosuppressive treatment is indicated for patients with disabling weakness, not sufficiently managed with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 3709 offsetEnd: 3844 A: depend on drug dosage, treatment duration, and patients' characteristics, and the serious side effects should be increased in late- and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 662 offsetEnd: 812 A: transmission OBJECTIVES: The objective was to examine the efficacy of treatment in Lambert-Eaton myasthenic syndrome. SEARCH STRATEGY: We searched the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 3879 offsetEnd: 4044 A: severe inhibition of muscle acetylcholinesterase following acute severe monocrotophos poisoning. This may protect rodents against the development of prolonged muscle
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23172384 offsetBegin: 153 offsetEnd: 297 A: of 3 different types of myasthenia gravis (MG). METHODS: The clinical and electrophysiological features among 15 cases of muscle-specific kinase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21296574 offsetBegin: 0 offsetEnd: 118 A: Current practice favors imaging of people with myasthenia gravis (MG) at the time of diagnosis to look for evidence of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23703814 offsetBegin: 3993 offsetEnd: 4130 A: and NCV is parallel with the development of IMS and OPIDN. Persistent inhibition of acetylcholinesterase (AChE) is responsible for muscle
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 1516 offsetEnd: 1672 A: neostigmine test which confirmed the diagnosis. This case illustrates the challenges in diagnosing congenital myasthenia gravis and highlights the potential
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 1912 offsetEnd: 2045 A: hAChE and it was confirmed as a non-competitive inhibitor of hAChE by kinetic analysis. A molecular modelling study further confirmed
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 782 offsetEnd: 927 A: focal myasthenia gravis based on history and clinical signs of dysphagia and regurgitation, multiple series of thoracic radiographs showing focal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 2667 offsetEnd: 2834 A: neuromuscular junction. Identification of LGM with TAs among patients with congenital myasthenic syndrome is important because treatment with cholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22770539 offsetBegin: 568 offsetEnd: 709 A: pathology to the clinical outcome in patients with generalized myasthenia gravis (MG). METHODS: We analyzed 138 patients with generalized MG,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22770539 offsetBegin: 709 offsetEnd: 852 A: patients with generalized myasthenia gravis (MG). METHODS: We analyzed 138 patients with generalized MG, who were thymectomized and assayed for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 337 offsetEnd: 510 A: pediatric myasthenia in Canada. METHODS: Through established Canadian Pediatric Surveillance Program methodology, physicians were anonymously surveyed for cases of pediatric
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23341732 offsetBegin: 340 offsetEnd: 506 A: against the acetylcholine receptor (AChR). Current symptomatic therapy is based on acetylcholinesterase (AChE) drugs. The available long-term current therapy includes
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 3087 offsetEnd: 3244 A: We additionally determined the ability of pyridostigmine, an acetylcholinesterase inhibitor, to ameliorate aspects of the behavioral phenotype related to NMJ
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 3581 offsetEnd: 3739 A: to NMJ dysfunction. Pyridostigmine treatment resulted in significant improvement in fatigable weakness and treadmill endurance. In all, these results describe
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 2789 offsetEnd: 2926 A: low-density lipoprotein (VLDL/LDL). High levels of lactate and low levels of NAC and VLDL/LDL were observed in the deltamethrin treatment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 969 offsetEnd: 1155 A: retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2484 offsetEnd: 2594 A: for MG. Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2967 offsetEnd: 3110 A: a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 0 offsetEnd: 145 A: BACKGROUND: Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 754 offsetEnd: 883 A: children with myasthenia gravis at two tertiary hospitals in Jamaica. METHODS: The case-notes of all children with a diagnosis of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 1139 offsetEnd: 1276 A: diagnosis of myasthenia gravis managed at the University Hospital of the West Indies and Bustamante Hospital for Children between January
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24141560 offsetBegin: 2937 offsetEnd: 3051 A: of the authors in a referral center with a cohort of patients affected by juvenile myasthenia gravis over a number
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22337799 offsetBegin: 132 offsetEnd: 296 A: is the use of polymeric surfactants in polyelectrolyte multilayer (PEM) coatings for the separation of the pharmaceutical substances acetylcholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22337799 offsetBegin: 296 offsetEnd: 458 A: in polyelectrolyte multilayer (PEM) coatings for the separation of the pharmaceutical substances acetylcholinesterase inhibitors (AChEIs). AChEIs are used for the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 3252 offsetEnd: 3397 A: follicular hyperplasia. This is the first clinical report of the presenting features of newly diagnosed myasthenia with anti-LRP4 antibodies. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 3518 offsetEnd: 3674 A: published or unpublished data. SELECTION CRITERIA: Types of studies: all randomised or quasi-randomised trials. TYPES OF PARTICIPANTS: all myasthenia gravis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 2125 offsetEnd: 2269 A: and acetylcholinesterase (AChE) activity were measured in the blood of subjects. Clinical examination and complete blood test were undertaken in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 4027 offsetEnd: 4162 A: management of myasthenic crisis requires intensive monitoring of the patient and institution of an efficient and safe treatment such as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24164490 offsetBegin: 2077 offsetEnd: 2218 A: The myasthenia gravis resolved, but the cat developed severe cutaneous erosions and ulcers primarily affecting the caudal ventral abdomen and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 646 offsetEnd: 758 A: China. The goal of the current study was to perform a comprehensive survey of myasthenia gravis in a hospital in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23423465 offsetBegin: 4450 offsetEnd: 4572 A: diagnostic tests. The relative increase in the prevalence of ocular myasthenia can be attributed to the impact of an aging
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21784757 offsetBegin: 0 offsetEnd: 131 A: OBJECTIVES: To evaluate the ability of tacrolimus to reduce the corticosteroid dose in patients with myasthenia gravis (MG) and the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 478 offsetEnd: 626 A: neuromuscular junction and is characterized by fatigability and weakness of the striated muscles. Immunosuppression is the mainstay of treatment for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 0 offsetEnd: 151 A: Myasthenia gravis (MG) is a disease affecting the nicotinic acetylcholine receptor of the post-synaptic membrane of the neuromuscular junction, causing
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 681 offsetEnd: 822 A: bilateral ptosis and hoarseness of voice. The symptoms progressed giving the clinical impression of congenital myasthenia gravis. A series of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 1461 offsetEnd: 1605 A: 20 mg/day. Simvastatin was discontinued and dosage of cholinesterase inhibitor was temporarily increased. The symptoms resolved and she was back
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23337001 offsetBegin: 886 offsetEnd: 1029 A: severity, and antibody status complicate the management. We summarize the unique clinical features of juvenile myasthenia gravis and review the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23566885 offsetBegin: 4381 offsetEnd: 4500 A: DMG, NAC, and VLDL/LDL. Changes in serum TMAO, alanine, choline and acetone in this treatment group were higher than in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2370 offsetEnd: 2484 A: used, are recommended as first-line therapy for MG. Pyridostigmine has been used as a treatment for MG for over 50
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2594 offsetEnd: 2697 A: as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24088269 offsetBegin: 126 offsetEnd: 256 A: fatigue in myasthenia gravis (MG), and fatigue in relation to the autonomic system has never been systematically explored in these
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 6644 offsetEnd: 6769 A: RCTs relevant to the treatment of ocular myasthenia, only one of which reported results in terms of the pre-specified outcome
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22525448 offsetBegin: 1017 offsetEnd: 1139 A: case-notes of all children with a diagnosis of myasthenia gravis managed at the University Hospital of the West Indies and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21854656 offsetBegin: 135 offsetEnd: 272 A: fluctuating ptosis or diplopia the diagnosis 'ocular myasthenia gravis' must be considered. The diagnosis can be difficult because of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5845 offsetEnd: 5980 A: than 14 days after the start of treatment.(3) Myasthenia Gravis Association of America post-intervention status more than 14 days after
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 3591 offsetEnd: 3727 A: There is a lack of evidence-based treatment guidelines for both acute and long-term management of ocular myasthenia. Acute management of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 3727 offsetEnd: 3880 A: treatment guidelines for both acute and long-term management of ocular myasthenia. Acute management of myasthenic crisis requires intensive monitoring of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 2217 offsetEnd: 2350 A: PubMed and a review of the references of the articles. The following keywords were used: myasthenia gravis AND neuromuscular blocking
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1782 offsetEnd: 1914 A: AChE inhibitors from botanicals is the need of the day. This review will cover some of the promising acetylcholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23909021 offsetBegin: 1234 offsetEnd: 1363 A: of congenital myasthenia caused by mutation in the long cytoplasmic loop of the epsilon subunit of the acetylcholine receptor and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 3397 offsetEnd: 3545 A: clinical report of the presenting features of newly diagnosed myasthenia with anti-LRP4 antibodies. The clinical and therapeutic implications of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22091897 offsetBegin: 3011 offsetEnd: 3163 A: gravis AND neuromuscular blockade reversal and myasthenia gravis AND pyridostigmine. The articles included were from reviews and clinical trials written
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 543 offsetEnd: 684 A: generalized MG (MGFA V) and at 11 years, she underwent thymectomy. She had been treated successfully only with anti-cholinesterase inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 684 offsetEnd: 828 A: 11 years, she underwent thymectomy. She had been treated successfully only with anti-cholinesterase inhibitors for 22 years despite lasting high
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 828 offsetEnd: 983 A: had been treated successfully only with anti-cholinesterase inhibitors for 22 years despite lasting high titer of anti-acetylcholine receptor antibody. She
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22849994 offsetBegin: 983 offsetEnd: 1134 A: anti-cholinesterase inhibitors for 22 years despite lasting high titer of anti-acetylcholine receptor antibody. She could manage everything in her life
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 2656 offsetEnd: 2784 A: drug class putting a special emphasis on AD therapy in the first place. Several inhibitors of cholinesterases with synthetic and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 2784 offsetEnd: 2912 A: on AD therapy in the first place. Several inhibitors of cholinesterases with synthetic and natural origins are available in drug
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 2912 offsetEnd: 3057 A: place. Several inhibitors of cholinesterases with synthetic and natural origins are available in drug market; however, the reasons including side
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 3466 offsetEnd: 3593 A: etc. limit their uses in medicine and there is still a great demand to discover new cholinesterase inhibitors. Galanthamine, an
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 3593 offsetEnd: 3740 A: and there is still a great demand to discover new cholinesterase inhibitors. Galanthamine, an alkaloid derivative isolated from snowdrop (Galanthus
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 3740 offsetEnd: 3906 A: demand to discover new cholinesterase inhibitors. Galanthamine, an alkaloid derivative isolated from snowdrop (Galanthus nivalis L.), is the latest anticholinesterase
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 4869 offsetEnd: 5002 A: in China. In this review, a short introduction will be given on known cholinesterase inhibitors and, then, galanthamine and huperzine
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 5002 offsetEnd: 5135 A: short introduction will be given on known cholinesterase inhibitors and, then, galanthamine and huperzine A will be covered in regard
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 5135 offsetEnd: 5284 A: known cholinesterase inhibitors and, then, galanthamine and huperzine A will be covered in regard with their cholinesterase inhibitory potentials and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21762104 offsetBegin: 5284 offsetEnd: 5419 A: and huperzine A will be covered in regard with their cholinesterase inhibitory potentials and mass productions by organic synthesis and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 2088 offsetEnd: 2257 A: annual MG-related pharmacy costs were $9.4 million; IVIg accounted for 85% of all MG-related pharmacy costs. Non-steroidal immunosuppressives, cholinesterase inhibitors,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 2257 offsetEnd: 2429 A: million; IVIg accounted for 85% of all MG-related pharmacy costs. Non-steroidal immunosuppressives, cholinesterase inhibitors, and corticosteroids accounted for 9.3%, 5.7%,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22102461 offsetBegin: 2429 offsetEnd: 2608 A: all MG-related pharmacy costs. Non-steroidal immunosuppressives, cholinesterase inhibitors, and corticosteroids accounted for 9.3%, 5.7%, and 0.2% of pharmacy costs, respectively.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 4447 offsetEnd: 4579 A: resulted in a dramatic increase in this ratio, and a significant recovery towards normal ratios occurred after EN101 treatment. This
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 4579 offsetEnd: 4719 A: this ratio, and a significant recovery towards normal ratios occurred after EN101 treatment. This improvement was primarily due to increased
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 4719 offsetEnd: 4866 A: towards normal ratios occurred after EN101 treatment. This improvement was primarily due to increased synaptic AChR content. Our findings emphasise
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22805122 offsetBegin: 4866 offsetEnd: 5008 A: treatment. This improvement was primarily due to increased synaptic AChR content. Our findings emphasise the tight connection between AChR and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23234677 offsetBegin: 442 offsetEnd: 602 A: gravis cases have acetylcholine receptor antibodies. Approximately 30% of the remaining cases have antibodies against muscle-specific kinase. Information on the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23404334 offsetBegin: 301 offsetEnd: 460 A: from impaired signal transmission at the neuromuscular synapse. They are characterized by fatigable muscle weakness. We performed linkage analysis, whole-exome
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23404334 offsetBegin: 460 offsetEnd: 623 A: neuromuscular synapse. They are characterized by fatigable muscle weakness. We performed linkage analysis, whole-exome and whole-genome sequencing to determine the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23404334 offsetBegin: 623 offsetEnd: 775 A: fatigable muscle weakness. We performed linkage analysis, whole-exome and whole-genome sequencing to determine the underlying defect in patients with an
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 1553 offsetEnd: 1712 A: we injected MuSK protein into mice deficient in complement component five (C5). MuSK-injected mice simultaneously developed severe muscle weakness, accompanied
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 1712 offsetEnd: 1876 A: deficient in complement component five (C5). MuSK-injected mice simultaneously developed severe muscle weakness, accompanied by an electromyographic pattern such as
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22142810 offsetBegin: 1876 offsetEnd: 2033 A: MuSK-injected mice simultaneously developed severe muscle weakness, accompanied by an electromyographic pattern such as is typically observed in MG patients.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24145588 offsetBegin: 778 offsetEnd: 953 A: consists of bedside assessment, antibody testing, and electrophysiologic studies. Various therapeutic options are available, which consist of anticholinesterase inhibitors for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24145588 offsetBegin: 953 offsetEnd: 1142 A: and electrophysiologic studies. Various therapeutic options are available, which consist of anticholinesterase inhibitors for symptomatic management, immunosuppressive agents as maintenance
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24145588 offsetBegin: 1142 offsetEnd: 1327 A: are available, which consist of anticholinesterase inhibitors for symptomatic management, immunosuppressive agents as maintenance therapy, and thymectomy. Plasmapheresis and intravenous
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24145588 offsetBegin: 1327 offsetEnd: 1500 A: inhibitors for symptomatic management, immunosuppressive agents as maintenance therapy, and thymectomy. Plasmapheresis and intravenous immunoglobulin are used in patients in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 295 offsetEnd: 463 A: antibodies to acetylcholine receptor or muscle specific kinase (double seronegative myasthenia). The presence of anti-low density lipoprotein receptor-related protein 4
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23768983 offsetBegin: 463 offsetEnd: 624 A: specific kinase (double seronegative myasthenia). The presence of anti-low density lipoprotein receptor-related protein 4 antibodies (LRP4 Abs) has recently been
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 506 offsetEnd: 622 A: review will touch upon some of his work as it discusses current therapies and the potential for new treatments based
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 622 offsetEnd: 740 A: his work as it discusses current therapies and the potential for new treatments based on the evolving knowledge of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 740 offsetEnd: 862 A: therapies and the potential for new treatments based on the evolving knowledge of the underlying basis of the disease. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 862 offsetEnd: 996 A: treatments based on the evolving knowledge of the underlying basis of the disease. The recognition of different immune mechanisms that
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 1671 offsetEnd: 1795 A: antibodies and other new therapies that can target specific aspects of the disease. This has raised our hopes for treatments
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 1795 offsetEnd: 1912 A: can target specific aspects of the disease. This has raised our hopes for treatments that will have less side effects
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 1912 offsetEnd: 2025 A: disease. This has raised our hopes for treatments that will have less side effects and be more effective. In some
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23938353 offsetBegin: 2025 offsetEnd: 2141 A: for treatments that will have less side effects and be more effective. In some cases these hopes have been realized.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 405 offsetEnd: 549 A: gravis, a neuromuscular disease that usually results in skeletal muscle weakness, which worsens with exercise and strenuous aerobic exercise, is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22311063 offsetBegin: 549 offsetEnd: 698 A: results in skeletal muscle weakness, which worsens with exercise and strenuous aerobic exercise, is generally contraindicated. Our runner completed a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4528 offsetEnd: 4672 A: of outcome measuresPrimary outcome measureImprovement in the presenting symptoms within 1 to 14 days of the start of treatment.Secondary outcome
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4672 offsetEnd: 4810 A: the presenting symptoms within 1 to 14 days of the start of treatment.Secondary outcome measures(1) Improvement in the presenting symptoms
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4810 offsetEnd: 4940 A: 14 days of the start of treatment.Secondary outcome measures(1) Improvement in the presenting symptoms more than 14 days after the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 4940 offsetEnd: 5090 A: treatment.Secondary outcome measures(1) Improvement in the presenting symptoms more than 14 days after the start of treatment.(2) Change in impairment
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5090 offsetEnd: 5221 A: presenting symptoms more than 14 days after the start of treatment.(2) Change in impairment measured by a recognised and preferably
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 5221 offsetEnd: 5356 A: after the start of treatment.(2) Change in impairment measured by a recognised and preferably validated scale, such as the quantitative
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 6136 offsetEnd: 6286 A: America post-intervention status more than 14 days after start of treatment.(4) Adverse events: muscarinic side effects. DATA COLLECTION AND ANALYSIS:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328290 offsetBegin: 6286 offsetEnd: 6427 A: days after start of treatment.(4) Adverse events: muscarinic side effects. DATA COLLECTION AND ANALYSIS: One author (MMM) extracted the data,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 312 offsetEnd: 492 A: (OP) pesticides in exposed farmers for electroencephalography, cognitive state, psychological disorders, clinical symptom, oxidative stress, acetylcholinesterase, and DNA damage. A
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 492 offsetEnd: 686 A: electroencephalography, cognitive state, psychological disorders, clinical symptom, oxidative stress, acetylcholinesterase, and DNA damage. A comparative cross-sectional analysis was carried out
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 686 offsetEnd: 841 A: symptom, oxidative stress, acetylcholinesterase, and DNA damage. A comparative cross-sectional analysis was carried out in 40 horticulture farmers who were
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 3246 offsetEnd: 3375 A: of SOD and LPO while their TAC decreased. Farmers showed clinical symptoms such as eczema, breathing muscle weakness, nausea, and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 3375 offsetEnd: 3529 A: TAC decreased. Farmers showed clinical symptoms such as eczema, breathing muscle weakness, nausea, and saliva secretion. Regarding cognitive function, the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21632574 offsetBegin: 3529 offsetEnd: 3697 A: such as eczema, breathing muscle weakness, nausea, and saliva secretion. Regarding cognitive function, the orientation, registration, attention and calculation, recall,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23794683 offsetBegin: 4617 offsetEnd: 4755 A: apoptotic nuclei. Glycoprotein expression in muscle was absent in patient 6 and reduced in 5 others. CONCLUSIONS: GFPT1-myasthenia is more
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23794683 offsetBegin: 4755 offsetEnd: 4902 A: was absent in patient 6 and reduced in 5 others. CONCLUSIONS: GFPT1-myasthenia is more heterogeneous than previously reported. Different parameters
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23794683 offsetBegin: 4902 offsetEnd: 5074 A: reduced in 5 others. CONCLUSIONS: GFPT1-myasthenia is more heterogeneous than previously reported. Different parameters of neuromuscular transmission are variably affected.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 1506 offsetEnd: 1667 A: the patient, and associated health care costs. Therapy is aimed at managing symptoms by improving neuromuscular junction transmission (cholinesterase inhibitors)
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 1667 offsetEnd: 1845 A: costs. Therapy is aimed at managing symptoms by improving neuromuscular junction transmission (cholinesterase inhibitors) and/or modifying the underlying immunopathogenetic cause
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20842584 offsetBegin: 3880 offsetEnd: 4027 A: long-term management of ocular myasthenia. Acute management of myasthenic crisis requires intensive monitoring of the patient and institution of an
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 0 offsetEnd: 148 A: Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 1249 offsetEnd: 1405 A: nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 1405 offsetEnd: 1560 A: management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21053987 offsetBegin: 1560 offsetEnd: 1720 A: considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 2451 offsetEnd: 2594 A: to fall during activities, such as climbing stairs. On examination,she had moderately severe fatigable proximal muscle weakness and ptosis. Her
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 2594 offsetEnd: 2772 A: climbing stairs. On examination,she had moderately severe fatigable proximal muscle weakness and ptosis. Her weakness improved with intravenous edrophonium administration.Initial
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21969350 offsetBegin: 2772 offsetEnd: 2949 A: severe fatigable proximal muscle weakness and ptosis. Her weakness improved with intravenous edrophonium administration.Initial binding acetylcholine receptor antibody titer was
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 0 offsetEnd: 170 A: Dynamin-2-related centronuclear myopathy (DNM2-CNM) is a clinically heterogeneous muscle disorder characterized by muscle weakness and centralized nuclei on biopsy. There
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 170 offsetEnd: 316 A: clinically heterogeneous muscle disorder characterized by muscle weakness and centralized nuclei on biopsy. There is little known about the muscle
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 316 offsetEnd: 452 A: muscle weakness and centralized nuclei on biopsy. There is little known about the muscle dysfunction underlying this disorder, and there
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 452 offsetEnd: 583 A: biopsy. There is little known about the muscle dysfunction underlying this disorder, and there are currently no treatments. In this
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 583 offsetEnd: 716 A: the muscle dysfunction underlying this disorder, and there are currently no treatments. In this study, we establish a novel zebrafish
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 716 offsetEnd: 849 A: and there are currently no treatments. In this study, we establish a novel zebrafish model for DNM2-CNM by transiently overexpressing
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 1560 offsetEnd: 1690 A: pathological changes in muscle and a severe motor phenotype. We further demonstrate that the muscle weakness seen in these animals
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 3621 offsetEnd: 3753 A: that deficits at the neuromuscular junction may play an important role in the pathogenesis of DNM2-CNM and that treatments targeting
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23338057 offsetBegin: 3753 offsetEnd: 3883 A: may play an important role in the pathogenesis of DNM2-CNM and that treatments targeting this dysfunction can provide an effective
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 792 offsetEnd: 948 A: role in ending cholinergic neurotransmission. Cholinesterase inhibitors are substances, either natural or man-made that interfere with the break-down of ACh
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 948 offsetEnd: 1079 A: inhibitors are substances, either natural or man-made that interfere with the break-down of ACh and prolong its action. Hence their
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 1802 offsetEnd: 1961 A: cholinesterases and their inhibition. Particular attention is paid to the toxicology and pharmacology of cholinesterase-related inhibitors such as nerve agents
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 1961 offsetEnd: 2104 A: is paid to the toxicology and pharmacology of cholinesterase-related inhibitors such as nerve agents (e.g. sarin, soman, tabun, VX), pesticides
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22286807 offsetBegin: 2104 offsetEnd: 2278 A: pharmacology of cholinesterase-related inhibitors such as nerve agents (e.g. sarin, soman, tabun, VX), pesticides (e.g. paraoxon, parathion, malathion, malaoxon, carbofuran),
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 1900 offsetEnd: 2033 A: to belong to the AChR-MG or MuSK-MG group of patients, this article reviews the pathophysiology, clinical features, and treatments in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 2033 offsetEnd: 2169 A: MuSK-MG group of patients, this article reviews the pathophysiology, clinical features, and treatments in these 2 groups of MG patients.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 2169 offsetEnd: 2307 A: reviews the pathophysiology, clinical features, and treatments in these 2 groups of MG patients. The pathophysiology of AChR-MG is closely
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 2307 offsetEnd: 2435 A: treatments in these 2 groups of MG patients. The pathophysiology of AChR-MG is closely related to the abnormal thymic pathology,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 3727 offsetEnd: 3866 A: define the indications of thymectomy in MuSK-MG patients are required. The responses to cholinesterase inhibitors are poor in patients with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 3866 offsetEnd: 4001 A: MuSK-MG patients are required. The responses to cholinesterase inhibitors are poor in patients with MuSK-MG, and these patients tend to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 4001 offsetEnd: 4132 A: to cholinesterase inhibitors are poor in patients with MuSK-MG, and these patients tend to show hyperactivity to the Tensilon test,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 5480 offsetEnd: 5629 A: to avoid cholinergic hyperactivity. In general, both types of MG patients respond well to treatments with immunosuppressants, including steroids, but
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747139 offsetBegin: 5629 offsetEnd: 5773 A: both types of MG patients respond well to treatments with immunosuppressants, including steroids, but some patients with MuSK-MG show persistent
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21681282 offsetBegin: 6451 offsetEnd: 6599 A: which are different from western patients or adult MG in morbidity, sex distribution, progress, laboratory examination and treatment. The prevalence
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 1907 offsetEnd: 2039 A: importance of the cholinergic nervous system, the biochemistry of AChE and the role of AChE inhibitors. Current efforts to introduce
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 2039 offsetEnd: 2170 A: the biochemistry of AChE and the role of AChE inhibitors. Current efforts to introduce potent drugs for Alzheimer's disease therapy
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 2170 offsetEnd: 2307 A: role of AChE inhibitors. Current efforts to introduce potent drugs for Alzheimer's disease therapy and reduce toxicity, while keeping the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 2605 offsetEnd: 2748 A: keeping the maximal pharmacological effect, are also discussed. EXPERT OPINION: The current research effort into AChE inhibitors can be divided
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 2748 offsetEnd: 2882 A: also discussed. EXPERT OPINION: The current research effort into AChE inhibitors can be divided into two categories. First, new toxins
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 2882 offsetEnd: 3017 A: research effort into AChE inhibitors can be divided into two categories. First, new toxins useful for agricultural purposes and second,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 3496 offsetEnd: 3616 A: less interest in the new toxins. The research for drugs for Alzheimer's disease needs to focus on inhibitors that reduce
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22768972 offsetBegin: 3616 offsetEnd: 3742 A: The research for drugs for Alzheimer's disease needs to focus on inhibitors that reduce the deposition of amyloid plaques, but
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 2288 offsetEnd: 2440 A: patients with disabling weakness, not sufficiently managed with cholinesterase inhibitors. Prednisolone (PSL) is used in the great majority of patients.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21747144 offsetBegin: 2440 offsetEnd: 2588 A: managed with cholinesterase inhibitors. Prednisolone (PSL) is used in the great majority of patients. Tacrolimus and cyclosporine are the first-line
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 154 offsetEnd: 311 A: heterogeneous group of disorders caused by genetic defects affecting neuromuscular transmission and leading to muscle weakness accentuated by exertion. Three
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 311 offsetEnd: 469 A: genetic defects affecting neuromuscular transmission and leading to muscle weakness accentuated by exertion. Three different aspects have been investigated by
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 469 offsetEnd: 605 A: leading to muscle weakness accentuated by exertion. Three different aspects have been investigated by members of the national French CMS
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 1121 offsetEnd: 1257 A: and long-term prognosis; and the response to therapy, especially for CMS that do not respond to cholinesterase inhibitors. CMS diagnosis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 1257 offsetEnd: 1381 A: to therapy, especially for CMS that do not respond to cholinesterase inhibitors. CMS diagnosis is late in most cases because
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 1381 offsetEnd: 1507 A: do not respond to cholinesterase inhibitors. CMS diagnosis is late in most cases because of confusion with other entities such
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 1763 offsetEnd: 1905 A: entities such as: congenital myopathies, due to the frequent presentation in patients of myopathies such as permanent muscle weakness, atrophy
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 1905 offsetEnd: 2042 A: to the frequent presentation in patients of myopathies such as permanent muscle weakness, atrophy and scoliosis, and the abnormalities of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23452772 offsetBegin: 2042 offsetEnd: 2187 A: of myopathies such as permanent muscle weakness, atrophy and scoliosis, and the abnormalities of internal structure, diameter and distribution of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 2394 offsetEnd: 2544 A: a diagnosis of Lambert-Eaton myasthenic syndrome, with or without small-cell lung cancer, receiving any form of pharmacological or physical treatment.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 2544 offsetEnd: 2686 A: with or without small-cell lung cancer, receiving any form of pharmacological or physical treatment. DATA COLLECTION AND ANALYSIS: All authors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 2686 offsetEnd: 2837 A: receiving any form of pharmacological or physical treatment. DATA COLLECTION AND ANALYSIS: All authors independently assessed studies for inclusion and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 2837 offsetEnd: 2992 A: physical treatment. DATA COLLECTION AND ANALYSIS: All authors independently assessed studies for inclusion and extracted data. Study authors were contacted
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 5104 offsetEnd: 5234 A: in the primary outcome, muscle strength score, or myometric limb measurement for between hours and a week following treatment, and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 5234 offsetEnd: 5375 A: score, or myometric limb measurement for between hours and a week following treatment, and significant improvement in resting compound muscle
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 5375 offsetEnd: 5540 A: between hours and a week following treatment, and significant improvement in resting compound muscle action potential (CMAP) amplitude following 3,4-diaminopyridine,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 5540 offsetEnd: 5715 A: treatment, and significant improvement in resting compound muscle action potential (CMAP) amplitude following 3,4-diaminopyridine, compared with placebo.A meta-analysis of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21328260 offsetBegin: 9077 offsetEnd: 9228 A: participants with Lambert-Eaton myasthenic syndrome. There are insufficient data at present to quantify this effect. Other possible treatments have not
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 665 offsetEnd: 800 A: weakness is a major cause of morbidity and mortality of poisoning. Organophosphate pesticide induced muscle weakness may not only arise
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 1484 offsetEnd: 1634 A: mitochondrial dysfunction, affecting the production of sufficient ATP for muscle function. This study examined whether muscle weakness in rats subject
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 1634 offsetEnd: 1776 A: sufficient ATP for muscle function. This study examined whether muscle weakness in rats subject to monocrotophos toxicity (0.8LD₅₀) was caused
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 1776 offsetEnd: 1912 A: study examined whether muscle weakness in rats subject to monocrotophos toxicity (0.8LD₅₀) was caused by inhibition of ATP synthesis, by
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 2060 offsetEnd: 2212 A: was caused by inhibition of ATP synthesis, by oxidative phosphorylation and glycolysis, in addition to inhibition of muscle acetylcholinesterase. Severe
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 2212 offsetEnd: 2380 A: synthesis, by oxidative phosphorylation and glycolysis, in addition to inhibition of muscle acetylcholinesterase. Severe muscle weakness in rats following monocrotophos
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 2380 offsetEnd: 2541 A: in addition to inhibition of muscle acetylcholinesterase. Severe muscle weakness in rats following monocrotophos administration was associated with inhibition of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20728503 offsetBegin: 3028 offsetEnd: 3159 A: not with reduced ATP production. The rats rapidly recovered muscle strength with no treatment. The ability of rats to spontaneously
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 642 offsetEnd: 802 A: with pyridostigmine, a cholinesterase inhibitor, or with 3,4-diaminopyridine, which increases the release of ACh quanta. The clinical efficacy of pyridostigmine
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 940 offsetEnd: 1065 A: of ACh quanta. The clinical efficacy of pyridostigmine is in doubt for certain forms of myasthenia. Here we formally examined
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1065 offsetEnd: 1187 A: of pyridostigmine is in doubt for certain forms of myasthenia. Here we formally examined the effects of these compounds in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 1187 offsetEnd: 1332 A: certain forms of myasthenia. Here we formally examined the effects of these compounds in the antibody-induced mouse model of anti-muscle-specific
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23440963 offsetBegin: 2079 offsetEnd: 2242 A: gravis. This caused reductions in postsynaptic AChR densities and in endplate potential amplitudes. Systemic delivery of pyridostigmine at therapeutically relevant
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 1394 offsetEnd: 1530 A: and pain. Review of published literature about MG. CONCLUSIONS: MG is a pure motor syndrome characterized by fluctuating muscle weakness
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 1530 offsetEnd: 1659 A: about MG. CONCLUSIONS: MG is a pure motor syndrome characterized by fluctuating muscle weakness and fatigue and is exacerbated by
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 1659 offsetEnd: 1793 A: pure motor syndrome characterized by fluctuating muscle weakness and fatigue and is exacerbated by sustained muscle use. It is usually
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 1793 offsetEnd: 1915 A: muscle weakness and fatigue and is exacerbated by sustained muscle use. It is usually caused by an autoimmune process that
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 2964 offsetEnd: 3092 A: The NP must include MG in the differential diagnosis with any report of fluctuating muscle weakness or other neurological, upper
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 3092 offsetEnd: 3254 A: the differential diagnosis with any report of fluctuating muscle weakness or other neurological, upper gastrointestinal, respiratory, or ophthalmic complaint. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 3254 offsetEnd: 3410 A: of fluctuating muscle weakness or other neurological, upper gastrointestinal, respiratory, or ophthalmic complaint. The key diagnostic finding is a specific
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 3410 offsetEnd: 3565 A: neurological, upper gastrointestinal, respiratory, or ophthalmic complaint. The key diagnostic finding is a specific muscle weakness that can be reproduced
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 3565 offsetEnd: 3698 A: complaint. The key diagnostic finding is a specific muscle weakness that can be reproduced and exacerbated with sustained muscle use.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20854638 offsetBegin: 3698 offsetEnd: 3832 A: a specific muscle weakness that can be reproduced and exacerbated with sustained muscle use. These considerations will lead to earlier
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23172384 offsetBegin: 297 offsetEnd: 442 A: gravis (MG). METHODS: The clinical and electrophysiological features among 15 cases of muscle-specific kinase antibody positive (MuSK Ab+) MG, 59
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 2192 offsetEnd: 2347 A: immunosuppressants were less frequently used in the ptosis group. There were no significant differences in the post-treatment condition and quality-of-life
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 2347 offsetEnd: 2495 A: the ptosis group. There were no significant differences in the post-treatment condition and quality-of-life (QOL) impairment between the two groups.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24291968 offsetBegin: 2495 offsetEnd: 2652 A: significant differences in the post-treatment condition and quality-of-life (QOL) impairment between the two groups. Forty-seven (38%) patients who failed to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23376659 offsetBegin: 1068 offsetEnd: 1211 A: gravis (MG) including similar patients who were previously documented. Six patients presented with neck weakness and three had bulbar symptoms.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23703814 offsetBegin: 4403 offsetEnd: 4508 A: for muscle weakness, but this is not the only factor involved in the incidence of this weakness in IMS or
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 2642 offsetEnd: 2793 A: response. These observations suggest that a neuromuscular transmission defect may accompany CNM and contribute to muscle weakness. Muscle biopsy should
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21440438 offsetBegin: 2793 offsetEnd: 2938 A: neuromuscular transmission defect may accompany CNM and contribute to muscle weakness. Muscle biopsy should be considered in infants suspected to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 163 offsetEnd: 309 A: genetic mutations affecting neuromuscular transmission, characterized by muscle weakness usually starting in childhood. A two and a half years old
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23823963 offsetBegin: 309 offsetEnd: 428 A: by muscle weakness usually starting in childhood. A two and a half years old male child presented with bilateral ptosis
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 870 offsetEnd: 1012 A: gravis (MG), whose MG status has been "minimal manifestation" for several years, developed moderately severe fluctuating bulbar weakness a few
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 3096 offsetEnd: 3238 A: The symptoms were again resolved after discontinuation of statin and temporarily increased dosage of cholinesterase inhibitor. She was back to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 3238 offsetEnd: 3393 A: discontinuation of statin and temporarily increased dosage of cholinesterase inhibitor. She was back to previous status in two months. Hypercholesterolemia
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21534375 offsetBegin: 3393 offsetEnd: 3539 A: dosage of cholinesterase inhibitor. She was back to previous status in two months. Hypercholesterolemia was then controlled with ezetimibe without
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 966 offsetEnd: 1126 A: based on presence or absence of acetylcholine receptor or muscle-specific kinase antibodies and presence of thymoma. Cholinesterase inhibitors partially improve
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 1126 offsetEnd: 1289 A: acetylcholine receptor or muscle-specific kinase antibodies and presence of thymoma. Cholinesterase inhibitors partially improve weakness, but the vast majority of
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/20927659 offsetBegin: 1289 offsetEnd: 1437 A: and presence of thymoma. Cholinesterase inhibitors partially improve weakness, but the vast majority of patients require therapies that moderate the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23757472 offsetBegin: 3799 offsetEnd: 3969 A: the attending anesthesiologists without the use of neuromuscular function monitoring devices. To ascertain the incidence of postoperative residual neuromuscular weakness,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23757472 offsetBegin: 3969 offsetEnd: 4137 A: of neuromuscular function monitoring devices. To ascertain the incidence of postoperative residual neuromuscular weakness, the train-of-four ratio (TOFR) was determined
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23757472 offsetBegin: 4137 offsetEnd: 4316 A: ascertain the incidence of postoperative residual neuromuscular weakness, the train-of-four ratio (TOFR) was determined acceleromyographically after tracheal extubation. Since our
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23757472 offsetBegin: 4316 offsetEnd: 4484 A: neuromuscular weakness, the train-of-four ratio (TOFR) was determined acceleromyographically after tracheal extubation. Since our practice also does not usually involve
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 1220 offsetEnd: 1348 A: Around 15% of cases are associated with a thymoma. MG presents with fatiguable painless muscle weakness. Diplopia and ptosis are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 1348 offsetEnd: 1485 A: with a thymoma. MG presents with fatiguable painless muscle weakness. Diplopia and ptosis are the most common presenting features. Around
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 1485 offsetEnd: 1628 A: fatiguable painless muscle weakness. Diplopia and ptosis are the most common presenting features. Around 80% of patients presenting with ocular
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 1767 offsetEnd: 1913 A: features. Around 80% of patients presenting with ocular MG will subsequently develop more generalised weakness. Respiratory muscle weakness is the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 1913 offsetEnd: 2052 A: with ocular MG will subsequently develop more generalised weakness. Respiratory muscle weakness is the most serious manifestation of MG and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 2052 offsetEnd: 2183 A: more generalised weakness. Respiratory muscle weakness is the most serious manifestation of MG and can be fatal. A detailed history
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 4627 offsetEnd: 4768 A: and prednisolone is generally used as the first-line agent. Despite the availability of symptomatic and immunomodulatory treatment, up to 20%
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 4768 offsetEnd: 4912 A: the first-line agent. Despite the availability of symptomatic and immunomodulatory treatment, up to 20% of patients will experience a myasthenic
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21133188 offsetBegin: 4912 offsetEnd: 5060 A: of symptomatic and immunomodulatory treatment, up to 20% of patients will experience a myasthenic crisis requiring admission for ventilatory support
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23640144 offsetBegin: 1639 offsetEnd: 1786 A: resolution of her renal function. CONCLUSIONS: Organophosphate poisoning can lead to renal failure, which, with proper treatment, may be reversible
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23640144 offsetBegin: 1786 offsetEnd: 1927 A: Organophosphate poisoning can lead to renal failure, which, with proper treatment, may be reversible but, if left unattended, might aggravate
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23640144 offsetBegin: 1927 offsetEnd: 2060 A: failure, which, with proper treatment, may be reversible but, if left unattended, might aggravate the clinical course of the disease.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22216416 offsetBegin: 1624 offsetEnd: 1776 A: cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 913 offsetEnd: 1059 A: was determined and the results were compared to the known effective inhibitors such as ambenonium dichloride, edrophonium bromide and experimental
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24220173 offsetBegin: 1059 offsetEnd: 1254 A: compared to the known effective inhibitors such as ambenonium dichloride, edrophonium bromide and experimental compound BW284C51. Two compounds, 1-(10-(pyridinium-1-yl)decyl)quinolinium dibromide
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22689834 offsetBegin: 271 offsetEnd: 404 A: gravis (MG), most common being ptosis. However, ptosis may be caused by a variety of non-myasthenic disorders; hence, the distinction
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 3913 offsetEnd: 4057 A: of autoimmune MG. As AChR deficiency is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 4057 offsetEnd: 4199 A: is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient's MuSK-IgG
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22981737 offsetBegin: 4199 offsetEnd: 4336 A: inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient's MuSK-IgG interferes with binding of ColQ to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23279780 offsetBegin: 419 offsetEnd: 555 A: gravis (MG) are significantly less likely to convert to a generalized disease when treated early on with corticosteroids. However, given
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21397501 offsetBegin: 688 offsetEnd: 853 A: (BChE). Their inhibitory (IC(50)) and was compared to the chosen standards ambenonium dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride. One
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1029 offsetEnd: 1154 A: and memory loss associated with these diseases. A variety of plants has been reported to possess AChE inhibitory activity and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1154 offsetEnd: 1267 A: diseases. A variety of plants has been reported to possess AChE inhibitory activity and so may be relevant to the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21222577 offsetBegin: 1664 offsetEnd: 1782 A: such as AD. Hence, developing potential AChE inhibitors from botanicals is the need of the day. This review will cover
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22316202 offsetBegin: 3697 offsetEnd: 3845 A: treatment. NEW OR UNIQUE INFORMATION PROVIDED: Cholinergic crisis and differentiation from a myasthenic crisis is described in the human literature.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 654 offsetEnd: 797 A: (GFPT1). METHODS: Clinical and neurophysiological assessment was made in a Korean boy who had proximal limb muscle weakness. Findings suggested
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 797 offsetEnd: 926 A: was made in a Korean boy who had proximal limb muscle weakness. Findings suggested a diagnosis of congenital myasthenic syndrome.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22987706 offsetBegin: 926 offsetEnd: 1076 A: who had proximal limb muscle weakness. Findings suggested a diagnosis of congenital myasthenic syndrome. RESULTS: Muscle biopsy disclosed numerous TAs
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 2448 offsetEnd: 2584 A: in 99%, accompanied with ophthalmoplegia in 63%, diplopia in 19.3%, extremity weakness in 13.4%, respiratory muscle weakness in 9%, head
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 2584 offsetEnd: 2710 A: 63%, diplopia in 19.3%, extremity weakness in 13.4%, respiratory muscle weakness in 9%, head tilt in 10.1%, dysphagia in 7.5%,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22043769 offsetBegin: 2710 offsetEnd: 2833 A: in 13.4%, respiratory muscle weakness in 9%, head tilt in 10.1%, dysphagia in 7.5%, hyperthyroidism in 3.4% and epilepsy in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 2493 offsetEnd: 2666 A: diseases, most commonly hyperthyroidism and Hashimoto's disease. Diagnosis relies on the clinical features, improvement with cholinesterase inhibitors, detection of specific
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 2666 offsetEnd: 2840 A: disease. Diagnosis relies on the clinical features, improvement with cholinesterase inhibitors, detection of specific autoantibodies (anti-AChR or anti-MuSK), and significant
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 2840 offsetEnd: 3027 A: features, improvement with cholinesterase inhibitors, detection of specific autoantibodies (anti-AChR or anti-MuSK), and significant decrement evidenced by electrophysiological tests. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4583 offsetEnd: 4739 A: is well codified: (1) respect of adverse drugs contra-indications, systematically use of cholinesterase inhibitors, (2) thymectomy if thymoma completed with
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4739 offsetEnd: 4912 A: adverse drugs contra-indications, systematically use of cholinesterase inhibitors, (2) thymectomy if thymoma completed with radiotherapy if malignant, (3) corticosteroids or
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24112993 offsetBegin: 4912 offsetEnd: 5076 A: cholinesterase inhibitors, (2) thymectomy if thymoma completed with radiotherapy if malignant, (3) corticosteroids or immunosuppressive agent in severe or disabling
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 293 offsetEnd: 438 A: from impaired signal transmission at the neuromuscular synapse. They are characterized by fatigable muscle weakness. This is a heterogenous group
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 438 offsetEnd: 579 A: neuromuscular synapse. They are characterized by fatigable muscle weakness. This is a heterogenous group of disorders with 15 different genes
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23278575 offsetBegin: 579 offsetEnd: 708 A: fatigable muscle weakness. This is a heterogenous group of disorders with 15 different genes implicated in the development of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 1273 offsetEnd: 1399 A: old with ≥1 of the following: (1) fluctuating ptosis or extraocular weakness, (2) skeletal muscle weakness or fatigue, and (3)
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 1399 offsetEnd: 1534 A: (1) fluctuating ptosis or extraocular weakness, (2) skeletal muscle weakness or fatigue, and (3) any of the following supportive tests:
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/24019417 offsetBegin: 2030 offsetEnd: 2195 A: inhibitor, positive antibodies, abnormal slow repetitive nerve stimulation, or single-fiber electromyography. RESULTS: In 2 years of surveillance, 57 confirmed cases
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 297 offsetEnd: 436 A: inherited disorders of the neuromuscular junction. A difficult to diagnose subgroup of CMS is characterised by proximal muscle weakness and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 436 offsetEnd: 568 A: A difficult to diagnose subgroup of CMS is characterised by proximal muscle weakness and fatigue while ocular and facial involvement
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21975507 offsetBegin: 568 offsetEnd: 701 A: CMS is characterised by proximal muscle weakness and fatigue while ocular and facial involvement is only minimal. DOK7 mutations have
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 460 offsetEnd: 614 A: lethality. MTM is defined by muscle biopsy findings that include centralized nuclei and disorganization of perinuclear organelles. No treatments currently
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 614 offsetEnd: 768 A: biopsy findings that include centralized nuclei and disorganization of perinuclear organelles. No treatments currently exist for MTM. We hypothesized that
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 768 offsetEnd: 928 A: and disorganization of perinuclear organelles. No treatments currently exist for MTM. We hypothesized that aberrant neuromuscular junction (NMJ) transmission is
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22645112 offsetBegin: 928 offsetEnd: 1084 A: treatments currently exist for MTM. We hypothesized that aberrant neuromuscular junction (NMJ) transmission is an important and potentially treatable aspect
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 771 offsetEnd: 916 A: to ensure peripheral effect of action and minimal blood-brain barrier penetration. The most prescribed carbamate inhibitors are however known for
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 916 offsetEnd: 1059 A: and minimal blood-brain barrier penetration. The most prescribed carbamate inhibitors are however known for many severe side effects related to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 1059 offsetEnd: 1191 A: most prescribed carbamate inhibitors are however known for many severe side effects related to the carbamylation of AChE. This paper
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 1320 offsetEnd: 1465 A: related to the carbamylation of AChE. This paper describes preparation and in vitro evaluation of 20 newly prepared bis-isoquinolinium inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 1465 offsetEnd: 1605 A: This paper describes preparation and in vitro evaluation of 20 newly prepared bis-isoquinolinium inhibitors of potential concern for MG. The
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 1605 offsetEnd: 1748 A: vitro evaluation of 20 newly prepared bis-isoquinolinium inhibitors of potential concern for MG. The newly prepared compounds were evaluated in
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 1748 offsetEnd: 1889 A: bis-isoquinolinium inhibitors of potential concern for MG. The newly prepared compounds were evaluated in vitro on human recombinant AChE and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 1889 offsetEnd: 2038 A: MG. The newly prepared compounds were evaluated in vitro on human recombinant AChE and human plasmatic butyrylcholinesterase (BChE). Their inhibitory
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 2038 offsetEnd: 2183 A: evaluated in vitro on human recombinant AChE and human plasmatic butyrylcholinesterase (BChE). Their inhibitory ability was expressed as IC50 and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 2183 offsetEnd: 2340 A: AChE and human plasmatic butyrylcholinesterase (BChE). Their inhibitory ability was expressed as IC50 and compared to chosen standards ambenonium dichloride,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 2340 offsetEnd: 2506 A: Their inhibitory ability was expressed as IC50 and compared to chosen standards ambenonium dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 3112 offsetEnd: 3234 A: both enzymes in vitro better or similar to edrophonium and BW284c51, but worse to ambenonium. The novel inhibitors did not
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 3234 offsetEnd: 3366 A: similar to edrophonium and BW284c51, but worse to ambenonium. The novel inhibitors did not present higher selectivity toward AChE or
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21236521 offsetBegin: 3366 offsetEnd: 3507 A: worse to ambenonium. The novel inhibitors did not present higher selectivity toward AChE or BChE. The kinetic assay confirmed non-competitive
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 152 offsetEnd: 316 A: chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1843 offsetEnd: 1981 A: pyridostigmine. Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 1981 offsetEnd: 2111 A: from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 2111 offsetEnd: 2243 A: support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG.
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 3258 offsetEnd: 3408 A: an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 3408 offsetEnd: 3563 A: severe disease who are also receiving immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 3563 offsetEnd: 3716 A: immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising. In general,
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 3716 offsetEnd: 3868 A: antisense oligonucleotides have been developed and preliminary results appear to be promising. In general, however, AChE inhibitors provide only partial
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 3868 offsetEnd: 4013 A: preliminary results appear to be promising. In general, however, AChE inhibitors provide only partial benefit and most patients eventually switch
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 4013 offsetEnd: 4172 A: In general, however, AChE inhibitors provide only partial benefit and most patients eventually switch to long-term immunosuppressive therapies, most frequently
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 4172 offsetEnd: 4348 A: only partial benefit and most patients eventually switch to long-term immunosuppressive therapies, most frequently corticosteroids and/or azathioprine. Although AChE inhibitors
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 4348 offsetEnd: 4516 A: eventually switch to long-term immunosuppressive therapies, most frequently corticosteroids and/or azathioprine. Although AChE inhibitors are known to be well tolerated
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 4516 offsetEnd: 4664 A: most frequently corticosteroids and/or azathioprine. Although AChE inhibitors are known to be well tolerated and effective in relieving the symptoms
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21815707 offsetBegin: 4664 offsetEnd: 4786 A: AChE inhibitors are known to be well tolerated and effective in relieving the symptoms of MG, further efforts are required
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 301 offsetEnd: 456 A: from impaired signal transmission at the neuromuscular synapse. They are characterized by fatigable muscle weakness. We performed whole-exome sequencing to
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 456 offsetEnd: 607 A: neuromuscular synapse. They are characterized by fatigable muscle weakness. We performed whole-exome sequencing to determine the underlying defect in a
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 607 offsetEnd: 748 A: fatigable muscle weakness. We performed whole-exome sequencing to determine the underlying defect in a group of individuals with an inherited
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22742743 offsetBegin: 2325 offsetEnd: 2463 A: inhibitors and 3,4-diaminopyridine, and the presence of tubular aggregates in muscle biopsies. Analyses of motor endplates from two of the
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22005151 offsetBegin: 1660 offsetEnd: 1775 A: gravis who underwent surgery between 1999 and 2009 were eligible for the study. The mean follow-up was of 67 months
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 0 offsetEnd: 155 A: Diabetic neuropathy is associated with functional and morphological changes of the neuromuscular junction (NMJ) associated with muscle weakness. This study
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 155 offsetEnd: 290 A: and morphological changes of the neuromuscular junction (NMJ) associated with muscle weakness. This study examines the effect of type 1
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/22739110 offsetBegin: 290 offsetEnd: 418 A: junction (NMJ) associated with muscle weakness. This study examines the effect of type 1 diabetes on NMJ function. Swiss Webster
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 285 offsetEnd: 420 A: symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1430 offsetEnd: 1568 A: specific questions. Are there any treatments that impact the progression from ocular to generalized disease? Are there any treatments that
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1568 offsetEnd: 1701 A: that impact the progression from ocular to generalized disease? Are there any treatments that improve symptoms of diplopia or ptosis?
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1701 offsetEnd: 1827 A: to generalized disease? Are there any treatments that improve symptoms of diplopia or ptosis? What is the frequency of adverse
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1827 offsetEnd: 1963 A: treatments that improve symptoms of diplopia or ptosis? What is the frequency of adverse effects associated with treatments used? SEARCH
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 1963 offsetEnd: 2090 A: or ptosis? What is the frequency of adverse effects associated with treatments used? SEARCH METHODS: In this updated review, we
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 2090 offsetEnd: 2234 A: of adverse effects associated with treatments used? SEARCH METHODS: In this updated review, we searched the Cochrane Neuromuscular Disease Group
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 6239 offsetEnd: 6378 A: ocular symptoms, and the frequency of treatment-related side effects. MAIN RESULTS: In the original review, we identified two RCTs relevant
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/23235620 offsetBegin: 6769 offsetEnd: 6895 A: ocular myasthenia, only one of which reported results in terms of the pre-specified outcome measures used in this review. This
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 2219 offsetEnd: 2386 A: cognitive event-related potentials to assess the patient's potential for awakening. Electrophysiological testing used to monitor muscle weakness showed the coexistence
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 2386 offsetEnd: 2547 A: patient's potential for awakening. Electrophysiological testing used to monitor muscle weakness showed the coexistence of 20 Hz-decremental responses in proximal
Q:Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis? Document:http://www.ncbi.nlm.nih.gov/pubmed/21370952 offsetBegin: 2547 offsetEnd: 2685 A: used to monitor muscle weakness showed the coexistence of 20 Hz-decremental responses in proximal muscles and severe denervation in distal
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3959 offsetEnd: 4088 A: and proportions of the isochore classes. The relative density of genes, Alu and long interspersed nuclear element repeats and the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 1260 offsetEnd: 1403 A: (particularly Alu elements) present in these upstream regions. This effect is completely separable from effects of isochore composition on gene
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/8276253 offsetBegin: 763 offsetEnd: 894 A: of Alu element retropositions within a TAA minisatellite. Extensive homologies between the left viral end and the host cellular DNA
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 3878 offsetEnd: 4016 A: more frequent in GC-poor isochores. Finally, the present results on Alu and LINE stability/exclusion predict significant losses of Alu DNA
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/8276253 offsetBegin: 505 offsetEnd: 627 A: in a genomic region which has been the target of multiple events of Alu element retropositions within a TAA minisatellite.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/8276253 offsetBegin: 627 offsetEnd: 763 A: been the target of multiple events of Alu element retropositions within a TAA minisatellite. Extensive homologies between the left viral
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 4016 offsetEnd: 4154 A: the present results on Alu and LINE stability/exclusion predict significant losses of Alu DNA from the GC-poor isochores during evolution,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 2535 offsetEnd: 2678 A: significant; (3) isochore boundaries are accurately defined to single base pair resolution; and (4) both gradual and abrupt isochore boundaries
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3828 offsetEnd: 3959 A: features, mainly size distribution, G+C range, and proportions of the isochore classes. The relative density of genes, Alu and long
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 4088 offsetEnd: 4227 A: The relative density of genes, Alu and long interspersed nuclear element repeats and the different types of single nucleotide polymorphisms
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 236 offsetEnd: 353 A: elements, the Alu sequences, has been investigated for the past 30 years, and the vast majority of Alu sequences were
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3694 offsetEnd: 3828 A: show many of the typical isochore features, mainly size distribution, G+C range, and proportions of the isochore classes. The relative
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 1541 offsetEnd: 1675 A: regions (LHGRs), thereby revealing the isochore structure of the human genome. The advantages of the isochore maps presented here are:
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3545 offsetEnd: 3694 A: isochores revealed through DNA centrifugation. LHGRs show many of the typical isochore features, mainly size distribution, G+C range, and proportions
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 4516 offsetEnd: 4667 A: nucleotide polymorphisms on LHGRs also coincide with expectations in true isochores. Potential applications of isochore maps range from the improvement
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 702 offsetEnd: 839 A: highest density in GC-rich isochores. Ten years ago, it was discovered, however, that the small "youngest" (most recently transposed) Alu
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 1101 offsetEnd: 1260 A: compositional structure of repetitive genomic sequences (particularly Alu elements) present in these upstream regions. This effect is completely separable from
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 1403 offsetEnd: 1555 A: upstream regions. This effect is completely separable from effects of isochore composition on gene expression. The results implicate repetitive elements
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 1555 offsetEnd: 1708 A: separable from effects of isochore composition on gene expression. The results implicate repetitive elements with some functional role in transcriptional
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 2120 offsetEnd: 2257 A: genes in whose promoter regions they reside and lend credence to suggestions that the general phenomenon of repetitive element insertions
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 2257 offsetEnd: 2401 A: reside and lend credence to suggestions that the general phenomenon of repetitive element insertions may be a fundamental evolutionary mechanism
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 997 offsetEnd: 1147 A: sequence context. We show that Alu elements are more highly concentrated around housekeeping genes while various longer (>400-bp) repetitive sequences
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 1493 offsetEnd: 1654 A: repetitive sequences ("repeats"), including Long Interspersed Nuclear Element-1 (LINE-1) elements, are excluded from these regions. We further show that isochore
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 1654 offsetEnd: 1804 A: Nuclear Element-1 (LINE-1) elements, are excluded from these regions. We further show that isochore membership does not distinguish housekeeping genes
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 3737 offsetEnd: 3878 A: to LINEs, processed pseudogenes are also more frequent in GC-poor isochores. Finally, the present results on Alu and LINE stability/exclusion
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 4154 offsetEnd: 4301 A: LINE stability/exclusion predict significant losses of Alu DNA from the GC-poor isochores during evolution, a phenomenon apparently due to negative
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 2534 offsetEnd: 2659 A: gene frequency. (iv) The frequency of Alu sequences also increases with increasing GC, but attains a maximum in H2 isochores,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/18032720 offsetBegin: 4315 offsetEnd: 4472 A: gene conversion. Fifth, transcription status and location in a particular isochore do not influence microsatellite mutability. Sixth, compared with intrinsic
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/18032720 offsetBegin: 4472 offsetEnd: 4625 A: location in a particular isochore do not influence microsatellite mutability. Sixth, compared with intrinsic features, regional genomic factors have only
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 4996 offsetEnd: 5139 A: evolutionary divergence shown by recently inserted Alu subfamilies and the higher frequency of old stand-alone Alus in L isochores-support such
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 1810 offsetEnd: 1938 A: advantages of the isochore maps presented here are: (1) sequence heterogeneities at different scales are shown in the same plot;
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 2229 offsetEnd: 2389 A: same plot; (2) pair-wise compositional differences between adjacent regions are all statistically significant; (3) isochore boundaries are accurately defined to
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 2389 offsetEnd: 2535 A: between adjacent regions are all statistically significant; (3) isochore boundaries are accurately defined to single base pair resolution; and (4)
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 2678 offsetEnd: 2818 A: defined to single base pair resolution; and (4) both gradual and abrupt isochore boundaries are simultaneously revealed. Taking advantage of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3398 offsetEnd: 3545 A: correspondence between LHGRs and true human isochores revealed through DNA centrifugation. LHGRs show many of the typical isochore features, mainly
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 4227 offsetEnd: 4372 A: and long interspersed nuclear element repeats and the different types of single nucleotide polymorphisms on LHGRs also coincide with expectations
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 2150 offsetEnd: 2273 A: 18 and 19. Further analysis revealed that both the 5' and 3' breakpoints were located within highly homologous Alu elements
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 2273 offsetEnd: 2393 A: that both the 5' and 3' breakpoints were located within highly homologous Alu elements (Alu-Sz in intron 18 and Alu-Sq2,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 4558 offsetEnd: 4688 A: 62 bp fragment corresponds to the Alu-Sz element integrated in intron 18.This represents the first description of a large deletion
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 466 offsetEnd: 580 A: and the vast majority of Alu sequences were shown to have the highest density in GC-rich isochores. Ten years ago,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 2127 offsetEnd: 2251 A: sequences, and 2) assessing the densities of acceptor sites TTTT/AA in isochore families. We could conclude 1) that the open
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 2251 offsetEnd: 2370 A: of acceptor sites TTTT/AA in isochore families. We could conclude 1) that the open state of chromatin structure plays a
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 3070 offsetEnd: 3184 A: that the distribution of old Alus can be explained as due to Alu sequences being unstable in the GC-poor isochores
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 2548 offsetEnd: 2693 A: chicken, turkey, and quail. Analysis of individual substitution frequencies is consistent with the biased gene conversion (BGC) model of isochore
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 2693 offsetEnd: 2831 A: individual substitution frequencies is consistent with the biased gene conversion (BGC) model of isochore evolution, and it is likely that
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 943 offsetEnd: 1101 A: depends most strongly originates in the compositional structure of repetitive genomic sequences (particularly Alu elements) present in these upstream regions.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 710 offsetEnd: 852 A: whether housekeeping genes can be distinguished from tissue-specific genes by their repetitive sequence context. We show that Alu elements are
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 852 offsetEnd: 997 A: from tissue-specific genes by their repetitive sequence context. We show that Alu elements are more highly concentrated around housekeeping genes
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 1369 offsetEnd: 1507 A: show such a different distribution in the genome. This problem was investigated here by studying the isochore distributions of subfamilies
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 4301 offsetEnd: 4438 A: Alu DNA from the GC-poor isochores during evolution, a phenomenon apparently due to negative selection against sequences that differ from
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/18032720 offsetBegin: 4183 offsetEnd: 4315 A: the latter suggesting a role for gene conversion. Fifth, transcription status and location in a particular isochore do not influence
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 1706 offsetEnd: 1845 A: of their evolutionary age, isochore membership, and intron vs. intergene location. Since Alus depend on the retrotransposase encoded by the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 5139 offsetEnd: 5278 A: Alu subfamilies and the higher frequency of old stand-alone Alus in L isochores-support such a conclusion. Other evolutionary factors, such
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 1261 offsetEnd: 1401 A: longest contigs in the human genome draft sequence into long homogeneous genome regions (LHGRs), thereby revealing the isochore structure of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 2818 offsetEnd: 2953 A: and (4) both gradual and abrupt isochore boundaries are simultaneously revealed. Taking advantage of the wide sample of genome sequence
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 2953 offsetEnd: 3108 A: isochore boundaries are simultaneously revealed. Taking advantage of the wide sample of genome sequence analyzed, we investigate the correspondence between
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 4667 offsetEnd: 4815 A: with expectations in true isochores. Potential applications of isochore maps range from the improvement of gene-finding algorithms to the prediction
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 2393 offsetEnd: 2525 A: breakpoints were located within highly homologous Alu elements (Alu-Sz in intron 18 and Alu-Sq2, in intron 19), suggesting that this
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 2525 offsetEnd: 2651 A: Alu elements (Alu-Sz in intron 18 and Alu-Sq2, in intron 19), suggesting that this deletion has probably resulted from Alu-Alu
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 4410 offsetEnd: 4558 A: from intron 18 (p.Arg1145Serfs*16). Interestingly, this 62 bp fragment corresponds to the Alu-Sz element integrated in intron 18.This represents the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 4688 offsetEnd: 4818 A: Alu-Sz element integrated in intron 18.This represents the first description of a large deletion identified in the GNPTAB gene and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 3184 offsetEnd: 3307 A: can be explained as due to Alu sequences being unstable in the GC-poor isochores but stable in the compositionally matching
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 1610 offsetEnd: 1749 A: genomes of birds and mammals--the isochore structure. In contrast to mammals, where GC content is becoming homogenized, heterogeneity in GC
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 2831 offsetEnd: 2951 A: the biased gene conversion (BGC) model of isochore evolution, and it is likely that patterns of evolution in the chicken
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 2659 offsetEnd: 2792 A: Alu sequences also increases with increasing GC, but attains a maximum in H2 isochores, in agreement with previous experimental data.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 4065 offsetEnd: 4216 A: strongly methylated Alu sequences in GC-rich isochores; this stresses the much lower relative methylation (5mC/CpG) of single-copy sequences located in
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 1580 offsetEnd: 1706 A: of the Alus as a function of their evolutionary age, isochore membership, and intron vs. intergene location. Since Alus depend
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 4275 offsetEnd: 4410 A: consisting of a 62 bp fragment from intron 18 (p.Arg1145Serfs*16). Interestingly, this 62 bp fragment corresponds to the Alu-Sz element
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 4818 offsetEnd: 4943 A: represents the first description of a large deletion identified in the GNPTAB gene and contributes to enrich the knowledge on
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 4943 offsetEnd: 5086 A: large deletion identified in the GNPTAB gene and contributes to enrich the knowledge on the molecular mechanisms underlying causative mutations
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 1991 offsetEnd: 2127 A: the integration and stability of retroviral sequences, and 2) assessing the densities of acceptor sites TTTT/AA in isochore families. We
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 2951 offsetEnd: 3069 A: of isochore evolution, and it is likely that patterns of evolution in the chicken genome closely resemble those in the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 1804 offsetEnd: 1951 A: from these regions. We further show that isochore membership does not distinguish housekeeping genes from tissue-specific genes and that repetitive
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 1507 offsetEnd: 1642 A: the genome. This problem was investigated here by studying the isochore distributions of subfamilies of LINES and Alus characterized by
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3932 offsetEnd: 4065 A: in spite of the increase of strongly methylated Alu sequences in GC-rich isochores; this stresses the much lower relative methylation
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 1401 offsetEnd: 1541 A: draft sequence into long homogeneous genome regions (LHGRs), thereby revealing the isochore structure of the human genome. The advantages of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 1675 offsetEnd: 1810 A: structure of the human genome. The advantages of the isochore maps presented here are: (1) sequence heterogeneities at different scales
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 4815 offsetEnd: 4964 A: applications of isochore maps range from the improvement of gene-finding algorithms to the prediction of linkage disequilibrium levels in association
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 3307 offsetEnd: 3441 A: Alu sequences being unstable in the GC-poor isochores but stable in the compositionally matching GC-rich isochores, again in line with
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 765 offsetEnd: 882 A: arises: What is the evolutionary mechanism that shifts the Alu density maximum from L to H isochores? To disclose the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 882 offsetEnd: 983 A: that shifts the Alu density maximum from L to H isochores? To disclose the role played by each of the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 1356 offsetEnd: 1489 A: origin and evolution of large-scale heterogeneity in GC content found in the genomes of birds and mammals--the isochore structure. In
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 1489 offsetEnd: 1610 A: in GC content found in the genomes of birds and mammals--the isochore structure. In contrast to mammals, where GC content
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 1642 offsetEnd: 1776 A: here by studying the isochore distributions of subfamilies of LINES and Alus characterized by different degrees of divergence from the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3806 offsetEnd: 3932 A: in GC-rich isochores, and takes place in spite of the increase of strongly methylated Alu sequences in GC-rich isochores; this
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 1458 offsetEnd: 1580 A: a genome-wide analysis of the density of the Alus as a function of their evolutionary age, isochore membership, and intron
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 1951 offsetEnd: 2121 A: that isochore membership does not distinguish housekeeping genes from tissue-specific genes and that repetitive sequence environment distinguishes housekeeping genes from
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 0 offsetEnd: 123 A: The distribution in the human genome of the largest family of mobile elements, the Alu sequences, has been investigated for
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 123 offsetEnd: 236 A: of the largest family of mobile elements, the Alu sequences, has been investigated for the past 30 years, and the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 645 offsetEnd: 765 A: into the L isochores, the question arises: What is the evolutionary mechanism that shifts the Alu density maximum from L
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 0 offsetEnd: 122 A: The human genome is a mosaic of isochores, which are long DNA segments (z.Gt;300 kbp) relatively homogeneous in G+C. Human
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 122 offsetEnd: 267 A: of isochores, which are long DNA segments (z.Gt;300 kbp) relatively homogeneous in G+C. Human isochores were first identified by density-gradient
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 267 offsetEnd: 423 A: segments (z.Gt;300 kbp) relatively homogeneous in G+C. Human isochores were first identified by density-gradient ultracentrifugation of bulk DNA, and differ
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 423 offsetEnd: 567 A: G+C. Human isochores were first identified by density-gradient ultracentrifugation of bulk DNA, and differ in important features, e.g. genes are
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 567 offsetEnd: 717 A: by density-gradient ultracentrifugation of bulk DNA, and differ in important features, e.g. genes are found predominantly in the GC-richest isochores.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 717 offsetEnd: 851 A: and differ in important features, e.g. genes are found predominantly in the GC-richest isochores. Here, we use a reliable segmentation
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 851 offsetEnd: 986 A: genes are found predominantly in the GC-richest isochores. Here, we use a reliable segmentation method to partition the longest contigs
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 986 offsetEnd: 1119 A: GC-richest isochores. Here, we use a reliable segmentation method to partition the longest contigs in the human genome draft sequence
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3108 offsetEnd: 3247 A: advantage of the wide sample of genome sequence analyzed, we investigate the correspondence between LHGRs and true human isochores revealed
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 3247 offsetEnd: 3398 A: genome sequence analyzed, we investigate the correspondence between LHGRs and true human isochores revealed through DNA centrifugation. LHGRs show many
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12468093 offsetBegin: 4372 offsetEnd: 4516 A: and the different types of single nucleotide polymorphisms on LHGRs also coincide with expectations in true isochores. Potential applications of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 2797 offsetEnd: 2946 A: that this deletion has probably resulted from Alu-Alu unequal homologous recombination. RT-PCR methods were used to further evaluate the consequences
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 2946 offsetEnd: 3091 A: from Alu-Alu unequal homologous recombination. RT-PCR methods were used to further evaluate the consequences of the alteration for the processing
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/23430906 offsetBegin: 3091 offsetEnd: 3213 A: methods were used to further evaluate the consequences of the alteration for the processing of the mutant pre mRNA GNPTAB,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 0 offsetEnd: 137 A: A new explanation for the emergence of heavy (GC-rich) isochores is proposed, based on the study of thermostability, bendability, ability
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 137 offsetEnd: 273 A: of heavy (GC-rich) isochores is proposed, based on the study of thermostability, bendability, ability to B-Z transition and curvature of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 273 offsetEnd: 402 A: based on the study of thermostability, bendability, ability to B-Z transition and curvature of the DNA helix. The absolute values
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 402 offsetEnd: 539 A: bendability, ability to B-Z transition and curvature of the DNA helix. The absolute values of thermostability, bendability and ability to
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 539 offsetEnd: 678 A: curvature of the DNA helix. The absolute values of thermostability, bendability and ability to B-Z transition correlated positively with GC
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 678 offsetEnd: 839 A: absolute values of thermostability, bendability and ability to B-Z transition correlated positively with GC content, whereas curvature correlated negatively. The
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 839 offsetEnd: 989 A: ability to B-Z transition correlated positively with GC content, whereas curvature correlated negatively. The relative values of these parameters were
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 989 offsetEnd: 1139 A: with GC content, whereas curvature correlated negatively. The relative values of these parameters were determined as compared to randomized sequences.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 1139 offsetEnd: 1278 A: negatively. The relative values of these parameters were determined as compared to randomized sequences. In genes and intergenic spacers of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 2647 offsetEnd: 2777 A: thermostability of DNA (as compared to synonymous codons with the same GC content). The analysis of transposable elements (Alu and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 2777 offsetEnd: 2896 A: synonymous codons with the same GC content). The analysis of transposable elements (Alu and B2 repeats in the human and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 2896 offsetEnd: 3012 A: content). The analysis of transposable elements (Alu and B2 repeats in the human and mouse) showed that the level of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 3992 offsetEnd: 4143 A: are known to relate to open chromatin and active transcription, whereas curvature facilitates chromatin condensation. Because heavy isochores are known
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 4143 offsetEnd: 4293 A: chromatin and active transcription, whereas curvature facilitates chromatin condensation. Because heavy isochores are known to be gene-rich and show a
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 4293 offsetEnd: 4424 A: facilitates chromatin condensation. Because heavy isochores are known to be gene-rich and show a high level of transcription, it is
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 4424 offsetEnd: 4535 A: are known to be gene-rich and show a high level of transcription, it is suggested here that isochores arose not
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 4535 offsetEnd: 4657 A: show a high level of transcription, it is suggested here that isochores arose not as an adaptation to elevated temperature
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12654999 offsetBegin: 4657 offsetEnd: 4774 A: it is suggested here that isochores arose not as an adaptation to elevated temperature but because of a certain grade
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 580 offsetEnd: 702 A: sequences were shown to have the highest density in GC-rich isochores. Ten years ago, it was discovered, however, that the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/22057813 offsetBegin: 3441 offsetEnd: 3567 A: GC-poor isochores but stable in the compositionally matching GC-rich isochores, again in line with what happens in the case of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 0 offsetEnd: 135 A: Interspersed repeats have emerged as a valuable tool for studying neutral patterns of molecular evolution. Here we analyze variation in
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 135 offsetEnd: 266 A: valuable tool for studying neutral patterns of molecular evolution. Here we analyze variation in the rate and pattern of nucleotide
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 3191 offsetEnd: 3333 A: the chicken genome closely resemble those in the ancestral amniote genome, when it is inferred that isochores originated. Microchromosomes and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 3333 offsetEnd: 3478 A: in the ancestral amniote genome, when it is inferred that isochores originated. Microchromosomes and distal regions of macrochromosomes are found
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/16551647 offsetBegin: 3478 offsetEnd: 3625 A: it is inferred that isochores originated. Microchromosomes and distal regions of macrochromosomes are found to have elevated substitution rates and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/8276253 offsetBegin: 1447 offsetEnd: 1583 A: region of viral integration is consistent with the observed insertion of exogenous DNA in isochores of similar composition [G. Bernardi,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 1708 offsetEnd: 1850 A: on gene expression. The results implicate repetitive elements with some functional role in transcriptional regulation of the specific genes in
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12948482 offsetBegin: 1850 offsetEnd: 1989 A: repetitive elements with some functional role in transcriptional regulation of the specific genes in whose promoter regions they reside and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 1147 offsetEnd: 1321 A: elements are more highly concentrated around housekeeping genes while various longer (>400-bp) repetitive sequences ("repeats"), including Long Interspersed Nuclear Element-1
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 1321 offsetEnd: 1493 A: housekeeping genes while various longer (>400-bp) repetitive sequences ("repeats"), including Long Interspersed Nuclear Element-1 (LINE-1) elements, are excluded from these
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 2121 offsetEnd: 2290 A: housekeeping genes from tissue-specific genes and that repetitive sequence environment distinguishes housekeeping genes from tissue-specific genes in every isochore. The
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 2290 offsetEnd: 2466 A: that repetitive sequence environment distinguishes housekeeping genes from tissue-specific genes in every isochore. The distinct repetitive sequence environment, in combination
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 2466 offsetEnd: 2630 A: genes from tissue-specific genes in every isochore. The distinct repetitive sequence environment, in combination with other previously published sequence properties
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17141428 offsetBegin: 2630 offsetEnd: 2787 A: isochore. The distinct repetitive sequence environment, in combination with other previously published sequence properties of housekeeping genes, was used to
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 243 offsetEnd: 371 A: unevenly distributed in the human genome. The majority of GC-poor LINEs reside in the GC-poor isochores whereas GC-rich Alus are
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 371 offsetEnd: 498 A: The majority of GC-poor LINEs reside in the GC-poor isochores whereas GC-rich Alus are mostly present in GC-rich isochores. The
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 498 offsetEnd: 624 A: in the GC-poor isochores whereas GC-rich Alus are mostly present in GC-rich isochores. The discovery that LINES and Alus share
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 624 offsetEnd: 747 A: Alus are mostly present in GC-rich isochores. The discovery that LINES and Alus share similar target site duplication and a
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 747 offsetEnd: 884 A: isochores. The discovery that LINES and Alus share similar target site duplication and a common AT-rich insertion site specificity raised
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 2494 offsetEnd: 2613 A: part of the genome than old Alus. This suggests that the gradual accumulation of Alus in GC-rich isochores has occurred
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 2613 offsetEnd: 2741 A: Alus. This suggests that the gradual accumulation of Alus in GC-rich isochores has occurred because of their higher stability in
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 2741 offsetEnd: 2891 A: accumulation of Alus in GC-rich isochores has occurred because of their higher stability in compositionally matching chromosomal regions. Densities of
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/11591470 offsetBegin: 3599 offsetEnd: 3737 A: of the analyzed chromosomes. In addition to LINEs, processed pseudogenes are also more frequent in GC-poor isochores. Finally, the present
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 369 offsetEnd: 495 A: led to the following observations. (i) Positive correlations hold between CpG levels and the GC levels of isochores and coding
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 495 offsetEnd: 628 A: Positive correlations hold between CpG levels and the GC levels of isochores and coding sequences, as expected from previous results.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 628 offsetEnd: 755 A: and the GC levels of isochores and coding sequences, as expected from previous results. (ii) The correlation between CpG levels
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 884 offsetEnd: 1011 A: previous results. (ii) The correlation between CpG levels and the GC levels of pseudogenes is characterized by lower CpG values
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 1011 offsetEnd: 1124 A: CpG levels and the GC levels of pseudogenes is characterized by lower CpG values (at comparable GC levels) and by
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 1124 offsetEnd: 1240 A: of pseudogenes is characterized by lower CpG values (at comparable GC levels) and by a lower slope compared with the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 1240 offsetEnd: 1363 A: CpG values (at comparable GC levels) and by a lower slope compared with the correlation with coding sequences; this finding
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 2792 offsetEnd: 2915 A: GC, but attains a maximum in H2 isochores, in agreement with previous experimental data. (v) The ratio 5mC/CpG (namely, the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 2915 offsetEnd: 3059 A: H2 isochores, in agreement with previous experimental data. (v) The ratio 5mC/CpG (namely, the methylation level over available sites) decreases
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3059 offsetEnd: 3202 A: experimental data. (v) The ratio 5mC/CpG (namely, the methylation level over available sites) decreases with increasing GC levels of isochores.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3202 offsetEnd: 3333 A: (namely, the methylation level over available sites) decreases with increasing GC levels of isochores. This decrease is due only to
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3333 offsetEnd: 3449 A: sites) decreases with increasing GC levels of isochores. This decrease is due only to a small extent to the increase
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3449 offsetEnd: 3563 A: of isochores. This decrease is due only to a small extent to the increase of (unmethylated) CpG islands in GC-rich
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3563 offsetEnd: 3678 A: only to a small extent to the increase of (unmethylated) CpG islands in GC-rich isochores, and takes place in spite
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 3678 offsetEnd: 3806 A: the increase of (unmethylated) CpG islands in GC-rich isochores, and takes place in spite of the increase of strongly methylated
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 4216 offsetEnd: 4366 A: isochores; this stresses the much lower relative methylation (5mC/CpG) of single-copy sequences located in GC-rich isochores relative to those located
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 4366 offsetEnd: 4514 A: relative methylation (5mC/CpG) of single-copy sequences located in GC-rich isochores relative to those located in GC-poor isochores. (vi) CpG levels
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 4514 offsetEnd: 4634 A: located in GC-rich isochores relative to those located in GC-poor isochores. (vi) CpG levels of Alus and CpG islands are
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/9931467 offsetBegin: 4634 offsetEnd: 4754 A: those located in GC-poor isochores. (vi) CpG levels of Alus and CpG islands are positively correlated with the GC levels
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12047939 offsetBegin: 1598 offsetEnd: 1736 A: insertions. This correlation with the intron size was stronger than with the gene-wide or isochore-wide parameters. The density of repeats
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12047939 offsetBegin: 1736 offsetEnd: 1857 A: size was stronger than with the gene-wide or isochore-wide parameters. The density of repeats (the number of repeats in a
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/12047939 offsetBegin: 1857 offsetEnd: 1991 A: gene-wide or isochore-wide parameters. The density of repeats (the number of repeats in a unit of intron length) correlated positively
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17442506 offsetBegin: 4166 offsetEnd: 4318 A: biased gene conversion, and also indicates that like chickens, but unlike eutherian mammals, GC content heterogeneity (isochore structure) is reinforced
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17442506 offsetBegin: 4318 offsetEnd: 4463 A: that like chickens, but unlike eutherian mammals, GC content heterogeneity (isochore structure) is reinforced by substitution processes in the M.
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/17442506 offsetBegin: 4463 offsetEnd: 4613 A: mammals, GC content heterogeneity (isochore structure) is reinforced by substitution processes in the M. domestica genome. Nevertheless, both high and
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 122 offsetEnd: 249 A: homogeneous distribution over the human genome but have a higher density in GC-rich (H) than in AT-rich (L) isochores. However,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 249 offsetEnd: 371 A: but have a higher density in GC-rich (H) than in AT-rich (L) isochores. However, since they preferentially insert into the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 371 offsetEnd: 503 A: GC-rich (H) than in AT-rich (L) isochores. However, since they preferentially insert into the L isochores, the question arises: What
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 503 offsetEnd: 645 A: isochores. However, since they preferentially insert into the L isochores, the question arises: What is the evolutionary mechanism that shifts
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 983 offsetEnd: 1093 A: from L to H isochores? To disclose the role played by each of the potential mechanisms involved in such biased
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 1845 offsetEnd: 1972 A: and intron vs. intergene location. Since Alus depend on the retrotransposase encoded by the LINE1 elements, we also studied the
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 1972 offsetEnd: 2093 A: Alus depend on the retrotransposase encoded by the LINE1 elements, we also studied the distribution of LINE1 to provide a
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 2093 offsetEnd: 2226 A: by the LINE1 elements, we also studied the distribution of LINE1 to provide a complete evolutionary scenario. We consecutively check,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 3668 offsetEnd: 3793 A: trimers are much more frequent than expected, the observed/expected ratio being higher in L than in H isochores. This result,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 3793 offsetEnd: 3923 A: expected, the observed/expected ratio being higher in L than in H isochores. This result, together with the known higher selective
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 3923 offsetEnd: 4046 A: in L than in H isochores. This result, together with the known higher selective disadvantage of recombination products in H
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 4046 offsetEnd: 4189 A: This result, together with the known higher selective disadvantage of recombination products in H isochores, points to Alu-Alu recombination as
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 4189 offsetEnd: 4332 A: higher selective disadvantage of recombination products in H isochores, points to Alu-Alu recombination as the main agent provoking the density
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 4332 offsetEnd: 4452 A: in H isochores, points to Alu-Alu recombination as the main agent provoking the density shift of Alus toward the GC-rich
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 5278 offsetEnd: 5429 A: of old stand-alone Alus in L isochores-support such a conclusion. Other evolutionary factors, such as population bottlenecks during primate speciation,
Q:In which isochores are Alu elements enriched? Document:http://www.ncbi.nlm.nih.gov/pubmed/15871047 offsetBegin: 5429 offsetEnd: 5594 A: isochores-support such a conclusion. Other evolutionary factors, such as population bottlenecks during primate speciation, may have accelerated the fast accumulation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 1939 offsetEnd: 2080 A: cancer growth. TPL2 activation by over-expressing either wild-type or a constitutively activated form of TPL2 induced ADI growth, whereas the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2210 offsetEnd: 2332 A: form of TPL2 induced ADI growth, whereas the suppression of TPL2 expression and its kinase activity in ADI prostate cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3773 offsetEnd: 3920 A: prostate cancer progression. Furthermore, the suppression of TPL2 diminishes ADI prostate cancer growth and a high frequency of TPL2 overexpression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3920 offsetEnd: 4046 A: of TPL2 diminishes ADI prostate cancer growth and a high frequency of TPL2 overexpression in human ADI prostate cancer samples
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1788 offsetEnd: 1918 A: luciferase (Fluc) genes were linked to form hNIS/Fluc double fusion reporter gene and then generate human gastric cancer cell line
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 1786 offsetEnd: 1939 A: serine/threonine kinase, as driving ADI prostate cancer growth. TPL2 activation by over-expressing either wild-type or a constitutively activated form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 0 offsetEnd: 113 A: Skin cancer is the most common form of cancer in the USA, with an estimated two million cases diagnosed annually.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2541 offsetEnd: 2672 A: Mcm2-7 associate with Cdc45 and GINS to form a relatively stable CMG (Cdc45-MCM-GINS) complex. The CMG proteins also associate less
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1918 offsetEnd: 2054 A: form hNIS/Fluc double fusion reporter gene and then generate human gastric cancer cell line NF-3xmir16 and its multidrug resistance cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12090470 offsetBegin: 0 offsetEnd: 129 A: Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer known. IBC carries a guarded prognosis
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 1488 offsetEnd: 1605 A: exploited as a strategy for killing human cancer cells, we used gene transfer experiments with a range of cancer cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 1605 offsetEnd: 1729 A: human cancer cells, we used gene transfer experiments with a range of cancer cell lines. We expressed the catalytic fragment
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2080 offsetEnd: 2210 A: either wild-type or a constitutively activated form of TPL2 induced ADI growth, whereas the suppression of TPL2 expression and its
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 4046 offsetEnd: 4164 A: growth and a high frequency of TPL2 overexpression in human ADI prostate cancer samples validates TPL2 as a target for
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1636 offsetEnd: 1765 A: this study, we used gene expression profiling to compare expression levels between Tpl2 (+/+) and Tpl2 (-) (/-) keratinocytes. We
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3509 offsetEnd: 3637 A: that TPL2 kinase plays a critical role in the promotion of ADI prostate cancer progression. Furthermore, the suppression of TPL2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3637 offsetEnd: 3773 A: role in the promotion of ADI prostate cancer progression. Furthermore, the suppression of TPL2 diminishes ADI prostate cancer growth and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 5048 offsetEnd: 5233 A: in 12-O-tetradecanoylphorbol-13-acetate-treated skin from Tpl2 (-/-) mice and grafted tumors formed from v-ras(Ha) retrovirus-infected Tpl2 (-/-) keratinocytes. Additionally, Tpl2 (-/-)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 113 offsetEnd: 234 A: form of cancer in the USA, with an estimated two million cases diagnosed annually. Tumor progression locus 2 (Tpl2), also
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2287 offsetEnd: 2411 A: bidirectional replication forks in S phase. We also show that after initiation, Mcm2-7 associate with Cdc45 and GINS to form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2411 offsetEnd: 2541 A: We also show that after initiation, Mcm2-7 associate with Cdc45 and GINS to form a relatively stable CMG (Cdc45-MCM-GINS) complex.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 0 offsetEnd: 151 A: MicroRNAs (miRNAs) are small noncoding RNA molecules of 20-24 nucleotides that regulate gene expression. In animals, miRNAs form imperfect interactions
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694536 offsetBegin: 0 offsetEnd: 173 A: BACKGROUND: Nectins are Ca2+-independent immunoglobulin-like cell-cell adhesion molecules which associate with cadherins to form adherens junctions (AJs) in epithelial cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 1513 offsetEnd: 1668 A: Additionally, mammalian DBHS proteins associate with the architectural long noncoding RNA NEAT1 (Menε/β) to form paraspeckles, subnuclear bodies that alter
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 3485 offsetEnd: 3638 A: tissue plasminogen activator (tPA) and matrix metallopeptidases (MMPs) is reported to associate with the development of cancer cell mobility, metastasis,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 3638 offsetEnd: 3798 A: metallopeptidases (MMPs) is reported to associate with the development of cancer cell mobility, metastasis, and subsequent malignant tumor. After administration
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 5211 offsetEnd: 5347 A: form colonies in soft agar, while FHL2 overexpression enhances colony formation of breast cancer cells. Thus, our findings indicate that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21635933 offsetBegin: 1815 offsetEnd: 1951 A: these topologies can play a role in telomere regulation and gene expression. The core structures of G-quadruplexes form stable scaffolds
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22724069 offsetBegin: 2968 offsetEnd: 3112 A: to form polymers and associate with membranes. Phosphorylation at these sites appears essential for CHMP4C function because their mutation leads
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 1584 offsetEnd: 1728 A: phosphorylated by c-Jun N-terminal kinase (JNK-1) associates with c-Fos to form the AP-1 transcription factor that activates gene expression. We
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 142 offsetEnd: 275 A: 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC). We have previously
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 2876 offsetEnd: 3025 A: into cells inducing gene silencing. Our explicit solvent molecular dynamics (MD) simulations showed that bolaamphiphiles associate with siRNAs due to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 1369 offsetEnd: 1488 A: and explore whether it can be exploited as a strategy for killing human cancer cells, we used gene transfer experiments
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 1635 offsetEnd: 1786 A: we have identified TPL2, encoding a serine/threonine kinase, as driving ADI prostate cancer growth. TPL2 activation by over-expressing either wild-type
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2332 offsetEnd: 2480 A: whereas the suppression of TPL2 expression and its kinase activity in ADI prostate cancer cells inhibited cell proliferation under androgen-depleted
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2480 offsetEnd: 2635 A: and its kinase activity in ADI prostate cancer cells inhibited cell proliferation under androgen-depleted conditions. Most importantly, TPL2 is upregulated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3221 offsetEnd: 3366 A: model and the clinical prostate cancer specimens. CONCLUSIONS/SIGNIFICANCE: Together these data suggest that TPL2 kinase plays a critical role in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3366 offsetEnd: 3509 A: specimens. CONCLUSIONS/SIGNIFICANCE: Together these data suggest that TPL2 kinase plays a critical role in the promotion of ADI prostate cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 3409 offsetEnd: 3561 A: form in one optical plane and mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells, which associate with the endothelial vessels
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 1497 offsetEnd: 1647 A: represses the tumor suppressor P53 in human cancer cells. Immunoprecipitation analysis shows that Piwil2 can directly associate with Signal Transducer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 1647 offsetEnd: 1800 A: human cancer cells. Immunoprecipitation analysis shows that Piwil2 can directly associate with Signal Transducer and Activator of Transcription 3 (STAT3)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23840421 offsetBegin: 1875 offsetEnd: 1995 A: (DRMs) along the secretory pathway. Its mature form is mainly insoluble in Lubrol WX, but does not associate with Triton
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23840421 offsetBegin: 1995 offsetEnd: 2118 A: mature form is mainly insoluble in Lubrol WX, but does not associate with Triton X-100-DRMs. To understand the mechanism of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 2893 offsetEnd: 3028 A: active form of STAT3, whereas tumor-derived mutants L71P, L91P and A95T significantly lost their ability to associate with STAT3, block
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 3028 offsetEnd: 3173 A: mutants L71P, L91P and A95T significantly lost their ability to associate with STAT3, block gene expression, and suppress cellular transformation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 3173 offsetEnd: 3316 A: lost their ability to associate with STAT3, block gene expression, and suppress cellular transformation and tumor growth in vivo. Additionally,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1492 offsetEnd: 1636 A: inflammation and increased skin carcinogenesis. In this study, we used gene expression profiling to compare expression levels between Tpl2 (+/+)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1765 offsetEnd: 1894 A: profiling to compare expression levels between Tpl2 (+/+) and Tpl2 (-) (/-) keratinocytes. We identified over 2000 genes as being
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1894 offsetEnd: 2042 A: Tpl2 (+/+) and Tpl2 (-) (/-) keratinocytes. We identified over 2000 genes as being differentially expressed between genotypes. Functional annotation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 5595 offsetEnd: 5751 A: Tpl2 (-/-) keratinocytes had significantly higher invasion, malignant conversion rates and increased endothelial cell tube formation when compared with Tpl2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 5902 offsetEnd: 6044 A: endothelial cell tube formation when compared with Tpl2 (+/+) keratinocytes. In summary, our studies reveal that keratinocytes from Tpl2 (-/-)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2672 offsetEnd: 2819 A: to form a relatively stable CMG (Cdc45-MCM-GINS) complex. The CMG proteins also associate less strongly with other replication proteins, consistent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 151 offsetEnd: 297 A: molecules of 20-24 nucleotides that regulate gene expression. In animals, miRNAs form imperfect interactions with sequences in the 3' Untranslated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 297 offsetEnd: 445 A: gene expression. In animals, miRNAs form imperfect interactions with sequences in the 3' Untranslated region (3'UTR) of mRNAs, causing translational
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 1236 offsetEnd: 1400 A: viral infectious diseases, virus-associated malignancies and cancer. TCR gene transfer utilizes retroviral or lentiviral constructs containing the gene sequences of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2699 offsetEnd: 2819 A: TCR-alpha and TCR-beta chains must form a heterodimer and associate with the CD3 complex in order to be stably expressed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1117 offsetEnd: 1264 A: reporter gene imaging system for noninvasively monitoring the kinetic expression of miRNA-16 during chemoresistance in gastric cancer both in vitro
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1655 offsetEnd: 1788 A: sodium iodide symporter (hNIS) and firefly luciferase (Fluc) genes were linked to form hNIS/Fluc double fusion reporter gene and then
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 301 offsetEnd: 430 A: and differentiation. In addition to its secreted form (sLF), an alternative form (ΔLF) lacking the signal sequence has been found
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 430 offsetEnd: 559 A: secreted form (sLF), an alternative form (ΔLF) lacking the signal sequence has been found to be downregulated in cancer. Although
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 644 offsetEnd: 773 A: pathways in breast cancer cells in 2D and 3D cultures. We found that cAMP potentiated TGFβ-dependent gene expression by enhancing
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 1801 offsetEnd: 1929 A: has been known that URG4/URGCP gene is an overexpressed gene in hepatocellular carcinoma and gastric cancers. This study aims to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 1929 offsetEnd: 2062 A: is an overexpressed gene in hepatocellular carcinoma and gastric cancers. This study aims to detect gene expression patterns of PPARα
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 4403 offsetEnd: 4549 A: with RA, the cells developed long neurites, resembling a neuronal phenotype. PPARα gene expression increased in RA-treated groups; URG4/URGCP gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694536 offsetBegin: 173 offsetEnd: 312 A: adhesion molecules which associate with cadherins to form adherens junctions (AJs) in epithelial cells and fibroblasts. Nectin-1 and -3 are
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 701 offsetEnd: 817 A: that the N-terminal sterile alpha motif (SAM) of Yan is able to self associate to form a helical polymeric structure
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 817 offsetEnd: 927 A: (SAM) of Yan is able to self associate to form a helical polymeric structure in vitro, although the extent and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 927 offsetEnd: 1072 A: self associate to form a helical polymeric structure in vitro, although the extent and functional significance of self-association of full-length
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23028043 offsetBegin: 2641 offsetEnd: 2766 A: brain tumors still form in Tlx mutant mice, these tumors are less infiltrative and rarely associate with the adult neurogenic
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19094066 offsetBegin: 582 offsetEnd: 699 A: In brain ischaemia RelA and p50 factors rapidly activate, but how they associate with c-Rel to form active dimers and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19094066 offsetBegin: 699 offsetEnd: 821 A: factors rapidly activate, but how they associate with c-Rel to form active dimers and contribute to the changes in diverse
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19094066 offsetBegin: 821 offsetEnd: 950 A: associate with c-Rel to form active dimers and contribute to the changes in diverse dimer activation for neuron susceptibility is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21983129 offsetBegin: 1522 offsetEnd: 1656 A: the enhanced viral replication in drs-KO MEFs. Drs protein could associate with stress-inducible GADD34 to form a complex with TSC1/2,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21983129 offsetBegin: 1656 offsetEnd: 1796 A: MEFs. Drs protein could associate with stress-inducible GADD34 to form a complex with TSC1/2, which suppresses mTOR activity. These findings
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 1668 offsetEnd: 1812 A: the architectural long noncoding RNA NEAT1 (Menε/β) to form paraspeckles, subnuclear bodies that alter gene expression via the nuclear retention
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 1812 offsetEnd: 1942 A: (Menε/β) to form paraspeckles, subnuclear bodies that alter gene expression via the nuclear retention of RNA. Here we describe the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 5084 offsetEnd: 5211 A: ability of MDA-MB 231 cells to form colonies in soft agar, while FHL2 overexpression enhances colony formation of breast cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21635933 offsetBegin: 1951 offsetEnd: 2087 A: in telomere regulation and gene expression. The core structures of G-quadruplexes form stable scaffolds while the loops have been shown,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22724069 offsetBegin: 2832 offsetEnd: 2968 A: region known to regulate its ability to form polymers and associate with membranes. Phosphorylation at these sites appears essential for
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 116 offsetEnd: 234 A: most common form of skin cancer with the incidence expected to double over the next 20 years. Inflammation is believed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 907 offsetEnd: 1031 A: pathway. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 1031 offsetEnd: 1167 A: used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12090470 offsetBegin: 129 offsetEnd: 250 A: most lethal form of locally advanced breast cancer known. IBC carries a guarded prognosis primarily due to rapid onset of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 0 offsetEnd: 142 A: The nitroreductase oxidored-nitro domain containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19373782 offsetBegin: 3105 offsetEnd: 3246 A: sporadic RCC tumors of the same histopathological subtype, and delineate chromosomal regions that associate with this very aggressive form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2635 offsetEnd: 2791 A: prostate cancer cells inhibited cell proliferation under androgen-depleted conditions. Most importantly, TPL2 is upregulated in ADI prostate cancers of both
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 3076 offsetEnd: 3221 A: of both the Pten deletion mouse model and the clinical prostate cancer specimens. CONCLUSIONS/SIGNIFICANCE: Together these data suggest that TPL2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 3113 offsetEnd: 3252 A: activation of serine 431 phosphorylation in K8. Tgase-2 gene silencing suppressed the expression of active form JNK (pJNK). Constitutive or
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15313166 offsetBegin: 2501 offsetEnd: 2653 A: form of p42 MAPK suppressed TCDD-dependent transcription of a reporter gene controlled by dioxin-response elements (DREs), and pretreatment with PD98059
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12374697 offsetBegin: 1214 offsetEnd: 1350 A: IGF-IR in human colon cancer growth and angiogenesis, HT29 cells were transfected with a truncated dominant-negative (DN) form of IGF-IR
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1662 offsetEnd: 1835 A: were infected with adenovirus/adeno-associated virus (Ad/AAV) hybrid vectors carrying the mouse HoxD10 gene (Hyb-HoxD10) or the beta-galactosidase gene (Hyb-Gal). Hyb-HoxD10
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1835 offsetEnd: 1993 A: hybrid vectors carrying the mouse HoxD10 gene (Hyb-HoxD10) or the beta-galactosidase gene (Hyb-Gal). Hyb-HoxD10 expression inhibited GH4 cell proliferation in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 5233 offsetEnd: 5408 A: mice and grafted tumors formed from v-ras(Ha) retrovirus-infected Tpl2 (-/-) keratinocytes. Additionally, Tpl2 (-/-) keratinocytes had significantly higher invasion, malignant
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 3773 offsetEnd: 3918 A: also contribute to high expression of E6/E7. The integrated form significantly increases with decrease of episomal form during tumor progression.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 1400 offsetEnd: 1544 A: cancer. TCR gene transfer utilizes retroviral or lentiviral constructs containing the gene sequences of the TCR-alpha and TCR-beta chains, which
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 152 offsetEnd: 301 A: protein involved in immunomodulation, cellular growth, and differentiation. In addition to its secreted form (sLF), an alternative form (ΔLF) lacking
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 2078 offsetEnd: 2218 A: named Nrl1 and Ctr1, which associate with splicing factors. Whereas Nrl1 targets transcripts with cryptic introns to form heterochromatin at
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 3533 offsetEnd: 3649 A: cervical cancer cells, and induction of a subset of these was also observed in cancer cell lines from breast (MCF-7)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 5501 offsetEnd: 5650 A: breast cancer cells. Thus, our findings indicate that overexpression of the transcriptional cofactor FHL2 contributes to breast cancer development by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22724069 offsetBegin: 2684 offsetEnd: 2832 A: Snf7 paralogues-CHMP4C-in its C-terminal tail, a region known to regulate its ability to form polymers and associate with membranes. Phosphorylation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 137 offsetEnd: 265 A: Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is an aggressive form of the disease
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 4581 offsetEnd: 4706 A: compared to other breast cancer subtypes in a meta-analysis of 11 studies and 1,878 breast cancer patients, including the two
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 6177 offsetEnd: 6307 A: and H3K27me3-enriched regions can form chromatin loops and physically interact in cis around a single gene in mammalian cells. The
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 6423 offsetEnd: 6539 A: around a single gene in mammalian cells. The loops associate with a poised, low transcription state in EC cells and,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 4357 offsetEnd: 4486 A: breast cancer by allowing epithelial cells to bypass cell death in the early stages of breast cancer development. This conclusion
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1993 offsetEnd: 2145 A: gene (Hyb-HoxD10) or the beta-galactosidase gene (Hyb-Gal). Hyb-HoxD10 expression inhibited GH4 cell proliferation in vitro. The expression of FGF-2 and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1353 offsetEnd: 1492 A: of this gene contributing to heightened inflammation and increased skin carcinogenesis. In this study, we used gene expression profiling to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 3918 offsetEnd: 4082 A: E6/E7. The integrated form significantly increases with decrease of episomal form during tumor progression. Methylation of the promoter/enhancer gradually decreased
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 1668 offsetEnd: 1801 A: and tumor recurrence in osteosarcoma. It has been known that URG4/URGCP gene is an overexpressed gene in hepatocellular carcinoma and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 4549 offsetEnd: 4705 A: neurites, resembling a neuronal phenotype. PPARα gene expression increased in RA-treated groups; URG4/URGCP gene expression decreased in SH-SY5Y cells after
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4266 offsetEnd: 4367 A: not reduce lytic viral gene expression induced by a vector in which the Z gene product is driven by a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 0 offsetEnd: 116 A: Squamous cell carcinoma is the second most common form of skin cancer with the incidence expected to double over the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 1728 offsetEnd: 1862 A: associates with c-Fos to form the AP-1 transcription factor that activates gene expression. We have investigated the regulation of the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 6307 offsetEnd: 6423 A: loops and physically interact in cis around a single gene in mammalian cells. The loops associate with a poised, low
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 3252 offsetEnd: 3411 A: K8. Tgase-2 gene silencing suppressed the expression of active form JNK (pJNK). Constitutive or tetracyclin-induced conditional expression of Tgase-2 increased
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2560 offsetEnd: 2699 A: the desired functional specificity, the introduced TCR-alpha and TCR-beta chains must form a heterodimer and associate with the CD3 complex
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 3748 offsetEnd: 3889 A: lytic gene expression after B-cell receptor engagement in Akata cells and constitutive lytic viral gene expression in EBV-positive AGS cells.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4024 offsetEnd: 4155 A: lytic viral gene expression in EBV-positive AGS cells. However, FAS inhibitors do not reduce lytic viral gene expression induced by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 5237 offsetEnd: 5371 A: the absence of Tpl2 may be responsible for the increased tumorigenesis found in Tpl2(-/-) mice. Defining the relationship between Tpl2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 1581 offsetEnd: 1724 A: NF-kappaB activation. PPM1A and PPM1B associate with the phosphorylated form of IKKbeta, and the interaction between PPM1A/PPM1B and IKKbeta is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 4705 offsetEnd: 4847 A: gene expression increased in RA-treated groups; URG4/URGCP gene expression decreased in SH-SY5Y cells after RA treatment compared with that in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15313166 offsetBegin: 2350 offsetEnd: 2501 A: of MEK-1. Overexpression of dominant negative form of p42 MAPK suppressed TCDD-dependent transcription of a reporter gene controlled by dioxin-response
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 2516 offsetEnd: 2578 A: than in tumors with the wild-type KRAS gene (30.6%)           
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 4048 offsetEnd: 4104 A: mutations and the active form of NF-κB in CRC           
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 1439 offsetEnd: 1581 A: and Ser181 and termination of IKKbeta-induced NF-kappaB activation. PPM1A and PPM1B associate with the phosphorylated form of IKKbeta, and the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 0 offsetEnd: 82 A: The relationship between KRAS and NF-κB in colorectal cancer is not clear.        
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 2429 offsetEnd: 2516 A:   mutations was higher (50.8%) than in tumors with the wild-type KRAS gene (30.6%)     
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 3963 offsetEnd: 4048 A: pathway. The presence of both KRAS mutations and the active form of NF-κB in CRC     
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15364949 offsetBegin: 639 offsetEnd: 776 A: showed that arrestin and CXCR2 form complexes with components of the ERK1/2 cascade following ligand stimulation. However, in contrast to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 906 offsetEnd: 1061 A: impair endothelial cell migration, block angiogenesis, and maintain a differentiated phenotype of cells. We investigated whether HoxD10 gene delivery could
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1201 offsetEnd: 1339 A: cells. We investigated whether HoxD10 gene delivery could inhibit the growth of prolactinoma. Rat GH4 lactotrope tumor cells were infected
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1497 offsetEnd: 1662 A: prolactinoma. Rat GH4 lactotrope tumor cells were infected with adenovirus/adeno-associated virus (Ad/AAV) hybrid vectors carrying the mouse HoxD10 gene (Hyb-HoxD10)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 2648 offsetEnd: 2769 A: GH4 cells transduced with Hyb-HoxD10 did not form tumors in nude mice. These results indicate that the delivery of HoxD10
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 2582 offsetEnd: 2742 A: somatic mutations in GRIM-19. Wild-type GRIM-19 suppressed cellular transformation by a constitutively active form of STAT3, whereas tumor-derived mutants L71P,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 2742 offsetEnd: 2893 A: suppressed cellular transformation by a constitutively active form of STAT3, whereas tumor-derived mutants L71P, L91P and A95T significantly lost their
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 951 offsetEnd: 1075 A: Tpl2 was identified by our laboratory as having a tumor suppressor function in skin carcinogenesis, with the absence of this
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1075 offsetEnd: 1210 A: as having a tumor suppressor function in skin carcinogenesis, with the absence of this gene contributing to heightened inflammation and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 5751 offsetEnd: 5902 A: invasion, malignant conversion rates and increased endothelial cell tube formation when compared with Tpl2 (+/+) keratinocytes. In summary, our studies
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 2825 offsetEnd: 2979 A: JNK activation by TGF-beta. Our findings associate Daxx directly with the TGF-beta apoptotic-signalling pathway, and make a biochemical connection between
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 2594 offsetEnd: 2756 A: of IL6 and form abdominal plasmacytomas with visceral involvement when injected intraperitoneally into syngeneic mice. These IL6-independent clones were dependent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 592 offsetEnd: 737 A: 3' Untranslated region (3'UTR) of mRNAs, causing translational inhibition and mRNA decay. In contrast, plant miRNAs mostly associate with protein
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 737 offsetEnd: 875 A: causing translational inhibition and mRNA decay. In contrast, plant miRNAs mostly associate with protein coding regions. Here we show that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 875 offsetEnd: 1013 A: In contrast, plant miRNAs mostly associate with protein coding regions. Here we show that human miR-148 represses DNA methyltransferase 3b
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 1013 offsetEnd: 1150 A: with protein coding regions. Here we show that human miR-148 represses DNA methyltransferase 3b (Dnmt3b) gene expression through a region
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18835704 offsetBegin: 2079 offsetEnd: 2247 A: the percentage for nontreated cells remained unchanged (12.3+/-0.8). Multiparametric flow cytometric analyses were used to associate activation of p38 mitogen-activated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18835704 offsetBegin: 2247 offsetEnd: 2412 A: unchanged (12.3+/-0.8). Multiparametric flow cytometric analyses were used to associate activation of p38 mitogen-activated protein kinase (MAPK) with cells arrested
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 2303 offsetEnd: 2428 A: their sensitivity to H(2)O(2)-induced cell death. We also found that RIP and TRAF2 form a complex upon H(2)O(2) exposure, but
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 1542 offsetEnd: 1683 A: non-invasive breast cancer cells. TLR4 ligand (LPS) and H₂O₂ cooperated with TGF-β1 to enhance the sustained activation of non-Smad pathways,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 4043 offsetEnd: 4218 A: signaling pathways, the invasive capacity and anoikis-resistance of non-invasive breast cancer cells were gradually increased after prolonged stimulation with TGF-β1/H₂O₂/LPS.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 4218 offsetEnd: 4399 A: anoikis-resistance of non-invasive breast cancer cells were gradually increased after prolonged stimulation with TGF-β1/H₂O₂/LPS. The metastatic potential induced by TGF-β1/H₂O₂/LPS
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 148 offsetEnd: 291 A: for T-cell lineage selection, antigen specificity, effector function and survival. Recently, TCR gene transfer has been developed as a reliable
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 291 offsetEnd: 416 A: effector function and survival. Recently, TCR gene transfer has been developed as a reliable method to generate ex vivo large
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 1079 offsetEnd: 1236 A: for the adoptive cellular therapy of viral infectious diseases, virus-associated malignancies and cancer. TCR gene transfer utilizes retroviral or lentiviral
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 1261 offsetEnd: 1390 A: 5-FU treatment may result from its capacity to interfere with TGF-beta signaling and resulting activation of type I collagen gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 1534 offsetEnd: 1678 A: and resulting activation of type I collagen gene expression. Using various molecular approaches to study the mechanisms underlying 5-FU effects,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 962 offsetEnd: 1097 A: ester (CAPE), known to inhibit NFkappaB, induced apoptosis via Fas signal activation in human breast cancer MCF-7 cells. CAPE activated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 120 offsetEnd: 256 A: for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi). PARP
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 963 offsetEnd: 1117 A: resistance. Here, we introduced a dual reporter gene imaging system for noninvasively monitoring the kinetic expression of miRNA-16 during chemoresistance
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 4829 offsetEnd: 4946 A: of miRNA-16 is p38MAPK dependent but NF-κB independent. This dual imaging reporter gene may be served as a novel tool
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 2728 offsetEnd: 2876 A: analyses indicate that DAF-18 negatively regulates vulval induction by inhibiting MAPK activation. Thus, mutations in the PTEN tumor suppressor gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 773 offsetEnd: 913 A: 2D and 3D cultures. We found that cAMP potentiated TGFβ-dependent gene expression by enhancing Smad3 phosphorylation. Higher levels of total
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 913 offsetEnd: 1065 A: that cAMP potentiated TGFβ-dependent gene expression by enhancing Smad3 phosphorylation. Higher levels of total Smad3, as observed in 3D-cultured cells,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 1763 offsetEnd: 1903 A: responsive to cAMP. While YAP had little effect on TGFβ-dependent expression and Smad3 phosphorylation, a constitutively active form of TβRI
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 2042 offsetEnd: 2178 A: Smad3 phosphorylation, a constitutively active form of TβRI mimicked the cAMP effect on TGFβ signaling. In 3D-cultured cells, which show
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 5393 offsetEnd: 5527 A: interact with breast cancer cells can simultaneously activate the cAMP and TGFβ pathways. In summary, these data suggest that combined
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 6168 offsetEnd: 6304 A: TβRI expression on the transcriptional level, likely due to changes in histone acetylation. As a consequence, cancer cell functions such
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14963144 offsetBegin: 4707 offsetEnd: 4841 A: wild-type vGPCR, and a C-tail deletion version of the receptor were equally able to associate physically with Galpha(q). Combined, our
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14963144 offsetBegin: 4841 offsetEnd: 4979 A: version of the receptor were equally able to associate physically with Galpha(q). Combined, our data demonstrate that HHV-8 vGPCR contains
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14963144 offsetBegin: 4979 offsetEnd: 5121 A: able to associate physically with Galpha(q). Combined, our data demonstrate that HHV-8 vGPCR contains discrete sites of Galpha interaction and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 416 offsetEnd: 556 A: (PSP94), with prostate cancer susceptibility. PSP94 is one of the most abundant proteins from prostatic secretions and a primary constituent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 3662 offsetEnd: 3790 A: these edges from two PSP94 monomers associate in antiparallel fashion, leading to formation of a dimer. Our studies further show
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 3790 offsetEnd: 3922 A: associate in antiparallel fashion, leading to formation of a dimer. Our studies further show that dimers dissociate into monomers at
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 144 offsetEnd: 302 A: insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1-R) signalling has an important role in colorectal cancer (CRC) development, progression and resistance
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 0 offsetEnd: 139 A: We recently showed that Hepatocyte Growth Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 139 offsetEnd: 288 A: Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front-line chemotherapeutics
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 288 offsetEnd: 447 A: factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front-line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX). Here
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 447 offsetEnd: 597 A: ovarian cancer cells treated with the front-line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX). Here we demonstrate that this effect depends
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 1596 offsetEnd: 1713 A: negative form of p38 MAPK abrogates apoptosis elicited by drugs, alone or in combination with HGF. HGF and drugs also
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 941 offsetEnd: 1100 A: (peroxisome proliferator-activated receptor) plays an important role in the oxidation of fatty acids, carcinogenesis, and differentiation. URG4/URGCP gene is a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 2187 offsetEnd: 2312 A: aims to detect gene expression patterns of PPARα and URG4/URGCP genes in SH-SY5Y NB cell line after RA treatment. Expressions
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 4258 offsetEnd: 4403 A: an undifferentiated state, and after treatment with RA, the cells developed long neurites, resembling a neuronal phenotype. PPARα gene expression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349819 offsetBegin: 4493 offsetEnd: 4642 A: reverses ABCB1-mediated MDR by directly inhibiting its transport function. These findings may be useful for cancer combinational therapy with BIRB796
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 577 offsetEnd: 701 A: Structural and biochemical studies have shown that the N-terminal sterile alpha motif (SAM) of Yan is able to self associate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 1489 offsetEnd: 1620 A: this study, we demonstrated that full-length Yan self associates via its SAM domain to form higher-order complexes in living cells.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23028043 offsetBegin: 2766 offsetEnd: 2909 A: mutant mice, these tumors are less infiltrative and rarely associate with the adult neurogenic niches, suggesting a non-stem-cell origin. Taken
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24194608 offsetBegin: 1154 offsetEnd: 1277 A: the cognate pairs of RNA-DNA hybrids which are programmed to recognize each other, re-associate and form a DNA duplex while
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24194608 offsetBegin: 1277 offsetEnd: 1402 A: which are programmed to recognize each other, re-associate and form a DNA duplex while also releasing the split RNA fragments
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24194608 offsetBegin: 1402 offsetEnd: 1533 A: other, re-associate and form a DNA duplex while also releasing the split RNA fragments which upon association regain their original
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 2580 offsetEnd: 2734 A: 600 mg bid. Extracellular signal-regulated kinase (ERK), an effector enzyme of Ras-mediated signaling, was detected in its phosphorylated (activated) form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19094066 offsetBegin: 440 offsetEnd: 582 A: neurotoxic agents, c-Rel drives neuroprotective effects. In brain ischaemia RelA and p50 factors rapidly activate, but how they associate with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22113612 offsetBegin: 2270 offsetEnd: 2430 A: variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons 4-8, a region that encompasses the RAS-binding domain. p61BRAF(V600E) shows enhanced dimerization
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 1431 offsetEnd: 1591 A: prostate-specific antigen (PSA)-encoding gene, a marker for prostate cancer development, treatment, and progression. By DNase I footprinting, we identified four
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 1591 offsetEnd: 1727 A: for prostate cancer development, treatment, and progression. By DNase I footprinting, we identified four NF-kappa B binding sites in the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 1854 offsetEnd: 1998 A: identified four NF-kappa B binding sites in the PSA core enhancer. We also demonstrate that androgen-independent prostate cancer xenografts have
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 1998 offsetEnd: 2149 A: in the PSA core enhancer. We also demonstrate that androgen-independent prostate cancer xenografts have higher constitutive NF-kappa B binding activity
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 2149 offsetEnd: 2329 A: also demonstrate that androgen-independent prostate cancer xenografts have higher constitutive NF-kappa B binding activity than their androgen-dependent counterparts. These results
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 2378 offsetEnd: 2551 A: transcripts with cryptic introns to form heterochromatin at developmental genes and retrotransposons, Ctr1 functions in processing intron-containing telomerase RNA. Together
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 4129 offsetEnd: 4270 A: reporter constructs, including the putative NF-kappa B site deleted and mutated form were significantly reduced after HRG-beta 1 treatment as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 4270 offsetEnd: 4400 A: B site deleted and mutated form were significantly reduced after HRG-beta 1 treatment as compared with the 1.5-kb VEGF-C promoter.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 1113 offsetEnd: 1274 A: well as for cancer prevention. Deoxyribonucleic acid microarray studies on transformed keratinocytes and tumor cell lines exposed to pharmacologic concentrations
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 3649 offsetEnd: 3763 A: a subset of these was also observed in cancer cell lines from breast (MCF-7) and prostate (DU145). The results are
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 3763 offsetEnd: 3890 A: observed in cancer cell lines from breast (MCF-7) and prostate (DU145). The results are consistent with activation of more than
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 123 offsetEnd: 256 A: cancer progression by acting as a tumor suppressor in the initial phase, but stimulating invasion and metastasis at later stage(1,2).
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 2007 offsetEnd: 2171 A: intracellular canonical signaling pathway by phosphorylating receptor Smads (R-Smads), i.e. Smad2 and Smad3. These activated R-Smads form heteromeric complexes with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 2171 offsetEnd: 2313 A: receptor Smads (R-Smads), i.e. Smad2 and Smad3. These activated R-Smads form heteromeric complexes with Smad4, which accumulate in the nucleus
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17145690 offsetBegin: 2052 offsetEnd: 2209 A: DNA-binding and altering ER-inducible gene expression. Immunoaffinity enrichment for low abundance proteins such as ER, coupled with modern mass spectrometry
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24040213 offsetBegin: 867 offsetEnd: 1014 A: and stress responses in yeast, we studied how different exogenous ceramides affect yeast cells. C2-phytoceramide, a soluble form of phytoceramides,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 1355 offsetEnd: 1513 A: rhythm, carcinogenesis, and progression of cancer. Additionally, mammalian DBHS proteins associate with the architectural long noncoding RNA NEAT1 (Menε/β) to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 5036 offsetEnd: 5189 A: the dimer for paraspeckle subnuclear body formation. These results suggest that paraspeckles may potentially form through self-association of DBHS dimers
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 686 offsetEnd: 810 A: culture and animal model systems. Exposure of keratin 8 (k-8) expressing human breast cancer cells (MCF7, T47D, SKBr3) to K3
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 810 offsetEnd: 937 A: of keratin 8 (k-8) expressing human breast cancer cells (MCF7, T47D, SKBr3) to K3 (50-100 microM) induced rapid, sustained, and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 937 offsetEnd: 1088 A: breast cancer cells (MCF7, T47D, SKBr3) to K3 (50-100 microM) induced rapid, sustained, and site-specific k-8 serine phosphorylation (pSer73) dependent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 2343 offsetEnd: 2461 A: and delayed but not prevented by MEK1/2 inhibition, was due to a form of stress-activated cell death known as oncosis.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22749352 offsetBegin: 1574 offsetEnd: 1746 A: described functions of the autophagy-related proteins Atg5-Atg12, but NLRX1 did not associate with Atg5-Atg12. High-throughput quantitative mass spectrometry and endogenous
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22749352 offsetBegin: 1746 offsetEnd: 1931 A: Atg5-Atg12, but NLRX1 did not associate with Atg5-Atg12. High-throughput quantitative mass spectrometry and endogenous protein-protein interaction revealed an NLRX1-interacting partner,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 0 offsetEnd: 155 A: Split-protein systems, an approach that relies on fragmentation of proteins with their further conditional re-association to form functional complexes, are
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 155 offsetEnd: 318 A: on fragmentation of proteins with their further conditional re-association to form functional complexes, are increasingly used for various biomedical applications.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 318 offsetEnd: 479 A: further conditional re-association to form functional complexes, are increasingly used for various biomedical applications. This approach offers tight control of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 2584 offsetEnd: 2714 A: is also shown. Furthermore, in vivo studies demonstrate a significant uptake of the hybrids by tumours together with specific gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 3002 offsetEnd: 3157 A: specific gene silencing. This split-functionality approach presents a new route in the development of 'smart' nucleic acid-based nanoparticles and switches
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 529 offsetEnd: 680 A: if 17β-estradiol treatment is sufficient to inhibit prostaglandin E2 (PGE2)-induced cellular motility in human colon cancer cells. METHODS: We analyzed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 680 offsetEnd: 835 A: inhibit prostaglandin E2 (PGE2)-induced cellular motility in human colon cancer cells. METHODS: We analyzed the protein expression of urokinase plasminogen
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 4534 offsetEnd: 4676 A: and MMP-9 expression via JNK1/2 signaling pathway, thus promoting cellular motility in human LoVo cancer cells. However, PGE2 treatment showed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 4676 offsetEnd: 4815 A: pathway, thus promoting cellular motility in human LoVo cancer cells. However, PGE2 treatment showed no effects on regulating expression of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 4815 offsetEnd: 4964 A: human LoVo cancer cells. However, PGE2 treatment showed no effects on regulating expression of tPA, MMP-2, plasminogen activator inhibitor-1 (PAI-1),
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 5674 offsetEnd: 5822 A: that 17β-estradiol treatment inhibited PGE2-induced uPA, MMP-9 and cellular motility by suppressing activation of JNK1/2 in human LoVo cancer cells.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 5822 offsetEnd: 5967 A: MMP-9 and cellular motility by suppressing activation of JNK1/2 in human LoVo cancer cells. CONCLUSIONS: Collectively, these results suggest that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 5967 offsetEnd: 6138 A: activation of JNK1/2 in human LoVo cancer cells. CONCLUSIONS: Collectively, these results suggest that 17β-estradiol treatment significantly inhibits PGE2-induced motility
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14694442 offsetBegin: 711 offsetEnd: 864 A: we investigated the molecular mechanism by which 2-methoxyestradiol (2-ME) effectively sensitizes a human prostate cancer cell line, PC3, to Fas-mediated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14694442 offsetBegin: 864 offsetEnd: 1036 A: which 2-methoxyestradiol (2-ME) effectively sensitizes a human prostate cancer cell line, PC3, to Fas-mediated apoptosis. 2-ME significantly inhibited nuclear factor-kappaB
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14694442 offsetBegin: 1036 offsetEnd: 1213 A: human prostate cancer cell line, PC3, to Fas-mediated apoptosis. 2-ME significantly inhibited nuclear factor-kappaB (NF-kappaB) activation and downregulated Fas-associated death
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 816 offsetEnd: 961 A: capability of the later stage, metastatic estrogen-independent human breast cancer cell lines MDA-231 and MDA-435. Our studies show that 8Br-cAMP
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 961 offsetEnd: 1105 A: estrogen-independent human breast cancer cell lines MDA-231 and MDA-435. Our studies show that 8Br-cAMP inhibits proliferation of these cells in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15949338 offsetBegin: 333 offsetEnd: 473 A: in hypoxia inducible factor (HIF)-1 trans-activation. METHODS: (1) Gastric cancer cells of the line SGC7901 were cultured, then continued to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15949338 offsetBegin: 473 offsetEnd: 599 A: METHODS: (1) Gastric cancer cells of the line SGC7901 were cultured, then continued to be cultured in hypoxic environment, and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21635933 offsetBegin: 1661 offsetEnd: 1815 A: extensive Watson-Crick/Hoogsteen hydrogen bonding. Thermally stable, these topologies can play a role in telomere regulation and gene expression. The core
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11751889 offsetBegin: 3136 offsetEnd: 3265 A: tetratricopeptide repeat (TPR) deletion mutant form of Hip (Delta TPR), which is unable to bind Hsc70 (Prapapanich, V., Chen, S.,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423715 offsetBegin: 833 offsetEnd: 998 A: S-transferase placental form (GST-P) during liver tumor promotion by fenbendazole, phenobarbital, piperonyl butoxide, or thioacetamide, using rats. Our study focused
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 128 offsetEnd: 249 A: protein BRLF1 (R) is a transcription factor that induces the lytic form of EBV infection. R activates certain early viral
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 249 offsetEnd: 378 A: factor that induces the lytic form of EBV infection. R activates certain early viral promoters through a direct binding mechanism
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 1098 offsetEnd: 1219 A: Z promoter (Zp). Here we demonstrate that R activates expression of the fatty acid synthase (FAS) cellular gene through a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 1219 offsetEnd: 1368 A: that R activates expression of the fatty acid synthase (FAS) cellular gene through a p38 stress mitogen-activated protein kinase-dependent mechanism.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 1368 offsetEnd: 1524 A: fatty acid synthase (FAS) cellular gene through a p38 stress mitogen-activated protein kinase-dependent mechanism. B-cell receptor engagement of Akata cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4155 offsetEnd: 4266 A: AGS cells. However, FAS inhibitors do not reduce lytic viral gene expression induced by a vector in which the Z
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4476 offsetEnd: 4594 A: the Z gene product is driven by a strong heterologous promoter. In addition, FAS inhibitors do not reduce R activation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4712 offsetEnd: 4827 A: addition, FAS inhibitors do not reduce R activation of a naked DNA reporter gene construct driven by the Z promoter
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4827 offsetEnd: 4945 A: R activation of a naked DNA reporter gene construct driven by the Z promoter (Zp). These results suggest that cellular
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4945 offsetEnd: 5075 A: reporter gene construct driven by the Z promoter (Zp). These results suggest that cellular FAS activity is important for induction
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 5792 offsetEnd: 5927 A: pathways or palmitoylated proteins. Furthermore, using FAS inhibitors may be a completely novel approach for blocking the lytic form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 137 offsetEnd: 287 A: therapeutic target for non-small cell lung cancer (NSCLC). Signaling interactions between c-Met and the mutant epidermal growth factor receptor (EGFR)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16484222 offsetBegin: 1026 offsetEnd: 1156 A: c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 350 offsetEnd: 484 A: over the next 20 years. Inflammation is believed to be a critical component in skin cancer progression. Therefore, understanding genes
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 1044 offsetEnd: 1198 A: the design of targeted therapies. Numerous studies show cyclooxygenases (COXs) play an essential role in inflammation-associated cancers. Tpl2 (MAP3K8) is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 758 offsetEnd: 907 A: induced apoptosis through the mitochondrial (intrinsic) pathway. In our current report, we used DLD-1 colorectal cancer cells stably transfected with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 1309 offsetEnd: 1471 A: cells and orthotopic medullary thyroid carcinomas in RET transgenic mice. METHODS: We constructed adenoviral vectors expressing a dominant-negative truncated form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 1471 offsetEnd: 1625 A: in RET transgenic mice. METHODS: We constructed adenoviral vectors expressing a dominant-negative truncated form of RET, termed RET(DeltaTK), and analyzed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 1625 offsetEnd: 1784 A: constructed adenoviral vectors expressing a dominant-negative truncated form of RET, termed RET(DeltaTK), and analyzed its effect on cell viability, apoptosis,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 1441 offsetEnd: 1584 A: Early Growth Factor (EGR-1). C-Jun, when phosphorylated by c-Jun N-terminal kinase (JNK-1) associates with c-Fos to form the AP-1 transcription
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 2392 offsetEnd: 2532 A: cancer cell lines PC-3 and LNCaP, which have been previously stimulated with human EGF or cisplatin. Co-transfections of plasmids expressing
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22879938 offsetBegin: 2306 offsetEnd: 2443 A: is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor that in vitro has been shown
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22879938 offsetBegin: 4466 offsetEnd: 4599 A: on exosome-stimulated angiogenesis. Our results indicate that CTO may be effective in targeting both cancer cell growth and the tumor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22879938 offsetBegin: 4599 offsetEnd: 4733 A: that CTO may be effective in targeting both cancer cell growth and the tumor microenvironment, thus suggesting a potential therapeutic
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 4706 offsetEnd: 4837 A: in a meta-analysis of 11 studies and 1,878 breast cancer patients, including the two cohorts published here. Patients identified by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 614 offsetEnd: 769 A: of mammary epithelial cells and breast cancer cells. However, the underlying cellular/molecular mechanisms remain unknown. By gelatin zymography, we showed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 3311 offsetEnd: 3435 A: kDa) to an active form (62 kDa). The activation was dependent on c-jun N-terminal kinases (JNKs) and reactive oxygen species
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12090470 offsetBegin: 250 offsetEnd: 376 A: breast cancer known. IBC carries a guarded prognosis primarily due to rapid onset of disease, typically within six months, and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 275 offsetEnd: 427 A: in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC). We have previously demonstrated that NOR1 overexpression is capable
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 427 offsetEnd: 587 A: cancer and nasopharyngeal carcinoma (NPC). We have previously demonstrated that NOR1 overexpression is capable of converting the monofunctional alkylating agent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 587 offsetEnd: 767 A: have previously demonstrated that NOR1 overexpression is capable of converting the monofunctional alkylating agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) into a toxic form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 2198 offsetEnd: 2329 A: tumor has not been fully explored. We introduced a dominant negative MAPKK gene into SVR murine angiosarcoma cells. Introduction of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 2886 offsetEnd: 3023 A: rate in vitro and morphological reversion. Cells expressing the dominant negative MAPKK have a greatly decreased ability to form colonies
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 3023 offsetEnd: 3154 A: Cells expressing the dominant negative MAPKK have a greatly decreased ability to form colonies in soft agar compared with wild-type
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 2303 offsetEnd: 2445 A: (PC12) cells. PC12 cells treated with Abeta25-35 (10-50 microM) showed intracellular ROS elevation, the formation of 8-oxodG (an oxidized form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 2725 offsetEnd: 2870 A: oxidized form of DNA), and underwent apoptotic cell death in a dose-dependent manner. Abeta(25-35) treatment upregulated pro-apoptotic p53 at the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 0 offsetEnd: 149 A: Specific small interfering RNAs (siRNAs) designed to silence different oncogenic pathways can be used for cancer therapy. However, non-modified naked
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 149 offsetEnd: 286 A: to silence different oncogenic pathways can be used for cancer therapy. However, non-modified naked siRNAs have short half-lives in blood
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 1741 offsetEnd: 1890 A: blood stream, and most importantly, in aqueous conditions can form poly-cationic micelles thus, becoming amenable to association with siRNAs. Herein,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 2606 offsetEnd: 2735 A: are compared for their abilities to complex with siRNAs and deliver them into cells inducing gene silencing. Our explicit solvent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 2735 offsetEnd: 2876 A: complex with siRNAs and deliver them into cells inducing gene silencing. Our explicit solvent molecular dynamics (MD) simulations showed that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 3025 offsetEnd: 3197 A: explicit solvent molecular dynamics (MD) simulations showed that bolaamphiphiles associate with siRNAs due to electrostatic, hydrogen bonding, and hydrophobic interactions.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 3197 offsetEnd: 3354 A: showed that bolaamphiphiles associate with siRNAs due to electrostatic, hydrogen bonding, and hydrophobic interactions. These in silico studies are supported
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 1258 offsetEnd: 1369 A: In order to test this hypothesis and explore whether it can be exploited as a strategy for killing human cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 5128 offsetEnd: 5250 A: kinase families JNK, ERK, and p38. Blocking these pathways either by coexpressing a dominant negative form of MKK4 or with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18455826 offsetBegin: 2255 offsetEnd: 2388 A: NaB and GCV combination in the EBV-positive cell line, B95-8. However, blocking Akt activity by expressing its dominant negative form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18455826 offsetBegin: 2388 offsetEnd: 2544 A: EBV-positive cell line, B95-8. However, blocking Akt activity by expressing its dominant negative form remarkably promoted NaB and GCV-mediated cytotoxicity
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18455826 offsetBegin: 2544 offsetEnd: 2702 A: Akt activity by expressing its dominant negative form remarkably promoted NaB and GCV-mediated cytotoxicity via a thymidine kinase (TK)-independent mechanism.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18455826 offsetBegin: 2702 offsetEnd: 2857 A: negative form remarkably promoted NaB and GCV-mediated cytotoxicity via a thymidine kinase (TK)-independent mechanism. Interestingly, it was found that the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 292 offsetEnd: 422 A: cells, termed CHP25, express a functional v-raf oncogene. However, they are non-tumorigenic, do not form colonies in soft agar and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 422 offsetEnd: 549 A: v-raf oncogene. However, they are non-tumorigenic, do not form colonies in soft agar and possess a flat morphology. CHP25 cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 549 offsetEnd: 668 A: do not form colonies in soft agar and possess a flat morphology. CHP25 cells are resistant to re-transformation by sis,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2791 offsetEnd: 2930 A: under androgen-depleted conditions. Most importantly, TPL2 is upregulated in ADI prostate cancers of both the Pten deletion mouse model and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 3886 offsetEnd: 4052 A: neuronal-specific MAP-2, Tau, and neurofilament (NF-160), accompanied by an increased expression of the neuronal marker gene neuropeptide tyrosine (NPY). Furthermore,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15629131 offsetBegin: 0 offsetEnd: 145 A: By cDNA library screening, here we isolated an unusual gene transcript encoding a 31-amino-acid zinc finger-like peptide that regulates apoptosis
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15629131 offsetBegin: 145 offsetEnd: 298 A: isolated an unusual gene transcript encoding a 31-amino-acid zinc finger-like peptide that regulates apoptosis (named Zfra). Northern blotting and RT/PCR
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15629131 offsetBegin: 834 offsetEnd: 972 A: several prostate and breast cancer cells. When stably expressed in L929 fibroblasts, Zfra conferred resistance to the cytotoxic effects of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 447 offsetEnd: 582 A: germline from Drosophila to mammals. The Piwi-like2 (piwil2) gene is mainly expressed in testis or embryonic cells among normal tissues
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 2076 offsetEnd: 2220 A: 3 (STAT3) protein via its PAZ domain and form a Piwil2/STAT3/c-Src triple protein-protein complex. Furthermore, STAT3 is phosphorylated by c-Src
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17440164 offsetBegin: 1694 offsetEnd: 1819 A: MCF-7 and T47D breast cancer cells were stably transfected with either full-length HER2 or p95HER2. We studied the effects of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23840421 offsetBegin: 1736 offsetEnd: 1875 A: with different types of detergent-resistant membranes (DRMs) along the secretory pathway. Its mature form is mainly insoluble in Lubrol WX,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23840421 offsetBegin: 2118 offsetEnd: 2259 A: Lubrol WX, but does not associate with Triton X-100-DRMs. To understand the mechanism of PSMA internalization we investigated its association
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 4961 offsetEnd: 5096 A: with K8 and JNK. Therefore, SPC-induced Tgase-2 might be a new target for modulating keratin reorganization, metastasis of cancer cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 3660 offsetEnd: 3802 A: inducible form of nitric oxide (iNOS), proteins related to ulcers. These results suggest that Cf-PS could help protect against alcohol-induced
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12374697 offsetBegin: 1350 offsetEnd: 1492 A: and angiogenesis, HT29 cells were transfected with a truncated dominant-negative (DN) form of IGF-IR or vector alone. RESULTS: IGF-I increased
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12374697 offsetBegin: 1492 offsetEnd: 1639 A: with a truncated dominant-negative (DN) form of IGF-IR or vector alone. RESULTS: IGF-I increased VEGF expression in parental and vector-transfected
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12374697 offsetBegin: 4257 offsetEnd: 4398 A: IGF ligand-receptor system plays an important role in multiple mechanisms that mediate human colon cancer growth including regulation of VEGF
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15364949 offsetBegin: 469 offsetEnd: 639 A: receptor endocytosis. Co-immunoprecipitation and co-localization experiments showed that arrestin and CXCR2 form complexes with components of the ERK1/2 cascade following
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1061 offsetEnd: 1201 A: and maintain a differentiated phenotype of cells. We investigated whether HoxD10 gene delivery could inhibit the growth of prolactinoma. Rat
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 1065 offsetEnd: 1206 A: apoptosis, promotes cell proliferation, and induces de novo micro-angiogenesis, three of the six cardinal hallmarks of a typical cancer cell.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 2431 offsetEnd: 2582 A: and neck tumors and identified three somatic mutations in GRIM-19. Wild-type GRIM-19 suppressed cellular transformation by a constitutively active form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 3316 offsetEnd: 3459 A: STAT3, block gene expression, and suppress cellular transformation and tumor growth in vivo. Additionally, these mutants lost their capacity to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 142 offsetEnd: 277 A: of MAPK pathway in the pathogenesis of human osteosarcoma. METHODS: Gene microarray (Human Genome U133A, Affymetrix) was used to screen
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 277 offsetEnd: 422 A: of human osteosarcoma. METHODS: Gene microarray (Human Genome U133A, Affymetrix) was used to screen the differential expression of genes involved
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 3684 offsetEnd: 3811 A: groups (P<0.01). CONCLUSION: MAPK pathway plays an important role in the pathogenesis of osteosarcoma. ERK, JNK and p38 form an
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 4847 offsetEnd: 5048 A: keratinocytes. Immunohistochemistry confirmed higher MMP9 staining in 12-O-tetradecanoylphorbol-13-acetate-treated skin from Tpl2 (-/-) mice and grafted tumors formed from v-ras(Ha) retrovirus-infected
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 1323 offsetEnd: 1450 A: the gene encoding Daxx - a protein associated with the Fas receptor that mediates activation of Jun amino-terminal kinase (JNK)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 2670 offsetEnd: 2825 A: Furthermore, Daxx is involved in mediating JNK activation by TGF-beta. Our findings associate Daxx directly with the TGF-beta apoptotic-signalling pathway,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 649 offsetEnd: 772 A: fraction of human malignancies and is a major target for the development of novel cancer treatments. We show that oncogenic
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 772 offsetEnd: 896 A: a major target for the development of novel cancer treatments. We show that oncogenic Ras activates Notch signaling and that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 896 offsetEnd: 1028 A: of novel cancer treatments. We show that oncogenic Ras activates Notch signaling and that wild-type Notch-1 is necessary to maintain
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 0 offsetEnd: 121 A: Icaritin (ICT) is a hydrolytic form of icariin isolated from plants of the genus Epimedium. This study was to investigate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 395 offsetEnd: 543 A: to investigate the radiosensitization effect of icaritin and its possible underlying mechanism using murine 4T1 breast cancer cells. The combination
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 543 offsetEnd: 666 A: icaritin and its possible underlying mechanism using murine 4T1 breast cancer cells. The combination of Icaritin at 3 µM or
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2159 offsetEnd: 2287 A: capable of initiating a pair of bidirectional replication forks in S phase. We also show that after initiation, Mcm2-7 associate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 2448 offsetEnd: 2594 A: long-term in vitro in the absence of IL6 and form abdominal plasmacytomas with visceral involvement when injected intraperitoneally into syngeneic
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 4099 offsetEnd: 4259 A: similarly protected plasmacytoma cells against IL6 withdrawal-induced apoptosis. Although K13 is known to up-regulate IL6 gene expression, its protective effect
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 4259 offsetEnd: 4396 A: withdrawal-induced apoptosis. Although K13 is known to up-regulate IL6 gene expression, its protective effect was not due to induction of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 2525 offsetEnd: 2671 A: constitutively active form of protein Kinase A (PKA). Unexpectedly, the promoter element of Tkdp-1 responsible for this up-regulation, unlike that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 1150 offsetEnd: 1286 A: show that human miR-148 represses DNA methyltransferase 3b (Dnmt3b) gene expression through a region in its coding sequence. This region
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 1474 offsetEnd: 1606 A: JNK3, activity in the presence of deleted in colorectal cancer (DCC) or Down syndrome cell adhesion molecule (DSCAM), and expression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 1606 offsetEnd: 1737 A: deleted in colorectal cancer (DCC) or Down syndrome cell adhesion molecule (DSCAM), and expression of both of them further enhanced
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 3617 offsetEnd: 3773 A: sites of negatively regulating transcription factors, also contribute to high expression of E6/E7. The integrated form significantly increases with decrease
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 4396 offsetEnd: 4529 A: gradually decreased with tumor progression and is inversely correlated to integration. Two novel variants were observed in E6 gene in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 4529 offsetEnd: 4679 A: is inversely correlated to integration. Two novel variants were observed in E6 gene in European- and North-American-1-lineages. Log-rank test revealed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 4679 offsetEnd: 4823 A: novel variants were observed in E6 gene in European- and North-American-1-lineages. Log-rank test revealed better prognosis of the patients with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 4823 offsetEnd: 4974 A: gene in European- and North-American-1-lineages. Log-rank test revealed better prognosis of the patients with episomal methylated HPV16 compared to the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18835704 offsetBegin: 2412 offsetEnd: 2539 A: were used to associate activation of p38 mitogen-activated protein kinase (MAPK) with cells arrested in G2/M, the size of these
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18835704 offsetBegin: 2861 offsetEnd: 2965 A: or absence of cyclin B1. After 4 h, there was a 26% increase in the activated phosphorylated form of p38
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18835704 offsetBegin: 2965 offsetEnd: 3077 A: 4 h, there was a 26% increase in the activated phosphorylated form of p38 MAPK in CE-treated cells compared with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 2034 offsetEnd: 2170 A: RIP and TRAF2 gene expression in their respective deficient MEF cells restored their sensitivity to H(2)O(2)-induced cell death. We also
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 2170 offsetEnd: 2303 A: their respective deficient MEF cells restored their sensitivity to H(2)O(2)-induced cell death. We also found that RIP and TRAF2 form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 2428 offsetEnd: 2543 A: We also found that RIP and TRAF2 form a complex upon H(2)O(2) exposure, but without the participation of TNFR1. The
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 707 offsetEnd: 845 A: cells. Here we report that the enhancement of TGF-β1 signaling is required for inducing metastatic potential of non-invasive breast cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 994 offsetEnd: 1139 A: for inducing metastatic potential of non-invasive breast cancer cells. TGF-β1 alone could not efficiently induce the sustained activation of Smad
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 1139 offsetEnd: 1279 A: breast cancer cells. TGF-β1 alone could not efficiently induce the sustained activation of Smad and non-Smad pathways in non-invasive breast
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 1279 offsetEnd: 1415 A: not efficiently induce the sustained activation of Smad and non-Smad pathways in non-invasive breast cancer cells. TLR4 ligand (LPS) and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 1415 offsetEnd: 1542 A: of Smad and non-Smad pathways in non-invasive breast cancer cells. TLR4 ligand (LPS) and H₂O₂ cooperated with TGF-β1 to enhance
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 4559 offsetEnd: 4706 A: with TGF-β1/H₂O₂/LPS. The metastatic potential induced by TGF-β1/H₂O₂/LPS was sufficient for tumor cells to extravasate and form metastatic foci in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 4706 offsetEnd: 4839 A: by TGF-β1/H₂O₂/LPS was sufficient for tumor cells to extravasate and form metastatic foci in an experimental metastasis model in nude
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 0 offsetEnd: 148 A: The T-cell receptor (TCR) is critical for T-cell lineage selection, antigen specificity, effector function and survival. Recently, TCR gene transfer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 1544 offsetEnd: 1673 A: or lentiviral constructs containing the gene sequences of the TCR-alpha and TCR-beta chains, which have been cloned from a clonal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 979 offsetEnd: 1122 A: demonstrate that activation of c-Jun N-terminal kinase (JNK) is critical for amplification of mitochondrial cell death in human cervical cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 1122 offsetEnd: 1250 A: kinase (JNK) is critical for amplification of mitochondrial cell death in human cervical cancer cells. Exposure of HeLa cells to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 1390 offsetEnd: 1534 A: capacity to interfere with TGF-beta signaling and resulting activation of type I collagen gene expression. Using various molecular approaches to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 1678 offsetEnd: 1830 A: collagen gene expression. Using various molecular approaches to study the mechanisms underlying 5-FU effects, we have demonstrated that 5-FU antagonizes
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 5218 offsetEnd: 5349 A: COL1A2 gene expression in a JNK-dependent manner. We thus provide a molecular explanation to the observed clinical benefits of 5-FU
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 1231 offsetEnd: 1371 A: in human breast cancer MCF-7 cells. CAPE activated Fas by a Fas ligand (Fas-L)-independent mechanism, induced p53-regulated Bax protein, and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 4298 offsetEnd: 4469 A: form of IkappaBalpha (IkappaBDeltaN) lacking the phosphorylation sites essential for NFkappaB activation. IkappaBDeltaN expression not only inhibited NFkappaB activity but
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 1066 offsetEnd: 1177 A: lethal form of DNA damage. These agents therefore may be the drugs of choice for BRCA mutant breast and ovarian
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 830 offsetEnd: 963 A: of miRNAs in the anticancer drug resistance. Here, we introduced a dual reporter gene imaging system for noninvasively monitoring the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 4144 offsetEnd: 4294 A: that in NF-3xmir16 tumor xenografts. Furthermore, using this reporter gene system, we found that etoposide (VP-16) and 5-fluorouracil (5-FU) activated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 4704 offsetEnd: 4829 A: and in vivo, and the upregulation of miRNA-16 is p38MAPK dependent but NF-κB independent. This dual imaging reporter gene may
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 4946 offsetEnd: 5059 A: NF-κB independent. This dual imaging reporter gene may be served as a novel tool for in vivo imaging of microRNAs
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 815 offsetEnd: 935 A: an invariant pattern of cell fates in three vulval precursor cells. We have discovered a novel form of crosstalk between
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 0 offsetEnd: 152 A: Human lactoferrin (LF) is a multifunctional protein involved in immunomodulation, cellular growth, and differentiation. In addition to its secreted form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 144 offsetEnd: 281 A: linked the human MSMB gene, encoding prostate secretory protein of 94 residues (PSP94), with prostate cancer susceptibility. PSP94 is one
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 3522 offsetEnd: 3662 A: PSP94 structure. Crystal structure shows that these edges from two PSP94 monomers associate in antiparallel fashion, leading to formation of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21075852 offsetBegin: 1335 offsetEnd: 1444 A: eIF4B. Prior to its engagement by the IFNλ receptor, the non-active form of RSK1 is present in a complex with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 302 offsetEnd: 443 A: (IGF1-R) signalling has an important role in colorectal cancer (CRC) development, progression and resistance to treatment. In this report, we
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 443 offsetEnd: 600 A: in colorectal cancer (CRC) development, progression and resistance to treatment. In this report, we demonstrate that downregulation of microRNA-497 (miR-497)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 4026 offsetEnd: 4168 A: 3-kinase/Akt signalling, as overexpression of an active form of Akt reversed its impact on cell survival and proliferation, recapitulating the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 4729 offsetEnd: 4851 A: appeared to associate with copy number loss of a segment of chromosome 17p13.1, where these miRs are located at proximity.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 1239 offsetEnd: 1358 A: further increased by the combined treatment with HGF and either CDDP or PTX. The expression of a dominant negative form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 1358 offsetEnd: 1474 A: with HGF and either CDDP or PTX. The expression of a dominant negative form of p38 MAPK abrogates apoptosis elicited
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 1474 offsetEnd: 1596 A: PTX. The expression of a dominant negative form of p38 MAPK abrogates apoptosis elicited by drugs, alone or in combination
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 2605 offsetEnd: 2723 A: Altogether data show that p38 MAPK is necessary for HGF sensitization of ovarian cancer cells to low-doses of CDDP and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15590739 offsetBegin: 1923 offsetEnd: 2069 A: metencephalon to the mesencephalon. Misexpression of a dominant negative form of Sprouty2 augmented ERK activation, and resulted in anterior shift
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 386 offsetEnd: 507 A: which is the biological active form of vitamin A regulates differentiation of NB cells, and RA derivatives have been used
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 2062 offsetEnd: 2187 A: carcinoma and gastric cancers. This study aims to detect gene expression patterns of PPARα and URG4/URGCP genes in SH-SY5Y NB
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 3174 offsetEnd: 3280 A: μM RA in the dark for 3-10 days. Gene expression of URG4/URGCP and PPARα genes were presented as the yield
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 3280 offsetEnd: 3408 A: 3-10 days. Gene expression of URG4/URGCP and PPARα genes were presented as the yield of polymerase chain reaction (PCR) products
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 4847 offsetEnd: 4984 A: URG4/URGCP gene expression decreased in SH-SY5Y cells after RA treatment compared with that in the control cells. NB cell differentiation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 4984 offsetEnd: 5115 A: cells after RA treatment compared with that in the control cells. NB cell differentiation might associate with PPARα and URG4/URGCP
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694536 offsetBegin: 312 offsetEnd: 436 A: to form adherens junctions (AJs) in epithelial cells and fibroblasts. Nectin-1 and -3 are members of the nectin family which
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11927016 offsetBegin: 2230 offsetEnd: 2370 A: increase in p27(Kip1) and a reduction in the hyperphosphorylated form of retinoblastoma protein (pRB). With YCU-N861 cells, ATRA also caused
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11927016 offsetBegin: 2370 offsetEnd: 2505 A: in the hyperphosphorylated form of retinoblastoma protein (pRB). With YCU-N861 cells, ATRA also caused a decrease in Bcl-2 and Bcl-X(L)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 4123 offsetEnd: 4259 A: we propose that the formation of higher-order Yan oligomers contributes to proper repression of target gene expression and RTK signaling
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188160 offsetBegin: 3470 offsetEnd: 3614 A: resulted in an enhanced transcriptional activation of inducible nitric oxide synthase, while transfection with a dominant negative form of Tpl-2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188160 offsetBegin: 3745 offsetEnd: 3890 A: transfection with a dominant negative form of Tpl-2 had the opposite effect. The findings assign an important pro-inflammatory signaling function
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23028043 offsetBegin: 2909 offsetEnd: 3061 A: infiltrative and rarely associate with the adult neurogenic niches, suggesting a non-stem-cell origin. Taken together, these results indicate a critical
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 3486 offsetEnd: 3635 A: p38, but not ERK1. Paclitaxel-induced IL-8 promoter activation was inhibited by dominant-inhibitory mutants of JNK, p38, and the super-repressor form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 4816 offsetEnd: 4943 A: of the 34 evaluable patients, including 2 complete remissions. Genomic analyses failed to detect N-ras gene mutations in any of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22113612 offsetBegin: 1857 offsetEnd: 1986 A: new resistance mechanism. We find that a subset of cells resistant to vemurafenib (PLX4032, RG7204) express a 61-kDa variant form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22113612 offsetBegin: 2126 offsetEnd: 2270 A: vemurafenib (PLX4032, RG7204) express a 61-kDa variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons 4-8, a region that encompasses the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 1270 offsetEnd: 1431 A: a transcription regulatory element of the prostate-specific antigen (PSA)-encoding gene, a marker for prostate cancer development, treatment, and progression. By
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11160206 offsetBegin: 1489 offsetEnd: 1638 A: we examined the kinetics of anti-IgM-induced activation of MAP kinases and established cell lines overexpressing a dominant-negative (dn) mutant form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 298 offsetEnd: 451 A: including chromatin modifications and gene silencing. However, the mechanisms that distinguish RNAs and mediate their functions are poorly understood. We
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 1752 offsetEnd: 1912 A: via distinct mechanisms. Mtl1 also forms Red1-independent interactions with evolutionarily conserved proteins named Nrl1 and Ctr1, which associate with splicing
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 2218 offsetEnd: 2378 A: with splicing factors. Whereas Nrl1 targets transcripts with cryptic introns to form heterochromatin at developmental genes and retrotransposons, Ctr1 functions
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 546 offsetEnd: 671 A: In this study, we identified that HRG-beta 1 stimulated up-regulation of VEGF-C mRNA and protein of human breast cancer cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 920 offsetEnd: 1059 A: cancer cells in a dosage- and time-dependent manner and that this up-regulation was de novo RNA synthesis-dependent. The HRG-beta 1-induced
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21983129 offsetBegin: 0 offsetEnd: 137 A: The drs gene is an apoptosis-inducing tumor suppressor. By using drs-knockout (KO) mouse embryonic fibroblasts (MEFs), we showed that drs
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21983129 offsetBegin: 1377 offsetEnd: 1522 A: TSC2 proteins was closely correlated with the enhanced viral replication in drs-KO MEFs. Drs protein could associate with stress-inducible GADD34
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21983129 offsetBegin: 1796 offsetEnd: 1944 A: stress-inducible GADD34 to form a complex with TSC1/2, which suppresses mTOR activity. These findings indicate that Drs suppresses viral replication
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 3100 offsetEnd: 3254 A: GRP78, GRP94, and asparagine synthase was documented by Western blot and real-time reverse transcriptase-polymerase chain reaction in C33A cervical cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 3254 offsetEnd: 3399 A: documented by Western blot and real-time reverse transcriptase-polymerase chain reaction in C33A cervical cancer cells, and induction of a subset
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 0 offsetEnd: 123 A: TGF-β has opposing roles in breast cancer progression by acting as a tumor suppressor in the initial phase, but stimulating
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 402 offsetEnd: 553 A: but stimulating invasion and metastasis at later stage(1,2). Moreover, TGF-β is frequently overexpressed in breast cancer and its expression correlates
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 553 offsetEnd: 703 A: later stage(1,2). Moreover, TGF-β is frequently overexpressed in breast cancer and its expression correlates with poor prognosis and metastasis (3,4).
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 703 offsetEnd: 843 A: overexpressed in breast cancer and its expression correlates with poor prognosis and metastasis (3,4). The mechanisms by which TGF-β induces
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22126971 offsetBegin: 2313 offsetEnd: 2455 A: Smad3. These activated R-Smads form heteromeric complexes with Smad4, which accumulate in the nucleus and regulate the transcription of target
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17145690 offsetBegin: 1740 offsetEnd: 1899 A: with excess exposure, these quinones can arylate ER zinc fingers, impairing ER DNA-binding and altering ER-inducible gene expression. Immunoaffinity enrichment
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17145690 offsetBegin: 1899 offsetEnd: 2052 A: arylate ER zinc fingers, impairing ER DNA-binding and altering ER-inducible gene expression. Immunoaffinity enrichment for low abundance proteins such as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21741201 offsetBegin: 0 offsetEnd: 154 A: BACKGROUND: Subcellular fractionation and proteomics form an ideal partnership when it comes to specific location and analysis of intracellular organelles
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 2944 offsetEnd: 3074 A: which has similarity to a region in the protein-binding site of TAZ2. The C/EBPbeta N- and C-terminal domains physically associate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 3555 offsetEnd: 3691 A: We propose a model in which the regulatory sequences form a hydrophobic core that reciprocally inhibits DNA binding and transactivation.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 3691 offsetEnd: 3831 A: the regulatory sequences form a hydrophobic core that reciprocally inhibits DNA binding and transactivation. We also suggest a mechanism for
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 738 offsetEnd: 882 A: and posttranscriptional gene regulatory functions as well as DNA repair. DBHS proteins influence a wide gamut of biological processes, including
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 551 offsetEnd: 686 A: model stress-inducing quinone in both cell culture and animal model systems. Exposure of keratin 8 (k-8) expressing human breast cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 2239 offsetEnd: 2343 A: evident within 4 h of treatment and delayed but not prevented by MEK1/2 inhibition, was due to a form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 2714 offsetEnd: 2864 A: studies demonstrate a significant uptake of the hybrids by tumours together with specific gene silencing. This split-functionality approach presents a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23542902 offsetBegin: 2864 offsetEnd: 3002 A: the hybrids by tumours together with specific gene silencing. This split-functionality approach presents a new route in the development of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 0 offsetEnd: 139 A: BACKGROUND: Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in women are lower than in men.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 139 offsetEnd: 261 A: incidence and mortality rates of colorectal cancer in women are lower than in men. However, it is unknown if 17β-estradiol
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 3798 offsetEnd: 3959 A: with the development of cancer cell mobility, metastasis, and subsequent malignant tumor. After administration of inhibitors including LY294002, U0126, SB203580,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14694442 offsetBegin: 1798 offsetEnd: 1959 A: enzyme inhibitory protein (FLIP). Overexpression of the dominant negative mutant form of IkappaBalpha (d/n IkappaBalpha) or treatment with Ikappa kinase-specific
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14694442 offsetBegin: 1959 offsetEnd: 2111 A: the dominant negative mutant form of IkappaBalpha (d/n IkappaBalpha) or treatment with Ikappa kinase-specific inhibitor Bay117082 gave the same results,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 2378 offsetEnd: 2508 A: of the cell cycle inhibitor p21Cip1/Waf1 (hereafter p21) is dependent on FHL2 in MDA-MB 231 breast cancer cells. Downregulation of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 2508 offsetEnd: 2630 A: (hereafter p21) is dependent on FHL2 in MDA-MB 231 breast cancer cells. Downregulation of FHL2 by shRNA abrogated the cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 2630 offsetEnd: 2754 A: in MDA-MB 231 breast cancer cells. Downregulation of FHL2 by shRNA abrogated the cell cycle dependent upregulation of p21 as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 4276 offsetEnd: 4417 A: the MAPK signaling identified FHL2 as an important downstream effector of MAPKs in breast cancer cells, capable of transactivating endogenous
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 4830 offsetEnd: 4956 A: well as AP1 dependent reporter genes. Finally, downregulation of FHL2 reduces the ability of MDA-MB 231 cells to form colonies
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 5811 offsetEnd: 5950 A: cofactor FHL2 contributes to breast cancer development by mediating transcriptional activation of MAPK target genes known to be involved in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19435930 offsetBegin: 2034 offsetEnd: 2241 A: 45-kDa phosphorylated form of TTP are blocked by the p38 mitogen-activated protein kinase (MAPK) inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580). By contrast, and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 1105 offsetEnd: 1231 A: MDA-231 and MDA-435. Our studies show that 8Br-cAMP inhibits proliferation of these cells in culture and their ability to form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 1231 offsetEnd: 1358 A: that 8Br-cAMP inhibits proliferation of these cells in culture and their ability to form colonies in soft agar. This inhibition
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15949338 offsetBegin: 176 offsetEnd: 333 A: of mitogen-activated protein kinase phosphatase-1 (MKP-1) in hypoxia inducible factor (HIF)-1 trans-activation. METHODS: (1) Gastric cancer cells of the line
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11751889 offsetBegin: 3007 offsetEnd: 3136 A: receptor with Hip. Overexpression of a tetratricopeptide repeat (TPR) deletion mutant form of Hip (Delta TPR), which is unable to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423715 offsetBegin: 511 offsetEnd: 666 A: related molecules was analyzed in relation with liver cell lesions expressing glutathione S-transferase placental form (GST-P) during liver tumor promotion
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20423715 offsetBegin: 666 offsetEnd: 833 A: with liver cell lesions expressing glutathione S-transferase placental form (GST-P) during liver tumor promotion by fenbendazole, phenobarbital, piperonyl butoxide, or
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 0 offsetEnd: 128 A: The Epstein-Barr virus (EBV) immediate-early (IE) protein BRLF1 (R) is a transcription factor that induces the lytic form of EBV
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 1679 offsetEnd: 1819 A: kinase-dependent mechanism. B-cell receptor engagement of Akata cells also increases FAS expression. The FAS gene product is required for de
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 3889 offsetEnd: 4024 A: engagement in Akata cells and constitutive lytic viral gene expression in EBV-positive AGS cells. However, FAS inhibitors do not reduce
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4594 offsetEnd: 4712 A: by a strong heterologous promoter. In addition, FAS inhibitors do not reduce R activation of a naked DNA reporter gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 287 offsetEnd: 439 A: cancer (NSCLC). Signaling interactions between c-Met and the mutant epidermal growth factor receptor (EGFR) have been studied extensively, but signaling
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 5641 offsetEnd: 5765 A: motility by ~81%, suggesting that a novel form of c-Met activation is utilized by EGFR to maximize these biological effects.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16484222 offsetBegin: 906 offsetEnd: 1026 A: is controlled by serum and the c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16484222 offsetBegin: 1156 offsetEnd: 1276 A: show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate Erk8, and we demonstrate that such
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 484 offsetEnd: 624 A: is believed to be a critical component in skin cancer progression. Therefore, understanding genes involved in the regulation of inflammatory
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 1198 offsetEnd: 1337 A: studies show cyclooxygenases (COXs) play an essential role in inflammation-associated cancers. Tpl2 (MAP3K8) is a protein kinase in the MAP
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 5371 offsetEnd: 5504 A: responsible for the increased tumorigenesis found in Tpl2(-/-) mice. Defining the relationship between Tpl2 and COX-2 may lead to new
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 1862 offsetEnd: 2011 A: AP-1 transcription factor that activates gene expression. We have investigated the regulation of the JNK-1 kinase by co-transfecting phosphatases PP4
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 2011 offsetEnd: 2147 A: expression. We have investigated the regulation of the JNK-1 kinase by co-transfecting phosphatases PP4 and M3/6 in prostate cancer cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 2147 offsetEnd: 2268 A: of the JNK-1 kinase by co-transfecting phosphatases PP4 and M3/6 in prostate cancer cell lines PC-3 and LNCaP, which have
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16238095 offsetBegin: 2268 offsetEnd: 2392 A: phosphatases PP4 and M3/6 in prostate cancer cell lines PC-3 and LNCaP, which have been previously stimulated with human EGF
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22139077 offsetBegin: 4732 offsetEnd: 4856 A: knock-down of either IL-8 or the NF-κB subunit p65, in ΔEGFR-expressing cells attenuated their ability to form tumors and to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22139077 offsetBegin: 4856 offsetEnd: 5001 A: NF-κB subunit p65, in ΔEGFR-expressing cells attenuated their ability to form tumors and to induce angiogenesis when injected subcutaneously into
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22879938 offsetBegin: 1956 offsetEnd: 2128 A: in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI),
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22879938 offsetBegin: 2128 offsetEnd: 2306 A: an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 0 offsetEnd: 137 A: BACKGROUND: Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 401 offsetEnd: 534 A: discordance) is an aggressive form of the disease which convey unpredictable, and poor prognosis due to limited treatment options and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 4837 offsetEnd: 4978 A: and 1,878 breast cancer patients, including the two cohorts published here. Patients identified by the Wnt/β-catenin classifier had a greater
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 284 offsetEnd: 441 A: cancer. We have previously demonstrated that over-expression of ErbB2 promoted ethanol-mediated invasion of mammary epithelial cells and breast cancer cells.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 441 offsetEnd: 614 A: over-expression of ErbB2 promoted ethanol-mediated invasion of mammary epithelial cells and breast cancer cells. However, the underlying cellular/molecular mechanisms remain
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 769 offsetEnd: 929 A: cancer cells. However, the underlying cellular/molecular mechanisms remain unknown. By gelatin zymography, we showed that over-expression of ErbB2 increased the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 3095 offsetEnd: 3196 A: but not HB2 cells; it enhanced the cleavage of proform MMP-2 (72 kDa) to an active form (62 kDa). The
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 3196 offsetEnd: 3311 A: the cleavage of proform MMP-2 (72 kDa) to an active form (62 kDa). The activation was dependent on c-jun N-terminal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 926 offsetEnd: 1073 A: alkylating agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) into a toxic form by reducing the 4-nitro group of CB1954. Toxic CB1954 is able to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 4366 offsetEnd: 4527 A: ethyl ketone (MEK) inhibtor PD98059 suppressed CB1954-induced cell killing. These results suggested that the NOR1 gene enhances CB1954-mediated cell cytotoxicity
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 2075 offsetEnd: 2198 A: and angiogenesis in a well established tumor has not been fully explored. We introduced a dominant negative MAPKK gene into
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 3154 offsetEnd: 3281 A: have a greatly decreased ability to form colonies in soft agar compared with wild-type cells. Despite the decreased cell growth
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 3281 offsetEnd: 3403 A: form colonies in soft agar compared with wild-type cells. Despite the decreased cell growth in vitro and inability to grow
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15087391 offsetBegin: 311 offsetEnd: 479 A: development of endometrial cancer. We previously demonstrated that endometrial cancer cells carrying oncogenic [(12)Val]K-ras were susceptible to apoptosis. The present
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15087391 offsetBegin: 479 offsetEnd: 631 A: demonstrated that endometrial cancer cells carrying oncogenic [(12)Val]K-ras were susceptible to apoptosis. The present study examined the role of K-and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15087391 offsetBegin: 1458 offsetEnd: 1600 A: whereas the H-Ras mutant rescued rat endometrial cells from apoptosis. Expression of a constitutively active form of Raf-1 (Raf-CAAX) promoted
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15288476 offsetBegin: 3774 offsetEnd: 3927 A: activation were reduced. Moreover, SU5416 caused reversion in NIH3T3 fibroblasts transformed by the oncogenic form of the receptor, Tpr-Met. CONCLUSIONS:
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 3211 offsetEnd: 3360 A: when Tera-2 cells receive differentiation signals which induce a approximately 60-fold increase in GATA-4 expression. In colon cancer cells, however,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 4349 offsetEnd: 4488 A: the methyl-cytosine binding protein MBD2 is localized to these CpG islands, including ones near the gene promoter. Removing DNA methylation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 4488 offsetEnd: 4636 A: localized to these CpG islands, including ones near the gene promoter. Removing DNA methylation through genetic disruption of DNA methyltransferases
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 6038 offsetEnd: 6177 A: also provide novel insight that PcG-occupied and H3K27me3-enriched regions can form chromatin loops and physically interact in cis around a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 2445 offsetEnd: 2587 A: Abeta25-35 (10-50 microM) showed intracellular ROS elevation, the formation of 8-oxodG (an oxidized form of DNA), and underwent apoptotic cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 2587 offsetEnd: 2725 A: elevation, the formation of 8-oxodG (an oxidized form of DNA), and underwent apoptotic cell death in a dose-dependent manner. Abeta(25-35)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 2870 offsetEnd: 3012 A: apoptotic cell death in a dose-dependent manner. Abeta(25-35) treatment upregulated pro-apoptotic p53 at the gene level, and Bax and caspase-3
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 286 offsetEnd: 424 A: be used for cancer therapy. However, non-modified naked siRNAs have short half-lives in blood serum and encounter difficulties in crossing
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 1597 offsetEnd: 1741 A: low toxicities, long persistence in the blood stream, and most importantly, in aqueous conditions can form poly-cationic micelles thus, becoming
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23511334 offsetBegin: 1890 offsetEnd: 2054 A: aqueous conditions can form poly-cationic micelles thus, becoming amenable to association with siRNAs. Herein, two different bolaamphiphiles with acetylcholine head
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 1729 offsetEnd: 1851 A: transfer experiments with a range of cancer cell lines. We expressed the catalytic fragment of human MEKK1 to activate JNK
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 2464 offsetEnd: 2611 A: at the level of Raf-1 substrate phosphorylation. Consistent with this interpretation CHP25 cells show specific alterations of early gene induction.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 2611 offsetEnd: 2759 A: phosphorylation. Consistent with this interpretation CHP25 cells show specific alterations of early gene induction. The serum induction of c-fos and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 4486 offsetEnd: 4601 A: to bypass cell death in the early stages of breast cancer development. This conclusion is supported by in vivo data
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 4601 offsetEnd: 4736 A: early stages of breast cancer development. This conclusion is supported by in vivo data showing that TMS1 is selectively down-regulated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19373782 offsetBegin: 396 offsetEnd: 526 A: well as renal cell cancer (RCC) as its clinical manifestations. HLRCC is caused by heterozygous germline mutations in the fumarate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19373782 offsetBegin: 2962 offsetEnd: 3105 A: in HLRCC renal tumors compared with sporadic RCC tumors of the same histopathological subtype, and delineate chromosomal regions that associate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 591 offsetEnd: 739 A: understanding of underlying genetic alterations for the transition from androgen-dependent (AD) to ADI prostate cancer growth hampers our ability to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 1498 offsetEnd: 1635 A: a library of activated human kinases, we have identified TPL2, encoding a serine/threonine kinase, as driving ADI prostate cancer growth.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 0 offsetEnd: 151 A: Insulin-like growth factor-I (IGF-I) is translated as a pre-pro-peptide that is posttranslationally processed to its mature form by proteolytic removal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 151 offsetEnd: 281 A: as a pre-pro-peptide that is posttranslationally processed to its mature form by proteolytic removal of the signal peptide and the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 1434 offsetEnd: 1572 A: colony formation is also observed in SK-N-F1 cells stably transfected with a bicistronic expression construct encoding a secretory form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 4052 offsetEnd: 4206 A: accompanied by an increased expression of the neuronal marker gene neuropeptide tyrosine (NPY). Furthermore, effects of signal transduction inhibitors are
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 2286 offsetEnd: 2473 A: Furthermore, knockdown of PPM1A and PPM1B expression enhances TNFalpha-induced IKKbeta phosphorylation, NF-kappaB nuclear translocation and NF-kappaB-dependent gene expression. These data
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 2473 offsetEnd: 2652 A: expression enhances TNFalpha-induced IKKbeta phosphorylation, NF-kappaB nuclear translocation and NF-kappaB-dependent gene expression. These data suggest that PPM1A and PPM1B play
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 2652 offsetEnd: 2796 A: nuclear translocation and NF-kappaB-dependent gene expression. These data suggest that PPM1A and PPM1B play an important role in the termination
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 3255 offsetEnd: 3409 A: assay, in which lumenized, vascular structures form in one optical plane and mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 309 offsetEnd: 447 A: cell maintenance and transposon control in germline from Drosophila to mammals. The Piwi-like2 (piwil2) gene is mainly expressed in testis
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 1800 offsetEnd: 1929 A: that Piwil2 can directly associate with Signal Transducer and Activator of Transcription 3 (STAT3) protein via its PAZ domain and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 1929 offsetEnd: 2076 A: Signal Transducer and Activator of Transcription 3 (STAT3) protein via its PAZ domain and form a Piwil2/STAT3/c-Src triple protein-protein complex.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 2220 offsetEnd: 2374 A: domain and form a Piwil2/STAT3/c-Src triple protein-protein complex. Furthermore, STAT3 is phosphorylated by c-Src and translocated to nucleus, then binds
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12810654 offsetBegin: 3180 offsetEnd: 3302 A: expresses a dominant-negative form of p53. In these cells too, the GA analogues antagonized DDP, suggesting a role for p53
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17440164 offsetBegin: 1432 offsetEnd: 1564 A: p95HER2 and tumors expressing the full-length HER2 receptor to these agents. METHODS: MCF-7 and T47D breast cancer cells were stably
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17440164 offsetBegin: 1564 offsetEnd: 1694 A: HER2 receptor to these agents. METHODS: MCF-7 and T47D breast cancer cells were stably transfected with either full-length HER2 or
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23840421 offsetBegin: 1584 offsetEnd: 1736 A: accumulation in the endosomes. PSMA associates with different types of detergent-resistant membranes (DRMs) along the secretory pathway. Its mature form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 290 offsetEnd: 438 A: tumor patients and induces perinuclear reorganization of keratin 8 (K8) filaments that contribute to the viscoelasticity of metastatic cancer cells.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 541 offsetEnd: 673 A: a previous study, we extracted polysaccharide from Cf (Cf-PS) and demonstrated its antitumor effect in gastric cancer cells. In this
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 3222 offsetEnd: 3371 A: against alcohol-induced cell death in AGS cells. Moreover, Cf-PS treatment reduced the expressions of cyclooxygenase-2 (COX-2) and the inducible form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 3519 offsetEnd: 3660 A: expressions of cyclooxygenase-2 (COX-2) and the inducible form of nitric oxide (iNOS), proteins related to ulcers. These results suggest that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19417161 offsetBegin: 5371 offsetEnd: 5516 A: suppressed GST-MDA-7 toxicity. Our data show that in kidney cancer cells GST-MDA-7 induces ceramide-dependent activation of CD95, which is causal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19417161 offsetBegin: 5516 offsetEnd: 5661 A: that in kidney cancer cells GST-MDA-7 induces ceramide-dependent activation of CD95, which is causal in promoting an endoplasmic reticulum stress
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 2769 offsetEnd: 2889 A: not form tumors in nude mice. These results indicate that the delivery of HoxD10 could potentially inhibit the growth of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 1332 offsetEnd: 1454 A: six cardinal hallmarks of a typical cancer cell. Earlier we reported the isolation of GRIM-19 as a growth suppressor using
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 1454 offsetEnd: 1593 A: cancer cell. Earlier we reported the isolation of GRIM-19 as a growth suppressor using a genome-wide expression knockdown strategy. GRIM-19
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 0 offsetEnd: 142 A: OBJECTIVE: To explore the functional effects of MAPK pathway in the pathogenesis of human osteosarcoma. METHODS: Gene microarray (Human Genome
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 3193 offsetEnd: 3328 A: identified several candidate genes, including Mmp1b, Mmp2, Mmp9 and Mmp13, involved in migration and invasion to be upregulated in Tpl2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 1205 offsetEnd: 1323 A: type II TGF-beta receptor to isolate the gene encoding Daxx - a protein associated with the Fas receptor that mediates
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 2515 offsetEnd: 2670 A: inhibit TGF-beta-induced apoptosis in mouse hepatocytes. Furthermore, Daxx is involved in mediating JNK activation by TGF-beta. Our findings associate Daxx
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 1568 offsetEnd: 1705 A: in vivo. Oncogenic Ras increases levels and activity of the intracellular form of wild-type Notch-1, and upregulates Notch ligand Delta-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2819 offsetEnd: 2962 A: (Cdc45-MCM-GINS) complex. The CMG proteins also associate less strongly with other replication proteins, consistent with the idea that a single
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21282109 offsetBegin: 2962 offsetEnd: 3087 A: associate less strongly with other replication proteins, consistent with the idea that a single CMG complex forms the core of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 2312 offsetEnd: 2448 A: of IL6-independent clones that could proliferate long-term in vitro in the absence of IL6 and form abdominal plasmacytomas with visceral
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 2267 offsetEnd: 2393 A: be increased over 700-fold in response to over-expression of Ets-2 and a constitutively active form of protein Kinase A (PKA).
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 1286 offsetEnd: 1425 A: methyltransferase 3b (Dnmt3b) gene expression through a region in its coding sequence. This region is evolutionary conserved and present in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 1352 offsetEnd: 1474 A: Netrin-1 increased JNK1, not JNK2 or JNK3, activity in the presence of deleted in colorectal cancer (DCC) or Down syndrome
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 2402 offsetEnd: 2542 A: expression of a dominant negative form of MKK4, a JNK upstream activator, blocked Netrin-1-induced JNK1 activation in HEK293 cells. Netrin-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 1765 offsetEnd: 1896 A: to ROS-induced cell death when compared to wild-type cells, and reconstitution of RIP and TRAF2 gene expression in their respective
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 1896 offsetEnd: 2034 A: to wild-type cells, and reconstitution of RIP and TRAF2 gene expression in their respective deficient MEF cells restored their sensitivity
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 845 offsetEnd: 994 A: enhancement of TGF-β1 signaling is required for inducing metastatic potential of non-invasive breast cancer cells. TGF-β1 alone could not efficiently
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 3886 offsetEnd: 4043 A: Consistent with the activation pattern of signaling pathways, the invasive capacity and anoikis-resistance of non-invasive breast cancer cells were gradually
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 416 offsetEnd: 519 A: gene transfer has been developed as a reliable method to generate ex vivo large numbers of T cells of a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2422 offsetEnd: 2560 A: generate a transduced T cell with the desired functional specificity, the introduced TCR-alpha and TCR-beta chains must form a heterodimer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 3416 offsetEnd: 3540 A: the field of TCR gene transfer have exploited many aspects of basic research in T-cell immunology relating to TCR structure,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 3572 offsetEnd: 3722 A: attenuated radiation-induced Bax and Bak activation, and Bcl-2 phosphorylation as well as Fas expression. In addition, dominant-negative form of c-Jun
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 3870 offsetEnd: 4024 A: Fas expression. In addition, dominant-negative form of c-Jun inhibited radiation-induced Fas expression and Bax and Bak activation. These results indicate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 3394 offsetEnd: 3531 A: or that of a dominant-negative form of MKK4 that interferes with c-Jun N-terminal kinase (JNK) activation, blocks the inhibitory activity
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 5067 offsetEnd: 5218 A: of blocking TGF-beta-induced, SMAD-driven up-regulation of COL1A2 gene expression in a JNK-dependent manner. We thus provide a molecular explanation to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 4133 offsetEnd: 4298 A: examined the effect of a truncated form of IkappaBalpha (IkappaBDeltaN) lacking the phosphorylation sites essential for NFkappaB activation. IkappaBDeltaN expression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 0 offsetEnd: 120 A: The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 815 offsetEnd: 952 A: of defective homologous recombination repair lead to double-strand DNA breaks, the most lethal form of DNA damage. These agents therefore
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 708 offsetEnd: 830 A: in vivo information on the functions of miRNAs in the anticancer drug resistance. Here, we introduced a dual reporter gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1531 offsetEnd: 1655 A: in vitro and in vivo. Human sodium iodide symporter (hNIS) and firefly luciferase (Fluc) genes were linked to form hNIS/Fluc
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 4001 offsetEnd: 4144 A: also increased in NF-3xmir16/VCR compared with that in NF-3xmir16 tumor xenografts. Furthermore, using this reporter gene system, we found that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 4294 offsetEnd: 4430 A: using this reporter gene system, we found that etoposide (VP-16) and 5-fluorouracil (5-FU) activated miRNA-16 expression in vitro and in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 935 offsetEnd: 1054 A: in three vulval precursor cells. We have discovered a novel form of crosstalk between components of the Insulin and the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 2876 offsetEnd: 3021 A: vulval induction by inhibiting MAPK activation. Thus, mutations in the PTEN tumor suppressor gene may result in the simultaneous hyper-activation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 786 offsetEnd: 912 A: of MAP kinase mediated transcriptional changes to the transformed phenotype, we used an inducible form of Raf to analyze early
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 530 offsetEnd: 644 A: We analyzed the cross-talk between these pathways in breast cancer cells in 2D and 3D cultures. We found that cAMP
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 1903 offsetEnd: 2042 A: little effect on TGFβ-dependent expression and Smad3 phosphorylation, a constitutively active form of TβRI mimicked the cAMP effect on TGFβ
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 5121 offsetEnd: 5263 A: on proliferation was observed. Finally, we show that mesenchymal stem cells that interact with breast cancer cells can simultaneously activate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 5263 offsetEnd: 5393 A: show that mesenchymal stem cells that interact with breast cancer cells can simultaneously activate the cAMP and TGFβ pathways. In
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 281 offsetEnd: 416 A: prostate secretory protein of 94 residues (PSP94), with prostate cancer susceptibility. PSP94 is one of the most abundant proteins from
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20184897 offsetBegin: 3398 offsetEnd: 3522 A: of an almost straight edge in PSP94 structure. Crystal structure shows that these edges from two PSP94 monomers associate in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21075852 offsetBegin: 1208 offsetEnd: 1335 A: and its downstream effector, initiation factor eIF4B. Prior to its engagement by the IFNλ receptor, the non-active form of RSK1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 2474 offsetEnd: 2605 A: of HGF to enhance drug-dependent apoptosis. Altogether data show that p38 MAPK is necessary for HGF sensitization of ovarian cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 1542 offsetEnd: 1668 A: of URG4/URGCP is associated with metastasis and tumor recurrence in osteosarcoma. It has been known that URG4/URGCP gene is an
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694536 offsetBegin: 2867 offsetEnd: 2985 A: Cdc42 or Rac was not essential for the association of nectin-1 and E-cadherin to form AJs. Reorganization of the actin
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694536 offsetBegin: 3110 offsetEnd: 3251 A: E-cadherin to form AJs. Reorganization of the actin cytoskeleton was not required for the association of nectin-1 and E-cadherin. CONCLUSION:
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 1620 offsetEnd: 1752 A: Yan self associates via its SAM domain to form higher-order complexes in living cells. Introduction of SAM domain missense mutations
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20048052 offsetBegin: 1752 offsetEnd: 1885 A: domain to form higher-order complexes in living cells. Introduction of SAM domain missense mutations that restrict Yan to a monomeric
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188160 offsetBegin: 3614 offsetEnd: 3745 A: of inducible nitric oxide synthase, while transfection with a dominant negative form of Tpl-2 had the opposite effect. The findings
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23028043 offsetBegin: 2422 offsetEnd: 2527 A: p21, p53, or Pten or combined deletion of Pten and p53. While brain tumors still form in Tlx mutant mice,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23028043 offsetBegin: 2527 offsetEnd: 2641 A: deletion of Pten and p53. While brain tumors still form in Tlx mutant mice, these tumors are less infiltrative and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 455 offsetEnd: 600 A: We reported previously that paclitaxel can induce interleukin (IL)-8 promoter activation in subgroups of ovarian cancer through the activation of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 600 offsetEnd: 739 A: induce interleukin (IL)-8 promoter activation in subgroups of ovarian cancer through the activation of both AP-1 and nuclear factor kappaB.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 4783 offsetEnd: 4912 A: (i) that paclitaxel activates the JNK signaling pathway and (ii) that JNK activation is a common point of paclitaxel-induced gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 2734 offsetEnd: 2870 A: (ERK), an effector enzyme of Ras-mediated signaling, was detected in its phosphorylated (activated) form in 8 (36.4%) of 22 pretreatment
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 4943 offsetEnd: 5063 A: 2 complete remissions. Genomic analyses failed to detect N-ras gene mutations in any of the 35 leukemias. The results of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22113612 offsetBegin: 1986 offsetEnd: 2126 A: a subset of cells resistant to vemurafenib (PLX4032, RG7204) express a 61-kDa variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 0 offsetEnd: 137 A: The transcription factor NF-kappa B regulates gene expression involved in cell growth and survival and has been implicated in progression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 137 offsetEnd: 280 A: gene expression involved in cell growth and survival and has been implicated in progression of hormone-independent breast cancer. By expressing
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 280 offsetEnd: 435 A: and survival and has been implicated in progression of hormone-independent breast cancer. By expressing a dominant-active form of mitogen-activated protein
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11160206 offsetBegin: 1638 offsetEnd: 1779 A: activation of MAP kinases and established cell lines overexpressing a dominant-negative (dn) mutant form of JNK1 (dnJNK1). Anti-IgM induced a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 0 offsetEnd: 150 A: The regulation of protein-coding and noncoding RNAs is linked to nuclear processes, including chromatin modifications and gene silencing. However, the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 150 offsetEnd: 298 A: RNAs is linked to nuclear processes, including chromatin modifications and gene silencing. However, the mechanisms that distinguish RNAs and mediate
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 671 offsetEnd: 801 A: HRG-beta 1 stimulated up-regulation of VEGF-C mRNA and protein of human breast cancer cells in a dosage- and time-dependent manner
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 0 offsetEnd: 144 A: The dietary phytochemical indole-3-carbinol (I3C) protects against cervical cancer in animal model studies and in human clinical trials. I3C and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 144 offsetEnd: 289 A: against cervical cancer in animal model studies and in human clinical trials. I3C and its physiologic condensation product diindolylmethane (DIM)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 3399 offsetEnd: 3533 A: reverse transcriptase-polymerase chain reaction in C33A cervical cancer cells, and induction of a subset of these was also observed in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 4804 offsetEnd: 4931 A: IRE1alpha was indicated by a rapid increase in the stress-specific spliced form of XBP-1 messenger ribonucleic acid and a rapid
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17145690 offsetBegin: 0 offsetEnd: 163 A: Hormone-dependent breast cancers that overexpress the ligand-binding nuclear transcription factor, estrogen receptor (ER), represent the most common form of breast
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 3201 offsetEnd: 3324 A: The C/EBPbeta N- and C-terminal domains physically associate in a manner that requires the basic region and CRD. We propose
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 3439 offsetEnd: 3555 A: requires the basic region and CRD. We propose a model in which the regulatory sequences form a hydrophobic core that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24040213 offsetBegin: 1014 offsetEnd: 1174 A: studied how different exogenous ceramides affect yeast cells. C2-phytoceramide, a soluble form of phytoceramides, the yeast counterparts of mammalian ceramides,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24040213 offsetBegin: 1174 offsetEnd: 1338 A: yeast cells. C2-phytoceramide, a soluble form of phytoceramides, the yeast counterparts of mammalian ceramides, greatly reduced clonogenic survival, particularly in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24040213 offsetBegin: 4193 offsetEnd: 4333 A: of yeast to understand the basis of synthetic ceramides' cytotoxicity to provide novel strategies for therapeutic intervention in cancer and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 595 offsetEnd: 738 A: nuclear, and are involved in transcriptional and posttranscriptional gene regulatory functions as well as DNA repair. DBHS proteins influence a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 1185 offsetEnd: 1355 A: processes, including the regulation of circadian rhythm, carcinogenesis, and progression of cancer. Additionally, mammalian DBHS proteins associate with the architectural
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 2318 offsetEnd: 2457 A: heterodimer of the multidomain conserved region of the DBHS proteins, PSPC1 and NONO. These proteins form an extensively intertwined dimer,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 2589 offsetEnd: 2738 A: NONO. These proteins form an extensively intertwined dimer, consistent with the observation that the different DBHS proteins are typically copurified
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 2461 offsetEnd: 2584 A: MEK1/2 inhibition, was due to a form of stress-activated cell death known as oncosis. Independent of MAPK signaling was the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 261 offsetEnd: 388 A: cancer in women are lower than in men. However, it is unknown if 17β-estradiol treatment is sufficient to inhibit prostaglandin
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 835 offsetEnd: 985 A: in human colon cancer cells. METHODS: We analyzed the protein expression of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA),
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21859479 offsetBegin: 3326 offsetEnd: 3485 A: Upregulation of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and matrix metallopeptidases (MMPs) is reported to associate with the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14694442 offsetBegin: 1620 offsetEnd: 1798 A: Fas-associated death domain (FADD) protein interluekin-1beta-converting enzyme inhibitory protein (FLIP). Overexpression of the dominant negative mutant form of IkappaBalpha (d/n
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 4417 offsetEnd: 4548 A: an important downstream effector of MAPKs in breast cancer cells, capable of transactivating endogenous AP1 target genes as well as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 4548 offsetEnd: 4691 A: in breast cancer cells, capable of transactivating endogenous AP1 target genes as well as AP1 dependent reporter genes. Finally, downregulation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 4956 offsetEnd: 5084 A: Finally, downregulation of FHL2 reduces the ability of MDA-MB 231 cells to form colonies in soft agar, while FHL2 overexpression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 5650 offsetEnd: 5811 A: indicate that overexpression of the transcriptional cofactor FHL2 contributes to breast cancer development by mediating transcriptional activation of MAPK target
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19435930 offsetBegin: 1736 offsetEnd: 1892 A: is nuclear factor-kappaB (NF-kappaB)-dependent. Likewise, TTP expression and formation of the approximately 45-kDa phosphorylated form of TTP are blocked by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19435930 offsetBegin: 1892 offsetEnd: 2034 A: expression and formation of the approximately 45-kDa phosphorylated form of TTP are blocked by the p38 mitogen-activated protein kinase (MAPK)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11007936 offsetBegin: 0 offsetEnd: 133 A: There has been considerable interest in the molecular mechanisms of apoptosis in mammalian neurons because this form of neuronal cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11007936 offsetBegin: 133 offsetEnd: 260 A: the molecular mechanisms of apoptosis in mammalian neurons because this form of neuronal cell death is important for the normal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11007936 offsetBegin: 260 offsetEnd: 384 A: mammalian neurons because this form of neuronal cell death is important for the normal development of the nervous system and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11069056 offsetBegin: 1913 offsetEnd: 2079 A: signaling complex and procaspase-8 activation. In parallel, co-stimulation strongly increases expression of the short form of the FLICE-inhibitory protein c-FLIPshort
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 665 offsetEnd: 816 A: alpha(s) on the proliferation and tumorigenic capability of the later stage, metastatic estrogen-independent human breast cancer cell lines MDA-231 and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15949338 offsetBegin: 6494 offsetEnd: 6631 A: different concentrations had no effect. (3) 24 hours after transfection, the expression of phosphorylated form of ERK in the SGC7901cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15949338 offsetBegin: 6631 offsetEnd: 6769 A: 24 hours after transfection, the expression of phosphorylated form of ERK in the SGC7901cells transfected with siRNA plasmid against MKP-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15949338 offsetBegin: 6769 offsetEnd: 6898 A: of phosphorylated form of ERK in the SGC7901cells transfected with siRNA plasmid against MKP-1 mRNA was higher compared with that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22724069 offsetBegin: 2553 offsetEnd: 2684 A: phosphorylates one of the three human Snf7 paralogues-CHMP4C-in its C-terminal tail, a region known to regulate its ability to form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 1819 offsetEnd: 1939 A: Akata cells also increases FAS expression. The FAS gene product is required for de novo synthesis of the palmitate fatty
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 3472 offsetEnd: 3610 A: Jijoye cells. In addition, cerulenin and C75 dramatically attenuate IE and early lytic gene expression after B-cell receptor engagement in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 3610 offsetEnd: 3748 A: C75 dramatically attenuate IE and early lytic gene expression after B-cell receptor engagement in Akata cells and constitutive lytic viral
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 0 offsetEnd: 137 A: The c-Met receptor is a potential therapeutic target for non-small cell lung cancer (NSCLC). Signaling interactions between c-Met and the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 5397 offsetEnd: 5525 A: with PF2341066 and siRNA decreases EGF-induced phenotypes of invasion by ~86% and motility by ~81%, suggesting that a novel form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 624 offsetEnd: 767 A: component in skin cancer progression. Therefore, understanding genes involved in the regulation of inflammatory pathways is vital to the design
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 1337 offsetEnd: 1486 A: essential role in inflammation-associated cancers. Tpl2 (MAP3K8) is a protein kinase in the MAP Kinase signal transduction cascade. Previous research
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23457529 offsetBegin: 5100 offsetEnd: 5237 A: These experiments illustrate COX-2 induction in the absence of Tpl2 may be responsible for the increased tumorigenesis found in Tpl2(-/-)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 1167 offsetEnd: 1320 A: transfected with the POX gene under the control of a tetracycline-inducible promoter and found POX-stimulated expression of tumor necrosis factor-related
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 1784 offsetEnd: 1923 A: truncated form of RET, termed RET(DeltaTK), and analyzed its effect on cell viability, apoptosis, and proliferation of TT medullary thyroid
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22139077 offsetBegin: 5001 offsetEnd: 5133 A: attenuated their ability to form tumors and to induce angiogenesis when injected subcutaneously into nude mice. On the contrary, the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 265 offsetEnd: 401 A: of the basal-like subtype (with limited discordance) is an aggressive form of the disease which convey unpredictable, and poor prognosis
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 4332 offsetEnd: 4466 A: transfected mammary cells, identified a disproportionate number of TNBC breast tumors as compared to other breast cancer subtypes in a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24209998 offsetBegin: 4466 offsetEnd: 4581 A: number of TNBC breast tumors as compared to other breast cancer subtypes in a meta-analysis of 11 studies and 1,878
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 767 offsetEnd: 926 A: is capable of converting the monofunctional alkylating agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) into a toxic form by reducing the 4-nitro group of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 1073 offsetEnd: 1180 A: toxic form by reducing the 4-nitro group of CB1954. Toxic CB1954 is able to enhance cell killing in the NPC
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 4527 offsetEnd: 4685 A: CB1954-induced cell killing. These results suggested that the NOR1 gene enhances CB1954-mediated cell cytotoxicity through the upregulation of Grb2 expression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 2460 offsetEnd: 2597 A: gene into SVR murine angiosarcoma cells. Introduction of a dominant negative MAPKK causes a significant decrease in proliferation rate in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15087391 offsetBegin: 148 offsetEnd: 311 A: that Ras signaling contributes to the development of endometrial cancer. We previously demonstrated that endometrial cancer cells carrying oncogenic [(12)Val]K-ras
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15288476 offsetBegin: 3927 offsetEnd: 4073 A: reversion in NIH3T3 fibroblasts transformed by the oncogenic form of the receptor, Tpr-Met. CONCLUSIONS: Inhibition of various solid tumors growth
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15288476 offsetBegin: 4073 offsetEnd: 4204 A: the oncogenic form of the receptor, Tpr-Met. CONCLUSIONS: Inhibition of various solid tumors growth and metastasis by SU5416 may be
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 3360 offsetEnd: 3504 A: which induce a approximately 60-fold increase in GATA-4 expression. In colon cancer cells, however, the frequency of the long-range interactions
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 4636 offsetEnd: 4771 A: ones near the gene promoter. Removing DNA methylation through genetic disruption of DNA methyltransferases (DKO cells) leads to loss of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 6539 offsetEnd: 6659 A: cells. The loops associate with a poised, low transcription state in EC cells and, with the addition of DNA methylation,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 6659 offsetEnd: 6796 A: poised, low transcription state in EC cells and, with the addition of DNA methylation, completely repressed transcription in adult cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 1851 offsetEnd: 1972 A: cancer cell lines. We expressed the catalytic fragment of human MEKK1 to activate JNK and the Ras-binding domain (RBD) of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 5250 offsetEnd: 5369 A: Blocking these pathways either by coexpressing a dominant negative form of MKK4 or with inhibitors of MEK or p38 failed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12565821 offsetBegin: 5369 offsetEnd: 5482 A: a dominant negative form of MKK4 or with inhibitors of MEK or p38 failed to inhibit apoptosis. This suggests that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 624 offsetEnd: 763 A: normal epithelial cells, the loss of such contact triggers a form of apoptosis known as detachment-induced apoptosis or "anoikis." TMS1/ASC
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 763 offsetEnd: 902 A: such contact triggers a form of apoptosis known as detachment-induced apoptosis or "anoikis." TMS1/ASC is a bipartite adaptor molecule that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 4111 offsetEnd: 4236 A: and suggest that silencing of TMS1 may contribute to the pathogenesis of breast cancer by allowing epithelial cells to bypass
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 4236 offsetEnd: 4357 A: may contribute to the pathogenesis of breast cancer by allowing epithelial cells to bypass cell death in the early stages
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23830814 offsetBegin: 1730 offsetEnd: 1874 A: lesions during the early stages of hepatocellular tumor promotion. TAA increased the number and area of glutathione S-transferase placental form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23830814 offsetBegin: 1874 offsetEnd: 2018 A: hepatocellular tumor promotion. TAA increased the number and area of glutathione S-transferase placental form (GST-P)(+) liver cell foci and the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23830814 offsetBegin: 2157 offsetEnd: 2293 A: placental form (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in the liver. Co-administration with a-LA
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 739 offsetEnd: 888 A: the transition from androgen-dependent (AD) to ADI prostate cancer growth hampers our ability to develop target-driven therapeutic strategies for the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 888 offsetEnd: 1034 A: ADI prostate cancer growth hampers our ability to develop target-driven therapeutic strategies for the efficient treatment of ADI prostate cancer.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21267413 offsetBegin: 2930 offsetEnd: 3076 A: is upregulated in ADI prostate cancers of both the Pten deletion mouse model and the clinical prostate cancer specimens. CONCLUSIONS/SIGNIFICANCE:
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 1572 offsetEnd: 1720 A: SK-N-F1 cells stably transfected with a bicistronic expression construct encoding a secretory form of the rtEa4 peptide. Furthermore, treatment with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 1720 offsetEnd: 1867 A: bicistronic expression construct encoding a secretory form of the rtEa4 peptide. Furthermore, treatment with the recombinant rtEa4 peptide, but not
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 1724 offsetEnd: 1854 A: with the phosphorylated form of IKKbeta, and the interaction between PPM1A/PPM1B and IKKbeta is induced by TNFalpha in a transient
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 0 offsetEnd: 144 A: In cancer patients, the development of resistance to anti-angiogenic agents targeting the VEGF pathway is common. Increased pericyte coverage of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15629131 offsetBegin: 580 offsetEnd: 702 A: and RT/PCR showed the transcript is abundant in spleen but absent in several prostate and breast cancer cells. When stably
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 582 offsetEnd: 717 A: Piwi-like2 (piwil2) gene is mainly expressed in testis or embryonic cells among normal tissues but widely expressed in tumors. However,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 1237 offsetEnd: 1359 A: is involved in tumorigenesis. Here we report that Human piwil2, or Hili represses the tumor suppressor P53 in human cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22303479 offsetBegin: 1359 offsetEnd: 1497 A: report that Human piwil2, or Hili represses the tumor suppressor P53 in human cancer cells. Immunoprecipitation analysis shows that Piwil2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12810654 offsetBegin: 3057 offsetEnd: 3180 A: in the HCTp5.2 cell line, which expresses a dominant-negative form of p53. In these cells too, the GA analogues antagonized
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17440164 offsetBegin: 5485 offsetEnd: 5605 A: with trastuzumab had no effect on any of these parameters. Of 46 patients with metastatic breast cancer who were treated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17440164 offsetBegin: 5726 offsetEnd: 5865 A: patients with metastatic breast cancer who were treated with trastuzumab, only one of nine patients (11.1%) expressing p95HER2 responded to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 438 offsetEnd: 567 A: of keratin 8 (K8) filaments that contribute to the viscoelasticity of metastatic cancer cells. In this study, we investigated the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 567 offsetEnd: 704 A: contribute to the viscoelasticity of metastatic cancer cells. In this study, we investigated the role and molecular mechanisms of Tgase-2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 704 offsetEnd: 843 A: cancer cells. In this study, we investigated the role and molecular mechanisms of Tgase-2 in SPC-induced K8 phosphorylation and perinuclear
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15313166 offsetBegin: 2653 offsetEnd: 2816 A: transcription of a reporter gene controlled by dioxin-response elements (DREs), and pretreatment with PD98059 also blocked this transcription. PD98059 pretreatment
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 673 offsetEnd: 801 A: from Cf (Cf-PS) and demonstrated its antitumor effect in gastric cancer cells. In this report, we describe the protective effect
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 3371 offsetEnd: 3519 A: cells. Moreover, Cf-PS treatment reduced the expressions of cyclooxygenase-2 (COX-2) and the inducible form of nitric oxide (iNOS), proteins related
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12374697 offsetBegin: 1097 offsetEnd: 1214 A: vitro and in vivo effects of IGF-IR in human colon cancer growth and angiogenesis, HT29 cells were transfected with a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14678992 offsetBegin: 3152 offsetEnd: 3316 A: (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14678992 offsetBegin: 3316 offsetEnd: 3487 A: (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14678992 offsetBegin: 3487 offsetEnd: 3648 A: form of retinoblastoma protein (3-fold). Up-regulation of p21(waf/cip1) protein expression was observed in SMMC7721-ICN cells stably expressing active Notch1 but
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 2403 offsetEnd: 2525 A: FGF-2 and cyclin D2 was inhibited in GH4 cells infected with Hyb-HoxD10. GH4 cells transduced with Hyb-HoxD10 did not form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 3811 offsetEnd: 3938 A: an important role in the pathogenesis of osteosarcoma. ERK, JNK and p38 form an intercoordinating network and regulate the cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 3938 offsetEnd: 4093 A: of osteosarcoma. ERK, JNK and p38 form an intercoordinating network and regulate the cell proliferation, differentiation, apoptosis, invasion and migration
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 1210 offsetEnd: 1353 A: in skin carcinogenesis, with the absence of this gene contributing to heightened inflammation and increased skin carcinogenesis. In this study,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 963 offsetEnd: 1088 A: screen for proteins that interact physically with the cytoplasmic domain of the type II TGF-beta receptor to isolate the gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 1088 offsetEnd: 1205 A: with the cytoplasmic domain of the type II TGF-beta receptor to isolate the gene encoding Daxx - a protein associated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 1436 offsetEnd: 1568 A: Ras-transformed human cells in vitro and in vivo. Oncogenic Ras increases levels and activity of the intracellular form of wild-type
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 666 offsetEnd: 759 A: using murine 4T1 breast cancer cells. The combination of Icaritin at 3 µM or 6 µM with 6 or 8
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 4396 offsetEnd: 4523 A: to up-regulate IL6 gene expression, its protective effect was not due to induction of endogenous IL6 production but instead was
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 4082 offsetEnd: 4235 A: with decrease of episomal form during tumor progression. Methylation of the promoter/enhancer gradually decreased with tumor progression and is inversely
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18835704 offsetBegin: 3077 offsetEnd: 3210 A: increase in the activated phosphorylated form of p38 MAPK in CE-treated cells compared with the nontreated control cells, with larger
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 2543 offsetEnd: 2669 A: TRAF2 form a complex upon H(2)O(2) exposure, but without the participation of TNFR1. The colocalization of RIP with a membrane
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23734265 offsetBegin: 4839 offsetEnd: 4961 A: cells to extravasate and form metastatic foci in an experimental metastasis model in nude mice. The findings in this study
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2819 offsetEnd: 2931 A: a heterodimer and associate with the CD3 complex in order to be stably expressed at the T-cell surface. In order
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 3174 offsetEnd: 3295 A: In order to optimize the function of TCR-transduced T cells, researchers in the field of TCR gene transfer have exploited
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 1384 offsetEnd: 1520 A: cervical cancer cells. Exposure of HeLa cells to radiation induced loss of mitochondrial membrane potential, release of cytochrome c and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 3722 offsetEnd: 3870 A: and Bcl-2 phosphorylation as well as Fas expression. In addition, dominant-negative form of c-Jun inhibited radiation-induced Fas expression and Bax
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 0 offsetEnd: 138 A: 5-Fluorouracil (5-FU), a pyrimidine analog widely used in cancer chemotherapy and in glaucoma surgery, has recently shown some efficacy in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 138 offsetEnd: 263 A: used in cancer chemotherapy and in glaucoma surgery, has recently shown some efficacy in the treatment of keloids, scars that
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 3121 offsetEnd: 3265 A: AP-1-specific transcription and DNA binding. Overexpression of an antisense c-jun expression vector, or that of a dominant-negative form of MKK4
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 4747 offsetEnd: 4903 A: these results identify 5-FU as a potent inhibitor of TGF-beta/SMAD signaling, capable of blocking TGF-beta-induced, SMAD-driven up-regulation of COL1A2 gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 4903 offsetEnd: 5067 A: potent inhibitor of TGF-beta/SMAD signaling, capable of blocking TGF-beta-induced, SMAD-driven up-regulation of COL1A2 gene expression in a JNK-dependent manner. We
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 1097 offsetEnd: 1231 A: induced apoptosis via Fas signal activation in human breast cancer MCF-7 cells. CAPE activated Fas by a Fas ligand (Fas-L)-independent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 682 offsetEnd: 815 A: DNA breaks, which in the presence of defective homologous recombination repair lead to double-strand DNA breaks, the most lethal form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 952 offsetEnd: 1066 A: to double-strand DNA breaks, the most lethal form of DNA damage. These agents therefore may be the drugs of choice
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1264 offsetEnd: 1397 A: monitoring the kinetic expression of miRNA-16 during chemoresistance in gastric cancer both in vitro and in vivo. Human sodium iodide
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 5059 offsetEnd: 5164 A: gene may be served as a novel tool for in vivo imaging of microRNAs in the chemoresistance of cancers, as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 912 offsetEnd: 1028 A: to the transformed phenotype, we used an inducible form of Raf to analyze early changes in the transcription of some
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349840 offsetBegin: 401 offsetEnd: 530 A: of particular importance in tumor progression. We analyzed the cross-talk between these pathways in breast cancer cells in 2D and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 3738 offsetEnd: 3881 A: of miR-497 on CRC cells was largely mediated by inhibition of phosphatidylinositol 3-kinase/Akt signalling, as overexpression of an active form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 3881 offsetEnd: 4026 A: largely mediated by inhibition of phosphatidylinositol 3-kinase/Akt signalling, as overexpression of an active form of Akt reversed its impact on
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 4168 offsetEnd: 4312 A: active form of Akt reversed its impact on cell survival and proliferation, recapitulating the effect of overexpression of IGF1-R. Downregulation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 4598 offsetEnd: 4729 A: IGF1-R. Downregulation of miR-497 and miR-195 appeared to associate with copy number loss of a segment of chromosome 17p13.1, where
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 2723 offsetEnd: 2837 A: is necessary for HGF sensitization of ovarian cancer cells to low-doses of CDDP and PTX and might be sufficient to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16395709 offsetBegin: 2837 offsetEnd: 2966 A: ovarian cancer cells to low-doses of CDDP and PTX and might be sufficient to overcome activation of survival pathways. Therefore,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 136 offsetEnd: 260 A: cells, is the most common extracranial tumor of childhood. Retinoic acid (RA) which is the biological active form of vitamin
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 260 offsetEnd: 386 A: tumor of childhood. Retinoic acid (RA) which is the biological active form of vitamin A regulates differentiation of NB cells,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 1100 offsetEnd: 1248 A: role in the oxidation of fatty acids, carcinogenesis, and differentiation. URG4/URGCP gene is a proto-oncogene and that overexpression of URG4/URGCP
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349819 offsetBegin: 3629 offsetEnd: 3763 A: may form the basis for future lead optimization studies. Importantly, BIRB796 also enhanced the effect of paclitaxel on the inhibition
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 739 offsetEnd: 878 A: subgroups of ovarian cancer through the activation of both AP-1 and nuclear factor kappaB. Further analysis of paclitaxel analogs indicates
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 3635 offsetEnd: 3789 A: promoter activation was inhibited by dominant-inhibitory mutants of JNK, p38, and the super-repressor form of IkappaBalpha, but not by dominant-inhibitory
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 2870 offsetEnd: 3001 A: signaling, was detected in its phosphorylated (activated) form in 8 (36.4%) of 22 pretreatment marrows and became undetectable in 4
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 3001 offsetEnd: 3113 A: (activated) form in 8 (36.4%) of 22 pretreatment marrows and became undetectable in 4 of those 8 after one cycle
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 801 offsetEnd: 920 A: mRNA and protein of human breast cancer cells in a dosage- and time-dependent manner and that this up-regulation was de
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12471041 offsetBegin: 3986 offsetEnd: 4129 A: assay, the luciferase activities of the reporter constructs, including the putative NF-kappa B site deleted and mutated form were significantly
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 821 offsetEnd: 968 A: vivo, suggesting that these phytochemicals might be useful as therapeutic agents as well as for cancer prevention. Deoxyribonucleic acid microarray
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 968 offsetEnd: 1113 A: be useful as therapeutic agents as well as for cancer prevention. Deoxyribonucleic acid microarray studies on transformed keratinocytes and tumor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 4678 offsetEnd: 4804 A: levels of ATF4 protein. Activation of IRE1alpha was indicated by a rapid increase in the stress-specific spliced form of XBP-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17145690 offsetBegin: 163 offsetEnd: 325 A: ligand-binding nuclear transcription factor, estrogen receptor (ER), represent the most common form of breast epithelial malignancy. Exposure of breast epithelial
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17145690 offsetBegin: 325 offsetEnd: 463 A: (ER), represent the most common form of breast epithelial malignancy. Exposure of breast epithelial cells to a redox-cycling and arylating
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 3324 offsetEnd: 3439 A: physically associate in a manner that requires the basic region and CRD. We propose a model in which the regulatory
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 2457 offsetEnd: 2589 A: of the DBHS proteins, PSPC1 and NONO. These proteins form an extensively intertwined dimer, consistent with the observation that the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15939799 offsetBegin: 2584 offsetEnd: 2735 A: form of stress-activated cell death known as oncosis. Independent of MAPK signaling was the progressive appearance of K3-induced cellular fluorescence,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22749352 offsetBegin: 1420 offsetEnd: 1574 A: function of NLRX1 paralleled the previously described functions of the autophagy-related proteins Atg5-Atg12, but NLRX1 did not associate with Atg5-Atg12.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17682292 offsetBegin: 5347 offsetEnd: 5501 A: FHL2 overexpression enhances colony formation of breast cancer cells. Thus, our findings indicate that overexpression of the transcriptional cofactor FHL2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 1358 offsetEnd: 1476 A: cells in culture and their ability to form colonies in soft agar. This inhibition may occur by different mechanisms in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11805301 offsetBegin: 1476 offsetEnd: 1590 A: to form colonies in soft agar. This inhibition may occur by different mechanisms in the two cell types. In MDA-231
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 1939 offsetEnd: 2055 A: The FAS gene product is required for de novo synthesis of the palmitate fatty acid, and high-level FAS expression is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 4367 offsetEnd: 4476 A: induced by a vector in which the Z gene product is driven by a strong heterologous promoter. In addition, FAS
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 5765 offsetEnd: 5890 A: novel form of c-Met activation is utilized by EGFR to maximize these biological effects. Combined targeting of c-Met and EGFR
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 3636 offsetEnd: 3802 A: of manganese superoxide dismutase (MnSOD). Overexpression of constitutively active form of MEK, acMEK, partially blocked POX-induced apoptosis. These findings suggest
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 3802 offsetEnd: 3951 A: of constitutively active form of MEK, acMEK, partially blocked POX-induced apoptosis. These findings suggest the involvement of MEK/ERK signaling and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 2650 offsetEnd: 2785 A: or in gene expression. The effect of RET(DeltaTK) in primary medullary thyroid carcinomas in transgenic mice was assessed by monitoring
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 1910 offsetEnd: 2053 A: activity of the MMP-2/-9 gene promoter; the upregulation of MMP-2/-9 expression was mediated by p38 mitogen-activated protein kinase (p38 MAPK)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 5892 offsetEnd: 6038 A: stem/precursor cells and adult cancers. We also provide novel insight that PcG-occupied and H3K27me3-enriched regions can form chromatin loops and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19373782 offsetBegin: 0 offsetEnd: 143 A: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition syndrome with cutaneous and uterine leiomyomatosis as well as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19373782 offsetBegin: 143 offsetEnd: 269 A: (HLRCC) is a tumor predisposition syndrome with cutaneous and uterine leiomyomatosis as well as renal cell cancer (RCC) as its
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19373782 offsetBegin: 269 offsetEnd: 396 A: with cutaneous and uterine leiomyomatosis as well as renal cell cancer (RCC) as its clinical manifestations. HLRCC is caused by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 2993 offsetEnd: 3117 A: this work, we have developed a novel in vitro blood vessel maturation assay, in which lumenized, vascular structures form in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 3117 offsetEnd: 3255 A: novel in vitro blood vessel maturation assay, in which lumenized, vascular structures form in one optical plane and mesenchymal progenitor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 3561 offsetEnd: 3727 A: mesenchymal progenitor cells (10T1/2) differentiate into pericyte-like cells, which associate with the endothelial vessels (HUVECs). The differentiation of the 10T1/2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15629131 offsetBegin: 702 offsetEnd: 834 A: abundant in spleen but absent in several prostate and breast cancer cells. When stably expressed in L929 fibroblasts, Zfra conferred
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12810654 offsetBegin: 2934 offsetEnd: 3057 A: tested GA/17-AAG and DDP in combination in the HCTp5.2 cell line, which expresses a dominant-negative form of p53. In these
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18524446 offsetBegin: 801 offsetEnd: 940 A: antitumor effect in gastric cancer cells. In this report, we describe the protective effect of Cf-PS against alcohol-induced gastric injury
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19417161 offsetBegin: 5224 offsetEnd: 5371 A: of ATG5 expression. Knockdown of ATG5 suppressed GST-MDA-7 toxicity. Our data show that in kidney cancer cells GST-MDA-7 induces ceramide-dependent
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 2525 offsetEnd: 2648 A: in GH4 cells infected with Hyb-HoxD10. GH4 cells transduced with Hyb-HoxD10 did not form tumors in nude mice. These results
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 1206 offsetEnd: 1332 A: de novo micro-angiogenesis, three of the six cardinal hallmarks of a typical cancer cell. Earlier we reported the isolation of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 1705 offsetEnd: 1844 A: and activity of the intracellular form of wild-type Notch-1, and upregulates Notch ligand Delta-1 and also presenilin-1, a protein involved
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 2393 offsetEnd: 2525 A: to over-expression of Ets-2 and a constitutively active form of protein Kinase A (PKA). Unexpectedly, the promoter element of Tkdp-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 3295 offsetEnd: 3416 A: of TCR-transduced T cells, researchers in the field of TCR gene transfer have exploited many aspects of basic research in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 1250 offsetEnd: 1384 A: of mitochondrial cell death in human cervical cancer cells. Exposure of HeLa cells to radiation induced loss of mitochondrial membrane
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 2734 offsetEnd: 2867 A: and Bak activation, but did not affect phosphorylation and downregulation of Bcl-2. Expression of a mutant form of Bcl-2 (S70A-Bcl-2)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 2867 offsetEnd: 3045 A: affect phosphorylation and downregulation of Bcl-2. Expression of a mutant form of Bcl-2 (S70A-Bcl-2) completely attenuated radiation-induced Bcl-2 downregulation. Interestingly,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 3876 offsetEnd: 3993 A: these phenomena are attributable to the inhibition of NFkappaB by CAPE, we examined the effect of a truncated form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14625298 offsetBegin: 3993 offsetEnd: 4133 A: inhibition of NFkappaB by CAPE, we examined the effect of a truncated form of IkappaBalpha (IkappaBDeltaN) lacking the phosphorylation sites
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 1397 offsetEnd: 1531 A: during chemoresistance in gastric cancer both in vitro and in vivo. Human sodium iodide symporter (hNIS) and firefly luciferase (Fluc)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1028 offsetEnd: 1145 A: an inducible form of Raf to analyze early changes in the transcription of some 6000 genes following activation of the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21075852 offsetBegin: 1444 offsetEnd: 1572 A: the IFNλ receptor, the non-active form of RSK1 is present in a complex with the translational repressor 4E-BP1 in IFNλ-sensitive
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15590739 offsetBegin: 2069 offsetEnd: 2193 A: a dominant negative form of Sprouty2 augmented ERK activation, and resulted in anterior shift of the posterior border of the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349819 offsetBegin: 3497 offsetEnd: 3629 A: of the transmembrane region of ABCB1 may form the basis for future lead optimization studies. Importantly, BIRB796 also enhanced the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11927016 offsetBegin: 2100 offsetEnd: 2230 A: a decrease in cyclin D1, an increase in p27(Kip1) and a reduction in the hyperphosphorylated form of retinoblastoma protein (pRB).
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 3932 offsetEnd: 4096 A: super-repressor form of IkappaBalpha, but not by dominant-inhibitory forms of ERK1. Dominant-inhibitory mutants of JNK1 also greatly reduced paclitaxel-induced cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11369625 offsetBegin: 5063 offsetEnd: 5167 A: to detect N-ras gene mutations in any of the 35 leukemias. The results of this first clinical trial of a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 589 offsetEnd: 725 A: By expressing a dominant-active form of mitogen-activated protein kinase kinase kinase 1, by exposure to tumor necrosis factor alpha, or
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11160206 offsetBegin: 1779 offsetEnd: 1916 A: cell lines overexpressing a dominant-negative (dn) mutant form of JNK1 (dnJNK1). Anti-IgM induced a sustained JNK1 activation with a peak
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24210919 offsetBegin: 1912 offsetEnd: 2078 A: Red1-independent interactions with evolutionarily conserved proteins named Nrl1 and Ctr1, which associate with splicing factors. Whereas Nrl1 targets transcripts with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15270080 offsetBegin: 4931 offsetEnd: 5066 A: increase in the stress-specific spliced form of XBP-1 messenger ribonucleic acid and a rapid and persistent phosphorylation of JNK1 and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20452968 offsetBegin: 3074 offsetEnd: 3201 A: in the protein-binding site of TAZ2. The C/EBPbeta N- and C-terminal domains physically associate in a manner that requires the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19435930 offsetBegin: 2796 offsetEnd: 2950 A: 4-fold induction of TTP mRNA, the anti-inflammatory glucocorticoid dexamethasone only modestly induced expression of the approximately 40-kDa form of TTP.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19435930 offsetBegin: 3112 offsetEnd: 3245 A: expression of the approximately 40-kDa form of TTP. In the context of IL-1beta, dexamethasone exerted a marginal repressive effect on
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11069056 offsetBegin: 2079 offsetEnd: 2229 A: parallel, co-stimulation strongly increases expression of the short form of the FLICE-inhibitory protein c-FLIPshort and of Bcl-xL. These data provide
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11069056 offsetBegin: 2229 offsetEnd: 2362 A: the short form of the FLICE-inhibitory protein c-FLIPshort and of Bcl-xL. These data provide important new insight into the molecular
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21635933 offsetBegin: 2087 offsetEnd: 2213 A: The core structures of G-quadruplexes form stable scaffolds while the loops have been shown, by the addition of small molecule
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15047835 offsetBegin: 3345 offsetEnd: 3472 A: early (BMRF1) lytic EBV proteins in Jijoye cells. In addition, cerulenin and C75 dramatically attenuate IE and early lytic gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21423210 offsetBegin: 5525 offsetEnd: 5641 A: phenotypes of invasion by ~86% and motility by ~81%, suggesting that a novel form of c-Met activation is utilized by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16619034 offsetBegin: 3478 offsetEnd: 3636 A: decrease was partially reversed by expression of manganese superoxide dismutase (MnSOD). Overexpression of constitutively active form of MEK, acMEK, partially
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23741254 offsetBegin: 4685 offsetEnd: 4824 A: that the NOR1 gene enhances CB1954-mediated cell cytotoxicity through the upregulation of Grb2 expression and the activation of MAPK signal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19053175 offsetBegin: 3504 offsetEnd: 3635 A: in GATA-4 expression. In colon cancer cells, however, the frequency of the long-range interactions are increased in a setting where
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 3012 offsetEnd: 3153 A: manner. Abeta(25-35) treatment upregulated pro-apoptotic p53 at the gene level, and Bax and caspase-3 at the protein level, but downregulated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16153742 offsetBegin: 3153 offsetEnd: 3295 A: at the gene level, and Bax and caspase-3 at the protein level, but downregulated anti-apoptotic Bcl-2 protein. Interestingly, co-treated green
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 2759 offsetEnd: 2874 A: cells show specific alterations of early gene induction. The serum induction of c-fos and junD as well as the serum
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 499 offsetEnd: 624 A: loss of extracellular matrix contact. In normal epithelial cells, the loss of such contact triggers a form of apoptosis known
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23830814 offsetBegin: 2018 offsetEnd: 2157 A: number and area of glutathione S-transferase placental form (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 1867 offsetEnd: 2005 A: form of the rtEa4 peptide. Furthermore, treatment with the recombinant rtEa4 peptide, but not the mature hIGF-I, resulted in morphological
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 4206 offsetEnd: 4362 A: the neuronal marker gene neuropeptide tyrosine (NPY). Furthermore, effects of signal transduction inhibitors are indicative of the involvement of MAP-kinase
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18930133 offsetBegin: 1295 offsetEnd: 1439 A: in dephosphorylation of IKKbeta at Ser177 and Ser181 and termination of IKKbeta-induced NF-kappaB activation. PPM1A and PPM1B associate with the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17440164 offsetBegin: 5605 offsetEnd: 5726 A: any of these parameters. Of 46 patients with metastatic breast cancer who were treated with trastuzumab, only one of nine
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12374697 offsetBegin: 980 offsetEnd: 1097 A: factor (VEGF). To elucidate the in vitro and in vivo effects of IGF-IR in human colon cancer growth and angiogenesis,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/14678992 offsetBegin: 3015 offsetEnd: 3152 A: ICN decreased expression of cyclin A (3.5-fold), cyclin D1 (2-fold), cyclin E (4.5-fold), CDK2 (2.8-fold), and the phosphorylated form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 2979 offsetEnd: 3127 A: associate Daxx directly with the TGF-beta apoptotic-signalling pathway, and make a biochemical connection between the receptors for TGF-beta and the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 2149 offsetEnd: 2271 A: vitro. Inhibition of JNK signaling either by a JNK inhibitor, SP600125, or expression of a dominant negative form of MKK4,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 2271 offsetEnd: 2402 A: by a JNK inhibitor, SP600125, or expression of a dominant negative form of MKK4, a JNK upstream activator, blocked Netrin-1-induced
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 3265 offsetEnd: 3394 A: of an antisense c-jun expression vector, or that of a dominant-negative form of MKK4 that interferes with c-Jun N-terminal kinase
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 2054 offsetEnd: 2196 A: and then generate human gastric cancer cell line NF-3xmir16 and its multidrug resistance cell line NF-3xmir16/VCR. Radioiodide uptake and Fluc
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 1054 offsetEnd: 1183 A: have discovered a novel form of crosstalk between components of the Insulin and the RAS/MAPK pathways. The insulin receptor DAF-2
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15590739 offsetBegin: 1787 offsetEnd: 1923 A: a fate change of the presumptive metencephalon to the mesencephalon. Misexpression of a dominant negative form of Sprouty2 augmented ERK
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23821302 offsetBegin: 1248 offsetEnd: 1405 A: acids, carcinogenesis, and differentiation. URG4/URGCP gene is a proto-oncogene and that overexpression of URG4/URGCP is associated with metastasis and tumor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12694536 offsetBegin: 2985 offsetEnd: 3110 A: for the association of nectin-1 and E-cadherin to form AJs. Reorganization of the actin cytoskeleton was not required for the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11909978 offsetBegin: 435 offsetEnd: 589 A: in progression of hormone-independent breast cancer. By expressing a dominant-active form of mitogen-activated protein kinase kinase kinase 1, by exposure
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11160206 offsetBegin: 1916 offsetEnd: 2026 A: mutant form of JNK1 (dnJNK1). Anti-IgM induced a sustained JNK1 activation with a peak at 8 h, with a marginal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 447 offsetEnd: 595 A: and Hrp65. DBHS proteins are predominately nuclear, and are involved in transcriptional and posttranscriptional gene regulatory functions as well as
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19435930 offsetBegin: 2950 offsetEnd: 3112 A: anti-inflammatory glucocorticoid dexamethasone only modestly induced expression of the approximately 40-kDa form of TTP. In the context of IL-1beta, dexamethasone
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11751889 offsetBegin: 2862 offsetEnd: 3007 A: the agonist-dependent association of the mutant receptor with Hip. Overexpression of a tetratricopeptide repeat (TPR) deletion mutant form of Hip
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 2361 offsetEnd: 2504 A: the effect of RET(DeltaTK) on downsteam signaling by assessing alterations in phosphorylation or in gene expression. The effect of RET(DeltaTK)
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19223547 offsetBegin: 3991 offsetEnd: 4111 A: TMS1 in the promotion of anoikis, and suggest that silencing of TMS1 may contribute to the pathogenesis of breast cancer
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12372341 offsetBegin: 281 offsetEnd: 403 A: processed to its mature form by proteolytic removal of the signal peptide and the E-domain peptide. Contrary to the mature
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23892038 offsetBegin: 3727 offsetEnd: 3881 A: pericyte-like cells, which associate with the endothelial vessels (HUVECs). The differentiation of the 10T1/2 cells into pericyte-like cells is visualized
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 2985 offsetEnd: 3113 A: the effect of Tgase-2 on JNK activation of serine 431 phosphorylation in K8. Tgase-2 gene silencing suppressed the expression of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21840417 offsetBegin: 3411 offsetEnd: 3560 A: expression of active form JNK (pJNK). Constitutive or tetracyclin-induced conditional expression of Tgase-2 increased the levels of pJNK. Tgase-2 was
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15364949 offsetBegin: 315 offsetEnd: 469 A: 1 and 2 (ERK1/2) and rapid receptor endocytosis. Co-immunoprecipitation and co-localization experiments showed that arrestin and CXCR2 form complexes with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 3045 offsetEnd: 3226 A: Expression of a mutant form of Bcl-2 (S70A-Bcl-2) completely attenuated radiation-induced Bcl-2 downregulation. Interestingly, inhibition of JNK clearly attenuated radiation-induced
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22710713 offsetBegin: 4459 offsetEnd: 4598 A: recapitulating the effect of overexpression of IGF1-R. Downregulation of miR-497 and miR-195 appeared to associate with copy number loss of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349819 offsetBegin: 3258 offsetEnd: 3378 A: paclitaxel on KBV200. The binding model of BIRB796 within the large cavity of the transmembrane region of ABCB1 may form
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23349819 offsetBegin: 3378 offsetEnd: 3497 A: of BIRB796 within the large cavity of the transmembrane region of ABCB1 may form the basis for future lead optimization
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22416126 offsetBegin: 1942 offsetEnd: 2063 A: that alter gene expression via the nuclear retention of RNA. Here we describe the crystal structure of the heterodimer of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15316058 offsetBegin: 2504 offsetEnd: 2650 A: signaling by assessing alterations in phosphorylation or in gene expression. The effect of RET(DeltaTK) in primary medullary thyroid carcinomas in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11106566 offsetBegin: 2329 offsetEnd: 2460 A: We introduced a dominant negative MAPKK gene into SVR murine angiosarcoma cells. Introduction of a dominant negative MAPKK causes a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15087391 offsetBegin: 1600 offsetEnd: 1755 A: endometrial cells from apoptosis. Expression of a constitutively active form of Raf-1 (Raf-CAAX) promoted apoptosis, whereas expression of a constitutively
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15087391 offsetBegin: 1755 offsetEnd: 1917 A: a constitutively active form of Raf-1 (Raf-CAAX) promoted apoptosis, whereas expression of a constitutively active catalytic subunit of phosphoinositide 3-kinase,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/8426742 offsetBegin: 2874 offsetEnd: 3013 A: gene induction. The serum induction of c-fos and junD as well as the serum and TPA (12-O-tetradecanoylphorbol-13-acetate) induction of junB
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15313166 offsetBegin: 2038 offsetEnd: 2192 A: treatment results in phosphorylation of p44/p42 mitogen-activated protein kinase (MAPK), a substrate of MEK-1. Overexpression of dominant negative form of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15313166 offsetBegin: 2192 offsetEnd: 2350 A: mitogen-activated protein kinase (MAPK), a substrate of MEK-1. Overexpression of dominant negative form of p42 MAPK suppressed TCDD-dependent transcription of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 1641 offsetEnd: 1773 A: transfection of ErbB2 cDNA to HB2 cells upregulated the transcripts and the activity of the MMP-2/-9 gene promoter; the upregulation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/9774447 offsetBegin: 3789 offsetEnd: 3932 A: mutants of JNK, p38, and the super-repressor form of IkappaBalpha, but not by dominant-inhibitory forms of ERK1. Dominant-inhibitory mutants of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16450376 offsetBegin: 1773 offsetEnd: 1910 A: cells upregulated the transcripts and the activity of the MMP-2/-9 gene promoter; the upregulation of MMP-2/-9 expression was mediated by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 3881 offsetEnd: 3963 A:       pathway. The presence of both KRAS mutations and the active form of NF-κB in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 2349 offsetEnd: 2429 A:         mutations was higher (50.8%) than in tumors with the wild-type KRAS gene
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 82 offsetEnd: 145 A: in colorectal cancer is not clear.             Western blotting
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22327383 offsetBegin: 2578 offsetEnd: 2644 A: KRAS gene (30.6%)             (P=0.012). Compared to patients with
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15364949 offsetBegin: 3415 offsetEnd: 3553 A: cytoplasmic Rac was translocated to the membrane fraction, which is a prerequisite for oxidant formation. The oxidative burst induced cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15364949 offsetBegin: 3553 offsetEnd: 3676 A: membrane fraction, which is a prerequisite for oxidant formation. The oxidative burst induced cell death within 6 h of IL-8
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15364949 offsetBegin: 3676 offsetEnd: 3796 A: for oxidant formation. The oxidative burst induced cell death within 6 h of IL-8 stimulation of these cells, which could
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 237 offsetEnd: 364 A: has been reported that a variety of growth factors and cytokines regulating cell growth and angiogenesis play an important role
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 364 offsetEnd: 496 A: of growth factors and cytokines regulating cell growth and angiogenesis play an important role in the growth of prolactinoma. HoxD10
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 496 offsetEnd: 622 A: cell growth and angiogenesis play an important role in the growth of prolactinoma. HoxD10 has been shown to impair endothelial
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 622 offsetEnd: 760 A: important role in the growth of prolactinoma. HoxD10 has been shown to impair endothelial cell migration, block angiogenesis, and maintain
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 760 offsetEnd: 906 A: prolactinoma. HoxD10 has been shown to impair endothelial cell migration, block angiogenesis, and maintain a differentiated phenotype of cells. We
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18442473 offsetBegin: 1339 offsetEnd: 1497 A: delivery could inhibit the growth of prolactinoma. Rat GH4 lactotrope tumor cells were infected with adenovirus/adeno-associated virus (Ad/AAV) hybrid vectors
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 918 offsetEnd: 1065 A: activation of STAT3 imparts resistance to apoptosis, promotes cell proliferation, and induces de novo micro-angiogenesis, three of the six cardinal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23386605 offsetBegin: 3459 offsetEnd: 3604 A: cellular transformation and tumor growth in vivo. Additionally, these mutants lost their capacity to prevent metastasis. These mutations define a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 422 offsetEnd: 561 A: (Human Genome U133A, Affymetrix) was used to screen the differential expression of genes involved in MAPK pathway between osteosarcoma cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 561 offsetEnd: 695 A: to screen the differential expression of genes involved in MAPK pathway between osteosarcoma cell lines and 3 osteoblastic cell lines.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 695 offsetEnd: 834 A: genes involved in MAPK pathway between osteosarcoma cell lines and 3 osteoblastic cell lines. KEGG metabolic pathway analysis was performed
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 834 offsetEnd: 983 A: osteosarcoma cell lines and 3 osteoblastic cell lines. KEGG metabolic pathway analysis was performed among significantly increased or decreased genes
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 983 offsetEnd: 1146 A: cell lines. KEGG metabolic pathway analysis was performed among significantly increased or decreased genes using the MATLAB software. Immunohistochemical technique
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 1146 offsetEnd: 1300 A: was performed among significantly increased or decreased genes using the MATLAB software. Immunohistochemical technique was used to detect the expressions
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 1300 offsetEnd: 1439 A: decreased genes using the MATLAB software. Immunohistochemical technique was used to detect the expressions of ERK1/2, JNK and p38 proteins
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 1953 offsetEnd: 2080 A: Using an entrance limit of > or = 2.0, 18 differentially expressed MAPK pathway-related genes were selected (10 up-regulated, 8
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 2080 offsetEnd: 2216 A: or = 2.0, 18 differentially expressed MAPK pathway-related genes were selected (10 up-regulated, 8 down-regulated) to mapped to the MAPK
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 2216 offsetEnd: 2344 A: MAPK pathway-related genes were selected (10 up-regulated, 8 down-regulated) to mapped to the MAPK pathway of KEGG which are all
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 2344 offsetEnd: 2468 A: up-regulated, 8 down-regulated) to mapped to the MAPK pathway of KEGG which are all important node genes. The positive rates
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 2468 offsetEnd: 2579 A: the MAPK pathway of KEGG which are all important node genes. The positive rates of ERK1/2, JNK and p38 proteins
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 2579 offsetEnd: 2697 A: are all important node genes. The positive rates of ERK1/2, JNK and p38 proteins were 83.3% (40/48), 72.9% (35/48) and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/19799081 offsetBegin: 3539 offsetEnd: 3684 A: were statistically different between the 2 groups (P<0.01). CONCLUSION: MAPK pathway plays an important role in the pathogenesis of osteosarcoma.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 2042 offsetEnd: 2221 A: keratinocytes. We identified over 2000 genes as being differentially expressed between genotypes. Functional annotation analysis identified cancer, cell growth/proliferation, cell
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 2221 offsetEnd: 2398 A: as being differentially expressed between genotypes. Functional annotation analysis identified cancer, cell growth/proliferation, cell death, cell development, cell movement and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 2398 offsetEnd: 2559 A: Functional annotation analysis identified cancer, cell growth/proliferation, cell death, cell development, cell movement and cell signaling as the top biological
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 2870 offsetEnd: 3036 A: top biological processes to be differentially regulated between genotypes. Further microarray analysis identified several candidate genes, including Mmp1b, Mmp2, Mmp9
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/24067898 offsetBegin: 3036 offsetEnd: 3193 A: regulated between genotypes. Further microarray analysis identified several candidate genes, including Mmp1b, Mmp2, Mmp9 and Mmp13, involved in migration and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 0 offsetEnd: 138 A: Transforming growth factor-beta (TGF-beta) is a multifunctional growth factor that has a principal role in growth control through both its
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11483955 offsetBegin: 1450 offsetEnd: 1587 A: protein associated with the Fas receptor that mediates activation of Jun amino-terminal kinase (JNK) and programmed cell death induced by
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 0 offsetEnd: 135 A: Truncated Notch receptors have transforming activity in vitro and in vivo. However, the role of wild-type Notch signaling in neoplastic
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 135 offsetEnd: 266 A: in vitro and in vivo. However, the role of wild-type Notch signaling in neoplastic transformation remains unclear. Ras signaling is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 266 offsetEnd: 401 A: the role of wild-type Notch signaling in neoplastic transformation remains unclear. Ras signaling is deregulated in a large fraction of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 401 offsetEnd: 532 A: in neoplastic transformation remains unclear. Ras signaling is deregulated in a large fraction of human malignancies and is a major
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 1028 offsetEnd: 1174 A: that oncogenic Ras activates Notch signaling and that wild-type Notch-1 is necessary to maintain the neoplastic phenotype in Ras-transformed human
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 1174 offsetEnd: 1303 A: and that wild-type Notch-1 is necessary to maintain the neoplastic phenotype in Ras-transformed human cells in vitro and in vivo.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12185362 offsetBegin: 1303 offsetEnd: 1436 A: to maintain the neoplastic phenotype in Ras-transformed human cells in vitro and in vivo. Oncogenic Ras increases levels and activity
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 3145 offsetEnd: 3286 A: effect; and 4) synergize with IR to enhance cell apoptosis. In addition, ICT suppressed angiogenesis in chick embryo chorioallantoic membrane
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 3286 offsetEnd: 3430 A: to enhance cell apoptosis. In addition, ICT suppressed angiogenesis in chick embryo chorioallantoic membrane (CAM) assay. Taken together, ICT is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 3430 offsetEnd: 3572 A: ICT suppressed angiogenesis in chick embryo chorioallantoic membrane (CAM) assay. Taken together, ICT is a new radiosensitizer and can enhance
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23977023 offsetBegin: 3572 offsetEnd: 3704 A: chorioallantoic membrane (CAM) assay. Taken together, ICT is a new radiosensitizer and can enhance anti-cancer effect of IR or other
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 129 offsetEnd: 267 A: for their survival and proliferation during the early stages of disease, and independence from IL6 is associated with disease progression.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 267 offsetEnd: 391 A: the early stages of disease, and independence from IL6 is associated with disease progression. The role of the NF-κB pathway
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 391 offsetEnd: 523 A: independence from IL6 is associated with disease progression. The role of the NF-κB pathway in the IL6-independent growth of myeloma
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 2756 offsetEnd: 2915 A: with visceral involvement when injected intraperitoneally into syngeneic mice. These IL6-independent clones were dependent on NF-κB activity for their survival
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 2915 offsetEnd: 3056 A: into syngeneic mice. These IL6-independent clones were dependent on NF-κB activity for their survival and proliferation but were resistant to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 4523 offsetEnd: 4658 A: protective effect was not due to induction of endogenous IL6 production but instead was associated with sustained expression of several
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 4658 offsetEnd: 4801 A: induction of endogenous IL6 production but instead was associated with sustained expression of several antiapoptotic members of the Bcl2 family
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21705340 offsetBegin: 4801 offsetEnd: 4950 A: instead was associated with sustained expression of several antiapoptotic members of the Bcl2 family upon IL6 withdrawal. Collectively, these results
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 0 offsetEnd: 176 A: BACKGROUND: The trophoblast Kunitz domain proteins (TKDPs) constitute a highly expressed, placenta-specific, multigene family restricted to ruminant ungulates and characterized
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 176 offsetEnd: 343 A: (TKDPs) constitute a highly expressed, placenta-specific, multigene family restricted to ruminant ungulates and characterized by a C-terminal "Kunitz" domain, preceded
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 343 offsetEnd: 485 A: multigene family restricted to ruminant ungulates and characterized by a C-terminal "Kunitz" domain, preceded by one or more unique N-terminal
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 1199 offsetEnd: 1311 A: in ruminants. Our goal here has been to determine whether the ovine (ov) Tkdp-1 and IFNT genes possess a similar
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 1311 offsetEnd: 1444 A: been to determine whether the ovine (ov) Tkdp-1 and IFNT genes possess a similar transcriptional code. RESULTS: The ovTkdp-1 promoter
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 1444 offsetEnd: 1579 A: (ov) Tkdp-1 and IFNT genes possess a similar transcriptional code. RESULTS: The ovTkdp-1 promoter has been cloned and characterized. As
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 5315 offsetEnd: 5445 A: enhancer, which binds Jun family members, is required for basal and cAMP/ C/EBP-beta-dependent activation of the gene, but not for
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 5445 offsetEnd: 5595 A: is required for basal and cAMP/ C/EBP-beta-dependent activation of the gene, but not for Ets-2-dependent activity. CONCLUSION: This paper demonstrates
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 5595 offsetEnd: 5751 A: C/EBP-beta-dependent activation of the gene, but not for Ets-2-dependent activity. CONCLUSION: This paper demonstrates how Ets-2, a key transcription factor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 5908 offsetEnd: 6054 A: paper demonstrates how Ets-2, a key transcription factor for trophoblast differentiation and function, can control expression of two genes (Tkdp-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 6054 offsetEnd: 6201 A: transcription factor for trophoblast differentiation and function, can control expression of two genes (Tkdp-1 and IFNT) having similar spatial and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/17326832 offsetBegin: 6201 offsetEnd: 6339 A: function, can control expression of two genes (Tkdp-1 and IFNT) having similar spatial and temporal expression patterns via very different
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 3348 offsetEnd: 3482 A: Thus, our results demonstrate that the coding sequence of Dnmt3b mediates regulation by the miR-148 family. More generally, we provide
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 3482 offsetEnd: 3615 A: coding sequence of Dnmt3b mediates regulation by the miR-148 family. More generally, we provide evidence that coding regions of human
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 3615 offsetEnd: 3735 A: by the miR-148 family. More generally, we provide evidence that coding regions of human genes can be targeted by miRNAs,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 3735 offsetEnd: 3848 A: we provide evidence that coding regions of human genes can be targeted by miRNAs, and that such a mechanism might
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18367714 offsetBegin: 3848 offsetEnd: 3952 A: of human genes can be targeted by miRNAs, and that such a mechanism might play a role in determining the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 267 offsetEnd: 417 A: physiological and pathological processes in brain development, such as neural survival, migration, and polarity as well as axon regeneration. However,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 417 offsetEnd: 555 A: development, such as neural survival, migration, and polarity as well as axon regeneration. However, whether JNK activation is involved in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 555 offsetEnd: 684 A: and polarity as well as axon regeneration. However, whether JNK activation is involved in axon guidance remains unknown. Here, we
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23223444 offsetBegin: 684 offsetEnd: 828 A: regeneration. However, whether JNK activation is involved in axon guidance remains unknown. Here, we provide evidence indicating the JNK pathway
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 0 offsetEnd: 134 A: OBJECTIVE: The study was aimed at understanding the complex interactions of genetic and epigenetic events in expression of HPV16 E6/E7
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 134 offsetEnd: 277 A: understanding the complex interactions of genetic and epigenetic events in expression of HPV16 E6/E7 and progression of cervical carcinoma. For
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 277 offsetEnd: 405 A: and epigenetic events in expression of HPV16 E6/E7 and progression of cervical carcinoma. For this, expression of E6/E7 was done
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 649 offsetEnd: 779 A: was done in 36 samples, along with the physical status, methylation and LCR sequence variations. Later, the genetic and epigenetic
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 779 offsetEnd: 916 A: with the physical status, methylation and LCR sequence variations. Later, the genetic and epigenetic studies were extended to 239 samples
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 916 offsetEnd: 1042 A: LCR sequence variations. Later, the genetic and epigenetic studies were extended to 239 samples to find out the association of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 1042 offsetEnd: 1167 A: and epigenetic studies were extended to 239 samples to find out the association of these factors with progression of cervical
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 1167 offsetEnd: 1301 A: 239 samples to find out the association of these factors with progression of cervical cancer. METHODS: E6/E7 expression was quantified
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 1301 offsetEnd: 1444 A: association of these factors with progression of cervical cancer. METHODS: E6/E7 expression was quantified by real-time PCR. Physical status of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 1444 offsetEnd: 1581 A: of cervical cancer. METHODS: E6/E7 expression was quantified by real-time PCR. Physical status of HPV16 was determined by mutiplex-PCR of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 2864 offsetEnd: 3032 A: Samples with episomal unmethylated virus showed comparatively high expression of E6/E7 than episomal methylated, integrated unmethylated and integrated methylated forms
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 3032 offsetEnd: 3185 A: comparatively high expression of E6/E7 than episomal methylated, integrated unmethylated and integrated methylated forms of HPV16. Variations in the LCR,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 3185 offsetEnd: 3331 A: episomal methylated, integrated unmethylated and integrated methylated forms of HPV16. Variations in the LCR, particularly in the binding sites of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 3331 offsetEnd: 3478 A: methylated forms of HPV16. Variations in the LCR, particularly in the binding sites of negatively regulating transcription factors, also contribute
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 4974 offsetEnd: 5109 A: test revealed better prognosis of the patients with episomal methylated HPV16 compared to the other forms. CONCLUSION: Our results show
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 5109 offsetEnd: 5244 A: patients with episomal methylated HPV16 compared to the other forms. CONCLUSION: Our results show higher expression of E6/E7 in samples
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/21911249 offsetBegin: 5244 offsetEnd: 5379 A: to the other forms. CONCLUSION: Our results show higher expression of E6/E7 in samples with episomal unmethylated virus having sequence
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 628 offsetEnd: 781 A: cell death are largely unknown. Data from this study suggest that receptor-interacting protein (RIP) and tumor necrosis factor receptor (TNFR)-associated
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 781 offsetEnd: 932 A: from this study suggest that receptor-interacting protein (RIP) and tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), two key effector
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 932 offsetEnd: 1075 A: protein (RIP) and tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), two key effector molecules of TNF signaling, are essential
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/15199146 offsetBegin: 1075 offsetEnd: 1215 A: receptor (TNFR)-associated factor 2 (TRAF2), two key effector molecules of TNF signaling, are essential for ROS-induced cell death. We found
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 519 offsetEnd: 641 A: a reliable method to generate ex vivo large numbers of T cells of a given antigen-specificity and functional avidity. Such
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 921 offsetEnd: 1079 A: avidity. Such approaches have major applications for the adoptive cellular therapy of viral infectious diseases, virus-associated malignancies and cancer. TCR
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2059 offsetEnd: 2186 A: desired antigen specificity. The TCR-encoding vector is then used to infect (transduce) primary T cells in vitro. To generate a
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2186 offsetEnd: 2295 A: is then used to infect (transduce) primary T cells in vitro. To generate a transduced T cell with the desired
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/20561357 offsetBegin: 2295 offsetEnd: 2422 A: primary T cells in vitro. To generate a transduced T cell with the desired functional specificity, the introduced TCR-alpha and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 4553 offsetEnd: 4674 A: of Fas and subsequent activation of Bax and Bak, and that JNK, but not c-Jun, is directly associated with phosphorylation
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 4674 offsetEnd: 4799 A: Bax and Bak, and that JNK, but not c-Jun, is directly associated with phosphorylation and downregulation of Bcl-2 in response
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/18373696 offsetBegin: 4799 offsetEnd: 4942 A: but not c-Jun, is directly associated with phosphorylation and downregulation of Bcl-2 in response to ionizing radiation. These results suggest
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 397 offsetEnd: 545 A: efficacy in the treatment of keloids, scars that overgrow the boundaries of original wounds. Given the physiopathological importance of transforming
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 545 offsetEnd: 699 A: scars that overgrow the boundaries of original wounds. Given the physiopathological importance of transforming growth factor-beta (TGF-beta) in keloid and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 699 offsetEnd: 856 A: original wounds. Given the physiopathological importance of transforming growth factor-beta (TGF-beta) in keloid and scar formation, we have examined whether
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 856 offsetEnd: 998 A: of transforming growth factor-beta (TGF-beta) in keloid and scar formation, we have examined whether the clinical benefits from 5-FU treatment
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 998 offsetEnd: 1123 A: keloid and scar formation, we have examined whether the clinical benefits from 5-FU treatment may result from its capacity to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 1830 offsetEnd: 1989 A: approaches to study the mechanisms underlying 5-FU effects, we have demonstrated that 5-FU antagonizes TGF-beta-driven COL1A2 transcription and associated type
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 1989 offsetEnd: 2147 A: 5-FU effects, we have demonstrated that 5-FU antagonizes TGF-beta-driven COL1A2 transcription and associated type I collagen production by dermal fibroblasts.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 2147 offsetEnd: 2314 A: 5-FU antagonizes TGF-beta-driven COL1A2 transcription and associated type I collagen production by dermal fibroblasts. In addition, 5-FU inhibits both SMAD3/4-specific
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 2314 offsetEnd: 2473 A: associated type I collagen production by dermal fibroblasts. In addition, 5-FU inhibits both SMAD3/4-specific transcription and formation of SMAD/DNA complexes
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 2473 offsetEnd: 2631 A: dermal fibroblasts. In addition, 5-FU inhibits both SMAD3/4-specific transcription and formation of SMAD/DNA complexes induced by TGF-beta. 5-FU induces c-Jun
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 2631 offsetEnd: 2805 A: both SMAD3/4-specific transcription and formation of SMAD/DNA complexes induced by TGF-beta. 5-FU induces c-Jun phosphorylation and activates both AP-1-specific transcription
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 3995 offsetEnd: 4146 A: COL1A2 transcription. Furthermore, in a cellular context devoid of JNK activity (i.e., JNK-/- fibroblasts), 5-FU inhibits neither formation of SMAD/DNA
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 4146 offsetEnd: 4298 A: context devoid of JNK activity (i.e., JNK-/- fibroblasts), 5-FU inhibits neither formation of SMAD/DNA complexes nor SMAD-driven COL1A2 transcription in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/12920208 offsetBegin: 4298 offsetEnd: 4458 A: JNK-/- fibroblasts), 5-FU inhibits neither formation of SMAD/DNA complexes nor SMAD-driven COL1A2 transcription in response to TGF-beta. Together, these results
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 1177 offsetEnd: 1302 A: agents therefore may be the drugs of choice for BRCA mutant breast and ovarian cancers. PARPi result in synergistic antitumor
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 1302 offsetEnd: 1445 A: of choice for BRCA mutant breast and ovarian cancers. PARPi result in synergistic antitumor effects when combined with cisplatin, temozolomide,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 1445 offsetEnd: 1608 A: and ovarian cancers. PARPi result in synergistic antitumor effects when combined with cisplatin, temozolomide, topoisomerase inhibitors and ionizing radiation. The
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 2660 offsetEnd: 2791 A: the recent failure of a phase III clinical trial of iniparib in triple-negative breast cancer, the identification of structural and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 2791 offsetEnd: 2948 A: III clinical trial of iniparib in triple-negative breast cancer, the identification of structural and functional differences between these inhibitors becomes
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22084640 offsetBegin: 2948 offsetEnd: 3113 A: triple-negative breast cancer, the identification of structural and functional differences between these inhibitors becomes critical. Acquired resistance to PARPi is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 480 offsetEnd: 589 A: were conducted at the in vitro level and could not provide the in vivo information on the functions of miRNAs
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 589 offsetEnd: 708 A: level and could not provide the in vivo information on the functions of miRNAs in the anticancer drug resistance. Here,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23613938 offsetBegin: 5164 offsetEnd: 5277 A: novel tool for in vivo imaging of microRNAs in the chemoresistance of cancers, as well as for early detection and
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 150 offsetEnd: 285 A: as an excellent model to examine the crosstalk between different conserved signaling pathways that are deregulated in human cancer. The
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 285 offsetEnd: 428 A: the crosstalk between different conserved signaling pathways that are deregulated in human cancer. The concerted action of the RAS/MAPK, NOTCH,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 428 offsetEnd: 560 A: pathways that are deregulated in human cancer. The concerted action of the RAS/MAPK, NOTCH, and WNT pathways determines an invariant
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/22916028 offsetBegin: 560 offsetEnd: 684 A: cancer. The concerted action of the RAS/MAPK, NOTCH, and WNT pathways determines an invariant pattern of cell fates in three
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 334 offsetEnd: 485 A: mediate cytokine- and growth factor-induced transcription. Constitutive activation of STAT3 has been shown in human cancers and transformed cell lines.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 485 offsetEnd: 607 A: Constitutive activation of STAT3 has been shown in human cancers and transformed cell lines. We report that STAT3, but not
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 607 offsetEnd: 730 A: shown in human cancers and transformed cell lines. We report that STAT3, but not STAT1 and STAT5, becomes phosphorylated in
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 2973 offsetEnd: 3098 A: the loss of the responsiveness to EGF. By blocking STAT3 activity with the dominant-negative form, we show the requirement of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 3098 offsetEnd: 3222 A: EGF. By blocking STAT3 activity with the dominant-negative form, we show the requirement of STAT3 for EGF induction of MMP-1
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 3222 offsetEnd: 3364 A: the dominant-negative form, we show the requirement of STAT3 for EGF induction of MMP-1 and MMP-10 (stromelysin-2). Furthermore, expression of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 3810 offsetEnd: 3946 A: sufficient to inhibit the constitutive and EGF-inducible cell migration and invasion and the tumor formation in nude mice. These results
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 3946 offsetEnd: 4086 A: EGF-inducible cell migration and invasion and the tumor formation in nude mice. These results demonstrate that STAT3 phosphorylation and its
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/16205632 offsetBegin: 4086 offsetEnd: 4225 A: the tumor formation in nude mice. These results demonstrate that STAT3 phosphorylation and its possible interaction with c-JUN are required
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 559 offsetEnd: 685 A: (ΔLF) lacking the signal sequence has been found to be downregulated in cancer. Although the signaling pathways mediated by LF
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 685 offsetEnd: 800 A: been found to be downregulated in cancer. Although the signaling pathways mediated by LF have been studied in a few
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 800 offsetEnd: 913 A: cancer. Although the signaling pathways mediated by LF have been studied in a few cell models, there have been no
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 1284 offsetEnd: 1400 A: this study was carried out to identify and compare signaling networks provoked by the two LF isoforms. For this, the
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 1400 offsetEnd: 1525 A: identify and compare signaling networks provoked by the two LF isoforms. For this, the two forms were overexpressed in HEK293
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 1525 offsetEnd: 1638 A: by the two LF isoforms. For this, the two forms were overexpressed in HEK293 cells using the Flp-In T-Rex system,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 1638 offsetEnd: 1770 A: this, the two forms were overexpressed in HEK293 cells using the Flp-In T-Rex system, after which genome-wide expression analysis of
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 1770 offsetEnd: 1908 A: in HEK293 cells using the Flp-In T-Rex system, after which genome-wide expression analysis of 18,367 genes was conducted. Pathway analysis
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 1908 offsetEnd: 2053 A: T-Rex system, after which genome-wide expression analysis of 18,367 genes was conducted. Pathway analysis of the genes showing altered expression
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 2053 offsetEnd: 2195 A: analysis of 18,367 genes was conducted. Pathway analysis of the genes showing altered expression identified pathways which are responsible for
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 2195 offsetEnd: 2339 A: Pathway analysis of the genes showing altered expression identified pathways which are responsible for cell survival and apoptosis. In addition,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 2478 offsetEnd: 2607 A: responsible for cell survival and apoptosis. In addition, the pathways mediated by the two LF forms were within distantly related
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 2607 offsetEnd: 2733 A: In addition, the pathways mediated by the two LF forms were within distantly related networks. GPCR, PI3K complex, and POU5F1,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 2733 offsetEnd: 2871 A: the two LF forms were within distantly related networks. GPCR, PI3K complex, and POU5F1, which are involved in receptor-mediated pathways,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 3565 offsetEnd: 3716 A: signaling, were centered in the ΔLF network. These results suggest that structural differences between the LF isoforms, mainly glycosylation, determine
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 3716 offsetEnd: 3870 A: network. These results suggest that structural differences between the LF isoforms, mainly glycosylation, determine the fate of LF signaling. Furthermore,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 3870 offsetEnd: 4024 A: differences between the LF isoforms, mainly glycosylation, determine the fate of LF signaling. Furthermore, these findings provide information relating to
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/23383159 offsetBegin: 4024 offsetEnd: 4159 A: glycosylation, determine the fate of LF signaling. Furthermore, these findings provide information relating to the role of ΔLF which is
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 0 offsetEnd: 121 A: Activation of the Raf/MAP kinase pathway is a critical event in tumorigenesis induced by RAS and other oncogenes, a major
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 121 offsetEnd: 237 A: is a critical event in tumorigenesis induced by RAS and other oncogenes, a major role of this signaling system being
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 237 offsetEnd: 366 A: induced by RAS and other oncogenes, a major role of this signaling system being the regulation of cellular transcription factors.
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 638 offsetEnd: 786 A: transcription factors. To address the contribution of MAP kinase mediated transcriptional changes to the transformed phenotype, we used an inducible
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1145 offsetEnd: 1266 A: analyze early changes in the transcription of some 6000 genes following activation of the kinase in a normal human breast
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1266 offsetEnd: 1378 A: of some 6000 genes following activation of the kinase in a normal human breast epithelial cell line. Of the more
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1487 offsetEnd: 1622 A: human breast epithelial cell line. Of the more than 120 significant changes in mRNA level detected, genes promoting cell proliferation,
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1622 offsetEnd: 1777 A: the more than 120 significant changes in mRNA level detected, genes promoting cell proliferation, invasiveness, and angiogenesis featured prominently. Some
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1777 offsetEnd: 1929 A: in mRNA level detected, genes promoting cell proliferation, invasiveness, and angiogenesis featured prominently. Some of the most strongly induced genes
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 1929 offsetEnd: 2075 A: cell proliferation, invasiveness, and angiogenesis featured prominently. Some of the most strongly induced genes encoded growth factors of the EGF
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 2075 offsetEnd: 2201 A: prominently. Some of the most strongly induced genes encoded growth factors of the EGF family: Autocrine activation of the EGF
Q:Which forms of cancer is the Tpl2 gene associated with? Document:http://www.ncbi.nlm.nih.gov/pubmed/11316792 offsetBegin: 2201 offsetEnd: 2325 A: induced genes encoded growth factors of the EGF family: Autocrine activation of the EGF receptor was shown to be responsible
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 3811 offsetEnd: 3938 A: its itaconic acid production on glucose. Nitrogen limitation was shown to be a crucial condition for the production of itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 3938 offsetEnd: 4069 A: Nitrogen limitation was shown to be a crucial condition for the production of itaconic acid. For itaconic acid concentrations above
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 1504 offsetEnd: 1663 A: itaconic acid. Additional expression of aconitase, the second enzyme metabolically linking citric acid and itaconic acid improves productivity. However, proper
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 4069 offsetEnd: 4205 A: a crucial condition for the production of itaconic acid. For itaconic acid concentrations above 25 g/L, a significant product inhibition
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 159 offsetEnd: 318 A: such as arachidonic acid (ARA, 20:4n-6), eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 4204 offsetEnd: 4331 A: yeast-like growth makes U. maydis MB215 a promising candidate for the production of valuable chemicals such as itaconic acid or
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 1545 offsetEnd: 1678 A: a P source. Glycerol was an excellent substrate for growth (10.2 g biomass L(-1)) and itaconic acid production (26.9 g L(-1)) by free
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 1678 offsetEnd: 1838 A: excellent substrate for growth (10.2 g biomass L(-1)) and itaconic acid production (26.9 g L(-1)) by free fungal cells after 120-h fermentation. Simultaneously,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 1838 offsetEnd: 1998 A: L(-1)) and itaconic acid production (26.9 g L(-1)) by free fungal cells after 120-h fermentation. Simultaneously, A. terreus solubilized the insoluble phosphate
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 138 offsetEnd: 280 A: based transcriptome analysis towards the identification of genes related to itaconic acid production in Aspergillus terreus was carried out as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 2077 offsetEnd: 2199 A: palmitic acid (16:0), 18.5 wt.% oleic acid (18:1), 4.5 wt.% stearic acid (18:0) and 4.0 wt.% linolenic-ω3 acid (18:3). The
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 2566 offsetEnd: 2725 A: exemplary pretreatment methods on the cultivation and itaconic acid production of this fungus. Cellulose enzymatically hydrolysed in seawater and salt-assisted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 3538 offsetEnd: 3680 A: as substrate. RESULTS: U. maydis was characterized on shake flask level regarding its itaconic acid production on glucose. Nitrogen limitation
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 3680 offsetEnd: 3811 A: characterized on shake flask level regarding its itaconic acid production on glucose. Nitrogen limitation was shown to be a crucial
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 4205 offsetEnd: 4354 A: of itaconic acid. For itaconic acid concentrations above 25 g/L, a significant product inhibition was observed. Performing experiments that simulated
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 4331 offsetEnd: 4475 A: a promising candidate for the production of valuable chemicals such as itaconic acid or glycolipids from lignocellulosic biomass. Therefore, the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 4369 offsetEnd: 4502 A: production capability. Toxigenic strains were also able to produce the toxins on media suggested for citric acid production with most
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 1773 offsetEnd: 1927 A: subvermispora intensively inhibited .OH production by the Fenton reaction by direct interaction with Fe ions, while non-substituted itaconic acid promoted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 989 offsetEnd: 1096 A: 3 to 5, while some species even tolerate pH values as low as 1.5. Organic acid production can be stimulated
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 2605 offsetEnd: 2718 A: the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 2546 offsetEnd: 2681 A: Itaconic acid was successfully used as a buffer to overcome pH-induced limitations of cell growth and to facilitate enhanced production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 0 offsetEnd: 138 A: BACKGROUND: In this paper, a clone based transcriptome analysis towards the identification of genes related to itaconic acid production in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 280 offsetEnd: 405 A: of genes related to itaconic acid production in Aspergillus terreus was carried out as an extension of a previously published
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 1613 offsetEnd: 1786 A: for A. terreus. RESULTS: Besides the itaconic acid gene cluster (cis-aconitate decarboxylase, mitochondrial tri-carboxylic acid transporter and major facilitator superfamily
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 1786 offsetEnd: 1978 A: itaconic acid gene cluster (cis-aconitate decarboxylase, mitochondrial tri-carboxylic acid transporter and major facilitator superfamily transporter) discovered previously, additional genes of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 4544 offsetEnd: 4685 A: based transcription array to identify genes correlating with itaconic acid production revealed novel genes both in the central metabolism and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 4685 offsetEnd: 4820 A: correlating with itaconic acid production revealed novel genes both in the central metabolism and in other more secondary pathways such
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 2427 offsetEnd: 2566 A: to evaluate the influence of three exemplary pretreatment methods on the cultivation and itaconic acid production of this fungus. Cellulose
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 2725 offsetEnd: 2888 A: and itaconic acid production of this fungus. Cellulose enzymatically hydrolysed in seawater and salt-assisted organic-acid catalysed cellulose were investigated as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5016 offsetEnd: 5129 A: 3.5 osmol/L as well as of 0.1 M oxalic acid. The production of itaconic acid was achieved on pretreated cellulose
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5129 offsetEnd: 5250 A: 0.1 M oxalic acid. The production of itaconic acid was achieved on pretreated cellulose in seawater and on the hydrolysed
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 0 offsetEnd: 119 A: Itaconic acid is an unsaturated dicarboxylic acid which has a high potential as a biochemical building block. It can be
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 1663 offsetEnd: 1814 A: the second enzyme metabolically linking citric acid and itaconic acid improves productivity. However, proper organelle targeting of the enzymes appears
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 1814 offsetEnd: 1946 A: acid and itaconic acid improves productivity. However, proper organelle targeting of the enzymes appears to be an important point to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 0 offsetEnd: 122 A: Itaconic acid is an unsaturated dicarbonic acid which has a high potential as a biochemical building block, because it can
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 5247 offsetEnd: 5400 A: every 20 days. The biotechnological potential for the production of bioactive compounds in these species for pharmacological, agricultural and industrial
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 4395 offsetEnd: 4544 A: based transcriptome analysis using a clone based transcription array to identify genes correlating with itaconic acid production revealed novel genes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 1954 offsetEnd: 2077 A: wt.% linoleic-ω6 acid (18:2), 20.4 wt.% palmitic acid (16:0), 18.5 wt.% oleic acid (18:1), 4.5 wt.% stearic acid (18:0) and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 442 offsetEnd: 594 A: compounds such as methacrylic acid in industry, the economic efficiency of the current biotechnological production processes with the fungus Aspergillus
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 1463 offsetEnd: 1622 A: alkylitaconic acid (ceriporic acid B) produced by the selective white-rot fungus Ceriporiopsis subvermispora intensively inhibited .OH production by the Fenton
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1824 offsetEnd: 1953 A: is exploited in large-scale production of a number of organic acids like citric-, gluconic- and itaconic acid. Both in production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 0 offsetEnd: 159 A: Very long chain polyunsaturated fatty acids such as arachidonic acid (ARA, 20:4n-6), eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3)
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 956 offsetEnd: 1113 A: (e.g., high secretion capacity and efficient production of metabolic products) of these species have increased the biotechnological applications of bacteria.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 1113 offsetEnd: 1267 A: production of metabolic products) of these species have increased the biotechnological applications of bacteria. However, owing to multiplicity from genes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 2771 offsetEnd: 2909 A: production of high-value organic acids like succinic acid, lactic acid, 3-hydroxypropanoic acid and glucaric acid as well as alcohols like
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 318 offsetEnd: 480 A: eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) are essential components of cell membranes, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2067 offsetEnd: 2207 A: with Fe ions, while non-substituted itaconic acid promoted the Fenton reaction. Suppression of the Fenton reaction by the alkylitaconic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 1835 offsetEnd: 1954 A: peaks for the seed oil: 42.9 wt.% linoleic-ω6 acid (18:2), 20.4 wt.% palmitic acid (16:0), 18.5 wt.% oleic acid (18:1),
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 2199 offsetEnd: 2317 A: acid (18:1), 4.5 wt.% stearic acid (18:0) and 4.0 wt.% linolenic-ω3 acid (18:3). The sum of the saturated palmitic and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7167 offsetEnd: 7313 A: affect the subsequent itaconic acid production. Although U. maydis is insusceptible to most possible impurities from pretreatment, high amounts of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 0 offsetEnd: 141 A: In the last years, itaconic acid has gained increasing interest as future bio-based platform chemical. To replace petrol-based compounds such
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 3338 offsetEnd: 3462 A: 3122 produced both toxins and several strains used for citric acid production were among the best producers of fumonisins in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 292 offsetEnd: 441 A: important microorganism for several biotechnological processes, such as the production of organic acids, lipases and proteases. It is also considered
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 0 offsetEnd: 122 A: Itaconic acid (IA) is an unsaturated dicarbonic organic acid. It can easily be incorporated into polymers and may serve as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 3156 offsetEnd: 3287 A: Rapeseed meal may also find use as an inexpensive and efficient substrate for a biotechnological production of laccase by white-rot
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 295 offsetEnd: 439 A: in itaconic acid fermentation processes on glycerol-based media. The purpose was to assess their suitability for animal bone char solubilization
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 813 offsetEnd: 956 A: titers are significantly lower as compared to the citric acid production by A. niger. Heterologous expression of cis-aconitate decarboxylase in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 1422 offsetEnd: 1590 A: requirements. Rational strain development of E. coli achieved by metabolic engineering strategies has provided new processes for efficiently biotechnological production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 1590 offsetEnd: 1758 A: coli achieved by metabolic engineering strategies has provided new processes for efficiently biotechnological production of various high-value chemical building blocks.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 1758 offsetEnd: 1918 A: has provided new processes for efficiently biotechnological production of various high-value chemical building blocks. Compared to previous reviews, this review
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 1918 offsetEnd: 2075 A: biotechnological production of various high-value chemical building blocks. Compared to previous reviews, this review focuses on recent advances in metabolic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 2484 offsetEnd: 2614 A: terreus, a species whose wild type is, without any strain development, capable of producing gluconic acid at high molar conversion
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1201 offsetEnd: 1314 A: as 1.5. Organic acid production can be stimulated and in a number of cases conditions have been found that result
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2484 offsetEnd: 2630 A: far the major organic acid. Citric acid (2-hydroxy-propane-1,2,3-tricarboxylic acid) is a true bulk product with an estimated global production of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2630 offsetEnd: 2771 A: acid (2-hydroxy-propane-1,2,3-tricarboxylic acid) is a true bulk product with an estimated global production of over 900 thousand tons in the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 2718 offsetEnd: 2836 A: niger showed that it is possible to produce itaconic acid also in a different host organism. This review will describe
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 2836 offsetEnd: 2960 A: to produce itaconic acid also in a different host organism. This review will describe the current status and recent advances
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 437 offsetEnd: 598 A: and enhanced metabolite production of active metabolites through biotechnological approaches has gained attention in recent years. RESULTS: Present study reveals
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 1842 offsetEnd: 2008 A: on two-component signal transduction in Corynebacterium glutamicum. This Gram-positive soil bacterium is used for the large-scale biotechnological production of amino
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 2008 offsetEnd: 2148 A: glutamicum. This Gram-positive soil bacterium is used for the large-scale biotechnological production of amino acids and can also be applied
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 4693 offsetEnd: 4833 A: of up to 500 m(3) volume, adaptability can also be crucial for good performance in biotechnological production processes. Detailed knowledge
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 4833 offsetEnd: 4999 A: adaptability can also be crucial for good performance in biotechnological production processes. Detailed knowledge on two-component signal transduction and regulatory
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 4999 offsetEnd: 5171 A: good performance in biotechnological production processes. Detailed knowledge on two-component signal transduction and regulatory networks therefore will contribute to both
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 0 offsetEnd: 131 A: Malabar glory lily (Gloriosa superba L.) is a medicinally potent plant species used for the production of alkaloid colchicine. With
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 143 offsetEnd: 285 A: glycerol from biodiesel production plants promote the search for novel biotechnological methods of its utilization. In this study we attempted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 3562 offsetEnd: 3718 A: Strep. macedonicus, confirming that these 2 species are different microbial entities. Comparison between genetic and phenotypic or biotechnological data did
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 2088 offsetEnd: 2246 A: carbon source utilization spectrum of T. neapolitana and to select non-metabolized or poorly metabolized carbohydrates as physiological buffers. Itaconic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 917 offsetEnd: 1069 A: of different Aspergillus terreus controlled batch fermentations, those cultures with the largest difference in itaconic acid titer and productivity were
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 1069 offsetEnd: 1214 A: fermentations, those cultures with the largest difference in itaconic acid titer and productivity were selected for mRNA isolation. cDNAs derived
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3132 offsetEnd: 3277 A: length coding region was shown to encode one of the crucial itaconic acid pathway enzymes cis-aconitate decarboxylase, by heterologous expression
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 2460 offsetEnd: 2571 A: the production of oxalic acid from glycerol in yeasts. Our results also showed that mature fruits can be a good
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 3462 offsetEnd: 3610 A: acid-dependent defence responses, which include the production of reactive oxygen species and cell wall reinforcement. We also showed that surfactin
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 3610 offsetEnd: 3745 A: production of reactive oxygen species and cell wall reinforcement. We also showed that surfactin lipopeptide is a major determinant for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 3460 offsetEnd: 3583 A: niger dataset corresponded to high itaconic acid / low pH expressed genes identified from the A. terreus data set. However,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 132 offsetEnd: 288 A: biotechnological production of platform chemicals for fuel components has become a major focus of interest. Although ligno-cellulosic material is considered
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 1031 offsetEnd: 1155 A: fermentation steps. In this study, the fungus Ustilago maydis was used to produce itaconic acid as platform chemical for the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 1155 offsetEnd: 1280 A: fungus Ustilago maydis was used to produce itaconic acid as platform chemical for the synthesis of potential biofuels such as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 1280 offsetEnd: 1434 A: produce itaconic acid as platform chemical for the synthesis of potential biofuels such as 3-methyltetrahydrofuran. No studies, however, have investigated
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 6862 offsetEnd: 7016 A: advantages of yeasts and filamentous fungi. Nevertheless, the biomass pretreatment does indeed affect the subsequent itaconic acid production. Although U.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7016 offsetEnd: 7167 A: Nevertheless, the biomass pretreatment does indeed affect the subsequent itaconic acid production. Although U. maydis is insusceptible to most possible
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 0 offsetEnd: 141 A: Yarrowia lipolytica has been developed as a production host for a large variety of biotechnological applications. Efficacy and safety studies
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 286 offsetEnd: 442 A: bio-based platform chemical. To replace petrol-based compounds such as methacrylic acid in industry, the economic efficiency of the current biotechnological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 101 offsetEnd: 203 A: acid (IA) is produced worldwide each year and is sold at a price of around US$ 2/kg. The IA production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 3219 offsetEnd: 3338 A: in industry NRRL 337, 3112 and 3122 produced both toxins and several strains used for citric acid production were among
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 3877 offsetEnd: 4055 A: strains used for other biotechnological processes also produced fumonisins. Strains optimized through random mutagenesis usually maintained their mycotoxin production capability.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 5454 offsetEnd: 5599 A: clusters for fumonisins and ochratoxins, or to choose isolates for biotechnological uses in related non-toxigenic species such as A. tubingensis,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 150 offsetEnd: 292 A: yeast which has emerged as an important microorganism for several biotechnological processes, such as the production of organic acids, lipases
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 246 offsetEnd: 381 A: distributed species of the perennial genus of glasswort in South America, and it shows great biotechnological potential as a salt-water
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 1191 offsetEnd: 1338 A: media required for optimal thraustochytrid growth and PUFA production poses a significant problem to the biotechnological industry due to corrosion
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 0 offsetEnd: 151 A: Cells of Aspergillus terreus, free and immobilized in polyurethane foam, were employed in itaconic acid fermentation processes on glycerol-based media.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 151 offsetEnd: 295 A: immobilized in polyurethane foam, were employed in itaconic acid fermentation processes on glycerol-based media. The purpose was to assess their
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 681 offsetEnd: 813 A: and Aspergillus terreus. However, the achieved titers are significantly lower as compared to the citric acid production by A. niger.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 834 offsetEnd: 979 A: for the production of recombinant proteins. Recombinant enzymes have been expressed in bacteria (e.g., Escherichia coli, Bacillus and lactic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 1595 offsetEnd: 1751 A: The favorable and very advantageous characteristics of these species have resulted in an increasing number of biotechnological applications. Bacterial hosts
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 1751 offsetEnd: 1883 A: of these species have resulted in an increasing number of biotechnological applications. Bacterial hosts (e.g., E. coli) can be used
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 2617 offsetEnd: 2771 A: to efficient recombinant biocatalysts for the production of high-value organic acids like succinic acid, lactic acid, 3-hydroxypropanoic acid and glucaric
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 1387 offsetEnd: 1538 A: through a biotechnological process. Thus, the bioconversion system introduced in this work provided not only a green hydroxypyruvate production process
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 1286 offsetEnd: 1463 A: first report that 1-nonadecene-2,3-dicarboxylic acid, an alkylitaconic acid (ceriporic acid B) produced by the selective white-rot fungus Ceriporiopsis subvermispora intensively
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1096 offsetEnd: 1201 A: even tolerate pH values as low as 1.5. Organic acid production can be stimulated and in a number of cases
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5738 offsetEnd: 5845 A: broad range of pH values (2 to 7). Citric acid has a pleasant acid taste which leaves little aftertaste. It
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5845 offsetEnd: 5964 A: to 7). Citric acid has a pleasant acid taste which leaves little aftertaste. It sometimes enhances flavour, but is also
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 1224 offsetEnd: 1355 A: can secrete significant amounts to the media (>80 g/L). However, compared with the citric acid production process (titers >200 g/L)
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 1355 offsetEnd: 1481 A: media (>80 g/L). However, compared with the citric acid production process (titers >200 g/L) the achieved titers are still low
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 2104 offsetEnd: 2216 A: unidentified species of the family Polyporaceae. The enzyme had a low optimal pH, was very stable to acid pH and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 0 offsetEnd: 143 A: BACKGROUND: High supply of raw, residual glycerol from biodiesel production plants promote the search for novel biotechnological methods of its
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 2246 offsetEnd: 2397 A: neapolitana and to select non-metabolized or poorly metabolized carbohydrates as physiological buffers. Itaconic acid was successfully used as a buffer
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 2397 offsetEnd: 2546 A: poorly metabolized carbohydrates as physiological buffers. Itaconic acid was successfully used as a buffer to overcome pH-induced limitations of cell
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 4083 offsetEnd: 4227 A: the current knowledge on mycolic acids structure, biosynthesis and transfer in C. glutamicum and their relevance for amino acid biotechnological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 2352 offsetEnd: 2460 A: time in this work, as is the production of oxalic acid from glycerol in yeasts. Our results also showed that
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 0 offsetEnd: 136 A: Recently, the microbial production of multifunctional organic acid has received interest due to their increased use in the food industry
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 821 offsetEnd: 962 A: involved in glutathione production and not influenced by feedback inhibition. The gshF gene exhibited high nucleotide and amino acid sequence
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 2906 offsetEnd: 3033 A: production of glutathione by E. italicus, a species that could be used as a safe adjunct culture for glutathione-enriched dairy
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 0 offsetEnd: 173 A: Biotechnological processes are of increasing significance for industrial production of fine and bulk chemicals, including biofuels. Unfortunately, under operative conditions
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 1267 offsetEnd: 1422 A: species have increased the biotechnological applications of bacteria. However, owing to multiplicity from genes encoding the proteins and expression hosts,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 3109 offsetEnd: 3254 A: cell line). In addition, based on the peptides identified, polyamine levels (free and conjugate), ethylene production and reactive oxygen species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 3254 offsetEnd: 3405 A: the peptides identified, polyamine levels (free and conjugate), ethylene production and reactive oxygen species (ROS) emission were analyzed using both
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 2313 offsetEnd: 2451 A: genes of interest were identified in the A. terreus transcriptome data correlating to itaconic acid production, including 6 genes encoding
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 2451 offsetEnd: 2590 A: the A. terreus transcriptome data correlating to itaconic acid production, including 6 genes encoding enzymes in glycolysis and the pentose
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 3222 offsetEnd: 3333 A: three of the 83 low pH specific genes identified from the A. niger dataset corresponded to high itaconic acid /
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 5088 offsetEnd: 5235 A: pathways such as vitamin biosynthesis and Cu2+ transport, providing targets for further metabolic and process engineering to optimize itaconic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 0 offsetEnd: 132 A: BACKGROUND: In the last years, the biotechnological production of platform chemicals for fuel components has become a major focus of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 4909 offsetEnd: 5016 A: affected by high osmolarities up to 3.5 osmol/L as well as of 0.1 M oxalic acid. The production of itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 141 offsetEnd: 274 A: a production host for a large variety of biotechnological applications. Efficacy and safety studies have demonstrated the safe use of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1439 offsetEnd: 1568 A: the species in food, particularly cheese, other dairy products and meat, is a further argument supporting its safety. The species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 4475 offsetEnd: 4637 A: of valuable chemicals such as itaconic acid or glycolipids from lignocellulosic biomass. Therefore, the characterization of the endo-1,4-beta-xylanase, encoded by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 0 offsetEnd: 101 A: More than 80,000 tons of itaconic acid (IA) is produced worldwide each year and is sold at a price of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 3462 offsetEnd: 3585 A: strains used for citric acid production were among the best producers of fumonisins in pure agar culture. Most strains used
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 1338 offsetEnd: 1468 A: and PUFA production poses a significant problem to the biotechnological industry due to corrosion of fermenters calling for a need
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 1140 offsetEnd: 1286 A: cellulose. In the present paper, we first report that 1-nonadecene-2,3-dicarboxylic acid, an alkylitaconic acid (ceriporic acid B) produced by the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 0 offsetEnd: 124 A: AIM: Aspergillus terreus produces itaconic acid at low pH but lovastatin and other secondary metabolites at higher pH in the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 1024 offsetEnd: 1189 A: about possibilities of their utilization in biotechnological and environmental applications. Research attempts have resulted in increased production of both laccases
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 1189 offsetEnd: 1340 A: biotechnological and environmental applications. Research attempts have resulted in increased production of both laccases and peroxidases by the aid of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1953 offsetEnd: 2071 A: a number of organic acids like citric-, gluconic- and itaconic acid. Both in production volume as well as in knowledge
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2071 offsetEnd: 2191 A: citric-, gluconic- and itaconic acid. Both in production volume as well as in knowledge available, citrate is by far the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2191 offsetEnd: 2339 A: in production volume as well as in knowledge available, citrate is by far the major organic acid. Citric acid (2-hydroxy-propane-1,2,3-tricarboxylic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 2498 offsetEnd: 2631 A: macrofungi, with a significant reduction in time and an increased production of metabolites. This increased production has led to the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 281 offsetEnd: 437 A: of remedies. In vitro plant propagation and enhanced metabolite production of active metabolites through biotechnological approaches has gained attention in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 5220 offsetEnd: 5355 A: glands and spider's spinning behaviors. Due to the biotechnological importance  of spider silks for the production of new biomaterials,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 131 offsetEnd: 256 A: is a medicinally potent plant species used for the production of alkaloid colchicine. With ever increasing demand, there is a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 1890 offsetEnd: 2030 A: by the presence of invasive crustacean species with detrimental impacts ranging from aggressive competition with native species for food and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 0 offsetEnd: 122 A: Several Aspergillus species are well-known for the production of a variety of organic acids. In this study, a cloned based
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 1214 offsetEnd: 1346 A: difference in itaconic acid titer and productivity were selected for mRNA isolation. cDNAs derived from these mRNA samples were used
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3277 offsetEnd: 3428 A: encode one of the crucial itaconic acid pathway enzymes cis-aconitate decarboxylase, by heterologous expression in Escherichia coli. Expression of this
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 3317 offsetEnd: 3462 A: by activation of jasmonate- and salicylic acid-dependent defence responses, which include the production of reactive oxygen species and cell wall
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 5103 offsetEnd: 5247 A: suspensions for both species, with sub-cultures every 20 days. The biotechnological potential for the production of bioactive compounds in these
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 2797 offsetEnd: 2906 A: is the first report regarding the production of glutathione by E. italicus, a species that could be used as a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 795 offsetEnd: 956 A: Streptomyces. The favorable and advantageous characteristics (e.g., high secretion capacity and efficient production of metabolic products) of these species have
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 2590 offsetEnd: 2725 A: to itaconic acid production, including 6 genes encoding enzymes in glycolysis and the pentose phosphate pathway, 4 genes functioning in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5250 offsetEnd: 5387 A: of itaconic acid was achieved on pretreated cellulose in seawater and on the hydrolysed hemicellulosic fraction of pretreated beech wood.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 740 offsetEnd: 896 A: current biotechnological production processes with the fungus Aspergillus terreus has to be improved. The recent progress in understanding the biosynthesis,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 5599 offsetEnd: 5734 A: to choose isolates for biotechnological uses in related non-toxigenic species such as A. tubingensis, A. brasiliensis, A vadensis or A.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 1711 offsetEnd: 1835 A: the hexane extracts showed five prominent peaks for the seed oil: 42.9 wt.% linoleic-ω6 acid (18:2), 20.4 wt.% palmitic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 7666 offsetEnd: 7796 A: and SsSS was efficient enough to warrant the development and use of such technology for the biotechnological production of scareol
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 956 offsetEnd: 1091 A: to the citric acid production by A. niger. Heterologous expression of cis-aconitate decarboxylase in A. niger leads to the accumulation
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 2631 offsetEnd: 2760 A: time and an increased production of metabolites. This increased production has led to the study of compounds that have medicinal,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 6119 offsetEnd: 6279 A: and biotechnological applications due to its non-pathogenic characteristics and efficiency as a platform for metabolic engineering and production of tailor-made
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 2148 offsetEnd: 2267 A: used for the large-scale biotechnological production of amino acids and can also be applied for the synthesis of a wide
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 2030 offsetEnd: 2180 A: species with detrimental impacts ranging from aggressive competition with native species for food and shelter, to affecting aquaculture facilities and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1408 offsetEnd: 1543 A: quantitatively vary between different species as well as among strains from the same species. The production from glycerol of succinic,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 2244 offsetEnd: 2352 A: fermentans is reported for the first time in this work, as is the production of oxalic acid from glycerol in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 2677 offsetEnd: 2797 A: group present into the cells. This is the first report regarding the production of glutathione by E. italicus, a species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 3405 offsetEnd: 3531 A: and conjugate), ethylene production and reactive oxygen species (ROS) emission were analyzed using both EC lines (R and B cell
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 1325 offsetEnd: 1450 A: data set was analyzed to evaluate the specificity of the approach followed for A. terreus. RESULTS: Besides the itaconic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 1450 offsetEnd: 1613 A: the specificity of the approach followed for A. terreus. RESULTS: Besides the itaconic acid gene cluster (cis-aconitate decarboxylase, mitochondrial tri-carboxylic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 3333 offsetEnd: 3460 A: specific genes identified from the A. niger dataset corresponded to high itaconic acid / low pH expressed genes identified from
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 4502 offsetEnd: 4611 A: able to produce the toxins on media suggested for citric acid production with most of the toxins found in the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 4611 offsetEnd: 4730 A: media suggested for citric acid production with most of the toxins found in the biomass, thereby questioning the use of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 1361 offsetEnd: 1504 A: the accumulation of small amounts of itaconic acid. Additional expression of aconitase, the second enzyme metabolically linking citric acid and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 2909 offsetEnd: 3057 A: succinic acid, lactic acid, 3-hydroxypropanoic acid and glucaric acid as well as alcohols like 1,3-propanediol, xylitol, mannitol, and glycerol with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 1927 offsetEnd: 2067 A: the Fenton reaction by direct interaction with Fe ions, while non-substituted itaconic acid promoted the Fenton reaction. Suppression of the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2457 offsetEnd: 2595 A: alkylitaconic acid was observed even in the presence of the Fe(3+) reductants, cysteine and hydroquinone. The inhibition of .OH production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5646 offsetEnd: 5738 A: useful as a buffer over a broad range of pH values (2 to 7). Citric acid has a pleasant acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 1481 offsetEnd: 1604 A: the citric acid production process (titers >200 g/L) the achieved titers are still low and the overall process is expensive
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3017 offsetEnd: 3132 A: of the MmgE-PrpD family, the full length coding region was shown to encode one of the crucial itaconic acid pathway
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 1321 offsetEnd: 1456 A: cellular transport of itaconic acid has facilitated the optimisation of existing processes as well as the construction of new microbial
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 1877 offsetEnd: 2013 A: 17 related black Aspergillus species were examined for mycotoxin production. None of the related 17 species of black Aspergilli produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 5355 offsetEnd: 5473 A: to the biotechnological importance  of spider silks for the production of new biomaterials, we also discuss about  the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 5195 offsetEnd: 5306 A: of DCW, respectively), and production of high titers of citric acid (59 g L(-1)) and 2-phenylethanol (up to 1 g
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 594 offsetEnd: 740 A: industry, the economic efficiency of the current biotechnological production processes with the fungus Aspergillus terreus has to be improved. The
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 3089 offsetEnd: 3232 A: will describe the current status and recent advances in the understanding of the molecular processes leading to the biotechnological production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 1746 offsetEnd: 1869 A: the production of new  biomaterials. During the evolution of spider species, complex behaviors of web  production and usage
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 1182 offsetEnd: 1321 A: the biosynthesis, the regulation and the cellular transport of itaconic acid has facilitated the optimisation of existing processes as well
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 5085 offsetEnd: 5195 A: and a peak value of 38%LIPIDS of DCW, respectively), and production of high titers of citric acid (59 g L(-1))
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2207 offsetEnd: 2336 A: acid promoted the Fenton reaction. Suppression of the Fenton reaction by the alkylitaconic acid was observed even in the presence
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 1039 offsetEnd: 1182 A: improved. The recent progress in understanding the biosynthesis, the regulation and the cellular transport of itaconic acid has facilitated the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 629 offsetEnd: 752 A: their life cycle, making a specialized use on  each of them. Presenting particularly tandemly arranged amino acid repeats, 
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 336 offsetEnd: 484 A: in batch cultivation. The influence of glycerol concentration, temperature, pH and yeast extract concentration on biomass production was studied for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2770 offsetEnd: 2900 A: mg g(-1)), were observed at 700 rpm and 0.5 vvm. These results demonstrated that glycerol from biodiesel production process showed
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2900 offsetEnd: 3029 A: rpm and 0.5 vvm. These results demonstrated that glycerol from biodiesel production process showed to be a feasible substrate for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 3029 offsetEnd: 3174 A: demonstrated that glycerol from biodiesel production process showed to be a feasible substrate for producing biomass and ribonucleotides by yeast
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 1542 offsetEnd: 1715 A: screened functionally for indole-3-acetic acid, siderophore production and inorganic phosphorus (Pi) solubilization. All isolates showed Pi solubilization except CJS-2. Nine
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2009 offsetEnd: 2138 A: CJS-2. Nine isolates (CSS-1, CBS-1, CLS-3, CCS-1, CHS-1, VS-1, VL-1, VN-1, VN-2) were found positive for IAA production and eight
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5666 offsetEnd: 5783 A: beech wood. CONCLUSION: The fungus U. maydis is a promising producer of itaconic acid, since it grows as single cells
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1568 offsetEnd: 1704 A: other dairy products and meat, is a further argument supporting its safety. The species causes rare opportunistic infections in severely
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1704 offsetEnd: 1858 A: a further argument supporting its safety. The species causes rare opportunistic infections in severely immunocompromised or otherwise seriously ill people
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 143 offsetEnd: 291 A: components such as cellulose or hemicellulose for the production of valuable chemicals has attracted considerable research interest in recent years.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 4070 offsetEnd: 4204 A: ability together with its unicellular and yeast-like growth makes U. maydis MB215 a promising candidate for the production of valuable
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 2177 offsetEnd: 2312 A: attempted to replace the carbon source used for microbial production of IA with cheaper alternative substrates. However, there is still
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 2580 offsetEnd: 2704 A: is still a need for new biotechnology innovations that would help to reduce the production costs, such as innovative process
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 3585 offsetEnd: 3719 A: were among the best producers of fumonisins in pure agar culture. Most strains used for other biotechnological processes also produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 4219 offsetEnd: 4369 A: random mutagenesis usually maintained their mycotoxin production capability. Toxigenic strains were also able to produce the toxins on media suggested
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 441 offsetEnd: 563 A: such as the production of organic acids, lipases and proteases. It is also considered a good candidate for single-cell oil
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 3264 offsetEnd: 3445 A: also demonstrated other ecologically important activities like phosphate solubilization, nitrogen fixation, and production of hydrolytic enzymes including amylase, protease, lipase,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 3628 offsetEnd: 3792 A: production of hydrolytic enzymes including amylase, protease, lipase, chitinase, cellulase, pectinase and phosphatase. Firmicutes were found to be metabolically the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 531 offsetEnd: 680 A: it shows great biotechnological potential as a salt-water irrigated crop. Qualitative and quantitative compositions of fatty acids were determined in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 3035 offsetEnd: 3167 A: the cultivated annual glasswort Salicornia bigelovii. No undesirable fatty acid components were found in S. ambigua seed oil, and it
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 3167 offsetEnd: 3289 A: No undesirable fatty acid components were found in S. ambigua seed oil, and it could be recommended for animal consumption
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 1682 offsetEnd: 1807 A: is restricted. At present, the production rates do not exceed 1 g l(-1) h(-1), accompanied by product concentrations of about
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 0 offsetEnd: 162 A: Marine microheterotrophs thraustochytrids are emerging as a potential source for commercial production of polyunsaturated fatty acids (PUFA) that have nutritional
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 162 offsetEnd: 318 A: a potential source for commercial production of polyunsaturated fatty acids (PUFA) that have nutritional and pharmacological values. With prospective demand
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 318 offsetEnd: 482 A: of polyunsaturated fatty acids (PUFA) that have nutritional and pharmacological values. With prospective demand for PUFAs increasing, biotechnological companies are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 1061 offsetEnd: 1191 A: levels of NaCl in the culture media required for optimal thraustochytrid growth and PUFA production poses a significant problem to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22007151 offsetBegin: 848 offsetEnd: 1008 A: microorganisms belonging to the Archaea domain are of significant biotechnological importance as their biopolymers possess unique properties that offer insights
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 380 offsetEnd: 521 A: and its two hydroxyl groups also make it a valued starting material for semisynthesis of numerous commercial substances, including production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 1829 offsetEnd: 1959 A: essential oil-producing trichomes that densely cover flower calices. Manool also is a minor diterpene of this species and the main
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 582 offsetEnd: 733 A: assess their suitability for animal bone char solubilization and the development of a biotechnological alternative to P fertilizers chemically produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 733 offsetEnd: 888 A: char solubilization and the development of a biotechnological alternative to P fertilizers chemically produced from rock phosphate. Animal bones constitute
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 1883 offsetEnd: 2027 A: an increasing number of biotechnological applications. Bacterial hosts (e.g., E. coli) can be used to quickly and easily overexpress recombinant
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 2793 offsetEnd: 2928 A: main bacterial expression hosts, with the exception of lactic acid bacteria and filamentous fungi, can produce several toxins which are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 455 offsetEnd: 601 A: platform chemicals from renewable carbohydrates is attracting growing interest. Escherichia coli has been chosen as a workhouse for the production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 601 offsetEnd: 730 A: attracting growing interest. Escherichia coli has been chosen as a workhouse for the production of many valuable chemicals due to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 2480 offsetEnd: 2617 A: model bacteria E. coli that lead to efficient recombinant biocatalysts for the production of high-value organic acids like succinic acid,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 513 offsetEnd: 648 A: fungi. In contrast, selective white-rot fungi have been considered to possess unknown systems for the suppression of .OH production due
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 884 offsetEnd: 998 A: production due to their wood decay pattern with a minimum loss of cellulose. In the present paper, we first report
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 998 offsetEnd: 1140 A: pattern with a minimum loss of cellulose. In the present paper, we first report that 1-nonadecene-2,3-dicarboxylic acid, an alkylitaconic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 1574 offsetEnd: 1728 A: precipitate, Pseudomonas fluorescens shuttles metabolites toward the production of organic acids and lipids that play key roles in chelating, immobilizing
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 2521 offsetEnd: 2658 A: of reactive oxygen species (ROS) promoted by Al toxicity. While in Rhizobium spp., exopolysaccharides have been invoked to sequester this
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 4078 offsetEnd: 4265 A: devising bioremediation technologies aimed at managing metal wastes. Metabolic engineering is essential in elaborating effective biotechnological processes to decontaminate metal-polluted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 646 offsetEnd: 777 A: investigated for secondary metabolite production by A. terreus. METHODS AND RESULTS: With a starting pH of 6.5, glucose was rapidly
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 777 offsetEnd: 892 A: A. terreus. METHODS AND RESULTS: With a starting pH of 6.5, glucose was rapidly metabolized to gluconic acid by the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 2351 offsetEnd: 2484 A: glucose catabolism was demonstrated in A. terreus, a species whose wild type is, without any strain development, capable of producing
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 2614 offsetEnd: 2743 A: is, without any strain development, capable of producing gluconic acid at high molar conversion efficiency (up to 0.7 mol mol(-1)
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24062137 offsetBegin: 0 offsetEnd: 132 A: Over 3,000 plant species are cyanogenic. Cyanogenesis is defined as the hydroxynitrile lyase catalysed release of a cyanide group in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 786 offsetEnd: 896 A: fungi with an ecological advantage, since they grow rather well at pH 3 to 5, while some species even tolerate
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 3496 offsetEnd: 3624 A: an Italian cartel, other means of production were sought. Chemical synthesis was possible, but not suitable due to expensive raw
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 3624 offsetEnd: 3759 A: production were sought. Chemical synthesis was possible, but not suitable due to expensive raw materials and a complicated process with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5281 offsetEnd: 5373 A: acid groups with pKa values of 3.1, 4.7 and 6.4, citrate is able to produce a very low pH in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5964 offsetEnd: 6090 A: pleasant acid taste which leaves little aftertaste. It sometimes enhances flavour, but is also able to mask sweetness, such as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 733 offsetEnd: 903 A: been described, such as anti-cancer, anti-tumour, cholesterol lowering, antiviral, antibacterial, or immunomodulatory, among others. Given that production of mushrooms by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 1562 offsetEnd: 1742 A: focused on Burkholderia kururiensis KP23(T), a trichloroethylene (TCE)-degrading, N-fixing, and plant growth-promoting bacterium. Herein, we describe the production of rhamnolipids
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 2691 offsetEnd: 2836 A: to its high selectivity, mass accuracy, and resolving power. The population of rhamnolipids produced by B. kururiensis revealed molecular species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 2836 offsetEnd: 2986 A: and resolving power. The population of rhamnolipids produced by B. kururiensis revealed molecular species commonly observed in Pseudomonas spp. and/or
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 3560 offsetEnd: 3728 A: platform for expression of two Pseudomonas aeruginosa biosynthetic enzymes: RhlA, which directly utilizes β-hydroxydecanoyl-ACP intermediates in fatty acid synthesis to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 5612 offsetEnd: 5784 A: dirhamnolipids are predominant. We conclude that B. kururiensis is a promising biosurfactant-producing organism, with great potential for environmental and biotechnological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 5784 offsetEnd: 5962 A: B. kururiensis is a promising biosurfactant-producing organism, with great potential for environmental and biotechnological applications due to its non-pathogenic characteristics
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 2728 offsetEnd: 2874 A: Since then, front-end desaturases have been identified and characterized from a wide range of eukaryotic species including algae, protozoa, fungi,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 139 offsetEnd: 299 A: basidiomycete proposed for a wide spectrum of biotechnological applications which presents an interesting, but still scarcely known, enzymatic oxidative system.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 299 offsetEnd: 467 A: of biotechnological applications which presents an interesting, but still scarcely known, enzymatic oxidative system. Among these enzymes, the production, purification,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 1695 offsetEnd: 1835 A: I. lacteus DyP showed high homology (>95%) with the hypothetical (not isolated or characterized) protein cpop21 from an unidentified species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 598 offsetEnd: 756 A: metabolites through biotechnological approaches has gained attention in recent years. RESULTS: Present study reveals that 6-benzyladenine (BA) either alone or
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 1189 offsetEnd: 1330 A: acetic acid (NAA) supplemented in Murashige and Skoog (MS) medium at different concentrations produced good quality callus from leaf explants
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 256 offsetEnd: 380 A: used for the production of alkaloid colchicine. With ever increasing demand, there is a pressing need to conserve it through
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 646 offsetEnd: 795 A: it through biotechnological approaches. A large number of complete plantlets were obtained by direct regeneration from the non-dormant tuber explants
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 1376 offsetEnd: 1521 A: 6-benzylaminopurine (BAP)+0.5 mg/l α-naphthalene acetic acid (NAA). Large number of plants can be produced in vitro under aseptic conditions, but
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 4601 offsetEnd: 4755 A: mass multiplication, germplasm conservation and further genetic transformation assays for colchicine production to meet the ever increasing demand of this
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 304 offsetEnd: 457 A: market is increasingly reliant on aquaculture, driving the need for better management techniques. Since most cultured crustacean species exhibit sexually
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 605 offsetEnd: 766 A: techniques. Since most cultured crustacean species exhibit sexually dimorphic growth patterns, the culture of monosex populations (either all-male or all-female)
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 4333 offsetEnd: 4506 A: important prawn species, IAG silencing, a temporal, non-genetically modifying and non-transmissible intervention, has enabled the production of non-breeding all-male monosex
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 563 offsetEnd: 724 A: we attempted modification of glycerol catabolism in a nonconventional yeast species Yarrowia lipolytica through genetic engineering approach. RESULTS: To address
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 2918 offsetEnd: 3054 A: and with respect to its biotechnological potential. Our experiments indicated that the novel recombinant strain stably borne one copy of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 3852 offsetEnd: 4009 A: expressed at lower level. Comparative shake flask cultivations in glucose- and glycerol-based media demonstrated higher biomass production by the recombinant
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 1264 offsetEnd: 1404 A: 121 strains belonging to both species and isolated from the same dairy environment were genetically characterized by random amplification of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 3415 offsetEnd: 3562 A: well separated from the strains of Strep. macedonicus, confirming that these 2 species are different microbial entities. Comparison between genetic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 1066 offsetEnd: 1214 A: O(2). T. neapolitana showed the highest H(2) production under these conditions. Microscopic counting techniques were used to determine growth curves
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 375 offsetEnd: 508 A: cloned based transcriptomics approach was used to identify genes crucial in the biosynthesis pathway for one of these acids, itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 771 offsetEnd: 917 A: acids, itaconic acid. From a number of different Aspergillus terreus controlled batch fermentations, those cultures with the largest difference in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 4406 offsetEnd: 4548 A: of an itaconate acid related gene cluster including genes encoding two pathway specific transporters and a Zinc finger protein. Interestingly,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 437 offsetEnd: 573 A: oxytoca. Unlikely other enterobacteria, BAS-10 is able to grow on Fe(III)-citrate as sole carbon and energy source, yielding acetic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 1283 offsetEnd: 1450 A: this growth condition, BAS-10 produces an exopolysaccharide (EPS) having a high rhamnose content and metal-binding properties, whose biotechnological applications were
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 1450 offsetEnd: 1617 A: exopolysaccharide (EPS) having a high rhamnose content and metal-binding properties, whose biotechnological applications were proven as very relevant. RESULTS: Further
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 1617 offsetEnd: 1778 A: content and metal-binding properties, whose biotechnological applications were proven as very relevant. RESULTS: Further phylogenetic analysis, based on 16S rDNA
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 4765 offsetEnd: 4914 A: The protein differential regulation seems to ensure efficient cell growth coupled with EPS production by adapting metabolic and biochemical processes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 4914 offsetEnd: 5049 A: ensure efficient cell growth coupled with EPS production by adapting metabolic and biochemical processes in order to face iron toxicity
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 1121 offsetEnd: 1250 A: 25% NaCl (w/v). In assaying for PGP properties, 59 (57.8%) isolates shown indole acetic acid (IAA) like substances production, 57
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 1392 offsetEnd: 1555 A: indole acetic acid (IAA) like substances production, 57 isolates (55.9%) produced siderophore and 34 (33.3%) solubilized inorganic phosphate qualitatively. Whereas
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 1555 offsetEnd: 1721 A: production, 57 isolates (55.9%) produced siderophore and 34 (33.3%) solubilized inorganic phosphate qualitatively. Whereas in the production of extracellular enzymes,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 3324 offsetEnd: 3464 A: that the PGP bacteria belonged to 22 different species comprising 13 genera. Based on multifunctional properties, nine isolates were further
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 3464 offsetEnd: 3603 A: 22 different species comprising 13 genera. Based on multifunctional properties, nine isolates were further selected to determine the PGP in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 6008 offsetEnd: 6157 A: with yet unknown and untapped potential biotechnological applications, for example, plant growth promoters, as evidenced from this study. The outcome
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 674 offsetEnd: 821 A: bifunctional enzyme, termed γ-GCS-GS or GshF, involved in glutathione production and not influenced by feedback inhibition. The gshF gene exhibited
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 962 offsetEnd: 1104 A: influenced by feedback inhibition. The gshF gene exhibited high nucleotide and amino acid sequence similarity to other reported sequences from
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 1248 offsetEnd: 1386 A: acid sequence similarity to other reported sequences from the Enterococcus genus and was constitutively expressed both in osmotic shock or
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 173 offsetEnd: 335 A: for industrial production of fine and bulk chemicals, including biofuels. Unfortunately, under operative conditions microorganisms meet multiple stresses, such as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 1503 offsetEnd: 1637 A: processes. Inhibitors include furan derivatives, phenolic compounds and weak organic acids, among which acetic acid is one of the most
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 2451 offsetEnd: 2581 A: cell factories with improved production rates and resistance is of crucial importance. Here we show that a yeast strain engineered
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 3242 offsetEnd: 3383 A: to acetic acid at moderately toxic concentrations, measured as viability on plates. Starting from this evidence, we investigated more deeply:
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 5235 offsetEnd: 5380 A: further investigating direct and indirect mechanism(s) by which an antioxidant can rescue cells from organic acid damage; moreover, these studies
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 5380 offsetEnd: 5515 A: by which an antioxidant can rescue cells from organic acid damage; moreover, these studies will possibly provide additional targets for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 1136 offsetEnd: 1263 A: (EC 3.4.23.40), are bilobed endopeptidases present in an ample variety of plant species with activity mainly at acidic pHs, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 1263 offsetEnd: 1377 A: in an ample variety of plant species with activity mainly at acidic pHs, and have two aspartic residues located on
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 1377 offsetEnd: 1493 A: species with activity mainly at acidic pHs, and have two aspartic residues located on each side of a catalytic cleft
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 3531 offsetEnd: 3643 A: oxygen species (ROS) emission were analyzed using both EC lines (R and B cell lines). A marked difference in the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 1978 offsetEnd: 2148 A: mitochondrial tri-carboxylic acid transporter and major facilitator superfamily transporter) discovered previously, additional genes of interest were identified in the A.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 2148 offsetEnd: 2313 A: facilitator superfamily transporter) discovered previously, additional genes of interest were identified in the A. terreus transcriptome data correlating to itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 2202 offsetEnd: 2350 A: for amylase, cellulase, protease, lipase, urease and catalase activity were carried out indicating varying amounts of enzyme production at different
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 2801 offsetEnd: 2929 A: in strain Cryptococcus sp. MLB-24 was performed. Fatty acid methyl ester (FAME) analysis of the cultures grown at four different
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 2929 offsetEnd: 3053 A: performed. Fatty acid methyl ester (FAME) analysis of the cultures grown at four different temperatures (1, 4, 15, and 20°C)
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 3696 offsetEnd: 3825 A: acids. High amount of oleic acid accumulated with increase in temperature. These fatty acids possibly help the strains to survive
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 439 offsetEnd: 572 A: They are produced by specific yeast species and among those, Starmerella bombicola (former Candida bombicola) is the most widely used
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 2648 offsetEnd: 2783 A: a common fatty acid - results in complete abolishment of sophorolipid production. This phenotype could be complemented by supplying the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 3679 offsetEnd: 3823 A: compared with the wild type, suggesting alternative routes for secretion. Finally, it was proved that hampering sophorolipid production does not
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 1511 offsetEnd: 1642 A: productivity (0.19 g L(-1) h(-1)). Citric acid, succinic acid, acetic acid and ethanol were found as the main metabolites produced.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2646 offsetEnd: 2770 A: as well as ribonucleotide production (13.13 mg g(-1)), were observed at 700 rpm and 0.5 vvm. These results demonstrated that
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 1205 offsetEnd: 1368 A: They also showed similarity with Rhizobium, Agrobacterium and Erwinia spp. Isolates were screened functionally for indole-3-acetic acid, siderophore production and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 1715 offsetEnd: 1873 A: production and inorganic phosphorus (Pi) solubilization. All isolates showed Pi solubilization except CJS-2. Nine isolates (CSS-1, CBS-1, CLS-3, CCS-1, CHS-1,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2138 offsetEnd: 2269 A: CCS-1, CHS-1, VS-1, VL-1, VN-1, VN-2) were found positive for IAA production and eight isolates (CBS-1, CCS-1, CHS-2, CKS-2, CNS-2,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2963 offsetEnd: 3113 A: of these microbes that interact with plants will be worthwhile to fully achieve the biotechnological potential of efficient plant-microbe partnerships
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 898 offsetEnd: 1031 A: material may interfere with the subsequent fermentation steps. In this study, the fungus Ustilago maydis was used to produce itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 3403 offsetEnd: 3538 A: from fractionated beech wood was applied as substrate. RESULTS: U. maydis was characterized on shake flask level regarding its itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5783 offsetEnd: 5908 A: maydis is a promising producer of itaconic acid, since it grows as single cells (yeast-like) in submerged cultivations and it
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1165 offsetEnd: 1310 A: product (as for British Petroleum's single-cell protein product). The natural occurrence of the species in food, particularly cheese, other dairy
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1310 offsetEnd: 1439 A: protein product). The natural occurrence of the species in food, particularly cheese, other dairy products and meat, is a further
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1858 offsetEnd: 2016 A: The species causes rare opportunistic infections in severely immunocompromised or otherwise seriously ill people with other underlying diseases or conditions.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 291 offsetEnd: 435 A: for the production of valuable chemicals has attracted considerable research interest in recent years. One promising approach is the application
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 1189 offsetEnd: 1319 A: grow on xylan, the second most abundant polysaccharide in nature, while at the same time it produces chemicals of biotechnological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 1319 offsetEnd: 1455 A: abundant polysaccharide in nature, while at the same time it produces chemicals of biotechnological interest. RESULTS: In this study, we
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 4637 offsetEnd: 4797 A: acid or glycolipids from lignocellulosic biomass. Therefore, the characterization of the endo-1,4-beta-xylanase, encoded by um06350.1, is a further step towards
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23298766 offsetBegin: 141 offsetEnd: 286 A: has gained increasing interest as future bio-based platform chemical. To replace petrol-based compounds such as methacrylic acid in industry, the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 203 offsetEnd: 300 A: year and is sold at a price of around US$ 2/kg. The IA production yield from sugar is higher than
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 931 offsetEnd: 1058 A: oil additives has resulted in an increased demand for this product. However, at present, the IA production capacity exceeds the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 1186 offsetEnd: 1317 A: at present, the IA production capacity exceeds the demand because this product has a restricted range of applications. Studies have
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 2051 offsetEnd: 2177 A: of IA. Recently, many researchers have attempted to replace the carbon source used for microbial production of IA with cheaper
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 2312 offsetEnd: 2449 A: used for microbial production of IA with cheaper alternative substrates. However, there is still a need for new biotechnology innovations
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 2704 offsetEnd: 2848 A: biotechnology innovations that would help to reduce the production costs, such as innovative process development and strain improvement to allow
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 2848 offsetEnd: 2979 A: reduce the production costs, such as innovative process development and strain improvement to allow the use of a low-quality carbon
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 2013 offsetEnd: 2153 A: examined for mycotoxin production. None of the related 17 species of black Aspergilli produced fumonisins. Fumonisins (B(2), B(4), and B(6))
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 2153 offsetEnd: 2277 A: the related 17 species of black Aspergilli produced fumonisins. Fumonisins (B(2), B(4), and B(6)) were detected in 81% of A.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 3719 offsetEnd: 3877 A: fumonisins in pure agar culture. Most strains used for other biotechnological processes also produced fumonisins. Strains optimized through random mutagenesis
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 3094 offsetEnd: 3264 A: medium. A significant proportion of isolates also demonstrated other ecologically important activities like phosphate solubilization, nitrogen fixation, and production of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 3445 offsetEnd: 3628 A: like phosphate solubilization, nitrogen fixation, and production of hydrolytic enzymes including amylase, protease, lipase, chitinase, cellulase, pectinase and phosphatase. Firmicutes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 381 offsetEnd: 531 A: of glasswort in South America, and it shows great biotechnological potential as a salt-water irrigated crop. Qualitative and quantitative compositions
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 2905 offsetEnd: 3035 A: well as the seed oil from the cultivated annual glasswort Salicornia bigelovii. No undesirable fatty acid components were found in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 864 offsetEnd: 1019 A: manufacture of synthetic fibres, in coatings, adhesives, thickeners and binders. The favoured production process is fermentation of carbohydrates by fungi,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 1019 offsetEnd: 1160 A: adhesives, thickeners and binders. The favoured production process is fermentation of carbohydrates by fungi, with a current market volume of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 1160 offsetEnd: 1282 A: production process is fermentation of carbohydrates by fungi, with a current market volume of about 15,000 t/a. Due to the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 1580 offsetEnd: 1682 A: US$ 4/kg, the use of IA is restricted. At present, the production rates do not exceed 1 g l(-1) h(-1),
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 482 offsetEnd: 644 A: have nutritional and pharmacological values. With prospective demand for PUFAs increasing, biotechnological companies are looking for potential increases in those
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 644 offsetEnd: 799 A: prospective demand for PUFAs increasing, biotechnological companies are looking for potential increases in those valuable products. However, high levels of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 3633 offsetEnd: 3754 A: as well as address the issue of yield quality (e.g., PUFA production in low-saline media). Using mannitol and sucrose for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 3754 offsetEnd: 3885 A: of yield quality (e.g., PUFA production in low-saline media). Using mannitol and sucrose for osmotic adjustment of the growth media
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22007151 offsetBegin: 683 offsetEnd: 848 A: conditions, called extremophiles. Among these, the microorganisms belonging to the Archaea domain are of significant biotechnological importance as their biopolymers
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22007151 offsetBegin: 1008 offsetEnd: 1166 A: are of significant biotechnological importance as their biopolymers possess unique properties that offer insights into their biology and evolution. Particular
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 521 offsetEnd: 674 A: make it a valued starting material for semisynthesis of numerous commercial substances, including production of Ambrox® and related ambergris substitutes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 4207 offsetEnd: 4357 A: S)-copalyl diphosphate. A class I diTPS (SsSS) then transformed these intermediates into sclareol and manool, respectively. The production of sclareol
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 4357 offsetEnd: 4507 A: (SsSS) then transformed these intermediates into sclareol and manool, respectively. The production of sclareol was reconstructed in vitro by combining
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 5792 offsetEnd: 5915 A: sequence that actively targets SsLPPS and SsSS to the chloroplast, a major site of GGPP and diterpene production in plants.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 6033 offsetEnd: 6169 A: site of GGPP and diterpene production in plants. CONCLUSIONS: SsLPPS and SsSS are two monofunctional diTPSs which, together, produce the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 7073 offsetEnd: 7247 A: dihydroxylated labdane sclareol without requirement for additional enzymatic oxidation by activities such as cytochrome P450 monoxygenases. Yeast-based production of sclareol
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 7402 offsetEnd: 7543 A: as cytochrome P450 monoxygenases. Yeast-based production of sclareol by co-expresssion of SsLPPS and SsSS was efficient enough to warrant the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 420 offsetEnd: 575 A: number of antinutrients, including phenolic compounds. Solid-state fermentation with white-rot fungi was used to decrease the sinapic acid concentration of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 575 offsetEnd: 706 A: Solid-state fermentation with white-rot fungi was used to decrease the sinapic acid concentration of rapeseed meal. After 7 days of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2057 offsetEnd: 2211 A: was observed. Moreover, cultivation of white-rot fungi on rapeseed meal resulted in the intensive production of extracellular laccase, particularly strong
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2619 offsetEnd: 2753 A: of growth of T. versicolor. The obtained results confirm that both fungal species may effectively be used to decompose antinutritional
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2753 offsetEnd: 2897 A: obtained results confirm that both fungal species may effectively be used to decompose antinutritional phenolics of rapeseed meal. Rapeseed meal
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 439 offsetEnd: 582 A: glycerol-based media. The purpose was to assess their suitability for animal bone char solubilization and the development of a biotechnological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 119 offsetEnd: 245 A: acid which has a high potential as a biochemical building block. It can be microbially produced from some Aspergillus species,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 1447 offsetEnd: 1595 A: Aspergillus) and yeasts (e.g., Pichia pastoris). The favorable and very advantageous characteristics of these species have resulted in an increasing
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 2635 offsetEnd: 2793 A: proteins that require post-translational modifications. The main bacterial expression hosts, with the exception of lactic acid bacteria and filamentous fungi,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 2928 offsetEnd: 3059 A: exception of lactic acid bacteria and filamentous fungi, can produce several toxins which are not compatible with the expression of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 730 offsetEnd: 853 A: been chosen as a workhouse for the production of many valuable chemicals due to its clear genetic background, convenient to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 853 offsetEnd: 985 A: the production of many valuable chemicals due to its clear genetic background, convenient to be genetically modified and good growth
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 137 offsetEnd: 263 A: was introduced for the green production of hydroxypyruvate. Whole cells of Pseudomonas sp. XP-LM were confirmed to have a good
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 1079 offsetEnd: 1237 A: is now potentially producible from glycerol, a by-product during biodiesel fuel production, through a biotechnological process. Thus, the bioconversion system
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 1237 offsetEnd: 1387 A: a by-product during biodiesel fuel production, through a biotechnological process. Thus, the bioconversion system introduced in this work provided not
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 1538 offsetEnd: 1675 A: bioconversion system introduced in this work provided not only a green hydroxypyruvate production process but also a potential pathway of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 648 offsetEnd: 770 A: have been considered to possess unknown systems for the suppression of .OH production due to their wood decay pattern with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 770 offsetEnd: 884 A: systems for the suppression of .OH production due to their wood decay pattern with a minimum loss of cellulose. In
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 1276 offsetEnd: 1428 A: environment. For instance, in order to expulse the metal as an insoluble precipitate, Pseudomonas fluorescens shuttles metabolites toward the production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 1428 offsetEnd: 1574 A: expulse the metal as an insoluble precipitate, Pseudomonas fluorescens shuttles metabolites toward the production of organic acids and lipids that
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 2392 offsetEnd: 2521 A: of iron (Fe) and the excess of reactive oxygen species (ROS) promoted by Al toxicity. While in Rhizobium spp., exopolysaccharides
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 375 offsetEnd: 512 A: in the fermentation. The utilization of glucose as a carbon substrate was investigated for secondary metabolite production by A. terreus.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 512 offsetEnd: 646 A: glucose as a carbon substrate was investigated for secondary metabolite production by A. terreus. METHODS AND RESULTS: With a starting
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 892 offsetEnd: 1018 A: a starting pH of 6.5, glucose was rapidly metabolized to gluconic acid by the wild-type strain and by transformants harbouring
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 1018 offsetEnd: 1178 A: was rapidly metabolized to gluconic acid by the wild-type strain and by transformants harbouring Aspergillus niger genes encoding 6-phosphofructo-1-kinases with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 1827 offsetEnd: 1964 A: glucose. On exhaustion of the glucose in batch fermentations, the accumulated gluconic acid was utilized as a carbon source. CONCLUSIONS:
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 1964 offsetEnd: 2101 A: in batch fermentations, the accumulated gluconic acid was utilized as a carbon source. CONCLUSIONS: A novel pathway of glucose catabolism
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 2223 offsetEnd: 2351 A: source. CONCLUSIONS: A novel pathway of glucose catabolism was demonstrated in A. terreus, a species whose wild type is, without
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 2743 offsetEnd: 2874 A: of producing gluconic acid at high molar conversion efficiency (up to 0.7 mol mol(-1) glucose consumed). SIGNIFICANCE AND IMPACT OF
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 3615 offsetEnd: 3752 A: With a new knowledge of glucose catabolism by A. terreus, fermentation strategies for secondary metabolite production can be devised with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 3752 offsetEnd: 3902 A: catabolism by A. terreus, fermentation strategies for secondary metabolite production can be devised with glucose feeding using feedback regulation by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 858 offsetEnd: 1024 A: variety of organic compounds which brings about possibilities of their utilization in biotechnological and environmental applications. Research attempts have resulted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24062137 offsetBegin: 2129 offsetEnd: 2278 A: include: history, discovery and natural sources of the hydroxynitrile lyase. Molecular cloning for mass production of this enzyme, including detailed
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2339 offsetEnd: 2484 A: in knowledge available, citrate is by far the major organic acid. Citric acid (2-hydroxy-propane-1,2,3-tricarboxylic acid) is a true bulk product
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 3238 offsetEnd: 3367 A: was exclusively extracted from lemons. Since the global market was dominated by an Italian cartel, other means of production were
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 3367 offsetEnd: 3496 A: the global market was dominated by an Italian cartel, other means of production were sought. Chemical synthesis was possible, but
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5181 offsetEnd: 5281 A: metal ions. Because of its three acid groups with pKa values of 3.1, 4.7 and 6.4, citrate is able to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 903 offsetEnd: 1075 A: cholesterol lowering, antiviral, antibacterial, or immunomodulatory, among others. Given that production of mushrooms by traditional cultivation and extraction of bioactive
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 1075 offsetEnd: 1216 A: among others. Given that production of mushrooms by traditional cultivation and extraction of bioactive metabolites is very difficult in some
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 2760 offsetEnd: 2909 A: metabolites. This increased production has led to the study of compounds that have medicinal, nutriceutical and quasi-farmaceutical potential, in the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 1742 offsetEnd: 1919 A: trichloroethylene (TCE)-degrading, N-fixing, and plant growth-promoting bacterium. Herein, we describe the production of rhamnolipids by B. kururiensis, and its characterization
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 1919 offsetEnd: 2068 A: bacterium. Herein, we describe the production of rhamnolipids by B. kururiensis, and its characterization by LTQ-Orbitrap Hybrid Mass Spectrometry, a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 3728 offsetEnd: 3885 A: aeruginosa biosynthetic enzymes: RhlA, which directly utilizes β-hydroxydecanoyl-ACP intermediates in fatty acid synthesis to generate the HAA, and RhlB, the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 4464 offsetEnd: 4600 A: fatty acids in the biosynthesis of rhamnolipids. We show that rhamnolipid production by the engineered B. kururiensis was increased over
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 4600 offsetEnd: 4733 A: rhamnolipids. We show that rhamnolipid production by the engineered B. kururiensis was increased over 600 % when compared to the wild
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 1628 offsetEnd: 1773 A: fatty acid desaturation and elongation. The desaturation is catalyzed by a unique class of oxygenases called front-end desaturases that introduce
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 442 offsetEnd: 583 A: monomer for the production of a plethora of products including resins, plastics, paints, and synthetic fibers. Some Aspergillus species, like
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 1102 offsetEnd: 1224 A: this organic acid and A. terreus can secrete significant amounts to the media (>80 g/L). However, compared with the citric
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 2496 offsetEnd: 2605 A: Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 0 offsetEnd: 139 A: Irpex lacteus is a white rot basidiomycete proposed for a wide spectrum of biotechnological applications which presents an interesting, but
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 1978 offsetEnd: 2104 A: or characterized) protein cpop21 from an unidentified species of the family Polyporaceae. The enzyme had a low optimal pH, was
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 140 offsetEnd: 281 A: L. is traditionallyused for a number of remedies. In vitro plant propagation and enhanced metabolite production of active metabolites through
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 756 offsetEnd: 901 A: attention in recent years. RESULTS: Present study reveals that 6-benzyladenine (BA) either alone or in combination with 1-naphthalene acetic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 901 offsetEnd: 1044 A: study reveals that 6-benzyladenine (BA) either alone or in combination with 1-naphthalene acetic acid (NAA) supplemented in Murashige and Skoog
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 1044 offsetEnd: 1189 A: alone or in combination with 1-naphthalene acetic acid (NAA) supplemented in Murashige and Skoog (MS) medium at different concentrations produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 4471 offsetEnd: 4606 A: appropriate medium. Furthermore, callus from leaf explant of C. asiatica can be a good source for production of antimicrobial compounds
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 752 offsetEnd: 889 A: use on  each of them. Presenting particularly tandemly arranged amino acid repeats,  silk proteins (spidroins) have mechanical properties
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 889 offsetEnd: 1035 A: Presenting particularly tandemly arranged amino acid repeats,  silk proteins (spidroins) have mechanical properties superior to most synthetic  or
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 1324 offsetEnd: 1466 A:  or natural high-performance fibers, which makes them very promising for  biotechnology industry, with putative applications in the production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 1869 offsetEnd: 2004 A: During the evolution of spider species, complex behaviors of web  production and usage have been coupled with anatomical specialization
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 380 offsetEnd: 515 A: colchicine. With ever increasing demand, there is a pressing need to conserve it through biotechnological approaches. A large number of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 515 offsetEnd: 646 A: is a pressing need to conserve it through biotechnological approaches. A large number of complete plantlets were obtained by direct
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 1081 offsetEnd: 1231 A: tuber explants on Murashige and Skoog (MS) medium supplemented with 2.0 mg/l 6-benzylaminopurine (BAP)+0.5 mg/l α-naphthalene acetic acid (NAA). Large
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 1231 offsetEnd: 1376 A: (MS) medium supplemented with 2.0 mg/l 6-benzylaminopurine (BAP)+0.5 mg/l α-naphthalene acetic acid (NAA). Large number of plants can be produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 4446 offsetEnd: 4601 A: can be successfully applied for the mass multiplication, germplasm conservation and further genetic transformation assays for colchicine production to meet
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23811099 offsetBegin: 4755 offsetEnd: 4897 A: genetic transformation assays for colchicine production to meet the ever increasing demand of this medicinally potent plant for industrial and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 457 offsetEnd: 605 A: driving the need for better management techniques. Since most cultured crustacean species exhibit sexually dimorphic growth patterns, the culture of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 1589 offsetEnd: 1736 A: Sexual manipulations may also render sustainable solutions to the environmental problems caused by the presence of invasive crustacean species with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 1736 offsetEnd: 1890 A: solutions to the environmental problems caused by the presence of invasive crustacean species with detrimental impacts ranging from aggressive competition
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 6230 offsetEnd: 6376 A: invasive and pest crustacean species. We also review the key considerations for devising a biotechnological approach that specifically tailors the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 2629 offsetEnd: 2773 A: cells. The obtained recombinant strain NCYC3825 was characterized at the molecular level and with respect to its biotechnological potential. Our
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 2773 offsetEnd: 2918 A: was characterized at the molecular level and with respect to its biotechnological potential. Our experiments indicated that the novel recombinant
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 4009 offsetEnd: 4156 A: flask cultivations in glucose- and glycerol-based media demonstrated higher biomass production by the recombinant strain when glycerol was the main
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 4156 offsetEnd: 4292 A: media demonstrated higher biomass production by the recombinant strain when glycerol was the main carbon source. During bioreactor (5 L)
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 5306 offsetEnd: 5417 A: high titers of citric acid (59 g L(-1)) and 2-phenylethanol (up to 1 g L(-1) in shake flask cultivation), which
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 1145 offsetEnd: 1264 A: to be clarified. In this study, 121 strains belonging to both species and isolated from the same dairy environment were
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 1710 offsetEnd: 1862 A: amplification of polymorphic DNA (RAPD)-PCR and compared for the main biochemical features of technological interest, such as acid production, galactose
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 1862 offsetEnd: 2033 A: compared for the main biochemical features of technological interest, such as acid production, galactose utilization, citrate metabolism, exopolysaccharide production, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 3279 offsetEnd: 3415 A: Strep. thermophilus grouped together and were well separated from the strains of Strep. macedonicus, confirming that these 2 species are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 0 offsetEnd: 190 A: H(2) production by Petrotoga miotherma, Thermosipho africanus, Thermotoga elfii, Fervidobacterium pennavorans, and Thermotoga neapolitana was compared under microaerobic conditions. Contrary
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 1214 offsetEnd: 1366 A: H(2) production under these conditions. Microscopic counting techniques were used to determine growth curves and doubling times, which were subsequently
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 799 offsetEnd: 955 A: sublethal concentration of certain antibiotics to the culture media. Although Gram-positive bacteria, C. glutamicum and related bacterial species and genera
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 1096 offsetEnd: 1234 A: C. glutamicum and related bacterial species and genera contain, in addition to the plasma membrane, an outer permeability membrane similar
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 508 offsetEnd: 627 A: to identify genes crucial in the biosynthesis pathway for one of these acids, itaconic acid. From a number of different
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 627 offsetEnd: 771 A: biosynthesis pathway for one of these acids, itaconic acid. From a number of different Aspergillus terreus controlled batch fermentations, those
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3720 offsetEnd: 3854 A: of this gene in Aspergillus niger, which is a natural citric acid producer, resulted in itaconate production. Genome analysis suggests
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3854 offsetEnd: 3990 A: which is a natural citric acid producer, resulted in itaconate production. Genome analysis suggests that in A. terreus the cis-aconitate
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 4128 offsetEnd: 4261 A: analysis suggests that in A. terreus the cis-aconitate decarboxylase gene is part of an itaconate acid related gene cluster including
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 4261 offsetEnd: 4406 A: the cis-aconitate decarboxylase gene is part of an itaconate acid related gene cluster including genes encoding two pathway specific transporters
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 573 offsetEnd: 698 A: able to grow on Fe(III)-citrate as sole carbon and energy source, yielding acetic acid and CO2 coupled with Fe(III) reduction
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 832 offsetEnd: 970 A: acetic acid and CO2 coupled with Fe(III) reduction to Fe(II) and showing unusual physiological characteristics. In fact, under this growth
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 4613 offsetEnd: 4765 A: anaerobic growth on Fe(III)-citrate were revealed. The protein differential regulation seems to ensure efficient cell growth coupled with EPS production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 1250 offsetEnd: 1392 A: PGP properties, 59 (57.8%) isolates shown indole acetic acid (IAA) like substances production, 57 isolates (55.9%) produced siderophore and 34
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 1721 offsetEnd: 1876 A: and 34 (33.3%) solubilized inorganic phosphate qualitatively. Whereas in the production of extracellular enzymes, 42 isolates (41.2%) produced protease and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 3203 offsetEnd: 3324 A: on 16 rRNA gene sequencing revealed that the PGP bacteria belonged to 22 different species comprising 13 genera. Based on
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 5669 offsetEnd: 5840 A: ecological niche, which harbours a diverse and hitherto largely uncharacterized microbial population with yet unknown and untapped potential biotechnological applications,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 5840 offsetEnd: 6008 A: and hitherto largely uncharacterized microbial population with yet unknown and untapped potential biotechnological applications, for example, plant growth promoters, as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 6157 offsetEnd: 6294 A: biotechnological applications, for example, plant growth promoters, as evidenced from this study. The outcome of this research may have a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 6294 offsetEnd: 6424 A: promoters, as evidenced from this study. The outcome of this research may have a practical effect on crop production methodologies
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 0 offsetEnd: 128 A: The production of organic acids from several yeasts isolated from mature plums on media containing glycerol as carbon source was
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 685 offsetEnd: 834 A: the 5.8S internal transcribed spacer as Pichia fermentans, Wickerhamomyces anomalus and Candida oleophila. The organic acid profiles of these strains
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 834 offsetEnd: 987 A: Pichia fermentans, Wickerhamomyces anomalus and Candida oleophila. The organic acid profiles of these strains comprise acetic, citric, succinic and malic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 987 offsetEnd: 1133 A: oleophila. The organic acid profiles of these strains comprise acetic, citric, succinic and malic acids that qualitatively and quantitatively vary
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 136 offsetEnd: 255 A: organic acid has received interest due to their increased use in the food industry and their potential as raw materials
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 382 offsetEnd: 533 A: food industry and their potential as raw materials for the manufacture of biodegradable polymers. Certain species of microorganisms produce significant
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 683 offsetEnd: 846 A: biodegradable polymers. Certain species of microorganisms produce significant quantities of organic acids in high yields under specific cultivation conditions from
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 2304 offsetEnd: 2436 A: and product recovery and downstream processing are likely to occupy an important role in the reduction of production costs. Finally,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 2436 offsetEnd: 2556 A: are likely to occupy an important role in the reduction of production costs. Finally, some aspects of process design and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 994 offsetEnd: 1115 A: relies on the production of the antifungal compounds iturin and fengycin. In a previous study, we found that UMAF6639 was
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 3159 offsetEnd: 3317 A: confers protection against cucurbit powdery mildew by activation of jasmonate- and salicylic acid-dependent defence responses, which include the production of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 1203 offsetEnd: 1334 A: local species J. curcas and J. gossypifolia, in order to allow future studies for novel compounds with pharmaceutical or industrial
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 542 offsetEnd: 674 A: presence of a gene encoding a bifunctional enzyme, termed γ-GCS-GS or GshF, involved in glutathione production and not influenced by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 1104 offsetEnd: 1248 A: gene exhibited high nucleotide and amino acid sequence similarity to other reported sequences from the Enterococcus genus and was constitutively
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 1637 offsetEnd: 1754 A: compounds and weak organic acids, among which acetic acid is one of the most abundant and detrimental for cells. They
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 1754 offsetEnd: 1879 A: which acetic acid is one of the most abundant and detrimental for cells. They impair cellular metabolism and growth, reducing
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 2311 offsetEnd: 2451 A: process: therefore, the development of robust cell factories with improved production rates and resistance is of crucial importance. Here we
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 2971 offsetEnd: 3109 A: C exhibits an increased tolerance compared to the parental strain when exposed to acetic acid at moderately toxic concentrations, measured
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 3109 offsetEnd: 3242 A: to the parental strain when exposed to acetic acid at moderately toxic concentrations, measured as viability on plates. Starting from
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 3518 offsetEnd: 3643 A: Starting from this evidence, we investigated more deeply: (a) the nature and levels of reactive oxygen species (ROS); (b) the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 4162 offsetEnd: 4297 A: oxygen species, such as superoxide dismutase (SOD) and catalase, in parental and engineered strains during acetic acid stress. The data
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 161 offsetEnd: 325 A: the genus Cynara-Cardueae tribe Cass. (Cynareae Less.), Asteraceae Dumortier-are traditionally used in the Mediterranean region for production of artisanal cheeses.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 1000 offsetEnd: 1136 A: Plant APs, collectively known as phytepsins (EC 3.4.23.40), are bilobed endopeptidases present in an ample variety of plant species with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 2621 offsetEnd: 2750 A: flowers of several species of the Cardueae tribe possess APs with extremely high specific activities in certain tissues. For this
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 0 offsetEnd: 145 A: Somatic embryogenesis is an important biotechnological tool in the large-scale propagation of elite genotypes and ex situ conservation of conifer
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 3583 offsetEnd: 3697 A: acid / low pH expressed genes identified from the A. terreus data set. However, in all three cases, the regulation
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 512 offsetEnd: 652 A: forming unit (CFUs) per ml. Sequence analysis of the isolates, using D1/D2 domain identified five species of yeasts: Cryptococcus adeliensis
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 2350 offsetEnd: 2500 A: and catalase activity were carried out indicating varying amounts of enzyme production at different temperatures. Characterization of lipase in strain
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 2500 offsetEnd: 2656 A: indicating varying amounts of enzyme production at different temperatures. Characterization of lipase in strain Cryptococcus sp. MLB-24 was performed. Fatty
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 2656 offsetEnd: 2801 A: at different temperatures. Characterization of lipase in strain Cryptococcus sp. MLB-24 was performed. Fatty acid methyl ester (FAME) analysis of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 156 offsetEnd: 292 A: or detergents which find application in household cleaning, personal care and cosmetics. They are produced by specific yeast species and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 292 offsetEnd: 439 A: household cleaning, personal care and cosmetics. They are produced by specific yeast species and among those, Starmerella bombicola (former Candida
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 2367 offsetEnd: 2502 A: the pathway - cytochrome P450 monooxygenase mediated terminal or subterminal hydroxylation of a common fatty acid - results in complete
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 2502 offsetEnd: 2648 A: mediated terminal or subterminal hydroxylation of a common fatty acid - results in complete abolishment of sophorolipid production. This phenotype
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 3823 offsetEnd: 3964 A: alternative routes for secretion. Finally, it was proved that hampering sophorolipid production does not affect cell growth or cell viability
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 3964 offsetEnd: 4095 A: was proved that hampering sophorolipid production does not affect cell growth or cell viability in laboratory conditions, as can be
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 1620 offsetEnd: 1765 A: root region is important for obtaining resistant cultivars by biotechnological breeding. Genetic and molecular data for this species, though, are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 1765 offsetEnd: 1914 A: resistant cultivars by biotechnological breeding. Genetic and molecular data for this species, though, are limited. In this paper, RNA-Seq technology
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 4181 offsetEnd: 4327 A: in biotechnology and ecology. CONCLUSIONS: This dataset of 10338 unigenes is crucially important for the biotechnological breeding of black pepper
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 484 offsetEnd: 633 A: glycerol concentration, temperature, pH and yeast extract concentration on biomass production was studied for the yeast selected. Further, the effect
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 633 offsetEnd: 772 A: extract concentration on biomass production was studied for the yeast selected. Further, the effect of agitation on glycerol utilization by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 1642 offsetEnd: 1775 A: acid, succinic acid, acetic acid and ethanol were found as the main metabolites produced. The increase of yeast extract concentration
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2524 offsetEnd: 2646 A: and productivity (0.31 g L(-1) h(-1)), as well as ribonucleotide production (13.13 mg g(-1)), were observed at 700 rpm and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 1368 offsetEnd: 1542 A: Agrobacterium and Erwinia spp. Isolates were screened functionally for indole-3-acetic acid, siderophore production and inorganic phosphorus (Pi) solubilization. All isolates
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2269 offsetEnd: 2405 A: were found positive for IAA production and eight isolates (CBS-1, CCS-1, CHS-2, CKS-2, CNS-2, VS-1, VJ-1) exhibited positive results for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 2298 offsetEnd: 2427 A: maydis in shake flasks and then to evaluate the influence of three exemplary pretreatment methods on the cultivation and itaconic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5527 offsetEnd: 5666 A: the hydrolysed hemicellulosic fraction of pretreated beech wood. CONCLUSION: The fungus U. maydis is a promising producer of itaconic acid,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 5908 offsetEnd: 6035 A: itaconic acid, since it grows as single cells (yeast-like) in submerged cultivations and it is extremely robust in high osmotic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 0 offsetEnd: 143 A: BACKGROUND: The utilization of raw biomass components such as cellulose or hemicellulose for the production of valuable chemicals has attracted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 1455 offsetEnd: 1594 A: the same time it produces chemicals of biotechnological interest. RESULTS: In this study, we present the identification of an endo-1,4-beta
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 1594 offsetEnd: 1750 A: of biotechnological interest. RESULTS: In this study, we present the identification of an endo-1,4-beta xylanase responsible for xylan degradation. Xylanase
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 300 offsetEnd: 405 A: price of around US$ 2/kg. The IA production yield from sugar is higher than 80 g/l. The widespread use of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 405 offsetEnd: 522 A: IA production yield from sugar is higher than 80 g/l. The widespread use of IA in synthetic resins, synthetic fibers,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 3370 offsetEnd: 3520 A: review, we discuss the following aspects of IA production: strain improvement, process development, identification of the key enzyme cis-aconitic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 1637 offsetEnd: 1753 A: strains of A. niger (180 strains) as well as 228 strains from 17 related black Aspergillus species were examined for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 1753 offsetEnd: 1877 A: as well as 228 strains from 17 related black Aspergillus species were examined for mycotoxin production. None of the related
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 4055 offsetEnd: 4219 A: also produced fumonisins. Strains optimized through random mutagenesis usually maintained their mycotoxin production capability. Toxigenic strains were also able to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 5315 offsetEnd: 5454 A: niger with inactive or inactivated gene clusters for fumonisins and ochratoxins, or to choose isolates for biotechnological uses in related
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 0 offsetEnd: 150 A: BACKGROUND: Yarrowia lipolytica is an oleaginous yeast which has emerged as an important microorganism for several biotechnological processes, such as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 408 offsetEnd: 537 A: valley, in order to determine their plant growth promoting (PGP) and biotechnological potential. The plant was found to exhibit a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 537 offsetEnd: 672 A: plant growth promoting (PGP) and biotechnological potential. The plant was found to exhibit a positive rhizosphere effect of 1.3-1.5. A
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 0 offsetEnd: 129 A: Sarcocornia ambigua (Michx.) M.A. Alonso & M.B. Crespo is the most widely distributed species of the perennial genus of glasswort
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 129 offsetEnd: 246 A: M.B. Crespo is the most widely distributed species of the perennial genus of glasswort in South America, and it shows
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 2317 offsetEnd: 2436 A: (18:0) and 4.0 wt.% linolenic-ω3 acid (18:3). The sum of the saturated palmitic and stearic acids (24.8%) in S. ambigua
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 3511 offsetEnd: 3633 A: number of strains and organic osmotica, as well as address the issue of yield quality (e.g., PUFA production in low-saline
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 1959 offsetEnd: 2082 A: flower calices. Manool also is a minor diterpene of this species and the main diterpene of related Salvia species. RESULTS:
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 4507 offsetEnd: 4647 A: sclareol and manool, respectively. The production of sclareol was reconstructed in vitro by combining the two recombinant diTPS enzymes with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 5915 offsetEnd: 6033 A: SsSS to the chloroplast, a major site of GGPP and diterpene production in plants. CONCLUSIONS: SsLPPS and SsSS are two
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 7247 offsetEnd: 7402 A: additional enzymatic oxidation by activities such as cytochrome P450 monoxygenases. Yeast-based production of sclareol by co-expresssion of SsLPPS and SsSS
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 1085 offsetEnd: 1204 A: and Pleurotus ostreatus, the sinapic acid content of rapeseed meal was reduced by 59.9 and 74.5 %, respectively. At the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 1204 offsetEnd: 1317 A: content of rapeseed meal was reduced by 59.9 and 74.5 %, respectively. At the end of the experiment, sinapic acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 1317 offsetEnd: 1443 A: by 59.9 and 74.5 %, respectively. At the end of the experiment, sinapic acid concentration of T. versicolor cultures decreased
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2211 offsetEnd: 2349 A: fungi on rapeseed meal resulted in the intensive production of extracellular laccase, particularly strong during the late phases of growth
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2491 offsetEnd: 2619 A: particularly strong during the late phases of growth of T. versicolor. The obtained results confirm that both fungal species may
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2897 offsetEnd: 3023 A: species may effectively be used to decompose antinutritional phenolics of rapeseed meal. Rapeseed meal may also find use as an
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22956279 offsetBegin: 888 offsetEnd: 1029 A: a biotechnological alternative to P fertilizers chemically produced from rock phosphate. Animal bones constitute a renewable source of P that
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 137 offsetEnd: 272 A: a large number of fields, such as chemical, agricultural and biopharmaceutical industries. The enzyme production rate and yield are the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 272 offsetEnd: 415 A: as chemical, agricultural and biopharmaceutical industries. The enzyme production rate and yield are the main factors to consider when choosing
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 684 offsetEnd: 834 A: when choosing the appropriate expression system for the production of recombinant proteins. Recombinant enzymes have been expressed in bacteria (e.g.,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 979 offsetEnd: 1133 A: Recombinant enzymes have been expressed in bacteria (e.g., Escherichia coli, Bacillus and lactic acid bacteria), filamentous fungi (e.g., Aspergillus) and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 1290 offsetEnd: 1447 A: lactic acid bacteria), filamentous fungi (e.g., Aspergillus) and yeasts (e.g., Pichia pastoris). The favorable and very advantageous characteristics of these
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 2345 offsetEnd: 2480 A: in metabolic engineering of the industrial model bacteria E. coli that lead to efficient recombinant biocatalysts for the production of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 1728 offsetEnd: 1862 A: the production of organic acids and lipids that play key roles in chelating, immobilizing and exuding Al. Further, the reconfiguration
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 1683 offsetEnd: 1827 A: properties for bioproduction of metabolites from glucose. On exhaustion of the glucose in batch fermentations, the accumulated gluconic acid was
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 1340 offsetEnd: 1481 A: have resulted in increased production of both laccases and peroxidases by the aid of heterologous and homologous expression. Through analysis
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24062137 offsetBegin: 2278 offsetEnd: 2443 A: of the hydroxynitrile lyase. Molecular cloning for mass production of this enzyme, including detailed information about several successful recombinant hydroxynitrile
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 896 offsetEnd: 989 A: they grow rather well at pH 3 to 5, while some species even tolerate pH values as low as 1.5.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1565 offsetEnd: 1697 A: that result in almost quantitative conversion of carbon substrate into acid. This is exploited in large-scale production of a number
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2771 offsetEnd: 2885 A: bulk product with an estimated global production of over 900 thousand tons in the year 2000. Till the beginning of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 4495 offsetEnd: 4609 A: decade later accounted for a large part of the global production. The application of citric acid is based on three
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 4723 offsetEnd: 4842 A: application of citric acid is based on three of its properties: (1) acidity and buffer capacity, (2) taste and flavour,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22449697 offsetBegin: 2367 offsetEnd: 2498 A: be cultivated in liquid medium of macrofungi, with a significant reduction in time and an increased production of metabolites. This
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 2986 offsetEnd: 3140 A: rhamnolipids produced by B. kururiensis revealed molecular species commonly observed in Pseudomonas spp. and/or Burkholderia spp. In addition, this strain
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 3140 offsetEnd: 3272 A: molecular species commonly observed in Pseudomonas spp. and/or Burkholderia spp. In addition, this strain was used as a platform for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 5962 offsetEnd: 6119 A: organism, with great potential for environmental and biotechnological applications due to its non-pathogenic characteristics and efficiency as a platform for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 1218 offsetEnd: 1357 A: various physiological activities in animals and humans. The biosynthesis of these fatty acids involves an alternating process of fatty acid
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 1497 offsetEnd: 1628 A: acids involves an alternating process of fatty acid desaturation and elongation. The desaturation is catalyzed by a unique class of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 2874 offsetEnd: 3020 A: identified and characterized from a wide range of eukaryotic species including algae, protozoa, fungi, plants and animals including humans. Unlike
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 3020 offsetEnd: 3173 A: range of eukaryotic species including algae, protozoa, fungi, plants and animals including humans. Unlike front-end desaturases from bacteria, those from
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 330 offsetEnd: 442 A: it can be used as a monomer for the production of a plethora of products including resins, plastics, paints, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 980 offsetEnd: 1102 A: terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media (>80
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 1466 offsetEnd: 1598 A: makes them very promising for  biotechnology industry, with putative applications in the production of new  biomaterials. During the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 1598 offsetEnd: 1746 A: biotechnology industry, with putative applications in the production of new  biomaterials. During the evolution of spider species, complex behaviors
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 2004 offsetEnd: 2138 A: complex behaviors of web  production and usage have been coupled with anatomical specialization of  spinning glands. Spiders retaining
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 4703 offsetEnd: 4828 A: identified from five spider species of the Brazilian biodiversity, and an  evolutionary study of them in correlation with the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 5473 offsetEnd: 5603 A: spider silks for the production of new biomaterials, we also discuss about  the new possible technical and biomedical applications
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 4506 offsetEnd: 4673 A: temporal, non-genetically modifying and non-transmissible intervention, has enabled the production of non-breeding all-male monosex populations that are the progeny of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 4673 offsetEnd: 4833 A: has enabled the production of non-breeding all-male monosex populations that are the progeny of sexually reversed males ('neo-females'). IAG manipulations-based
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 285 offsetEnd: 418 A: the search for novel biotechnological methods of its utilization. In this study we attempted modification of glycerol catabolism in a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 418 offsetEnd: 563 A: of its utilization. In this study we attempted modification of glycerol catabolism in a nonconventional yeast species Yarrowia lipolytica through
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 724 offsetEnd: 871 A: in a nonconventional yeast species Yarrowia lipolytica through genetic engineering approach. RESULTS: To address this, we developed a novel genetic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 0 offsetEnd: 145 A: The species Streptococcus thermophilus is widely used for the preparation of several dairy products, and its technological contribution is clear.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 1026 offsetEnd: 1145 A: macedonicus in cheese making has yet to be clarified. In this study, 121 strains belonging to both species and isolated
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 2033 offsetEnd: 2227 A: of technological interest, such as acid production, galactose utilization, citrate metabolism, exopolysaccharide production, and lipolytic, ureolytic, exocellular proteolytic, and decarboxylasic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 918 offsetEnd: 1066 A: the presence of micromolar levels of O(2). T. neapolitana showed the highest H(2) production under these conditions. Microscopic counting techniques
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 955 offsetEnd: 1096 A: the culture media. Although Gram-positive bacteria, C. glutamicum and related bacterial species and genera contain, in addition to the plasma
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 122 offsetEnd: 243 A: the production of a variety of organic acids. In this study, a cloned based transcriptomics approach was used to identify
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3428 offsetEnd: 3580 A: acid pathway enzymes cis-aconitate decarboxylase, by heterologous expression in Escherichia coli. Expression of this gene in Aspergillus niger, which is
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3580 offsetEnd: 3720 A: heterologous expression in Escherichia coli. Expression of this gene in Aspergillus niger, which is a natural citric acid producer, resulted
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 5049 offsetEnd: 5189 A: EPS production by adapting metabolic and biochemical processes in order to face iron toxicity and to optimize energy production. CONCLUSION:
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 1876 offsetEnd: 2029 A: qualitatively. Whereas in the production of extracellular enzymes, 42 isolates (41.2%) produced protease and amylase, 26 (25.5%) isolates produced lipase
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 4571 offsetEnd: 4713 A: research proves plausible practical applicability of these PGPB for crop production in soils of saline and arid environments. SIGNIFICANCE AND
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1133 offsetEnd: 1276 A: these strains comprise acetic, citric, succinic and malic acids that qualitatively and quantitatively vary between different species as well as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1276 offsetEnd: 1408 A: and malic acids that qualitatively and quantitatively vary between different species as well as among strains from the same species.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1543 offsetEnd: 1668 A: well as among strains from the same species. The production from glycerol of succinic, acetic, citric, malic and oxalic acids
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1668 offsetEnd: 1797 A: same species. The production from glycerol of succinic, acetic, citric, malic and oxalic acids from C. oleophila and W. anomalus,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 2138 offsetEnd: 2244 A: oxalic and acetic acids by P. fermentans is reported for the first time in this work, as is the production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 3880 offsetEnd: 4027 A: that surfactin lipopeptide is a major determinant for stimulation of the immune response. These results reinforce the biotechnological potential of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 847 offsetEnd: 967 A: study was to establish a long-term method for the maintenance of calli and cell suspension cultures of the local species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 1086 offsetEnd: 1203 A: and cell suspension cultures of the local species J. curcas and J. gossypifolia, in order to allow future studies for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 3643 offsetEnd: 3763 A: more deeply: (a) the nature and levels of reactive oxygen species (ROS); (b) the activation of enzymes that act directly
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 4427 offsetEnd: 4560 A: engineered strains during acetic acid stress. The data indicate that the engineered strain can better recover from stress by limiting
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 325 offsetEnd: 473 A: Less.), Asteraceae Dumortier-are traditionally used in the Mediterranean region for production of artisanal cheeses. This is because of the presence
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 2369 offsetEnd: 2494 A: activity in plants is normally present at relatively low levels overall, the flowers of several species of the Cardueae tribe
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 2494 offsetEnd: 2621 A: at relatively low levels overall, the flowers of several species of the Cardueae tribe possess APs with extremely high specific
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 1643 offsetEnd: 1764 A: acid and osmotic agents) is highly desirable. To develop molecular markers for the early detection of ECs able to develop
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 652 offsetEnd: 820 A: analysis of the isolates, using D1/D2 domain identified five species of yeasts: Cryptococcus adeliensis (MLB-18 JX192655), Cryptococcus albidosimilis (MLB-19 JX192656),
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 3424 offsetEnd: 3557 A: in temperature was reported to cause increase in concentration of unsaturated fatty acids. High amount of oleic acid accumulated with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 572 offsetEnd: 709 A: species and among those, Starmerella bombicola (former Candida bombicola) is the most widely used and studied one. Despite the commercial
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 315 offsetEnd: 434 A: used in cooking and the preservation of food and even has medicinal properties. Losses in production from disease are a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 434 offsetEnd: 551 A: of food and even has medicinal properties. Losses in production from disease are a major limitation in the culture of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 1473 offsetEnd: 1620 A: between the pathogens and the host's root region is important for obtaining resistant cultivars by biotechnological breeding. Genetic and molecular
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 1387 offsetEnd: 1511 A: biomass yield (0.30 g g(-1)) and productivity (0.19 g L(-1) h(-1)). Citric acid, succinic acid, acetic acid and ethanol were
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 274 offsetEnd: 441 A: variety of biotechnological applications. Efficacy and safety studies have demonstrated the safe use of Yarrowia-derived products containing significant proportions of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 1058 offsetEnd: 1186 A: increased demand for this product. However, at present, the IA production capacity exceeds the demand because this product has a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 3520 offsetEnd: 3669 A: of IA production: strain improvement, process development, identification of the key enzyme cis-aconitic acid decarboxylase (CAD) in the IA metabolic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 3669 offsetEnd: 3814 A: development, identification of the key enzyme cis-aconitic acid decarboxylase (CAD) in the IA metabolic pathway, metabolic importance of CAD, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21853139 offsetBegin: 5734 offsetEnd: 5869 A: in related non-toxigenic species such as A. tubingensis, A. brasiliensis, A vadensis or A. acidus, which neither produce fumonisins nor
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 3785 offsetEnd: 3916 A: yeast, providing a base for future metabolic improvement, and a starting point for the metabolic reconstruction of other species in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 272 offsetEnd: 408 A: plant Ajuga bracteosa in the Kangra valley, in order to determine their plant growth promoting (PGP) and biotechnological potential. The
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 674 offsetEnd: 824 A: for semisynthesis of numerous commercial substances, including production of Ambrox® and related ambergris substitutes used in the formulation of high
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 706 offsetEnd: 831 A: used to decrease the sinapic acid concentration of rapeseed meal. After 7 days of growth of Trametes versicolor and Pleurotus
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 961 offsetEnd: 1085 A: days of growth of Trametes versicolor and Pleurotus ostreatus, the sinapic acid content of rapeseed meal was reduced by 59.9
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 3057 offsetEnd: 3191 A: and glucaric acid as well as alcohols like 1,3-propanediol, xylitol, mannitol, and glycerol with the discussion of the future research
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 0 offsetEnd: 137 A: In this work, bio-oxidation of glycerate was introduced for the green production of hydroxypyruvate. Whole cells of Pseudomonas sp. XP-LM
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 1935 offsetEnd: 2080 A: expression patterns and culture conditions manipulations it was possible to compare and identify common pathways of these enzymes' production and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 2080 offsetEnd: 2220 A: it was possible to compare and identify common pathways of these enzymes' production and secretion. Although laccase and peroxidase proteins
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 2220 offsetEnd: 2377 A: identify common pathways of these enzymes' production and secretion. Although laccase and peroxidase proteins have been crystallized and thoroughly analyzed,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 2377 offsetEnd: 2516 A: production and secretion. Although laccase and peroxidase proteins have been crystallized and thoroughly analyzed, there are still a lot of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1697 offsetEnd: 1824 A: of carbon substrate into acid. This is exploited in large-scale production of a number of organic acids like citric-, gluconic-
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 3885 offsetEnd: 4041 A: utilizes β-hydroxydecanoyl-ACP intermediates in fatty acid synthesis to generate the HAA, and RhlB, the rhamnosyltransferase 1, which catalyzes the transfer
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 480 offsetEnd: 612 A: (DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) are essential components of cell membranes, and are precursors for a group of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 1835 offsetEnd: 1978 A: (>95%) with the hypothetical (not isolated or characterized) protein cpop21 from an unidentified species of the family Polyporaceae. The enzyme
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 2216 offsetEnd: 2325 A: The enzyme had a low optimal pH, was very stable to acid pH and temperature, and showed improved activity and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 2325 offsetEnd: 2452 A: pH, was very stable to acid pH and temperature, and showed improved activity and stability at high H2O2 concentrations compared
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 4580 offsetEnd: 4703 A: from each family of spidroin  identified from five spider species of the Brazilian biodiversity, and an  evolutionary study
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 5086 offsetEnd: 5220 A: with the anatomical specialization of  glands and spider's spinning behaviors. Due to the biotechnological importance  of spider silks
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 6376 offsetEnd: 6533 A: also review the key considerations for devising a biotechnological approach that specifically tailors the molecular technological abilities to the management
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/15289678 offsetBegin: 792 offsetEnd: 918 A: strains grew and produced H(2) in the presence of micromolar levels of O(2). T. neapolitana showed the highest H(2) production
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 698 offsetEnd: 832 A: sole carbon and energy source, yielding acetic acid and CO2 coupled with Fe(III) reduction to Fe(II) and showing unusual physiological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 4445 offsetEnd: 4571 A: and BAN43. The outcome of this research proves plausible practical applicability of these PGPB for crop production in soils of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24134431 offsetBegin: 4713 offsetEnd: 4835 A: these PGPB for crop production in soils of saline and arid environments. SIGNIFICANCE AND IMPACT OF THE STUDY: The present
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 533 offsetEnd: 683 A: raw materials for the manufacture of biodegradable polymers. Certain species of microorganisms produce significant quantities of organic acids in high
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 724 offsetEnd: 857 A: fusca, which is a major threat to cucurbits worldwide. The antagonistic activity relies on the production of the antifungal compounds
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 857 offsetEnd: 994 A: to cucurbits worldwide. The antagonistic activity relies on the production of the antifungal compounds iturin and fengycin. In a previous
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 3939 offsetEnd: 4066 A: with 35-day calli, and at day 21 for cultures initiated with 60-day calli. Higher biomass production was obtained with sucrose.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 4206 offsetEnd: 4335 A: calli. Higher biomass production was obtained with sucrose. Cell cultures were established with 35-day calli in MS media with the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 4297 offsetEnd: 4427 A: (SOD) and catalase, in parental and engineered strains during acetic acid stress. The data indicate that the engineered strain can
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 625 offsetEnd: 795 A: hosts such as Corynebacterium, Brevibacterium, and Streptomyces. The favorable and advantageous characteristics (e.g., high secretion capacity and efficient production of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 1255 offsetEnd: 1385 A: Thus, the identification of molecular markers for the screening of ECs able to respond to maturation conditions (abscisic acid and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 1385 offsetEnd: 1509 A: for the screening of ECs able to respond to maturation conditions (abscisic acid and osmotic agents) is highly desirable. To
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 1509 offsetEnd: 1643 A: to respond to maturation conditions (abscisic acid and osmotic agents) is highly desirable. To develop molecular markers for the early
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 405 offsetEnd: 540 A: production in Aspergillus terreus was carried out as an extension of a previously published a clone-based transcriptome analysis from a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 820 offsetEnd: 1015 A: domain identified five species of yeasts: Cryptococcus adeliensis (MLB-18 JX192655), Cryptococcus albidosimilis (MLB-19 JX192656), Cryptococcus saitoi (MLB-22 JX192659), Rhodosporidium lusitaniae
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2400 offsetEnd: 2524 A: g L(-1)), yield (0.45 g g(-1)) and productivity (0.31 g L(-1) h(-1)), as well as ribonucleotide production (13.13 mg g(-1)),
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23889751 offsetBegin: 4797 offsetEnd: 4953 A: Therefore, the characterization of the endo-1,4-beta-xylanase, encoded by um06350.1, is a further step towards the biotechnological application of U. maydis
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 3916 offsetEnd: 4052 A: metabolic improvement, and a starting point for the metabolic reconstruction of other species in the Yarrowia clade and other oleaginous
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 1479 offsetEnd: 1580 A: to the high price of about US$ 4/kg, the use of IA is restricted. At present, the production rates do
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22007151 offsetBegin: 2339 offsetEnd: 2467 A: that provide an internal reserve of carbon and energy. Here, we report the composition, biosynthesis, and production of EPSs and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 824 offsetEnd: 969 A: including production of Ambrox® and related ambergris substitutes used in the formulation of high end perfumes. Most of the commercially-produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 2082 offsetEnd: 2211 A: minor diterpene of this species and the main diterpene of related Salvia species. RESULTS: Based on previous general knowledge of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 1443 offsetEnd: 1566 A: At the end of the experiment, sinapic acid concentration of T. versicolor cultures decreased by 93%of the initial value; in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 1091 offsetEnd: 1228 A: A. niger. Heterologous expression of cis-aconitate decarboxylase in A. niger leads to the accumulation of small amounts of itaconic acid.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 1228 offsetEnd: 1361 A: decarboxylase in A. niger leads to the accumulation of small amounts of itaconic acid. Additional expression of aconitase, the second
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 540 offsetEnd: 684 A: are the main factors to consider when choosing the appropriate expression system for the production of recombinant proteins. Recombinant enzymes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 1133 offsetEnd: 1290 A: bacteria (e.g., Escherichia coli, Bacillus and lactic acid bacteria), filamentous fungi (e.g., Aspergillus) and yeasts (e.g., Pichia pastoris). The favorable
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 1622 offsetEnd: 1773 A: by the selective white-rot fungus Ceriporiopsis subvermispora intensively inhibited .OH production by the Fenton reaction by direct interaction with Fe
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23201464 offsetBegin: 2278 offsetEnd: 2392 A: the microorganism to combat the dearth of iron (Fe) and the excess of reactive oxygen species (ROS) promoted by Al
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 2101 offsetEnd: 2223 A: acid was utilized as a carbon source. CONCLUSIONS: A novel pathway of glucose catabolism was demonstrated in A. terreus, a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 712 offsetEnd: 858 A: specificity resulting in oxidation of a variety of organic compounds which brings about possibilities of their utilization in biotechnological and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 2885 offsetEnd: 2998 A: production of over 900 thousand tons in the year 2000. Till the beginning of the 20th century, it was exclusively
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 4609 offsetEnd: 4723 A: part of the global production. The application of citric acid is based on three of its properties: (1) acidity and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 4958 offsetEnd: 5075 A: acidity and buffer capacity, (2) taste and flavour, and (3) chelation of metal ions. Because of its three acid groups
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 5075 offsetEnd: 5181 A: and flavour, and (3) chelation of metal ions. Because of its three acid groups with pKa values of 3.1, 4.7
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 4328 offsetEnd: 4464 A: the transfer of dTDP-L-rhamnose to β-hydroxy fatty acids in the biosynthesis of rhamnolipids. We show that rhamnolipid production by the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 1357 offsetEnd: 1497 A: humans. The biosynthesis of these fatty acids involves an alternating process of fatty acid desaturation and elongation. The desaturation is
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 4319 offsetEnd: 4452 A: the biosynthesis of very long chain polyunsaturated fatty acids offers the opportunity to engineer production of these fatty acids in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 122 offsetEnd: 226 A: acid which has a high potential as a biochemical building block, because it can be used as a monomer for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 861 offsetEnd: 980 A: species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22911606 offsetBegin: 4456 offsetEnd: 4580 A: review we present descriptions of members from each family of spidroin  identified from five spider species of the Brazilian
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 2180 offsetEnd: 2326 A: aggressive competition with native species for food and shelter, to affecting aquaculture facilities and harvests and causing structural damage to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24188724 offsetBegin: 4968 offsetEnd: 5085 A: accumulation (up to 42 gDCW L(-1), and a peak value of 38%LIPIDS of DCW, respectively), and production of high titers
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 967 offsetEnd: 1086 A: method for the maintenance of calli and cell suspension cultures of the local species J. curcas and J. gossypifolia, in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 4066 offsetEnd: 4206 A: 21 for cultures initiated with 60-day calli. Higher biomass production was obtained with sucrose. Cell cultures were established with 35-day
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 4967 offsetEnd: 5103 A: the maintenance and growth of cell suspensions for both species, with sub-cultures every 20 days. The biotechnological potential for the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 2164 offsetEnd: 2311 A: growth, reducing the productivity of the process: therefore, the development of robust cell factories with improved production rates and resistance
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 3557 offsetEnd: 3696 A: increase in concentration of unsaturated fatty acids. High amount of oleic acid accumulated with increase in temperature. These fatty acids
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 551 offsetEnd: 671 A: properties. Losses in production from disease are a major limitation in the culture of this crop. The major diseases are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 726 offsetEnd: 864 A: in resins and also in the manufacture of synthetic fibres, in coatings, adhesives, thickeners and binders. The favoured production process
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23568670 offsetBegin: 1468 offsetEnd: 1587 A: problem to the biotechnological industry due to corrosion of fermenters calling for a need to reduce the amount of NaCl
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 1566 offsetEnd: 1686 A: sinapic acid concentration of T. versicolor cultures decreased by 93%of the initial value; in the case of cultures of P.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 226 offsetEnd: 330 A: as a biochemical building block, because it can be used as a monomer for the production of a plethora of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 3763 offsetEnd: 3894 A: levels of reactive oxygen species (ROS); (b) the activation of enzymes that act directly as detoxifiers of reactive oxygen species,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 1032 offsetEnd: 1165 A: the yeast itself as the final product (as for British Petroleum's single-cell protein product). The natural occurrence of the species
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 831 offsetEnd: 961 A: concentration of rapeseed meal. After 7 days of growth of Trametes versicolor and Pleurotus ostreatus, the sinapic acid content of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24022781 offsetBegin: 2349 offsetEnd: 2491 A: the intensive production of extracellular laccase, particularly strong during the late phases of growth of T. versicolor. The obtained results
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 415 offsetEnd: 540 A: The enzyme production rate and yield are the main factors to consider when choosing the appropriate expression system for the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 3617 offsetEnd: 3777 A: this review also discusses several platform chemicals, including fumaric acid, aspartic acid, glutamic acid, sorbitol, itaconic acid, and 2,5-furan dicarboxylic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 2389 offsetEnd: 2496 A: the cadA gene in A. terreus. Cloning of the cadA gene into the citric acid producing fungus A. niger showed
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23462976 offsetBegin: 2549 offsetEnd: 2677 A: glutathione, which represented the main thiol group present into the cells. This is the first report regarding the production of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23701679 offsetBegin: 473 offsetEnd: 603 A: the Mediterranean region for production of artisanal cheeses. This is because of the presence of aspartic proteases (APs) with the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 4327 offsetEnd: 4464 A: dataset of 10338 unigenes is crucially important for the biotechnological breeding of black pepper and the ecogenomics of the Magnoliids,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2336 offsetEnd: 2457 A: of the Fenton reaction by the alkylitaconic acid was observed even in the presence of the Fe(3+) reductants, cysteine and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2595 offsetEnd: 2738 A: the presence of the Fe(3+) reductants, cysteine and hydroquinone. The inhibition of .OH production by the diffusible fungal metabolite accounts
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2738 offsetEnd: 2878 A: cysteine and hydroquinone. The inhibition of .OH production by the diffusible fungal metabolite accounts for the extracellular system of the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 2878 offsetEnd: 3013 A: .OH production by the diffusible fungal metabolite accounts for the extracellular system of the fungus that attenuates the formation of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 3777 offsetEnd: 3928 A: chemicals, including fumaric acid, aspartic acid, glutamic acid, sorbitol, itaconic acid, and 2,5-furan dicarboxylic acid, which have not been produced
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 1262 offsetEnd: 1387 A: anomala CCT 2648 showed the highest biomass yield (0.30 g g(-1)) and productivity (0.19 g L(-1) h(-1)). Citric acid, succinic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 1891 offsetEnd: 2017 A: metabolites produced. The increase of yeast extract concentration from 1 to 3 g L(-1) resulted in high biomass production. The
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2017 offsetEnd: 2143 A: extract concentration from 1 to 3 g L(-1) resulted in high biomass production. The highest biomass concentration (21 g L(-1)),
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2143 offsetEnd: 2273 A: g L(-1) resulted in high biomass production. The highest biomass concentration (21 g L(-1)), yield (0.45 g g(-1)) and productivity
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22653682 offsetBegin: 2273 offsetEnd: 2400 A: production. The highest biomass concentration (21 g L(-1)), yield (0.45 g g(-1)) and productivity (0.31 g L(-1) h(-1)), as well
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 773 offsetEnd: 910 A: and genetic approaches. Sequencing data showed that most isolates belonged to genus, Pseudomonas spp. being a dominant species. They also
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 910 offsetEnd: 1052 A: that most isolates belonged to genus, Pseudomonas spp. being a dominant species. They also showed similarity with Rhizobium, Agrobacterium and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 1052 offsetEnd: 1205 A: Pseudomonas spp. being a dominant species. They also showed similarity with Rhizobium, Agrobacterium and Erwinia spp. Isolates were screened functionally
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2405 offsetEnd: 2550 A: and eight isolates (CBS-1, CCS-1, CHS-2, CKS-2, CNS-2, VS-1, VJ-1) exhibited positive results for siderophore production. An understanding of the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2550 offsetEnd: 2697 A: CKS-2, CNS-2, VS-1, VJ-1) exhibited positive results for siderophore production. An understanding of the phonetic and functional diversity of these
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24205759 offsetBegin: 2697 offsetEnd: 2839 A: results for siderophore production. An understanding of the phonetic and functional diversity of these microbes that interact with plants will
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 2888 offsetEnd: 3077 A: fungus. Cellulose enzymatically hydrolysed in seawater and salt-assisted organic-acid catalysed cellulose were investigated as substrates. Lastly, hydrolysed hemicellulose from fractionated
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 3077 offsetEnd: 3248 A: and salt-assisted organic-acid catalysed cellulose were investigated as substrates. Lastly, hydrolysed hemicellulose from fractionated beech wood was applied as substrate.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7313 offsetEnd: 7446 A: Although U. maydis is insusceptible to most possible impurities from pretreatment, high amounts of salts or residues of organic acids
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7446 offsetEnd: 7579 A: most possible impurities from pretreatment, high amounts of salts or residues of organic acids can slow microbial growth and decrease
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7579 offsetEnd: 7715 A: amounts of salts or residues of organic acids can slow microbial growth and decrease the production. Consequently, the pretreatment step
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7715 offsetEnd: 7858 A: organic acids can slow microbial growth and decrease the production. Consequently, the pretreatment step needs to fit the prerequisites defined
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22480369 offsetBegin: 7858 offsetEnd: 8002 A: and decrease the production. Consequently, the pretreatment step needs to fit the prerequisites defined by the actual microorganisms applied for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 604 offsetEnd: 758 A: use of Yarrowia-derived products containing significant proportions of Yarrowia biomass (as for DuPont's eicosapentaenoic acid-rich oil) or with the yeast
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 758 offsetEnd: 888 A: proportions of Yarrowia biomass (as for DuPont's eicosapentaenoic acid-rich oil) or with the yeast itself as the final product (as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23488872 offsetBegin: 888 offsetEnd: 1032 A: DuPont's eicosapentaenoic acid-rich oil) or with the yeast itself as the final product (as for British Petroleum's single-cell protein product).
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/19629471 offsetBegin: 3215 offsetEnd: 3370 A: low-quality carbon source. In this short review, we discuss the following aspects of IA production: strain improvement, process development, identification
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 563 offsetEnd: 694 A: acids, lipases and proteases. It is also considered a good candidate for single-cell oil production. Although some of its metabolic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 694 offsetEnd: 830 A: also considered a good candidate for single-cell oil production. Although some of its metabolic pathways are well studied, its metabolic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 830 offsetEnd: 965 A: single-cell oil production. Although some of its metabolic pathways are well studied, its metabolic engineering is hindered by the lack
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 2197 offsetEnd: 2363 A: model of the well-studied but phylogenetically distant yeast S. cerevisiae, we mapped conserved reactions, rewrote gene associations, added species-specific reactions
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 2363 offsetEnd: 2526 A: distant yeast S. cerevisiae, we mapped conserved reactions, rewrote gene associations, added species-specific reactions and inserted specialized copies of scaffold
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 2526 offsetEnd: 2702 A: conserved reactions, rewrote gene associations, added species-specific reactions and inserted specialized copies of scaffold reactions to account for species-specific expansion
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 2702 offsetEnd: 2867 A: species-specific reactions and inserted specialized copies of scaffold reactions to account for species-specific expansion of protein families. We used physiological
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 2867 offsetEnd: 3015 A: of scaffold reactions to account for species-specific expansion of protein families. We used physiological measures obtained under lab conditions to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22558935 offsetBegin: 3015 offsetEnd: 3179 A: species-specific expansion of protein families. We used physiological measures obtained under lab conditions to validate our predictions. CONCLUSIONS: Y. lipolytica
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 1772 offsetEnd: 1931 A: the rhizospheric soil isolates belonged to α- and γ-Proteobacteria, with Pseudomonas constituting the most dominant species. Endophytic bacterial community, on
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 1931 offsetEnd: 2091 A: α- and γ-Proteobacteria, with Pseudomonas constituting the most dominant species. Endophytic bacterial community, on other hand, consisted almost exclusively of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 2091 offsetEnd: 2240 A: the most dominant species. Endophytic bacterial community, on other hand, consisted almost exclusively of Firmicutes. Majority of the isolates showed
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 2384 offsetEnd: 2527 A: exclusively of Firmicutes. Majority of the isolates showed PGP activity by producing siderophores and indole acetic acid. Several isolates were
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 2527 offsetEnd: 2666 A: isolates showed PGP activity by producing siderophores and indole acetic acid. Several isolates were found to exhibit very high antioxidant
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21968325 offsetBegin: 2666 offsetEnd: 2797 A: siderophores and indole acetic acid. Several isolates were found to exhibit very high antioxidant activity in the culture medium. A
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 680 offsetEnd: 813 A: a salt-water irrigated crop. Qualitative and quantitative compositions of fatty acids were determined in the seeds of S. ambigua that
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 813 offsetEnd: 944 A: quantitative compositions of fatty acids were determined in the seeds of S. ambigua that were cultivated in southern Brazil. Hexane
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 2436 offsetEnd: 2552 A: (18:3). The sum of the saturated palmitic and stearic acids (24.8%) in S. ambigua seed oil exceeded values cited for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22801376 offsetBegin: 2552 offsetEnd: 2667 A: palmitic and stearic acids (24.8%) in S. ambigua seed oil exceeded values cited for commercial oils use, as well as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 122 offsetEnd: 255 A: dicarbonic organic acid. It can easily be incorporated into polymers and may serve as a substitute for petrochemical-based acrylic or
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 255 offsetEnd: 381 A: be incorporated into polymers and may serve as a substitute for petrochemical-based acrylic or methacrylic acid. It is used at
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 381 offsetEnd: 500 A: serve as a substitute for petrochemical-based acrylic or methacrylic acid. It is used at 1-5% as a co-monomer in resins
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11548996 offsetBegin: 500 offsetEnd: 604 A: acrylic or methacrylic acid. It is used at 1-5% as a co-monomer in resins and also in the manufacture of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 2211 offsetEnd: 2353 A: the main diterpene of related Salvia species. RESULTS: Based on previous general knowledge of diterpene biosynthesis in angiosperms, and based
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22834731 offsetBegin: 2353 offsetEnd: 2494 A: species. RESULTS: Based on previous general knowledge of diterpene biosynthesis in angiosperms, and based on mining of our recently published
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 245 offsetEnd: 386 A: as a biochemical building block. It can be microbially produced from some Aspergillus species, such as Aspergillus itaconicus and Aspergillus
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 386 offsetEnd: 533 A: can be microbially produced from some Aspergillus species, such as Aspergillus itaconicus and Aspergillus terreus. However, the achieved titers are
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23727192 offsetBegin: 533 offsetEnd: 681 A: Aspergillus species, such as Aspergillus itaconicus and Aspergillus terreus. However, the achieved titers are significantly lower as compared to the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 3728 offsetEnd: 3861 A: from high-level expression of genes encoding the enzymes and expression hosts, the goal of overproduction can hardly be achieved, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 3861 offsetEnd: 3993 A: the enzymes and expression hosts, the goal of overproduction can hardly be achieved, and therefore, the yield of recombinant enzymes
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23686280 offsetBegin: 3993 offsetEnd: 4119 A: goal of overproduction can hardly be achieved, and therefore, the yield of recombinant enzymes is limited. In this review, the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21052988 offsetBegin: 3470 offsetEnd: 3617 A: future research in this area. Besides, this review also discusses several platform chemicals, including fumaric acid, aspartic acid, glutamic acid,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23415941 offsetBegin: 942 offsetEnd: 1079 A: from glycerate of 200 mM. Glycerate is now potentially producible from glycerol, a by-product during biodiesel fuel production, through a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/12359241 offsetBegin: 0 offsetEnd: 119 A: A cellulolytic active oxygen species, hydroxyl radicals (.OH), play a leading role in the erosion of wood cell walls by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 1344 offsetEnd: 1525 A: transformants harbouring Aspergillus niger genes encoding 6-phosphofructo-1-kinases with superior kinetic and regulatory properties for bioproduction of metabolites from glucose. On
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 1525 offsetEnd: 1683 A: 6-phosphofructo-1-kinases with superior kinetic and regulatory properties for bioproduction of metabolites from glucose. On exhaustion of the glucose in batch
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 3146 offsetEnd: 3270 A: IMPACT OF THE STUDY: Aspergillus terreus is a potential novel producer organism for gluconic acid, a compound with many uses
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 3270 offsetEnd: 3380 A: is a potential novel producer organism for gluconic acid, a compound with many uses as a bulk chemical. With a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/20618892 offsetBegin: 3380 offsetEnd: 3490 A: for gluconic acid, a compound with many uses as a bulk chemical. With a new knowledge of glucose catabolism by
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 0 offsetEnd: 152 A: Extensive research efforts have been dedicated to characterizing expression of laccases and peroxidases and their regulation in numerous fungal species.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 152 offsetEnd: 292 A: to characterizing expression of laccases and peroxidases and their regulation in numerous fungal species. Much attention has been brought to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 292 offsetEnd: 439 A: peroxidases and their regulation in numerous fungal species. Much attention has been brought to these enzymes broad substrate specificity resulting
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23199732 offsetBegin: 439 offsetEnd: 570 A: fungal species. Much attention has been brought to these enzymes broad substrate specificity resulting in oxidation of a variety of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 0 offsetEnd: 136 A: Fungi, in particular Aspergilli, are well known for their potential to overproduce a variety of organic acids. These microorganisms have
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 136 offsetEnd: 271 A: known for their potential to overproduce a variety of organic acids. These microorganisms have an intrinsic ability to accumulate these
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 271 offsetEnd: 405 A: a variety of organic acids. These microorganisms have an intrinsic ability to accumulate these substances and it is generally believed
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 1435 offsetEnd: 1565 A: of cases conditions have been found that result in almost quantitative conversion of carbon substrate into acid. This is exploited
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 4374 offsetEnd: 4495 A: a fermentation process, which only a decade later accounted for a large part of the global production. The application of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/11791342 offsetBegin: 4842 offsetEnd: 4958 A: on three of its properties: (1) acidity and buffer capacity, (2) taste and flavour, and (3) chelation of metal ions.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 4041 offsetEnd: 4182 A: synthesis to generate the HAA, and RhlB, the rhamnosyltransferase 1, which catalyzes the transfer of dTDP-L-rhamnose to β-hydroxy fatty acids
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23053103 offsetBegin: 4182 offsetEnd: 4328 A: RhlB, the rhamnosyltransferase 1, which catalyzes the transfer of dTDP-L-rhamnose to β-hydroxy fatty acids in the biosynthesis of rhamnolipids. We
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 1073 offsetEnd: 1218 A: and docosanoids) involved in regulation of various physiological activities in animals and humans. The biosynthesis of these fatty acids involves
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 2056 offsetEnd: 2188 A: that introduce double bonds between the pre-existing double bond and the carboxyl end of polyunsaturated fatty acids. The first gene
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 2188 offsetEnd: 2323 A: pre-existing double bond and the carboxyl end of polyunsaturated fatty acids. The first gene encoding a front-end desaturase was cloned
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 2323 offsetEnd: 2456 A: end of polyunsaturated fatty acids. The first gene encoding a front-end desaturase was cloned in 1993 from cyanobacteria. Since then,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22009657 offsetBegin: 4195 offsetEnd: 4319 A: as well as their roles in the biosynthesis of very long chain polyunsaturated fatty acids offers the opportunity to engineer
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 583 offsetEnd: 727 A: plethora of products including resins, plastics, paints, and synthetic fibers. Some Aspergillus species, like A. itaconicus and A. terreus, show
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23420787 offsetBegin: 727 offsetEnd: 861 A: paints, and synthetic fibers. Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 467 offsetEnd: 629 A: interesting, but still scarcely known, enzymatic oxidative system. Among these enzymes, the production, purification, and identification of a new dye-decolorizing
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 629 offsetEnd: 783 A: oxidative system. Among these enzymes, the production, purification, and identification of a new dye-decolorizing peroxidase (DyP)-type enzyme, as well as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23666335 offsetBegin: 783 offsetEnd: 957 A: production, purification, and identification of a new dye-decolorizing peroxidase (DyP)-type enzyme, as well as its physico-chemical, spectroscopic, and catalytic properties,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 3421 offsetEnd: 3564 A: using agar well diffusion method. Agar tube dilution method for antifungal assay showed 3.2-76% growth inhibition of Mucor species, Aspergillus
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 3564 offsetEnd: 3722 A: tube dilution method for antifungal assay showed 3.2-76% growth inhibition of Mucor species, Aspergillus fumigatus and Fusarium moliniformes. CONCLUSIONS: The
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 3722 offsetEnd: 3896 A: showed 3.2-76% growth inhibition of Mucor species, Aspergillus fumigatus and Fusarium moliniformes. CONCLUSIONS: The present investigation reveals that non-embryogenic callus
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21989222 offsetBegin: 3896 offsetEnd: 4059 A: species, Aspergillus fumigatus and Fusarium moliniformes. CONCLUSIONS: The present investigation reveals that non-embryogenic callus can be turned into embryos and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 2267 offsetEnd: 2368 A: of amino acids and can also be applied for the synthesis of a wide variety of other products, such as
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 2368 offsetEnd: 2490 A: be applied for the synthesis of a wide variety of other products, such as organic acids, biofuels, or proteins. Therefore,
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 2490 offsetEnd: 2618 A: a wide variety of other products, such as organic acids, biofuels, or proteins. Therefore, C. glutamicum has become an important
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22539022 offsetBegin: 2618 offsetEnd: 2759 A: such as organic acids, biofuels, or proteins. Therefore, C. glutamicum has become an important model organism in industrial biotechnology and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 1179 offsetEnd: 1312 A: for gaining higher yields, with the ecological benefit of reducing the risk of invasion by the cultured species. Sexual manipulations
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 1312 offsetEnd: 1450 A: ecological benefit of reducing the risk of invasion by the cultured species. Sexual manipulations may also render sustainable solutions to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 1450 offsetEnd: 1589 A: of invasion by the cultured species. Sexual manipulations may also render sustainable solutions to the environmental problems caused by the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 3514 offsetEnd: 3640 A: manipulation is already a part of sustainable solutions in fish aquaculture and in the bio-control of insect pest species, and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 3640 offsetEnd: 3764 A: sustainable solutions in fish aquaculture and in the bio-control of insect pest species, and attempts are also being made to
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 3764 offsetEnd: 3885 A: in the bio-control of insect pest species, and attempts are also being made to implement it with crustaceans. As recently
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 3885 offsetEnd: 4018 A: species, and attempts are also being made to implement it with crustaceans. As recently exemplified in a commercially important prawn
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 4018 offsetEnd: 4166 A: made to implement it with crustaceans. As recently exemplified in a commercially important prawn species, IAG silencing, a temporal, non-genetically
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 4166 offsetEnd: 4333 A: As recently exemplified in a commercially important prawn species, IAG silencing, a temporal, non-genetically modifying and non-transmissible intervention, has enabled
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 5962 offsetEnd: 6097 A: decapod crustacean groups and suggest a sustainable solution for the management of invasive and pest crustacean species. We also review
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22561950 offsetBegin: 6097 offsetEnd: 6230 A: sustainable solution for the management of invasive and pest crustacean species. We also review the key considerations for devising a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 2227 offsetEnd: 2428 A: production, galactose utilization, citrate metabolism, exopolysaccharide production, and lipolytic, ureolytic, exocellular proteolytic, and decarboxylasic activities. Analysis by RAPD-PCR highlighted a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 2428 offsetEnd: 2608 A: production, and lipolytic, ureolytic, exocellular proteolytic, and decarboxylasic activities. Analysis by RAPD-PCR highlighted a remarkable genotypic heterogeneity among strains in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 2608 offsetEnd: 2760 A: and decarboxylasic activities. Analysis by RAPD-PCR highlighted a remarkable genotypic heterogeneity among strains in both species, and, at a similarity
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 2760 offsetEnd: 2891 A: highlighted a remarkable genotypic heterogeneity among strains in both species, and, at a similarity level of 78%, all the isolates
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22118078 offsetBegin: 2891 offsetEnd: 3012 A: strains in both species, and, at a similarity level of 78%, all the isolates and reference strains of Strep. thermophilus
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 0 offsetEnd: 159 A: Corynebacterium glutamicum is the world's largest producer of glutamate and lysine. Industrial glutamate overproduction is induced by empirical processes, such
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 159 offsetEnd: 320 A: producer of glutamate and lysine. Industrial glutamate overproduction is induced by empirical processes, such as biotin limitation, supplementation with specific
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 320 offsetEnd: 487 A: glutamate overproduction is induced by empirical processes, such as biotin limitation, supplementation with specific surfactants or addition of sublethal concentration
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 1372 offsetEnd: 1505 A: the plasma membrane, an outer permeability membrane similar to that of Gram-negative microorganisms. As the amino acids have to cross
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 1505 offsetEnd: 1644 A: membrane similar to that of Gram-negative microorganisms. As the amino acids have to cross both membranes, their integrity, composition and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 1644 offsetEnd: 1786 A: microorganisms. As the amino acids have to cross both membranes, their integrity, composition and fluidity influence the export process. While
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 1924 offsetEnd: 2045 A: composition and fluidity influence the export process. While the precise mechanism of the export of the amino acids by C.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 2045 offsetEnd: 2160 A: process. While the precise mechanism of the export of the amino acids by C. glutamicum is not fully understood, the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 2160 offsetEnd: 2272 A: the export of the amino acids by C. glutamicum is not fully understood, the excretion of amino acids through the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 2272 offsetEnd: 2389 A: by C. glutamicum is not fully understood, the excretion of amino acids through the inner membrane involved at least a
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 2389 offsetEnd: 2526 A: understood, the excretion of amino acids through the inner membrane involved at least a major export system mechanosensitive channel MscS
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 3280 offsetEnd: 3419 A: it is strongly believed that defects in the hallmark of the outer membrane, 2-alkyl, 3-hydroxylated long-chain fatty acids (mycolic acids),
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 3419 offsetEnd: 3549 A: in the hallmark of the outer membrane, 2-alkyl, 3-hydroxylated long-chain fatty acids (mycolic acids), could be key factors in the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 3549 offsetEnd: 3696 A: membrane, 2-alkyl, 3-hydroxylated long-chain fatty acids (mycolic acids), could be key factors in the glutamate overproduction. This review aims at
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 3696 offsetEnd: 3820 A: (mycolic acids), could be key factors in the glutamate overproduction. This review aims at giving an overview of the current
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 3820 offsetEnd: 3957 A: in the glutamate overproduction. This review aims at giving an overview of the current knowledge on mycolic acids structure, biosynthesis
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24113823 offsetBegin: 3957 offsetEnd: 4083 A: aims at giving an overview of the current knowledge on mycolic acids structure, biosynthesis and transfer in C. glutamicum and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 243 offsetEnd: 375 A: organic acids. In this study, a cloned based transcriptomics approach was used to identify genes crucial in the biosynthesis pathway
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/21324422 offsetBegin: 3990 offsetEnd: 4128 A: producer, resulted in itaconate production. Genome analysis suggests that in A. terreus the cis-aconitate decarboxylase gene is part of an
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 1931 offsetEnd: 2073 A: RESULTS: Further phylogenetic analysis, based on 16S rDNA sequence, definitively confirmed that BAS-10 belongs to K. oxytoca species. In order
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 2073 offsetEnd: 2214 A: 16S rDNA sequence, definitively confirmed that BAS-10 belongs to K. oxytoca species. In order to rationalize the biochemical peculiarities of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 2214 offsetEnd: 2367 A: BAS-10 belongs to K. oxytoca species. In order to rationalize the biochemical peculiarities of this unusual enterobacteriun, combined 2D-Differential Gel
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 5189 offsetEnd: 5337 A: biochemical processes in order to face iron toxicity and to optimize energy production. CONCLUSION: Differential proteomics provided insights on the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 5337 offsetEnd: 5504 A: iron toxicity and to optimize energy production. CONCLUSION: Differential proteomics provided insights on the molecular mechanisms necessary for anaeorobic utilization
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 5504 offsetEnd: 5687 A: production. CONCLUSION: Differential proteomics provided insights on the molecular mechanisms necessary for anaeorobic utilization of Fe(III)-citrate in a biotechnologically promising
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 5687 offsetEnd: 5851 A: on the molecular mechanisms necessary for anaeorobic utilization of Fe(III)-citrate in a biotechnologically promising enterobacteriun, also revealing genes that can
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23176641 offsetBegin: 5851 offsetEnd: 6009 A: anaeorobic utilization of Fe(III)-citrate in a biotechnologically promising enterobacteriun, also revealing genes that can be targeted for the rational design
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1797 offsetEnd: 1916 A: of succinic, acetic, citric, malic and oxalic acids from C. oleophila and W. anomalus, and that of succinic, oxalic and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 1916 offsetEnd: 2029 A: oxalic acids from C. oleophila and W. anomalus, and that of succinic, oxalic and acetic acids by P. fermentans is
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 2029 offsetEnd: 2138 A: W. anomalus, and that of succinic, oxalic and acetic acids by P. fermentans is reported for the first time in
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23561074 offsetBegin: 2676 offsetEnd: 2799 A: showed that mature fruits can be a good source of new yeasts able to metabolise glycerol, producing different organic acids
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 846 offsetEnd: 1007 A: produce significant quantities of organic acids in high yields under specific cultivation conditions from biomass-derived carbohydrates. The accumulation of some
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 1007 offsetEnd: 1154 A: in high yields under specific cultivation conditions from biomass-derived carbohydrates. The accumulation of some acids, such as fumaric, malic and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 1154 offsetEnd: 1298 A: conditions from biomass-derived carbohydrates. The accumulation of some acids, such as fumaric, malic and succinic acid, are believed to involve
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 1298 offsetEnd: 1418 A: of some acids, such as fumaric, malic and succinic acid, are believed to involve CO2-fixation which gives high yields of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/10533437 offsetBegin: 1418 offsetEnd: 1556 A: malic and succinic acid, are believed to involve CO2-fixation which gives high yields of products. The application of special fermentation
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302493 offsetBegin: 2993 offsetEnd: 3159 A: activation. Our results demonstrated that UMAF6639 confers protection against cucurbit powdery mildew by activation of jasmonate- and salicylic acid-dependent defence
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 302 offsetEnd: 457 A: pharmacological and industrial properties have been reported. More recently, it has been considered an important alternative source for biofuel production.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 457 offsetEnd: 592 A: reported. More recently, it has been considered an important alternative source for biofuel production. The objective of this study was
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 592 offsetEnd: 726 A: considered an important alternative source for biofuel production. The objective of this study was to establish a long-term method for
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 726 offsetEnd: 847 A: biofuel production. The objective of this study was to establish a long-term method for the maintenance of calli and cell
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24027910 offsetBegin: 4837 offsetEnd: 4967 A: This medium was considered optimum for the maintenance and growth of cell suspensions for both species, with sub-cultures every 20
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 1333 offsetEnd: 1503 A: constitute the preferential substrate for second-generation processes. Inhibitors include furan derivatives, phenolic compounds and weak organic acids, among which acetic
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 3894 offsetEnd: 4023 A: (b) the activation of enzymes that act directly as detoxifiers of reactive oxygen species, such as superoxide dismutase (SOD) and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23847041 offsetBegin: 4023 offsetEnd: 4162 A: act directly as detoxifiers of reactive oxygen species, such as superoxide dismutase (SOD) and catalase, in parental and engineered strains
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 0 offsetEnd: 149 A: Gram-positive bacteria are widely used to produce recombinant proteins, amino acids, organic acids, higher alcohols, and polymers. Many proteins have
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 149 offsetEnd: 299 A: produce recombinant proteins, amino acids, organic acids, higher alcohols, and polymers. Many proteins have been expressed in Gram-positive hosts such
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24068337 offsetBegin: 299 offsetEnd: 456 A: acids, higher alcohols, and polymers. Many proteins have been expressed in Gram-positive hosts such as Corynebacterium, Brevibacterium, and Streptomyces. The
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 145 offsetEnd: 276 A: tool in the large-scale propagation of elite genotypes and ex situ conservation of conifer species. Protocols for the induction and
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 276 offsetEnd: 415 A: elite genotypes and ex situ conservation of conifer species. Protocols for the induction and proliferation of embryogenic cultures (ECs) of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24327423 offsetBegin: 415 offsetEnd: 563 A: of conifer species. Protocols for the induction and proliferation of embryogenic cultures (ECs) of Brazilian pine (Araucaria angustifolia (Bert.) O.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 3817 offsetEnd: 3947 A: set. However, in all three cases, the regulation of pH dependent gene expression was completely different between the two species.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 3947 offsetEnd: 4094 A: the regulation of pH dependent gene expression was completely different between the two species. CONCLUSIONS: An extended clone based transcriptome
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 4094 offsetEnd: 4248 A: expression was completely different between the two species. CONCLUSIONS: An extended clone based transcriptome analysis using a clone based transcription
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/24304666 offsetBegin: 4248 offsetEnd: 4395 A: two species. CONCLUSIONS: An extended clone based transcriptome analysis using a clone based transcription array to identify genes correlating with
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 3295 offsetEnd: 3424 A: and 20°C) was also done. Decrease in temperature was reported to cause increase in concentration of unsaturated fatty acids. High
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 3825 offsetEnd: 3959 A: accumulated with increase in temperature. These fatty acids possibly help the strains to survive in glacial ice core cold environment.
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23353800 offsetBegin: 3959 offsetEnd: 4093 A: fatty acids possibly help the strains to survive in glacial ice core cold environment. The extracellular and intracellular filtrate of
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 2783 offsetEnd: 2928 A: in complete abolishment of sophorolipid production. This phenotype could be complemented by supplying the yeast with hydroxylated fatty acids. On
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 2928 offsetEnd: 3054 A: This phenotype could be complemented by supplying the yeast with hydroxylated fatty acids. On the other hand, knocking out the
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 3054 offsetEnd: 3183 A: supplying the yeast with hydroxylated fatty acids. On the other hand, knocking out the transporter gene yields mutants still able
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/23516968 offsetBegin: 3183 offsetEnd: 3309 A: acids. On the other hand, knocking out the transporter gene yields mutants still able to secrete sophorolipids, though only at
Q:Which species may be used for the biotechnological production of itaconic acid? Document:http://www.ncbi.nlm.nih.gov/pubmed/22984782 offsetBegin: 1914 offsetEnd: 2038 A: and molecular data for this species, though, are limited. In this paper, RNA-Seq technology has been employed, for the first
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 2221 offsetEnd: 2374 A: histone methyltransferase to the imprinting control regions, inhibiting production of an activating methylation mark on histone H3 lysine 4. H1-dependent
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/24097338 offsetBegin: 263 offsetEnd: 401 A: the polycomb group complex, is vital for stem cell development, including hematopoiesis. Its primary function, to deposit the histone mark
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/24097338 offsetBegin: 401 offsetEnd: 562 A: for stem cell development, including hematopoiesis. Its primary function, to deposit the histone mark H3K27me3, promotes transcriptional repression. The activity
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/24097338 offsetBegin: 562 offsetEnd: 712 A: Its primary function, to deposit the histone mark H3K27me3, promotes transcriptional repression. The activity of EZH2 influences cell fate regulation,
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 3589 offsetEnd: 3740 A: In vascular endothelial cells the histone methyltransferase Set7 can write the mono-methylation mark H3K4m1 and this methyl-writing enzyme is recruited
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 3149 offsetEnd: 3270 A: the deposit of H3K27me3 mark at the Bim promoter. SUZ12 and the histone methyltransferase EZH2, two PRC2 subunits bind to
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 3452 offsetEnd: 3589 A: H3K4m3, on the NFκB p65 gene. In vascular endothelial cells the histone methyltransferase Set7 can write the mono-methylation mark H3K4m1
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 3020 offsetEnd: 3149 A: of Polycomb is directly responsible for the deposit of H3K27me3 mark at the Bim promoter. SUZ12 and the histone methyltransferase
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2773 offsetEnd: 2922 A: effect on modifications deposited during transcription initiation. We also found that the histone H3S10 phosphorylation mark is catalyzed by mitogen-
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2922 offsetEnd: 3061 A: initiation. We also found that the histone H3S10 phosphorylation mark is catalyzed by mitogen- and stress-activated protein kinase 1 (MSK1)
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 3740 offsetEnd: 3884 A: methyltransferase Set7 can write the mono-methylation mark H3K4m1 and this methyl-writing enzyme is recruited as a gene co-activator in response
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 3884 offsetEnd: 4023 A: mark H3K4m1 and this methyl-writing enzyme is recruited as a gene co-activator in response to glucose. Furthermore, Set7 knockdown prevents
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 267 offsetEnd: 380 A: histones. Here we show that the H1 linker histone plays a key role in regulating both DNA methylation and histone
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 0 offsetEnd: 148 A: Drosophila PR-Set7 or SET8 is a histone methyltransferase that specifically monomethylates histone H4 lysine 20 (H4K20). L(3)MBT has been identified
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 148 offsetEnd: 297 A: histone methyltransferase that specifically monomethylates histone H4 lysine 20 (H4K20). L(3)MBT has been identified as a reader of methylated H4K20.
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 1508 offsetEnd: 1672 A: are found in the SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain-containing lysine methyltransferases SET7 and SETDB1, whereby the histone H3 trimethylated on
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 1672 offsetEnd: 1838 A: Enhancer-of-zeste, Trithorax) domain-containing lysine methyltransferases SET7 and SETDB1, whereby the histone H3 trimethylated on lysine 4 (H3K4 (me3) ) modification
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 2318 offsetEnd: 2444 A: the histone H3 trimethylated on lysine 9 (H3K9 (me3) ) modification prevents methylation by SET7 on H3K4. A similar cross-talk
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/24097338 offsetBegin: 712 offsetEnd: 869 A: histone mark H3K27me3, promotes transcriptional repression. The activity of EZH2 influences cell fate regulation, namely the balance between self-renewal and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 3326 offsetEnd: 3452 A: with H3K4m1, but not H3K4m2 and H3K4m3, on the NFκB p65 gene. In vascular endothelial cells the histone methyltransferase Set7
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 2067 offsetEnd: 2221 A: interferes with binding of the SET7/9 histone methyltransferase to the imprinting control regions, inhibiting production of an activating methylation mark
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 2374 offsetEnd: 2511 A: regions, inhibiting production of an activating methylation mark on histone H3 lysine 4. H1-dependent recruitment of DNMT1 and DNMT3B and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 2511 offsetEnd: 2640 A: methylation mark on histone H3 lysine 4. H1-dependent recruitment of DNMT1 and DNMT3B and interference with the binding of SET7/9
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 291 offsetEnd: 436 A: structural and functional diversity in biology. These modifications are encrypted as histone codes or histone languages and function to establish
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 393 offsetEnd: 540 A: of histone lysine methyltransferases. Histone lysine methylation is known to either activate or repress gene expression depending upon the position
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 380 offsetEnd: 491 A: H1 linker histone plays a key role in regulating both DNA methylation and histone H3 methylation at the H19 and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 2531 offsetEnd: 2651 A: and by promoting the trimethylation of histone 3 on lysine 27 (H3K27me3, a repressive histone mark) on the Bim promoter.
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 436 offsetEnd: 578 A: These modifications are encrypted as histone codes or histone languages and function to establish and maintain heritable epigenetic codes that
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 3061 offsetEnd: 3204 A: histone H3S10 phosphorylation mark is catalyzed by mitogen- and stress-activated protein kinase 1 (MSK1) and is recognized by a 14-3-3ζ/14-3-3ε
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 2651 offsetEnd: 2772 A: histone 3 on lysine 27 (H3K27me3, a repressive histone mark) on the Bim promoter. The PRC2 repressive complex of Polycomb
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 2772 offsetEnd: 2899 A: a repressive histone mark) on the Bim promoter. The PRC2 repressive complex of Polycomb is directly responsible for the deposit
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 258 offsetEnd: 393 A: to the discoveries of a variety of histone lysine methyltransferases. Histone lysine methylation is known to either activate or repress
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 2899 offsetEnd: 3020 A: Bim promoter. The PRC2 repressive complex of Polycomb is directly responsible for the deposit of H3K27me3 mark at the Bim
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 121 offsetEnd: 258 A: of histones have moved rapidly thanks to the discoveries of a variety of histone lysine methyltransferases. Histone lysine methylation is
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 142 offsetEnd: 267 A: methylation and posttranslational modifications of core histones. Here we show that the H1 linker histone plays a key role in
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 155 offsetEnd: 291 A: a major contributing factor to the structural and functional diversity in biology. These modifications are encrypted as histone codes or
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 1584 offsetEnd: 1720 A: is not fully understood. Here we describe spatial and temporal analyses of the histone modifications that are introduced during estrogen
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 1720 offsetEnd: 1881 A: describe spatial and temporal analyses of the histone modifications that are introduced during estrogen receptor α (ERα)-activated transcription. We demonstrated
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2039 offsetEnd: 2193 A: during estrogen receptor α (ERα)-activated transcription. We demonstrated that aborting RNA polymerase II caused a disruption of the histone modifications
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 4559 offsetEnd: 4733 A: monomethylation is implicated in both transcription initiation and elongation. Our experiments provide a relatively comprehensive analysis of histone modifications associated
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 1960 offsetEnd: 2110 A: of our epigenetic studies. Transcriptional silencing in both glioma and breast carcinoma cells predominantly involved the repressive histone H3 Lys-27
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 2259 offsetEnd: 2418 A: cells predominantly involved the repressive histone H3 Lys-27 trimethylation (H3K27me3) mark. In turn, epigenetic stimulation was primarily performed through a
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 4787 offsetEnd: 4952 A: confirmed using orthotopic xenografts and tumor specimens. We suggest that the epigenetic mechanisms allow gliomas to deposit an invasion-promoting collagen-enriched
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1407 offsetEnd: 1552 A: those enzymes, the most extensively studied is Set9, a SET domain-containing lysine methyltransferase. Set9 was initially found to target histone
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 1613 offsetEnd: 1762 A: histone and non-histone proteins. Recent reports have suggested a new mechanism of epigenetic gene regulation via SET7/9 modulated DNMT1 methylation.
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 601 offsetEnd: 700 A: and histone H3 methylation at the H19 and Gtl2 loci in mouse ES cells. Some, but not all, murine H1
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 0 offsetEnd: 155 A: Transcription regulation by histone modifications is a major contributing factor to the structural and functional diversity in biology. These modifications
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 1881 offsetEnd: 2039 A: the histone modifications that are introduced during estrogen receptor α (ERα)-activated transcription. We demonstrated that aborting RNA polymerase II caused
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2193 offsetEnd: 2339 A: We demonstrated that aborting RNA polymerase II caused a disruption of the histone modifications that are associated with transcription elongation
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2339 offsetEnd: 2468 A: II caused a disruption of the histone modifications that are associated with transcription elongation but had a minimal effect on
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2627 offsetEnd: 2773 A: transcription elongation but had a minimal effect on modifications deposited during transcription initiation. We also found that the histone H3S10
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 4733 offsetEnd: 4903 A: initiation and elongation. Our experiments provide a relatively comprehensive analysis of histone modifications associated with ERα-regulated transcription and define the
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 4903 offsetEnd: 5067 A: a relatively comprehensive analysis of histone modifications associated with ERα-regulated transcription and define the biological meaning of several key components
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 2595 offsetEnd: 2744 A: methylation by SET7 on H3K4. A similar cross-talk between posttranslational modifications regulates the functions of non-histone proteins such as the
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 0 offsetEnd: 154 A: Epigenetic parameters (DNA methylation, histone modifications, and miRNAs) play a significant role in cancer. To identify the common epigenetic signatures
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 2110 offsetEnd: 2259 A: in both glioma and breast carcinoma cells predominantly involved the repressive histone H3 Lys-27 trimethylation (H3K27me3) mark. In turn, epigenetic
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 3492 offsetEnd: 3628 A: bivalent mark (enrichment in both H3K27me3 and H3K4me2), a characteristic of developmental genes. In contrast with other MMPs, MMP-8 was
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 4952 offsetEnd: 5097 A: specimens. We suggest that the epigenetic mechanisms allow gliomas to deposit an invasion-promoting collagen-enriched matrix and then to use this
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1552 offsetEnd: 1689 A: is Set9, a SET domain-containing lysine methyltransferase. Set9 was initially found to target histone H3 lysine 4 for monomethylation and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1821 offsetEnd: 1972 A: target histone H3 lysine 4 for monomethylation and was subsequently shown to target a variety of non-histone proteins, especially transcription-related
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 1334 offsetEnd: 1475 A: to lysine methylation. SET7/9 plays a prominent role in lysine methylation of histone and non-histone proteins. Recent reports have suggested
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 1475 offsetEnd: 1613 A: prominent role in lysine methylation of histone and non-histone proteins. Recent reports have suggested a new mechanism of epigenetic gene
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 1782 offsetEnd: 1917 A: DNA methylation of the H19 and Gtl2 imprinting control regions. H1 also interferes with binding of the SET7/9 histone methyltransferase
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 2415 offsetEnd: 2531 A: by binding to the Bim promoter and by promoting the trimethylation of histone 3 on lysine 27 (H3K27me3, a repressive
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 972 offsetEnd: 1131 A: the fate of the cell. Despite recent advances revealing numerous histone modifications associated with transcription regulation, how such modifications dictate
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 1131 offsetEnd: 1296 A: recent advances revealing numerous histone modifications associated with transcription regulation, how such modifications dictate the process of transcription is not
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 1447 offsetEnd: 1584 A: modifications dictate the process of transcription is not fully understood. Here we describe spatial and temporal analyses of the histone
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 2468 offsetEnd: 2627 A: histone modifications that are associated with transcription elongation but had a minimal effect on modifications deposited during transcription initiation. We
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 5067 offsetEnd: 5217 A: modifications associated with ERα-regulated transcription and define the biological meaning of several key components of the histone code that governs
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 0 offsetEnd: 147 A: The establishment of the epigenetic mark H4K20me1 (monomethylation of H4K20) by PR-Set7 during G2/M directly impacts S-phase progression and genome
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 1838 offsetEnd: 1962 A: and SETDB1, whereby the histone H3 trimethylated on lysine 4 (H3K4 (me3) ) modification prevents methylation by SETDB1 on H3
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 1962 offsetEnd: 2083 A: trimethylated on lysine 4 (H3K4 (me3) ) modification prevents methylation by SETDB1 on H3 lysine 9 (H3K9) and the histone
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/24097338 offsetBegin: 0 offsetEnd: 128 A: The histone methyltransferase Enhancer of Zeste Homologue 2 (EZH2), a component of the polycomb group complex, is vital for stem
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 2418 offsetEnd: 2554 A: H3 Lys-27 trimethylation (H3K27me3) mark. In turn, epigenetic stimulation was primarily performed through a gain in the histone H3 Lys-4
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 2554 offsetEnd: 2697 A: turn, epigenetic stimulation was primarily performed through a gain in the histone H3 Lys-4 dimethylation (H3K4me2) and H3 hyperacetylation and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 3091 offsetEnd: 3220 A: of H3K27me3. Inactive pro-invasive genes in MCF-7 cells but not in U251 cells frequently exhibited a stem cell-like bivalent mark
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 3220 offsetEnd: 3348 A: MCF-7 cells but not in U251 cells frequently exhibited a stem cell-like bivalent mark (enrichment in both H3K27me3 and H3K4me2),
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 3348 offsetEnd: 3492 A: cells frequently exhibited a stem cell-like bivalent mark (enrichment in both H3K27me3 and H3K4me2), a characteristic of developmental genes. In
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 1188 offsetEnd: 1334 A: suppressor and membrane-associated receptors are subject to lysine methylation. SET7/9 plays a prominent role in lysine methylation of histone and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 491 offsetEnd: 601 A: role in regulating both DNA methylation and histone H3 methylation at the H19 and Gtl2 loci in mouse ES cells.
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 1917 offsetEnd: 2067 A: Gtl2 imprinting control regions. H1 also interferes with binding of the SET7/9 histone methyltransferase to the imprinting control regions, inhibiting
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 3311 offsetEnd: 3432 A: the de novo monomethyl mark appears essential for cell viability in the presence or absence of the DNA damage checkpoint,
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 2285 offsetEnd: 2415 A: demonstrate that Spi-1 represses Bim transcription by binding to the Bim promoter and by promoting the trimethylation of histone 3
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 3388 offsetEnd: 3514 A: histone methyltransferase EZH2, two PRC2 subunits bind to the Bim promoter at the same location than H3K27me3, distinct of the
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 835 offsetEnd: 972 A: codes that define the identity and the fate of the cell. Despite recent advances revealing numerous histone modifications associated with
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 2697 offsetEnd: 2822 A: through a gain in the histone H3 Lys-4 dimethylation (H3K4me2) and H3 hyperacetylation and by a global reduction of H3K27me3.
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1689 offsetEnd: 1821 A: methyltransferase. Set9 was initially found to target histone H3 lysine 4 for monomethylation and was subsequently shown to target a
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 3191 offsetEnd: 3311 A: functions of PR-Set7, the setting of the de novo monomethyl mark appears essential for cell viability in the presence or
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 2083 offsetEnd: 2201 A: ) modification prevents methylation by SETDB1 on H3 lysine 9 (H3K9) and the histone H3 trimethylated on lysine 9 (H3K9
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 2201 offsetEnd: 2318 A: on H3 lysine 9 (H3K9) and the histone H3 trimethylated on lysine 9 (H3K9 (me3) ) modification prevents methylation by
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20404328 offsetBegin: 5097 offsetEnd: 5243 A: mechanisms allow gliomas to deposit an invasion-promoting collagen-enriched matrix and then to use this matrix to accomplish their rapid migration
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 0 offsetEnd: 121 A: Recent studies on the lysine methylation of histones have moved rapidly thanks to the discoveries of a variety of histone
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/21378170 offsetBegin: 578 offsetEnd: 708 A: codes or histone languages and function to establish and maintain heritable epigenetic codes that define the identity and the fate
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 3074 offsetEnd: 3191 A: the absence of any other known functions of PR-Set7, the setting of the de novo monomethyl mark appears essential for
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23852375 offsetBegin: 3270 offsetEnd: 3388 A: the Bim promoter. SUZ12 and the histone methyltransferase EZH2, two PRC2 subunits bind to the Bim promoter at the same
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 0 offsetEnd: 142 A: Epigenetic silencing in mammals involves DNA methylation and posttranslational modifications of core histones. Here we show that the H1 linker
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 3239 offsetEnd: 3358 A: plays an active role in helping direct two processes that lead to the formation of epigenetic silencing marks. The data
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 3358 offsetEnd: 3494 A: direct two processes that lead to the formation of epigenetic silencing marks. The data also provide evidence for functional differences
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23302691 offsetBegin: 3494 offsetEnd: 3631 A: the formation of epigenetic silencing marks. The data also provide evidence for functional differences among the H1 subtypes expressed in
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 1454 offsetEnd: 1582 A: size of interphase nuclei, and drastic reduction of cell viability. L(3)mbt on the other hand stabilizes the monomethyl mark, as
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 1582 offsetEnd: 1714 A: reduction of cell viability. L(3)mbt on the other hand stabilizes the monomethyl mark, as L(3)mbt-depleted S2 cells show a reduction
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 1714 offsetEnd: 1831 A: the other hand stabilizes the monomethyl mark, as L(3)mbt-depleted S2 cells show a reduction of more than 60% of bulk
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 1831 offsetEnd: 1958 A: mark, as L(3)mbt-depleted S2 cells show a reduction of more than 60% of bulk monomethylated H4K20 (H4K20me1) while viability is
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23024815 offsetBegin: 3555 offsetEnd: 3688 A: presence or absence of the DNA damage checkpoint, but once newly assembled chromatin is established the monomethyl mark, protected by
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 563 offsetEnd: 690 A: involved in the regulation of this event are not well understood. Here we show that SirT2 regulates H4K20me1 deposition through
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 690 offsetEnd: 827 A: event are not well understood. Here we show that SirT2 regulates H4K20me1 deposition through the deacetylation of H4K16Ac (acetylation of
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 827 offsetEnd: 964 A: we show that SirT2 regulates H4K20me1 deposition through the deacetylation of H4K16Ac (acetylation of H4K16) and determines the levels of
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 964 offsetEnd: 1107 A: deposition through the deacetylation of H4K16Ac (acetylation of H4K16) and determines the levels of H4K20me2/3 throughout the cell cycle. SirT2
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 1861 offsetEnd: 1993 A: chromatin levels, alters the size and number of PR-Set7 foci, and decreases the overall mitotic deposition of H4K20me1. Upon stress,
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 1993 offsetEnd: 2129 A: number of PR-Set7 foci, and decreases the overall mitotic deposition of H4K20me1. Upon stress, the interaction between SirT2 and PR-Set7
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23468428 offsetBegin: 2129 offsetEnd: 2269 A: the overall mitotic deposition of H4K20me1. Upon stress, the interaction between SirT2 and PR-Set7 increases along with the H4K20me1 levels,
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 0 offsetEnd: 159 A: Lysine methylation of histones and non-histone proteins has emerged in recent years as a posttranslational modification with wide-ranging cellular implications
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 2744 offsetEnd: 2895 A: similar cross-talk between posttranslational modifications regulates the functions of non-histone proteins such as the tumor suppressor p53 and the DNA
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/23625014 offsetBegin: 2895 offsetEnd: 3025 A: the functions of non-histone proteins such as the tumor suppressor p53 and the DNA methyltransferase DNMT1. Herein, in cis effects
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 944 offsetEnd: 1104 A: methylated lysine residue. Recently, an increasing number of lysine methyltransferases have been identified to modify non-histone proteins. Among those enzymes,
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1104 offsetEnd: 1251 A: number of lysine methyltransferases have been identified to modify non-histone proteins. Among those enzymes, the most extensively studied is Set9,
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1251 offsetEnd: 1407 A: identified to modify non-histone proteins. Among those enzymes, the most extensively studied is Set9, a SET domain-containing lysine methyltransferase. Set9
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 1972 offsetEnd: 2148 A: monomethylation and was subsequently shown to target a variety of non-histone proteins, especially transcription-related factors. Functional studies revealed that Set9-mediated
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 2148 offsetEnd: 2330 A: target a variety of non-histone proteins, especially transcription-related factors. Functional studies revealed that Set9-mediated methylation of different non-histone proteins leads
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 2330 offsetEnd: 2515 A: especially transcription-related factors. Functional studies revealed that Set9-mediated methylation of different non-histone proteins leads to distinct biological consequences, most of
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19829087 offsetBegin: 2515 offsetEnd: 2669 A: that Set9-mediated methylation of different non-histone proteins leads to distinct biological consequences, most of which point to protein stability. Here
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 1470 offsetEnd: 1612 A: promoter that are mediated by changes in epigenetic modifications. In a follow-up study we identified two histone-specific writing and erasing
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 1612 offsetEnd: 1762 A: in epigenetic modifications. In a follow-up study we identified two histone-specific writing and erasing enzymes involved in the underlying regulation
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/20599797 offsetBegin: 1762 offsetEnd: 1918 A: study we identified two histone-specific writing and erasing enzymes involved in the underlying regulation of gene expression during transient hyperglycemia
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 0 offsetEnd: 165 A: Lysine methylation has emerged as a major posttranslational modification for histones in eukaryotes. Crosstalk between lysine methylation and other posttranslational
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 165 offsetEnd: 344 A: major posttranslational modification for histones in eukaryotes. Crosstalk between lysine methylation and other posttranslational modifications is crucial for transcriptional gene
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 521 offsetEnd: 690 A: other posttranslational modifications is crucial for transcriptional gene regulation and epigenetic inheritance. In addition to histones, several other cellular proteins
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 690 offsetEnd: 860 A: transcriptional gene regulation and epigenetic inheritance. In addition to histones, several other cellular proteins including transcription factors, tumor suppressor and
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 860 offsetEnd: 1022 A: In addition to histones, several other cellular proteins including transcription factors, tumor suppressor and membrane-associated receptors are subject to lysine
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 2365 offsetEnd: 2509 A: mediated protein degradation, and antagonist lysine specific demethylase (LSD), may prevent this degradation by removing the methyl mark. Thus a
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 2509 offsetEnd: 2649 A: specific demethylase (LSD), may prevent this degradation by removing the methyl mark. Thus a fine-tuning and balance between cellular SET7/9
Q:Which histone marks are deposited by Set7? Document:http://www.ncbi.nlm.nih.gov/pubmed/19684477 offsetBegin: 2649 offsetEnd: 2779 A: degradation by removing the methyl mark. Thus a fine-tuning and balance between cellular SET7/9 and LSD interaction with DNMT1 may
